<SEC-DOCUMENT>0001558370-21-016181.txt : 20211118
<SEC-HEADER>0001558370-21-016181.hdr.sgml : 20211118
<ACCEPTANCE-DATETIME>20211118070133
ACCESSION NUMBER:		0001558370-21-016181
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211118
DATE AS OF CHANGE:		20211118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		211422586

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tmb-20210930x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7908.23199 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/18/2021 1:42:30 AM -->
      <!-- iXBRL Library version: 1.0.7908.23207 -->
      <!-- iXBRL Service Job ID: 41ab4593-53a0-454f-b698-46ae5f564951 -->

  <html xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:epix="http://www.essapharma.com/20210930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityCentralIndexKey" id="Tc_5506VaekE0O27JvC4c9vlQ_2_1">0001633932</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:CurrentFiscalYearEndDate" id="Tc_qR7I-Dcy1kCeK1QuUIk72Q_3_1">--09-30</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:DocumentFiscalYearFocus" id="Tc_f0vaQ9NNkUuZmq4mfplB8A_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:DocumentFiscalPeriodFocus" id="Tc_VxwrGzQ65UeUWMxAhPWGzQ_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:AmendmentFlag" id="Tc_iOLzkWaM8k6vC4fYTXz7sw_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EclFUGrZHEu0hCdXhGSRtg" decimals="1" name="epix:UnitsIssuedInPrivatePlacementConversionRatio" id="Hidden_Cq_ppVfGcEWPX38oEjsM7A">0.5</ix:nonFraction><ix:nonNumeric contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_LQbZKgvpMkSuPJkLK-6o4A">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_smbzU3-LrEiEpofGJXZ0jQ">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7TyLnsxiZkm33Ed-1uTPOw" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_93qUCOn8jU2BvXa947ry6Q">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7TyLnsxiZkm33Ed-1uTPOw" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_QDBLvhGsQUeMEe7FQU06dg">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_6BX3OeUYGUyxMKVAjbP3ng">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7TyLnsxiZkm33Ed-1uTPOw" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_BNXa2upcvUaUska1jS5ngQ">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_RPrZ07gL9EKwo3zFCZTqrQ">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_VdjHFZpuu0Gaw-U_hHH3mg">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_-5WrOmKIy0aUmOgHj7jFrA">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_oH1NQJf7jEaRneoPXDn_6A">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_XtTWqNg7CkSa4uffoyvABg">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_9O-seddiG0O-DtG3IZ7HSA" name="epix:TermOfUnderwritersOption" id="Hidden_AZRAwVMkb0-1Z3ZiwRVKQw">P30D</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_jETlY65jEkmfBRASRzirag">32064411</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_MU1HXvcdzECgRj3WjIKibw">43984346</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" sign="-" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" id="Hidden_I8yCBUa3N0W0JSccZZb-kw">34349</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" sign="-" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" id="Hidden_Y6jwuf91OUyOdeLUzsBsTA">288647</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" id="Hidden_qGTwKPFLwU6oUyoQmQDV4A">37920</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EclFUGrZHEu0hCdXhGSRtg" decimals="INF" name="epix:UnitsIssuedInPrivatePlacementConversionRatio" id="Hidden_zEYEXFo-FkWGt12ydoujMA">0.5</ix:nonFraction><ix:nonNumeric contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_qojYrx_Z1UW0vuZx-arG5A">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7TyLnsxiZkm33Ed-1uTPOw" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_EsUTpCDv1Eui8u7BVbNk7g">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg" name="epix:TermOfUnderwritersOption" id="Hidden_jpTTNPtrr0yX_oiBe_gYnw">P30D</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tmb-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7TyLnsxiZkm33Ed-1uTPOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:TwoYearWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:SevenYearWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_R-OfI-78tEubD9EHvwxUZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-31</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Xn7g0Te520GAvoVLIuOBjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Qr_emV94JEaOw_wTone2GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QEC_5wIz9U2D4cVesXTV0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_r3QV4PsPVU2qBc_HlNDLwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GwqowEA_CUeSgGO-fqQICA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_iDxFp3CBoUyduJ7ED7-iBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Qsq5hVVbp0yyXHTenb2ZaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_86DwwqBAdEWFbExnOSHKzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d_ASZ3MtTkuEthOiE92plw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rbJc2rOPu0KwHjun-BlNLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UBkybJOYYUOqeW1pxoqlrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2GRojpFcoki1Uc0vSHlB6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0yAp7cE-MUSaXxmCP5yQmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iCrDPxN440W6E11tKIReqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JUboWpxLbki2h1YPzqSmdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HeTz-es_FUOKI2zSdF0t_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_xthkLsF1tU2jKESbtnAPiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">epix:February2021financingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_IVc9duJPY0u5zFzTth4c9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">epix:July2020FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_BRMWk_Qg8UerO040qIU5dA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_mbmDp3ur_EKGdhOHg5IO0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_jO7GpLA2mEqKLGWR63S2zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInCadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_wGr8DRkOREKQQphM6FzNzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceThreeInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_bXZJbL6ROEGmQrETPpTNlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_qaj1qKiQnkaOQmjeCWPVtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSixInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_zuHf0nv_ZkuPd0J8bn1NBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSevenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_7aa-mYodb0C8Ab3SyV0S2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_0jMN-msT_kSZlDa8zsXivA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInCadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_DeJ3daQ9SkyjDkICey1iBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceNineInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_lOFEC9XHq0q7TKCRGrQ1gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFourInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_oZ40Ld43p02RRIboS_eC8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFiveInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_K5b0pB-fBkuoUKefft0NWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceEightInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_wlpmAoIsWkC93lTFzSx58Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_ShZSeTSzbUaq092C2OXCQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInCadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_eWAgb-BJak-hBFlUcl4JKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceThreeInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_N-YP2HmjGk2zaMleH3iyZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_VvO15Me_VUKyqrliUVeTGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSixInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_hiBG1IedoEC4ewOINgWhIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSevenInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_H4_0hNFzBUGvroxmeu8AMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_oPWk0JmRaEyyBh0fzA7Y4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInCadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember__kUWs0yIX0ye8hi1Zc6tpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceNineInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_-Tmwt7iVW0SBnjnGzdbEZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFourInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_LTgKbV_VaEKbcbftrCEzCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFiveInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_1PenuuxZeEyE5f-LOycT4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceEightInUsdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_zeWUu5tnb0Wgo8Zb8VADZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_XbywsLIR-0K_GbIr8abXkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_WEBFjPZWXUWEyRoGCQubVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_wiQZ0GbLlkimzzAcX5zh1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_SMYfJ5aGWk-8_6eAqyWYbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_U7-LX1-3mUqaUlE6IXrBYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_00qP2q4hEkunoH2xAUStyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_taVuJ4126U26vyjixzsKcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9blgNKOQw0-dAjx9wbg0OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RPs6X-s5OUmfzGYNLQRNYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uiguQmWhpEG-xHaL8MHmpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_epix_SouthFransicoOfficeMember_X6eZYkSuvEC6FzZjAFnRZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">epix:SouthFransicoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_epix_HoustonOfficeMember_ZJp_lQNFrUuwmx7ZRbXpsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">epix:HoustonOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_U1mgWv7DPEuRz4Cu7N7uCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_YemvLESzuEy-rvMFb5JkQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_Uot5G89xX0qdEQQjGB5lPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_rj2UHMCflEe1q86RKPHdAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_apbVsSWBtk-56toVL5ECFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_98MIq4VaTEK2WLibJUF1nA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_E5NkLJ4ccEW-hVrvKYeF-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_-Vb12dGpuEmhyC8WUpSCCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_5REs_qrLRkG1-jsr4Wd88A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_P2nPti2-iUCuSEEd1ouQ-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Y0xPeL08wEaJiqQOv0tbTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_Juvh3KilQk6ebtQh2shs2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_vNbAiWbcgEmqGICZO6KNCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_Owqnc6-qBky5k4C7VJfSvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_PY96o3zHKEWmfUlTziLA5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_sshfj9h3UEqQ_5aRwRdsVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_hzqNHICFq0eM1Zmd4JcmoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DzMDwGmdD0qgqtbE68ow2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_hAyflyNNBEWF35w4BVawNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_us-gaap_VariableRateAxis_epix_WallStreetJournalPrimeRateMember_Y1By_7fOBkCONtSvQElMhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">epix:WallStreetJournalPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-18</xbrli:startDate><xbrli:endDate>2016-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_4dedr1AwQkWdcCVB7ocbbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:VendorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_RMrB863qE0qS6tVtlOO3Ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LeaseOnUsOfficeSpacesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_ConsultingAgreementMember_cW0iNp2Vx0-QozLErFC7rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_epix_StockOptionsAndRsuPlanMember_k54Kg0Qt60iP9qnC85_xSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">epix:StockOptionsAndRsuPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_BIcTAMLdhk2c5modB4s8VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_RfUnofClWECxZ2F7pgy_Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_5XGUa66jJ0abwyCuuh-5NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">epix:August2019FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_QlJ05My24UihYsCtnSc8oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceThreeMember_Poysa79t_k26dJwrtpr7cA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceOneMember_peg5Z3r7MkaJuDu2VWniig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_TR1RCu8S8U-alcwoR2y6RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_2x7YFW6kN0SPIIof17z1gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6U4ydYiIA0OEYvfjKh5H-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_fqbH1auJ50GUwQiIlByUJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_TDUXu41ajUSQhlC8jIdvlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_BTVGr7R3tkSQWqwCNPWc3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_h64usUGAzEWawEzuZH2-hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_67NPSE9QlEiBk2PCAmKn_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_C8RcT1oob06aTUsGlCRHHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_nL-lTHW6WU6Z5yoLkjYTEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_vvA5BqUJTUC4h92fKpnqdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_3oGU29vPGEui7qvSdXkMuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_O_W2ARKP1US6svZnbqUj6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_idUWwoe5Nk-eyz-isT07Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_G_hgzoPX3UCgJ-qR7IE_LA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_5sfNjYNtMEWcos30T-GAsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_I94A-tgVzEeSta5_6-UjwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_KbHplZS_S0-4Q0j_S03PtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EclFUGrZHEu0hCdXhGSRtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:TwoYearWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zBSTNeNKaU6nRdYrbBaOkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:SevenYearWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve_0ZTn0TU-gXeCf2aO7nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_KZCcAZEQ0ky6YptH37I2xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">epix:February2021financingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-22</xbrli:startDate><xbrli:endDate>2021-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_9O-seddiG0O-DtG3IZ7HSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">epix:July2020FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-31</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jbYIpU0s4Uy0gHFtYiCEog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93sQ70dbA0m6nn-4DY6rIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementScenarioAxis_epix_AggregateRoyaltyPaymentUpTo24000000Member_5AdkqvcbzUyIueGZN5F9LQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:AggregateRoyaltyPaymentUpTo24000000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementScenarioAxis_epix_AggregateRoyaltyPaymentAfter24000000Member_xk53XTvPeE29Kge7zRUczA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:AggregateRoyaltyPaymentAfter24000000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_kVSb8-wpv0K1-njgvNHdsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_27_2019_To_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_I44o30_JAkC59GqmUmKdIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">epix:August2019FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-27</xbrli:startDate><xbrli:endDate>2019-08-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipn3WcQ-WkyTVclyeT1LWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_RealmTherapeuticsPlcMember_F9zuOVt_vk2IQHvJ990kRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">epix:RealmTherapeuticsPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_RealmTherapeuticsIncMember_spJ0dJs8xkexamG5z198jQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">epix:RealmTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_XOz0eBSbkU2BL3yWpajTpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">epix:EssaPharmaceuticalsCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_epix_FinancingCostsMember_q3XBHIhLlEORxUBDy4pazA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">epix:FinancingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_1_31_2016_dei_LegalEntityAxis_epix_ClarusLifesciencesIiiL.pMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_nZaedBWVMkOE0FrReIaxeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">epix:ClarusLifesciencesIiiL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_IncreaseInVolatilityOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9H1bHzeQPUejA4aXszVdcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:IncreaseInVolatilityOfWarrantsBy10Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_DecreaseInVolatilityOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_WLVJwCesyEOoKBOC_nuHTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:DecreaseInVolatilityOfWarrantsBy10Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_IncreaseInMarketPriceOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_TVV9GdC9SUqfmn3lDBu8_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:IncreaseInMarketPriceOfWarrantsBy10Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_DecreaseInMarketPriceOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_gtQZa6KYHEGyPwd35QmJOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:DecreaseInMarketPriceOfWarrantsBy10Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_stpr_TX_30zEwfkPH0eCYhn7ePIwpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2014_To_2_28_2014_srt_ProductOrServiceAxis_us-gaap_GrantMember_3kTJC-T1iU2z88W1B5pfng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-02-01</xbrli:startDate><xbrli:endDate>2014-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_srt_StatementScenarioAxis_epix_TenPercentChangeInForeignExchangeRateMember_bvuH6gka5U6JPsf7-52JbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:TenPercentChangeInForeignExchangeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2017_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_Aizgt9l5YUetmoZ6ZgsyMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DOZiFA-O_USUr64PZMvTXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_9_30_2019_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_uhVPf69j8U6JNC0OpomEGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_ZnXLMrzY2kKNEOanG51mYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-18</xbrli:startDate><xbrli:endDate>2016-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">epix:RealmTherapeuticsPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">epix:RealmTherapeuticsPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-31</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_XqG7x_Aqjk2REwmcJTq1IQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_3J-meWS_KUKrbz1_u2iGlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_18_2021_iz31dcV6aUOIbNIDv5A8Qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001633932</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Y_NMesmjSO1UGw6iRoGrNeyg"><xbrli:measure>epix:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_bQM1D9rk7USEKwcghht0TA"><xbrli:measure>epix:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_CAD_shares_HPEmoMmb7kGhCh3wegQo4A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f4133f40_1a9f_4c48_883c_f10afa85f7aa"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:DocumentType" id="Narr_jKyefAlw3UeykAetHgdqbA"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:DocumentAnnualReport" id="Narr_ggk0HrcwZUaZBCw2hP8ezw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9746;</span></ix:nonNumeric></span><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:DocumentPeriodEndDate" id="Narr_DLEtlkYb8E6dzQJA9svmFQ"><b style="font-size:8pt;font-weight:bold;">September 30, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">or</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:DocumentTransitionReport" id="Narr_FOjiIGS4yEePX0umJt9DGg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">For the transition period from</b><span style="display:inline-block;width:4.46pt;"></span><b style="font-weight:bold;">to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityFileNumber" id="Narr_qfzGatCz-0uqm2d0wCc2rw"><b style="font-size:8pt;font-weight:bold;">001-37410</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:20pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityRegistrantName" id="Narr_xh0yK7XxZ0auxhG8xBe9zw"><b style="font-weight:bold;">ESSA Pharma&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_aa9e82d9_a7e4_4720_a10a_d5a278cfc3de"></a><a id="Tc_ASjnp-c_FEOUq5i1KmRYWg_1_0"></a><a id="Tc_j_PWbfYamEG9rK5KxHLi6A_2_0"></a><a id="Tc_zP-BKOX66EKP0vnhb-LP4A_2_1"></a><a id="Tc_SZDmKz1q5kG8gTiQNC84ag_3_0"></a><a id="Tc_HGIUsQufJU-opPdNcpDRMw_3_1"></a><a id="Tc_z5JDqdJEEEucaOkKau4s_A_4_0"></a><a id="Tc_V8NLgXTbz0KIdA3xUfVpsw_5_0"></a><a id="Tc_dFfadMqUok-yaczzAIw8rg_6_0"></a><a id="Tc_zJf4fzipQ0qToH9Lx33hnw_7_0"></a><a id="Tc_syGcNI1BhkqGFZQ7Y4z0xA_8_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:edgarprovcountryen" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityIncorporationStateCountryCode" id="Narr_WNoOF2AfdE6Q6uPC8jW2ZQ"><b style="font-size:8pt;font-weight:bold;">British Columbia</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityAddressCountry" id="Narr_MkeKbz19zkCn_FLXboLBQQ"><b style="font-size:8pt;font-weight:bold;">Canada</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityTaxIdentificationNumber" id="Tc_nAmP3VugO0iKerfHqoXhXA_1_1"><b style="font-size:8pt;font-weight:bold;">47-2569713</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification Number)</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityAddressAddressLine1" id="Narr_Rp_gOw2oA0maaHi6kS0Y1w"><b style="font-size:8pt;font-weight:bold;">Suite 720</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityAddressAddressLine2" id="Narr_UdbQTGJRH0KZDQoXO7RRXA"><b style="font-size:8pt;font-weight:bold;">999 West Broadway</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityAddressCityOrTown" id="Narr_FnJUKDZqmE-TEwEuQxH07A"><b style="font-size:8pt;font-weight:bold;">Vancouver</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityAddressStateOrProvince" id="Narr_KT0ivOLqAkq-vaNDWRQeDA"><b style="font-size:8pt;font-weight:bold;">BC</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityAddressPostalZipCode" id="Narr_XD31pMqfs0-fI1qV1jUowA"><b style="font-size:8pt;font-weight:bold;">V5Z 1K5</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices, including zip code)</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:CityAreaCode" id="Narr_T1rVB6xk5kaXa-A9apfoxw"><b style="font-size:8pt;font-weight:bold;">778</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:LocalPhoneNumber" id="Narr_TsM2TD1pDUuF4VI0AfNkVw"><b style="font-size:8pt;font-weight:bold;">331-0962</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_f7a99698_79f1_42e9_a214_33bce7640f37"></a><a id="Tc_0MzR_iw6TUKo1K8daV-VAw_1_0"></a><a id="Tc_h6A6OKpTFEiX4kPrF0Od-A_1_2"></a><a id="Tc_8pEqOVd97kKRj7zyravA2A_1_4"></a><a id="Tc_dcGqCVsQYUC6Kxu-KTSM4w_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:30.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:31.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:34.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:30.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:Security12bTitle" id="Tc_xz9_PE8X7U-kk615-soo1g_2_0"><b style="font-size:8pt;font-weight:bold;">Common Shares</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:TradingSymbol" id="Tc_9ukBP23gd02_A6Ufl43XXg_2_2"><b style="font-size:8pt;font-weight:bold;">EPIX</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:SecurityExchangeName" id="Narr_xVdinSWeo0KvHd0eOYLLOw"><b style="font-size:8pt;font-weight:bold;">Nasdaq</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> Capital Market</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. </span><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_QjtqGzyQ8k6E1DP0GMBVwg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityVoluntaryFilers" id="Narr_Aa1ZimF7ckWBuVZuMvqgmA"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityCurrentReportingStatus" id="Narr_P1S_kRU850KQEAXRfdwCJg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityInteractiveDataCurrent" id="Narr_f-hOahE_uUKxdM6zcS5agg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_64fddc81_a108_4818_8135_01cf3842b9f7"></a><a id="Tc_lr9AJBOQdkCzP697Dq1XWA_1_1"></a><a id="Tc_8KVpXNR3pkuYhqIwiDh4nQ_1_3"></a><a id="Tc_5dTbLHjsJkqf1V_sGof82g_1_4"></a><a id="Tc_rOkEL3rydE6Qo3KZg--zQQ_2_0"></a><a id="Tc_X4K6muaTP0W3JwmU8Vh3DQ_2_1"></a><a id="Tc_MaLoVYyfCEu3zsxLtospwQ_2_3"></a><a id="Tc_U8PgM2DWjUa8WThniXSNdQ_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:23.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityFilerCategory" id="Tc_cq1bpCWJDU-fG1rBWSU1xw_1_0"><span style="font-size:8pt;">Large accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:33.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-accelerated filer</p></td><td style="vertical-align:top;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:33.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntitySmallBusiness" id="Tc_uubHWEnrRU6EKHVoqMYDsQ_2_4"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:EntityEmergingGrowthCompany" id="Tc_lF5bMtxghUmUlERbi-jwNg_3_4"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="dei:IcfrAuditorAttestationFlag" id="Narr_ITVVf5L48EaoEwalwRKzRQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Securities Exchange Act of 1934). Yes </span><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="Narr_hkPb24hP40uBRc5Nus4jPg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">The aggregate market value of the voting and non-voting common shares held by non-affiliates of the registrant, based on the closing sale price of the registrant&#8217;s common shares on the last business day of its most recently completed second fiscal quarter, as reported on the Nasdaq was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_3_31_2021_3J-meWS_KUKrbz1_u2iGlw" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="Narr_6rB7L9l6gEO_So-GMfHOjg">915.9</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">The number of outstanding common shares of the registrant, no par value per share, as of November 18, 2021 was <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_11_18_2021_iz31dcV6aUOIbNIDv5A8Qw" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="Narr_M1y6-1zWYEqgK5GVIlwjzw">43,984,346</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cbfa92f0_66cd_4757_b02a_bbc439bdedff"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">DOCUMENTS INCORPORATED BY REFERENCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Portions of the registrant&#8217;s definitive proxy statement in connection with the registrant&#8217;s 2022 annual meeting of shareholders, which will be filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) subsequent to the date hereof, are incorporated by reference into Part&#160;III of this Form&#160;10-K. Such proxy statement will be filed with the SEC not later than 120&#160;days following the end of the registrant&#8217;s fiscal&#160;year ended September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_bcfca1bf_2a27_4e70_ba62_dcc10e87461b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ESSA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FORM&#160;10-K</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">For the Fiscal&#160;Year Ended September 30, 2021</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Table of Contents</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101.11%;"><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTI_971828"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">PART I</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_294150"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_294150"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Business</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1A"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 1A.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1A"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1B"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 1B.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1B"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">60</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Properties</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">60</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">60</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">60</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTII"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">PART II</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 5.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Market for Registrant&#8217;s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 6.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Selected Financial Data</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 7.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7A"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 7A.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7A"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosure About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 8.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 9.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9A"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 9A.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9A"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9B"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 9B.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9B"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIII"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">PART III</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 10.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 11.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 12.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 13.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certain Relationships and Related Transactions and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 14.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIV"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">PART IV</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 15.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits, Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 16.</span></a></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form 10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">110</p></td></tr><tr><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">SIGNATURES</span></a></p></td><td style="vertical-align:bottom;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">111</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_00fcb74c_6d74_499a_9600_9908b06d509c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;text-indent:0pt;text-transform:uppercase;margin:6pt 0pt 6pt 0pt;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 6pt 7.2pt;">This Annual Report on Form 10-K includes &#8220;forward-looking statements&#8221; within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and &#8220;forward-looking information&#8221; within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Forward-looking statements can often be identified by the use of terminology such as &#8220;subject to&#8221;, &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;hope,&#8221; &#8220;can,&#8221; the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company&#8217;s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Examples of such forward looking statements include, but are not limited to statements related to:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to maintain operations, development programs, preclinical studies, clinical trials and raise capital as a result of the coronavirus disease 2019 outbreak (&#8220;COVID 19&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to advance our product candidate and potential future product candidates through, and successfully complete, clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to recruit sufficient numbers of patients for future clinical trials, and the benefits expected therefrom;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to establish and maintain relationships with collaborators with acceptable development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to obtain funding for operations, including research funding, and the timing and potential sources of such funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the initiation, timing, cost, location, progress and success of, strategy and plans with respect to our research and development programs (including research programs and related milestones with regards to next-generation drug candidates and compounds), preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the therapeutic benefits, properties, effectiveness, pharmacokinetic profile and safety of our product candidate and potential future product candidates, if any, including the expected benefits, properties, effectiveness, pharmacokinetic profile and safety of our next-generation Aniten compounds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">developments relating to our competitors and our industry, including the success of competing therapies that are or may become available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to achieve profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the grant (&#8220;CPRIT Grant&#8221;) under the Cancer Prevention and Research Institute of Texas (&#8220;CPRIT&#8221;) and payments thereunder, including any residual obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our intended use of proceeds from past and future offerings of our securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the implementation of our business model and strategic plans, including strategic plans with respect to patent applications and strategic collaborations and partnerships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to identify, develop and commercialize product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our commercialization, marketing and manufacturing capabilities and strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our expectations regarding federal, state, provincial and foreign regulatory requirements, including our plans with respect to anticipated regulatory filings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">whether we will receive, and the timing and costs of obtaining, regulatory approvals in the United States, Canada and other jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our product candidate and potential future product candidates, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the rate and degree of market acceptance and clinical utility of our potential future product candidates, if any;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the timing of, and our ability and our collaborators&#8217; ability, if any, to obtain and maintain regulatory approvals for our product candidate and potential future product candidates, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our expectations regarding market risk, including inflation, interest rate changes and foreign currency fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to engage and retain the employees required to grow our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the compensation that is expected to be paid to our employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our future financial performance and projected expenditures; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">estimates of our financial condition, expenses, future revenue, capital requirements and our need for additional financing and potential sources of capital and funding.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 6pt 0pt;">Such statements reflect our current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including those described under &#8220;Risk Factors&#8221;. All forward-looking statements included in this Annual Report on Form 10-K, are based upon our current expectations and various assumptions. Certain assumptions made in preparing the forward-looking statements include, but are not limited to:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to maintain operations as a result of the COVID-19 outbreak;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to conduct a clinical study involving our product candidate and to identify any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to obtain regulatory and other approvals to commence a clinical trial involving any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to obtain positive results from research and development activities, including clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the availability of sufficient financing on reasonable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to obtain required regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to protect patents and proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to successfully out-license or sell future products, if any, and in-license and develop new products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the absence of material adverse changes in our industry or the global economy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to attract and retain key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our continued compliance with third party license terms and non-infringement of third-party intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to maintain good business relationships with our strategic partners; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to understand and predict market competition.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;">We believe there is a reasonable basis for our current expectations, views and assumptions, but they are inherently uncertain. We may not realize our expectations and our views and assumptions may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. &#160;In evaluating forward-looking statements, investors should specifically consider the following uncertainties and factors, among others (including those set forth under the heading &#8220;Risk Factors&#8221; within this document), that could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ability to maintain operations and execute on our business plan as a result of the COVID-19 outbreak or other health epidemics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to clinical trial development and our ability to conduct the clinical trial of our product candidate and the predictive value of our current or planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to clinical trials being conducted by third parties under collaboration and clinical supply agreements, including combination studies, using the Company&#8217;s product candidate, studies which the Company may not control, and ensuing reputational risk related to clinical trial results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our future success being dependent primarily on identification through preclinical studies, clinical studies, regulatory approval for commercialization of a single product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our license agreement with third parties;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">uncertainty related to our ability to obtain required regulatory approvals for our proposed products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to the Company&#8217;s ability to conduct a clinical trial or submit a future NDA/NDS or IND/CTA (each, as defined herein);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ability to successfully commercialize future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to the possibility that our product candidate and potential future product candidates, if any, may have undesirable side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ability to enroll subjects in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks that the FDA may not accept data from trials conducted in locations outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ongoing obligations and continued regulatory review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to potential administrative or judicial sanctions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the risk of increased costs associated with prolonged, delayed or terminated clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the risk that third parties may not carry out their contractual duties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to the possibility that our relationships with clinical research organizations or academic institutions may terminate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our lack of experience manufacturing product candidates on a large clinical or commercial scale and our lack of manufacturing facility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks inherent in foreign operations, including related to foreign sourced raw materials, manufacturing or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to disruptions in domestic and foreign supply chains that the Company relies on for the production and shipment of raw materials and clinical trial materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our failure to obtain regulatory approval in international jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to recently enacted and future legislation in the United States that may increase the difficulty and cost for us to obtain marketing approval of, and commercialize, our product candidate and potential future products, if any, and affect the prices we may obtain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to new legislation, new regulatory requirements, and the continuing efforts of governmental and third-party payors to contain or reduce the costs of healthcare;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">uncertainty as to our ability to raise additional funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks related to our ability to raise additional capital on favorable terms and the impact of dilution from incremental financing; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks of a deemed default on any residual obligations of the agreement providing for the CPRIT Grant and having to reimburse all of the CPRIT Grant, if such deemed default is not waived by CPRIT;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our incurrence of significant losses in every quarter since inception and our anticipation that it will continue to incur significant losses in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks related to our limited operating history;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our reliance on proprietary technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ability to protect our intellectual property rights throughout the world;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to claims by third parties asserting that we, or our employees or consultants have misappropriated their intellectual property, or claiming ownership of what we regard as our intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ability to comply with governmental patent agency requirements in order to maintain patent protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to computer system failures or security breaches and increasing cyber threats;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to business disruptions that could seriously harm our future revenues and financial condition and increase our costs and expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our dependence on the use of information technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ability to attract and maintain highly qualified personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks relating to the possibility that third-party coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to potential conflicts of interest between us and our directors and officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to competition from other biotechnology and pharmaceutical companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to movements in foreign currency exchange rates, interest rates and rate of inflation;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ability to convince public payors and hospitals to include our product candidate and potential future products, if any, on their approved formulary lists;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ability to establish an effective sales force and marketing infrastructure, or enter into acceptable third-party sales and marketing or licensing arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ability to manage growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ability to achieve or maintain expected levels of market acceptance for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ability to realize benefits from acquired businesses or products or form strategic alliances in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to collaborations with third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks that employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to product liability lawsuits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to compulsory licensing and/or generic competition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to no longer being considered an emerging growth company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks related to our ability to maintain an active trading market for the Company&#39;s common shares; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to share price volatility in the event there is low liquidity for the trading of the Company&#8217;s common shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to the possibility that laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and Canada and require us to develop and implement costly compliance programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to laws that govern fraud and abuse and patients&#8217; rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ability to comply with environmental, health and safety laws and regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to us being a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">&#8220;passive foreign investment company&#8221;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to United States investors&#8217; ability to effect service of process or enforcement of actions against us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to market price and trading volume volatility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our dividend policy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks associated with future sales of our securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to our ability to implement and maintain effective internal controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">risks related to provisions in our charter documents and Canadian law affecting corporate governance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks related to analyst coverage.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;">If one or more of these risks or uncertainties or a risk that is not currently known to us, materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from those expressed or implied by forward-looking statements. The forward-looking statements represent our expectations, plans, estimates and views as of the date of this document. We do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events, except as required by law. &#160;Investors are cautioned that we cannot guarantee future results, events, levels of activity, performance or achievements and that forward-looking statements are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements. We advise you that these cautionary remarks expressly qualify in their entirely all forward-looking statements attributable to us or persons acting on our behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;">In December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread to multiple countries, including the United States, Canada, and all European countries. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. COVID-19 has had a broad adverse impact on the global economy across many industries and has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions and business shutdowns, as well as significant volatility in global financial markets. Although COVID-19 has not to date had any material impact on our business, operations or financial condition, there can be no assurances that it will not have an impact on our business, operations or financial condition going forward. Management has taken recommended precautions, including adherence to local and facility-related pandemic mandates, support for work at home, and encouragement and monitoring of employee vaccination. &#160;See &#8220;Risk Factors - Risks Relating to COVID-19&#8221; below.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">We express all amounts in this Annual Report on Form 10-K in U.S. dollars, except where otherwise indicated. References to &#8220;$&#8221; and &#8220;US$&#8221; are to U.S. dollars and references to &#8220;C$&#8221; are to Canadian dollars. Except as otherwise indicated, references in this Annual Report on Form 10-K to &#8220;ESSA,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to ESSA Pharma Inc. and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ca4b23c6_9be1_4370_8ac8_c2ef8876d174"></a><a id="_Toc75278512"></a><a id="PARTI_971828"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:10pt 0pt 10pt 0pt;">PART I</p><a id="_Toc75278513"></a><a id="Item1Business_294150"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:10pt;">Item 1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:10pt;">Business</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:10pt 0pt 10pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">ESSA is a clinical stage pharmaceutical company, focused on developing novel and proprietary therapies for the treatment of prostate cancer with an initial focus on patients whose disease is progressing despite treatment with current standard of care therapies, including second-generation antiandrogen drugs such as abiraterone, enzalutamide, apalutamide, and darolutamide. The Company believes its latest series of investigational compounds, including its product candidate EPI-7386, have the potential to significantly expand the interval of time in which patients with castration-resistant prostate cancer (&#8220;CRPC&#8221;) can benefit from anti-hormone-based therapies. Specifically, the compounds are designed to disrupt the androgen receptor (&#8220;AR&#8221;) signaling pathway, the primary pathway that drives prostate cancer growth and prevent AR activation through selective binding to the N-terminal domain (&#8220;NTD&#8221;) of the AR. In this respect, the Company&#8217;s compounds are designed to mechanistically differ from classical non-steroid antiandrogens. These antiandrogens interfere either with androgen synthesis (i.e., abiraterone), or with the binding of androgens to the ligand-binding domain (&#8220;LBD&#8221;), located at the opposite end of the receptor from the NTD (i.e., &#8220;lutamides&#8221;). A functional NTD is essential for the functionality of the AR; blocking the NTD inhibits AR-driven transcription and therefore androgen-driven biology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">The Company believes that the transcription inhibition mechanism of its preclinical compounds is unique and has the potential advantage of bypassing several of the identified mechanisms of resistance to the antiandrogens currently used in the treatment of CRPC. The Company has been granted by the United States Adopted Names (&quot;USAN&quot;) Council a unique USAN stem &quot;-Aniten&quot; to recognize this new first-in-class mechanistic class. The Company refers to this series of proprietary investigational compounds as the &#8220;Aniten&#8221; series. In preclinical studies, blocking the NTD has demonstrated the capability to prevent AR-driven gene expression. A previously completed Phase I clinical trial of ESSA&#8217;s first-generation agent, ralAniten acetate (&#8220;EPI-<span style="white-space:pre-wrap;">506&#8221;) administered to patients with metastatic CRPC (&#8220;mCRPC&#8221;) refractory to current standard of care therapies demonstrated prostate-specific antigen (&#8220;PSA&#8221;) declines, a sign of inhibition of AR-driven biology.  This inhibition, however, was neither deep nor sustained enough to confer clinical benefit and the Company made the decision to develop a more potent next generation drug which would also have a longer half-life.  The Company has done so and is now in clinical trial with this next generation Aniten, EPI-7386.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">According to the American Cancer Society, in the United States, prostate cancer is the second most frequently diagnosed cancer among men, behind skin cancer. Approximately one-third of all prostate cancer patients who have been treated for local disease with curative intent will subsequently have rising serum levels of PSA, which is an indication of recurrent  disease with or without development of distant metastasis. Patients with recurrent disease as indicated by rising PSA usually undergo initial androgen ablation therapy using analogues of luteinizing hormone releasing hormone or surgical castration; this approach is termed &#8220;androgen deprivation therapy&#8221; (&#8220;ADT&#8221;). Most of these patients initially respond to this androgen ablation therapy; however, many experience a recurrence in tumor growth despite the reduction of testosterone to castrate levels, and at that point are considered to have CRPC. Following diagnosis of CRPC, patients have been generally treated with antiandrogens that block the binding of androgens (darolutamide, enzalutamide, apalutamide or bicalutamide) to the AR, or inhibit synthesis of androgens (abiraterone). More recently, significant improvements in progression free survival and overall survival have been achieved by utilizing this latest generation of antiandrogens in combination with ADT earlier in the disease natural history (i.e HSPC and nmCRPC).</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Since the mid-20th century, it has been recognized that the growth of prostate tumors is in large part mediated by an activated AR. Generally, there are three means of activating the AR. First, androgens such as dihydrotestosterone can activate AR by binding to its LBD. Second, CRPC can be driven by variants of AR that lack an LBD, are constitutively activated, and consequently do not require androgen for activation. A third mechanism, of less certain clinical significance, may involve certain signaling pathways that activate AR independent of androgen activity.  Generally, current drugs for the treatment of prostate cancer are directed against the first mechanism by either (i) interfering with the production of androgen, or (ii) preventing androgen from binding to the LBD. Over time, these approaches eventually fail due to mechanisms of resistance which  involve the LBD end of the receptor, whether at the DNA (AR amplification or LBD mutations) or RNA level (emergence of AR splice variants). With respect to the development of alternative pathway mechanisms of AR activation,  tumors might also be insensitive to anti-androgen activity.  Finally, in patients who have been treated for years with various anti-androgen therapies, genomic changes may lead to additional, non-AR-related oncogenic drivers, also insensitive to inhibition of AR biology.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company believes that through their potential to block androgen-driven gene transcription by using a unique mechanism involving the NTD and thereby bypassing these known mechanisms of resistance to current antiandrogens, the Aniten series of compounds hold the potential to be effective in cases where LBD-based mechanisms of resistance to second generation antiandrogens in otherwise AR-driven disease are operating. The results from both extensive preclinical studies and the initial clinical experience support the Company&#8217;s belief. In preclinical studies, the Aniten series of compounds has been observed to shrink AR-dependent prostate cancer xenografts, including tumors both sensitive and resistant to the second-generation antiandrogens such as enzalutamide. Plasma PSA level declines were observed in the initial results of the Phase I study of EPI-7386 as described below.  Importantly with respect to the potential clinical application of NTD inhibition, recent studies by the Company and its collaborators have also suggested the potential advantage for combinations of the Company&#8217;s Aniten compounds with currently approved antiandrogens to inhibit AR-driven biology more completely than AR inhibition from either end of the receptor alone. This hypothesis is supported by the clinical trial results obtained in recent years of the superior overall survival obtained with initial combination therapy with ADT and latest generation anti-androgens relative to the administration of these two therapies sequentially.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Phase I clinical trial of the first generation Aniten EPI-506 provided evidence regarding the safety and tolerability for the potential mechanism of transcription inhibition of AR-driven biology. Patients generally tolerated doses of EPI-<span style="white-space:pre-wrap;">506 at overall exposures consistent with those associated with therapeutic activity in animal models. Possible proof of concept was observed with short duration PSA declines of up to 37% being observed in some patients whose disease was highly refractory to second-generation antiandrogen treatment. However, this first-generation drug demonstrated poor pharmaceutical properties.  The drug was rapidly metabolized in humans, leading to a very short half-life of circulating drug and suboptimal drug exposures. Consequently, very high doses were required to achieve modest drug exposures, with the relatively short half-life limiting the therapeutic exposure of the drug within a 24-hour period. This limitation, together with other demonstrated unfavorable pharmaceutical properties, led to the Company&#8217;s decision to discontinue EPI-</span><span style="white-space:pre-wrap;">506 development in favor of focusing on the development of a next generation of Anitens.  This next generation includes significantly more potent drugs designed also to exhibit increased resistance to metabolism and therefore a longer predicted circulating half-life.  The Company&#8217;s lead product candidate EPI-7386 has demonstrated these and other favorable characteristics in extensive preclinical characterization studies which the Company has presented in a series of poster presentations at scientific meetings over the last&#160;two years.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While the potential importance of the NTD as a drug target has been appreciated for more than two decades, for technical reasons this has been a difficult target for therapeutic agent development.&#160; The NTD of the AR is flexible with a high degree of intrinsic disorder making it difficult for use in classic crystal structure-based drug design. The Company is not currently aware of any clinical-stage NTD AR inhibitors that are in development by other drug development companies. The nature of the highly specific binding of the Aniten compounds to the NTD, and the biological consequences of that binding, have been defined in recent scientific studies. The selectivity of the binding, based on <i style="font-style:italic;">in vivo</i> imaging as well as <i style="font-style:italic;">in vitro</i> studies, has been consistent with the favorable toxicological results observed in preclinical studies of the first-generation EPI-506 and the subsequent safety results observed in the Phase I trial of EPI-506.&#160; The Company has completed a series of biophysical and biological studies revealing the interaction and binding of EPI-7386 to the NTD of the AR and presented these findings at several medical conferences in 2021.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The incidence of both metastatic and non-metastatic CRPC continues to rise, and using a dynamic progression model, Scher et al.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"><a style="margin-bottom:12pt;vertical-align:super;" href="#footnote-2">1</a></sup> projected a 2020 incidence of 546,955 and prevalence of 3,072,480. The Company believes that the Aniten series of compounds could ultimately hold potential benefit for many of those patients. In its early clinical development, the Company intends to initially focus on patients who have failed second-generation antiandrogen therapies (i.e. abiraterone and/or lutamides) for the following reasons:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">CRPC treatment remains a prostate cancer market segment with an apparent and significant unmet therapeutic need and is therefore a potentially large market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the Company believes that the unique mechanism of action of its Aniten compounds is well suited to treat those patients who have failed AR LBD focused therapies and whose biological characterization reveals that their tumors are still largely driven by AR biology; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the Company expects that the relatively large number of patients with an apparent unmet therapeutic need in this area will facilitate timely enrollment in its clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the Company believes that a successful Phase I clinical trial will facilitate the early study of the combination of EPI-7386 with second-generation antiandrogens. The Company and its collaborators have developed preclinical <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i> evidence supporting further evaluation of the combination of NTD inhibitors together with the LBD inhibiting antiandrogens. The Company believes that the application of two independent, complementary mechanisms of AR transcription inhibition may result in greater suppression of androgen activity and the delay or prevention of drug resistance. Recent progress in the clinical treatment of prostate cancer has resulted from the earlier utilization of antiandrogens in combination with classic ADT, consistent with the premise that more effective androgen suppression may yield clinical benefit. The Company believes that the introduction of NTD inhibitors such as EPI-7386 therefore has potential to improve androgen suppression, delay the emergence of resistance, and result in improved clinical benefit. The first collaboration, with Janssen Research &amp; Development, LLC (&#8220;Janssen&#8221;), to study in clinical trials the safety and potential benefit of combination of EPI-7386 with abiraterone acetate with prednisone as well as the combination of EPI-7386 with apalutamide was announced January 13, 2021. A second collaboration and supply agreement with Astellas Pharma Inc. (&#8220;Astellas&#8221;) to evaluate EPI-7386 in combination with Astellas and Pfizer Inc.&#8217;s androgen receptor inhibitor, enzalutamide, in patients with metastatic castration-resistant prostate cancer (&#8220;mCRPC&#8221;) was announced on February 24, 2021. A third collaboration and supply agreement with Bayer Consumer Care AG (&#8220;Bayer&#8221;) to evaluate EPI-7386 in combination with Bayer&#8217;s androgen receptor inhibitor, darolutamide, in patients with mCRPC was announced on April 28, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company is party to a license agreement with the British Columbia Cancer Agency and the University of British Columbia dated December 22, 2010, as amended on February 10, 2011, May 27, 2014, and May 25, 2021  (the &#8220;License Agreement&#8221;), which provides the Company with exclusive world-wide rights to the issued patents and patent applications related to the EPI 002, EPI-506 compound, and the EPI-7386 compounds.</span></p><div style="margin-bottom:5pt;margin-top:15pt;width:25%;border-bottom:1px solid black;"></div><a id="footnote-2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup> Scher HI, Solo K, Valant J, Todd MB, Mehra M (2015) Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS ONE 10(10): e0139440. doi:10.1371/journal.pone.013944</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company believes that it has developed a strong and defensive intellectual property position for Aniten structural classes. As of November 1, 2021, ESSA owns rights to 47 issued patents, including 12 issued U.S. patents, that are in force and cover multiple EPI- and Aniten structural classes of compounds with different structural motifs/analogues. As of November 1, 2021, 4 of these issued patents cover the EPI-7386 compound and are expected to provide protection until 2036 to 2039.  Patent applications are also pending in the United States and in contracting states to the Patent Cooperation Treaty for the Aniten next-generation NTD inhibitors, with expected expiration dates between 2036-2041.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Completed Phase I Clinical Study of EPI-506</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company conducted an initial proof-of-concept Phase I clinical study utilizing the first-generation Aniten compound, EPI-506. The objective of the EPI-506 Phase I clinical trial was to explore the safety, tolerability, maximum tolerated dose and pharmacokinetics of EPI-506, in addition to anti-tumor activity in asymptomatic or minimally symptomatic patients with mCRPC who were no longer responding to either abiraterone or enzalutamide treatments, or both. Efficacy endpoints, such as PSA reduction, and other disease progression criteria were evaluated. Details relating to the design of the Phase I/II clinical trial of EPI-506 are available on the U.S. National Institutes of Health clinical trials website (see https://clinicaltrials.gov).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Investigational New Drug (&#8220; IND&#8221;) application to the FDA for EPI-506, to begin a Phase I clinical trial, was allowed in September&#160;2015, with the first clinical patient enrolled in November&#160;2015. The Company&#8217;s Clinical Trial Application (&#8220;CTA&#8221;) submission to Health Canada was subsequently also cleared. Based on allometric scaling, an initial dose level of EPI-506 of 80 mg was determined. However, following the enrollment of the initial cohorts, it became apparent that EPI-506 exposure was much lower in humans than projected. EPI-506 dosing was escalated aggressively to allow patients in the clinical study greater exposure to the drug. The highest dose patients ultimately received was 3600 mg of EPI-506, administered in a single dose or split into two doses daily. The initial data from the Phase I clinical trial was presented at the European Society of Medical Oncology meeting in September&#160;2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Conducted at five sites in the United States and Canada, the open-label, single-arm, dose-escalation study evaluated the safety, pharmacokinetics, maximum-tolerated dose and anti-tumor activity of EPI-506 in men with end-stage mCRPC who had progressed after prior enzalutamide and/or abiraterone treatment and who may have received one prior line of chemotherapy. Twenty-eight patients were available for analysis, with each patient having received four or more prior therapies for prostate cancer at the time of study entry. Patients self-administered oral doses of EPI-506 ranging from 80 mg to 3600 mg, with a mean drug exposure of 85&#160;days (range of eight to 535&#160;days). Four patients underwent prolonged treatment (with a median of 318&#160;days; and a range of 219 to 535&#160;days at data cut-off), following intra-patient dose escalation. PSA declines, a measure of potential efficacy, ranging from 4% to 37% were observed in five patients, which occurred predominantly in the higher dose cohorts (&#8805;1280 mg).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">EPI-506 was generally well-tolerated with favorable safety results observed across all doses up to 2400 mg. At a dose of 3600 mg, gastrointestinal adverse events (nausea, vomiting and abdominal pain) were observed in two patients: one patient in the once-daily (&#8220;QD&#8221;) dosing cohort and one patient in the 1800 mg twice-daily dosing cohort, leading to study discontinuation and a dose-limiting toxicity (&#8220;DLT&#8221;) due to more than 25% of doses being missed in the 28-day safety reporting period. A separate patient in the 3600 mg QD cohort experienced a transient Grade 3 increase in liver enzymes (AST/ALT), which also constituted a DLT, and enrollment was consequently concluded in this cohort.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Although the Company believes that the safety results and possible signs of anti-tumor activity observed at higher dose levels support the concept that inhibiting the AR-NTD may provide a clinical benefit to mCRPC patients, the pharmacokinetic and metabolic studies revealed the limitations of the first generation agent EPI-506.  Through its discovery research the Company had concluded that it should be feasible to develop a next generation of NTD inhibitor which would demonstrate greater potency, reduced metabolism and other improved pharmaceutical properties. As a result, the Company announced on September&#160;11, 2017 its decision to discontinue the further clinical development of EPI-506 and to implement a corporate restructuring plan to focus research and development resources on its next-generation Anitens targeting the AR-NTD. The restructuring included a decrease in headcount and a reduction of operational expenditures related to the clinical program.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase I Clinical Study of EPI-7386</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s family of next-generation investigational Aniten compounds incorporate multiple chemical scaffold changes to the first-generation drugs which in preclinical studies retain NTD inhibition of the AR. In addition, they have shown improvement in a range of attributes when compared to the first-generation compound, EPI-506, in preclinical studies. In <i style="font-style:italic;">in vitro</i> assays measuring inhibition of AR transcriptional activity, these product candidates demonstrated 20 times higher potency than EPI-506 or its active metabolite, EPI-002. In addition, the compounds have demonstrated increased metabolic stability in preclinical studies, suggesting the potential for longer half-lives in humans. Lastly, the compounds have demonstrated more favorable pharmaceutical properties relative to EPI-506. The Company believes that these product candidates, if successfully developed and approved, may offer advancements in ease and cost of large-scale manufacture, drug product stability, and suitability for commercialization globally. From this series of next-generation compounds, EPI-7386 was selected as the lead candidate for clinical development and an IND was submitted to the FDA on March&#160;30, 2020 and was allowed by the FDA on April&#160;30, 2020. A CTA was filed with Health Canada in April&#160;2020 and clearance was subsequently received. The Phase I clinical trial of EPI-7386 &#8220;Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer (EPI-7386)&#8221; was started in June 2020 with the first patient dosed in July 2020 and is currently actively enrolling patients (www.clinicaltrials.gov). In September 2021 the Company <span style="white-space:pre-wrap;">filed a protocol amendment with the FDA to focus further monotherapy development in less heavily pretreated patients with mCRPC.  </span>The Company has presented preclinical and clinical scientific data relative to EPI-7386 in a number of poster presentations at scientific meetings in the past year. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company&#8217;s initial therapeutic goal is to develop a safe and effective therapy for prostate cancer patients whose tumors have progressed on current antiandrogen therapy while remaining prevalently driven by the AR pathway. However, preclinical studies suggest the potential of the Company&#8217;s Aniten compounds to increase therapeutic activity when combined with antiandrogens at the earlier stage of the disease. Therefore, while the Company&#8217;s initial priority is to continue Phase I clinical development of EPI 7386 as a single agent, in parallel the Company has also been conducting preclinical studies in collaboration with industry and academic institutions.  In addition, the Company has developed collaborations with the relevant pharmaceutical companies in the prostate cancer space for the conduct of clinical trials of combination therapies in earlier line of treatment for patients with mCRPC.  The Company&#8217;s intent to support these collaborative clinical trials with Janssen, Astellas, and Bayer have been announced. The first of these studies, involving the combination of EPI-7386 with enzalutamide, is being conducted in collaboration with Astellas and Pfizer.  ESSA will operationally conduct this trial, with an initial Phase I dose equilibration phase following by a randomized Phase 2 trial involving a planned 120 patients.  The enzalutamide for this trial will be supplied by Astellas. The Company anticipates that this trial will be initiated in the fourth calendar quarter of 2021. Combination trials with abiraterone acetate with prednisone and apalutamide will be conducted by Janssen and will initiate soon thereafter, and a combination clinical trial with darolutamide will be conducted by Bayer.  In future preclinical studies, the Company intends to further explore other potential applications for AR-NTD inhibitors, including breast cancer and other AR-associated cancers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The identification and characteristics of the IND candidate EPI-7386</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The purpose of the next-generation program has been to identify drug candidates with increased potency, reduced metabolic susceptibility and superior pharmaceutical properties compared to ESSA&#8217;s first-generation compounds. Structure-activity relation studies conducted on the chemical scaffold of ESSA&#8217;s first-generation compounds have resulted in the generation of a new series of compounds that have demonstrated higher potency and predicted longer half-lives. Multiple changes in the chemical scaffold have also been incorporated with the goal of improving ADME (absorption, distribution, metabolism, and excretion) and pharmaceutical properties of the chemical class.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Several next-generation Aniten molecules met prespecified preclinical target product profile goals regarding potency, stability, selectivity and pharmaceutical properties. On March&#160;26, 2019, the Company announced the nomination of EPI-7386 as its lead clinical candidate for the treatment of mCRPC through inhibition of the NTD of the androgen receptor. In preclinical studies, EPI-7386 has displayed activity <i style="font-style:italic;">in vitro</i><span style="white-space:pre-wrap;"> in numerous AR-dependent  prostate cancer models including models where second-generation antiandrogens are inactive. In addition, EPI-7386 is significantly more potent, metabolically stable and more effective in preclinical studies compared to ESSA&#8217;s first-generation compound, EPI-506. Lastly, EPI-7386 has demonstrated a favorable tolerability profile in all animal studies of the compound conducted to date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Following IND-enabling studies, ESSA filed an IND for EPI-7386 in mCRPC at the end of the first calendar quarter of 2020, and following the receipt of clearance by the FDA and allowance by Health Canada, commenced clinical testing of EPI-7386 in July 2020, allowing for accommodations to the planned timeline as a result of the impact of the COVID-19 situation at individual clinical trial sites (see &#8220;Risk Factors&#160;- Risks Relating to COVID-19&#8221; in this Annual report on Form 10-K).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Advancing EPI-7386 through clinical development and regulatory approval in CRPC patients</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company is conducting an open-label, dose-escalation Phase I clinical trial to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose and/or recommended phase 2 dose (&#8220;RP2D&#8221;), and potential therapeutic benefits of the drug in mCRPC patients, who are refractory to standard-of-care treatments.  The design of the Phase I clinical trial includes the standard 3+3 design per dose cohort for the Part 1a dose escalation phase, with subjects receiving a daily oral dose of EPI-7386 until there is objective evidence of clinical disease progression, and or occurrence of an unacceptable toxicity. The Part 1b dose expansion phase will commence when the RP2D is determined.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patients for the Part 1a are initially selected clinically, on the basis of having progressive metastatic CRPC as exemplified by rising PSA values and/or radiological disease progression despite latest generation antiandrogen treatment. However, all patients are also retrospectively biologically characterized for underlying tumor genomic characteristics, for evidence of AR pathway activation and during the conduct of the trial, for dose-related biological, pharmacological and pharmacodynamic effects. The goal of the dose escalation phase is to establish a RP2D which will be confirmed by the treatment of a larger group of patients treated at this optimal dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Once the Phase I clinical trial is complete, the Company plans to review the totality of the data, including the safety, tolerability, evidence of efficacy and pharmacological and biomarker data. This overall experience will inform the final size, design, and timing of a Phase II clinical trial, and importantly, the clinical as well as biological characteristics of the patients with mCRPC considered most likely to benefit from this therapeutic approach despite the late stage of their disease.  Subsequent Phase II and additional clinical trials, including trials of combination Aniten/lutamide therapy in earlier lines of treatment, should benefit from this initial clinical trial experience.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has presented preclinical scientific data relative to EPI-7386 in a number of poster presentations at scientific meetings. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics (&#8220;ENA&#8221;) on October 24, 2020, an oral poster presentation titled, &#8220;The preclinical characterization of the N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer,&#8221; presented new information about EPI-7386 including: (i) in an <i style="font-style:italic;">in vitro </i>cellular thermal shift assay (CETSA), EPI-7386 was shown to physically interact with the both the full-length and the splice variant (AR-V7) form of the androgen receptor (&#8220;AR&#8221;) (ii) in an <i style="font-style:italic;">in vitro </i>full-length AR-driven cellular model (LNCaP), RNAseq data was analyzed by pathway enrichment analysis. EPI-7386 demonstrates largely similar modulation of AR-regulated genes compared to enzalutamide, but with additional unique elements; and (iii) EPI-7386 exhibits superior activity to enzalutamide in the AR-V7-driven cellular models LNCaP95 and 22Rv1 by modulating AR-driven gene expression with or without the addition of an external androgen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Previously, <i style="font-style:italic;">in vitro </i>data had been presented demonstrating that EPI-7386 binds to the full-length AR and can inhibit the transcription of AR-regulated genes. The new data demonstrate that EPI-7386 can also physically interact with the splice variant form, AR-V7, of the androgen receptor and inhibit its activity. The importance of this interaction with AR-V7 is seen through the superior transcriptional inhibition of AR-regulated genes by EPI-7386 compared to enzalutamide in the AR-V7-driven cell models LNCaP95 and 22Rv1. Together, these data provide insights into mechanistic aspects related to the binding and utility of EPI-7386 against AR-V7 splice-variant driven prostate cancer models. The data supports the Company&#8217;s rationale for studying EPI-7386 in men with prostate cancer resistant to current antiandrogens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On February 11, 2021, the Company presented preclinical and clinical pharmacology data from ESSA&#8217;s Phase 1 clinical trial of EPI-7386 for the treatment of patients with metastatic castration-resistant prostate cancer (&#8220;mCRPC&#8221;) at the 2021 American Society of Clinical Oncology Genitourinary (&#8220;ASCO GU&#8221;) Cancers Symposium in an oral poster presentation titled, &#8220;Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer.&#8221; The poster is available on the Company website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Data on the poster included a comparison of preclinical projections of EPI-7386 clinical pharmacokinetic parameters to the pharmacokinetic, safety and preliminary clinical data from the initial 200 mg cohort of patients enrolled in ESSA&#8217;s multi-center, open-label, ascending multiple-dose Phase 1 study of EPI-7386 to treat patients with mCRPC who have become resistant to standard of care treatments. Patients participating in this trial have progressed on two or more approved systemic therapies for mCRPC, including at least one second generation antiandrogen therapy not necessarily in the metastatic disease setting. In this initial cohort of patients receiving the 200 mg once-daily dose, EPI-7386 was well-tolerated with no SAEs observed. The results from this cohort support ESSA&#8217;s preclinical projections regarding the pharmacologic properties of EPI-7386 in humans. EPI-7386 was well-absorbed, demonstrated high exposure levels and was confirmed to have a long half-life of at least 24 hours. The predicted exposures of EPI-7386 in patients at that 200 mg dose level were similar to the Company&#8217;s modeled projections and were still below optimal target exposures of EPI-7386 associated with anti-tumor activity in animal models. Although the 200 mg dose exposure was suboptimal, one out of three patients who completed 12 weeks of therapy experienced a prostate specific antigen (&#8220;PSA&#8221;) decline of more than 50 percent after three cycles of EPI-7386 therapy (12 weeks) with ongoing continued PSA declines continuing through seventeen cycles of therapy, despite previously having failed enzalutamide and abiraterone acetate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">At the 2021 American Association of Cancer Research (AACR) Annual Meeting, which took place virtually April 10-15, 2021, ESSA presented an e-poster presentation titled, &#8220;Comprehensive in vitro characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal inhibitor.&#8221;   The content of this poster added to previously presented data that EPI-7386 binds to the full-length androgen receptor, inhibits the transcription of AR-regulated genes, and physically interacts with the splice variant form AR-V7, by demonstrating that EPI-7386 can prevent the androgen receptor from binding to genomic DNA and is active against additional androgen receptor splice variants, including AR-v567es. These preclinical data suggest EPI-7386 can potentially inhibit AR related transcription, a key driver of prostate cancer, and further supports the ongoing Phase 1 dose escalation study.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The data also showed that EPI-7386, in combination with enzalutamide, may result in broader and deeper inhibition of the AR pathway, underscoring the potential clinical benefit of combining EPI-7386 with current standard-of-care antiandrogen therapies for prostate cancer patients at earlier stages of the disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">On October 7, 2021 at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics the Company presented a virtual poster of preclinical data confirming EPI-7386&#8217;s target engagement with the NTD of the androgen receptor, the primary driver of prostate cancer growth.  The multiple studies showed (i) three separate orthogonal NMR approaches confirm that EPI-7386 binds to the Tau5 region of the NTD; (ii) cellular thermal shift assays (CETSA) confirm engagement of EPI-7386 with both full length AR (AR-FL) and AR-V567es, a splice variant lacking the ligand-binding domain (LBD); (iii) gene expression driven by the AR splice variant, AR-V567es, can be inhibited by EPI-7386 whereas enzalutamide and darolutamide, which bind to the LBD, cannot inhibit AR-V567es-driven gene expression; and (iv) chromatin immunoprecipitation sequencing (ChIP-Seq) data indicate that EPI-7386 inhibits androgen-induced changes at the AR cistrome and when combined with enzalutamide, can completely abrogate genome-wide androgen-induced AR binding.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additionally, the data demonstrated that the combination of EPI-7386 with enzalutamide results in complete inhibition of genome-wide androgen-induced AR binding, supporting the rationale for the upcoming Phase 1/2 combination trials of EPI-7386 with approved antiandrogens in patients with metastatic castration-resistant prostate cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company believes these results from the initial clinical data and ongoing in vitro studies are encouraging and suggest a favorable pharmacokinetic profile of EPI-7386 in patients. The Company believes the data demonstrate proof of concept by suggesting that EPI-7386, through its novel mechanism of action of targeting the N-terminal domain, may bypass the resistant mechanisms in at least a subset of mCRPC patients in whom the disease continues to remain AR-dependent despite progression on current antiandrogen therapies. While early in the Phase 1 clinical study, the Company is encouraged to have seen early signs of biological activity and declining PSA levels in a multi-refractory patient at the initial 200 mg dose as presented at the February 11, 2021 ASCO-GU meeting. EPI-7386 continues to be safe, well-tolerated, with generally good drug exposures, and adverse-events typical of those associated with antiandrogen therapy.  Patients are currently being dosed at 600 mg, 800 mg, and 1,000 mg QD, with each of these dose levels being cleared as safe and tolerable. Given the favorable tolerability of the drug and the wide therapeutic window seen in preclinical studies, the Company plans to enroll additional dose cohorts using a twice daily (BID) dosing schedule to further enhance patient drug exposures. The protocol amendment filed with the FDA in September 2021 allows for  monotherapy development in less heavily pretreated patients in whom the Company believes the androgen receptor pathway continues to be the primary driver of tumor growth. The Company&#8217;s goal is to establish a recommended Phase 2 dose (&#8220;RP2D&#8221;) for monotherapy during the first half of 2022 based on multiple inputs, including pharmacokinetic and biological observations, in addition to clinical experience, and commence the expansion Phase 1b study soon thereafter in earlier, less heavily pre-treated and more biologically characterized patients. It is expected that a clinical readout of the Phase 1a monotherapy trial will be presented in the first half of calendar 2022. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Developing a product candidate as an essential component of a new standard of care for the treatment of pre-CRPC and expanding usage earlier in the disease stage</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">An activated AR is required for the growth and survival of most prostate cancer. Unlike current antiandrogen therapies which can only inhibit full-length AR, NTD inhibition of AR-directed biology occurs both in full length AR and splice variant ARs. Therefore, the Company believes that the AR-NTD is an ideal target for next-generation antiandrogen hormone therapy. If ESSA&#8217;s product candidate is successful in treating CRPC patients, it is reasonable to expect that such clinical candidate may be effective in treating earlier stage patients. Preclinical studies suggest particular value to the use of Anitens in combination with the currently widely used antiandrogens. As a result, the Company intends to conduct additional clinical studies potentially leading to the approval of EPI-7386 for use in prostate cancer patients at an earlier disease stage in combination with second-generation antiandrogens. In this regard, the Company continues to develop <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i><span style="white-space:pre-wrap;"> data in collaboration with academic investigators and clinical data with  industry investigators as in the collaboration with Janssen to study EPI-7386 in combination clinical trials with abiraterone acetate/prednisone, as well as with apalutamide, and in the collaboration and supply agreement with Astellas to evaluate EPI-7386 in combination with Astellas and Pfizer Inc.&#8217;s enzalutamide, as well as in the collaboration and supply agreement with Bayer to evaluate EPI-7386 in combination with Bayer&#8217;s darolutamide, in patients with mCRPC. Preclinical data supporting this approach highlights  the potential benefits of combining an NTD inhibitor, such as an Aniten compound, with an antiandrogen that works through inhibition of the LBD of the AR by directly blocking androgen binding (e.g. lutamides) or by inhibiting androgen synthesis (abiraterone acetate). Other emerging potential clinical applications for NTD inhibitors are in combination with other agents, such as poly ADP ribose polymerase (&#8220;PARP&#8221;) inhibitors, Pin1 inhibitors, CDK4/6 inhibitors, as well as in the subset of metastatic breast cancer patients whose tumors have been demonstrated to have activation of the AR pathway.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Evaluating strategic collaborations to maximize value</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company currently retains all commercial rights for its Aniten series drug portfolio. The Company continues to evaluate potential collaborations that could enhance the value of its prostate cancer program and allow it to leverage the expertise of such strategic collaborators such as those with Janssen, Astellas, and Bayer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Future Clinical Development Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase I/II Clinical Trial Design for treating CRPC patients</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">With the allowance by the FDA of the IND and clearance of the CTA by Health Canada for EPI-7386, the Company is conducting a Phase I, multi-dose escalation clinical trial to determine the safety, tolerability, maximum tolerated dose/recommended Phase 2 dose pharmacokinetics, and efficacy of the compound in refractory mCRPC patients at clinical sites in the US and Canada. The clinical trial is expected to enroll approximately 42 patients at multiple medical institutions in a standard 3+3 trial design with an approximate 12 additional patients enrolled in a dose expansion cohort at the recommended Phase 2 dose level.  The Company is working with clinicals sites so patients can be enrolled ensuring compliance with COVID-19 risk management guidance as provided by FDA (see &#8220;Risk Factors - Risks Relating to COVID-19&#8221; in this Annual Report on Form 10-K).  Learnings from the Phase I clinical trial of EPI-506 have been incorporated into the design and conduct of the Phase I study. The Company has included in the study design, for example, extensive biological characterization of the patients entered into the trial. Depending on the results of the Phase 1 study, a Phase II single arm clinical trial evaluating the activity of EPI-7386 single agent in a larger group of biologically-characterized mCRPC patients might be conducted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">In October 2021 the company disclosed the development of a collaboration with Caris Life Sciences, involving the incorporation of Caris&#8217; newly developed cNAS (&#8220;circulating nucleic acid sequencing&#8221;) assay in the characterization of patients receiving EPI-7386.  The Company believes that the characterization of real time individual patient biology will contribute significantly to the understanding the extent to which individual patient&#8217;s tumors are still AR driven and what mechanisms of resistance exist.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Early Conduct of a Combination Phase I/II Clinical Trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Given the evolution of prostate cancer therapeutics towards combination therapy strategies from the earlier stages of the disease, the biological rationale for combining NTD and LBD inhibitors, and compelling early <i style="font-style:italic;">in vitro</i> and preclinical animal model results, the Company intends to perform combination studies of EPI-7386 with current generation antiandrogens. Since these combination studies will involve earlier lines of therapy, they will commence only after sufficient experience with safety, tolerability and efficacy has been accumulated with single agent EPI-7386 therapy in patients with metastatic disease resistant to standard of care treatments. Under the collaboration agreement with Janssen, Janssen will pay for and conduct two trials with EPI-7386 and each of their antiandrogens, apalutamide and abiraterone acetate, and ESSA will provide the clinical trial material of EPI-7386. Under the collaboration with Astellas, ESSA will pay for and conduct a trial with EPI-7386 and enzalutamide, with Astellas providing enzalutamide, and under the collaboration with Bayer, Bayer will pay for and conduct a clinical trial with EPI-7386 and darolutamide, with ESSA providing the clinical trial material EPI-7386.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Once the RP2D for each drug has been established, Phase 2 of the study will commence. Phase 2 is a two-arm, randomized (2:1), open-label study and is expected to enroll 120 mCRPC patients who have not yet been treated with second-generation antiandrogen therapies. The goal of the Phase 2 of the study is to evaluate the safety, tolerability and antitumor activity of EPI-7386 in combination with a fixed dose of enzalutamide compared with enzalutamide as a single agent. &#160;The combination studies being run by Janssen and Bayer are anticipated to begin in early 2022, at the discretion of those firms.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Phase III Clinical Trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In order to ultimately obtain full single agent regulatory approval, the Company expects that at least one Phase III clinical trial will be required, most likely in patients similar to the population of mCRPC patients who will have been enrolled in the planned Phase I/II clinical trial. However, the results of the Phase I/II clinical trial may also suggest modification of the initial patient population based on anti-tumor response and biomarker assessment. In a Phase III clinical trial, the key end-point is expected to be progression-free survival or overall survival relative to patients receiving the standard-of-care. It is expected that such a Phase III clinical trial would be conducted at numerous sites around the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The competition in the prostate cancer market is very high, many of the companies against which we compete or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Several pharmaceutical therapies already have approved and many new molecules are being tested for their effect in this patient population. In addition, generic forms of Zytiga (abiraterone acetate) are now approved and commercially available in the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Currently approved therapies include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:22.26%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">GENERIC/PROGRAM<br />NAME</b></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BRAND NAME</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMPANY NAME(S)</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STAGE</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Enzalutamide</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Xtandi</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Astellas and Pfizer</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Abiraterone acetate</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Zytiga</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Johnson&#160;&amp; Johnson</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sipuleucel-T</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provenge</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valeant</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Docetaxel</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">n/a</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sanofi and various</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cabazitaxel</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jevtana</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sanofi</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Radium-233</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Xofigo</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bayer</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Apalutamide (ARN-509)</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Erleada</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Johnson&#160;&amp; Johnson</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Darolutamide</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nubeqa</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bayer</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pembrolizumab</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Keytruda</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Merck</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Olaparib</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lynparza</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AstraZeneca</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rucaparib</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:23.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rubraca</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:27.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clovis Oncology</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketed</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In this market, ESSA believes that its competitive position is strong because its product candidate, if successful, involves a mechanistically unique, differentiated approach to prostate cancer involving the therapeutic modality that has been shown to make the biggest difference to the survival of recurrent prostate cancer patients: blocking AR activation. Since Anitens have been shown to directly bind to AR-NTD and prevent AR-mediated transcription, they have the potential to bypass the AR-dependent resistance pathways (discussed above) that may develop as a result of treatment with current hormone-related therapies that target the AR LBD. If successful, ESSA believes this could represent a significant step forward in the treatment of prostate cancer. To ESSA&#8217;s knowledge, no other antagonist to the AR-NTD is currently undergoing clinical trials for prostate cancer or any other indication. Other approaches to interfering with AR signaling include strategies to degrade the AR such as that being pursued by Arvinas, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Patents and Proprietary Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">License Agreement with UBC and the BCCA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESSA has in-licensed intellectual property embodied in issued patents, pending patents applications and know-how relating to compounds that modulate AR activity. ESSA refers to these intellectual property rights as the &#8220;Licensed IP.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the License Agreement, ESSA has been granted a worldwide, exclusive license to develop and commercialize products based on the Licensed IP. ESSA paid a minimum annual royalty of C$40,000 in the 2014 calendar year, increasing to C$65,000 in each of 2015 and 2016 and C$85,000 in 2017, 2018, and 2019 and must continue to pay a minimum of C$85,000 for each year thereafter. For a First Compound entering clinical development, an additional C$50,000 and C$900,000 must be paid upon enrollment of a patient in a Phase II and Phase III clinical trial, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Licensors may terminate the License Agreement upon ESSA&#8217;s insolvency, or the License Agreement may be terminated by either party for certain material breaches by the other party. ESSA has already spent more than C$5,000,000 in connection with the commercialization of products relating directly to the Licensed IP, as required under the License Agreement. ESSA is required to allocate reasonable time to the development and commercialization of the Licensed IP and to use reasonable efforts to promote, market and sell products covered by the Licensed IP. The terms of the License Agreement required ESSA to issue to the Licensors, 1,000,034 pre-Consolidation common shares, in lieu of payment of an initial license fee. If ESSA develops products covered by the Licensed IP in the future, it will be required to pay certain development and regulatory milestone payments up to an aggregate of C$2.4 million for the first drug product developed under the license and up to an aggregate of C$510,000 for each subsequent product. ESSA must also pay the Licensors low single-digit royalties based on aggregate worldwide net sales of products covered by the Licensed IP and a percentage of sublicensing revenue in the low teens.. The License Agreement will expire on the later of 20 years after the date of the License Agreement or the expiry of the last issued patent included in the Licensed IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ESSA&#8217;s Intellectual Property Strategy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Both ESSA and the broader pharmaceutical industry attach significant importance to patents for the protection of new technologies, products and processes. Accordingly, ESSA&#8217;s success depends, in part, on its ability to obtain patents or rights thereto, to protect commercial secrets and carry on activities without infringing the rights of third parties. See &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. Where appropriate, and consistent with management&#8217;s objectives, ESSA will continue to seek patents in relation to components or concepts of its technology that it perceives to be important.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Patent Applications</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESSA has licensed certain patent rights, with respect to some of its compounds that modulate AR activity, from the Licensors, jointly. ESSA has the right to acquire ownership of the licensed patents and patent applications upon specified payment to the Licensors, and providing that payments required under the License Agreement continue to be made.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">As of November 1, 2021, ESSA  owns rights to 47 issued patents worldwide, including 12 issued U.S. patents, that are in force and cover multiple EPI- and Aniten structural classes of compounds with different structural motifs/analogues. As of November 1, 2021, 4 of these issued patents cover the EPI-7386 compound, and are expected to provide protection between 2036 to 2039.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESSA currently has 16 pending and maintained patent families which cover multiple EPI- and Aniten structural classes of compounds with different structural motifs/analogues, that provide a strong and defensive intellectual property portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Regulatory Environment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The production and manufacture of ESSA&#8217;s product candidate and potential future product candidates and its R&amp;D activities are subject to regulation for safety, efficacy, quality and ethics by various governmental authorities around the world. In the United States, drugs and biological products are subject to regulation by the FDA. In Canada, these activities are regulated by the Food and Drugs Act and the rules and regulations thereunder, which are enforced by the TPD. Drug approval laws require registration of manufacturing facilities, carefully controlled research and testing of product candidates, government review and approval of experimental results prior to giving approval to sell drug products. Regulators also require that rigorous and specific standards such as cGMP, good laboratory practices (&#8220;GLP&#8221;) and current good clinical practices (&#8220;GCP&#8221;) are followed in the manufacture, testing and clinical development respectively of any drug product. See &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The process of obtaining regulatory approvals and the corresponding compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Drug Products Development Process</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">completion of extensive nonclinical, sometimes referred to as preclinical laboratory tests, and preclinical animal trials in compliance with applicable requirements for the humane use of laboratory animals and formulation studies, including GLPs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">submission to the FDA of an IND, which must take effect before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">approval by an institutional review board (&#8220;IRB&#8221;), representing each clinical site before each clinical trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as GCP regulations and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed drug product for its intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">preparation and submission to the FDA of a New Drug Application (&#8220;NDA&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">review of the product by an FDA advisory committee, where appropriate or if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">payment of user fees and securing FDA approval of the NDA; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) and post-approval studies required by the FDA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preclinical studies are conducted <i style="font-style:italic;">in vitro</i> and in animals to evaluate pharmacokinetics, metabolism and possible toxic effects to provide evidence of the safety of the product candidate prior to its administration to humans in clinical studies and throughout development. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Initiation of Human Testing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written trial protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. In Canada, this application is called a CTA. An IND/CTA application must be filed and accepted by the FDA or TPD, as applicable, before human clinical trials may begin. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the trial at least annually. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to trial subjects. An IRB must operate in compliance with FDA regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Two key factors influencing the rate of progression of clinical trials are the rate at which patients can be enrolled to participate in the research program and whether effective treatments are currently available for the disease that the drug is intended to treat. Patient enrollment is largely dependent upon the incidence and severity of the disease, the treatments available and the potential side effects of the drug to be tested and any restrictions for enrollment that may be imposed by regulatory agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase I Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Phase I clinical trials for cancer therapeutics are typically conducted on a small number of patients to evaluate safety, dose limiting toxicities, tolerability, pharmacokinetics and to determine the dose for Phase II clinical trials in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase II Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Phase II clinical trials typically involve a larger patient population than Phase I clinical trials and are conducted to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of a product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase III Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Phase III clinical trials typically involve testing an experimental drug on a much larger population of patients suffering from the targeted condition or disease&#160;&#8211; in ESSA&#8217;s case, CRPC. These studies involve testing the experimental drug in an expanded patient population at geographically dispersed test sites (multi-center trials) to establish clinical safety and effectiveness. These trials also generate information from which the overall risk-benefit relationship relating to the drug can be determined.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In most cases FDA requires two adequate and well controlled Phase III clinical trials to demonstrate the efficacy of the drug. A single Phase III trial with other confirmatory evidence may be sufficient in rare instances where the trial is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">New Drug Application</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA, or the TPD as part of a New Drug Submission (&#8220;NDS&#8221;), requesting approval to market the drug product for one or more indications. The NDS or NDA is then reviewed by the applicable regulatory body for approval to market the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA conducts a preliminary review of an NDA within 60&#160;days of its receipt and informs the sponsor by the 74th day after the FDA&#8217;s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten&#160;months from the date of filing, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within nine&#160;months of filing. The review process may be extended by the FDA for three additional&#160;months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections cover all facilities associated with an NDA submission, including drug component manufacturing (such as Active Pharmaceutical Ingredients), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee, currently exceeding $2,500,000 and the manufacturer or sponsor under an approved new drug application are also subject to significant annual program and establishment user fees. These fees are typically increased annually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or nine&#160;months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-Approval Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, significant changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">product seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Orphan Designation and Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESSA may, in the future, seek orphan drug designation for its product candidates. Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the product generally will receive orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven&#160;years, except in certain limited circumstances. Competitors may receive approval of different products for the indication for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:10pt 0pt 10pt 0pt;">Government Regulation Outside of the United States and Canada</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any commercial sales and distribution of our products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. In the European Union, for example, a CTA must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical study development may proceed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The requirements and process governing the conduct of clinical studies, product licensing, coverage, pricing and reimbursement vary from country to country. In all cases, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:10pt 0pt 10pt 0pt;">Human Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">As of the date of this Annual Report, ESSA has a total of approximately 30 employees and consultants on a full-time or part-time basis. ESSA has in the past, and may in the future, retain additional expert consultants on an ad-hoc basis if required in connection with the Company&#8217;s development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">We believe that our future success will depend, in part, on our ability to continue to attract, hire, and retain qualified personnel. We continue to seek additions to our science and technical staff. Through our experience with technological innovation, we appreciate the importance of retention, growth and development of our employees. We believe we offer competitive compensation (including salary, incentive bonus, and equity) and benefits packages. None of our employees is represented by a labor union, and we have never experienced a work stoppage.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Corporate Structure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company was incorporated under the name &#8220;ESSA Pharma Inc.&#8221; pursuant to the Business Corporations Act (British Columbia) on January 6, 2009. The Company&#8217;s articles of incorporation (the &#8220;Articles&#8221;) were amended on December 16, 2010 to attach certain special rights and restrictions to the Common Shares, on April 22, 2014 to authorize the creation of a new class of preferred shares in the capital of the Company, issuable in one or more series, and again on July 28, 2014 to create the class A preferred shares in the capital of the Company (the &#8220;Preferred Shares&#8221;) and attach certain special rights and restrictions to such Preferred Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company&#8217;s registered and records office is located at Suite 2600, 595 Burrard Street, Vancouver, British Columbia, Canada V7X 1L3. The Company&#8217;s head office is located at Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada V5Z 1K5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Since July 9, 2015, the Company&#8217;s Common Shares have traded on the Nasdaq under the symbol &#8220;EPIX.&#8221; The Company&#8217;s Common Shares traded under the symbol &#8220;EPI&#8221; on the Toronto Stock Exchange (the &#8220;TSX&#8221;) from July 28, 2015 until November 24, 2017. On November 27, 2017, the Company delisted its Common Shares from the TSX and began trading on the TSX-V under the same symbol, &#8220;EPI.&#8221; On October 26, 2020, the Company announced its decision to voluntarily delist its Common Shares from the TSX-V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company has the following wholly owned subsidiaries:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ESSA Pharmaceuticals Corp. (&#8220;ESSA Texas&#8221;), existing under the laws of the State of Texas. The head office of ESSA Texas is located at Suite 1300, 700 Milam Street, Houston, Texas, USA 77002; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Realm Therapeutics plc. (&#8220;Realm&#8221;), existing under the laws of the England and Wales, and its wholly owned subsidiary Realm Therapeutics Inc., existing under the laws under the State of Delaware, which were both acquired on July 31, 2019 and are being liquidated with final certificates being awaited.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:10pt 0pt 10pt 0pt;">Available Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">This Annual Report on Form 10-K, our quarterly reports on Form 10-Q or Form 6-K, our current reports on Form 8-K or Form 6-K, and any amendments to these reports are filed, or will be filed, as appropriate, with the SEC and the Canadian Securities Administrators (&#8220;CSA&#8221;). These reports are available free of charge on our website, <span style="text-decoration:underline;text-decoration-color:#000000;">www.essapharma.com</span>, as soon as reasonably practicable after we electronically file such reports with or furnish such reports to the SEC and the Canadian regulatory authorities. Information contained on, or accessible through, our website is not a part of this Annual Report on Form 10-K, and the inclusion of our website address in this document is an inactive textual reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Additionally, our filings with the SEC may be accessed through the SEC&#8217;s website at <span style="text-decoration:underline;text-decoration-color:#000000;">www.sec.gov</span> and our filings with the CSA may be accessed through the CSA&#8217;s System for Electronic Document Analysis and Retrieval (&#8220;SEDAR&#8221;) at <span style="text-decoration:underline;text-decoration-color:#000000;">www.sedar.com</span>. Our annual report on Form 10-K from the year ended September 30, 2020, which includes a full discussion of the general development of our business, can be found at <span style="text-decoration:underline;text-decoration-color:#000000;">https://sec.report/Document/0001558370-20-014403/</span>.<span style="text-decoration:underline;text-decoration-color:#000000;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_8627b10b_9ebe_43e0_a07e_b65e09f45329"></a><a id="Item1A"></a><a id="_Toc75278514"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;">Item 1A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;">Risk Factors </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:10pt 0pt 10pt 0pt;">Risk Factor Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">We are providing the following summary of the risk factors contained in this Annual Report on Form 10-K to enhance the readability and accessibility of our risk factor disclosures. This summary does not address all the risks &#160;that we face. We encourage you to carefully review the full risk factors contained in this Annual Report on Form 10-K in their entirety, together with our other filings with the SEC, for additional information regarding the material factors that make an investment in our securities speculative or risky, and before making an investment decision regarding our common shares. These risks and uncertainties include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We are subject to risks related to COVID-19;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our future success is dependent primarily on the regulatory approval for commercialization of a single product candidate, which is in the clinical development stage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We may not be able to obtain required regulatory approvals for our proposed products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We may not be able to successfully commercialize our Aniten series of compounds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our product candidate and potential future product candidates may have undesirable side effects that may delay or prevent marketing approval or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Even if we obtain marketing approval for any product candidate and potential future products, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We may fail to comply with applicable legal and regulatory requirements, which may result in administrative or judicial sanctions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We have limited experience manufacturing product candidates on a large clinical or commercial scale and have no manufacturing facility</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, this could substantially harm our business because we may not be able to obtain regulatory approval for or commercialize product candidates in a timely manner or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our business may be materially adversely affected by new legislation, new regulatory requirements and the continuing efforts of governmental and third-party payors to contain or reduce the costs of healthcare through various means;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We will have significant additional future capital needs for future clinical trials and there are uncertainties as to the Company&#8217;s ability to raise additional funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We may not be able to raise additional capital on favorable terms, which may result in dilution to our existing shareholders, restrictions on our operations or the requirement for us to relinquish rights to technologies or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We have incurred significant losses in every quarter since our inception and anticipate that we will continue to incur significant losses in the future and may never generate profits from operations or maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We have a limited operating history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We rely on proprietary technology, the protection of which can be unpredictable and costly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We may not be able to protect our intellectual property rights throughout the world;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We may be subject to claims by third parties asserting that we, or our employees or consultants have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our business and operations would suffer in the event of computer system failures or security breaches;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We face intense competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We have never marketed a drug before, and if we are unable to establish an effective sales force and marketing infrastructure, or enter into acceptable third-party sales and marketing or licensing arrangements, we may be unable to generate any revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our product candidate and potential future products may, if approved for sale, not achieve or maintain expected levels of market acceptance, which could have a material adverse effect on our business, financial condition and results of operations and could cause the market value of our securities to decline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and Canada and require us to develop and implement costly compliance programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">We are and there is a risk that we may continue to be a &#8220;passive foreign investment company&#8221; which would likely result in materially adverse U.S. federal income tax consequences for U.S. investors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The market price and trading volume of our Common Shares may be volatile, which could result in rapid and substantial losses for our shareholders or securities litigation.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:10pt 0pt 10pt 0pt;">Risks Relating to COVID-19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The COVID-19 pandemic has had a broad adverse impact on the global economy across many industries and has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions and business shutdowns, as well as significant volatility in global financial markets. In March 2020, the Company made the decision to transition employees to primarily remote working arrangements. &#160; This continues to the present, but the Company has taken steps to maintain internal communication, and operations have thus far continued on schedule and with minimal interruption. In particular, the Company has been able to continue to move towards activating initial clinical trial sites; with patients being dosed, and with additional patients in screening. Although COVID-19 has not yet had any material adverse impact on our business, operations or financial condition, there can be no assurances that it will not have an impact on our business, operations or financial condition going forward. The potential still remains that we may experience future delays with third party vendor operations, including foreign and domestic supply chains, or delays in clinical trial activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">While the Company will continue to work to minimize any emerging complications, the extent to which COVID-19 may cause more significant disruptions to our business and operations will depend on future developments, which are highly uncertain and cannot be definitively predicted. These uncertainties include the duration of the pandemic (including future potential waves or cycles), travel restrictions and social distancing measures, and the effectiveness of actions taken to contain and treat the disease and to address its impact, including its impact on global financial markets. A lack of coordinated response on risk mitigation and vaccination deployment with respect to the COVID-19 pandemic could result in significant increases to the duration and severity of the pandemic and could have a corresponding negative impact on our business. For example, with the increased availability of vaccines in North America and certain countries around the world, the rate of additional COVID-19 infections and hospitalizations has declined in certain locations, resulting in relaxed restrictions and a general reopening of the economy and travel across many jurisdictions. While these developments are promising, reduced vaccine availability or resistance to vaccination by certain persons may result in increasing infection and hospitalization rates, which could be further complicated by the emergence of more virulent or infectious variants of the virus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">If the COVID-19 pandemic worsens or continues for a prolonged period of time, we could experience disruptions that could significantly impact our current and planned clinical trials, preclinical studies and our business activities including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays or difficulties in initiating clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays or difficulties in enrolling patients in our current and potential future clinical trials of EPI-7386;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">disruption to and delays in preclinical research and analysis activities due to an extended temporary closure of contract lab facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">disruptions in supply, logistics or other activities related to the procurement of materials, which could have a negative impact on our ability to conduct preclinical studies, initiate or complete our clinical trials or commercialize our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">diversion of healthcare resources away from the conduct of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">interruption of key preclinical studies and clinical trial activities, due to limitations on travel imposed or recommended by federal, state, provincial or municipal governments, employers and others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">limitations in resources that would otherwise be focused on the conduct of our business or our current or planned preclinical studies or clinical trials, including due to sickness, restrictions on travel, prolonged stay-at-home or shelter-in-place orders and other COVID-19 related concerns;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">changes in regulations as part of a response to the COVID-19 outbreak which may require us to change the ways in which our preclinical studies and clinical trials are conducted and incur unexpected costs, or requires us to discontinue our preclinical research or clinical trials altogether;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays in receiving regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or furlough of government or contractor personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">limitations on our ability to recruit preclinical research, clinical, regulatory and other professional staff on the timeframe required to support our research and development programs.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In addition, COVID-19 could result in continued significant disruption of global financial markets, reducing our ability to access capital, which could have negative future impacts on our liquidity and financial condition. Financial volatility has adversely affected, and may continue to adversely affect, the value of our Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:10pt 0pt 10pt 0pt;">ESSA&#8217;s Product Candidate and Regulatory Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and trials may not be predictive of future trial results and ESSA&#8217;s product candidate and potential future product candidates may not have favorable results in later trials or in the commercial setting or satisfy the requirements of the FDA or non-US regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. ESSA&#8217;s planned clinical trials may produce negative or inconclusive results, and ESSA or any of its current and future collaborators may decide, or regulators may require ESSA, to conduct additional clinical or preclinical testing. The results of preclinical studies and early clinical trials may not be predictive of the results of later-stage clinical trials. Preclinical tests and Phase I and Phase II clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in preclinical or animal studies and early clinical trials does not ensure that later large-scale efficacy trials will be successful nor does it predict final results. Favorable results in early trials may not be repeated in later trials. The Company cannot assure you that the FDA, TPD or EMA or other similar government bodies will view the results as the Company does, or that any future trials of ESSA&#8217;s proposed products for other indications will achieve positive results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Any current or future clinical trial results for ESSA&#8217;s proposed products may not be successful. Similarly, preclinical interim results of a clinical trial do not necessarily predict final results. A number of factors could contribute to a lack of favorable safety and efficacy results for ESSA&#8217;s proposed products for other indications. For example, such trials could result in increased variability due to varying site characteristics, such as local standards of care, differences in evaluation period and due to varying patient characteristics including demographic factors and health status. There can be no assurance that the Company&#8217;s clinical trials will demonstrate sufficient safety and efficacy for the FDA EMA to approve ESSA&#8217;s potential products for the treatment of CRPC, or any other indication that the Company may consider in any additional NDA or NDS submissions for ESSA&#8217;s potential products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The Company will be required to demonstrate through large scale clinical trials that any product candidate and potential future product candidate is safe and effective for use in a diverse population before ESSA can seek regulatory approvals for its commercial sale. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical and post-approval trials. If ESSA&#8217;s potential products fail to demonstrate sufficient safety and efficacy in ongoing or future clinical trials, the Company could experience potentially significant delays in, or be required to abandon development of a product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In addition, clinical trials and nonclinical studies performed by research organizations and other independent third parties may yield negative results regarding the effect of ESSA&#8217;s potential products on CRPC, either in absolute terms or relative to other products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA&#8217;s future success is dependent primarily on the regulatory approval for commercialization of a single product candidate, which is in the clinical development stage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company does not have any products that have obtained regulatory approval for commercialization. Currently, ESSA is engaged in the clinical testing of a product candidate, EPI-7386, to take forward from its Aniten series of compounds through clinical development to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and potential therapeutic benefits of such candidate in patients with CRPC, and to ultimately receive regulatory approval. As a result, the Company&#8217;s near-term prospects, including its ability to finance its operations and generate revenue, are substantially dependent on its ability to develop, obtain regulatory approval for, and, if approved, to successfully commercialize a product candidate in a timely manner. ESSA cannot commercialize its product candidates in the United States without first conducting multiple preclinical and clinical trials to establish the product&#8217;s safety and efficacy and obtaining regulatory approval for the product from the FDA; similarly, ESSA cannot commercialize its product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. The FDA development and review process typically varies in time and may take years to complete and approval is not guaranteed. Developing, obtaining regulatory approval for and successfully commercializing ESSA&#8217;s product candidates will depend on many factors, including, but not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">successfully completing formulation and process development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">completing multiple clinical trials that demonstrate the efficacy and safety of ESSA&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">receiving marketing approval from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">establishing commercial manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">launching commercial sales, marketing and distribution operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">acceptance of ESSA&#8217;s product candidates by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">a continued acceptable safety profile following approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">competing effectively with other therapies, including with respect to the sales and marketing of ESSA&#8217;s product candidates, if approved.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Many of these factors are wholly or partially beyond ESSA&#8217;s control, including clinical development, the regulatory submission process and changes in the competitive landscape. If ESSA does not achieve one or more of these factors in a timely manner, it could experience significant delays or an inability to develop ESSA&#8217;s product candidates at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">If the Company breaches any of the agreements under which the Company licenses rights to its technology from third parties, the Company could lose license rights that are important to ESSA&#8217;s business. ESSA&#8217;s current license agreement may not provide an adequate remedy for its breach by the licensor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA entered into a License Agreement with UBC and the BC Cancer Agency that covers certain Aniten compound candidates. The Company is subject to a number of risks associated with the Company&#8217;s collaboration with UBC and the BC Cancer Agency, including the risk that UBC or the BC Cancer Agency may terminate the License Agreement upon the occurrence of certain specified events. ESSA&#8217;s License Agreement requires, among other things, that the Company make certain payments and use reasonable commercial efforts to meet certain clinical and regulatory milestones. See &#8220;Patents and Proprietary Rights&#8221; in Item 4 of this Annual Report. If ESSA fails to comply with any of these obligations or otherwise breaches this or similar agreements, UBC, the BC Cancer Agency or any future licensors may have the right to terminate the license. ESSA could also suffer the consequences of non-compliance or breaches by licensors in connection with ESSA&#8217;s license agreements. Such non-compliance or breaches by such third parties could in turn result in ESSA&#8217;s breaches or defaults under the Company&#8217;s agreements with the Company&#8217;s other collaboration partners, and the Company could be found liable for damages or lose certain rights, including rights to develop and/or commercialize a product or product candidate. Loss of ESSA&#8217;s rights to the Licensed IP or any similar license granted to ESSA in the future, or the exclusivity rights provided therein, could harm ESSA&#8217;s financial condition and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">The Company may not be able to obtain required regulatory approvals for the Company&#8217;s proposed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The research, testing, manufacturing, labeling, packaging, storage, approval, sale, marketing, advertising and promotion, pricing, export, import and distribution of drug products developed by ESSA or ESSA&#8217;s future collaborative partners, if any, is subject to extensive regulation by federal, provincial, state and local governmental authorities and those regulations differ from country to country. ESSA&#8217;s product candidate and potential future product candidates will be principally regulated in the United States by the FDA, in the European Union by the EMA and the regulators in the individual European Union member countries, in Canada by the TPD, and by other similar regulatory authorities in Japan and other jurisdictions. Government regulation substantially increases the cost and risk of researching, developing, manufacturing and selling products. Following several widely publicized issues in recent years, the FDA and similar regulatory authorities in other jurisdictions have become increasingly focused on product safety. This development has led to requests for more clinical trial data, for the inclusion of a significantly higher number of patients in clinical trials and for more detailed analysis of trial results. Consequently, the process of obtaining regulatory approvals, particularly from the FDA, is time-consuming and has become more costly than in the past. Any product developed by ESSA or ESSA&#8217;s future collaborative partners, if any, must receive all relevant regulatory approvals or clearances from the applicable regulatory authorities before it may be marketed and sold in a particular country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA will not be permitted to market any potential products in the United States, Europe, Japan, Canada or in other countries where ESSA intends to market its product candidate and potential future product candidates until such product candidate receives approval of a NDA from the FDA or similar approval in other countries as restrictions apply. In the United States, the FDA generally requires the completion of preclinical testing and clinical trials of each drug to establish its safety and efficacy and extensive pharmaceutical development to ensure its quality before an NDA is approved. This process takes many years and requires the expenditure of substantial resources and may include post-marketing studies and surveillance. Regulatory authorities in other jurisdictions impose similar requirements. Of the large number of drugs in development, only a small percentage result in the submission of an NDA to the FDA and even fewer are approved for commercialization. Other than the INDs submitted for EPI-506 and EPI-7386, the Company has not submitted an IND or an NDA to date for any of the Company&#8217;s potential products to the FDA or comparable applications to other regulatory authorities. If the Company&#8217;s development efforts for potential products are not successful for the treatment of CRPC and regulatory approval is not obtained in a timely fashion or at all, the Company&#8217;s business will be adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">The receipt of required regulatory approvals for the Company&#8217;s product candidate and potential future product candidate(s) is uncertain and subject to a number of risks, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the FDA, IRBs or comparable foreign regulatory authorities may disagree with the design or implementation of the Company&#8217;s clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the Company may not be able to provide acceptable evidence of the safety, efficacy or quality of its potential products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the results of the Company&#8217;s clinical trials may not meet the level of statistical or clinical significance required by the FDA or other regulatory agencies for marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the dosing of the Company&#8217;s potential products in a particular clinical trial may not be at an optimal level;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">patients in the Company&#8217;s clinical trials may suffer adverse effects for reasons that may or may not be related to the Company&#8217;s potential products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the data collected from the Company&#8217;s clinical trials may not be sufficient to support the submission of an NDA for the Company&#8217;s potential products or to obtain regulatory approval in the United States, Europe, Japan, Canada, or elsewhere;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the FDA or comparable foreign regulatory authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers with which the Company contracts for clinical and commercial supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering the Company&#8217;s clinical data insufficient for approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The FDA and other regulators have substantial discretion in the approval process and may refuse to accept any application or may decide that the Company&#8217;s data is insufficient for approval and require additional clinical trials, or other studies. In addition, varying interpretations of the data obtained from preclinical studies and clinical trials could delay, limit or prevent regulatory approval of the Company&#8217;s potential products. ESSA, or ESSA&#8217;s future collaborative partner, if any, must obtain and maintain regulatory authorization to conduct clinical trials. ESSA&#8217;s preclinical research is subject to GLP and other requirements and ESSA&#8217;s clinical research is subject to good clinical practice and other requirements. Failure to adhere to these requirements could invalidate ESSA&#8217;s data. In addition, the relevant regulatory authority or independent review board may modify, suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the benefits. Further, the process of obtaining regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon, among other things, the type, complexity and novelty of the prescription product candidates involved, the jurisdiction in which regulatory approval is sought and the substantial discretion of the regulatory authorities. If regulatory approval is obtained in one jurisdiction, it does not necessarily mean that ESSA&#8217;s potential products will receive regulatory approval in all jurisdictions in which the Company may seek approval, or any regulatory approval obtained may not be as broad as what was obtained in other jurisdictions. However, the failure to obtain approval for ESSA&#8217;s potential products in one or more jurisdictions may negatively impact the Company&#8217;s ability to obtain approval in a different jurisdiction. Accordingly, despite ESSA&#8217;s expenditures and investment of time and effort, it may be unable to receive required regulatory approvals for product candidates developed by it. If a significant portion of these development efforts are not successfully completed, required regulatory approvals are not obtained, or any approved products are not commercially successful, ESSA&#8217;s business, financial condition and results of operations may be materially harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">As an organization, ESSA has never submitted an NDA/NDS and may be unable to do so for any future products ESSA develops.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA is currently undergoing a Phase I clinical trial for EPI-7386. ESSA will need to conduct Phase II and Phase III clinical trials, which it has not previously undertaken. The conduct of Phase III clinical trials and the submission of a successful IND or CTA and NDA or NDS is a complicated process. As an organization, ESSA has limited experience in preparing, submitting and prosecuting regulatory filings and has not submitted an NDA or NDS. ESSA&#8217;s interactions with the FDA to date have been limited to the completed EPI-506 clinical trial and the initiation of the Phase I clinical trial for EPI-7386. Consequently, even if ESSA&#8217;s initial clinical trials are successful, the Company may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to NDA or NDS submission and approval of ESSA&#8217;s proposed products or any other future product candidate ESSA may develop. The Company may require more time and incur greater costs than competitors and may not succeed in obtaining regulatory approvals of products that the Company develops. Failure to commence or complete, or delays in, ESSA&#8217;s planned clinical trials, would prevent ESSA from or delay ESSA in commercializing proposed products or any other future product candidate ESSA develops.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA may not be able to successfully commercialize its Aniten series of compounds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Even if a candidate from ESSA&#8217;s Aniten series were to be successfully developed and obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, may be subject to burdensome post-approval study or risk management requirements, or may be limited to a subset of CRPC patients with limited commercial value. If ESSA is unable to obtain regulatory approval in one or more jurisdictions, or any approval contains significant limitations, ESSA may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of any other future product candidates that ESSA may discover, in-license, develop or acquire in the future. Also, any regulatory approval of any future product candidates, once obtained, may be withdrawn. Furthermore, even if ESSA obtains regulatory approval for a product candidate, the commercial success of such product candidate will depend on a number of factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">development of a commercial organization or establishment of a commercial collaboration with a commercial infrastructure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">establishment of commercially viable pricing and approval for adequate reimbursement from third-party and government payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the ability of ESSA&#8217;s third-party manufacturers to manufacture quantities of the compound using commercially efficient processes and at a scale sufficient to meet anticipated demand and enable ESSA to reduce its cost of manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ESSA&#8217;s success in educating physicians and patients about the benefits, administration and use of the compound;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the effectiveness of ESSA&#8217;s own or its potential strategic collaborators&#8217; marketing, sales and distribution strategy and operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">acceptance of the product candidate as safe and effective by patients and the medical community; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">a continued acceptable safety profile of a product candidate following approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Many of these factors are beyond ESSA&#8217;s control. If ESSA, or its potential commercialization collaborators, are unable to successfully commercialize a product candidate, ESSA may not be able to earn sufficient revenues to continue the Company&#8217;s business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">The Company&#8217;s product candidate and potential future product candidates may have undesirable side effects that may delay or prevent marketing approval or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Although any future product candidates will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of ESSA&#8217;s product candidate and potential future product candidates could arise either during clinical development or, if approved by regulatory authorities, after the approved product has been marketed. The results of any future clinical trials may show that the product candidate (s) cause undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings, limited patient populations or potential product liability claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">If any of ESSA&#8217;s product candidate and potential future product candidates receive marketing approval and it or others later identify undesirable or unacceptable side effects caused by such products:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">regulatory authorities may require us to take ESSA&#8217;s approved product off the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">it may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">it may be subject to limitations on how it may promote or distribute the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">sales of the product may decrease significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">it may be subject to litigation or product liability claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ESSA&#8217;s reputation may suffer.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Any of these events could prevent ESSA or its future collaborative partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent ESSA from generating significant revenue from the sale of ESSA&#8217;s products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">If ESSA is unable to enroll subjects in clinical trials, ESSA will be unable to complete these trials on a timely basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the impact of COVID-19, the proximity of subjects to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, ability to obtain and maintain patient consents, risk that enrolled subjects will drop out before completion, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications ESSA is investigating. Furthermore, ESSA plans to rely on clinical research organizations (&#8220;CROs&#8221;) and clinical trial sites to ensure the proper and timely conduct of the Company&#8217;s clinical trials, and while the Company has agreements governing their committed activities, the Company has limited influence over their actual performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">If ESSA experiences delays in the completion or termination of any clinical trial of any future product candidates, the commercial prospects of product candidates will be harmed, and ESSA&#8217;s ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing ESSA&#8217;s clinical trials will increase costs, slow down product candidate development and approval process and could shorten any periods during which ESSA may have the exclusive right to commercialize product candidates or allow competitors to bring products to market before ESSA does, and jeopardize ESSA&#8217;s ability to commence product sales, which would impair ESSA&#8217;s ability to generate revenues and may harm ESSA&#8217;s business, results of operations, financial condition and cash flows and future prospects. In addition, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of ESSA&#8217;s proposed products or future product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">ESSA may conduct trials for future product candidates at sites outside the United States and the FDA may not accept data from trials conducted in such locations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA may in the future choose to conduct more clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the studies also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside of the United States. If the FDA chooses to not accept data collected outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt the development of the Company&#8217;s proposed products or any future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">Even if the Company obtains marketing approval for any product candidate and potential future products, the Company will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Even if the Company obtains U.S., Canadian or European regulatory approval for a future product candidate, which would not occur until the Company successfully completes multiple clinical trials, including Phase III clinical trials, the FDA, TPD or EMA may still impose significant restrictions on its indicated uses or marketing or the conditions of approval, or impose ongoing requirements for potentially costly and time-consuming post-approval studies, including Phase 4 clinical trials or clinical outcome studies and post-market surveillance to monitor the safety and efficacy of ESSA&#8217;s potential products. Even if the Company secures U.S., Canadian or European regulatory approval, the Company would continue to be subject to ongoing regulatory requirements governing manufacturing, labeling, packaging, storage, quality assurance, distribution, import, export, safety surveillance, advertising, promotion, recordkeeping and reporting of adverse events and other post-market information. These requirements include registration with the FDA, as well as continued compliance with GCP obligations, for any clinical trials that the Company conducts post approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">With respect to any product candidates for which ESSA obtains regulatory approval, ESSA will be subject to post-marketing regulatory obligations, including the requirements by the FDA, EMA and similar agencies in other jurisdictions to maintain records regarding product safety and to report to regulatory authorities serious or unexpected adverse events. Compliance with extensive post-marketing record keeping and reporting requirements requires a significant commitment of time and funds, which may limit ESSA&#8217;s ability to successfully commercialize approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In addition, manufacturing of approved drug products must comply with extensive regulations governing cGMP. Manufacturers and their facilities are subject to continual review and periodic inspections. As ESSA will be dependent on third parties for manufacturing, ESSA will have limited ability to ensure that any entity manufacturing products on its behalf is doing so in compliance with applicable cGMP requirements. Failure or delay by any manufacturer of ESSA&#8217;s products to comply with cGMP regulations or to satisfy regulatory inspections could have a material adverse effect on ESSA, including potentially preventing ESSA from being able to supply products for clinical trials or commercial sales. In addition, manufacturers may need to obtain approval from regulatory authorities for product, manufacturing, or labeling changes, which requires time and money to obtain and can cause delays in product availability. ESSA is also required to comply with good distribution practices such as maintenance of storage and shipping conditions, as well as security of products, in order to ensure product quality determined by cGMP is maintained throughout the distribution network. In addition, ESSA is subject to regulations governing the import and export of its products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Sales and marketing of pharmaceutical products are subject to extensive federal and state or other laws governing on -label and off-label advertising, scientific/educational grants, gifts, consulting and pricing and are also subject to consumer protection and unfair competition laws. Compliance with these extensive regulatory requirements will require training and monitoring of any future sales force, which will impose a substantial cost on ESSA and ESSA&#8217;s collaborators. To the extent any future ESSA products are marketed by collaborators, ESSA&#8217;s ability to ensure their compliance with applicable regulations will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">Failure to comply with applicable legal and regulatory requirements may result in administrative or judicial sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">If the Company or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, lack of efficacy, problems with the facility where the product is manufactured, or the Company or its manufacturers fail to comply with applicable regulatory requirements, the Company may be subject to the following administrative or judicial sanctions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">issuance of warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">clinical holds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">injunctions or the imposition of civil or criminal penalties or monetary fines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">suspension or withdrawal of regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">suspension of any ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">refusal to approve pending applications or supplements to approved applications filed by the Company, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">suspension or imposition of restrictions on operations, including costly new manufacturing requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">withdrawal of the product from the market and product recalls; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">product seizure or detention or refusal to permit the import or export of product.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The occurrence of any event or penalty described above may inhibit the Company&#8217;s ability to commercialize potential products and generate revenue. Adverse regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase the Company&#8217;s product liability exposure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In the future, the regulatory climate might change due to changes in the FDA and other regulatory authorities&#8217; staffing, policies or regulations and such changes could impose additional post-marketing obligations or restrictions and related costs. While it is impossible to predict future legislative or administrative action, if the Company is not able to maintain regulatory compliance, the Company will not be able to market its drugs and its business could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">If clinical trials for ESSA&#8217;s product candidate and potential future product candidates are prolonged, delayed or stopped, ESSA may be unable to obtain regulatory approval and commercialize such product candidates on a timely basis, or at all, which would require ESSA to incur additional costs and delay receipt of any product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA may experience delays in any future preclinical studies or clinical trials, and ESSA does not know whether future preclinical studies or clinical trials will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. The commencement of these planned clinical trials could be substantially delayed or prevented by several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">discussions with the FDA or other regulatory agencies regarding the scope or design of ESSA&#8217;s clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the limited number of, and competition for, suitable sites to conduct ESSA&#8217;s clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as ESSA&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">inability to obtain sufficient funds required for a clinical trial;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delay or failure to manufacture sufficient supplies of the product candidate for ESSA&#8217;s clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delay or failure to obtain IRB approval to conduct a clinical trial at a prospective site.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The completion of ESSA&#8217;s clinical trials, once started, could also be substantially delayed or prevented by several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">slower than expected rates of patient recruitment and enrollment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">failure of patients to complete the clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the inability to enroll a sufficient number of patients in studies to ensure adequate statistical power to detect statistically significant treatment effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">lack of efficacy during clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">termination of ESSA&#8217;s clinical trials by one or more clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">inability or unwillingness of patients or clinical investigators to follow ESSA&#8217;s clinical trial protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">inability to monitor patients adequately during or after treatment by ESSA and/or ESSA&#8217;s CROs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ESSA&#8217;s CROs or clinical study sites failing to comply with regulatory requirements or meet their contractual obligations to ESSA in a timely manner, or at all, deviating from the protocol or dropping out of a study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the inability to produce or obtain sufficient quantities of the product candidate to complete clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the inability to scale up manufacture of the product candidate into a commercially acceptable formulation at reasonable cost;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the inability to address any noncompliance with regulatory requirements or safety concerns that arise during the course of a clinical trial; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Changes in regulatory requirements, policies and guidelines may also occur and ESSA may need to significantly amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Such changes may require ESSA to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. ESSA&#8217;s clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of ESSA&#8217;s clinical trial sites with respect to that site, or ESSA, due to a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">failure to conduct the clinical trial in accordance with regulatory requirements or ESSA&#8217;s clinical protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of ESSA&#8217;s product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Product development costs for any of ESSA&#8217;s potential products will increase if it has delays in testing or approval or if the Company needs to perform more or larger clinical studies than planned. Any delays in completing the Company&#8217;s future clinical trials will increase its costs, slow down its development and approval process and jeopardize its ability to generate revenues. Any of these occurrences may have a material adverse effect on the Company&#8217;s business, financial condition and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ESSA relies on third parties to conduct its preclinical studies and clinical trials, and has entered into collaboration agreements with companies related to combination studies, in addition to the combination study the Company controls. If these third parties do not successfully carry out their contractual duties, fail to meet expected deadlines, or if unfavorable results related to combination studies are announced, this could have a negative impact on ESSA&#8217;s reputation and substantially harm ESSA&#8217;s business because it may not be able to obtain regulatory approval for or commercialize product candidates in a timely manner or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA has extensively relied upon and plans to continue to extensively rely upon entities outside of its control, including CROS and academic institutions, to monitor and manage data for its ongoing preclinical and clinical programs. ESSA relies on these parties for execution of its preclinical studies and clinical trials, and it controls only some aspects of their activities. Nevertheless, ESSA is responsible for ensuring that each of its studies and clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and ESSA&#8217;s reliance on CROS and academic institutions does not relieve it of these responsibilities. ESSA also relies on third parties to assist in conducting its preclinical studies in accordance with GLP and the Animal Welfare Act requirements. ESSA and the third parties that it relies on are required to comply with federal regulations and current GCP, which are international standards meant to protect the rights and health of patients that are enforced by the FDA and comparable foreign regulatory authorities for all of ESSA&#8217;s products in clinical development. Regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators and trial sites. If ESSA or any of the third parties it relies on fail to comply with applicable GCP, the clinical data generated in ESSA&#8217;s clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require ESSA to perform additional clinical trials before approving ESSA&#8217;s marketing applications. ESSA cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of its clinical trials comply with GCP requirements. In addition, ESSA&#8217;s clinical trials must be conducted with product produced under cGMP requirements. Failure to comply with these regulations may require ESSA to repeat preclinical studies and clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA has ongoing combination studies with Astellas and Pfizer, Janssen, and Bayer, not all of which are under ESSA&#8217;s control. These combination studies involve additional risks due to their reliance on circumstances outside of ESSA&#8217;s control, such as those relating to the availability and marketability of the third-party product in the study. In addition, because we have established collaborations with leading biotechnology and pharmaceutical companies, we may be subject to greater reputational risk depending on the outcomes of the combination studies conducted through these collaborations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The third parties that ESSA relies upon are not its employees, and except for remedies available to the Company under its agreements with such third parties, ESSA cannot control whether or not they devote sufficient time and resources to the Company&#8217;s ongoing clinical, nonclinical and preclinical programs. Academic institutions may not operate under the same commercial standards as other third-party CROs that undertake such work and may not be able to devote adequate time and resources to preclinical studies. If CROs or academic institutions do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, ESSA&#8217;s preclinical or clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize future product candidates. As a result, ESSA&#8217;s results of operations and the commercial prospects for its future product candidates would be harmed, its costs could increase and its ability to generate revenues could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 0pt 0pt;">Because ESSA has relied on third parties, its internal capacity to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform to ESSA&#8217;s standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires ESSA to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. ESSA currently has a small number of employees, which limits the internal resources we have available to identify and monitor third-party providers. To the extent ESSA is unable to identify and successfully manage the performance of third-party service providers in the future, its business may be adversely affected. Though ESSA carefully manages its relationships with CROs and academic institutions, there can be no assurance that it will not encounter challenges or delays in the future or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">that these delays or challenges will not have a material adverse impact on ESSA&#8217;s business, results of operations, financial condition and cash flows and future prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">If ESSA&#8217;s relationships with CROs or academic institutions terminate, its drug development efforts could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA relies on entities outside of its control, including CROs and academic institutions, for preclinical studies and clinical trials related to its drug development efforts. Switching or adding additional CROs or academic institutions would involve additional cost and would require management time and focus. The CROs and academic institutions that ESSA relies on have the right to terminate their agreements with the Company in the event of an uncured material breach. If any of ESSA&#8217;s relationships with CROs and academic institutions terminate, the Company could experience a significant delay in identifying, qualifying and managing performance of a comparable third-party service provider, which could adversely affect its development programs. In addition, there is a natural transition period when a new CRO or academic institution commences work and the new CRO or academic institution may not provide the same type or level of services as the original provider. ESSA may not be able to enter into arrangements with alternative CROs or academic institutions or be able to do so on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA has limited experience manufacturing product candidates on a large clinical or commercial scale and has no manufacturing facility. As a result, ESSA may in the future be dependent on third party manufacturers for the manufacture of product candidates as well as on third parties for ESSA&#8217;s supply chain, and if ESSA experiences problems with any future third parties, the manufacturing of ESSA&#8217;s product candidates or products could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA does not own or operate facilities for the manufacture of future potential product candidates. ESSA currently has no plans to build internal clinical or commercial scale manufacturing capabilities. As a result, ESSA potentially may rely on third-party contract manufacturing organizations, in the future, for the manufacture of active pharmaceutical ingredients for ESSA&#8217;s potential products. Also, ESSA may potentially rely on another contract manufacturing organization for the production of the final product formulation. To meet ESSA&#8217;s projected potential needs for clinical supplies to support its activities through regulatory approval and commercial manufacturing, the contract manufacturing organizations with whom ESSA may potentially work will need to increase the scale of production. ESSA may need to identify additional contract manufacturing organizations for continued production of supply for product candidates in the event the current potential contract manufacturing organizations ESSA chooses to utilize are unable to scale production, or if ESSA otherwise experiences any problems with them. Although alternative third-party suppliers with the necessary manufacturing and regulatory expertise and facilities exist, it could be expensive and take a significant amount of time to arrange for alternative suppliers. ESSA may encounter technical difficulties or delays in the transfer of any future potential product manufacturing on a commercial scale to additional third-party manufacturers. ESSA may be unable to enter into agreements for commercial supply with third-party manufacturers, or may be unable to do so on acceptable terms. If ESSA is unable to arrange for alternative third-party manufacturing sources or to do so on commercially reasonable terms or in a timely manner, ESSA may not be able to complete development of its potential product candidates, market or distribute them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 0pt 0pt;">Reliance on third-party manufacturers entails risks to which ESSA would not be subject if ESSA manufactured product candidates or products ourselves, including reliance on the third party for regulatory compliance and quality assurance, the possibility of breach of the manufacturing agreement by the third party because of factors beyond ESSA&#8217;s control, including a failure to synthesize and manufacture product candidates or any products ESSA may eventually commercialize in accordance with ESSA&#8217;s specifications and the possibility of termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or damaging to ESSA. In addition, the FDA and other regulatory authorities require that ESSA&#8217;s product candidates and any products that ESSA may eventually commercialize be manufactured according to cGMP and similar foreign standards. Any failure by ESSA&#8217;s third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of ESSA&#8217;s potential product candidates and could cause ESSA to incur higher costs and prevent ESSA from commercializing product candidates successfully. In addition, such failure could be the basis for the FDA to issue a warning letter, withdraw approvals for product candidates previously granted to ESSA, or take other regulatory or legal action, including recall or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">seizure of outside supplies of the product candidate, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention or product, refusal to permit the import or export of products, injunction, or imposing civil and criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Any significant disruption in ESSA&#8217;s supplier relationships could harm the Company&#8217;s business. Any significant delay in the supply of a product candidate or its key materials for a potential ongoing clinical study could considerably delay completion of ESSA&#8217;s potential clinical trials, product testing and regulatory approval of ESSA&#8217;s potential product candidates. If ESSA&#8217;s manufacturers or ESSA is unable to purchase these key materials after regulatory approval has been obtained for ESSA&#8217;s product candidates, the commercial launch of ESSA&#8217;s product candidates would be delayed or there would be a shortage in supply, which would impair ESSA&#8217;s ability to generate revenues from the sale of its product candidates. It may take several years to establish an alternative source of supply for ESSA&#8217;s product candidates and to have any such new source approved by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">Failure to obtain regulatory approval in international jurisdictions would prevent any product candidates from being marketed outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In order to market and sell ESSA&#8217;s products in the European Union and many other jurisdictions, it must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside of the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for ESSA and could delay or prevent the introduction of its potential products in certain countries. ESSA may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. A failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. ESSA may not be able to file for marketing approvals and may not receive necessary approvals to commercialize its potential products in any market. If ESSA is unable to obtain approval of any of its future product candidates by regulatory authorities in the European Union or another jurisdiction, the commercial prospects of that product candidate may be significantly diminished and its business prospects could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">Recently enacted and future legislation in the United States may increase the difficulty and cost for the Company to obtain marketing approval of, and commercialize, its products and affect the prices the Company may obtain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In the United States, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval for ESSA&#8217;s products, restrict or regulate post-approval activities and affect the Company&#8217;s ability to profitably sell products. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. The Company does not know whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of ESSA&#8217;s products, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject the Company to more stringent product labeling and post-marketing testing and other requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In recent years, the U.S. Congress has considered reductions in Medicare reimbursement levels for drugs administered by physicians. CMS also has authority to revise Medicare reimbursement rates and to implement Medicare coverage restrictions for some drugs. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products, which in turn would affect the price ESSA can receive for those products, if approved. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">In March 2010, the Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) was signed into law. This law, which was intended to broaden access to health insurance, significantly impacted the pharmaceutical industry. Among other things, the ACA imposed an annual fee on manufacturers of branded prescription drugs, increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; expanded the healthcare fraud and abuse laws, implemented a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer discounts off negotiated prices; expanded the eligibility criteria for Medicaid programs; expanded the entities eligible for discounts under the Public Health Service Act pharmaceutical pricing program; and imposed a number of substantial new compliance provisions related to pharmaceutical companies&#8217; interactions with healthcare practitioners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. For example, the Tax Cuts and Jobs Act, signed into law by President Trump in 2017, effectively repealed the individual health insurance mandate, which is considered a key component of the ACA. In November 2020, the United States Supreme Court heard oral argument in a case regarding the constitutionality of the ACA and the individual mandate. The ongoing challenges to the ACA and new legislative proposals have resulted in uncertainty regarding the ACA&#8217;s future viability and destabilization of the health care market. These reforms could have an adverse effect on anticipated revenue from product candidates that ESSA may successfully develop and for which ESSA may obtain marketing approval and may affect ESSA&#8217;s overall financial condition and ability to develop or commercialize product candidates. For example, it is possible that efforts to repeal the ACA, if enacted into law, could ultimately result in fewer individuals having health insurance coverage or in individuals having insurance coverage with less generous benefits. The scope of potential future legislation to repeal and replace the ACA provisions is highly uncertain in many respects, as is the effect of such future legislation on ESSA&#8217;s business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. Beginning April 1, 2013, Medicare payments for all items and services, including drugs and biologics, were reduced by 2% under the sequestration (i.e., automatic spending reductions) required by the Budget Control Act of 2011. Although Medicare sequestration will remain in effect through 2027 unless additional Congressional action is taken, the Coronavirus Aid, Relief, and Economic Security (CARES) Act passed in March 2020 temporarily suspended Medicare sequestration from May 1, 2020 through December 31, 2020. Separately, in January 2013, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to certain providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. New laws may result in additional reductions in Medicare and other healthcare funding, which may materially adversely affect future customer demand and affordability for any future our products, if approved and, accordingly, the results of our financial operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Further, the FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. In response to the global COVID-19 pandemic, in March 2020 the FDA announced its intention to postpone most domestic and foreign inspections of manufacturing facilities, and regulatory authorities outside the United States adopted similar restrictions or other policy measures in response to the COVID-19 pandemic. Although the FDA resumed domestic on-site inspections in July 2021, inspections are being scheduled based upon each state&#8217;s phase of reopening and the current intensity and risk of COVID-19 infections in a geographic region, and foreign inspections have not resumed. This or other decreases in FDA inspection or regulatory activity could delay regulatory approval of our product candidates. Changes to the FDA&#8217;s policies and regulations may also impact our product candidates. For example, in December 2016, the 21st Century Cures Act (&#8220;Cures Act&#8221;) was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and biologics and spur innovation, but its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. In addition, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (&#8220;Right to Try Act&#8221;) was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. ESSA cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on its product candidates, if any, may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action in the United States. For example, there has been heightened governmental scrutiny recently over the manner in which pharmaceutical companies set and advertise prices for their marketed products, which have resulted in several Congressional inquiries and proposed federal legislation, as well as state efforts, designed to, among other things, bring more transparency to product pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. On July 24, 2020, President Trump announced four executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals, including eliminating protection under an Anti-Kickback Statute safe harbor for certain retrospective price reductions provided by drug manufacturers to sponsors of Medicare Part D plans or pharmacy benefit managers that are not applied at the point-of-sale; allowing the importation of certain drugs from other countries through individual waivers, permitting the re-importation of insulin products and prioritizing finalization of FDA&#8217;s December 2019 proposed rule to permit the importation of drugs from Canada; ensuring that payment by the Medicare program for certain Medicare Part B drugs is not higher than the payment by other comparable countries; and reducing the cost of insulin and epinephrine to patients of Federally Qualified Health Centers. While the scope and details of these executive orders are not clear, this continues to signal that the U.S. executive branch may pursue new measures to constrain drug costs and Medicare payments for drugs. The volume of drug pricing-related bills has dramatically increased under the recent Congresses and, among other recent proposals, Congress has proposed bills to change the Medicare Part D benefit to impose an inflation-based rebate in Medicare Part D and to alter the benefit structure to increase manufacturer contributions in the catastrophic phase. While the U.S. election cycle creates uncertainty about which, if any, measures will ultimately be enacted and their potential impacts, the U.S. Congress and executive branch may continue to seek new legislative and/or administrative measures to control drug costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">At the state level, individual states in the United States are increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries, such as Canada, as well as bulk purchasing. There has also been increased discussion at the federal level, including by the Trump Administration, of proposals intended to encourage re-importation. These and other potential reforms could have a significant impact on the pharmaceutical industry and on the development and potential future pricing of ESSA&#8217;s product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">ESSA&#8217;s business may be materially adversely affected by new legislation, new regulatory requirements and the continuing efforts of governmental and third-party payors to contain or reduce the costs of healthcare through various means.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Governments and regulatory authorities in Europe and other markets in which ESSA intends to sell its products may propose and adopt new legislation and regulatory requirements relating to pharmaceutical approval criteria and manufacturing requirements. Such legislation or regulatory requirements, or the failure to comply with such, could adversely impact ESSA&#8217;s operations and could have a material adverse effect on ESSA&#8217;s business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In recent years, national, federal, provincial, state, and local officials and legislators have proposed, or are reportedly considering proposing, a variety of price-based reforms to the healthcare systems in the European Union, the United States and other countries. Some proposals include measures that would limit or eliminate payments for certain medical procedures and treatments or subject the pricing of pharmaceuticals to government control. Furthermore, in certain foreign markets, the pricing or profitability of healthcare products is subject to government controls and other measures that have been prepared by legislators and government officials. While ESSA cannot predict whether any such legislative or regulatory proposals or reforms will be adopted, the adoption of any such proposals or reforms could adversely affect the commercial viability of the Company&#8217;s existing and potential products. Significant changes in the healthcare system in the European Union and other countries may have a substantial impact on the manner in which ESSA conducts its business. Such changes could also have a material adverse effect on ESSA&#8217;s business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:10pt 0pt 10pt 0pt;">Risks Related to ESSA&#8217;s Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA will have significant additional future capital needs for future clinical trials and there are uncertainties as to the Company&#8217;s ability to raise additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Management has forecasted that ESSA&#8217;s working capital will be sufficient to execute its planned expenditures for the coming fiscal year. On current plans, ESSA believes it has sufficient capital resources to continue and expand its business, including the development of its preclinical Aniten series of compounds (&#8220;Aniten&#8221;) through the conduct of the initial Phase I trial of its IND candidate EPI-7386, a subsequent initial expansion phase, and at least one initial Phase I combination trial of EPI-7386 with an anti-androgen. Advancing ESSA&#8217;s novel and proprietary therapies beyond these activities or acquisition and development of any new products or product candidates would require considerable resources and additional access to capital. In addition, ESSA&#8217;s future cash requirements may vary materially from those now expected. For example, ESSA&#8217;s future capital requirements may increase if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the Company experiences setbacks in its progress with non-clinical studies or if future clinical trials are delayed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the Company is required to perform additional non-clinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the Company elects to develop, acquire or license new technologies, products or businesses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the Company experiences competition from other life sciences companies or in more markets than anticipated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the Company experiences delays or unexpected increases in connection with obtaining regulatory approvals in the various markets where ESSA hopes to sell its products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the Company experiences unexpected or increased costs relating to preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, or other lawsuits, brought by either ESSA or ESSA&#8217;s competition; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the Company experiences scientific progress sooner than expected in its discovery and R&amp;D projects, if ESSA expands the magnitude and scope of these activities, or if ESSA changes its focus as a result of ESSA&#8217;s discoveries.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA could potentially seek additional funding through strategic collaborations, alliances and licensing arrangements, through public or private equity or debt financing, or through other transactions. However, if future sales are slow to increase or if capital market conditions in general, or with respect to life sciences companies such as ESSA&#8217;s, are unfavorable, ESSA&#8217;s ability to obtain significant additional funding on acceptable terms, if at all, will be negatively affected. There is no certainty that any such financing will be provided or provided on favorable terms.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If sufficient capital is not available, ESSA may be required to delay or abandon its business expansion or R&amp;D projects, either of which could have a material adverse effect on ESSA&#8217;s business, financial condition, prospects or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA may not be able to raise additional capital on favorable terms, which may result in dilution to ESSA&#8217;s existing shareholders, restrictions on ESSA&#8217;s operations or the requirement for ESSA to relinquish rights to technologies or any future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Until the Company can generate substantial revenue from product sales, if ever, the Company expects to finance future cash needs through a combination of private and public equity offerings, debt financings, strategic collaborations and alliances and licensing arrangements. Additional financing that the Company may pursue may involve the sale of its Common Shares or financial instruments that are exchangeable for, or convertible into, its Common Shares, which could result in significant dilution to ESSA&#8217;s shareholders and the terms may include liquidation or other preferences that adversely affect the rights of existing shareholders. Additional capital may not be available on reasonable terms, if at all. Furthermore, these securities may have rights senior to those of ESSA&#8217;s Common Shares and could contain covenants that include restrictive covenants limiting ESSA&#8217;s ability to take important actions and potentially impair ESSA&#8217;s competitiveness, such as limitations on ESSA&#8217;s ability to incur additional debt, make capital expenditures, acquire, sell or license intellectual property rights or declare dividends. If ESSA raises additional funds through strategic collaborations and alliances or licensing arrangements with third parties, ESSA may have to relinquish valuable rights to technologies or future product candidates, or grant licenses on terms that are not favorable to ESSA. If the Company is unable to raise additional funds when needed, the Company may be required to delay, limit, reduce or terminate its product development or commercialization efforts or grant rights to develop and market product candidates that ESSA would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company was subject to the restrictions and conditions of the CPRIT Agreement for a period of time after receipt of the last grant payment. Failure to have complied with the CPRIT Agreement may materially and adversely affect ESSA&#8217;s financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA relied on the CPRIT Grant to fund a portion of its preclinical and Phase 1 clinical development costs of clinical candidate EPI-506, which ceased development in September 2017. The total of the CPRIT Grant was US$12 million. The CPRIT Grant was subject to various requirements, including ESSA&#8217;s compliance with the scope of work outlined in the CPRIT Agreement. &#160;If ESSA was found not to have complied with the terms of the CPRIT Agreement, or found to have used any grant proceeds for purposes other than intended, or found to have failed to maintain the required level of operations in the State of Texas for three years following the final payment of grant funds, CPRIT could determine that ESSA was in default of its obligations under the CPRIT Agreement and could, among other things, seek reimbursement of all proceeds of the CPRIT Grant received by ESSA. ESSA received and responded to a request in October 2018 for information from CPRIT regarding the nature and extent of the Company&#8217;s operations in Texas. Although the Company believes it has at all times acted in compliance with the CPRIT Agreement and believes its response to CPRIT&#8217;s request for information was satisfactory, there can be no assurance that CPRIT will agree with ESSA&#8217;s determination. If ESSA is found to be in default under the CPRIT Agreement and such default is not waived by CPRIT, the Company could be required to reimburse a portion or all of the CPRIT Grant. Being required to reimburse a portion or all of the CPRIT Grant would impact ESSA&#8217;s ongoing operations, which could materially and adversely affect its financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">The Company has incurred significant losses in every quarter since its inception and anticipates that it will continue to incur significant losses in the future and may never generate profits from operations or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA is a clinical stage pharmaceutical company with a limited operating history. Investment in pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval or become commercially viable. ESSA does not have any products approved by regulatory authorities for marketing or commercial sale and has not generated any revenue from product sales, or otherwise, to date. Furthermore, ESSA continues to incur significant research, development and other expenses related to its ongoing operations. As a result, ESSA is not profitable and has incurred losses in every reporting period since inception in 2009. For the years ended September 30, 2021 and September 30, 2020, ESSA reported net losses of $36,805,461 and $23,445,370, respectively. As of September 30, 2021, ESSA had an accumulated deficit since inception of $117,775,765.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company expects to continue to incur significant expenses and operating losses for the foreseeable future. ESSA anticipates these losses will increase as it continues the research and development of, and seeks regulatory approvals for, its product candidate and any of its potential future product candidates and potentially begins to commercialize any products that may achieve regulatory approval. ESSA may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect its financial condition. The size of ESSA&#8217;s future net losses will depend, in part, on the rate of future growth of ESSA&#8217;s expenses and ESSA&#8217;s ability to generate revenues. The Company&#8217;s prior losses and expected future losses have had and will continue to have an adverse effect on the Company&#8217;s financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Even if the Company is able to commercialize any product candidate, there can be no assurance that the Company will generate significant revenues or ever achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company expects to continue to incur substantial losses for the foreseeable future, and these losses may be increasing. The Company is uncertain about when or if it will be able to achieve or sustain profitability. If the Company achieves profitability in the future, it may not be able to sustain profitability in subsequent periods. Failure to become and remain profitable would impair the Company&#8217;s ability to sustain operations and adversely affect the price of the Common Shares and its ability to raise capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA has a limited operating history, which may make it difficult for you to evaluate the success of ESSA&#8217;s business to date and to assess ESSA&#8217;s future viability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company&#8217;s operations in 2020 have been primarily limited to organizing and staffing ESSA, establishing relationships with consultants and contract vendors with relevant expertise, acquiring the in-licensing of intellectual property, discovering and developing novel small molecule product candidates, conducting preliminary preclinical research, preparing for the execution of a Phase I clinical study of its next-generation agent EPI-7386 and conducting a Phase I clinical study of its next-generation agent EPI-7386. ESSA is a development stage company with limited operating history and no revenue. ESSA has identified a product candidate, EPI-7386, to advance through clinical development but does not have any products ready for commercialization. Consequently, evaluating ESSA&#8217;s performance, viability or future success will be more difficult than if ESSA had a longer operating history or approved products on the market.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Risks Related to ESSA&#8217;s Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA relies on proprietary technology, the protection of which can be unpredictable and costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company&#8217;s activities depend, in part, on its ability to (i) obtain and maintain patents, trade secret protection and operate without infringing the intellectual proprietary rights of third parties, (ii) successfully defend these patents (including patents owned by or licensed to the Company) against third-party challenges and (iii) successfully enforce these patents against third-party competitors. There is no assurance that the Company will be granted such patents or proprietary technology or that such granted patents or proprietary technology will not be circumvented through the adoption of a competitive, though non-infringing, process or product. The patent positions of pharmaceutical companies can be highly uncertain and involve complex legal, scientific and factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in interpretations of patent laws may diminish the value of the Company&#8217;s intellectual property. Accordingly, the Company cannot predict the breadth of claims that may be allowable or enforceable in its patents (including patents owned by or licensed to the Company). Failure to protect the Company&#8217;s existing and future intellectual property rights could seriously harm its business and prospects and may result in the loss of its ability to exclude others from using the Company&#8217;s technology or its own right to use the technologies. If the Company does not adequately ensure the right to use certain technologies, it may have to pay others for the right to use their intellectual property, pay damages for infringement or misappropriation or be enjoined from using such intellectual property. The Company&#8217;s patents do not guarantee the right to use the technologies if other parties own intellectual property rights that are necessary in order to use such technologies. The Company&#8217;s patent position is subject to complex factual and legal issues that may give rise to uncertainty as to the validity, scope and enforceability of a particular patent. The Company&#8217;s and the Company&#8217;s licensors&#8217; patents and patent applications, if issued, may be challenged, invalidated or circumvented by third parties. U.S. patents and patent applications may also be subject to interference proceedings, re-examination proceedings, derivation proceedings, post-grant review or inter partes review in the United States Patent and Trademark Office (&#8220;USPTO&#8221;), challenging the Company&#8217;s or the Company&#8217;s licensors&#8217; patent rights. Foreign patents may be subject also to opposition or comparable proceedings in the corresponding foreign patent office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In addition, there is a risk that improved versions of ESSA&#8217;s own product developed by third parties will be granted patent protection and compete with ESSA&#8217;s products. For example, any patents ESSA obtains may not be sufficiently broad to prevent others from utilizing its technologies or from developing competing products and technologies. Third parties may attempt to circumvent ESSA&#8217;s patents by means of alternative designs and processes or may independently develop similar products, duplicate any of ESSA&#8217;s products not under patent protection, or design around the inventions ESSA claims in any of its existing patents, existing patent applications or future patents or patent applications. The actual protection afforded by a patent varies on a product-by-product basis, from country to country and depends upon many factors, including the type of patent, the scope of ESSA&#8217;s coverage, the availability of regulatory related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patents. It is impossible to anticipate the breadth or degree of protection that patents will afford products developed by ESSA or their underlying technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In any case, there can be no assurance that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">any rights under U.S., Canadian, or foreign patents owned by the Company or other patents that third parties license to the Company will not be curtailed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the Company was the first inventor of inventions covered by its issued patents or pending applications or that the Company was the first to file patent applications for such inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the Company&#8217;s pending or future patent applications will be issued with the breadth of claim coverage sought by the Company, or be issued at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the Company&#8217;s competitors will not independently develop or patent technologies that are substantially equivalent or superior to the Company&#8217;s technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">third parties will not attempt to circumvent ESSA&#8217;s patents by means of alternative designs and processes or that third parties will not also independently develop similar products, duplicate any of ESSA&#8217;s products not under patent protection, or design around the inventions ESSA claims in any of the Company&#8217;s existing patents, existing patent applications or future patents or patent applications;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">any of the Company&#8217;s trade secrets will not be learned independently by its competitors; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the steps the Company takes to protect its intellectual property will be adequate.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In addition, effective patent, trademark, copyright and trade secret protection may be unavailable, limited or not sought in certain foreign countries. Further, countries ESSA may sell to may not protect its intellectual property to the same extent as the laws of the United States, Canada or Europe, and may lack rules and procedures required for defending ESSA&#8217;s patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">There is a risk that any patents issued relating to ESSA&#8217;s products or any patents licensed to ESSA may be successfully challenged or that the practice of its products might infringe the patents of third parties. If the practice of ESSA&#8217;s products infringes the patents of third parties, the Company may be required to design around such patents, potentially causing increased costs and delays in product development and introduction or precluding ESSA from developing, manufacturing or selling its planned products. In addition, disputes may arise as to the rights to know-how and inventions among ESSA&#8217;s employees and consultants who use intellectual property owned by others for the work performed for the Company. The scope and validity of patents which may be obtained by third parties, the extent to which ESSA may wish or need to obtain patent licenses and the cost and availability of such licenses are currently unknown. If such licenses are obtained, it is likely they would be royalty bearing, which could reduce ESSA&#8217;s income. If licenses cannot be obtained on an economical basis, delays in market introduction of its planned products could occur or introduction could be prevented, in some cases causing the expenditure of substantial funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In certain instances, ESSA may elect not to seek patent protection but instead rely on the protection of the Company&#8217;s technology through confidentiality agreements or trade secrets. There can be no assurance that these agreements will not be breached, that the Company will have adequate remedies for any breach or that such persons or institutions will not assert rights to intellectual property arising out of these relationships. The value of ESSA&#8217;s assets could also be reduced to the extent that third parties are able to obtain patent protection with respect to aspects of ESSA&#8217;s technology or products or that confidential measures ESSA has in place to protect the Company&#8217;s proprietary technology are breached or become unenforceable. However, third parties may independently develop or obtain similar technology and such third parties may be able to market competing products and obtain regulatory approval through a showing of equivalency to one of ESSA&#8217;s products which has obtained regulatory approval, without being required to undertake the same lengthy and expensive clinical studies that ESSA would have already completed. The cost of enforcing the Company&#8217;s patent rights or defending rights against infringement charges by other patent holders may be significant and could limit operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Litigation may also be necessary to enforce patents issued or licensed to ESSA or to determine the scope and validity of a third party&#8217;s proprietary rights. ESSA could incur substantial costs if the Company is required to defend itself in patent suits brought by third parties, if ESSA participates in patent suits brought against or initiated by ESSA&#8217;s corporate collaborators or if ESSA initiates such suits. The Company may not have the necessary resources to participate in or defend any such activities or litigation. Even if ESSA did have the resources to vigorously pursue its interests in litigation, because of the complexity of the subject matter, it is impossible to predict whether ESSA would prevail in any such action. Any claims of patent infringement asserted by third parties may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">divert the time and attention of the Company&#8217;s technical personnel and management;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">cause product development or commercialization delays;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">require the Company to cease or modify its use of the technology and/or develop non-infringing technology; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">require the Company to enter into royalty or licensing agreements.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">An adverse outcome in litigation, or interference or derivation proceeding to determine priority or other proceeding in a court or patent or selling office could subject ESSA to significant liabilities, require disputed rights to be licensed from third parties or require ESSA to cease using certain technology or products, any of which may have a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">ESSA may not be able to protect its intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Filing, prosecuting and defending patents on ESSA&#8217;s product candidate and potential future product candidates throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States or federal and provincial laws in Canada. Consequently, ESSA may not be able to prevent third parties from practicing its inventions in all countries outside the United States or Canada, or from selling or importing products made using its inventions in and into the United States, Canada or other jurisdictions. Competitors may use ESSA&#8217;s technologies in jurisdictions where it has not obtained patent protection to develop their own products and may export otherwise infringing products to territories where ESSA has patent protection, but where enforcement is not as strong as that in the United States or Canada. These products may compete with ESSA&#8217;s products in jurisdictions where it does not have any issued patents and its patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for ESSA to stop the infringement of its patents or marketing of competing products in violation of its proprietary rights generally. Proceedings to enforce ESSA&#8217;s patent rights in foreign jurisdictions could result in substantial cost and divert its efforts and attention from other aspects of its business. ESSA may not prevail in any lawsuits that it initiates and the damages or other remedies awarded, if any, may not be commercially meaningful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The requirements for patentability may differ in certain countries, particularly developing countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. In India, unlike the United States, there is no link between regulatory approval of a drug and its patent status. Furthermore, generic or biosimilar drug manufacturers or other competitors may challenge the scope, validity or enforceability of ESSA&#8217;s patents, requiring it to engage in complex, lengthy and costly litigation or other proceedings. Generic or biosimilar drug manufacturers may develop, seek approval for, and launch biosimilar versions of ESSA&#8217;s products. In addition to India, certain countries in Europe and developing countries, including China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, ESSA may have limited remedies if patents are infringed or if it is compelled to grant a license to a third-party, which could materially diminish the value of those patents. This could limit ESSA&#8217;s potential revenue opportunities. Accordingly, ESSA&#8217;s efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that it owns or licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA may be subject to claims by third parties asserting that ESSA, or ESSA&#8217;s employees or consultants have misappropriated their intellectual property, or claiming ownership of what ESSA regards as its own intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Certain of ESSA&#8217;s current or former employees or consultants, including senior management, were previously employed, or continue to be employed, at universities or other public institutions, or at other biotechnology or pharmaceutical companies, including ESSA&#8217;s competitors or potential competitors. Some of these employees, executed proprietary rights, nondisclosure and noncompetition agreements, in connection with such previous employment. ESSA may be subject to claims that ESSA, or these employees, have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. If ESSA fails in prosecuting or defending any such claims, in addition to paying monetary damages, ESSA may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third-party, and ESSA could be required to obtain a license from such third-party to commercialize ESSA&#8217;s technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if ESSA is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">Obtaining and maintaining ESSA&#8217;s patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and its patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If ESSA or its future potential licensors fail to maintain the patents and patent applications covering product candidates, ESSA&#8217;s competitive position would be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:10pt 0pt 10pt 0pt;">Risks Related to ESSA&#8217;s Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">The Company&#8217;s business and operations would suffer in the event of computer system failures or security breaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In the ordinary course of ESSA&#8217;s business, the Company collects, stores and transmits confidential information, including intellectual property, proprietary business information and personal information. Despite the implementation of security measures, ESSA&#8217;s internal computer systems, and those of other third parties on which the Company relies, are vulnerable to damage from computer viruses, unauthorized access, cyberattacks, natural disasters, fire, terrorism, war and telecommunication and electrical failures. Cyberattacks are increasing in their frequency, sophistication and intensity. Cyberattacks could include the deployment of harmful malware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Significant disruptions of ESSA&#8217;s information technology systems or security breaches could adversely affect ESSA&#8217;s business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), and could result in financial, legal, business and reputational harm to the Company. If such disruptions were to occur and cause interruptions in ESSA&#8217;s operations, it could result in a material disruption of ESSA&#8217;s drug development program. For example, the loss of preclinical study or clinical trial data from completed, ongoing or planned preclinical studies or clinical trials could result in delays in ESSA&#8217;s efforts to identify and develop product candidates and significantly increase its costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of, or damage to, ESSA&#8217;s data or applications, or inappropriate disclosure of confidential or proprietary information, the Company could incur liability and the further development of EPI compounds or the Company&#8217;s product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">Business disruptions could seriously harm ESSA&#8217;s future revenues and financial condition and increase costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA&#8217;s operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which ESSA is predominantly self-insured. ESSA does not carry insurance for all categories of risk that ESSA&#8217;s business may encounter. The occurrence of any of these business disruptions could seriously harm ESSA&#8217;s operations and financial condition and increase costs and expenses. Further, any significant uninsured liability may require ESSA to pay substantial amounts, which would adversely affect ESSA&#8217;s business, results of operations, financial condition and cash flows from future prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">ESSA&#8217;s business depends heavily on the use of information technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Several key areas of ESSA&#8217;s business depend on the use of information technologies. Despite ESSA&#8217;s best efforts to prevent such behavior, third parties may nonetheless attempt to hack into ESSA&#8217;s systems and obtain data relating to ESSA&#8217;s preclinical studies or proprietary information on potential products. If ESSA fails to maintain or protect ESSA&#8217;s information systems and data integrity effectively, ESSA could lose or have difficulty attracting customers, have difficulty preventing, detecting and controlling fraud, have regulatory sanctions or penalties imposed, experience increases in operating expenses, incur expenses or lose revenues, or suffer other adverse consequences as a result of a data privacy breach. While ESSA has invested in the protection of data and information technology, there can be no assurance that ESSA&#8217;s efforts, or those of ESSA&#8217;s third-party collaborators, if any, to implement adequate security and quality control measures for data processing would be sufficient to protect against data deterioration or loss in the event of a system malfunction, or to prevent data from being stolen or corrupted in the event of a security breach. Any such loss or breach could have a material adverse effect on ESSA&#8217;s business, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">If the Company is not successful in attracting and retaining highly qualified personnel, the Company may not be able to successfully implement its business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company&#8217;s ability to compete in the highly competitive pharmaceuticals industry depends in large part upon its ability to attract and retain highly qualified managerial, scientific and medical personnel. Competition affects the Company&#8217;s ability to hire and retain highly qualified personnel on acceptable terms. The Company is highly dependent on its management, scientific and medical personnel. The Company&#8217;s management team has substantial knowledge in many different aspects of drug development and commercialization. Despite the Company&#8217;s efforts to retain valuable employees, members of its management, scientific and medical teams may terminate their employment with the Company on short notice or, potentially, without any notice at all. The loss of the services of any of the Company&#8217;s executive officers or other key employees could potentially harm its business, operating results or financial condition. The Company&#8217;s success may also depend on its ability to attract, retain and motivate highly skilled junior, mid-level, and senior managers and scientific personnel. Other pharmaceutical companies with which the Company competes for qualified personnel have greater financial and other resources, different risk profiles, and a longer history in the industry than the Company does. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what the Company has to offer. If the Company is unable to continue to attract and retain high-quality personnel, the rate and success at which the Company can develop and commercialize product candidates would be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">Third-party coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain the Company&#8217;s future revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In many of the markets ESSA hopes to sell future products in, successful commercialization of any product candidate will depend, in part, on the extent to which coverage and reimbursement for such product candidates and related treatments will be available from government healthcare programs, private health insurers, managed care plans and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, no uniform policy for coverage and reimbursement for products exists among third -party payors in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require ESSA to provide scientific and clinical support for the use of ESSA&#8217;s products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">A primary trend in the U.S. healthcare industry is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. ESSA cannot be sure that coverage and reimbursement will be available for any product candidates that it or any future collaborator commercialize and, if reimbursement is available, the level of reimbursement. In addition, coverage and reimbursement may impact the demand for, or the price of, any product candidate for which ESSA or a collaborator obtains marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, ESSA or its collaborators may not be able to successfully commercialize any product candidate for which marketing approval is obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the TPD, FDA or other regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers ESSA&#8217;s costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also be insufficient to cover ESSA&#8217;s and any collaborator&#8217;s costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. ESSA&#8217;s or any collaborator&#8217;s inability to promptly obtain coverage and profitable payment rates from both government-funded and private payers for any approved products that ESSA or its collaborators develop could have a material adverse effect on ESSA&#8217;s operating results, ability to raise capital needed to commercialize product candidates and overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">The directors and officers of ESSA may be subject to conflicts of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Some of the directors and officers are engaged and will continue to be engaged in the search for additional business opportunities on behalf of other corporations and situations may arise where these directors and officers will be in direct competition with the Company. Not all of the Company&#8217;s directors or officers are subject to non-competition agreements. Some of the directors and officers of the Company are or may become directors or officers of the other companies engaged in other business ventures whose operations may, from time to time, be in direct competition with ESSA&#8217;s operations. Conflicts, if any, will be dealt with in accordance with the relevant provisions of the Business Corporations Act (British Columbia) and under the Company&#8217;s articles of incorporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">The Company faces intense competition from other biotechnology and pharmaceutical companies and its operating results will suffer if the Company fails to compete effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. The Company&#8217;s potential competitors in the United States and globally include large, well-established pharmaceutical companies, specialty pharmaceutical sales and marketing companies and specialized cancer treatment companies. Many companies, as well as research organizations, currently engage in, or have in the past engaged in, efforts related to the development of products in the same therapeutic areas as ESSA does. Due to the size of the prostate cancer treatment market and the large unmet medical need for products that treat CRPC, a number of the world&#8217;s largest pharmaceutical companies are developing, or could potentially develop, products that could compete with the Company&#8217;s future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 0pt 0pt;">Many of the companies developing competing technologies and products in ESSA&#8217;s field have significantly greater financial resources and expertise in discovery, R&amp;D, manufacturing, preclinical studies and clinical testing, obtaining regulatory approvals and marketing than ESSA does. Other smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Academic institutions, government agencies and other public and private research organizations may also conduct research, seek patent protection and establish collaborative arrangements for discovery, research, clinical development and marketing of products similar to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">ESSA&#8217;s. There is a risk that one or more of ESSA&#8217;s competitors may develop more effective or more affordable products and that such competitors will commercialize products that will render its product candidates obsolete. ESSA faces competition with respect to product efficacy and safety, ease of use and adaptability to various modes of administration, acceptance by physicians, the timing and scope of regulatory approvals, availability of resources, reimbursement coverage, price and patent positions of others. In addition, these companies and institutions also compete with ESSA in recruiting and retaining qualified personnel, and in seeking and entering into new strategic partnerships. If the Company is not able to compete effectively against its current and future competitors, its business will not grow and its financial condition and operations will suffer materially adverse effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">The Company may face exposure to adverse movements in foreign currency exchange rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA&#8217;s business may expand internationally and as a result, a significant portion of its revenues, expenses, current assets and current liabilities may be preliminary denominated in foreign currencies, while its financial statements are expressed in U.S. dollars. A decrease in the value of such foreign currencies relative to the U.S. dollar could result in losses in revenues from currency exchange rate fluctuations. To date, ESSA has not hedged against risks associated with foreign exchange rate exposure. ESSA cannot be sure that any hedging techniques it may implement in the future will be successful or that its business, financial condition, and results of operations will not be materially adversely affected by exchange rate fluctuations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">If ESSA is not able to convince public payors and hospitals to include ESSA&#8217;s products on their approved formulary lists, revenues may not meet expectations and ESSA&#8217;s business, results of operations and financial condition may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Hospitals establish formularies, which are lists of drugs approved for use in the hospital. If a drug is not included on the hospital&#8217;s formulary, the ability to promote and sell ESSA&#8217;s products may be limited or denied. If ESSA fails to secure and maintain formulary inclusion for products on favorable terms or are significantly delayed in doing so, ESSA may have difficulty achieving market acceptance of products and ESSA&#8217;s business, results of operations and financial condition could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">The Company has never marketed a drug before, and if the Company is unable to establish an effective sales force and marketing infrastructure, or enter into acceptable third-party sales and marketing or licensing arrangements, the Company may be unable to generate any revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA does not currently have an infrastructure for the sales, marketing and distribution of pharmaceutical drug products and the cost of establishing and maintaining such an infrastructure may exceed the cost-effectiveness of doing so. In order to market any products that may be approved by the FDA and comparable foreign regulatory authorities, ESSA must build its sales, marketing, managerial and other nontechnical capabilities or make arrangements with third parties to perform these services. If ESSA is unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, ESSA may not be able to generate product revenue and may not become profitable. ESSA will be competing with many companies that currently have extensive and well-funded sales and marketing operations. Without an internal commercial organization or the support of a third party to perform sales and marketing functions, ESSA may be unable to compete successfully against these more established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">In order to establish the Company&#8217;s sales and marketing infrastructure, the Company will need to expand the size of its organization and the Company may experience difficulties in managing this growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">As the Company&#8217;s development and commercialization plans and strategies develop, the Company expects that it will need to expand the size of its employee base for managerial, operational, sales, marketing, financial and other resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 0pt 0pt;">Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. In addition, the Company&#8217;s management may have to divert </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">a disproportionate amount of its attention away from the Company&#8217;s day-to-day activities and devote a substantial amount of time to managing these growth activities. The Company&#8217;s future financial performance and its ability to commercialize its potential products and any other future product candidates and its ability to compete effectively will depend, in part, on the Company&#8217;s ability to effectively manage any future growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA&#8217;s product candidate and potential future products may, if approved for sale, not achieve or maintain expected levels of market acceptance, which could have a material adverse effect on its business, financial condition and results of operations and could cause the market value of its securities to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Even if ESSA is able to obtain regulatory approvals for its product candidates, the success of those products is dependent upon achieving and maintaining market acceptance. New product candidates that appear promising in development may fail to reach the market or may have only limited or no commercial success. Levels of market acceptance for ESSA&#8217;s products could be impacted by several factors, many of which are not within ESSA&#8217;s control, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">demonstration of clinical safety and efficacy of ESSA&#8217;s potential products and other possible AR-NTD inhibitors generally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">safety, efficacy, convenience and cost-effectiveness of ESSA&#8217;s products compared to products of its competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the prevalence and severity of any adverse side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">scope of approved uses and marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">limitations or warnings contained in FDA-approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">timing of market approvals and market entry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the willingness of physicians to prescribe ESSA&#8217;s potential products and of the target patient population to try new therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the inclusion of AR-NTD inhibitor products in applicable treatment guidelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">new procedures or methods of treatment that may reduce the incidences of any of the indications for which ESSA&#8217;s potential products shows utility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">difficulty in, or excessive costs to, manufacture;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">infringement or alleged infringement of the patents or intellectual property rights of others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the introduction of any new products, including generic AR-NTD inhibitor products, that may in the future become available to treat indications for which ESSA&#8217;s potential product may be approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">availability of alternative products from ESSA&#8217;s competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">acceptance of the price of ESSA&#8217;s products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ability to market ESSA&#8217;s products effectively at the retail level.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In addition, the success of any new product will depend on ESSA&#8217;s ability to either successfully build its in-house sales capabilities or to secure new, or to realize the benefits of existing arrangements with third-party marketing or distribution partners. Seeking out, evaluating and negotiating marketing or distribution agreements may involve the commitment of substantial time and effort and may not ultimately result in an agreement. In addition, the third-party marketing or distribution partners may not be as successful in promoting ESSA&#8217;s products as it had anticipated. If ESSA is unable to commercialize new products successfully, whether through a failure to achieve market acceptance, a failure to build its own in-house sales capabilities, a failure to secure new marketing partners or to realize the benefits of ESSA&#8217;s arrangements with existing marketing partners, there may be a material adverse effect on ESSA&#8217;s business, financial condition and results of operations and it could cause the market value of ESSA&#8217;s securities to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In addition, by the time any products are ready to be commercialized, what ESSA believes to be the market for these products may have changed. The Company&#8217;s estimates of the number of patients who have received or might have been candidates to use a specific product may not accurately reflect the true market or market prices for such products or the extent to which such products, if successfully developed, will actually be used by patients. If ESSA&#8217;s projections are inaccurate, the market opportunities for any of its product candidates could be significantly diminished. ESSA&#8217;s failure to successfully introduce and market its products that are under development would have a material adverse effect on its business, financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">The Company may acquire businesses or products or form strategic alliances in the future and the Company may not realize the benefits of such acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that the Company believes will complement or augment its existing business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">If the Company acquires businesses in the future, it may not be able to realize the benefit of acquiring such businesses if the Company is unable to successfully integrate them with its existing operations and company culture. The Company may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent the Company from realizing their expected benefits. The potential failure of the due diligence processes to identify significant problems, liabilities or other shortcomings or challenges with respect to intellectual property, product quality, revenue recognition or other accounting practices, taxes, corporate governance and internal controls, regulatory compliance, employee, customer or partner disputes or issues and other legal and financial contingencies could decrease or eliminate the anticipated benefits and synergies of any acquisition and could negatively affect ESSA&#8217;s future business and financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">As part of ESSA&#8217;s business strategy, it may also continue to acquire additional companies, products or technologies principally related to, or complementary to, ESSA&#8217;s current operations. Any such acquisitions will be accompanied by certain risks including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">exposure to unknown liabilities of acquired companies and the unknown issues with any associated technologies or research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">higher than anticipated acquisition costs and expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the difficulty and expense of integrating operations, systems and personnel of acquired companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">disruption of ESSA&#8217;s ongoing business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">inability to retain key customers, distributors, vendors and other business partners of the acquired company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">diversion of management&#8217;s time and attention; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">possible dilution to shareholders.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Also, the anticipated benefit of any joint venture or acquisition may not materialize or such strategic alliance, joint venture or acquisition may be prohibited. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of ESSA&#8217;s equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm ESSA&#8217;s financial condition. ESSA cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on its operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA may not be able to successfully overcome these risks and other problems associated with acquisitions and this may adversely affect ESSA&#8217;s business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA may seek to enter into collaborations with third parties for the development and commercialization of its product candidate and potential future product candidates. If ESSA fails to enter into such collaborations, or such collaborations are not successful, it may not be able to capitalize on the market potential of its product candidate and potential future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company may seek third-party collaborators for development and commercialization of its product candidate and potential future product candidates. ESSA is not currently party to any such arrangement. However, if ESSA does enter into any such arrangements with any third parties in the future, it will likely have limited control over the amount and timing of resources that its collaborators dedicate to the development or commercialization of ESSA&#8217;s product candidates. The Company&#8217;s ability to generate revenues from these arrangements will depend on its collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Collaborations involving ESSA&#8217;s product candidates would pose the following risks:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">collaborators may not pursue development and commercialization of ESSA&#8217;s product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with ESSA&#8217;s products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ESSA&#8217;s;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">collaborators with marketing and distribution rights to one or more of ESSA&#8217;s products may not commit sufficient resources to the marketing and distribution of such product or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">collaborators may not properly maintain or defend ESSA&#8217;s intellectual property rights or may use ESSA&#8217;s proprietary information in such a way as to invite litigation that could jeopardize or invalidate ESSA&#8217;s intellectual property or proprietary information or expose ESSA to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">collaborators may infringe the intellectual property rights of third parties, which may expose ESSA to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">disputes may arise between the collaborators and ESSA that result in the delay or termination of the research, development or commercialization of ESSA&#8217;s products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a collaborator of ESSA&#8217;s were to be involved in a business combination, the continued pursuit and emphasis on ESSA&#8217;s product development or commercialization program could be delayed, diminished or terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA&#8217;s employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for ESSA and harm ESSA&#8217;s reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA is exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards ESSA has established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to ESSA. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to ESSA&#8217;s reputation. If any such actions are instituted against ESSA and ESSA is not successful in defending itself or asserting ESSA&#8217;s rights, those actions could have a significant impact on ESSA&#8217;s business, results of operations, financial condition and cash flows from future prospects, including the imposition of significant fines or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">If product liability lawsuits are brought against the Company, it may incur substantial liabilities and may be required to cease the sale, marketing and distribution of its product candidate and potential future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 0pt 0pt;">The Company could face a potential risk of product liability as a result of its potential sales, marketing and distribution activities relating to any future commercialization of any future product. For example, the Company may be sued if any product it develops allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under U.S. state or Canadian provincial or other foreign consumer protection legislation. If the Company cannot successfully defend itself against product liability claims, it may incur substantial liabilities or be required to cease the sale, marketing and distribution of its products. Even successful defense against product liability claims would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">decreased demand for any future products that the Company may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">injury to the Company&#8217;s reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">a diversion of management&#8217;s time and the Company&#8217;s resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">substantial monetary awards to consumers, trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the inability to commercialize;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the inability to continue the sale, marketing and distribution of ESSA&#8217;s product candidate and potential future products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">a decline in the price of the Common Shares or other outstanding securities.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company currently maintains insurance that it believes has sufficient coverage to protect against the liability risks discussed above and the Company believes this coverage is consistent with industry norms for companies at a similar stage of development. However, if the Company is unable to obtain and retain sufficient product liability insurance in the future at an acceptable cost to protect against potential product liability claims, the commercialization of products it develops could be hindered or prevented.</p><a id="_Hlk84962185"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">Compulsory licensing or generic competition may affect the Company&#8217;s business in certain countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In a number of countries, governmental authorities and other groups have suggested that companies which manufacture medical products (e.g., pharmaceuticals) should make products available at a low cost. In some cases, governmental authorities have held that where a pharmaceutical company does not do so, its patents might not be enforceable to prevent generic competition. Alternatively, some governmental authorities could require that ESSA grant compulsory licenses to allow competitors to manufacture and sell their own versions of ESSA&#8217;s products, thereby reducing ESSA&#8217;s sales or the sales of ESSA&#8217;s licensee(s). In all of these situations, the results of future operations in these countries if any, could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA incurs significantly increased costs and devotes substantial management time as a result of operating as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">As a public company, ESSA incurs significant legal, accounting and other expenses. For example, ESSA is subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and may be required to comply with the applicable requirements of Sarbanes-Oxley and the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as rules and regulations subsequently implemented by the SEC and including the establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. ESSA&#8217;s continued compliance with these requirements increase its legal and financial compliance costs and make some activities more time consuming and costly. In addition, ESSA&#8217;s management and other personnel need to divert attention from operational and other business matters to devote substantial time to these public company requirements. In particular, ESSA may or in the future incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section 404 of Sarbanes-Oxley, which involves annual assessments of a company&#8217;s internal controls over financial reporting. ESSA may in the future need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and may need to establish an internal audit function. ESSA cannot always predict or estimate the amount of additional costs incurred as a result of being a public company or the timing of such costs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">Effective September 30, 2021, ESSA no longer qualifies as an &#8220;an emerging growth company&#8221; and the reduced disclosure requirements applicable to emerging growth companies no longer apply, which will increase the Company&#8217;s costs and demands on management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">As a result of ESSA&#8217;s public float (the market value of the Company&#8217;s Common Shares held by non-affiliates) as of March 31, 2021, ESSA becomes a large accelerated filer as of September 30, 2021 and therefore no longer qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">As an emerging growth company and a smaller reporting company, ESSA has had the option to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies, including, but not limited to, reduced disclosure obligations regarding executive compensation in the Company&#8217;s periodic reports and proxy statements and exemptions related to certain &#8220;Say-on-Pay&#8221; rules under Section 14A of the Exchange Act, including requirements to hold a nonbinding advisory vote on named executive officer compensation, the frequency of such votes and arrangements with named executive officers regarding compensation based on or related to an acquisition, merger, or similar transaction. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Further, as an emerging growth company, ESSA has not been subject to Section 404(b) of the Sarbanes Oxley Act (&#8220;Section 404&#8221;), which requires that the Company&#8217;s independent registered public accounting firm provide an attestation report of the Company&#8217;s internal controls over financial reporting. Preparing such attestation report and the cost of compliance with reporting requirements that ESSA has not previously implemented will increase ESSA&#8217;s expenses and require significant management time. Investors may find the Company&#8217;s Common Shares less attractive because of the additional compliance costs. In addition, even if the Company&#8217;s management concludes that the Company&#8217;s internal control over financial reporting is effective, ESSA&#8217;s independent registered public accounting firm may conclude that there are material weaknesses or significant deficiencies with respect to the Company&#8217;s internal controls or the level at which the Company&#8217;s internal controls are documented, designed, implemented or reviewed. Undetected material weaknesses in ESSA&#8217;s internal controls could lead to financial statement restatements and require the Company to incur the expense of remediation. Inferior internal controls could also cause investors to lose confidence in ESSA&#8217;s reported financial information, which could have a negative effect on the trading price of the Company&#8217;s Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:10pt 0pt 10pt 0pt;">Risks Related to Additional Legal Compliance and Regulatory Matters </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA is subject to risks inherent in foreign operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA intends to pursue international market growth opportunities, such that international sales may account for a significant portion of its revenue. ESSA is subject to a number of risks associated with its potential international business operations, sales and marketing activities that may increase liability, costs, lengthen sales cycles and require significant management attention. These risks include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">compliance with the laws of the United States, Canada, the European Union and other jurisdictions where ESSA may conduct business, including import and export legislation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">increased reliance on third parties to establish and maintain foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the complexities and expenses of administering a business abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">complications in compliance with, and unexpected changes in, foreign regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">instability in economic or political conditions, including inflation, recession and actual or anticipated military conflicts, social upheaval or political uncertainty;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">foreign currency fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">foreign exchange controls and cash repatriation restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">tariffs and other trade barriers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">difficulties in collecting accounts receivable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">differing tax structures and related potential adverse tax consequences;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">uncertainties of laws and enforcement relating to the protection of intellectual property or secured technology;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">litigation in foreign court systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">unauthorized copying or use of ESSA&#8217;s intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">cultural and language differences;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">difficulty in managing a geographically dispersed workforce in compliance with local laws and customs that vary from country to country; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">other factors, depending upon the country involved.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">There can be no assurance that the policies and procedures ESSA implements to address or mitigate these risks will be successful, that ESSA&#8217;s personnel will comply with them or that ESSA will not experience these factors in the future or that they will not have a material adverse effect on ESSA&#8217;s business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">Laws and regulations governing international operations may preclude ESSA from developing, manufacturing and selling certain product candidates outside of the United States and Canada and require ESSA to develop and implement costly compliance programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA must comply with numerous laws and regulations in each jurisdiction in which ESSA plans to operate. ESSA must also comply with U.S. laws applicable to the foreign operations of U.S. individuals, such as the FCPA, and Canadian laws applicable to the foreign operations of Canadian businesses and individuals, such as the CFPOA. The creation and implementation of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The CFPOA prohibits Canadian businesses and individuals from giving or offering to give a benefit of any kind to a foreign public official, or any other person for the benefit of the foreign public official, where the ultimate purpose is to obtain or retain a business advantage. Furthermore, a company may be found liable for violations by not only its employees, but also by its third-party agents. Any failure to comply with the CFPOA, as well as applicable laws and regulations in foreign jurisdictions, could result in substantial penalties or restrictions on ESSA&#8217;s ability to conduct business in certain foreign jurisdictions, which may have a material adverse impact on ESSA and its share price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring ESSA to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the books and records provisions of the FCPA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical studies and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of ESSA&#8217;s failure to satisfy any of its obligations under laws governing international business practices would have a negative impact on its operations and harm its reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">ESSA&#8217;s employees or other agents may, without the Company&#8217;s knowledge and despite the Company&#8217;s efforts, engage in prohibited conduct under its policies and procedures and the CFPOA, FCPA or other anti-bribery laws that ESSA may be subject to for which it may be held responsible. If ESSA&#8217;s employees or other agents are found to have engaged in such practices, it could suffer severe penalties and other consequences that may have a material adverse effect on its business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If ESSA expands its presence outside of the United States in the future, it will be required to dedicate additional resources to comply with these laws, and these laws may preclude ESSA from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit ESSA&#8217;s growth potential and increase development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA is subject to U.S. laws relating to fraud and abuse and patients&#8217; rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">As a pharmaceutical company, even though ESSA does not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to ESSA&#8217;s future arrangements with third-party payors and customers who are in a position to purchase, recommend and/or prescribe ESSA&#8217;s product candidates for which the Company obtains marketing approval. These broadly applicable fraud and abuse and other healthcare laws and regulations may constrain ESSA&#8217;s future business or financial arrangements and relationships with healthcare professionals, principal investigators, consultants, customers, and third-party payors and other entities, including ESSA&#8217;s marketing practices, educational programs and pricing policies. Restrictions under applicable federal and state healthcare laws and regulations that may affect ESSA&#8217;s ability to operate include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the U.S. Anti-Kickback Statute, among other things, prohibits persons from knowingly and willfully soliciting, offering, receiving or providing paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">civil and criminal false claims laws and civil monetary penalty laws impose criminal and civil penalties, including through civil whistleblower or qui tam actions, among other things, prohibits individuals or entities from knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent or from knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Efforts to ensure that ESSA&#8217;s business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that ESSA&#8217;s business practices do not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If ESSA&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations that may apply to ESSA, the Company may be subject to penalties, including without limitation, significant civil, criminal and administrative penalties, damages, fines, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings, and the curtailment or restructuring of ESSA&#8217;s operations. If any physicians or other healthcare providers or entities with whom ESSA expects to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Moreover, ESSA expects there will continue to be federal and state laws and regulations, proposed and implemented, that could impact ESSA&#8217;s operations and business. The extent to which future legislation or regulations, if any, relating to healthcare fraud abuse laws or enforcement, may be enacted or what effect such legislation or regulation would have on ESSA&#8217;s business remains uncertain.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">If ESSA fails to comply with environmental, health and safety laws and regulations, ESSA could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of ESSA&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA is subject to numerous environmental, health and safety laws and regulations in the United States and in Canada, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. ESSA&#8217;s operations could involve the use of hazardous and flammable materials, including chemicals and biological materials. ESSA&#8217;s operations could also produce hazardous waste products. The Company&#8217;s general practice would be to contract with third parties for the disposal of such materials and wastes. ESSA cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from ESSA&#8217;s use of hazardous materials, it could be held liable for any resulting damages, and any liability could exceed its resources. ESSA also could incur significant costs associated with civil or criminal fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Although ESSA maintains workers&#8217; compensation insurance to cover for costs and expenses ESSA may incur due to injuries to employees resulting from the use of any hazardous materials, this insurance may not provide adequate coverage against potential liabilities. ESSA does not maintain insurance for environmental liability or toxic tort claims that may be asserted against it in connection with its storage or disposal of biological or hazardous materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">In addition, ESSA may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair ESSA&#8217;s research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">The change from foreign private issuer to U.S. domestic issuer status may result in additional costs and expenses to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">As of March 31, 2020, we determined that we no longer qualify as a &#8220;foreign private issuer,&#8221; as such term is defined in Rule 405 under the U.S. Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). As a result, as of October 1, 2020, we are no longer eligible to use the rules and forms designated for foreign private issuers and we are considered a U.S. domestic issuer. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more than the costs incurred as a foreign private issuer. As a result, we are now required to file periodic and current reports and registration statements on U.S. domestic issuer forms with the SEC, which are generally more detailed and extensive than the forms available to a foreign private issuer. In addition, we are required to comply with U.S. proxy requirements and Regulation FD (Fair Disclosure) and our officers, directors and principal shareholders are subject to the beneficial ownership reporting and short-swing profit recovery requirements in Section 16 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). We are also no longer eligible to rely upon exemptions from corporate governance requirements that are available to foreign private issuers or to benefit from other accommodations for foreign private issuers under the rules of the SEC or Nasdaq, which may involve additional costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">ESSA is and there is a risk that ESSA may continue to be a &#8220;passive foreign investment company&#8221; which would likely result in materially adverse U.S. federal income tax consequences for U.S. investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA believes it was classified as a PFIC for the taxable year ending September 30, 2021, and believes it may be classified as a PFIC for the current taxable year and in future taxable years. However, the determination as to whether ESSA is a PFIC for any taxable year is based on the application of complex U.S. federal income tax rules that are subject to differing interpretations. If ESSA is a PFIC for any taxable year during which a U.S. Holder (as defined under &#8220;United States Federal Income Tax Considerations&#8221;) holds the Common Shares, it would likely result in adverse U.S. federal income tax consequences for such U.S. Holder. U.S. Holders should carefully read &#8220;United States Federal Income Tax Considerations&#8212;Passive Foreign Investment Company Rules&#8221; for more information and consult their own tax advisors regarding the consequences of ESSA being treated as a PFIC for U.S. federal income tax purposes, including the advisability of making a qualified electing fund (&#8220;QEF&#8221;) election (including a protective election), which may mitigate certain possible adverse U.S. federal income tax consequences but may result in an inclusion in gross income without receipt of such income.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">It may be difficult for United States investors to effect services of process or enforcement of actions against the Company or certain of its directors and officers under U.S. federal securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The Company is incorporated under the laws of the Province of British Columbia, Canada. Its directors and officers reside in Canada or the United States. Because a number of these persons and a substantial portion of the assets of the Company are located outside the United States, it will be difficult for United States investors to effect service of process in the United States upon the Company or the directors or officers of the Company, or to realize in the United States upon judgments of United States courts predicated upon civil liabilities under the Exchange Act or other United States laws. There is substantial doubt as to whether an original action could be brought successfully in Canada against any of such persons or the Company predicated solely upon such civil liabilities and whether a judgment of a United States court predicated solely upon such civil liabilities would be enforceable in Canada by a Canadian court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:10pt 0pt 10pt 0pt;">Risks Relating to ESSA&#8217;s Common Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">The market price and trading volume of ESSA&#8217;s Common Shares may be volatile, which could result in rapid and substantial losses for its shareholders or securities litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The market price of ESSA&#8217;s Common Shares may be highly volatile and could be subject to wide fluctuations. In addition, the trading volume in the Common Shares may fluctuate and cause significant price variations to occur as demonstrated by ESSA&#8217;s share price&#8217;s low on the Nasdaq was $5.40 and high was $36.00 during the fiscal year. The market price of the Common Shares may fluctuate or decline significantly in the future. Some of the factors that could negatively affect ESSA&#8217;s share price or result in fluctuations in the price or trading volume of the Common Shares include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">quarterly variations in operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">operating results that vary from the expectations of securities analysts and investors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">change in valuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">changes in ESSA&#8217;s operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">expenses ESSA incurs related to future research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">fluctuations in the demand for ESSA&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">changes in the industry in which ESSA operates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">announcements by ESSA or other companies of significant contracts, acquisitions, dispositions, strategic partnerships, joint ventures, capital commitments, plans, prospects, service offerings or operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">results of clinical studies of our product candidates, including our combination studies, or those of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">additions or departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">future sales of ESSA&#8217;s securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">trading of ESSA&#8217;s securities by a large shareholder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">other risk factors discussed herein; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">other unforeseen events.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Stock markets in the United States and Canada have experienced extreme price and volume fluctuations. Market fluctuations, as well as general political and economic conditions such as acts of terrorism, prolonged economic uncertainty, a recession or interest rate or currency rate fluctuations, could adversely affect the market price of ESSA&#8217;s Common Shares resulting in substantial losses for shareholders. Also, in the past, companies that have experienced volatility in the market price of their common shares have been subject to securities litigation. ESSA may be the target of this type of litigation in the future. Securities litigation against ESSA could result in substantial costs and divert management&#8217;s attention from other business concerns, which could materially harm ESSA&#8217;s business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">The Company has never declared dividends and may not do so in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">ESSA has not declared or paid any cash dividends on Common Shares to date. The payment of dividends in the future will be dependent on ESSA&#8217;s earnings and financial condition and on such other factors as ESSA&#8217;s Board considers appropriate. Unless and until ESSA pays dividends, shareholders may not receive a return on their shares. There is no present intention by the Board to pay dividends on the Common Shares.</p><a id="_Hlk84962211"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">The Company may experience future sales or issue additional securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The market price of the Company&#8217;s equity securities could decline as a result of issuances of securities by the Company or sales by the Company&#8217;s existing shareholders of Common Shares in the market, or the perception that such sales could occur. Sales of Common Shares by shareholders might also make it more difficulty for the Company to sell equity securities at a time and price that the Company deems appropriate. Sales or issuances of substantial numbers of Common Shares, or the perception that such sales could occur, may adversely affect the prevailing market prices of the Common Shares. With any additional sale or issuance of Common Shares, investors will suffer dilution to their voting power and the Company may experience dilution in its earnings per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Additionally, as of September 30, 2021, there are 2,920,000 pre-funded warrants outstanding, which are exercisable into Common Shares at a nominal exercise price. If holders of these pre-funded warrants exercise these securities, existing shareholders will suffer dilution to their voting power and the Company may experience dilution in its earnings per share, as well as a negative impact on its share price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">An active trading market for the Common Shares may not be sustained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Although ESSA has listed the Common Shares on the Nasdaq, an active trading market for the Common Shares may not be sustained. If an active trading market for the Common Shares is not maintained, the liquidity of the Common Shares and the prices that may be obtained for the Common Shares will be adversely affected. As of September 30, 2021, ESSA&#8217;s public float, which is defined as Common Shares outstanding minus Common Shares held by officers, directors, or beneficial holders of greater than 10% of ESSA&#8217;s outstanding Common Shares, represented approximately 84.39% of ESSA&#8217;s outstanding Common Shares. In addition, the Company is aware of a number of significant shareholders, defined as a holding greater than 5%, who have participated in recent financings. The average number of shares traded in any given day over the past year has been relatively small compared to the public float. Thus, the actions of a few shareholders either buying or selling ESSA&#8217;s Common Shares may adversely affect the price of the Common Shares. Historically, securities similar to ESSA&#8217;s Common Shares have experienced extreme price and volume fluctuations that do not necessarily relate to operating performance and could result in rapid and substantial losses for shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:10pt 0pt 10pt 0pt;">General Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">If ESSA is unable to implement and maintain effective internal controls over financial reporting in the future, ESSA may not be able to report financial results accurately or prevent fraud. In that case, investors may lose confidence in the accuracy and completeness of ESSA&#8217;s financial reports and the market price of ESSA&#8217;s Common Shares may be negatively affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Maintaining effective internal control over financial reporting is necessary for ESSA to produce reliable financial reports and is important in helping to prevent financial fraud. If ESSA is unable to maintain adequate internal controls, ESSA&#8217;s business and operating results could be harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Pursuant to Section 404(a) of the Sarbanes-Oxley Act and the related rules of the SEC, ESSA&#8217;s management is required to, among other things, assess annually the effectiveness of its internal control over financial reporting and certify that it has established effective disclosure controls and procedures and internal controls over financial reporting for the period ended September 30, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Preparing ESSA&#8217;s consolidated financial statements involves a number of complex manual and automated processes which are dependent on individual data input or review and require significant management judgment. One or more of these elements may result in errors that may not be detected and could result in a material misstatement of ESSA&#8217;s consolidated financial statements. Management&#8217;s significant estimates and judgements with respect to financial reporting are discussed and disclosed in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The process of designing and implementing effective internal controls and procedures, and expanding ESSA&#8217;s internal accounting capabilities, is a continuous effort that requires ESSA to anticipate and react to changes in ESSA&#8217;s business and the economic and regulatory environments and expend significant resources to establish and maintain a system of internal controls that is adequate to satisfy ESSA&#8217;s reporting obligations as a public company. The standards that must be met for management to assess the internal control over financial reporting as effective are complex, and require significant documentation, testing and possible remediation to meet the detailed standards. ESSA cannot be certain at this time whether the Company will be able to successfully complete the continuing implementation of controls and procedures or the certification and attestation requirements of Section 404(a) of Sarbanes-Oxley on a continuous basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">If a material misstatement occurs in the future, ESSA may fail to meet its future reporting obligations, it may need to restate its financial results and the price of its Common Shares may decline. Any failure of ESSA&#8217;s internal controls could also adversely affect the results of the periodic management evaluations and any future annual independent registered public accounting firm attestation reports regarding the effectiveness of ESSA&#8217;s internal control over financial reporting that may be required when Section 404 of Sarbanes-Oxley becomes fully applicable to ESSA. Effective internal controls are necessary for ESSA to produce reliable financial reports and are important to helping prevent financial fraud. If ESSA cannot provide reliable financial reports or prevent fraud, ESSA&#8217;s business and results of operations could be harmed, investors could lose confidence in ESSA&#8217;s reported financial information, and the trading price of ESSA&#8217;s Common Shares could drop significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 0pt 0pt;">Provisions in ESSA&#39;s corporate charter documents and Canadian law could make an acquisition of the Company, which may be beneficial to ESSA&#39;s shareholders, more difficult and may prevent attempts by the shareholders to replace or remove ESSA&#39;s current management and/or limit the market price of the Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">Provisions in ESSA&#39;s articles, as well as certain provisions under the Business Corporations Act (British Columbia) may discourage, delay or prevent a merger, acquisition or other change in control of ESSA that shareholders may consider favorable, including transactions in which they might otherwise receive a premium for their Common Shares. These provisions could also limit the price that investors might be willing to pay in the future for ESSA&#8217;s Common Shares, thereby depressing the market price of ESSA&#8217;s Common Shares. In addition, because the Board is responsible for appointing the members of the Company&#39;s management team, these provisions may frustrate or prevent any attempts by ESSA&#39;s shareholders to replace or remove current management by making it more difficult for shareholders to replace members of the Board. Among other things, these provisions include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">shareholders cannot amend ESSA&#39;s articles unless such amendment is approved by shareholders holding at least two-thirds of the votes cast on the proposal;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the Board may, without shareholder approval, issue preferred shares having any terms, conditions, rights, preferences and privileges as the Board may determine; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">shareholders must give advance notice to nominate directors.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about ESSA&#8217;s business, its stock price and trading volume could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:10pt 0pt 10pt 0pt;">The trading market for ESSA&#8217;s Common Shares depends in part on the research and reports that securities or industry analysts publish about it, or its business. If one or more of the securities or industry analysts who cover ESSA downgrade its Common Shares or publish inaccurate or unfavorable research about its business, its stock price would likely decline. If one or more of these analysts cease coverage of ESSA or fail to publish reports on it regularly, demand for ESSA&#8217;s stock could decrease, which might cause its stock price and trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5dde3871_763f_492e_a63a_f56a6101a8ee"></a><a id="Item1B"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B.&#160;&#160;&#160;&#160;&#160;Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">None.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4dfd6379_327e_4d97_8fed_c831a7d09f60"></a><a id="Item2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:6pt 0pt 6pt 0pt;">Item&#160;2.&#160;&#160;&#160;&#160;&#160;Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;">Our headquarters are located in Vancouver, British Columbia, where we rent office space on a short-term lease. Our U.S. offices are located in Houston, Texas and South San Francisco, California. On April 23, 2021, we renewed a lease agreement for the Houston office effective August 1, 2021 through July 31, 2023 with an option to renew for an additional two years. In March 2018, we entered into a lease for the South San Francisco office that expired on March 31, 2021 and which we have extended to May 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;">We believe that our existing facilities are adequate for our immediate needs and can accommodate our anticipated growth. We believe that, should it be needed, additional space can be leased to accommodate any future growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_bf473024_69d9_4197_99a8_5775140f1f69"></a><a id="Item3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;&#160;&#160;&#160;Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. As of September 30, 2021, we are not a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_de62387a_604d_4065_907c_4d1eec0ce812"></a><a id="Item4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">Not applicable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="PARTII"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="_43c712d0_2a9c_4fa8_8770_c0270daebb90"></a><a id="Item5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5.&#160;&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our Common Shares began trading on the Nasdaq under the symbol &#8220;EPIX&#8221; on July&#160;9, 2015. Our Common Shares traded under the symbol &#8220;EPI&#8221; on the TSX from July&#160;28, 2015 until November&#160;24, 2017. On November&#160;27, 2017, we delisted our Common Shares from the TSX and began trading on the TSX-V under the same symbol, &#8220;EPI.&#8221; On October 30, 2020, we delisted our Common Shares from the TSX-V. The following table sets forth the high and low sales prices per Common Share as reported on the Nasdaq and TSX-V for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nasdaq</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TSX-V</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">High</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Low</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">High</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Low</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="9" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">C$</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quarter Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 30.26</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7.42</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 36.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23.30</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;31,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 32.69</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11.27</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12.49</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.40</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">September&#160;30,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.31</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7.48</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11.34</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7.52</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6.29</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.60</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.50</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.36</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.94</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.70</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7.60</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4.00</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6.14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.45</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4.04</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 18, 2021, the last reported sale price of our Common Shares on the Nasdaq was $13.03 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Holders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">As at November 18, 2021, we had 43,984,346 shareholders of record holding our Common Shares, of which 40,313,998 were U.S. shareholders. A substantially greater number of holders of ESSA&#8217;s Common Shares are &#8220;street name&#8221; or beneficial holders whose shares of record are held by banks, brokers, and other financial institutions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never paid any dividends on our Common Shares or any of our other securities. We currently intend to retain any future earnings to finance the growth and development of our business, and we do not anticipate that we will declare or pay any cash dividends in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our board of directors and will be dependent upon our financial condition, results of operations, capital requirements, restrictions under any future indebtedness and other factors the board of directors deems relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Canadian Federal Income Tax Considerations for United States Holders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following is a summary, as of today&#8217;s date, of the principal Canadian federal income tax considerations under the&#160;<i style="font-style:italic;">Income Tax Act</i>&#160;(Canada) (&#8220;Tax Act&#8221;) that generally apply to an investor who acquires Common Shares, who, for the purposes of the Tax Act and at all relevant times, deals at arm&#8217;s length, and is not affiliated with ESSA and who acquires and holds Common Shares, as capital property (a&#160;&#8220;Holder&#8221;). Generally, Common Shares will be considered to be capital property to a Holder provided that the Holder does not use Common Shares in the course of carrying on a business of trading or dealing in securities and such Holder has not acquired them or been deemed to have acquired them in one or more transactions considered to be an adventure or concern in the nature of trade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This summary is based upon the current provisions of the&#160;<i style="font-style:italic;">Canada-United States Income Tax Convention (1980)</i>&#160;(&#8220;Treaty&#8221;), the Tax Act and its regulations and the current published administrative policies and assessing practices of the Canada Revenue Agency (&#8220;CRA&#8221;). This summary takes into account all specific proposals to amend the Tax Act and its regulations publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (the&#160;&#8220;Tax Proposals&#8221;) and assumes that the Tax Proposals will be enacted in the form proposed, although no assurance can be given that the Tax Proposals will be enacted in their current form or at all. This summary does not otherwise take into account any changes in law or in the administrative policies or assessing practices of the CRA, whether by legislative, governmental or judicial decision or action, nor does it take into account or consider any provincial, territorial or foreign income tax considerations, which considerations may differ significantly from the Canadian federal income tax considerations discussed in this summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This summary only applies to Holders who (i)&#160;for the purposes of the Tax Act, have not and will not be resident in Canada at any time, (ii)&#160;do not use or hold the Common Shares in carrying on a business in Canada, and (iii)&#160;are resident in the United States for income tax purposes and entitled to benefits under the Treaty. Special rules, which are not discussed in this summary, may apply to such a Holder that is an insurer that carries on business in Canada and elsewhere.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This summary is of a general nature only, is not exhaustive of all possible Canadian federal income tax considerations and is not intended to be, nor should it be construed to be, legal or tax advice to any particular Holder. Holders should consult their own tax advisors with respect to their particular circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Currency</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of Common Shares must be expressed in Canadian dollars. Amounts denominated in any other currency must be converted into Canadian dollars using the rate of exchange quoted by the Bank of Canada on the day the amount first arose, or such other rate of exchange as is acceptable to the CRA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Dividends</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividends paid or credited or deemed to be paid or credited to a Holder by ESSA are subject to Canadian withholding tax at the rate of 25% on the gross amount of the dividend unless such rate is reduced by the terms of the Treaty. The rate of withholding tax on dividends paid or credited to a Holder who is resident in the U.S. for purposes of the Treaty, entitled to benefits under the Treaty, and is the beneficial owner of the dividend is generally limited to 15% of the gross amount of the dividend (or 5% in the case of such a Holder that is a company beneficially owning at least 10% of ESSA&#8217;s voting shares). Holders should consult their own tax advisors regarding the application of the Treaty to dividends based on their particular circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Dispositions of Common Shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A Holder generally will not be subject to tax under the Tax Act in respect of a capital gain realized on the disposition or deemed disposition of Common Shares, nor will capital losses arising therefrom be recognized under the Tax Act, unless Common Shares constitute &#8220;taxable Canadian property&#8221; to the Holder for purposes of the Tax Act, and the gain is not exempt from tax pursuant to the terms of the Treaty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Provided Common Shares are listed on a &#8220;designated stock exchange,&#8221; as defined in the Tax Act (which currently includes the Nasdaq), at the time of disposition, the Common Shares generally will not constitute taxable Canadian property of a Holder at that time, unless at any time during the 60-month period immediately preceding the disposition the following two conditions are met concurrently:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">(i) the Holder, persons with whom the Holder did not deal at arm&#8217;s length, and partnerships in which the Holder or such non-arm&#8217;s length person holds a membership interest (either directly or indirectly through one or more partnerships), or the Holder together with all such persons, owned 25% or more of the issued shares of any class or series of ESSA&#8217;s shares; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;">(ii) more than 50% of the fair market value of the Common Shares was derived directly or indirectly from one or any combination of real or immovable property situated in Canada, &#8220;Canadian resource properties&#8221; (as defined in the Tax Act), &#8220;timber resource properties&#8221; (as defined in the Tax Act) or an option, an interest or right in such property, whether or not such property exists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Notwithstanding the foregoing, a Common Share may otherwise be deemed to be taxable Canadian property to a Holder for purposes of the Tax Act in particular circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Holders whose Common Shares are taxable Canadian property should consult their own tax advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">United States Income Tax Considerations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the anticipated U.S. federal income tax consequences generally applicable to U.S. Holders (as defined below) of the ownership and disposition of the Company&#8217;s Common Shares. This summary addresses only holders who acquire and hold the Common Shares as &#8220;capital assets&#8221; (generally, assets held for investment purposes).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following summary does not purport to address all U.S. federal income tax consequences that may be relevant to a U.S. Holder (as defined below) as a result of the ownership and disposition of the Common Shares, nor does it take into account the specific circumstances of any particular holder, some of which may be subject to special tax rules (including, but not limited to, brokers, dealers in securities or currencies, traders in securities that elect to use a mark-to-market method of accounting for securities holdings, tax-exempt organizations, insurance companies, banks, thrifts and other financial institutions, persons liable for alternative minimum tax, persons that hold an interest in an entity that holds the Common Shares, persons that will own, or will have owned, directly, indirectly or constructively 10% or more (by vote or value) of our stock, persons that hold the Common Shares as part of a hedging, integration, conversion or constructive sale transaction or a straddle, former citizens or permanent residents of the United States, or persons whose functional currency is not the U.S. dollar).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This summary is based on the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), U.S. Treasury regulations, administrative pronouncements and rulings of the United States Internal Revenue Service (the &#8220;IRS&#8221;), judicial decisions and the Canada-United States Income Tax Convention (1980), as amended, all as in effect on the date hereof, and all of which are subject to change (possibly with retroactive effect) and to differing interpretations. Except as specifically set forth below, this summary does not discuss applicable income tax reporting requirements. This summary does not describe any state, local or foreign tax law considerations, or any aspect of U.S. federal tax law other than income taxation (e.g., estate or gift tax or the Medicare contribution tax). U.S. Holders (as defined below) should consult their own tax advisers regarding such matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">No legal opinion from U.S. legal counsel or ruling from the IRS has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the ownership or disposition of the Common Shares. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to different interpretations, the IRS and U.S. courts could disagree with one or more of the positions taken in this summary.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As used in this summary, a &#8220;U.S. Holder&#8221; is a beneficial owner of the Common Shares who, for U.S. federal income tax purposes, is (i) a citizen or individual resident of the United States, (ii) a corporation (or other entity that is classified as a corporation for U.S. federal income tax purposes) that is created or organized in or under the laws of the United States, any State thereof or the District of Columbia, (iii) an estate whose income is subject to U.S. federal income tax regardless of its source, or (iv) a trust if (A) a U.S. court can exercise primary supervision over the trust&#8217;s administration and one or more U.S. persons are authorized to control all substantial decisions of the trust, or (B) the trust has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The tax treatment of a partner in a partnership (or other entity or arrangement classified as a partnership for U.S. federal income tax purposes) that holds the Common Shares may depend on both the partnership&#8217;s and the partner&#8217;s status and the activities of the partnership. Partnerships (or other entities or arrangements classified as a partnership for U.S. federal income tax purposes) that are beneficial owners of the common shares, and their partners and other owners, should consult their own tax advisers regarding the tax consequences of the ownership and disposition of the Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Passive Foreign Investment Company Rules</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A foreign corporation will be considered a passive foreign investment company (&#8220;PFIC&#8221;) for any taxable year in which (1) 75% or more of its gross income is &#8220;passive income&#8221; under the PFIC rules or (2) 50% or more of the average quarterly value of its assets produce (or are held for the production of) &#8220;passive income.&#8221; For this purpose, &#8220;passive income&#8221; generally includes interest, dividends, certain rents and royalties, and certain gains. Moreover, for purposes of determining if the foreign corporation is a PFIC, if the foreign corporation owns, directly or indirectly, at least 25%, by value, of the shares of another corporation, it will be treated as if it holds directly its proportionate share of the assets and receives directly its proportionate share of the income of such other corporation. If a corporation is treated as a PFIC with respect to a U.S. Holder for any taxable year, the corporation will continue to be treated as a PFIC with respect to that U.S. Holder in all succeeding taxable years, regardless of whether the corporation continues to meet the PFIC requirements in such years, unless certain elections are made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The determination as to whether a foreign corporation is a PFIC is based on the application of complex U.S. federal income tax rules, which are subject to differing interpretations, and the determination will depend on the composition of the income, expenses and assets of the foreign corporation from time to time and the nature of the activities performed by its officers and employees. ESSA believes that it was classified as a PFIC for the taxable year ending September 30, 2021, and ESSA believes that it may be classified as a PFIC for the current taxable year and in future taxable years. However, our actual PFIC status for the current or any future taxable year is uncertain and cannot be determined until after the end of such taxable year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we are classified as a PFIC, a U.S. Holder that does not make any of the elections described below would be required to report any gain on the disposition of Common Shares as ordinary income, rather than as capital gain, and to compute the tax liability on the gain and any &#8220;Excess Distribution&#8221; (as defined below) received in respect of Common Shares as if such items had been earned ratably over each day in the U.S. Holder&#8217;s holding period (or a portion thereof) for the common shares. The amounts allocated to the taxable year during which the gain is realized or distribution is made, and to any taxable years in such U.S. Holder&#8217;s holding period that are before the first taxable year in which we are treated as a PFIC with respect to the U.S. Holder, would be included in the U.S. Holder&#8217;s gross income as ordinary income for the taxable year of the gain or distribution. The amount allocated to each other taxable year would be taxed as ordinary income in the taxable year during which the gain is realized or distribution is made at the highest tax rate in effect for the U.S. Holder in that other taxable year and would be subject to an interest charge as if the income tax liabilities had been due with respect to each such prior year. For purposes of these rules, gifts, exchanges pursuant to corporate reorganizations and use of Common Shares as security for a loan may be treated as a taxable disposition of the Common Shares. An &#8220;Excess Distribution&#8221; is the amount by which distributions during a taxable year in respect of a Common Share exceed 125% of the average amount of distributions in respect thereof during the three preceding taxable years (or, if shorter, the U.S. Holder&#8217;s holding period for the Common Shares).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain additional adverse tax rules will apply to a U.S. Holder for any taxable year in which we are treated as a PFIC with respect to such U.S. Holder and any of our subsidiaries is also treated as a PFIC (a &#8220;Subsidiary PFIC&#8221;). In such a case, the U.S. Holder will generally be deemed to own its proportionate interest (by value) in any Subsidiary PFIC and be subject to the PFIC rules described above with respect to the Subsidiary PFIC regardless of such U.S. Holder&#8217;s percentage ownership in us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The adverse tax consequences described above may be mitigated if a U.S. Holder makes a timely &#8220;qualified electing fund&#8221; election (a &#8220;QEF election&#8221;) with respect to its interest in the PFIC. Consequently, if we are classified as a PFIC, it may be advantageous for a U.S. Holder to elect to treat us as a &#8220;qualified electing fund&#8221; with respect to such U.S. Holder in the first year in which it holds Common Shares. If a U.S. Holder makes a timely QEF election with respect to ESSA, the electing U.S. Holder would be required in each taxable year that we are considered a PFIC to include in gross income (i) as ordinary income, the U.S. Holder&#8217;s pro rata share of the ordinary earnings of ESSA and (ii) as capital gain, the U.S. Holder&#8217;s pro rata share of the net capital gain (if any) of ESSA, whether or not the ordinary earnings or net capital gain are distributed. An electing U.S. Holder&#8217;s basis in Common Shares will be increased to reflect the amount of any taxed but undistributed income. Distributions of income that had previously been taxed will result in a corresponding reduction of basis in the Common Shares and will not be taxed again as distributions to the U.S. Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A QEF election made with respect to ESSA will not apply to any Subsidiary PFIC; a QEF election must be made separately for each Subsidiary PFIC (in which case the treatment described above would apply to such Subsidiary PFIC). If a U.S. Holder makes a timely QEF election with respect to a Subsidiary PFIC, it would be required in each taxable year to include in gross income its pro rata share of the ordinary earnings and net capital gain of such Subsidiary PFIC, but may not receive a distribution of such income. Such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge (which would not be deductible for U.S. federal income tax purposes if the U.S. Holder were an individual).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we determine that we, and any subsidiary in which we own, directly or indirectly, more than 50% of such subsidiary&#8217;s total aggregate voting power, is likely a PFIC in any taxable year, we intend to make available to U.S. Holders, upon request and in accordance with applicable procedures, a &#8220;PFIC Annual Information Statement&#8221; with respect to ESSA and any such subsidiary for such taxable year. The &#8220;PFIC Annual Information Statement&#8221; may be used by U.S. Holders for purposes of complying with the reporting requirements applicable to a QEF election with respect to ESSA and any Subsidiary PFIC. The U.S. federal income tax on any gain from the disposition of Common Shares or from the receipt of Excess Distributions may be greater than the tax if a timely QEF election is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Alternatively, if we were to be classified as a PFIC, a U.S. Holder could also avoid certain of the rules described above by making a mark-to-market election (instead of a QEF election), provided the Common Shares are treated as regularly traded on a qualified exchange or other market within the meaning of the applicable U.S. Treasury Regulations. However, a U.S. Holder will not be permitted to make a mark-to-market election with respect to a Subsidiary PFIC. U.S. Holders should consult their own tax advisers regarding the potential availability and consequences of a mark-to-market election, as well as the advisability of making a protective QEF election in case we are classified as a PFIC in any taxable year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During any taxable year in which we or any Subsidiary PFIC is treated as a PFIC with respect to a U.S. Holder, that U.S. Holder generally must file IRS Form 8621. U.S. Holders should consult their own tax advisers concerning annual filing requirements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Common Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Distributions on the Common Shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In general, subject to the passive foreign investment company rules discussed above, the gross amount of any distribution received by a U.S. Holder with respect to the Common Shares (including amounts withheld to pay Canadian withholding taxes) will be included in the gross income of the U.S. Holder as a dividend to the extent attributable to our current and accumulated earnings and profits, as determined under U.S. federal income tax principles. We may not calculate our earnings and profits for each year under U.S. federal income tax rules. Accordingly, U.S. Holders should expect that a distribution generally will be treated as a dividend for U.S. federal income tax purposes. Subject to the passive foreign investment company rules discussed above, distributions on the Common Shares to certain non-corporate U.S. Holders that are treated as dividends may be taxed at preferential rates provided we are not treated as a PFIC for the taxable year of the distribution or the preceding taxable year. Such dividends will not be eligible for the &#8220;dividends received&#8221; deduction ordinarily allowed to corporate shareholders with respect to dividends received from U.S. corporations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The amount of any dividend paid in Canadian dollars (including amounts withheld to pay Canadian withholding taxes) will equal the U.S. dollar value of the Canadian dollars calculated by reference to the exchange rate in effect on the date the dividend is received by the U.S. Holder, regardless of whether the Canadian dollars are converted into U.S. dollars. A U.S. Holder will have a tax basis in the Canadian dollars equal to their U.S. dollar value on the date of receipt. If the Canadian dollars received are converted into U.S. dollars on the date of receipt, the U.S. Holder should generally not be required to recognize foreign currency gain or loss in respect of the distribution. If the Canadian dollars received are not converted into U.S. dollars on the date of receipt, a U.S. Holder may recognize foreign currency gain or loss on a subsequent conversion or other disposition of the Canadian dollars. Such gain or loss will be treated as U.S. source ordinary income or loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Distributions on the Common Shares that are treated as dividends generally will constitute income from sources outside the United States and generally will be categorized for U.S. foreign tax credit purposes as &#8220;passive category income.&#8221; A U.S. Holder may be eligible to elect to claim a U.S. foreign tax credit against its U.S. federal income tax liability, subject to applicable limitations and holding period requirements, for Canadian tax withheld, if any, from distributions received in respect of the Common Shares. A U.S. Holder that does not elect to claim a U.S. foreign tax credit may instead claim a deduction for Canadian tax withheld, but only for a taxable year in which the U.S. Holder elects to do so with respect to all foreign income taxes paid or accrued in such taxable year. The rules relating to U.S. foreign tax credits are complex, and each U.S. Holder should consult its own tax adviser regarding the application of such rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sale, Exchange or Other Taxable Disposition of the Common Shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A U.S. Holder generally will recognize gain or loss on the sale, exchange or other taxable disposition of Common Shares in an amount equal to the difference, if any, between the amount realized on the sale, exchange or other taxable disposition and the U.S. Holder&#8217;s adjusted tax basis in the Common Shares exchanged therefor. Subject to the passive foreign investment company rules discussed above, such gain or loss will be capital gain or loss and will be long-term capital gain (currently taxable at a reduced rate for non-corporate U.S. Holders) or loss if, on the date of the sale, exchange or other taxable disposition, the Common Shares have been held by such U.S. Holder for more than one year. The deductibility of capital losses is subject to limitations. Such gain or loss generally will be sourced within the United States for U.S. foreign tax credit purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Required Disclosure with Respect to Foreign Financial Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Certain U.S. Holders are required to report information relating to an interest in the Common Shares, subject to certain exceptions (including an exception for common shares held in accounts maintained by certain financial institutions), by attaching a completed IRS Form 8938, Statement of Specified Foreign Financial Assets, with their tax return for each year in which they hold an interest in Common Shares. U.S. Holders should consult their own tax advisers regarding information reporting requirements relating to their ownership of the Common Shares.</span> </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:256.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Performance Graph</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The following performance graph illustrates a comparison of the total cumulative shareholder return on the Common Shares from September 30, 2016 to September 30, 2021, to three indices: the S&amp;P 500, the Dow Jones Industrial Average and the Nasdaq Composite. The graph assumes an initial investment of $100 on September 30, 2016, and, where applicable, includes the reinvestment of dividends.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:10pt 0pt 10pt 0pt;"><img src="tmb-20210930x10k001.jpg" alt="Graphic" style="display:inline-block;height:255.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The comparisons in the graph above are not intended to forecast or be indicative of possible future performance of the Common Shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuer Repurchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_4c1502ca_7b8f_4d5c_b9dd_706e93cb6a97"></a><a id="Item6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;6.&#160;&#160;&#160;&#160;&#160;[Reserved.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_1a8f61cf_16e6_42af_a6f2_908263c2cf87"></a><a id="_Hlk56170122"></a><a id="Item7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">The following discussion should be read in conjunction with the attached financial statements and notes thereto. This Annual Report on Form 10-K, including the following sections, contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those expressed or implied by such forward-looking statements. For a detailed discussion of these risks and uncertainties, see Item 1A, &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K. We caution the reader not to place undue reliance on these forward -looking statements, which reflect management&#8217;s analysis only as of the date of this Annual Report on Form 10-K. We undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Annual Report on Form 10-K. Throughout this discussion, unless the context specifies or implies otherwise, the terms &#8220;ESSA,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to ESSA Pharma Inc. and its subsidiaries. For a discussion regarding our financial condition and results of operations for fiscal 2020 as compared to fiscal 2019 see Item 7 of our Annual Report on Form 10-K for the fiscal year ended September 30, 2020, filed with the SEC on December 15, 2020.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 11pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESSA is a clinical stage pharmaceutical company, focused on developing novel and proprietary therapies for the treatment of prostate cancer with an initial focus on patients whose disease is progressing despite treatment with current standard of care therapies, including second-generation antiandrogen drugs such as abiraterone, enzalutamide, apalutamide, and darolutamide. The Company believes its latest series of investigational compounds, including its product candidate EPI 7386, have the potential to significantly expand the interval of time in which patients with castration-resistant prostate cancer (&#8220;CRPC&#8221;) can benefit from anti-hormone-based therapies. Specifically, the compounds are designed to disrupt the androgen receptor (&#8220;AR&#8221;) signaling pathway, the primary pathway that drives prostate cancer growth and prevent AR activation through selective binding to the N-terminal domain (&#8220;NTD&#8221;) of the AR. In this respect, the Company&#8217;s compounds are designed to differ from classical non-steroid antiandrogens. These antiandrogens interfere either with androgen synthesis (i.e. abiraterone), or with the binding of androgens to the ligand-binding domain (&#8220;LBD&#8221;), located at the opposite end of the receptor from the NTD (i.e. &#8220;lutamides&#8221;). A functional NTD is essential for activation of the AR; blocking the NTD inhibits AR-driven transcription and therefore androgen-driven biology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:10pt 0pt 10pt 0pt;">General Development of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:10pt 0pt 12pt 0pt;">Significant Business Developments for the Year Ended September 30, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On October 14, 2020, the Company issued 1,493,504 Common Shares upon the cashless exercise of 1,493,504 pre-funded warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On October 26, 2020, ESSA Pharma Inc. announced its strategic decision to voluntarily delist its Common Shares from the TSX-V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November 25, 2020, the Company filed a Registration Statement on Form S-3 with the SEC to replace the existing Registration Statement on Form F-3, which, once effective, will allow the Company to raise up to $200 million worth of the securities listed therein. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On December 3, 2020, the Company issued 42,207 Common Shares for stock options exercised for gross proceeds of $153,701.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 8, 2021, the Company issued 9,000 Common Shares for stock options exercised for gross proceeds of C$44,100.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 11, 2021, the Company issued 46,655 Common Shares for stock options exercised for gross proceeds of C$228,610 and 21,345 Common Shares for stock options exercised for gross proceeds of $72,262.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 13, 2021, the Company issued 34,716 Common Shares for stock options exercised for gross proceeds of $126,124.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 13, 2021, the Company announced a clinical collaboration with Janssen to evaluate EPI-7386 combination for patients with metastatic castration-resistant prostate cancer. Under the terms of the agreement, Janssen may sponsor and conduct up to two Phase 1/2 studies evaluating the safety, tolerability and preliminary efficacy of the combination of EPI-7386 and apalutamide as well as the combination of EPI-7386 with abiraterone acetate plus prednisone in patients with mCRPC who have failed a current second-generation antiandrogen therapy. Janssen will assume all costs associated with the studies, other than the manufacturing costs associated with the clinical drug supply of EPI-7386. The parties will form a joint oversight committee for the clinical studies, which are planned to start in late 2021 or early 2022. ESSA will retain all rights to EPI-7386.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 20, 2021, the Company issued 15,000 Common Shares for stock options exercised for gross proceeds of C$73,500 and 15,000 common shares for stock options exercised for gross proceeds of $48,450.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On February 5, 2021, the Company issued 2,965 Common Shares upon the cashless exercise of 3,825 broker warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On February 9, 2021, the Company issued 30,000 Common Shares for stock options exercised for gross proceeds of C$147,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On February 11, 2021, the Company presented preclinical and clinical pharmacology data from ESSA&#8217;s Phase 1 clinical trial of EPI-7386 for the treatment of patients with metastatic castration-resistant prostate cancer (&#8220;mCRPC&#8221;) at the 2021 American Society of Clinical Oncology Genitourinary (&#8220;ASCO GU&#8221;) Cancers Symposium in an oral poster presentation titled, &#8220;Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer,&#8221;. The poster is available on the Company website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On February 25, 2021, the Company announced a clinical collaboration with Astellas to evaluate the combination of EPI-7386 and Enzalutamide for patients with metastatic castration-resistant prostate cancer. Under the terms of the agreement, ESSA will sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of the combination of EPI-7386 and enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies. Astellas will supply enzalutamide for the trial. ESSA will retain all rights to EPI-7386. The clinical study is expected to start in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On March 26, 2021, Dr. Ari Brettman, nominee of Clarus Lifesciences III, L.P., resigned from the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2021, the Company extended the lease for the South San Francisco office to May 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On April 10, 2021, at the 2021 American Association of Cancer Research (AACR) Annual Meeting, the Company presented an e-poster presentation titled, &#8220;Comprehensive in vitro characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal inhibitor.&#8221;  The poster is available on the Company website.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On April 23, 2021, the Company renewed a lease agreement for the Houston office effective August 1, 2021 through July 31, 2023 with an option to renew for an additional two years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On April 28, 2021, the Company announced that it had entered into a clinical trial collaboration and supply agreement with Bayer to evaluate EPI-7386 in combination with Bayer&#8217;s androgen receptor inhibitor, darolutamide, in patients with mCRPC.  Under the terms of the agreement, following review of certain clinical data, Bayer may sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the combination of EPI-7386 and darolutamide in mCRPC patients. ESSA will supply EPI-7386 for the trial and will retain all rights to EPI-7386.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financing and Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On February 22, 2021, the Company completed an underwritten public offering for aggregate gross proceeds of $149,999,985 (the &#8220;February 2021 Financing&#8221;). The Company issued a total of 5,555,555 common shares of the Company at a public offering price of $27.00 per share, which includes the underwriters having exercised their 30-day option to purchase an additional 724,637 common shares. In connection with the February 2021 Financing, the Company paid cash commissions of $8,999,999 and incurred other transaction costs of $150,498.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESSA has never been profitable and has incurred net losses since inception. ESSA&#8217;s net losses were $36,805,461 and $23,445,370 and $12,756,832 for the years ended September 30, 2021, 2020 and 2019, respectively. ESSA expects to incur losses for the foreseeable future, and it expects these losses to increase as it continues the development of, and seek regulatory approvals for, its product candidate. Because of the numerous risks and uncertainties associated with product development, ESSA is unable to predict the timing or amount of increased expenses or when, or if, it will be able to achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table sets forth ESSA&#8217;s consolidated statements of financial position and consolidated statements of loss and comprehensive loss as at and for the fiscal&#160;years ended September 30, 2021, 2020 and 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(US$)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Income Statement Data</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development, net of recoveries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,258,989</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,145,968</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,696,234</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,220</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 618,109</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 602,744</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administration, net of recoveries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,884,581</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,373,952</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,455,189</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (37,165,790)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (24,138,029)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,754,167)</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36,839,810)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23,734,017)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,718,912)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss, net of income tax</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36,805,461)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23,445,370)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,756,832)</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheet Data</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 137,825,024</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 56,320,763</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 53,322,723</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaids and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,773,053</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,921,003</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 976,285</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deposits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 259,455</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 277,637</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 274,085</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right of use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 308,286</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 55,162</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 198,165,818</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 80,574,565</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,573,093</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,808,944</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,144,230</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,565,789</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 300,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 120,719</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,094</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 210,251</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,708,955</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Derivative liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,352</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 127,376</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,520</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Shareholders&#8217; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 194,005,552</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 79,243,865</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 48,981,829</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities and shareholders&#8217; equity </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 198,165,818</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 80,574,565</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,573,093</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations for the Fiscal&#160;Years Ended September 30, 2021 and 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There was no revenue in any of the fiscal&#160;years as reported. The Company incurred a comprehensive loss of $36,805,461 for the&#160;year ended September 30, 2021 compared to a comprehensive loss of $23,445,370 for the&#160;year ended September 30, 2020. Variations in ESSA&#8217;s expenses and net loss for the periods resulted primarily from the following factors:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenditures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">R&amp;D expense included the following major expenses by nature:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,597,114</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,689,143</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 596,271</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 512,790</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal patents and license fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,051,379</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 755,867</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CMC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,867,397</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,898,911</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 116,537</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 72,275</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preclinical and data analysis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,760,269</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,823,117</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research grants and administration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 157,080</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 153,379</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66,759</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,186</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salaries and benefits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,731,852</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,264,855</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,643,382</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,878,372</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Travel and other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 441,748</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 32,073</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment of CPRIT receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 229,201</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,258,989</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,145,968</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The overall R&amp;D expense for the&#160;year ended September 30, 2021 was $24,258,989 compared to $12,145,968 for the&#160;year ended September 30, 2020 and includes non-cash expense related to share-based payments expense of $3,643,382 (2020 - $1,878,372). R&amp;D expense in 2021 reflects the ongoing clinical trial of EPI-7386 and in 2020 was incurred primarily in preclinical research with work directed to the completion of the IND filing in March 2020 and chemistry and manufacturing cost in preparation for the Phase 1 study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The share-based payments expense of $3,643,382 (2020 - $1,878,372), which is a non-cash expense, relates to the value assigned to stock options and employee share purchase rights granted to key management personnel and consultants of the Company. The expense is recognized in relation to the grant and vesting of these equity instruments, net of expiries and forfeitures, and allocated to research and development, general and administration and financing expenditures relative to the activity of the underlying optionee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Clinical costs of $4,597,114 (2020&#160;- $1,689,143) were generated in relation to expenditures associated with the Company&#8217;s clinical research organizations conducting the Phase 1 clinical trial of EPI-7386. In the prior period, the costs related to clinical consulting work in preparation and completion of the IND and CTA filings and preparation for the Phase 1 clinical trial of EPI-7386 which began in July 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preclinical costs of $4,760,269 (2020&#160;<span style="white-space:pre-wrap;">- $2,823,117) were incurred in the identification of the lead compound EPI-7386 in 2019 and the subsequent filing of the IND in 2020.  In the current year, the amount includes pharmacokinetic data analysis on data from the clinical trial related to the Phase I study.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CMC costs of $6,867,397 (2020&#160;- $2,898,911) for the&#160;year ended September 30, 2021 includes amount for cGMP manufacturing of EPI 7386 drug supply to support the ongoing clinical trial as well as costs incurred in formulation and chemistry work around the Company&#8217;s pharmaceutical characteristics of EPI-7386. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting costs increased to $596,271 (2020&#160;- $512,790) for the&#160;year ended September 30, 2021 primarily resulting from contract project management services. In the comparative period, costs were related to consulting fees for scientific advisors in connection with candidate selection and preparation of the IND filing, including contract project management services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Salaries and benefits, related to preclinical and clinical staff, have increased to $1,731,852 (2020&#160;- $1,264,855) as a result of an increased number of preclinical and clinical staff involved in the development of the Company&#8217;s next-generation Aniten compounds.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal patents and license fees were increased to $1,051,379 (2020&#160;- $755,867). The Company has adopted a tiered patent strategy to protect its intellectual property as the pharmaceutical industry places significant importance on patents for the protection of new technologies, products and processes. The costs reflect that ongoing investment and the timing of associated maintenance costs. The Company anticipates that there will be continued investment into patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administration Expenditures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses include the following major expenses by nature:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 109,464</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 110,324</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting and subcontractor fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 218,262</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 135,181</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 355,805</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 377,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 943,848</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 594,170</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investor relations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 646,058</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 344,233</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office, insurance, IT and communications</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 342,026</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 313,922</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,228,456</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 919,335</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Regulatory fees and transfer agent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 110,553</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 159,744</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45,418</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,747</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salaries and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,036,894</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,619,120</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,832,731</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,644,235</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Travel and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,066</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 96,941</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,884,581</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,373,952</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administration expenses increased to $12,884,581 for the&#160;year ended September 30, 2021 from $11,373,952 in the&#160;<span style="white-space:pre-wrap;">year ended September 30, 2020 and included non-cash expense related to share-based payments of $5,832,731 (2020 - $5,644,235).  This non-cash expense relates to the value assigned to stock options and employee share purchase rights granted to key management and consultants of the Company. The expense is recognized in relation to the grant and vesting of these equity instruments, net of expiries and forfeitures, and allocated to research and development, general and administration and financing expenditures relative to the activity of the underlying optionee.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting and subcontractor fees of $218,262 (2020&#160;- $135,181) were incurred for administrative and legal support in conjunction with increased corporate activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Insurance expense of $943,848 (2020 - $594,170) relates to increased cost of insurance coverage for directors and officers of the Company as a reporting issuer and publicly listed company in the United States, as well as general liability insurance. The Company has realized an increase in premiums which is in line with market trends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Investor relations expense increased to $646,058 (2020 - $344,233) due to the cost of additional investor communications support engaged in the current year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees of $1,228,456 (2020&#160;- $919,335) were incurred for legal and accounting services in conjunction with increased corporate activities. Over the periods presented, the Company prepared for and implemented changes with respect to its transition to a domestic issuer from foreign private issuer, including the transition of financial statements to U.S. GAAP. The Company is now a US domestic issuer and has ongoing costs to support compliance and contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk56180972"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Salaries and benefits expense increased to $3,036,894 (2020&#160;- $2,619,120) reflecting merit related salary adjustment and bonuses paid to employees and additional support staff costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations for the Fiscal&#160;Years Ended September&#160;30, 2020 and 2019</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There was no revenue in any of the fiscal&#160;years as reported. The Company incurred a comprehensive loss of $23,445,370 for the&#160;year ended September&#160;30, 2020 compared to a comprehensive loss of $12,756,832 for the&#160;year ended September&#160;30, 2019. Variations in ESSA&#8217;s expenses and net loss for the periods resulted primarily from the following factors:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenditures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">R&amp;D expense included the following major expenses by nature:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,689,143</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 80,021</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 512,790</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 301,817</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal patents and license fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 755,867</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 781,133</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CMC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,898,911</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 946,705</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 72,275</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 111,750</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preclinical</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,823,117</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,789,753</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research grants and administration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 153,379</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 254,970</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,186</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,405</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salaries and benefits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,264,855</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,012,344</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,878,372</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 304,786</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Travel and other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 32,073</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,550</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,145,968</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,696,234</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The overall R&amp;D expense for the&#160;year ended September&#160;30, 2020 was $12,145,968 compared to $6,696,234 for the&#160;year ended September 30, 2019 and included non-cash expense related to share-based payments expense of $1,878,372 (2019 - $304,786). R&amp;D expense in 2020 and 2019 was incurred primarily in preclinical research and IND-enabling work on the Company&#8217;s next-generation Aniten compounds, with expenditures in 2020 reflecting ongoing preclinical work on IND candidate EPI-7386 and the increased expenditure on chemistry and manufacturing of drug product at third party vendors, in anticipation of the Phase 1 clinical trial which commenced with the dosing of the first patient in July 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The share-based payments expense of $1,878,372 (2019 - $304,786), which is a non-cash expense, relates to the value assigned to stock options and employee share purchase rights granted to key management and consultants of the Company. The expense is recognized in relation to the grant and vesting of these equity instruments, net of expiries and forfeitures, and allocated to research and development, general and administration and financing expenditures relative to the activity of the underlying optionee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Clinical costs of $1,689,143 (2019&#160;- $80,021) relate to clinical consulting work in preparation for the IND filing in March 2020, clinical site activation costs, and commencement of the Phase I clinical trial of EPI-7386 in July 2020. Only minor preparatory clinical costs were incurred in late 2019 following selection of EPI-7386 as a clinical candidate in March 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preclinical costs of $2,823,117 (2019&#160;<span style="white-space:pre-wrap;">- $2,789,753) were incurred in the identification of the lead compound EPI-7386 in 2019 and the subsequent filing of the IND in 2020.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CMC costs of $2,898,911 (2019&#160;- $946,705) for the&#160;year ended September&#160;30, 2020 were incurred in formulation and chemistry work around the Company&#8217;s next-generation Aniten compounds, and specifically the pharmaceutical characteristics of EPI-7386. In 2020 costs included additional formulation work and cGMP manufacturing of EPI-7386 drug supply in preparation for the clinical trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting costs increased to $512,790 for the&#160;year ended September&#160;30, 2020 (2019&#160;- $301,817) relating to consulting fees for scientific advisors in connection with candidate selection and preparation of the IND filing, including contract project management services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Salaries and benefits, related to preclinical and clinical staff, have increased to $1,264,855 (2019&#160;- $1,012,344) as a result of the increased number of preclinical and clinical staff involved in the development of the Company&#8217;s next-generation Aniten compounds, including the appointment of the Company&#8217;s Chief Medical Officer in July&#160;2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal patents and license fees are comparable at $755,867 (2019&#160;<span style="white-space:pre-wrap;">- $781,133). In the prior period, the Company submitted a number of patent applications on its next-generation compounds for which the Company owns the rights. The Company has adopted a tiered patent strategy to protect its intellectual property as the pharmaceutical industry places significant importance on patents for the protection of new technologies, products and processes. The costs in the current period reflect that ongoing investment and the Company anticipates that there will be continued investment into patent applications.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research grants and administration costs were $153,379 (2019 - $254,970) and relate to amounts payable pursuant to collaborative research agreements with the BCCA and UBC. The amounts incurred vary in relation to the timing of milestone payments pursuant to such agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administration Expenditures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses include the following major expenses by nature:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 110,324</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting and subcontractor fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 135,181</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 142,780</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 377,000</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 252,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 594,170</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 471,852</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investor relations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 344,233</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 319,373</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal patents and license fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50,323</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office, insurance, IT and communications</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 313,922</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 155,208</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 869,012</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 675,412</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Regulatory fees and transfer agent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 159,744</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 91,764</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,747</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 192,479</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Salaries and benefits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,619,120</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,072,746</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,644,235</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 841,921</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Travel and other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 96,941</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 239,654</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,373,952</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,455,189</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administration expenses increased to $11,373,952 for the&#160;year ended September&#160;30, 2020 from $5,455,189 in the&#160;year ended September&#160;<span style="white-space:pre-wrap;">30, 2019 and included non-cash expense related to share-based payments of $5,644,235 (2019 - $841,921).  This non-cash expense relates to the value assigned to stock options and employees share purchase rights granted to key management and consultants of the Company. The expense is recognized in relation to the grant and vesting of these equity instruments, net of expiries and forfeitures, and allocated to research and development, general and administration and financing expenditures relative to the activity of the underlying optionee.</span></p><a id="_Hlk56180876"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Director fees of $377,000 (2019 - $252,000) were incurred for remuneration paid to directors for attendance at meetings and participation in various committees during the period. On July 31, 2019, in connection with the Realm Acquisition, the Company appointed three additional members to the board of directors who receive compensation as directors and members of board committees, which resulted in increased fees in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Salaries and benefits expense of $2,619,120 (2019&#160;- $2,072,746) in 2020 reflects merit related salary adjustment and bonuses paid to employees and additional support staff costs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Insurance expense of $594,170 (2019 - $471,852) relates to the increased cost of insurance coverage for directors and officers of the Company as a reporting issuer and publicly listed company in the United States, as well as general liability insurance. The Company has realized an increase in premiums which is in line with market trends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees of $869,012 (2019&#160;- $675,412) were incurred for legal and accounting services in conjunction with increased corporate activities compared to activities in 2019. Specifically, in the current year, the Company incurred costs to implement an at-the-market equity offering facility. The Company also prepared for, and implemented changes with respect to its transition to a domestic issuer from foreign private issuer, including the transition of financial statements to US GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Rent expense of $59,747 (2019 - $192,479) decreased relative to the previous period as a consequence of adopting new lease standards for accounting. Rent expense previously incurred on the South San Francisco office is now classified as a lease payment. Concurrently, the Company recognized amortization of $110,324 (2019 - $Nil) for the related operating lease right-of-use asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESSA is a clinical stage company and does not currently generate revenue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As at September 30, 2021, the Company had working capital of $193,668,414 (2020 - $79,093,604). Operational activities during the year ended September 30, 2021 were financed mainly by proceeds from the July 2020 Financing and February 2021 Financing. At September 30, 2021, the Company had available cash reserves and short-term investments of $194,927,183 (2020 - $78,332,100) to settle current liabilities of $3,929,663 (2020 - $1,203,324). At September 30, 2021, the Company believed that it had sufficient capital to satisfy its obligations as they became due and execute its planned expenditures for more than twelve months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESSA&#8217;s future cash requirements may vary materially from those now expected due to a number of factors, including the costs associated with future preclinical work and to take advantage of strategic opportunities, such as partnering collaborations or mergers and acquisitions activities. In the future, it may be necessary to raise additional funds. These funds may come from sources such as entering into strategic collaboration arrangements, the issuance of shares from treasury, or alternative sources of financing. However, there can be no assurance that ESSA will successfully raise funds to continue its operational activities. See &#8220;Risk Factors&#8221; in Item&#160;1A. elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company makes estimates and assumptions about the future that affect the reported amounts of assets and liabilities. Estimates and judgments are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made that relate to the following key estimates:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Derivative financial instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Certain warrants are treated as derivative financial liabilities. The estimated fair value, based on the Black-Scholes model, is adjusted on a quarterly basis with gains or losses recognized in the statement of loss and comprehensive loss. The Black-Scholes model is based on significant assumptions such as volatility, dividend yield, expected term and liquidity discounts as detailed in Note&#160;10 of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based payments and compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date of grant and the cost is recorded when the Company receives the goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has applied estimates with respect to the valuation of pre-funded warrants issued for cash. Pre-funded warrants are valued at an amount equal to the cash proceeds received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying Common Shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The fair value of the underlying Common Shares is assessed as the most recent issuance price per common share for cash proceeds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trend Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESSA is a clinical development stage company and does not currently generate revenue. The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain Licensed IP. As at the date of this Annual Report, no products are in commercial production or use. The Company&#8217;s financial success will be dependent upon its ability to continue development of its compounds through preclinical and clinical stages to commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESSA has no material undisclosed off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on its results of operations, financial condition, revenues or expenses, liquidity, capital expenditures or capital resources that is material to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Safe Harbor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">See &#8220;<i style="font-style:italic;">Cautionary Note&#160;Regarding Forward-Looking Statements</i>&#8221; in the introduction to this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_c46c975a_532b_4e76_ba9d_576ab4e82ec0"></a><a id="Item7A"></a><a id="_Toc75278523"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-top:0pt;">Item 7A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-top:0pt;">Quantitative and Qualitative Disclosure About Market Risk</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;">We are exposed to market risks in the ordinary course of our business that may affect our results of operations, cash flows and fair values of assets and liabilities, including interest rate movements, volatility in foreign currency exchange rates, and changes in economic conditions as a result of the COVID-19 pandemic. The primary market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates and foreign exchange rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Interest Rate Risk </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;">Our exposure to interest rate risk relates primarily to our cash and cash equivalents balances and short-term investments which are interest bearing. At September 30, 2021 and September 30, 2020, we had cash reserves and short-term investments of $194,927,183 and $78,332,100 respectively, consisting primarily of funds in cash, cash equivalent and guaranteed investment certificates. The primary objective of our investment activities is to preserve principal while also maintaining liquidity and maximizing investment returns without significantly increasing risk. We do not enter into investments for trading or speculative purposes. Our investment portfolio is primarily composed of short-term investments with maturities up to 12 months. Interest income is not significant to the Company&#8217;s projected operational budget and related interest rate fluctuations are not significant to the Company&#8217;s risk assessment. Accordingly, we do not expect our operating results or cash flows to be materially affected by a sudden change in market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Foreign Currency Exchange Risk </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;">Our functional currency is the U.S. dollar as most of our operating expenses are denominated in U.S. dollars. We incur certain operating expenses in Canadian dollars and accordingly, are subject to foreign currency transaction risk. We do not use derivative instruments to hedge exposure to foreign currency transaction risk due to the low volume of transactions denominated in Canadian dollars and other foreign currencies. We do not anticipate that foreign currency transaction gains or losses will be significant at our current level of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:6pt 0pt 6pt 0pt;">At September 30, 2021, our net monetary assets denominated in Canadian dollars were $292,346 (C$372,478) and our net monetary liabilities in UK Pound dollars were $4,213 (&#163;3,135) and Euro dollars were $15,523 (&#8364;13,363). We are subject to foreign currency translation risk when translating these foreign currency denominated net monetary assets to U.S. dollars for period end financial statement preparation. The fluctuation of the Canadian dollar relative to the U.S. dollar will have an impact on the reported balances for net assets, net loss and shareholders&#8217; equity in our consolidated financial statements. A hypothetical 10% increase (decrease) in the value of the Canadian dollar relative to the U.S. dollar would result in a foreign exchange gain (loss) of $27,261 in our Consolidated Statements of Operations and Comprehensive Loss for the year ended September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:180.02pt;"><a id="_66cca2c1_47a6_4e05_a710_e25c2923e7b4"></a><a id="Item8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8.&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ESSA Pharma&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20210930x10k002.jpg" alt="Graphic" style="display:inline-block;height:179.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:467.94pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Expressed in United States dollars)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FOR THE&#160;YEARS ENDED SEPTEMBER 30, 2021, 2020 and 2019</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:787.5pt;"><a id="_4e075a3f_0161_46a0_9611_c213d69b8dff"></a><div style="height:787.5pt;position:absolute;right:0pt;top:-63.35pt;width:607.5pt;z-index:-9223372036603117568;"><div style="height:787.5pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:606.75pt;"><img src="tmb-20210930x10k003.jpg" alt="172720 Davidson - Nexia LH 2016" style="height:787.5pt;width:606.75pt;" /></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:6pt;margin-top:6pt;text-transform:uppercase;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;">To the Shareholders and Directors of</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;">ESSA Pharma Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Consolidated Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have audited the accompanying consolidated balance sheets of ESSA Pharma Inc. (the &#8220;Company&#8221;), as of September 30, 2021 and 2020, and the related consolidated statements of operations and comprehensive loss, changes in shareholders&#8217; equity, and cash flows for the years ended September 30, 2021, 2020, and 2019, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). &#160;In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of ESSA Pharma Inc. as of September 30, 2021 and 2020, and the results of its operations and its cash flows for the three years ended September 30, 2021 in conformity with accounting principles generally accepted in the United States of America. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)<span style="font-size:12pt;"> </span>(&#8220;PCAOB&#8221;), the Company&#8217;s<span style="font-size:12pt;"> </span>internal control over financial reporting as of September 30, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) (&#8220;COSO&#8221;) and our report dated November 18, 2021 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatements of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:790.51pt;"><div style="height:790.51pt;left:-10.08%;position:absolute;top:-63.35pt;width:609pt;z-index:-9223372036603116544;"><div style="height:789.96pt;left:0pt;padding-bottom:0.55pt;position:relative;top:0pt;width:608.6pt;"><img src="tmb-20210930x10k003.jpg" alt="172720 Davidson - Nexia LH 2016" style="height:789.96pt;width:608.6pt;" /></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-style:italic;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-style:italic;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Critical Audit Matters </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have not identified any critical audit matters for the years ended September 30, 2021, 2020, and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2012.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">/s/ DAVIDSON &amp; COMPANY LLP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Vancouver, Canada                                                                                                         Chartered Professional Accountants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 18, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:790.64pt;"><div style="height:790.64pt;left:-9.91%;position:absolute;top:-63.35pt;width:607.5pt;z-index:-9223372036603115520;"><div style="height:790.64pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:607.2pt;"><img src="tmb-20210930x10k003.jpg" alt="172720 Davidson - Nexia LH 2016" style="height:790.64pt;width:607.2pt;" /></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-transform:uppercase;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;">To the Shareholders and Directors of</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;">ESSA Pharma Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Internal Controls Over Financial Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 6pt 0pt;">We have audited ESSA Pharma Inc.&#8217;s (the &#8220;Company&#8221;) internal controls over financial reporting as of September 30, 2021, based on &#160;criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) ( the &#8220;COSO criteria&#8221;). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of September 30, 2021, based on the COSO criteria. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s consolidated balance sheets as of September 30, 2021 and 2020, and the related consolidated statements of operations and comprehensive loss, changes in shareholders&#8217; equity, and cash flows for the years ended September 30, 2021, 2020, and 2019, and the related notes and our report dated November 18, 2021 expressed an unqualified opinion thereon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in Management&#8217;s Report on Internal Control over Financial Reporting of the annual report on Form 10-K dated November 18, 2021. Our responsibility is to express an opinion on the entity&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.<i style="font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:790.64pt;"><div style="height:790.64pt;left:-9.91%;position:absolute;top:-61.95pt;width:607.5pt;z-index:-9223372036603114496;"><div style="height:790.64pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:607.2pt;"><img src="tmb-20210930x10k003.jpg" alt="172720 Davidson - Nexia LH 2016" style="height:790.64pt;width:607.2pt;" /></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">An entity&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. An entity&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the entity; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, and that receipts and expenditures of the entity are being made only in accordance with authorizations of management and directors of the entity; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the entity&#8217;s assets that could have a material effect on the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">/s/ DAVIDSON &amp; COMPANY LLP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Vancouver, Canada &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; Chartered Professional Accountants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">November 18, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:6pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_52666b2e_8df6_494d_869f_f5637d5fca06"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ESSA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Expressed in United States dollars)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:3px double #000000;margin:0pt;">AS AT SEPTEMBER&#160;30</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d1178942_a09a_4f3f_86c6_6f076c275fd9"></a><a id="Tc_-mdABNrQgkyU3uGk_qTQLQ_2_2"></a><a id="Tc_ww6gZ-mF8kqE9uLb99XvVw_2_5"></a><a id="Tc_sQ23zy-lKkO-D_qsV8Evow_4_0"></a><a id="Tc_nBMxPGZp0EG7qfBbd03w8Q_6_0"></a><a id="Tc_Vu9wl9BApk2MxcdS18sjWw_7_0"></a><a id="Tc_EGThd-Ra50u2yEJh4lyOGA_7_2"></a><a id="Tc_1ikqEvvZv0qtEq7_VVhr8Q_7_5"></a><a id="Tc_GTJy1QTT40qyaeS1SbxTBA_8_0"></a><a id="Tc_J09IAdlpJEmnC-y_tUG69A_9_0"></a><a id="Tc_7sEhDBIiH0mGktWnPL48yQ_10_0"></a><a id="Tc_a2TDfLOXf0ipDkasT7StNQ_11_0"></a><a id="Tc_k_VJEKGJBkqKweq9ySd3ww_15_0"></a><a id="Tc_S8J4ozCGdUGi7quh08h6BA_16_0"></a><a id="Tc_UfGjWqXBW0-grW_q9_GUTA_18_0"></a><a id="Tc_HLenheHoJk26LPeF_t7cqA_18_2"></a><a id="Tc_z3idVHoZq0qk8tEcZaMTcg_18_5"></a><a id="Tc_F_wXAphhv0az5n_r6ZNw5w_20_0"></a><a id="Tc_I9OtrhXjxUGujxHTse3o5A_22_0"></a><a id="Tc_3MGouu3pSUa6JR7Wc0YZmA_23_0"></a><a id="Tc_Ea3UhchhQ0mEgc1mEyLiFA_23_2"></a><a id="Tc_Q7Ti3vSa1EiU9UX-y12_gw_23_5"></a><a id="Tc_HbAtn8ZqIU2kjSlLROXpEw_24_0"></a><a id="Tc_3nmqrR-r3EW5F5tbEZJrxw_28_0"></a><a id="Tc_-UoNLsXbXUqooGDrF2vlyA_29_0"></a><a id="Tc_gYzHf9Drr02GEZCzotV5Ig_31_0"></a><a id="Tc_qxE8h-8cgEuLqhRo6LS0RA_33_0"></a><a id="Tc_AEUdDhrtGUKpy4z3R8IKqg_34_0"></a><a id="Tc_KcMWw_9gJEK64vPeu9yacw_35_0"></a><a id="Tc_Ga2Le3BfwUi5Zl1C8lnZ9w_36_0"></a><a id="Tc_ZCsuVUasiUSncAoSWZ9V2g_37_0"></a><a id="Tc_iFFQRTnNMkejynNVLPjFdg_38_0"></a><a id="Tc_pROpIzTRNUelw3KtSQs1Zw_39_0"></a><a id="Tc_XnEl03gRmUaVwSL-yjjEwg_40_0"></a><a id="Tc_IumVtIAzL02neCrqeBYODg_44_0"></a><a id="Tc_pkDRj37jU0i_kEDMiUGrRQ_44_2"></a><a id="Tc_eCjQKLfZtE2YXHTLs74soA_44_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_Euhj1Mz5yUqV046gkOVB-A_7_3">137,825,024</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_oXJR9UfEN0GEaRjfKyyPVg_7_6">56,320,763</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Short-term investments (Note 5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="0" id="Tc_Jl6DQfTzHkykSlNfEe_9Dw_8_3">57,102,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="0" id="Tc_tISGrD9UI0OviWYqHpJLvw_8_6">22,011,337</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Receivables</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="0" id="Tc_bd-WodXH0kOO-DB_0u6enw_9_3">489,012</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="0" id="Tc_fFtW49RqXE2VxikQpqkHtw_9_6">309,538</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Prepaids (Note&#160;6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_RIg4K2BAZkKcgK6BxuXW5A_10_3">2,181,882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_sP0PzynIQEixiJ-HSgVBeA_10_6">1,600,128</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Operating lease right-of-use assets (Note&#160;8)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:zerodash" name="epix:OperatingLeaseRightOfUseAssetsCurrent" scale="0" id="Tc_-PJQUkhRRkepxAGldjJ7Aw_11_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeaseRightOfUseAssetsCurrent" scale="0" id="Tc_UJoYL5HimkuQ9P1J6mY37g_11_6">55,162</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_3-k__joZ5U6YVhPtttVwEw_13_3">197,598,077</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_DhFhr6SrTEWwcEHHBkZ3Zg_13_6">80,296,928</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Deposits</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" id="Tc_-4_4mvPTxkeNP4cMQBVM9Q_15_3">259,455</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" id="Tc_IhGRQWEM9U2KPeNG3PVGQg_15_6">277,637</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Operating lease right-of-use assets (Note&#160;8)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_O86ZSdZbSkSuo-SPYuFLMA_16_3">308,286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_ZqJS3zdEZE2w8aydWUoZNQ_16_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_UBP9phsBiUCWC7OD0oP94w_18_3">198,165,818</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_R-o21wz46kqXIwLsez3AWA_18_6">80,574,565</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accounts payable and accrued liabilities (Note 7)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_Gv3NmvlLmE-kUYs8zLkp4w_23_3">3,808,944</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_RY4CJN_zTUu87_tmYRZdzA_23_6">1,144,230</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Current portion of operating lease liabilities (Note&#160;8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_OGih-VpdGUKNh-Fix_4_cw_24_3">120,719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_h385ElsEmkaQJTxw4lFXZA_24_6">59,094</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_aq80aBGnKE-sOloVLU0tUQ_26_3">3,929,663</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_WSZI36yPLUOBWLjD13VnoQ_26_6">1,203,324</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Derivative liabilities (Note&#160;10)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="Tc_WMOQ5-4BTESpCKHIK4S5RQ_28_3">20,352</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="Tc_AFEE7_JMOEWZjx7HbAy4fQ_28_6">127,376</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Operating lease liabilities (Note 8)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_JsAxQZ_P7EufkiEiREufJw_29_3">210,251</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_pgZVm-xxKkCkH7LQN79rIg_29_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_qYbsNmhSC0Oeo-lKLW9_Ig_31_3">4,160,266</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_WxPnAtDEFUGv4rs7jD2ojw_31_6">1,330,700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Shareholders&#8217; equity</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Authorized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Unlimited common shares, without par value</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Unlimited preferred shares, without par value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;">Common shares </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_KyTANoU_sk6cbJ9WN7YWLw">43,984,346</ix:nonFraction></span><span style="font-size:9pt;"> </span><span style="-sec-ix-hidden:Hidden_jETlY65jEkmfBRASRzirag;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_MU1HXvcdzECgRj3WjIKibw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span><span style="font-size:9pt;"> (September 30, 2020&#160;&#8211; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_aoJuDU5ChE2WYB7gClMKAQ">32,064,411</ix:nonFraction></span><span style="font-size:9pt;">) (Note&#160;11)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_ZWZVpVaTo0Ce-wA7nSPL4w_37_3">277,415,176</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_gkpRhYl6TUaP-YjHL2rPPQ_37_6">131,086,364</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital (Note&#160;11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_CGBhUkYMvU-7I7__tQg_cA_38_3">36,442,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_3Me9W2S_qUisU_Vj0-_YgA_38_6">31,204,284</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_SjM83KoyUUqUHMXSLLQW2w_39_3">2,076,479</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_gUCn5GaJpUyARuFJi5dBbg_39_6">2,076,479</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_-wamogYAwkqZY20YkZRQzw_40_3">117,775,765</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_WTE4-uNLjkOqa-ZFf2RdVQ_40_6">80,970,304</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_fDdrr4-ItkiBN1eiwY0zdg_42_3">194,005,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_jeNcrDAuuUeFb8EGSdH9Jw_42_6">79,243,865</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total liabilities and shareholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc__sHj1-Kjkk-QXW48icL9-w_44_3">198,165,818</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_j0urWbcx20aqHeDAcoXsDg_44_6">80,574,565</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><b style="font-style:normal;font-weight:bold;">Nature of operations (Note&#160;1)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><b style="font-style:normal;font-weight:bold;">Commitments (Note&#160;17)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_e9e0a299_3b8d_49f3_948c_2b5c8a67bbff"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ESSA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Expressed in United States dollars)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:3px double #000000;margin:0pt;">FOR THE&#160;YEARS ENDED SEPTEMBER&#160;30</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_715e4f5a_3581_435d_a75f_2f92582742ec"></a><a id="Tc_tGJLbk7mWUOfFTJTKKicKw_4_2"></a><a id="Tc_yoKvPJafBk6acMEaXQ9H-g_4_5"></a><a id="Tc_FZgdvQmtyUSfoAfpV3eaJQ_4_8"></a><a id="Tc_3g_XaUk7REaCfqbcZQfQ1g_6_0"></a><a id="Tc_Wm-i4ZZmFECxxGRCKkvDfQ_7_0"></a><a id="Tc_Z1q56dUBWU-Erl5whJGuDw_7_2"></a><a id="Tc_1zx7gwFzM0CiUnwYe8ygzg_7_5"></a><a id="Tc_fhg9KCea80qGlIq6VqstvA_7_8"></a><a id="Tc_ldXYg6rU90SDmkyWd5HyLg_8_0"></a><a id="Tc_b6fKrinNU0OAf_wZ83Zpkg_9_0"></a><a id="Tc_MSVupdZVU061AouCrrn63Q_11_0"></a><a id="Tc_3aLFdwkl-U6EPjnXObvgwQ_13_0"></a><a id="Tc_TuLkkenhaU2gzZXNa7hpjg_14_0"></a><a id="Tc_5XauL5MGEESGxjAQ2YK9wg_15_0"></a><a id="Tc_QwFqhPB8gEWH_--88AP6BA_17_0"></a><a id="Tc_1cDclHPZwkeLI-DEBNhI3w_19_0"></a><a id="Tc_zgcc4nHAU0G3oMaIBmQrfw_21_0"></a><a id="Tc___v-CfHAQESEXzoMkK0Uxw_21_2"></a><a id="Tc_nE3LO9YCjkiLMCfICQjKUA_21_5"></a><a id="Tc_Umad-cK7Sk-loFveU3EGGw_21_8"></a><a id="Tc_k8ZNN4PdJUScQY7v6jCD8A_23_0"></a><a id="Tc_uREpLTPx10y49x_YC0IqjQ_23_2"></a><a id="Tc_iLARrpTshkiafxXsSgzkzg_23_5"></a><a id="Tc_omqxvdP27kOsvUUAGP7eqg_23_8"></a><a id="Tc_zRl_GR9hU0Kx8kd7UkRnsg_25_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:39.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:39.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">OPERATING EXPENSES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_zFcdYIaLkEmbMtHMfjDj6g_7_3">24,258,989</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_xdR3s5RNCUi3LaH7EZKVQA_7_6">12,145,968</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_TU0cqi2emUygUypaI2DOUw_7_9">6,696,234</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing costs (Notes&#160;8 and 9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="epix:FinancingCosts" scale="0" id="Tc_l72TRPS23U2FqhkSlU_Hsw_8_3">22,220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="epix:FinancingCosts" scale="0" id="Tc_m0Jb581RGkuxiOAAa2d35A_8_6">618,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:FinancingCosts" scale="0" id="Tc_cqeh5c4HEkirspH_pdPP7w_8_9">602,744</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administration </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_AKhiALs_2USDZTxErKDSPQ_9_3">12,884,581</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_TlzUVd3bqk-2cyqaIDYRFA_9_6">11,373,952</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_CqFGm6E1jE6M5PqncVBLFg_9_9">5,455,189</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_7yQ81RovNkG1WUDoWX-9Hg_11_3">37,165,790</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_CY0eTTxK3UOm2q0UR6UzQA_11_6">24,138,029</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_kGxmZokYt0K4QyR9m6NKkQ_11_9">12,754,167</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign exchange</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_jyhlDdCn2UqX1hZ9t5n7dg_13_3">16,041</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_aJWd8qL5cUKx2Oyjsss6SQ_13_6">44,851</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc_PkN_UXB2gEyINX-dZs5ZBA_13_9">7,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="0" id="Tc__8aDzO9azUOR44sCknXwJg_14_3">234,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="0" id="Tc_Isx30LuFV0CqLnonvpNAWQ_14_6">559,719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="0" id="Tc_g4omYabbBEuCTUWpgg-Rfg_14_9">26,251</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Derivative liability gain (loss) (Note&#160;10)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="Tc_Gu0qNKX_lkia-nZ5Y8ZxLA_15_3">107,024</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" sign="-" scale="0" id="Tc_Z0FfiRxOTESAiQibWUhOhg_15_6">110,856</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="Tc_7ge6eg2OQ0CvEpuboYf_KA_15_9">1,159</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Loss for the&#160;year before taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_mgGrg92rGkK3xrabiaW1_g_17_3">36,839,810</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_CTqjwJMi1UKaJMwgEZPfug_17_6">23,734,017</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_nhFDQLl11UShfYf1h_K9QQ_17_9">12,718,912</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="white-space:pre-wrap;">Income tax recovery (expense)  (Note 14)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_Wtu5VHtfFEmAouLIp0Rr7w_19_3">34,349</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_kEZdiX_uU0iShUeKNNafSQ_19_6">288,647</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_hgEGkLD0qUO0Wj38_QX70w_19_9">37,920</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Loss and comprehensive loss for the&#160;year</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_aAvLeiQ6TUOnKMER5jRMiw_21_3">36,805,461</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_3L3YBYHzYE-f8DMtqg7VbA_21_6">23,445,370</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_A8lPeIWpwUqIm25wvfWHEw_21_9">12,756,832</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Basic and diluted loss per common share</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_wmARO_RkMkCfgNByVoUtwQ_23_3">0.96</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_4-CH7hRBGEScizgVkl-7ZQ_23_6">1.04</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_5HiuQKkHZEGb3o95X-761A_23_9">1.51</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Weighted average number of common shares outstanding &#8211; basic and diluted</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_86D2vwR_MkGyx1KDNQpLJg_25_3">38,480,378</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_kc2hv90jPU23Mam22zui2g_25_6">22,443,893</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_y3rq5pM1NU6K64U_aFXuzg_25_9">8,433,441</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_fed0bb13_b35b_42a1_8c2c_39afc7276687"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ESSA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Expressed in United States dollars)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:3px double #000000;margin:0pt;">FOR THE&#160;YEARS ENDED SEPTEMBER&#160;30</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f173c36d_c41d_4235_915c_f2474f8b5fe9"></a><a id="Tc_qojQNxYwjEC-RidJ77U06w_1_2"></a><a id="Tc_WMULV0_MwUi76mjEIQ_myg_1_5"></a><a id="Tc_LJrt-fNr90WMJrBgN16TYQ_1_8"></a><a id="Tc_N1oZ2vv6PEK12xeS3HGnvA_3_0"></a><a id="Tc_sxlVh1zkNk6H_pSEET1iZA_4_0"></a><a id="Tc_NiJ5NOkk20OuPiBeKRZvuw_4_2"></a><a id="Tc_Fv9zpfcwFka2425FUdd9WQ_4_5"></a><a id="Tc_Ze3Hd-d5SE2LfBb_2kWBTA_4_8"></a><a id="Tc_U1jFBn7dGUCFnhoW27dlwg_5_0"></a><a id="Tc_nPZSiamp_0eowIJGMEWXog_6_0"></a><a id="Tc_eAcAZ2cOj06pzrAJjUimzA_7_0"></a><a id="Tc_Yzw_IVjYyU6S_1I3-hbR2w_8_0"></a><a id="Tc_I2c9vmAQ-06H-rg5pe50Tw_9_0"></a><a id="Tc_9pMDO1QoJ02VTHoObnm3Gg_10_0"></a><a id="Tc_eznROM4K-EqE3cmPpIm7tg_11_0"></a><a id="Tc_4u2fXzD4I0CB0mEm1lsVKg_12_0"></a><a id="Tc_6BuI2r1cCUWsUqMq3X6tZg_13_0"></a><a id="Tc_qJqsNWWK7U6KA7oa1U8NOw_15_0"></a><a id="Tc_qny3Hzzn60eKYTVvYhF0pQ_16_0"></a><a id="Tc_QOs9-a37mUqIeovPaR3frQ_17_0"></a><a id="Tc_g4-J57h4d0uxrQrZfhH30g_18_0"></a><a id="Tc_l9_dzVyORkmRtmOI4BNtFQ_19_0"></a><a id="Tc_XIIYp0E5EEmJh1WF9sZADg_21_0"></a><a id="Tc_Jq6PgNdanEahl7f3MlTj7w_23_0"></a><a id="Tc_ayGdvj8fPEC7no5ohCPxJQ_24_0"></a><a id="Tc_DRi7Uf-2ZUeHzkuy7-d9Cg_25_0"></a><a id="Tc_W2qntdwSXE2j1XLbkup3_A_26_0"></a><a id="Tc_MJgyLYHZD0-2QtBfqRJrWQ_27_0"></a><a id="Tc_J4_BPNF4YUOMnH9Q88vcKw_29_0"></a><a id="Tc_TTymyg7wz0me9_OybTaeHg_31_0"></a><a id="Tc_FRnGB4Ef00aCYkGoGjZbvQ_32_0"></a><a id="Tc_wHzyoex3p0Kwm6m4NGC4BA_33_0"></a><a id="Tc_Ci4HG4qJGkKE4ZeWR_IK9w_34_0"></a><a id="Tc_l0vpRWpRc0qa_imXHJDxVg_35_0"></a><a id="Tc_twuuCtg_AU2EG6UwNZZzrA_36_0"></a><a id="Tc_FQ_xxIpIrESKUg0YDvbzxQ_37_0"></a><a id="Tc_ZI8h94pPskehrbxv9Ju31Q_38_0"></a><a id="Tc_4ZC8AZwIo0-Ngmi6G4bXRA_39_0"></a><a id="Tc_ypNx1iil9U26i9lt21kaHQ_40_0"></a><a id="Tc_Q-1GdejOIkOabdRD0lK6gA_41_0"></a><a id="Tc_ODy44EmfOkOpeXwSH2YcHw_42_0"></a><a id="Tc_9YjJpuD3ik6wIavSknRNXA_43_0"></a><a id="Tc_IAtyISb9Z0qmHSkseIaIYg_45_0"></a><a id="Tc_DuT9dbH5l0eCR-ATVfZIPw_47_0"></a><a id="Tc_-q0eg0HZkU6uUlGsXrwTUw_48_0"></a><a id="Tc_oru1MWrTeE2YBF0X0aXkSQ_49_0"></a><a id="Tc_0CyMQQhnDUq3rtAfMWEk1g_51_0"></a><a id="Tc_GPKRKFRaokGFRvvHzUzmXg_51_2"></a><a id="Tc_dI9IpXSFfUmytIIy24Im3A_51_5"></a><a id="Tc_85MeyROqdEWa-YTUYF_sUw_51_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Loss for the&#160;year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_suulakwyrUS3no9gMmTMYw_4_3">36,805,461</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_4dABUYvMNkaJYpnxaegXCw_4_6">23,445,370</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_PeGNpVsLbkqtgSGue0iSVQ_4_9">12,756,832</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Items not affecting cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Amortization of right-of-use asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_VYVoraCaxkuxKDhTyAI0vA_6_3">109,464</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_UQrY2ik7Y0iM2ar4pAqdIQ_6_6">110,324</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_mA7-2Hjk2kKnx7K8KJ72Vw_6_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accretion of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccretionExpense" scale="0" id="Tc_9fD5ZvFCi02JpJv-_jIhKQ_7_3">9,570</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccretionExpense" scale="0" id="Tc_m2x9mK2ymkO0izBJSFovkQ_7_6">12,992</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:zerodash" name="us-gaap:AccretionExpense" scale="0" id="Tc_8VJHNyq_KEetc0yOPbITQA_7_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Derivative liability loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="Tc_-V1aZm3tC0CrCH14GBc8tg_8_3">107,024</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" sign="-" scale="0" id="Tc_SYaCf_b0-UOQs5h_PxEH1g_8_6">110,856</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="0" id="Tc_WaGY6moSkUCNTYgtRmbvmw_8_9">1,159</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Income tax recovery</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:zerodash" name="epix:IncomeTaxExpenseRecoveryOperatingActivities" scale="0" id="Tc_o6Gu5DYgQkWSD1XOT5QLeg_9_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="epix:IncomeTaxExpenseRecoveryOperatingActivities" scale="0" id="Tc_KWqlyRf7jkyZJLsE6AND-w_9_6">280,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:zerodash" name="epix:IncomeTaxExpenseRecoveryOperatingActivities" scale="0" id="Tc_r0rc7qbb7kOA8dYBrTe4jA_9_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="epix:InterestIncomeOperatingActivities" scale="0" id="Tc_QFZewL6xukOunP8tCpAMmQ_10_3">76,056</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:zerodash" name="epix:InterestIncomeOperatingActivities" scale="0" id="Tc_zEUQe7zlwkSf5REJ8Y5Tog_10_6">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:zerodash" name="epix:InterestIncomeOperatingActivities" scale="0" id="Tc_eoXu__LIkUynUbbOzFpsPQ_10_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Finance expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="epix:FinanceExpenseOperatingActivities" scale="0" id="Tc_2fGeyNuuQ0C88nw8-b64ww_11_3">31,192</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="epix:FinanceExpenseOperatingActivities" scale="0" id="Tc_j1LuGxeAsUufjg0ynutg3A_11_6">211,079</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:FinanceExpenseOperatingActivities" scale="0" id="Tc_LY3mhQK240WPTmz2MKczWw_11_9">602,744</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Unrealized foreign exchange</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:zerodash" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="0" id="Tc_w5YJ-rUJgEeUm06uWRddHw_12_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="0" id="Tc_3l-wUYxZXE-w29TF51uLVw_12_6">13,059</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="0" id="Tc_ISurLJkhe0mCF4edh5AQsw_12_9">16,457</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_VvEobFg8402zIwrUSVzJvQ_13_3">9,476,113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_ZDPhiwl4CU6gx22ingOzfg_13_6">7,522,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_qJ55nHGzv0OsFpWFmi52AA_13_9">1,146,707</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Changes in non-cash working capital items:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Receivables</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" id="Tc_Md3LtCxslEGLFVMO8sw04A_16_3">157,575</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" sign="-" scale="0" id="Tc_errh-n4Sd0ucjKaT4Qc-BA_16_6">89,938</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" id="Tc_wZZDpPN2gk-tDPFigI9DNg_16_9">59,665</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="Tc_yRBtS4XhaEGEaU99BdN9dQ_17_3">563,572</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="Tc_cAsCvE7SjE-H49WQAdX5lQ_17_6">1,262,280</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="Tc_TGFnjl965UadYCrncOFKaQ_17_9">179,416</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accrued liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_pPdaSi9NJ0eB-vTa-Kp3rw_18_3">2,667,738</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_1jHyb66yaEiY51u0L8RejQ_18_6">46,358</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_2qTWb0y6sUmiuM05Enya8Q_18_9">1,014,049</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Income tax payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" id="Tc_8mgKeFxR7UWnv9xnV0UAUw_19_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" sign="-" scale="0" id="Tc_zqYODgs29EKaK_0gL_kwjg_19_6">20,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" sign="-" scale="0" id="Tc_OZEDPuiA-k2sSDc5sWYd3A_19_9">4,722</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_IzzwxiLnMEamTBEhTinktA_21_3">25,415,611</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_xQ5jkAKRt0aONlP9vgMxyw_21_6">16,983,152</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_cJxRrVCJiUyrQDv90aNedQ_21_9">12,249,935</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Deposits </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromOtherDeposits" scale="0" id="Tc_8Rm4oLOYyEuPHupG8WWPpA_24_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromOtherDeposits" scale="0" id="Tc_Et4T-oruFU20NnMxI583xg_24_6">274,085</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromOtherDeposits" scale="0" id="Tc_ojGhSQ8470-8h--weP0m-A_24_9">201,399</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Purchase of short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="Tc_ZmMNWyFFoUaBuxf_n1PYpQ_25_3">57,026,103</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="Tc_1fVqe5v_X0mD7CgY8A2MoA_25_6">22,011,337</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="Tc_su6_AkBzukKEDMbn2SErFQ_25_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Proceeds from short-term investments sold</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="Tc_9q3CN3i8CkekzDuFiAW6iw_26_3">22,000,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="Tc_CQFv3hEQkUOp8jhj0d4ZUA_26_6">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="Tc_5ITSpjwg90aia2yqXTUVZg_26_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Interest from short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="epix:InterestFromShortTermInvestments" scale="0" id="Tc_Tcg9L4F4uU-JBN9P1k4mkg_27_3">11,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:zerodash" name="epix:InterestFromShortTermInvestments" scale="0" id="Tc_eS0ETEP08keEtIjG4R7uWQ_27_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:zerodash" name="epix:InterestFromShortTermInvestments" scale="0" id="Tc_ODJyMuJyYUah-UEws7uEuQ_27_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net cash (used in) provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_z2oxKHm-gEupyDzN4lv9RQ_29_3">35,014,766</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_qMZpTrPVO0iAvt_g5ysPuw_29_6">21,737,252</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="Tc_vViB0Bb2IUufcACu1OwHqw_29_9">201,399</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash acquired on acquisition of Realm</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:zerodash" name="epix:CashAcquisitionFromAcquisitionOfBusiness" scale="0" id="Tc_CqBHjjDAyEKvYFN3RLdmjg_32_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:zerodash" name="epix:CashAcquisitionFromAcquisitionOfBusiness" scale="0" id="Tc_Hnb07zHIpkeGu_WGFAQibg_32_6">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:CashAcquisitionFromAcquisitionOfBusiness" scale="0" id="Tc_bemKBnUD0kOAMrRkHL_b5w_32_9">22,244,248</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Transaction costs on acquisition of Realm</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" scale="0" id="Tc_cak59ALNWUKK8k4jbaVqZQ_33_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" scale="0" id="Tc_eHUkS1MpGEunczZlDp3p5A_33_6">64,804</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" scale="0" id="Tc_4PJNpB6LZE2obuza7hB0qw_33_9">1,860,341</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Termination costs on Realm sublease</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:zerodash" name="epix:PaymentOfSubleaseTerminationCosts" scale="0" id="Tc_kvLMniv0TkqVqi4ApC7pkw_34_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:zerodash" name="epix:PaymentOfSubleaseTerminationCosts" scale="0" id="Tc_SSfyT6Ge-Eq68m7a1R7RjA_34_6">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">(<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:PaymentOfSubleaseTerminationCosts" scale="0" id="Tc_TwnnhOH8XUGEaB0edSGK8A_34_9">246,906</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Proceeds on issuance of common shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_CoqLW24YQEerKcGz_W9SzA_35_3">149,999,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_smxczNMpeE2mk4WWDVCfsQ_35_6">48,990,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_7ksvCxBfUk2wYAdEt7iJ8g_35_9">36,000,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Share issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_vicUNAs4gkaovQKQ3ckjXA_36_3">9,229,450</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_bCma0vTRk0KPhiRD-NYJwQ_36_6">3,447,954</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_9eTfwaA6ZUOZ5Q7Z5lAoCw_36_9">2,362,329</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_F4DKonoJl0ymloL8BX4X9g_37_3">1,186,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_7x5ipA5WaU2WCptvaNChWg_37_6">915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_BVHsT9e4NEKOOfWeRXmCpQ_37_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Warrants exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Tc_0OrXfnwhVEi0HBSE7Dk2pw_38_3">596</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Tc_VCyDRLDzXUWzTpTY6UKkXQ_38_6">257,172</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Tc_fa_2sMiSnkO9utt6gEjyKQ_38_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Shares purchased through employee share purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="0" id="Tc_HQ34sss7SUm73uOW7x4Brg_39_3">133,071</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="0" id="Tc_sQOn31CboEur-jTvBEbMjg_39_6">80,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="0" id="Tc_vamDE0FYDUCtdvpVb37pdA_39_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeasePaymentsFinancingActivities" scale="0" id="Tc_XaYYj1J9x0SbzyE6iwrTnA_40_3">100,282</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeasePaymentsFinancingActivities" scale="0" id="Tc_s4z7ODKY-0uzFHhyNQ29sg_40_6">119,384</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:zerodash" name="epix:OperatingLeasePaymentsFinancingActivities" scale="0" id="Tc_IfXqSALHvkOOAW-x8tfOJg_40_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Loan principal repaid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:zerodash" name="us-gaap:RepaymentsOfDebt" scale="0" id="Tc_MMUZLSzUgECEeizlh23g4A_41_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Tc_zwAF02lGkEShjxnk8qOLFQ_41_6">3,199,799</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Tc_XGqTVL8y50-J-IMh0Q4kyA_41_9">2,808,823</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Loan final payment paid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:zerodash" name="epix:RepaymentsOfFinalPaymentOfDebt" scale="0" id="Tc_Hb9fDzD3_0y_GnOIbDjqTw_42_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="epix:RepaymentsOfFinalPaymentOfDebt" scale="0" id="Tc_WeLh4RSea0uNITYxZ4o8Pg_42_6">688,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:zerodash" name="epix:RepaymentsOfFinalPaymentOfDebt" scale="0" id="Tc_VvRyZlYMUkWHgtIsATZzFA_42_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Interest and financing costs paid </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfFinancingCosts" scale="0" id="Tc_AOEX1FsnK06uCa0uVSfpDQ_43_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="0" id="Tc_Eac5IR43IkONPYFQnq9tTg_43_6">32,235</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">(<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="0" id="Tc_Wk_wgL5n0EmIitQGcWirIQ_43_9">401,929</ix:nonFraction>)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_86xQRZ6QrkS_TWf-waaxMw_45_3">141,990,753</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_O5idSx7QNEGTE_86ClTF4w_45_6">41,776,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_bC8V7fL3f0SqhcpO49IG3Q_45_9">50,563,920</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Effect of foreign exchange on cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="0" id="Tc_6NTJLGwdgUOGoJRE4opgrw_47_3">56,115</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="0" id="Tc_ZHJ9LFnpOU24IQ-bGuzIVg_47_6">58,181</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="0" id="Tc_pofZBUCkuk2g7pJTOF0ovg_47_9">21,805</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Change in cash and cash equivalents for the&#160;year</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_X4GT9vfCtk-JtYb9V5gLoA_48_3">81,504,261</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_tjwkn0m6HUueEPZQ0qGHDA_48_6">2,998,040</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_em1Av77NTk6PKG4ZGCXYlA_48_9">38,493,579</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents, beginning of&#160;year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_29B2z-gshE2rFnW0XgLS2Q_49_3">56,320,763</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_Oiw0q3D7OEmLWHPWMxQ6WQ_49_6">53,322,723</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_HzEJmHHSXEWYNrUS2su49Q_49_9">14,829,144</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents, end of&#160;year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_A2XkIIkt0EKWMzCoygG0Nw_51_3">137,825,024</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_li6WA2FgTkSchmEXgvzvsg_51_6">56,320,763</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_YnLCyv_idEi6PmNI82MFXw_51_9">53,322,723</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Supplemental Disclosure with respect to Cash Flows (Note&#160;12)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The accompanying</span> <span style="font-style:normal;">notes are an integral part of these consolidated</span> <span style="font-style:normal;">financial statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_60f5fa5d_f617_4839_87bd_eebf4845c4ff"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">ESSA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:3px double #000000;margin:0pt;">(Expressed in United States dollars)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_bd3e3538_aee1_4a0f_935d_38ca7aaea23f"></a><a id="Tc_42TFulVqnkiTQeTuQyMZRw_1_10"></a><a id="Tc_w3AtSXKXcUCeUh71SNnAzQ_2_7"></a><a id="Tc_xWsZOXK7L0ae_ivz9_9fFg_2_10"></a><a id="Tc_gjT8l7NYpEmn-BWgu54fmw_3_2"></a><a id="Tc_fOBzsIl-xEGa6110lTZKsQ_3_4"></a><a id="Tc_biTix4jOJEq3uG4Lp-mHIQ_3_7"></a><a id="Tc_N36yN1xHbk2eiGgiQd3nZA_3_10"></a><a id="Tc_xqx5qNrekEmMjcT1umQkkA_4_2"></a><a id="Tc_9bKAlyeI5EGCoDc6VKFNlg_4_4"></a><a id="Tc_SHW6_vgha0iGFsfaRk6o1A_4_7"></a><a id="Tc_UTAbBsCyiUKIiFVut0ah2Q_4_10"></a><a id="Tc_SaFzSRltBESS9NssCf6Kjg_4_13"></a><a id="Tc_JLLE-y9ju02_2nq89P7WCA_4_16"></a><a id="Tc_4N9CJ7O4M0qIN1gmsLb7mw_6_0"></a><a id="Tc_U4vzdYCn0UipHmNfEukKcA_6_4"></a><a id="Tc_wya4H3g0g06Q4QHv0QIyJg_6_7"></a><a id="Tc_XZD17fsbhkqGv0UtjQUJ9g_6_10"></a><a id="Tc_avdXjr33sU2TLlMwkEJM2A_6_13"></a><a id="Tc_0dPrHEG0g0e6igcRAMZgDA_6_16"></a><a id="Tc_hz354VjkHkiqbFRZa9tgXw_7_0"></a><a id="Tc_Zh8EygVZL0mwXY8GDksG-g_7_8"></a><a id="Tc_XwiOb1HcG0uElzlLrgjVAA_7_11"></a><a id="Tc_qm_UICmQvUOmCcT5vgtq8w_7_14"></a><a id="Tc_o3JXF6FU6U-qoWdsw-8xDw_8_0"></a><a id="Tc_2eRr5eiuKEiP_3m_VGnGow_8_11"></a><a id="Tc__V5-0sH8GU2lGqpJS1eDpg_8_14"></a><a id="Tc_4qNixve7m0K4ZHUbMVLvbA_9_0"></a><a id="Tc_WxmOqnOtGEm4gIdS3Ob4Hw_9_2"></a><a id="Tc_XcKEgG9o3kyPAiQCyT6kmA_9_11"></a><a id="Tc_JNoVvP392UmledqRQ-BmlQ_9_14"></a><a id="Tc_ZxIbDSlUgkCrnATjlmx2ag_10_0"></a><a id="Tc_9W5EPvM4y0q43YqKWjUaPw_10_11"></a><a id="Tc_JurPmjvYWEilCYuMFsTijw_10_14"></a><a id="Tc_Nl9NmhyKOUCj8f4IpKHzdA_11_0"></a><a id="Tc_rElwTXSaLkew3seO3_OuUw_11_2"></a><a id="Tc_uNAaKYefVE-vXtoIwOoRpg_11_5"></a><a id="Tc_xPi7i4LnLkiK_rTgdTsdmg_11_11"></a><a id="Tc_ix2pZ3LTXkCKDW4Or7v-fQ_11_14"></a><a id="Tc_C9ee7iPBlUuhaRlyb8QZMA_12_0"></a><a id="Tc_1AhP7xOsK0-w1yzzy0sltw_12_2"></a><a id="Tc_hE9OKiZLEkO7wWjesWfAKg_12_5"></a><a id="Tc_n-Encbypv0SUPRD9Z32Xfw_12_8"></a><a id="Tc_dX_dwWcTm02mVji1jmN8Fg_12_11"></a><a id="Tc_qIP65Jz6EkC-Ykrltcm1Ww_14_0"></a><a id="Tc_UvEHsULb50Wxt1pr4OBUFQ_14_4"></a><a id="Tc_icdM8_TzwEiqSAOvEnIbFQ_14_7"></a><a id="Tc_3din0wDu8k6O-THhC6ckyA_14_10"></a><a id="Tc_pNTAk3npz0WpPyvPEDaFnw_14_13"></a><a id="Tc_7NK3aA57sEK4979bvacjcA_14_16"></a><a id="Tc_GqLyIirF-EichtmI3CILyg_15_0"></a><a id="Tc_yTwdPr6HDECItOlLVFkBuA_15_8"></a><a id="Tc_TRJD3M4h6kKfwhuDpFpxiA_15_11"></a><a id="Tc_qH_RhISXTkeX-zC4enxH0A_15_14"></a><a id="Tc_IIj4W8zZa0GSR2Kcpfobgw_16_0"></a><a id="Tc_LdCLG4kSYE2LpjSaBqayfQ_16_2"></a><a id="Tc_iVf88q4lbkm9ES5X1onUkw_16_11"></a><a id="Tc_on06KD9IVU2U6cfm9g4HOg_16_14"></a><a id="Tc_QgIZ41Mt3kaSb-0IX_u9Cw_17_0"></a><a id="Tc_sgChnpI_YEeaNApH0XFBnQ_17_11"></a><a id="Tc_3bSyKnxUk0KvXla6KEz0Yg_17_14"></a><a id="Tc_tTutLYQ_1kecNyTsZFdjaw_18_0"></a><a id="Tc_uzSsOBiJYECYtOQSb3YroA_18_11"></a><a id="Tc_nAI8TENo9USFsP9pLhUjuA_18_14"></a><a id="Tc_yUA7P66FME2AiQrTN4FMbA_19_0"></a><a id="Tc_VJBLgN13yEKCYlP020Trzw_19_11"></a><a id="Tc_mt8OVMBP4kSDHZVh_deAHw_19_14"></a><a id="Tc_THTtpucBUkqhOG7UiRSEYA_20_0"></a><a id="Tc__Sg1-o_xDEGt_tXpBQfz4A_20_2"></a><a id="Tc_RWBb0W0idE2abkvwPRK3Xg_20_5"></a><a id="Tc_RlLKZzIRQkCFRQ8gVLWfjg_20_11"></a><a id="Tc_Q0kVDT68e0mJ52OsgbAe2g_20_14"></a><a id="Tc_NkTNOJpx50GLViIeIwL8_Q_21_0"></a><a id="Tc_TH371gyZEEaFnDyXU9Ww0A_21_2"></a><a id="Tc_g0dnDJYHHU-Bu5WysnThwQ_21_5"></a><a id="Tc_r6d1c3yAWEm1MkSnKhyEYg_21_8"></a><a id="Tc_D1Of2O99UUyttKCIlRxfnw_21_11"></a><a id="Tc_x9qWjPQIk0WolwVc-TZehA_23_0"></a><a id="Tc_-NlTR9xR10an318ns_vM3Q_23_4"></a><a id="Tc_RYaY1HwA4EeUo63R1gKJSw_23_7"></a><a id="Tc__WvLrj3caU-vaHGUBhvXNQ_23_10"></a><a id="Tc_e8f7pL9ZYECoVx8WZAPfdg_23_13"></a><a id="Tc_vHs_cSeUhEictmbHRe3n_w_23_16"></a><a id="Tc_aQ3aA3ogVUWXaaCfqTieGw_24_0"></a><a id="Tc_oFE3Ll6Pw0uSltx-1YtXxw_24_8"></a><a id="Tc_O9UQrMmvCEuD1hwKkyczsw_24_11"></a><a id="Tc_FxZetCqaMEaAvlbeI12Y8A_24_14"></a><a id="Tc_kR6oC37o8UWQ3RM3VOfcsA_25_0"></a><a id="Tc_X5kdIWQgrEuP7CRzgAlceQ_25_2"></a><a id="Tc_3zAUQd_ThUu13iNKMC5y4g_25_8"></a><a id="Tc_xAHCHnzHFU6xil6Wl7rfIA_25_11"></a><a id="Tc_2k2kYckMnESnvqTUh98rGw_25_14"></a><a id="Tc_8iTvaJg6EEOnqUcVMDEsLg_26_0"></a><a id="Tc_tWRWLbkiuESZ4CzXRId-Dg_26_11"></a><a id="Tc_a4orPRKFPEyXgGkJperTUA_26_14"></a><a id="Tc_tHkWkk9BYkagqIvtmEcR2g_27_0"></a><a id="Tc_ch2PEYK_A0yU4aov0Wm2GA_27_11"></a><a id="Tc_FCHGE6ds60-B49Bf7hPe6g_27_14"></a><a id="Tc_Y1yJpWVruUKh8qdtAe50yA_28_0"></a><a id="Tc_LCCQBYhcQkytV1tHbmiHgg_28_11"></a><a id="Tc_BvaEEG7PC0eQcgY1o6IWcw_28_14"></a><a id="Tc_duEhOMXLx0eifnTKSnN8Jg_29_0"></a><a id="Tc_8p44b0qhwkeUglMkB_5KsA_29_2"></a><a id="Tc_X-C_V8c6MUC8CLDKvryhvA_29_5"></a><a id="Tc_2yfY1-4GSEyx7IB4lIh_kg_29_11"></a><a id="Tc_GuSe6Ubt-EamCyb9UVQkJA_29_14"></a><a id="Tc_wZXmWQKTb06RFvOZEj8Ukg_30_0"></a><a id="Tc_ezK-r65Pr0mFc8QQyf8cyA_30_2"></a><a id="Tc_MQJhmMPJAU2sWAi2ewDkKA_30_5"></a><a id="Tc_4j6VdcZLfkKGv4KhOsGcvQ_30_8"></a><a id="Tc_1GHqEFVglUaq8VPe3ekf7g_30_11"></a><a id="Tc_Lf2iRVYVu0KjfzoXhoSsOQ_32_0"></a><a id="Tc_shTG2FXyGU2OtMW_r-FYbg_32_4"></a><a id="Tc_5PArq4Xx0kORzRxlhbMo9w_32_7"></a><a id="Tc_ejeQP7H0VEeVxhDUZSHeEA_32_10"></a><a id="Tc_t5DET-0rc0eAhU-uLFAhKA_32_13"></a><a id="Tc_Kt8R5aakNkmNGNEjyn7eUw_32_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Balance, September 30, 2018</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HeTz-es_FUOKI2zSdF0t_Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_5P4nKoV64kim9KDRMeZh-g_6_2">5,776,098</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HeTz-es_FUOKI2zSdF0t_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_g_iPJ-E65kOcFNN5OTLrvw_6_5">40,205,997</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UBkybJOYYUOqeW1pxoqlrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_IIkY8GLabkuaZ-BMIfSxcQ_6_8">15,573,597</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2GRojpFcoki1Uc0vSHlB6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_ERceFFpoOk6wsUF8PseSKw_6_11">2,076,479</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rbJc2rOPu0KwHjun-BlNLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_fRThXwJsjUq9wSi63JZe2A_6_14">44,768,102</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_UWfBpoFFEUCu9Rhy0RNWAg_6_17">8,935,013</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Acquisition of Realm</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Tc_Z1poAJ12S0e1FI79dyfRew_7_2">6,718,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" id="Tc_MhsgCB2suEinmtqlGQDFpQ_7_5">20,247,296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" id="Tc_dA_2oOcNY0Cpg64PAfqe8A_7_17">20,247,296</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Financing</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_vBsquQ7iHUOYWdR3OTyFrg_8_2">6,080,596</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_l3Am7cHgFEiLms9WLaM_SA_8_5">12,161,192</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipn3WcQ-WkyTVclyeT1LWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_4DMtAEE1_E-16a6lDlDUJQ_8_8">23,838,808</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_GKsO-3FtGkiHulaU8Gf5hw_8_17">36,000,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Share issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_R7kU7XmH70-sAqGoXup9IA_9_5">2,826,443</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipn3WcQ-WkyTVclyeT1LWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_TJhLJ2LSyEiI3XSkPlemqQ_9_8">1,764,982</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_Z3C2HVKAak2mhnY4q8UaiQ_9_17">4,591,425</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Pre-funded warrants exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA" decimals="INF" format="ixt:numdotdecimal" name="epix:PrefundedWarrantExercisedShares" scale="0" id="Tc_HW8gji9FZ0SMWrLV7StNdg_10_2">2,187,530</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA" decimals="0" format="ixt:numdotdecimal" name="epix:PrefundedWarrantExercisedValue" scale="0" id="Tc_9k60aYrMF0u-YbcXLO17iw_10_5">8,757,066</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipn3WcQ-WkyTVclyeT1LWQ" decimals="0" format="ixt:numdotdecimal" name="epix:PrefundedWarrantExercisedValue" sign="-" scale="0" id="Tc_-jiSKXEdkEOLf4-AVcHNdQ_10_8">8,755,996</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:PrefundedWarrantExercisedValue" scale="0" id="Tc_IX3X9omBE0C1AeBK_kNX9A_10_17">1,070</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipn3WcQ-WkyTVclyeT1LWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_4sPwkVMGI02lMrLcb4VQHA_11_8">1,146,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_jDe4_amd0kig9ob1ndwvqQ_11_17">1,146,707</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Loss for the&#160;year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uiguQmWhpEG-xHaL8MHmpA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_PAoJdrzjrUyr_KWeo_KrXA_12_14">12,756,832</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_A3VuGaeh2kOtm5gRmSSdJw_12_17">12,756,832</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Balance, September 30, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JUboWpxLbki2h1YPzqSmdg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_NnQsegkFbEm-3ELUBTMp9A_14_2">20,762,374</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JUboWpxLbki2h1YPzqSmdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_bqLVVW15uke-L55wsJv2Qw_14_5">78,545,108</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_86DwwqBAdEWFbExnOSHKzA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_FC1cZQS2tUmmAfcTX3NfUw_14_8">30,038,134</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d_ASZ3MtTkuEthOiE92plw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_YihY6JK9r0uhikNglihFXw_14_11">2,076,479</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Qsq5hVVbp0yyXHTenb2ZaA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Y4mM0lJrxUGJ-J5M3H8lng_14_14">57,524,934</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_M65mkpH07kOSufsGwVmBTw_14_17">48,981,829</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_XBYo15E2M0ibV-bnLI4UQw_15_2">8,165,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_EkW060Aj1E60my-8uCgZpw_15_5">48,990,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_z731uxeh8kWHJ6vWwStf_Q_15_17">48,990,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Share issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_l0tXJ1WvJUyIKKpc0TGhXA_16_5">3,136,949</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93sQ70dbA0m6nn-4DY6rIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_mbfdTszyPkmPS8IViC3UZw_16_8">7,054</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_I4XVeD8wTkqDrHtsD4gxHw_16_17">3,144,003</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA" decimals="INF" format="ixt:numdotdecimal" name="epix:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_c4U2ngXmZ0aAZEwe_gxzsw_17_2">3,120,115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA" decimals="0" format="ixt:numdotdecimal" name="epix:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_jfYHHDTKfEmGJgJzyvY_2w_17_5">6,549,631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93sQ70dbA0m6nn-4DY6rIw" decimals="0" format="ixt:numdotdecimal" name="epix:StockIssuedDuringPeriodValueWarrantsExercised" sign="-" scale="0" id="Tc_oelGudUID0aT7NHXPhvV5Q_17_8">6,292,459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="epix:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_97chih8ZLkiLSnzzig2qBg_17_17">257,172</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_utph5Htsx0CCjm5WkdvJDw_18_2">416</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_GiBcW1N7IE-a9iusjH7hXQ_18_5">1,648</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93sQ70dbA0m6nn-4DY6rIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" sign="-" scale="0" id="Tc_NOFi0oMxuUCveK4kenNmZA_18_8">733</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_QixIh14IV0S30VAUfSK3xA_18_17">915</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Shares issued through employee share purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_IAcTn24ZWUS4fIq4zZQcyA_19_2">16,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="Tc_pPgZz4WKbUmMTpyNMLD3pg_19_5">136,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93sQ70dbA0m6nn-4DY6rIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" sign="-" scale="0" id="Tc_S1suUJSOFUyM73GF2b2j_g_19_8">56,212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="Tc_xe3GPan1xUWSU-IUHDti5w_19_17">80,714</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Share-based payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93sQ70dbA0m6nn-4DY6rIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_ByF-lkXAlE2aRKNJVx-klw_20_8">7,522,608</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_u3CoKSggHk6aihX2vRjkWA_20_17">7,522,608</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Loss for the&#160;year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RPs6X-s5OUmfzGYNLQRNYw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_F90ULODYYEKcW_9v9GBAIg_21_14">23,445,370</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_Swo-2fH7nki8dwJFlaoA8A_21_17">23,445,370</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Balance, September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iCrDPxN440W6E11tKIReqA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Cunii9_-pU--_vZqBpI68Q_23_2">32,064,411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iCrDPxN440W6E11tKIReqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc__6F-m0RMC0uoWw3ibu1XwA_23_5">131,086,364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GwqowEA_CUeSgGO-fqQICA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_f4qnhKEsdE6U5SqMxUr9cw_23_8">31,204,284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_iDxFp3CBoUyduJ7ED7-iBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_l--k__cjT0mkua4Rxl_erQ_23_11">2,076,479</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_r3QV4PsPVU2qBc_HlNDLwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_s2SYsCBoLU2bN5D3OLgD3g_23_14">80,970,304</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_QupzEiHQ90u6zzFAStCpsw_23_17">79,243,865</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Financing</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_69g2g5qn90aHzlRJYFLVLw_24_2">5,555,555</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_YGbjrxuaQUebMolFdxG82w_24_5">149,999,985</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_4acXuV5DTESAR0-NMzzKeg_24_17">149,999,985</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Share issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_koIXb3HaSE6XE7RI_bjbwg_25_5">9,229,450</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_Pg9YToE5KES-nqfvmRYrWw_25_17">9,229,450</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Warrants exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ" decimals="INF" format="ixt:numdotdecimal" name="epix:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_YNOhge2kmkKipFFNvP5Hdw_26_2">6,024,807</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ" decimals="0" format="ixt:numdotdecimal" name="epix:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_nF2T7mUUIE-ZLBctgUDsBw_26_5">3,254,460</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jbYIpU0s4Uy0gHFtYiCEog" decimals="0" format="ixt:numdotdecimal" name="epix:StockIssuedDuringPeriodValueWarrantsExercised" sign="-" scale="0" id="Tc_Zl247r9RKUSHfRIDwTPoiA_26_8">3,253,864</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="epix:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_y_6JuCOK-UWV26uxeSyHiw_26_17">596</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_16VikJCX1Uu9M0ZxgBF9Og_27_2">323,610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_5RFQO647R0Gp15vKUsn5MQ_27_5">2,105,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jbYIpU0s4Uy0gHFtYiCEog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" sign="-" scale="0" id="Tc_v3nTkQbeM06SYPTSVNdQXg_27_8">918,634</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_Mi9dEkYQgEO7rk7tTlCDJg_27_17">1,186,833</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Shares issued through employee share purchase plan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_7VK9zL24gE2AAAKn9--UMA_28_2">15,963</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="Tc_2cL3EktA_kq_sNZ8ZJqsBw_28_5">198,350</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jbYIpU0s4Uy0gHFtYiCEog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" sign="-" scale="0" id="Tc_IeZoFMg7ekGzmc1Q31mJdw_28_8">65,279</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="Tc_r6MdyUoWz0qAIfV2VjEgVg_28_17">133,071</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jbYIpU0s4Uy0gHFtYiCEog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc__CX9KMufwke1fAJt7KhVmw_29_8">9,476,113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_jPobs12dtk6rNqVRP2jlFA_29_17">9,476,113</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Loss for the&#160;year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9blgNKOQw0-dAjx9wbg0OA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_v8UhPxcVvU6J8KurO2jZ1g_30_14">36,805,461</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_cedGW7eN2kmAieG3Rf0cCA_30_17">36,805,461</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Balance, September 30, 2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0yAp7cE-MUSaXxmCP5yQmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Byy4aSeh3UmFegPoEJ8T0w_32_2">43,984,346</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0yAp7cE-MUSaXxmCP5yQmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_LEdB5F2tVUiLZOObcWJjoA_32_5">277,415,176</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Qr_emV94JEaOw_wTone2GA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_JoceRYSs5UGaAxVp74LGsw_32_8">36,442,620</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QEC_5wIz9U2D4cVesXTV0A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_oFuh4DGqTEavlGvRT8SmVg_32_11">2,076,479</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Xn7g0Te520GAvoVLIuOBjQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_f1GUlRLFfUuDb2PBS7dzhQ_32_14">117,775,765</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_vFMX8rP0sEeY8RPdJ57B5A_32_17">194,005,552</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:NatureOfOperations" id="Tb_uIF-98fBck2gH-q8PWRlfg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESSA Pharma&#160;Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the Province of British Columbia on January&#160;6, 2009. The Company&#8217;s head office address is Suite&#160;720&#160;&#8211; 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;Floor at 595 Burrard Street, Three Bentall Centre, Vancouver, BC, V7X 1L3. The Company is listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;EPIX&#8221;. On October 30, 2020 the Company&#8217;s common shares delisted in Canada from the TSX Venture Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (the &#8220;NTD Technology&#8221;) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As at September 30, 2021, no products are in commercial production or use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Acquisition of Realm Therapeutics plc</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On <ix:nonNumeric contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA" format="ixt:datemonthdayyearen" name="us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1" id="Narr_SNaH69tqsEq0p4M3dkjT5A">July&#160;31, 2019</ix:nonNumeric>, the Company acquired all of the issued and outstanding shares of <ix:nonNumeric contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" id="Narr_0QOTSXVpUk6t1PwlJwTxHA">Realm Therapeutics plc (&#8220;Realm&#8221;)</ix:nonNumeric> pursuant to a Scheme of Arrangement as sanctioned on July&#160;29, 2019 by the High Court of Justice in England and Wales (the &#8220;Realm Acquisition&#8221;) (Note&#160;4).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="Tb_flD09CbtFEuWTbskZbCcSw" continuedAt="Tb_flD09CbtFEuWTbskZbCcSw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;BASIS OF PRESENTATION</p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_ltpxfEnljUqPyN1J1GXGQQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All amounts expressed in these accompanying consolidated financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise indicated. References to &#8220;$&#8221; are to United States dollars and references to &#8220;C$&#8221; are to Canadian dollars.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_MLc7S-VKY0G7txkBoOnuCg" continuedAt="Tb_MLc7S-VKY0G7txkBoOnuCg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of Consolidation and Functional Currency</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Consolidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accounts of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated upon consolidation. The consolidated financial statements comprise the accounts of ESSA Pharma&#160;Inc., the parent company, and its wholly owned subsidiaries.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_1cb5fd66_c0c6_4ae4_b6e4_dc46198cce4b"></a><a id="Tc_XZ19eY8vhkieoTDe24202g_1_2"></a><a id="Tc_u72SvngZVk69_wJpcYWwLQ_1_4"></a><a id="Tc_chAaUl93hkOIeT0HPYMTcA_1_6"></a><a id="Tc_56NYeMkQMEWhs_3QAK7Hag_2_2"></a><a id="Tc_2XJC4Q2DaEGZ9l3i3-4ouw_2_4"></a><a id="Tc_wXqQNRulI0-5Fm_5PXTKwA_2_6"></a><a id="Tc_fBIQP5NtpkeFDNifljKRKQ_4_0"></a><a id="Tc_EbAdYePIOUe9KgFK1GBzzA_4_2"></a><a id="Tc_KPj20h7YZUmU697qzrvKSA_4_4"></a><a id="Tc_TGbK3G1qV06vj23M4RFDtg_4_6"></a><a id="Tc_efgF1YVwhk6FivrAIBXBnA_5_0"></a><a id="Tc_leyAa6Mh20a6M936m7sEkg_5_2"></a><a id="Tc_-noKZZVKEU20z0QinhimMg_5_5"></a><a id="Tc_MDx2TimcS0CsNI3Elx49rg_5_6"></a><a id="Tc_mQ7Sw-asuE-ln947XFDVxw_6_0"></a><a id="Tc_scE4nI0Fr0uN6fkkUf5CDg_6_2"></a><a id="Tc_pCPz4TiaD0GOk6-kcvwaXA_6_5"></a><a id="Tc_Q8-dqCfUB0WrSA9p8eSYNQ_6_6"></a><a id="Tc_1ITCMFrihkSHlbGRFaFLJg_7_0"></a><a id="Tc_i3ddlxtTpUapTFY8Exdb0g_7_2"></a><a id="Tc_rDFm4bPin0OjQGUzzqKTvA_7_5"></a><a id="Tc_XtefCp3pSUSuAK_rA44Dww_7_6"></a><ix:continuation id="Tb_flD09CbtFEuWTbskZbCcSw_cont1" continuedAt="Tb_flD09CbtFEuWTbskZbCcSw_cont2"><ix:continuation id="Tb_MLc7S-VKY0G7txkBoOnuCg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Functional Currency</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">The functional currency of an entity is the currency of the primary economic environment in which the entity operates.</p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" id="Tb_Q9NQIz_aJEy3At9rVqJmoA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The functional currency of the Company and its subsidiaries have been determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Country of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effective</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Functional</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharma&#160;Inc.</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Canada</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharmaceuticals Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_XOz0eBSbkU2BL3yWpajTpA" decimals="2" format="ixt:numdotdecimal" name="epix:PercentageOfEffectiveInterestInSubsidiaries" scale="-2" id="Tc_bAekOqqNPEyTai9hs8g9nA_5_4">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Realm Therapeutics plc <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">United Kingdom</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_RealmTherapeuticsPlcMember_F9zuOVt_vk2IQHvJ990kRA" decimals="2" format="ixt:numdotdecimal" name="epix:PercentageOfEffectiveInterestInSubsidiaries" scale="-2" id="Tc_K14zwJy55Uq4cQYMPD8rMw_6_4">100</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Pound Sterling</p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Realm Therapeutics&#160;Inc. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_RealmTherapeuticsIncMember_spJ0dJs8xkexamG5z198jQ" decimals="2" format="ixt:numdotdecimal" name="epix:PercentageOfEffectiveInterestInSubsidiaries" scale="-2" id="Tc_s9RGm99OcEe4oSZk0L9Q3w_7_4">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">In the process of liquidation and dissolution as at September 30, 2021.</span></td></tr></table><div style="margin-top:10pt;"></div></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:UseOfEstimates" id="Tb_6nwV0_QZskyVJvCZRXxEug" continuedAt="Tb_6nwV0_QZskyVJvCZRXxEug_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liabilities, the valuation of equity instruments issued for services, income taxes and the product development and relocation grant. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Income tax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Derivative financial instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Certain warrants are treated as derivative financial liabilities. The estimated fair value, based on the Black-Scholes model, is adjusted on a quarterly basis with gains or losses recognized in the statement of loss and comprehensive loss. The Black-Scholes model is based on significant assumptions such as volatility, dividend yield, expected term and liquidity discounts (Note&#160;10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based payments and compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_flD09CbtFEuWTbskZbCcSw_cont2"><ix:continuation id="Tb_6nwV0_QZskyVJvCZRXxEug_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying common shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note&#160;11.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_gTyJ3oQBrUiA7kCEvM2sLA" continuedAt="Tb_gTyJ3oQBrUiA7kCEvM2sLA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_L4TDvh_oS0mY2iAhNFNrPw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of cash in banks and high-interest savings accounts and cash collateral which are recorded at cost, which approximates fair value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:InvestmentPolicyTextBlock" id="Tb_q6WvRgAP4EOv8MCaWv5lAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Short-term investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s short-term investments consist of guaranteed investment certificates and term deposits with original maturities exceeding three months and less than one year. The investments are recorded at cost plus accrued interest, which approximates fair value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_FxnV6UerO0OMmioHjjq6Ig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Foreign exchange</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Transactions in currencies other than the United States dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are included in comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">On translation of the entities whose functional currency is other than the United States dollar, revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Assets and liabilities are translated at the rate of exchange at the reporting date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Translation gains and losses are recorded in other comprehensive income (loss) as the cumulative translation adjustment along with the historical effects of a change in the functional currency.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="epix:GovernmentAssistancePolicyPolicyTextBlock" id="Tb_c1Fay8HhkUe463Aj0IfqCQ" continuedAt="Tb_c1Fay8HhkUe463Aj0IfqCQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Government assistance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Government grants, including grants from similar bodies, consisting of investment tax credits are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research grants that compensate the Company for expenses incurred are recognized in the statement of operations and comprehensive loss on a systematic basis in the same&#160;years in which the expenses are recognized. Grants that compensate the Company for the cost of an asset are recognized on a systematic basis over the useful life of the asset.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gTyJ3oQBrUiA7kCEvM2sLA_cont1" continuedAt="Tb_gTyJ3oQBrUiA7kCEvM2sLA_cont2"><ix:continuation id="Tb_c1Fay8HhkUe463Aj0IfqCQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_9JmREIua5k-n-t3lKG9Lmw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Research and development costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Expenditures on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred. Investment tax credits related to current expenditures are included in the determination of net income as the expenditures are incurred when there is reasonable assurance they will be realized.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_gEtNrFvz50eees_oZ-PeLw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Fair Value of financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities, long-term debt and derivative liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company provides disclosures that enable users to evaluate (a)&#160;the significance of financial instruments for the entity&#8217;s financial position and performance; and (b)&#160;the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and at the date of the statement of financial position, and how the entity manages these risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 1&#160;&#8211; quoted prices (unadjusted) in active markets for identical assets or liabilities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 2&#160;&#8211; inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:40.3pt;margin:0pt 0pt 12pt 0pt;">directly (i.e., as prices) or indirectly (i.e., derived from prices); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 3&#160;&#8211; inputs for the asset or liability that are not based on observable market data (unobservable inputs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of cash and cash equivalents, receivables and accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The derivative liabilities are measured using level 3 inputs (Note 10).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_PVJPKQbVvESuwnZCtoKgWQ" continuedAt="Tb_PVJPKQbVvESuwnZCtoKgWQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Share-based payments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Share based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity settled share-based payment transactions and measured at the fair value of at grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company grants stock options to acquire common shares of the Company to directors, officers, employees and consultants. The Company has elected to early adopt ASU 2018-07 which treats the measurement of employee and nonemployee options similarly and has been applied to all periods presented. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of stock options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the requisite service or vesting period as applicable. Consideration paid for the shares on the exercise of stock options is credited to share capital. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gTyJ3oQBrUiA7kCEvM2sLA_cont2" continuedAt="Tb_gTyJ3oQBrUiA7kCEvM2sLA_cont3"><ix:continuation id="Tb_PVJPKQbVvESuwnZCtoKgWQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_Hqpubk9D5EudJHcafk7IHw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basic and diluted loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic loss per share is computed by dividing the loss available to common shareholders by the weighted average number of common shares outstanding during the&#160;year. The computation of diluted earnings per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the &#8220;if converted&#8221; method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the weighted-average method. Since the Company has losses, the exercise of outstanding options and warrants has not been included in this calculation as it would be anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_G0EE0efWBkiHwS7TxI-vlA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one&#160;year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of a lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the assessment unless there is reasonable certainty that the Company will renew.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_dqnjv9TJE066eOSJHBhZJg" continuedAt="Tb_dqnjv9TJE066eOSJHBhZJg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at period end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Deferred tax is recognized in respect of temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes and an excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary that is essentially permanent in duration.  The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted at the financial position reporting date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A valuation allowance is recognized for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets are reviewed at each reporting date and a valuation allowance is recorded to the extent that it is no longer more likely than not that the related tax benefit will be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gTyJ3oQBrUiA7kCEvM2sLA_cont3" continuedAt="Tb_gTyJ3oQBrUiA7kCEvM2sLA_cont4"><ix:continuation id="Tb_dqnjv9TJE066eOSJHBhZJg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_ZIUT_RxK20Kn3J_d-ibGtA" continuedAt="Tb_ZIUT_RxK20Kn3J_d-ibGtA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2018-18&#160;&#8211; Collaborative Arrangements (Topic 808)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In November 2018, the FASB issued ASU 2018-18, &#8220;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#8221;. This ASU: (i) clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer, (ii) provides guidance specifying that a distinct good or service is the unit of account for evaluating whether a transaction is with a customer, and (iii) precludes a company from presenting transactions with a collaborative arrangement participant that are not in the scope of ASC 606 together with revenue from contracts with customers. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020. The Company will present collaboration revenue separate from product revenues. The adoption of this new accounting standard did not have a significant impact on the Company&#8217;s consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2018-15&#160;&#8211; Intangibles &#8211; Goodwill and Other (Subtopic 350-40)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In August 2018, the FASB issued ASU 2018&#8211;15, Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350&#8211;40). This ASU addresses the accounting for implementation costs incurred by a customer in a cloud computing arrangement that is a service contract and also adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The amendment aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020 and has applied it prospectively to all implementation costs incurred after October 1, 2020. The adoption of this new accounting standard did not have a significant impact on the Company&#8217;s consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2018-13&#160;&#8211; Fair Value Measurement (Topic 820-10)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820-10): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (&#8220;ASU 2018-13&#8221;), which changes the fair value measurement disclosure requirements of ASC Topic 820, Fair Value Measurements and Disclosures. Under this ASU, certain disclosure requirements for fair value measurements are eliminated, amended or added. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October&#160;1, 2020. The adoption of the standard had no impact on the Company&#8217;s consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2019-12&#160;&#8211; Income Taxes (Topic 740)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#8220;ASU 2019-12&#8221;), which simplifies the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new ASU also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company&#8217;s consolidated financial statements and disclosures.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gTyJ3oQBrUiA7kCEvM2sLA_cont4" continuedAt="Tb_gTyJ3oQBrUiA7kCEvM2sLA_cont5"><ix:continuation id="Tb_ZIUT_RxK20Kn3J_d-ibGtA_cont1" continuedAt="Tb_ZIUT_RxK20Kn3J_d-ibGtA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2016-13&#160;&#8211; Financial Instruments-Credit Losses (Topic 326)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In June&#160;2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including trade receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. This guidance is effective for annual reporting periods beginning after December&#160;15, 2019, with early adoption permitted. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company&#8217;s consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Recently accounting pronouncements not yet adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2020-06&#160;</i><i style="font-style:italic;font-weight:normal;white-space:pre-wrap;">&#8211; Debt with Conversion and Other Options (Subtopic  470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;white-space:pre-wrap;">In August 2020, the FASB issued ASU No. 2020-06 (&#8220;ASU 2020-06&#8221;) &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic   815-40):   Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity.&#8221; ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP.  Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity&#8217;s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company&#8217;s accounting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2020-10&#160;&#8211; Codification Improvements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the FASB issued ASU 2020-10, Codification Improvements. The guidance contains improvements to the Codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the Disclosure Section of the Codification. The guidance also contains Codifications that are varied in nature and may affect the application of the guidance in cases in which the original guidance may have been unclear. For public business entities, the amendments in the ASU are effective for fiscal years beginning after December 15, 2020. For all other entities, the amendments are effective for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022. Early adoption is permitted. We do not expect the adoption of ASU 2020-10 to have a material impact on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2021-04&#160;&#8211; Earnings per share</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40). &#160;The new ASU addresses issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company will evaluate the impact of the pronouncement closer to the effective date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gTyJ3oQBrUiA7kCEvM2sLA_cont5"><ix:continuation id="Tb_ZIUT_RxK20Kn3J_d-ibGtA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statement presentation or disclosures.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4c178a5e_02f3_4e02_ab22_ba6722c5c4d4"></a><a id="Tc_I5wbV1vEXEGrDMmMkvIsEA_1_0"></a><a id="Tc_-bXf_ZSAzUK_tcK48UzvRQ_2_0"></a><a id="Tc_Fg4A3LBr00OWiR0GjlNEGQ_2_2"></a><a id="Tc_EI9ayxdGxkOrTI_C67Po1Q_3_0"></a><a id="Tc_fLyjGBMfuk6-_0rkXburHw_4_0"></a><a id="Tc_5gG3hDD750mbx5kVB38GjQ_6_0"></a><a id="Tc_9kP7hD7kjE2xAo1VZkNDvA_6_2"></a><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="Tb_40GmSPs_tEu8rDu4cPt5xg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;&#160;&#160;REALM ACQUISITION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On <ix:nonNumeric contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA" format="ixt:datemonthdayyearen" name="us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1" id="Narr_CoPC29hiNUOeJnnGzvd2HQ">July&#160;31, 2019</ix:nonNumeric>, the Company acquired all of the issued and outstanding shares of Realm. Realm shareholders received a total of <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="Narr_1uluBOmYyEupkM5iH-8kkg">6,718,150</ix:nonFraction> common shares of the Company (&#8220;New ESSA Shares&#8221;) at a ratio of <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA" decimals="INF" format="ixt:numdotdecimal" name="epix:BusinessCombinationConversionRatioPerShare" scale="0" id="Narr_phJA7WSSbE-pMmIkjkyY4g">0.05763</ix:nonFraction> of a New ESSA Share per share of Realm (or <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA" decimals="INF" format="ixt:numdotdecimal" name="epix:BusinessCombinationConversionRatioPerAmericanDepositoryShare" scale="0" id="Narr_wxLQgiKHJE24a6RUh0IpTA">1.4409</ix:nonFraction> New ESSA Shares for every one Realm ADS, representing <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA" decimals="INF" format="ixt:numdotdecimal" name="epix:BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare" scale="0" id="Narr_BRXzRL7wbEaXShYZ46aAPQ">25</ix:nonFraction> Realm shares). The fair value of the Realm net assets on July&#160;31, 2019, substantially all of which consisted of cash, was $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="0" id="Narr_1jUK4tnMCUizmNZsuEXhWg">20,247,296</ix:nonFraction>. Additionally, the Company incurred issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="0" id="Narr_LlhmcA7eu0C6pdT2kykBmA">1,925,145</ix:nonFraction>.</p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="Tb_81gjTpZERUK1Ho4ilG31_w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Realm is not considered to be a business under the definitions of ASU 2017-01; accordingly, the Realm Acquisition is accounted for as a financing transaction. The shares issued in connection with the acquisition of Realm were valued on the basis of the value of assets received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Net assets of Realm acquired:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="0" id="Tc_3yTFIixD60qJzT_3nBglzQ_2_3">22,244,248</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receivables and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw" decimals="0" format="ixt:numdotdecimal" name="epix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets" scale="0" id="Tc_iopHfOgvwkyCPVnrAralxg_3_3">240,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and accrued liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw" decimals="0" format="ixt:numdotdecimal" name="epix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_-1UvZIuynU6bgvOSArKIxg_4_3">2,236,952</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total net assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="0" id="Tc_ru6XsfFkvkSUwY-GwGIUJA_6_3">20,247,296</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="Tb_8-sABns-3ky0_11m_zsF9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5.&#160;&#160;&#160;&#160;&#160;SHORT-TERM INVESTMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments consist of guaranteed investment certificates (&#8220;GICs&#8221;) held at financial institutions purchased in accordance with the Company&#8217;s treasury policy. These GICs and term deposits bear interest at <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_U1mgWv7DPEuRz4Cu7N7uCw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:InvestmentInterestRate" scale="-2" id="Narr_HT2nWraKLEm7Nmq0xAr2vg">0.22</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_YemvLESzuEy-rvMFb5JkQw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:InvestmentInterestRate" scale="-2" id="Narr_0WtX1yWQA0KFdFGK_qtGDQ">0.40</ix:nonFraction>% per annum and have maturities of up to 12 months.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="Tc_YNzQrpootUC6F9Qp3pwbFA_1_3"></a><a id="Tc_YZ82AX-QVE6rCYQuCGbqrA_1_6"></a><a id="Tc_hE5vP8ZeU0GhWrRmIDI7IQ_2_2"></a><a id="Tc_xXyHjgSso0C1bW0s7iaS5w_2_5"></a><a id="Tc_t_rinWm-M0SfuGaX2tEVsw_4_0"></a><a id="Tc_BjSXBvlGLkytelLw_XkMjQ_4_2"></a><a id="Tc_bOZrFDvyW0Wq5C1r7WPN3w_4_5"></a><a id="Tc_Sv2PnVln-UmnIjB5ZE_9sg_5_0"></a><a id="Tc_9UAT22Ul5kSs9rni88pT5g_6_0"></a><a id="Tc_N0ud1clQX0OBlVhtGbkevA_8_0"></a><a id="Tc_Ym83Je97J0uXiASckYNPfw_8_2"></a><a id="Tc_CStJbEBHKkKFEI7pe-TJ9Q_8_5"></a><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="epix:PrepaidExpensesTextBlock" id="Tb_EGUpfZ2S2ECUn4v2dEUhtA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">6.&#160;&#160;&#160;&#160;&#160;PREPAIDS</b></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="epix:ScheduleOfPrepaidExpensesTableTextBlock" id="Tb_Io4xC7HSkEKF_RcVerVr5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_TCnvMTmsCUeyQevqhJeqyw_4_3">1,751,052</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_GBid3uEI6kWGp_v_xO7bPA_4_6">825,014</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid CMC and clinical expenses and deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="epix:PrepaidPreclinicalAndClinicalExpensesAndDeposits" scale="0" id="Tc_vX4sHP8M406AmXN-Abf2jQ_5_3">240,513</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="epix:PrepaidPreclinicalAndClinicalExpensesAndDeposits" scale="0" id="Tc_00cwCX9ob0az8D0mLcq_nw_5_6">650,586</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other deposits and prepaid expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" id="Tc_jDxWXlFvuUWin94RmhsbZw_6_3">190,317</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" id="Tc_jyPACk37t0KHXJxtjzcl9g_6_6">124,528</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, end of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_BE8wWjU2WUK87L9ATL1HQg_8_3">2,181,882</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_k5A1Exwjl0Ca5onF59jkhg_8_6">1,600,128</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="Tc_xCiKV0FcH0CgZh7yGvGUnQ_1_3"></a><a id="Tc_0SrBzuEPEEOAvrQWbC6WBw_1_6"></a><a id="Tc_GstFVuCirk2Del6vH17RCg_2_2"></a><a id="Tc_sLHOgdxhfU2F8GhukKQExA_2_5"></a><a id="Tc_ZrnVvvzFKkyitKH1guCI0w_4_0"></a><a id="Tc_YTQNzO9cVU-qoBEOUYnysA_4_2"></a><a id="Tc_YPL5Ed3zXEeDlX8Of2SxeQ_4_5"></a><a id="Tc_Q7-50_n9oUWM2Vx_g6OLNw_5_0"></a><a id="Tc_z3tx1TjaUkyYIw9PaVEdcQ_6_0"></a><a id="Tc_1K4W6Vzk_kawhj8iQ0geKQ_8_0"></a><a id="Tc_0e5IlvCC2UygrJwkpng4KA_8_2"></a><a id="Tc_9XlQ8I5ZTk6ibq-UYJyppg_8_5"></a><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_U5gGGLvqe0md8wzyR2V_uA" continuedAt="Tb_U5gGGLvqe0md8wzyR2V_uA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">7.&#160;&#160;&#160;&#160;&#160;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</b></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_ptNZxfYysEGBBiLvAwRnJw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_og6eO4xorkiFGr5a0Ivhqg_4_3">1,425,871</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_1QFfQtgO10mG58a8LIyMOQ_4_6">678,643</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_omSeYepn7Ealsj4_l6MwKQ_5_3">2,062,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_sMU_GFcLik2JxTOZEIpLJA_5_6">310,604</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="0" id="Tc_cgrFfluFDUalX0uRfZiz5g_6_3">320,632</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="0" id="Tc_TtUQcblwdU2hjVcXLRitUg_6_6">154,983</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, end of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_WZ0c_5OtbUe7YAu534NBog_8_3">3,808,944</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_tGMax2RP10mFDhFkNGbRJA_8_6">1,144,230</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_U5gGGLvqe0md8wzyR2V_uA_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_1JLSaaPPi0KzGJuq57qswg_1_0"></a><a id="Tc_I9X146lpfUO6lAQA52UoXg_2_0"></a><a id="Tc_BByXCNErP0i7HBXuaueL9A_2_2"></a><a id="Tc_ymTMnJ6hvEyIAz5hKJv-Sg_3_0"></a><a id="Tc_8LdRaMApPEqmLrQc9iQQ_g_4_0"></a><a id="Tc_2DbqNnOsBUKZ9Itgoz1Dmg_6_0"></a><a id="Tc_29FLZoAOAUWXRBtMP8G2bw_6_2"></a><a id="Tc_PrQGiW6m50GDaFUUOLsIwg_7_0"></a><a id="Tc_55X8DwCvx0mpYku8VKPvRg_8_0"></a><a id="Tc_cpcFrZTf20u907udpQsTPg_10_0"></a><a id="Tc_0KZWHNaX50qAzfjwkCHhRw_10_2"></a><a id="Tc_gH5PR0lRi0CM3Y2SeIFjYA_13_0"></a><a id="Tc_acAOHrp6OkSPwATBwxBEhw_14_0"></a><a id="Tc_N6uVR59ONUuez8H-be5XOQ_14_2"></a><a id="Tc_6mZvNxSHyU-UzNazrXhf0A_15_0"></a><a id="Tc_qVbJLWrhyUCscG1NrPHf6g_16_0"></a><a id="Tc_kVt7nQ-JqkCsOv3QHtlzMg_17_0"></a><a id="Tc_R8KI1G0c70irzhPnm0Fw0g_19_0"></a><a id="Tc__MGSHb8qKUmtoMyFBsUl8g_19_2"></a><a id="Tc_9N5sajwLCEiwrAMkBi5dPw_20_0"></a><a id="Tc_gXKdjQH7rUq1HReSdDYKAQ_21_0"></a><a id="Tc_kb5sRKjRO0uJ1OVL177OFg_22_0"></a><a id="Tc_qxm29QSpkk2ISE2onbwZMg_24_0"></a><a id="Tc_0YmEXvjAlU-BC-iFCqleGQ_24_2"></a><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_ShPuH3cO50-XUo__2ymyIQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;&#160;&#160;OPERATING LEASE</p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="epix:ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" id="Tb_trA71C5hZE2RJQ5aM-yTbg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s operating leases included on the balance sheet are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease right-of-use asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2018 and 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_l4NDfF7CDEibVNg_JElq9A_2_3">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_00qP2q4hEkunoH2xAUStyg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_5E06BJ8lx0K3dNWrtsdiWA_3_3">165,486</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_6faTOv_Gh0SEcai4f8dCEw_4_3">110,324</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeaseRightOfUseAssetsCurrent" scale="0" id="Tc_yiqWXcrctka6qCnxVpbY3g_6_3">55,162</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeaseRightOfUseAssetAddition" scale="0" id="Tc_9RYqgNJjVUu6WXQeApNCsQ_7_3">362,588</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_LYx3VDwJA0GiqnCmk-aYVw_8_3">109,464</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_Lrv0ujh1FUmypbObkzsD3w_10_3">308,286</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2018 and 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_tP8_K-8CxEuJ6dbax783qQ_14_3">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_00qP2q4hEkunoH2xAUStyg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_2v8mm1lRqkSVOs8eK4lkEQ_15_3">165,486</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeaseLiabilitiesAccretionExpenses" scale="0" id="Tc_vrdwFGN_CUeDaRHTyY-ElA_16_3">12,992</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_uqBkjd9eV0WNjrSDjAmiiw_17_3">119,384</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_Japv4df6iESeTODkJBjBHg_19_3">59,094</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Addition</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeaseLiabilitiesAddition" scale="0" id="Tc_9yEy6ixOKEyUWb3YOjwVNA_20_3">362,588</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeaseLiabilitiesAccretionExpenses" scale="0" id="Tc_lhTEKEhspk6M-1cr42YAXA_21_3">9,570</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_7yMrPVftDkOvWf5o3XjYlg_22_3">100,282</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_EiItkImhiESqfd1wmQM3AA_24_3">330,970</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes a right-of-use asset for the right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company&#8217;s obligation to make payments over the lease term. The present value of the lease payments is calculated using an incremental borrowing rate as the Company&#8217;s leases do not provide an implicit interest rate. At September 30, 2021, the Company&#8217;s incremental borrowing rate was <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_fIBdpzmXHE6eQgpO-FlR0g">5.0</ix:nonFraction>% and the remaining lease term for the South Francisco office was <ix:nonNumeric contextRef="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_epix_SouthFransicoOfficeMember_X6eZYkSuvEC6FzZjAFnRZA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Narr_D_ntuHNS60iU-c3CvxrHjw">32&#160;months</ix:nonNumeric> and Houston office was <ix:nonNumeric contextRef="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_epix_HoustonOfficeMember_ZJp_lQNFrUuwmx7ZRbXpsA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Narr_wSzNXTDWGU-LA4x6jRG5eQ">22 months</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease costs of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_taVuJ4126U26vyjixzsKcg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Narr_5CnXNL3bckqUDRhHWnyb7Q">100,282</ix:nonFraction> (2020 - $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Narr_Lw-NeLuZe025ssfWOc4grw">119,384</ix:nonFraction>) and accretion expense of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_epix_FinancingCostsMember_q3XBHIhLlEORxUBDy4pazA" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeaseLiabilitiesAccretionExpenses" scale="0" id="Narr_BnBNPgDBS0WUS2KpwU4QHg">9,570</ix:nonFraction> (2020 - $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="epix:OperatingLeaseLiabilitiesAccretionExpenses" scale="0" id="Narr_Do1SkEcIvEmKQdvseMQQxA">12,992</ix:nonFraction>) have been recorded in &#8220;general and administrative expenses&#8221; and &#8220;financing costs&#8221; in the statement of operations and comprehensive loss respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:DebtDisclosureTextBlock" id="Tb_eYZPmYHmkEqnJ3julhPPZw" continuedAt="Tb_eYZPmYHmkEqnJ3julhPPZw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9.&#160;&#160;&#160;&#160;&#160;LONG-TERM DEBT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November&#160;18, 2016, Silicon Valley Bank (&#8220;SVB&#8221;) entered into a $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_2x7YFW6kN0SPIIof17z1gw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_StpbXoQ3WEy9FOHQvw1QPA">10,000,000</ix:nonFraction> capital term loan facility agreement (&#8220;SVB Term Loan&#8221;) with the Company. The Company drew down $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="Narr_HxTJh-Ek10O9FNVQQkOT_w">8,000,000</ix:nonFraction> from the SVB Term Loan. The option to draw an additional $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_7_31_2017_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_Aizgt9l5YUetmoZ6ZgsyMQ" decimals="0" format="ixt:numdotdecimal" name="epix:DebtInstrumentAdditionalBorrowingCapacityLapsed" scale="0" id="Narr_Z8cZBjGvDEKUt0lWvmjUVA">2,000,000</ix:nonFraction> lapsed on July&#160;31, 2017.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_0d9cf476_0a90_409e_8e5f_17a06cbea60e"></a><a id="Tc_3jUc9QJHGE-vtSvp4DIjKw_1_2"></a><a id="Tc_3q4X_zCCCUOumrYx2pBscQ_2_2"></a><a id="Tc_exM7XkvlkUeiHYjudXQHhw_4_0"></a><a id="Tc_UKuZDTt64Ua3Ebwqsr79BA_4_2"></a><a id="Tc_3SMjEeniikWp9CiHNWRQdA_5_0"></a><a id="Tc_n0Mf9zjDCEmHt2nKYQeeLA_6_0"></a><a id="Tc_p6ztdTmhF0Ws0eOPHf6NPQ_7_0"></a><a id="Tc_NL_24o_bkU-nRJop4NkFpw_9_0"></a><a id="Tc_UGENGyFgCkqRxyHqRL4pQA_9_2"></a><a id="Tc_Uq-LunJMXUiYblmQm2wmWQ_11_0"></a><a id="Tc_kp9okss7jk2mduXvw9iQ7g_12_0"></a><a id="Tc_uYPZ9Py1d0md19OSnVVSlg_13_0"></a><a id="Tc_rtY3WPpkEk-2x0gxFqRCvg_14_0"></a><a id="Tc_sTQV92vEJESkJhjcBtfL8Q_16_0"></a><a id="Tc_qtgWRenbOkOfJ1pWprpYMw_16_2"></a><ix:continuation id="Tb_eYZPmYHmkEqnJ3julhPPZw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The SVB Term Loan bore interest at the Wall Street Journal Prime Rate (&#8220;WSJ Prime Rate&#8221;) plus <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_us-gaap_VariableRateAxis_epix_WallStreetJournalPrimeRateMember_Y1By_7fOBkCONtSvQElMhA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_6IDpjbfVE0OPLGmhp2Nb2g">3</ix:nonFraction>% per annum and with a maturity date of <ix:nonNumeric contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="Narr_k1yN_J7JFk-5lObBLn2JFg">September&#160;1, 2020</ix:nonNumeric>. The SVB Term Loan required a final payment of <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g" decimals="3" format="ixt:numdotdecimal" name="epix:PercentageOfFinalPaymentOnAmountAdvanced" scale="-2" id="Narr_R4aAiAIbNke7IZt-RQM1FA">8.6</ix:nonFraction>% of the amount advanced (&#8220;Final Payment&#8221;), due upon the earlier of the maturity or termination of the SVB Term Loan. The Company was required to make interest only payments until December&#160;31, 2017. The SVB Term Loan contained a voluntary prepayment option whereby the principal amount can be prepaid in whole, or in part, for a fixed fee if a prepayment is made on or before the second anniversary of the SVB Term Loan. In the year ended September 30, 2020, the Company repaid the SVB Term Loan in full totalling $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DOZiFA-O_USUr64PZMvTXg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="0" id="Narr_vFJZHaBqjkSEx_DaOgm9YQ">3,708,955</ix:nonFraction>, comprising $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_kVSb8-wpv0K1-njgvNHdsg" decimals="0" format="ixt:numdotdecimal" name="epix:RepaymentsOfLongTermDebtPrincipal" scale="0" id="Narr_T_py3fRFFk6rrULB5tcD9w">3,199,799</ix:nonFraction> in principal, $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_kVSb8-wpv0K1-njgvNHdsg" decimals="0" format="ixt:numdotdecimal" name="epix:RepaymentsOfLongTermDebtInterest" scale="0" id="Narr_wBbDYI-JXEeK8uSR6j_lqw">32,235</ix:nonFraction> in accrued interest, $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_kVSb8-wpv0K1-njgvNHdsg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="0" id="Narr_PyfN_hrlk0mbKNLRciawWA">211,079</ix:nonFraction> in financing costs and the Final Payment of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_kVSb8-wpv0K1-njgvNHdsg" decimals="0" format="ixt:numdotdecimal" name="epix:RepaymentsOfLongTermDebtFinalPayment" scale="0" id="Narr_taxYHE9AlkyQrTuhel0axw">688,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="Narr_xdDXmUJSgUacfqmkTobPxA">8,000,000</ix:nonFraction> draw, the Company granted an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g" decimals="0" format="ixt:numdotdecimal" name="epix:ClassOfWarrantOrRightGranted" scale="0" id="Narr_HJTi0eO_ek60iRoF9A4QeA">7,477</ix:nonFraction> warrants to SVB (the &#8220;SVB Warrants&#8221;), exercisable at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_2x7YFW6kN0SPIIof17z1gw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_sChQESU5DU-ZQQoStv9lkQ">42.80</ix:nonFraction> per share for a period of <ix:nonNumeric contextRef="As_Of_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_2x7YFW6kN0SPIIof17z1gw" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_3Bb3nLKB00O21f4gKstM8Q">seven years</ix:nonNumeric> until November&#160;18, 2023, with a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g" decimals="0" format="ixt:numdotdecimal" name="epix:FairValueOfWarrantIssued" scale="0" id="Narr_yRMXmOkyNkuA7JhaJLa8-A">167,022</ix:nonFraction>. The Company incurred total additional transaction costs of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_2x7YFW6kN0SPIIof17z1gw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="Narr_IVxASKEItUeRqd_RVyXgqw">220,898</ix:nonFraction> related to the SVB Term Loan and First Amendment. The transaction costs and Final Payment were being amortized into profit and loss over the estimated term of the facility, being the legal term, resulting in an effective interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_hzqNHICFq0eM1Zmd4JcmoQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_VVQd6FMLH0ql36S1fDjfzA">12.6</ix:nonFraction>% (2019&#160;- <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_sshfj9h3UEqQ_5aRwRdsVg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_84IXlWrth0CFEVYFEuMxyQ">12.19</ix:nonFraction>%).</p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:ScheduleOfDebtTableTextBlock" id="Tb_JJtB23-9Z0uKwnB8VfJGIw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The SVB Term Loan was fully repaid during the fiscal&#160;year ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SVB Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loan</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, September&#160;30,&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2018_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_hAyflyNNBEWF35w4BVawNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="Tc_kditqIc6CUWHgNTCVzv4pQ_4_3">6,316,963</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Principal repaid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_uhVPf69j8U6JNC0OpomEGA" decimals="0" format="ixt:numdotdecimal" name="epix:RepaymentsOfLongTermDebtPrincipal" scale="0" id="Tc_FWXvYl_NcUWHN2CwZzPfNg_5_3">2,808,823</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest paid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_uhVPf69j8U6JNC0OpomEGA" decimals="0" format="ixt:numdotdecimal" name="epix:RepaymentsOfLongTermDebtInterest" scale="0" id="Tc_dybYQwif2EaBzJ_BS3iDjA_6_3">401,929</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_uhVPf69j8U6JNC0OpomEGA" decimals="0" format="ixt:numdotdecimal" name="epix:DebtInstrumentAccretion" scale="0" id="Tc_cADbaDRhlEqq4W3Qt6fONg_7_3">602,744</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, September&#160;30,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2019_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DzMDwGmdD0qgqtbE68ow2Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="Tc_GVR-zEAatESYMPLO9ehEbA_9_3">3,708,955</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Principal repaid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DOZiFA-O_USUr64PZMvTXg" decimals="0" format="ixt:numdotdecimal" name="epix:RepaymentsOfLongTermDebtPrincipal" scale="0" id="Tc_5sNhKv02tEe2XHysoEcSig_11_3">3,199,799</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest paid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DOZiFA-O_USUr64PZMvTXg" decimals="0" format="ixt:numdotdecimal" name="epix:RepaymentsOfLongTermDebtInterest" scale="0" id="Tc_37VgeYP5hUuUfJx-aXzWbw_12_3">32,235</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DOZiFA-O_USUr64PZMvTXg" decimals="0" format="ixt:numdotdecimal" name="epix:DebtInstrumentAccretion" scale="0" id="Tc_HvK33KZWfUi-EV_9zWEzRA_13_3">211,079</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Final payment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DOZiFA-O_USUr64PZMvTXg" decimals="0" format="ixt:numdotdecimal" name="epix:RepaymentsOfLongTermDebtFinalPayment" scale="0" id="Tc_TJ_55UwzSUOnyHJymnZcbA_14_3">688,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, September&#160;30,&#160;2020 and 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_hzqNHICFq0eM1Zmd4JcmoQ" decimals="0" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="Tc_6RKwKR-k6EidYbXMU4wXRQ_16_3">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="Tb_5ehuSCSx6ESoV9BH3qgnCg" continuedAt="Tb_5ehuSCSx6ESoV9BH3qgnCg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10.&#160;&#160;&#160;&#160;&#160;DERIVATIVE LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2016, the Company completed a private placement of <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve_0ZTn0TU-gXeCf2aO7nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_SuD-yr0dUUWQUmTOPxeqoQ">227,273</ix:nonFraction> units of the Company at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6U4ydYiIA0OEYvfjKh5H-w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_bEkm6WPZFEmi0lfFOmH2-w">66.00</ix:nonFraction> per unit (&#8220;Unit&#8221;) for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve_0ZTn0TU-gXeCf2aO7nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" id="Narr_WWL4CnUHC0WsQxz5Ap_-ng">14,999,992</ix:nonFraction>. Each Unit consisted of <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve_0ZTn0TU-gXeCf2aO7nQ" decimals="0" format="ixt-sec:numwordsen" name="epix:UnitsIssuedInPrivatePlacementConversionRatio" scale="0" id="Narr_qXRkJgtZm0Ww2U2SlxDjMA">one</ix:nonFraction> common share of the Company, <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zBSTNeNKaU6nRdYrbBaOkA" decimals="0" format="ixt-sec:numwordsen" name="epix:UnitsIssuedInPrivatePlacementConversionRatio" scale="0" id="Narr_oJeKtknp_USWLjZYk8GR0g">one</ix:nonFraction> <span style="-sec-ix-hidden:Hidden_LQbZKgvpMkSuPJkLK-6o4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-year</span></span> cash and cashless exercise warrant (the &#8220;<span style="-sec-ix-hidden:Hidden_smbzU3-LrEiEpofGJXZ0jQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrants&#8221;), and <span style="-sec-ix-hidden:Hidden_Cq_ppVfGcEWPX38oEjsM7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one half</span></span> of one <span style="-sec-ix-hidden:Hidden_93qUCOn8jU2BvXa947ry6Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2-year</span></span> cash exercise warrant (the &#8220;<span style="-sec-ix-hidden:Hidden_QDBLvhGsQUeMEe7FQU06dg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2-Year</span></span> Warrants&#8221;). The <span style="-sec-ix-hidden:Hidden_6BX3OeUYGUyxMKVAjbP3ng;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrants and <span style="-sec-ix-hidden:Hidden_BNXa2upcvUaUska1jS5ngQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2-Year</span></span> Warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6U4ydYiIA0OEYvfjKh5H-w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_iwbv0ggszEWVkr0MNZId3g">66.00</ix:nonFraction> per common share (collectively, the &#8220;2016 Warrants&#8221;). The holders of the <span style="-sec-ix-hidden:Hidden_RPrZ07gL9EKwo3zFCZTqrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrants may elect, in lieu of exercising the <span style="-sec-ix-hidden:Hidden_VdjHFZpuu0Gaw-U_hHH3mg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrants for cash, a cashless exercise option, in whole or in part, to receive common shares equal to the fair value of the <span style="-sec-ix-hidden:Hidden_-5WrOmKIy0aUmOgHj7jFrA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrants based on the number of <span style="-sec-ix-hidden:Hidden_oH1NQJf7jEaRneoPXDn_6A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrants to be exercised multiplied by a ten-day weighted average market price less the exercise price with the difference divided by the weighted average market price. If a warrant holder exercises this option, there will be variability in the number of shares issued per <span style="-sec-ix-hidden:Hidden_XtTWqNg7CkSa4uffoyvABg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrant.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_7bc0ae10_9de1_4d4d_bbf8_f82693e00a74"></a><a id="Tc_Dfe7T4hnUkGAOHB0D2axaw_2_2"></a><a id="Tc_c6NGZH03uEOK1yuwvIQXWg_2_5"></a><a id="Tc_x1DciI15I0uY--0jwA_j5A_3_2"></a><a id="Tc_ek1yvBDFfEqB6mo7D2hrpQ_3_5"></a><a id="Tc_Clvf_TidKk2IfU41UlK_Hw_5_0"></a><a id="Tc_kQcRbaridUCcKHbqnO9W4A_5_3"></a><a id="Tc_P1qa3fBFMkKTb-8q5_qM1A_5_6"></a><a id="Tc_RwHxxeZwRkSVazfO2CJMzw_6_0"></a><a id="Tc_udy-2TxEBkq5vPW2NuT8Gw_6_3"></a><a id="Tc_rw7hYO7xbk2RqDB9gwDNBg_6_6"></a><a id="Tc_XV-GIqt88EiW9wlBevcj-Q_7_0"></a><a id="Tc_z9XwgTuJP0aIPHYb65SgOg_7_3"></a><a id="Tc_Adm9B39he0a5WCH4h0yeYA_7_6"></a><a id="Tc_jP5fxGq1XEChNWjUw0ZaqA_8_0"></a><a id="Tc_wV_JhjCSvUyDsU33wXXdXQ_9_0"></a><a id="Tc_BZiNdaX_a0ewwyTt9xvczw_9_3"></a><a id="Tc_frlDanQRm0CFK4aKMcbzPA_9_6"></a><a id="_e733b169_6daa_4fb2_ae83_7caf62bc84f0"></a><a id="Tc_eKIuq1hnvES4CO6sqxu_2A_1_2"></a><a id="Tc_hoAChSN0p0aQx4ct5O-KRA_3_0"></a><a id="Tc_Tdsf6iPdgUyQlZXvnxVUKg_3_2"></a><a id="Tc_g3cKONuZ50uuujNC3KMBzA_4_0"></a><a id="Tc_7tjvsn36KkGFJJ19eRo1HQ_6_0"></a><a id="Tc_GKeqH9IDkE6HMyDYt_dCtQ_6_2"></a><a id="Tc_KxBnBst_AkqncYqGCXAYtg_7_0"></a><a id="Tc_HNoToO3z40iYaTPwZCJEKA_9_0"></a><a id="Tc_kq5pLFxqYE6rqGtvl0nfZg_9_2"></a><a id="Tc_Z6A1Gf5h40CwRLGCu0Q7_A_10_0"></a><a id="Tc_s3hGpN8MBkSl8pZRze-pnw_12_0"></a><a id="Tc_8kcyRkbPa0mj3o3eezreSw_12_2"></a><a id="Tc_t2wBWfKRGkuf2ZE-Rpx2Kw_14_0"></a><a id="Tc_9TPto7llv0q03xO7OsN8rA_14_2"></a><a id="Tc_5yO3NrGlwkWhaEWc3GQGCw_15_0"></a><a id="Tc_0ARlysqFU0uY5H8M1ev5vg_15_2"></a><ix:continuation id="Tb_5ehuSCSx6ESoV9BH3qgnCg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, the 2016 Warrants contain provisions which may require the Company to redeem the 2016 Warrants, at the option of the holder, in the event of a major transaction, such as a change of control or sale of the Company&#8217;s assets (&#8220;Major Transaction&#8221;). The redemption value would be subject to a Black-Scholes valuation at the time of exercise. In the event the consideration for a Major Transaction payable to the common shareholders is in cash, in whole or in part, the redemption of the 2016 Warrants would be made in cash pro-rata to the composition of the consideration. The potential for a cash settlement for the 2016 Warrants outside the control of the Company, in accordance with U.S. GAAP, requires the 2016 Warrants to be treated as financial liabilities measured at fair value through profit or loss. The 2016 Warrants are not traded in an active market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Valuation</i></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_wnvi4tmOdUempSQ5DK_DiA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liabilities on September 30, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:31.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_98MIq4VaTEK2WLibJUF1nA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_2lkCIFklgEmbHUrSFTZHzw_5_2">0.49</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Y0xPeL08wEaJiqQOv0tbTw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_y94tbUQ78UmA216Gjs96IA_5_5">0.22</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_NMesmjSO1UGw6iRoGrNeyg" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_-Vb12dGpuEmhyC8WUpSCCQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_ktyu_6vhiEaSx6ZywAmzhA_6_2">1.28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_NMesmjSO1UGw6iRoGrNeyg" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_vNbAiWbcgEmqGICZO6KNCA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_gA8ejfyV9k29QRGeEKCGJA_6_5">2.28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_E5NkLJ4ccEW-hVrvKYeF-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_Nya645t9Z0yWmOVkmWQHJg_7_2">86.0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_Juvh3KilQk6ebtQh2shs2Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_aSruU8ykNkWbeHIBxWzEvg_7_5">97.3</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_5REs_qrLRkG1-jsr4Wd88A" decimals="4" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_Phnh5HNqK0qldRcvVQKTIA_8_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_Owqnc6-qBky5k4C7VJfSvg" decimals="4" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_feU-pa7zCU-X7LzZDH8a5A_8_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Liquidity discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_P2nPti2-iUCuSEEd1ouQ-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_B5-AkeABJUCZV-GKsgoHgw_9_2">20</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_PY96o3zHKEWmfUlTziLA5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_fyiqxRJt_0-YdmHbzBffZQ_9_5">20</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Sensitivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The derivative warrants are a recurring Level 3 fair value measurement. The key level 3 inputs used by management to determine the fair value are the market price, expected volatility and liquidity discount. If the market price were to increase by a factor of 10% this would increase the obligation by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_IncreaseInMarketPriceOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_TVV9GdC9SUqfmn3lDBu8_A" decimals="0" format="ixt:numdotdecimal" name="epix:IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice" scale="0" id="Narr_ApcVmZnSS02y6tdb2S7EIA">745,868</ix:nonFraction> as at September 30, 2021. If the market price were to decrease by a factor of 10% this would decrease the obligation by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_DecreaseInMarketPriceOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_gtQZa6KYHEGyPwd35QmJOg" decimals="0" format="ixt:numdotdecimal" name="epix:IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice" scale="0" id="Narr_X9EmMV2hlEqyArFLMHiByg">429,170</ix:nonFraction> as at September 30, 2021. If the volatility were to increase by 10%, this would increase the obligation by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_IncreaseInVolatilityOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9H1bHzeQPUejA4aXszVdcA" decimals="0" format="ixt:numdotdecimal" name="epix:IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility" scale="0" id="Narr_NqAEPNj2PUOxjRgSKom0wA">741,813</ix:nonFraction> as at September 30, 2021. If the volatility were to decrease by 10%, this would decrease the obligation by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_DecreaseInVolatilityOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_WLVJwCesyEOoKBOC_nuHTw" decimals="0" format="ixt:numdotdecimal" name="epix:IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility" scale="0" id="Narr_4FLdDuxuSEmVyEoEl7Yjbg">423,842</ix:nonFraction> as at September 30, 2021.</p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="Tb_54x4ReT6rES-MWJ4ybgRUA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table is a continuity schedule of changes to the Company&#8217;s derivative liabilities:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Balance, September&#160;30,&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="Tc_k19jZgemAEyEftkdaVRDtg_3_3">17,679</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="0" id="Tc_40LCIPy7wkqjNm5xtKh-fg_4_3">1,159</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Balance, September&#160;30,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="Tc_HDvc4D3U_0GDg64hZ4z1aA_6_3">16,520</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" sign="-" scale="0" id="Tc_SP18waGS_EKhX9zKmkzjbg_7_3">110,856</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="Tc_FGwiBvIEQkqG9-ywLBA2tg_9_3">127,376</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="0" id="Tc_jK3DWkhcwkqZiJ6AVTDQaw_10_3">107,024</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="Tc_n7NSk8rHmk6MbnRiuoSNIg_12_3">20,352</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Derivatives with expected life of less than one&#160;year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" id="Tc_xY_gEvvbjU-X8GIG1ATaYw_14_3">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Derivatives with expected life greater than one&#160;year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="Tc_xtlkQJRwfEaamAAJFxKFqw_15_3">20,352</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk58313732"></a><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_OGo6FvMF3ESBCPh85Cr9xw" continuedAt="Tb_OGo6FvMF3ESBCPh85Cr9xw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;&#160;&#160;SHAREHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Authorized</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unlimited common shares, without par value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unlimited preferred shares, without par value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">February 2021 Financing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On February 22, 2021, the Company completed an underwritten public offering for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_y3Sd-SWchUysmVD7P7BDmg">149,999,985</ix:nonFraction> (the &#8220;<b style="font-weight:bold;">February 2021 Financing</b>&#8221;). The Company issued a total of <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_3ZXTDynLS0SaIc_LSjLb0w">5,555,555</ix:nonFraction> common shares of the Company at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_xthkLsF1tU2jKESbtnAPiQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_lca7Xs8GgEuSQg-wuGog-A">27.00</ix:nonFraction> per share, which includes the underwriters having exercised their <span style="-sec-ix-hidden:Hidden_jpTTNPtrr0yX_oiBe_gYnw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">30-day</span></span> option to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg" decimals="INF" format="ixt:numdotdecimal" name="epix:UnderwriterOptionToPurchaseAdditionalSecurities" scale="0" id="Narr_rVPT6dmJoUCevgixdVhNiA">724,637</ix:nonFraction> common shares. In connection with the February 2021 Financing, the Company paid cash commissions of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForCommissions" scale="0" id="Narr_NOWGk7K6RUC3S3aOV9rrCA">8,999,999</ix:nonFraction> and incurred other transaction costs of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_GWwfUM0X9E-hR8NWqr3ieQ">229,451</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">July&#160;2020 Financing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July&#160;31, 2020, the Company completed an underwritten public offering for aggregate gross proceeds of US$<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_9O-seddiG0O-DtG3IZ7HSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_ABYLinpWxEGZWOxH3q1q8w">48,990,000</ix:nonFraction> (the &#8220;<b style="font-weight:bold;">July&#160;2020 Financing</b>&#8221;). The Company issued a total of <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_9O-seddiG0O-DtG3IZ7HSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Lfvv5RufRkWEf3_8jy5UuA">7,100,000</ix:nonFraction> common shares of the Company at a public offering price of US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_IVc9duJPY0u5zFzTth4c9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_eahQ5EF68U6eWBw6Yu38Dg">6.00</ix:nonFraction> per share. Additionally, the underwriters exercised a <span style="-sec-ix-hidden:Hidden_AZRAwVMkb0-1Z3ZiwRVKQw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">30-day</span></span> option to purchase up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_R-OfI-78tEubD9EHvwxUZw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_6JJSQRRMgkqYePnf1atlfg">1,065,000</ix:nonFraction> common shares. In connection with the July 2020 Financing, the Company paid cash commissions of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_9O-seddiG0O-DtG3IZ7HSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForCommissions" scale="0" id="Narr_IFtZ25vEhkOeeqPSXte2XA">2,939,400</ix:nonFraction> and incurred other transaction costs of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_9O-seddiG0O-DtG3IZ7HSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_wU_-QIsRpEuQq0of2BR09w">212,256</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">August&#160;2019 Financing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On August&#160;27, 2019, the Company closed a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the &#8220;<b style="font-weight:bold;">August&#160;2019 Financing</b>&#8221;). The Company issued a total of <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_8_27_2019_To_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_I44o30_JAkC59GqmUmKdIA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_cvSi5MRGWEGIbYIdZtpEjA">6,080,596</ix:nonFraction> common shares and <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_8_27_2019_To_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_I44o30_JAkC59GqmUmKdIA" decimals="2" format="ixt:numdotdecimal" name="epix:PreFundedWarrantsIssuedForCommonShares" scale="0" id="Narr_qlPJKRhzoUqWkbCOkpAXKw">11,919,404</ix:nonFraction> pre-funded warrants in lieu of common shares of the Company at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_5XGUa66jJ0abwyCuuh-5NQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_rUONmfm1qEik9zWHAiR0NQ">2.00</ix:nonFraction> per security for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_8_27_2019_To_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_I44o30_JAkC59GqmUmKdIA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_FfCu1TyA8ESWsQ2-oYIfZw">36,000,000</ix:nonFraction>. Each pre-funded warrant entitles the holder thereof to acquire <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_5XGUa66jJ0abwyCuuh-5NQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_MWnX3IQDJkWUuV41VEaxhA">one</ix:nonFraction> common share at a nominal exercise price for a period of <ix:nonNumeric contextRef="As_Of_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_5XGUa66jJ0abwyCuuh-5NQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_ZUQ7oHXmMkyP99b48K8x6Q">five years</ix:nonNumeric>. In connection with the August&#160;2019 Financing, the Company paid cash commissions of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_8_27_2019_To_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_I44o30_JAkC59GqmUmKdIA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForCommissions" scale="0" id="Narr_bH430mOrS0iR_kAWwawdtA">1,978,770</ix:nonFraction> and incurred other transaction costs of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_8_27_2019_To_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_I44o30_JAkC59GqmUmKdIA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_swygk2ZWlUSf46VLDFD_tA">698,162</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Realm Acquisition</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July&#160;31, 2019, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="Narr_keA-r_YGRkO-l8hybO0SZw">6,718,150</ix:nonFraction> shares in relation to the Realm Acquisition (Note&#160;4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Nomination Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with a January&#160;2016 private placement of <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve_0ZTn0TU-gXeCf2aO7nQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_9J8-hJCLr0erT2oHcwrRxw">227,273</ix:nonFraction> Units, a Unit consisting of <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve_0ZTn0TU-gXeCf2aO7nQ" decimals="INF" format="ixt-sec:numwordsen" name="epix:UnitsIssuedInPrivatePlacementConversionRatio" scale="0" id="Narr_uKH9nxDx6kqEJFUv-zQMIA">one</ix:nonFraction> common share, <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zBSTNeNKaU6nRdYrbBaOkA" decimals="INF" format="ixt-sec:numwordsen" name="epix:UnitsIssuedInPrivatePlacementConversionRatio" scale="0" id="Narr_fEz2Q9_t-Eug0Jkis-jaOQ">one</ix:nonFraction> <span style="-sec-ix-hidden:Hidden_qojYrx_Z1UW0vuZx-arG5A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-year</span></span> warrant and <span style="-sec-ix-hidden:Hidden_zEYEXFo-FkWGt12ydoujMA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one</span></span>-half of one <span style="-sec-ix-hidden:Hidden_EsUTpCDv1Eui8u7BVbNk7g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2-year</span></span> warrant, of the Company, Clarus Lifesciences III,&#160;L.P. (&#8220;<b style="font-weight:bold;">Clarus</b>&#8221;) acquired <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_1_1_2016_To_1_31_2016_dei_LegalEntityAxis_epix_ClarusLifesciencesIiiL.pMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_nZaedBWVMkOE0FrReIaxeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_MoXdLIeMkEyP-i1-SaA6oA">106,061</ix:nonFraction> common shares. Clarus is entitled to nominate two directors to the board of directors of the Company, one of which must be an independent director and preapproved by the Company. These nomination rights will continue for so long as Clarus holds greater than or equal to <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_1_1_2016_To_1_31_2016_dei_LegalEntityAxis_epix_ClarusLifesciencesIiiL.pMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_nZaedBWVMkOE0FrReIaxeg" decimals="0" format="ixt:numdotdecimal" name="epix:MinimumNumberOfSharesRequiredToBeHeldForNominationRights" scale="0" id="Narr_mBNGPYPEmk6-j3pAfeZ2Fg">53,030</ix:nonFraction> common shares, subject to adjustment in certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Equity incentive plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Restricted share units plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has adopted a Restricted Share Unit Plan (&#8220;RSU Plan&#8221;) consistent with the policies and rules&#160;of the TSX-V and Nasdaq. Pursuant to the RSU Plan, RSUs may be granted with vesting criteria and periods are approved by the Board of Directors at its discretion. The RSUs issued under the RSU Plan may be accounted for as either equity-settled or cash-settled share-based payments. At September 30, 2021, there are <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_XbywsLIR-0K_GbIr8abXkg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Narr_OOjesnPNbU6MDssrNGzK7Q">no</ix:nonFraction> RSUs outstanding.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_f461ef82_1a44_47b6_8a61_7de5bb959f2a"></a><a id="Tc_Bba1Kn8iyUOun2MX6tDOcQ_1_2"></a><a id="Tc_g6JseNfSwEejaUHOK-7qcg_2_2"></a><a id="Tc_R5zBK9UsxkaRWEKflL8iFA_2_6"></a><a id="Tc_LYSfsbGt4UWKpBTjX3QDhg_2_8"></a><a id="Tc_3GGQ3dVNW0i2C6QZq1w-Eg_4_0"></a><a id="Tc_a057Teqpp0ODF6PdYxlCkw_4_2"></a><a id="Tc_XyKZEFyjW0aKzAgnBM3uTw_4_5"></a><a id="Tc_lmkPomQbWkuCGp1KXIxWAA_4_8"></a><a id="Tc_t_9yqiupX0KjVEB4sImslw_5_0"></a><a id="Tc_HRTPOGDJ20qKR0bDvI3tLQ_6_2"></a><a id="Tc_W7DaoJzC2EKU4lvwYW-duQ_6_5"></a><a id="Tc_6WGFNC0B2EGa0gDPifuicQ_6_8"></a><a id="_4484d52d_f4fc_4db9_bb8b_de31826e6c52"></a><a id="Tc_OLKXxjrH2UOMfKnUPrTckQ_3_1"></a><a id="Tc_YiSeY0yr-0yOQrOc7y0uOg_3_4"></a><a id="Tc_tTA1IFITK0eYYFzejzS1Qw_3_6"></a><a id="Tc_h5NOIlYgGkijByvOwhcRoA_5_0"></a><a id="Tc_XE-tE8xqQkuBgkcAMd36LA_5_3"></a><a id="Tc_6C3QDZS3Yk-Z9rnFo3q4cQ_5_5"></a><a id="Tc_uNiJsin7BEWxqjtomv5Kjw_6_0"></a><a id="Tc_WZYMYgcDN0uwEblHtVzlQQ_6_6"></a><a id="Tc_NvCWbBCwbkSV3gtcfKEVow_7_0"></a><a id="Tc_HG8C3YOxLUWvURvZJ6jYTQ_7_3"></a><a id="Tc_I6uJZsQNXEyV7VuNDrGZGg_7_5"></a><a id="Tc_wX0J3c9PEkCrOk0p1qTBKQ_8_0"></a><ix:continuation id="Tb_OGo6FvMF3ESBCPh85Cr9xw_cont1" continuedAt="Tb_OGo6FvMF3ESBCPh85Cr9xw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As at September 30, 2021 the Stock Option Plan and RSU Plan have a combined maximum of <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_epix_StockOptionsAndRsuPlanMember_k54Kg0Qt60iP9qnC85_xSA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_K6xbIBRi5kuY7Oq6iyIYFA">7,342,788</ix:nonFraction> common shares which may be reserved for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Employee Share Purchase Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has adopted an Employee Share Purchase Plan (&#8220;ESPP&#8221;) under which qualifying employees may be granted purchase rights (&#8220;Purchase Rights&#8221;) to the Company&#8217;s common shares at not less of <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_BRMWk_Qg8UerO040qIU5dA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_AQtWyt3wqkWy1I5N4W8c6Q">85</ix:nonFraction>% of the market price at the lesser of the date the Purchase Right is granted or exercisable. The Company currently holds offerings consisting of <ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw" format="ixt-sec:durwordsen" name="epix:PurchaseRightsOfferingTerm" id="Narr_Tk3cywg8p0qGCoWd_-9w7Q">six-month</ix:nonNumeric> periods commencing on January&#160;1 and July&#160;1 and ending on June&#160;30 and December&#160;31 of each calendar&#160;year. As at September 30, 2021, the ESPP has a maximum of <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_BIcTAMLdhk2c5modB4s8VQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_5zgbjhyek06mXjmVHYzhZA">252,418</ix:nonFraction> (2020&#160;&#8211;<ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_RfUnofClWECxZ2F7pgy_Mg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_JRpFK825k0WlVsrGUXLmfg">268,381</ix:nonFraction>) common shares reserved for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Eligible employees are able to contribute up to <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_ZnXLMrzY2kKNEOanG51mYg" decimals="2" format="ixt:numdotdecimal" name="epix:ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" scale="-2" id="Narr_rjardE4TLUeOvCQHFJgPyA">15</ix:nonFraction>% of their gross base earnings for purchases under the ESPP through regular payroll deductions. Purchase of shares under the ESPP are limited for each employee at $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw" decimals="0" format="ixt:numdotdecimal" name="epix:MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" scale="0" id="Narr__QfEmWaeEE6j1TZp8A_pDQ">25,000</ix:nonFraction> worth of the Company&#8217;s common shares (determined using the lesser of (i)&#160;the market price of a common share on the first day of an applicable purchase period and (ii)&#160;the market price of a common share on the purchase date) for each calendar&#160;year in which a purchase right is outstanding.</p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Tb_8NNKT6tZH0q561jGLw9J8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the&#160;year ended September 30, 2021, the Company issued a total of <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_iHeEw83QWkyZCKwotjOWtQ">15,963</ix:nonFraction> (2020&#160;&#8211;<ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_nV5YVUCA0k6ZWD9Hm6F7xA">16,506</ix:nonFraction>; 2019 - <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_KbHplZS_S0-4Q0j_S03PtQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_dv66pyDi8kSPiqL6Se8QdQ">nil</ix:nonFraction>) common shares upon the exercise of Purchase Rights. The Company recognizes compensation expense for purchase rights on a straight-line basis over the service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:middle;white-space:nowrap;width:32.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended September&#160;30,&#160; </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_TDUXu41ajUSQhlC8jIdvlg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_gcUZ-JD8S0KG8OyCNxYEnw_4_3">32,299</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_C8RcT1oob06aTUsGlCRHHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_DhHTzK2exketeFftLA4zNw_4_6">24,984</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_idUWwoe5Nk-eyz-isT07Fw" decimals="0" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_g4VM4zXKSUidtDlxkhEUeg_4_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_h64usUGAzEWawEzuZH2-hg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_OgOmUUJHh0OxZTn0BEnm-Q_5_3">36,132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_vvA5BqUJTUC4h92fKpnqdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_vB1ZmKLAyk-qfHDLCu3p5w_5_6">46,033</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_5sfNjYNtMEWcos30T-GAsg" decimals="0" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_bHAjQ-yml0CZdg5TcxYfVQ_5_9">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_SSiI-GC9OUaYdfwKZ3nK0A_6_3">68,431</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_UQQNb0BWqUChL2V0iHto-Q_6_6">71,017</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_KbHplZS_S0-4Q0j_S03PtQ" decimals="0" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_avTqOUlO4UK23IcBNFfBZA_6_9">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_e7Dm0z6YP0a2D4nKbwLrxA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company measures the purchase rights based on their estimated grant date fair value using the Black-Scholes option pricing model and the estimated number of shares that can be purchased. The following weighted average assumptions were used for the valuation of purchase rights:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_Z75XQ3elC02ebNBi4U2xLQ_5_2">0.19</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_-7kIG1tBWEePBYEynmYe2Q_5_4">1.44</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_KbHplZS_S0-4Q0j_S03PtQ" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_PmH38fekakuhZe_SXw5UbA_5_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life of share purchase rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_J_5tTxtobk-m408kySsdLw_6_2">6&#160;months</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_ZZWsh5GVmkiBxG1BL9lkVw_6_4">6&#160;months</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_U2b_mc5r8USVPKxUD76_cA_7_2">61.54</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_hW4Pb_RcUkqzXNS_xQ2R5w_7_4">90.34</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_KbHplZS_S0-4Q0j_S03PtQ" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_-nW-xoMO8UyOa1n7PrVrTQ_7_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_leCXCHJ2NkmfU49wQJpQTQ_8_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_jwSCuZ-kRk28UtEMrLHSzw_8_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_KbHplZS_S0-4Q0j_S03PtQ" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_WdsCnTni2EmdxjWCa-eBSA_8_6">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Stock options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has adopted a Stock Option Plan consistent with the policies and rules&#160;of the TSX-V and Nasdaq. Pursuant to the Stock Option Plan, options may be granted with expiry terms of up to <ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_zeWUu5tnb0Wgo8Zb8VADZA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_hCvx-FypfUmx-dgZa5zKiA">10 years</ix:nonNumeric>, and vesting criteria and periods are approved by the Board of Directors at its discretion. The options issued under the Stock Option Plan are accounted for as equity-settled share-based payments.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_dd1ab335_d4db_40f6_9032_6077b9d5c63b"></a><a id="Tc_RRvxg6HlI0KIUA3bacZGXg_1_4"></a><a id="Tc_e5tZjr9DaEyO_Iq7H7VOdA_2_2"></a><a id="Tc_PHqNQmSnbUqUKzjfClGtwA_2_4"></a><a id="Tc_2iJZYeS5O0GtLnDqZwPb_g_3_2"></a><a id="Tc_CYArANTEC0C28y2Qef-H6A_3_4"></a><a id="Tc_b6hfN4-WlUmgZentgxa6vw_5_0"></a><a id="Tc_z9N6-vpgRkCN-rUz9Khq_g_5_4"></a><a id="Tc_tv547erAAESFSf3Zq2cOew_6_0"></a><a id="Tc_5BR-71KjBk-97hPt8GssUg_7_0"></a><a id="Tc_XMYQEX3y30-AsW0X-PIeyA_9_0"></a><a id="Tc_xcVLo29_wUmyW7LdMsIObA_9_4"></a><a id="Tc_FQgBhfLamE2urTvlMoM6aA_10_0"></a><a id="Tc_WLQqOvdvsU-PsvSMBcjQsg_11_0"></a><a id="Tc_BPFnttmHZ0irpSjd-Rl6aA_12_0"></a><a id="Tc_rvtS5mNzvkKPvHNV5frSrQ_14_0"></a><a id="Tc_1YemfVFm9EGqh-R2DfbV7g_14_4"></a><a id="Tc_SaMUujjdokymkgXpY3Bx8w_15_0"></a><a id="Tc_-sFNO-Er0U-NM3bqg-7CSw_16_0"></a><a id="Tc_xf9ezwbwukWyGYyXA2eI8g_17_0"></a><a id="Tc_QQXr7lTYpUmDxaU-7nsnLw_19_0"></a><a id="Tc_g06gAnY8e0K2uAb7HQG4LA_19_4"></a><a id="Tc_ZnuPcttkz0ejnEkLAeFMjA_20_0"></a><a id="Tc_hBit_QoLh0GHAg2V-76rlQ_20_4"></a><a id="_1b06176e_15eb_41ad_b723_1da293d851cf"></a><a id="Tc_MyQtZ3Q5PkmAM2uX1ljDdw_1_5"></a><a id="Tc_cY_p_D9lsUO5YO-_OalTtA_2_1"></a><a id="Tc_HBwHyuF2kU6WbO7Yz1UJaA_2_3"></a><a id="Tc_ECLxS5snvkyKbNn8JZb-dQ_2_5"></a><a id="Tc_XazA9azM4kSleGUgIUS68w_4_0"></a><a id="Tc_kjkwvTPhi0u6Y31s62tVRg_5_0"></a><a id="Tc_QTgJ-9jhoUSFuj3PjHTPRw_6_0"></a><a id="Tc_xIyB2L6PwkiCHlmKBzZ2fA_7_0"></a><a id="Tc_UtgUOYYh20-Wa3dwNdM4Aw_8_0"></a><a id="Tc_C9wFa9oPPkeqoXnr7bUwAA_9_0"></a><a id="Tc_qyBfrtmZm0yHLQTmQag1hA_10_0"></a><a id="Tc_W64SkOY9Z0qgJLe_q5N70w_11_0"></a><a id="Tc_03kZgKTeVUGjQ_6mJupiMA_12_0"></a><a id="Tc_XVWvkGVu9UuKQLDlV9yYag_13_0"></a><a id="Tc_ceChUVMQn0qUm7FsXRB5-Q_14_0"></a><a id="Tc_BgOETnec2UmUgDP8zhnLig_15_0"></a><a id="Narr_QTj45MtPFUuc4dJIW9mDwA"></a><ix:continuation id="Tb_OGo6FvMF3ESBCPh85Cr9xw_cont2" continuedAt="Tb_OGo6FvMF3ESBCPh85Cr9xw_cont3"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_jDAKGRAp4k66s2yNCd3cxg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock option transactions are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price*</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_LxMkWJbIykaxOKWRCfb-og_5_2">900,459</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_k_iywfugqEOfDygQR1Yegw_5_5">4.59</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_Ae1J-s-AcE-H-V-KrnAqiw_6_2">255,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_mxwWiHF39UmUMR-V5ewY8A_6_5">3.77</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_Zhzk5wMWLkWiM6l5XiicKA_7_2">32,998</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_FeBVZiCSrkCnScdYZkohdw_7_5">4.10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_5Ny6pPA1iUe3kjwEYIzbKg_9_2">1,122,461</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_EPdzYkUmBUOsmrpBs2gU8w_9_5">4.59</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_h9lDkKzeb06bL_2fmWrqxw_10_2">4,218,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_jHPRV4iMxki5xdbRccEVaQ_10_5">3.31</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_mQIfZrfj_EKeU5z_4f9EaQ_11_2">416</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_EOStpRgP20aVosHUrMr3wQ_11_5">2.20</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_9BtSVYiWaEW6QDGVUPbGFQ_12_2">30,461</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_DsS2Hhm9A0S4onKzCDYNaw_12_5">28.46</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_CYnShLUbwE2dCUFgxRx4Ew_14_2">5,309,584</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_igdj1OAWikG0pRp3-2j-5g_14_5">3.42</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_PQ84bx8m7U2-D8B8ymstAQ_15_2">1,889,646</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_p-khy2Jq50OMH7VQVguWdQ_15_5">9.87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_h_VauAH6nkO86mG-Dlc_bQ_16_2">323,610</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_kytCg_Rlm0Woz0IlE22C2A_16_5">3.68</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_uTA9sQkPWU-CqeUJUWrCkg_17_2">72,390</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_h11q0GG8h0CszfTpx6oTrg_17_5">4.46</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance outstanding, September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_N5DFDc_N2Ei_TBIs7i8YRg_19_2">6,803,230</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_zw8sD7pmakWUTWR7p5PGUw_19_5">5.20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance exercisable, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_yaDzGDlbeU-8mGuXM4ugYg_20_2">2,799,226</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_Fp2SKIyA8kau2pDr8zn0nA_20_5">3.49</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Options exercisable in Canadian dollars as at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">September 30, 2021</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding options.</span></td></tr></table><div style="margin-top:10pt;"></div></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="Tb_1QyQx0eNi0-3VaJEEgBd7Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At September 30, 2021, options were outstanding enabling holders to acquire common shares as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual life (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_H4_0hNFzBUGvroxmeu8AMg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_zavlz1nQPUKEkAWABEB7ng_4_1">2.20</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_H4_0hNFzBUGvroxmeu8AMg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_kRYAEemgykahyLjZnTl2yA_4_3">4,584</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_7aa-mYodb0C8Ab3SyV0S2w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_d-eJEHHLe0Wo1r19hdpE6Q_4_5">7.70</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_wlpmAoIsWkC93lTFzSx58Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_XeeXGLbH806h5mZIARz7YQ_5_1">3.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_wlpmAoIsWkC93lTFzSx58Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_jmFF_Sl97kOKFIJj4VyhQg_5_3">3,794,603</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_mbmDp3ur_EKGdhOHg5IO0Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_hR9370S8u0a-DAIOm50xwQ_5_5">8.02</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_eWAgb-BJak-hBFlUcl4JKw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_vtxxXwGeoEmaXGh9Rb1U4Q_6_1">3.59</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_eWAgb-BJak-hBFlUcl4JKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_fIpTHT9Q0kGsvFC5qt5REQ_6_3">26,667</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_wGr8DRkOREKQQphM6FzNzQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Ols_GoHVZk-GkJSxGjvCmQ_6_5">8.05</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_-Tmwt7iVW0SBnjnGzdbEZw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_0RULs7sJsEqDso3lxkm2XA_7_1">3.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_-Tmwt7iVW0SBnjnGzdbEZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_v7F_7wl31EGOHfj-Basg1w_7_3">185,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_lOFEC9XHq0q7TKCRGrQ1gQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_J81RjlOl-UmqnDSRNJyg-g_7_5">7.36</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_LTgKbV_VaEKbcbftrCEzCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_QZFSICBu1EKZMteXaSwU_g_8_1">4.00</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_LTgKbV_VaEKbcbftrCEzCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_4aoeu1wQJkiX0qGgzobNLA_8_3">539,518</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_oZ40Ld43p02RRIboS_eC8A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_ksd32_Z_N0qXtWFKDDkL4w_8_5">6.22</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_VvO15Me_VUKyqrliUVeTGQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_i04yv6oKAEm-_M6YUdOclg_9_1">4.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_VvO15Me_VUKyqrliUVeTGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_vDT15-YShkyCVsOMnjN8sA_9_3">183,511</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_qaj1qKiQnkaOQmjeCWPVtA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_deobwbmdG0GxVLgF3xk1dg_9_5">8.09</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_hiBG1IedoEC4ewOINgWhIw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_29Y-AfCJyEq1QWDmOUvrOg_10_1">7.00</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_hiBG1IedoEC4ewOINgWhIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_bkcOMwlmzUCMmldEm0wsQw_10_3">1,508,146</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_zuHf0nv_ZkuPd0J8bn1NBg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_0VWDc-oLr06nkJMFNAoy1A_10_5">9.20</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_1PenuuxZeEyE5f-LOycT4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_82DG02hYxESNI62UqscdMA_11_1">13.96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_1PenuuxZeEyE5f-LOycT4w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_Lxr_bszu_UyXsJmwP1BY3A_11_3">190,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_K5b0pB-fBkuoUKefft0NWw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_m8QQpYP1vEyZm5fwGOiHXA_11_5">9.29</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember__kUWs0yIX0ye8hi1Zc6tpA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_FR7jZ4lWtE2K89teZW15YQ_12_1">29.63</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember__kUWs0yIX0ye8hi1Zc6tpA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_bJvqXoFhw0GL0NNy_4s1TQ_12_3">100,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_DeJ3daQ9SkyjDkICey1iBg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_WqLh3NRCDki1K07lzwOVDw_12_5">9.58</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_N-YP2HmjGk2zaMleH3iyZw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_9it7BgB1L0S2cKpgNXXqLg_13_1">31.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_N-YP2HmjGk2zaMleH3iyZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_zN62supZ8k-6mpk4EEiICA_13_3">75,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_bXZJbL6ROEGmQrETPpTNlQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_cmFwLniOU0ODs3qOR1w5Yw_13_5">9.67</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_CAD_shares_HPEmoMmb7kGhCh3wegQo4A" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_oPWk0JmRaEyyBh0fzA7Y4A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_LkQbV3V11k6p2soxhGGmtQ_14_1">4.90</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_oPWk0JmRaEyyBh0fzA7Y4A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_pO1vKne8B0Gv87HdGUsjiw_14_3">163,154</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_0jMN-msT_kSZlDa8zsXivA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_XqGuSPqeq0K6IvR0-M3KAQ_14_5">5.81</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_CAD_shares_HPEmoMmb7kGhCh3wegQo4A" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_ShZSeTSzbUaq092C2OXCQA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_RPzf65USzkaz49hXt1-RUA_15_1">5.06</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_ShZSeTSzbUaq092C2OXCQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_XmxFlF1pFUqYt9xBD8tX8A_15_3">32,231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_jO7GpLA2mEqKLGWR63S2zg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_ULXegc_Z8k2T3DK2k7v0kA_15_5">7.36</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_JRrCUSbN8kmYU11jk4wmmw_16_3">6,803,230</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_2rXLSR61QEOdLDMPRRUlhQ_16_5"> 8.15</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Share-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended September 30, 2021, the Company granted a total of <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_iaC6MQPNpEOYILPsJzACcA">1,889,646</ix:nonFraction> (2020&#160;&#8211; 4,218,000, 2019 - 255,000) stock options with a weighted average fair value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_mQ15ZXcrpkqxGOBDN4uNqg">8.04</ix:nonFraction> per option (2020&#160;&#8211; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_8QuhkjKDkU-oOI03ZMr8RQ">2.98</ix:nonFraction>, 2019 - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_ALbErH-QL0y77T8y4pW4mQ">3.00</ix:nonFraction>).</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_64762826_c608_4aa5_8f7c_c5bb41e14e5a"></a><a id="Tc_Dy5O3bg3gECHAk2H3wZY8w_1_2"></a><a id="Tc_KGI8SBm290COrwuqYkDmhQ_2_2"></a><a id="Tc_CQi9wZzCmUq0b-CfZ_lMYQ_2_6"></a><a id="Tc_UXQ-3QUidUOJolwtqzuvmA_2_8"></a><a id="Tc_mp3KjWG-UEmEM-oX3dUuhQ_4_0"></a><a id="Tc_2COZCT_3-E237dDZaR_fSA_4_2"></a><a id="Tc_uDCikDiBR0Oabnp5Qn9w6w_4_5"></a><a id="Tc_7iHTaDEmnUinwOWiN0QvUw_4_8"></a><a id="Tc_gwpL-gBQsE2YQ2V4jf37Vw_5_0"></a><a id="Tc_1w-pEnvsL0-QCPV8lORoMA_6_2"></a><a id="Tc_BypmEs49UEafV7eSdnheAg_6_5"></a><a id="Tc_CQXAABiCZUCMzhZqklTg9Q_6_8"></a><a id="_5196000c_6aba_481d_a841_5f38a8eaae07"></a><a id="Tc_MrEVWr6wtk6OkL-ju5sTqw_3_1"></a><a id="Tc_F1_l0Id4pUOKsGDWXOlqkA_3_4"></a><a id="Tc_1eN1T7_GrUywwfzeNVUESw_3_6"></a><a id="Tc_ielauFkS00m5yNbh_-Bxow_5_0"></a><a id="Tc_RyHOinFFiUKevqQEODsNOg_5_3"></a><a id="Tc_oo-5KZwAwk2T9-lVsIAJDw_5_5"></a><a id="Tc_kyksaH30RkKqZRKCg_m8Kw_5_7"></a><a id="Tc_4v5UOVtZfEekJtNRg9EQ5A_6_0"></a><a id="Tc_ufV5fzYLZEupCa0A8Wc1wg_6_3"></a><a id="Tc_qanhI3jUn0alYapMCX0TMg_6_5"></a><a id="Tc_GQvkvX-j_kKEbGWX9xvZkg_6_7"></a><a id="Tc_HK6XD67dc0uP8QSAJod2WQ_7_0"></a><a id="Tc_F-s1xNG3ikiVzMNiKxeysw_7_3"></a><a id="Tc_HnMLmLsttUClLQI7edNiuQ_7_5"></a><a id="Tc_3ZDrue3cdkeWqS08IWInrw_7_7"></a><a id="Tc_ar2n3Clv5ESb2ww6HhoI3w_8_0"></a><a id="_8f49fdc1_5d2b_4626_b892_28444bd129ec"></a><a id="Tc_VGQ-YYj0n0aiSLscuBorxw_1_4"></a><a id="Tc_luS1KjSjaE6lkzbX0LFRbw_2_2"></a><a id="Tc_sf3nJNiRs0OhRQyJdqX4ag_2_4"></a><a id="Tc_-vO4nOe6BEOi1AMabR1qAA_3_2"></a><a id="Tc_FneG-GnUQ0m4NtC0NRe4-Q_3_4"></a><a id="Tc_fxZVnxpJREORQxfBJE8L3g_5_0"></a><a id="Tc_Ia_lMLL-6ESKr1a-MYF3zg_5_4"></a><a id="Tc_3FWERGm5zU2rLKnc-3u0fQ_6_0"></a><a id="Tc_2hR5x8IBlkmZqjntcHYz9w_7_0"></a><a id="Tc_Qa-xWeSqJ0qih4_hipG_OQ_8_0"></a><a id="Tc_Eo_Wd1rWxk-MWZTWFosggg_10_0"></a><a id="Tc_gl_7ExI0EUqrlepYXsYdBw_10_4"></a><a id="Tc_oJiDMzJICEenFCIvMos-Cw_11_0"></a><a id="Tc_KMPgxecePUiXMMrsMpMa9w_13_0"></a><a id="Tc_0Ma801sYCUabeLCjfIv2WQ_13_4"></a><a id="Tc_G-HahwzINkSWD_tJEefKSA_14_0"></a><a id="Tc_EW0ZvxrZpEi5ztbCJ57i1A_16_0"></a><a id="Tc_3_reIZ7o3k2sXcByOAMBMQ_16_4"></a><ix:continuation id="Tb_OGo6FvMF3ESBCPh85Cr9xw_cont3" continuedAt="Tb_OGo6FvMF3ESBCPh85Cr9xw_cont4"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Tb_Fmmt2GvfbUGHK35Gpl-reA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company recognized share-based payments expense for options granted and vesting, net of recoveries on cancellations of unvested options, during the&#160;years ended September 30, 2021, 2020 and 2019 with allocations to its functional expense as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended September&#160;30,&#160; </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expense </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_fqbH1auJ50GUwQiIlByUJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_W9LHYHank06nDwcpqzmQVQ_4_3">3,611,083</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_67NPSE9QlEiBk2PCAmKn_w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_EJURUghihkiUu7X3Za9YrA_4_6">1,853,388</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_O_W2ARKP1US6svZnbqUj6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_BRsIAfcyeUK6wxmfgJR-xg_4_9">304,786</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_BTVGr7R3tkSQWqwCNPWc3g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_4kmv6Ym-t0ieuD83POil3A_5_3">5,796,599</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_nL-lTHW6WU6Z5yoLkjYTEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_OATptCyvcU-mVPy1rTKvyQ_5_6">5,598,202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_G_hgzoPX3UCgJ-qR7IE_LA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_xhrHkpl0S0-7j1Hesjlxfg_5_9">841,921</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_PUY4zvDRs0KYidvqroZtXQ_6_3">9,407,682</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_3oGU29vPGEui7qvSdXkMuw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_lDKUMTBPvEKQ3gthz3bhXg_6_6">7,451,590</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_I94A-tgVzEeSta5_6-UjwQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_foXh8UJ8hEWmg4-uFNWieg_6_9">1,146,707</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_0Lo6wp0FmU6FKJdhvmT1kQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following weighted average assumptions were used for the Black-Scholes option-pricing model valuation of stock options granted:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_Gu78OkRfSUWMsKdhKXVoPw_5_2">0.44</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_3oGU29vPGEui7qvSdXkMuw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_2gdDZ5BChkWkhtEK8g_ABw_5_4">1.55</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_I94A-tgVzEeSta5_6-UjwQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_T7qeKy8dzE66CaPs3RIvLg_5_6">2.55</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_sSiMx4DnYkqLaY05ejujqw_6_2"> 10.00</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_3oGU29vPGEui7qvSdXkMuw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_rKIZL5uJs0yeo4O_pahjUg_6_4"> 10.00</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_I94A-tgVzEeSta5_6-UjwQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_q1TaMhyJZkWhrtzuU5a4iA_6_6"> 10.00</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_XtoNAOboQkStTQCoBzYI4Q_7_2">78.16</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_3oGU29vPGEui7qvSdXkMuw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_nhePNdiCp0qIDvKn3D4JsQ_7_4">77.00</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_I94A-tgVzEeSta5_6-UjwQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_SKFMFnSuB0GaSYcVPbzpVQ_7_6">79.33</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_n2rJl3cAlk2334m8LpuFGQ_8_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_3oGU29vPGEui7qvSdXkMuw" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_knl-jeICSUeRLqM6lbNxig_8_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_I94A-tgVzEeSta5_6-UjwQ" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_JyN2-hklLkW-_5VXx3EiIg_8_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Warrants</b></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_pJTBwr3yr02sDy_rKZ1zbA" continuedAt="Tb_pJTBwr3yr02sDy_rKZ1zbA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant transactions are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_kOWrk1tJ_0OJy0q6WbKCIA_5_2">2,663,937</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_SUqNOzEkAEOxaQDtjf5fJw_5_5">6.13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:ClassOfWarrantOrRightGranted" scale="0" id="Tc_fcs_fcPldkGR0NwX6b2xPw_6_2">11,919,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="4" format="ixt:numdotdecimal" name="epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted" scale="0" id="Tc_BaH1-r-jBkOEgaym5EfThA_6_5">0.0001</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:ClassOfWarrantOrRightExercised" scale="0" id="Tc_zwbAi8gJXU-h-RaSblOPsQ_7_2">2,188,999</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="3" format="ixt:numdotdecimal" name="epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised" sign="-" scale="0" id="Tc_z4p3neRT-EOyhQN_Ov5woQ_7_5">0.002</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:ClassOfWarrantOrRightExpired" scale="0" id="Tc_BhCslbCwDEmAWghtTTzgyg_8_2">1,250</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="2" format="ixt:numdotdecimal" name="epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" sign="-" scale="0" id="Tc_YwWsJNg2V0WLcHtZGXGewQ_8_5">31.17</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Wp-AAycrlEafigkc4h86OQ_10_2">12,393,092</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_VGVydudZu0mOcdC2rQSEEg_10_5">1.31</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="epix:ClassOfWarrantOrRightExercised" scale="0" id="Tc_9yXpAzfhSkagkXly0diTeA_11_2">3,120,115</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="3" format="ixt:numdotdecimal" name="epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised" sign="-" scale="0" id="Tc_7cwYFYLaW0a7a6fdL1IFrw_11_5">0.08</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_jD6VNGaDrkmDmwJu7sydHQ_13_2">9,272,977</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_5nAhebTPy0SBjQRwFdsUcQ_13_5">1.73</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="epix:ClassOfWarrantOrRightExercised" scale="0" id="Tc_JzOQSkh8dEKsrGCH0A0mBw_14_2">6,038,227</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="3" format="ixt:numdotdecimal" name="epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised" sign="-" scale="0" id="Tc_-QWB7TTG60-pDJz4EGBnPQ_14_5">0.06</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance outstanding and exercisable, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_DUU0pYfsLEy52OJi2ip_ew_16_2">3,234,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_u4ikvv9puEqTUs_csz8ppQ_16_5">4.84</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Warrants exercisable in Canadian dollars as at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">September 30, 2021</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding warrants.</span></td></tr></table><div style="margin-top:10pt;"></div></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_988edfd2_1d44_415c_ac6d_e2dbb1b08ea5"></a><a id="Tc_l0OsvwtjM069OJPFo24kvA_1_0"></a><a id="Tc_pN9U811Nn06DzMBPZvOYDQ_2_0"></a><a id="Tc_yx7geGmG6UO0O-HKZB05Hg_2_2"></a><a id="Tc_d38UOdrFg0aVkwcEAq3vDg_2_5"></a><a id="Tc_DzkR6E8ALUWYSZWAT6wAUw_4_1"></a><a id="Tc_SFnEIxrFikaFgG7KEhO1iA_4_2"></a><a id="Tc_9KbnKzYkek-HLgsw7LGqlw_5_2"></a><a id="Tc_FZUkqOhYTUS2G_0GZ_VkXw_6_2"></a><a id="Tc_CcSj47feT06GUEfD9Qqh2w_7_2"></a><ix:continuation id="Tb_OGo6FvMF3ESBCPh85Cr9xw_cont4"><ix:continuation id="Tb_pJTBwr3yr02sDy_rKZ1zbA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="epix:ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" id="Tb_eC166xY3IUe-POH07imSsg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">At September 30, 2021, warrants were outstanding enabling holders to acquire common shares as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiry Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceOneMember_peg5Z3r7MkaJuDu2VWniig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_fHPrz9aNME6ONkNwhhzIIg_4_0">227,273</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceOneMember_peg5Z3r7MkaJuDu2VWniig" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_m7LErgkG5UuOfOnKYmUhKg_4_3">66.00</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceOneMember_peg5Z3r7MkaJuDu2VWniig" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="Tc_vFzinmJ8rkKyjP78btaCKw_4_5">January&#160;14, 2023</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_QlJ05My24UihYsCtnSc8oA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_5929N8OnkkCzmcq-5cdHDQ_5_0">7,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_QlJ05My24UihYsCtnSc8oA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_VWQrFnWfdUKL68J-C2ni2A_5_3">42.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_QlJ05My24UihYsCtnSc8oA" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="Tc_c2GdZ55qbkCf3a-vk_BW3g_5_5">November&#160;18, 2023</ix:nonNumeric></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceThreeMember_Poysa79t_k26dJwrtpr7cA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_JS8lyMRNHU-ChlJtJ4wVmQ_6_0">80,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceThreeMember_Poysa79t_k26dJwrtpr7cA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_1flxYzcLFkOZNyEGtSMCxQ_6_3">4.00</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceThreeMember_Poysa79t_k26dJwrtpr7cA" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="Tc_WNbtKfhw4U2-qsGwGUeszg_6_5">January&#160;9, 2023</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_TR1RCu8S8U-alcwoR2y6RA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_DtjyhZklnEasOW4hDeJxqg_7_0">2,920,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_TR1RCu8S8U-alcwoR2y6RA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_C5j6O3ZqX0-hIPx3wAEhNg_7_3">0.0001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_TR1RCu8S8U-alcwoR2y6RA" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="Tc_bGAbnDA1PE2YA52CjiUtDw_7_5">August&#160;23, 2024</ix:nonNumeric></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_-3lehuHRp0mIZ5ilc_CdaA_8_0">3,234,750</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Detailed terms of the 2016 Warrants are included in Note&#160;10.</span></td></tr></table></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="Tb_dLcyAccqFUqfK11i0kz7bg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">12.&#160;&#160;&#160;&#160;SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended September 30, 2021, the Company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="epix:StockIssuedDuringPeriodValuePreFundedWarrantsExercised" scale="0" id="Narr_N5JP6z4o70WzMiASZ4M4Qg">81,303</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> common shares upon the cashless exercise of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="epix:PreFundedWarrantsExercised" scale="0" id="Narr_LwfynKy5mEamyR4PQyl6nw">94,723</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> pre-funded warrants.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There were no significant non-cash financing or investing activities during the year ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended September&#160;30, 2019, the Company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:StockIssuedDuringPeriodValuePreFundedWarrantsExercised" scale="0" id="Narr_Q_2AVTreXUecBOZWu0E-pw">1,652,530</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> common shares upon the cashless exercise of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:PreFundedWarrantsExercised" scale="0" id="Narr_fVzZTLNCWk6iJaODjO6zLg">1,653,999</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> pre-funded warrants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">incurred </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability" scale="0" id="Narr_Uc2Nx_hiUEG1ELsWyCYEAA">64,804</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> in transaction costs related to the Realm Transaction through accounts payable and accrued liabilities (Note&#160;4); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">incurred </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities" scale="0" id="Narr_PgIedhpt7UWl3MI1ch2X8w">303,951</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> in share issuance costs through accounts payable and accrued liabilities.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_7dElGTJv-062x-J0aZ4GDA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">13.&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Included in accounts payable and accrued liabilities at September 30, 2021 is $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_rj2UHMCflEe1q86RKPHdAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Narr_21DhuCALeEOPEOxodxFcmQ">82,036</ix:nonFraction> (2020&#160;- $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_apbVsSWBtk-56toVL5ECFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Narr_cpeLtz-yTECeHLkbSF312g">87,846</ix:nonFraction>) due to related parties with respect to key management personnel compensation and expense reimbursements. Amounts due to related parties are non-interest bearing, with no fixed terms of repayment.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_8iquwa4RgUuMh2ORa0ZRSw_1_0"></a><a id="Tc_7YSfYo-3hEa5g-foafqvcA_1_2"></a><a id="Tc_8-pCqcRVDU-fZGYq0KlB0g_1_5"></a><a id="Tc_3IkHqy2E30m_1S8h9UDbiA_1_8"></a><a id="Tc_95FWMYwRjUiKAltnSeBZoA_3_0"></a><a id="Tc_vaDe6HitFE23bTT52pmOyQ_3_2"></a><a id="Tc_hGOWcI8V1k6hfDPSg4xJAg_3_5"></a><a id="Tc_-4XRX1wCHUCf-v9IAWCr8Q_3_8"></a><a id="Tc__x6M61FyxkSqgiaeG17XqA_5_0"></a><a id="Tc_tXZkXadVBE-eOs3g_XxDKw_5_2"></a><a id="Tc_2WUZVH0_F0KZHv6jFeKJjQ_5_5"></a><a id="Tc_3j1IoQ-dSEqELZuID-dahw_5_8"></a><a id="Tc_nNl41lcBzUmC5bYWK2_adQ_6_0"></a><a id="Tc_UsOQ23zBP0q8yv7roqWoeg_7_0"></a><a id="Tc_P6TGCbXfVEid_iocUo0X2A_7_6"></a><a id="Tc_JpuzhhjHlkKFuJ7nwp_YjA_8_0"></a><a id="Tc_J-aIA4PHsEiT00ISJwQ3Qg_9_0"></a><a id="Tc_ByQhEVKZPkGH63riFlI93g_10_0"></a><a id="Tc_CbJXdGrgbUe5APYQpxyymQ_11_0"></a><a id="Tc_6VAr8TUUhUuqIdmV302Z9w_12_0"></a><a id="Tc_qn8lTHNjVEa4I_G3X-FmXQ_14_0"></a><a id="Tc_xJvQPV1tGE-LqgtewjTzRw_14_2"></a><a id="Tc_mOJVsPG3K0-0a1Bg_gpzdA_14_5"></a><a id="Tc_P01sDc14h0GXrlgDXTAayQ_14_8"></a><a id="_1aaf646d_e136_49fb_8d7d_b4d07470fbee"></a><a id="Tc_bGhHteFiPk69HQQUrJse-w_1_0"></a><a id="Tc_nZ5I8gJ-4E-lVDvaFzOu1Q_1_2"></a><a id="Tc_Nf8kKIEfh0OKZ8eRde4aiA_1_5"></a><a id="Tc_9b5qXKh1Cky5l6yAngvpaQ_3_0"></a><a id="Tc_VQn0zzCtY0KZ7uy2FWxQQQ_3_2"></a><a id="Tc_uXm0zucS6U-s0axUfTTbbw_3_5"></a><a id="Tc_q_yW4dIFBU2A-uNB_UpLGA_4_0"></a><a id="Tc_Nca55J3d0U2eFBZHDr2fEA_5_0"></a><a id="Tc_ejMeh-vdAEmf3sBV7fJZlQ_6_0"></a><a id="Tc_XWdIFv2TRUK0427ZBgu_vQ_7_0"></a><a id="Tc_bgugna0P3ESpdIpPOBhjFw_8_0"></a><a id="Tc_4_sqGGqI8USGTAPBLFineQ_11_0"></a><a id="Tc_DDthvY7EXESdcURyUZq_AA_13_0"></a><a id="Tc_YuzqX0Noc0ahAOjXJKL4Gw_13_2"></a><a id="Tc_zei1JK4Zr068bj4ER91ixg_13_5"></a><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_ZwCeWM_mLEm-5vBHGZ-SVQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;&#160;&#160;&#160;INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a reconciliation of income taxes calculated at the combined Canadian federal and provincial income statutory corporate tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_6oDupUI2gEK8jRgQT_dG_w">27.0</ix:nonFraction>% (2020 &#8211; <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_bMR2VTR1_EeEcB8CcUP7iw">27.0</ix:nonFraction>%, 2019 &#8211; <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_UKY28GzEh0yAgiruLS-MrQ">27.0</ix:nonFraction>%) to the tax expense:</p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_PSKL-HdKNke79X363yjHzQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">For the&#160;years ended September&#160;30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Loss for the&#160;year before income tax</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_4pnbVKBbUEGBBo19-WMYqQ_3_3">36,839,810</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_1T62A9WSk0-qnt_2qTCZsA_3_6">23,734,017</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_H98U4rT7gE-mZI9RwaOPWg_3_9">12,718,912</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax recovery at statutory income tax rates</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_dVO94cuX2UGsL06jsS-WOg_5_3">9,947,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_AH8YC9GX5EyjO6m5_4XWgw_5_6">6,408,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_wf7j5fjtI0qqUnErZQs8zQ_5_9">3,434,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-deductible share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" id="Tc_7usEyvaFok680RXBFTM72A_6_3">1,575,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" id="Tc_zjS2guZqYkqSLnJU4atapw_6_6">2,031,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" id="Tc_iUmDsgwRDE2bYbCMfLwRJA_6_9">227,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxable capital gains</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:IncomeTaxReconciliationTaxableCapitalGains" scale="0" id="Tc_7yZI9jDGiUKf_5AowV5Pgg_7_9">346,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other permanent differences including foreign exchange</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" sign="-" scale="0" id="Tc_amJFCwlRTUa4cM2XeKaBLA_8_3">49,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" id="Tc_2CMOV7WPVEySmVp6zBzjzA_8_6">21,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" id="Tc_el1QNOu6ikOz6JmAmAyYRA_8_9">3,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share issue costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="epix:IncomeTaxReconciliationFinancingCosts" sign="-" scale="0" id="Tc_CopV32Rp1kuZg7VAXoM7Iw_9_3">2,492,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="epix:IncomeTaxReconciliationFinancingCosts" sign="-" scale="0" id="Tc_J9Y-FH06IES-oH8xDiDGuw_9_6">849,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="epix:IncomeTaxReconciliationFinancingCosts" sign="-" scale="0" id="Tc_uRttlQBdW0yF_Bj9XlLkzQ_9_9">720,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in statutory, foreign tax, foreign exchange rates and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" id="Tc_2_N0aY7Whk-Lx1a7KjaK7A_10_3">1,260,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" id="Tc_i5LzVqZJs0OU2Ss_059hQw_10_6">1,013,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" id="Tc_R7SxSGLAX0Oor6XVyn2MXA_10_9">458,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" sign="-" scale="0" id="Tc_vVnNX59EdkGHx0FNCh-z9Q_11_3">725,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" sign="-" scale="0" id="Tc_9D_u4y-rUk-noURCx1QnlA_11_6">307,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" sign="-" scale="0" id="Tc_m8zpwmDCzUWVEpQ8127O0Q_11_9">196,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_1jKCew__dU2QTnFgo9ZDPw_12_3">10,344,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_dyOp_QjTIkmYVuZTQc4mIQ_12_6">4,210,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_Kw-RqYyE5EOk87k8F1QtWg_12_9">3,354,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_I8yCBUa3N0W0JSccZZb-kw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> (34,000)</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Y6jwuf91OUyOdeLUzsBsTA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> (289,000)</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qGTwKPFLwU6oUyoQmQDV4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> 38,000</span></span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax attributes are subject to review, and potential adjustment, by tax authorities. The Company has recorded an income tax recovery of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Narr_fWbgQYo040GZ0CmKQ-_q2g">34,349</ix:nonFraction> for the&#160;year ended September 30, 2021 (2020&#160;&#8211; recovery of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Narr_NQdJ9SMRC0K_hKOdEffujw">288,647</ix:nonFraction>, 2019 &#8211; expense of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_jjrlCBS-_02-XYKp8oB-xA">37,920</ix:nonFraction>) in relation to taxable income generated by its US subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the years ended September 30, 2021 and 2020, the Company did not record a provision for income taxes due to a full valuation allowance against our deferred tax assets. The significant components of the Company&#8217;s deferred tax assets are as follows:</p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_ZiVTbFEcL0y0BOBHsyXmxQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating losses carried forward</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_wCw9wg0nBE-2Tw4L67euHQ_3_3">29,749,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_J5jl0bPN2kOXFEjnsmX5-A_3_6">21,297,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equipment and intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="epix:DeferredTaxAssetsEquipmentAndIntangibleAssets" scale="0" id="Tc_KPokMXSSLkSutZLllu1qYA_4_3">77,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="epix:DeferredTaxAssetsEquipmentAndIntangibleAssets" scale="0" id="Tc_A4DW_GMx3kaVDKU0UFEWmw_4_6">77,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investment tax credits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInvestments" scale="0" id="Tc_u1wUxxdq9kiFF6oOAGoMaQ_5_3">29,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInvestments" scale="0" id="Tc_xxXhE_mdwUe_bUPZgvwlzw_5_6">39,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="epix:DeferredTaxAssetsFinancingCosts" scale="0" id="Tc_tUfxvPdo70i2qUsS8p6lJw_6_3">3,025,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="epix:DeferredTaxAssetsFinancingCosts" scale="0" id="Tc_yvPf3tP4tk-XMizn6qCDTg_6_6">1,462,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal R&amp;D credit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_ABh0j-yL90Gzcoyh5NDcsg_7_3">210,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_R8XczcN1L0GsLjv6d9pksQ_7_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="Tc_Z9Ln3tlAAkWkbHjJGyaagQ_8_3">79,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="Tc_P30CTndgcUiTLh1RhuzJYQ_8_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_HP97auE5e0qPMZq3ElvzxQ_10_3">33,169,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_y2uHoyZCv0iYKj4hiF4smQ_10_6">22,875,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_02wyqdGpiUCnQxeY85ZPzQ_11_3">33,169,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_ZG0m2Gq60UmxCWAL5F25ug_11_6">22,875,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net future tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_nQJyDH1xkkqqG1jjq4qSOw_13_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_Pb7LaFi8HkeS9crK8pheWg_13_6">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As at September 30, 2021, the Company has non-capital loss carry-forwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_wiQZ0GbLlkimzzAcX5zh1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_LysVAO5ZAEqcqA5lpsJ6bA">78,416,000</ix:nonFraction> (2020 - $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_U7-LX1-3mUqaUlE6IXrBYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_5Fxt73d5hE-qwWDI3rQuow">64,494,000</ix:nonFraction>) available to offset future taxable income in Canada and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_WEBFjPZWXUWEyRoGCQubVA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_JRoBnKvwT06EpyteN1MILw">40,843,000</ix:nonFraction> (2020 - $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_SMYfJ5aGWk-8_6eAqyWYbg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_PxqGuj_VrEqAk8RMA-wVZw">20,249,000</ix:nonFraction>) available to offset future taxable income in the US. These non-capital loss carryforwards begin to expire in 2031.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_UYNoXACFW02C4zeMCKMO_A" continuedAt="Tb_UYNoXACFW02C4zeMCKMO_A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15.&#160;&#160;&#160;&#160;SEGMENTED INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company works in <ix:nonFraction unitRef="Unit_Standard_segment_bQM1D9rk7USEKwcghht0TA" contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_JIy69_XLcUWqtpWDR7EAZg">one</ix:nonFraction> industry being the development of small molecule drugs for prostate cancer. The Company&#8217;s right of use asset is located in the USA.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_UYNoXACFW02C4zeMCKMO_A_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="Tb_MYYmubqubk2_brR-4KLA-Q" continuedAt="Tb_MYYmubqubk2_brR-4KLA-Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16.&#160;&#160;&#160;&#160;FINANCIAL INSTRUMENTS AND RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities, long-term debt and derivative liabilities. The fair value of cash and cash equivalents, receivables and accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The derivative liabilities are measured using level 3 inputs (Note&#160;10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of judgement, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Financial risk factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s risk exposures and the impact on the Company&#8217;s financial instruments are summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Credit risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and receivables. The Company&#8217;s receivables are refunds from vendors. The Company limits its exposure to credit loss by placing its cash with major financial institutions. The Company considers highly liquid investments with a maturity of up to twelve months when purchased to be short-term investments. As at September 30, 2021, cash and cash equivalents consisted of cash in Canada and the United States.  and term deposits in Canada. Balances exceed amounts insured by the Canada Deposit Insurance Corporation for up to C</span>$<ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="epix:CashCanadaDepositInsuranceCorporationInsuredAmount" scale="0" id="Narr_dCuR3EKNbU-85y7wSXeefQ">100,000</ix:nonFraction> and by the Federal Deposit Insurance Corporation for up to $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashFDICInsuredAmount" scale="0" id="Narr_PuNR4mZGF0yLUqc6wznjFg">250,000</ix:nonFraction>. Amounts due from government agencies are considered to have minimal credit risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Liquidity risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at September 30, 2021, the Company had working capital of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A" decimals="0" format="ixt:numdotdecimal" name="epix:WorkingCapital" scale="0" id="Narr_wA-EaKob60af77JnS0Ilag">193,668,414</ix:nonFraction>. The Company does not generate revenue and will be reliant on external financing to fund operations. Debt and equity financing are dependent on market conditions and may not be available on favorable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Market risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Market risk is the risk of loss that may arise from changes in market factors such as interest rates, and foreign exchange rates.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">(a)</span>Interest rate risk</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">As at September 30, 2021, the Company has cash and cash equivalents balances and GICs which are interest bearing. Interest income is not significant to the Company&#8217;s projected operational budget and related interest rate fluctuations are not significant to the Company&#8217;s risk assessment.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">(b)</span>Foreign currency risk</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company&#8217;s foreign currency risk exposure relates to net monetary assets denominated in Canadian, UK pound and Euro dollars. The Company maintains its cash and cash equivalents in US dollars and converts on an as needed basis to discharge Canadian denominated expenditures. A 10% change in the foreign exchange rate between the Canadian, UK Pound, Euro and U.S. dollar in relation to Canadian, UK Pound, Euro dollars held at September 30, 2021 would result in a fluctuation of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_srt_StatementScenarioAxis_epix_TenPercentChangeInForeignExchangeRateMember_bvuH6gka5U6JPsf7-52JbA" decimals="0" format="ixt:numdotdecimal" name="epix:ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" scale="0" id="Narr_W7Ukptudu02LYwEo20ATXg">27,261</ix:nonFraction> in the net loss recognized for the period. The Company does not currently engage in hedging activities.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_MYYmubqubk2_brR-4KLA-Q_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_kDuIIWqzyEafEj6i23MFTw_1_0"></a><a id="Tc_BhJUbCiY0EaklZlnpgt-mA_1_2"></a><a id="Tc_7yYeavt64E-d2TJ07FSVjg_1_5"></a><a id="Tc_kCEV-ypzlUWATh0kQe_-dg_1_8"></a><a id="Tc_83YShipwlkW1w3s14WhC9w_1_11"></a><a id="Tc_LETxw-zHEkummk8PsPcjFg_1_14"></a><a id="Tc_hlHgpUN3iUK2x1fAWOKn0Q_3_0"></a><a id="Tc_NsTM5rRJ-ESaYMnYzMnpeQ_3_2"></a><a id="Tc_PaqMMOQk2Eqwn-owHT2l-A_3_5"></a><a id="Tc_adyYG2-dRUCbh77c4gVrJg_3_8"></a><a id="Tc_dtiDcuW5102HTIq3elALFA_3_11"></a><a id="Tc_BuVL0fVq8UeDpDu3yKf0Dg_3_14"></a><a id="Tc_AaMMOUJrlUinlFkHwL3GsA_4_0"></a><a id="Tc_IivRIRJdwUyZLNZ_dC1lng_4_2"></a><a id="Tc_ldC9DO_WJUKSD-YqPk_Ekw_4_5"></a><a id="Tc_Q0gK2Mh2g0Ki6gZG7SoRFQ_4_8"></a><a id="Tc_1uSVT4h4u0Ckccr137NpYA_4_11"></a><a id="Tc_s_PK7Pl000-wNg38L0yAhQ_4_14"></a><a id="Tc_yIrKg-K_6EO6xuPloKP5PQ_6_0"></a><a id="Tc_oS8hEXuv30K794AO6h7utA_6_2"></a><a id="Tc_FCgMeVv8eUK3tKPqCRIkig_6_5"></a><a id="Tc_y4K_ncUCOE-F7Yv4pz9mew_6_8"></a><a id="Tc_U79EEE50WE6mJ6vJO9-6mQ_6_11"></a><a id="Tc_scrlrc-Ac0CzvaErBZ4XXA_6_14"></a><a id="Tc_kqMTd5d16UaRQclgWKThZQ_7_0"></a><a id="Tc_FpI3-gZRLUmUe1St1KfJlA_7_2"></a><a id="Tc_VlzVktdSCkeKWnure1aaNg_7_5"></a><a id="Tc_TtC6kGKJ1U2uf5XXct4b9Q_7_8"></a><a id="Tc_q03wDEUux0u9qC_xQGsTNA_7_11"></a><a id="Tc_VEICsLAtNU2WTvNhTTc_Xg_7_14"></a><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_8n0LDB2oWUOfxNfRY9FNtw" continuedAt="Tb_8n0LDB2oWUOfxNfRY9FNtw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17.&#160;&#160;&#160;&#160;COMMITMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Product Development and Relocation Grant</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2014 the Company was awarded a product development and relocation grant by CPRIT whereby the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_2_1_2014_To_2_28_2014_srt_ProductOrServiceAxis_us-gaap_GrantMember_3kTJC-T1iU2z88W1B5pfng" decimals="0" format="ixt:numdotdecimal" name="epix:GrantAmount" scale="0" id="Narr_so1wGh4kTkK3gVCoLJ7Ivg">12,000,000</ix:nonFraction> on eligible expenditures over a <ix:nonNumeric contextRef="Duration_2_1_2014_To_2_28_2014_srt_ProductOrServiceAxis_us-gaap_GrantMember_3kTJC-T1iU2z88W1B5pfng" format="ixt-sec:durwordsen" name="epix:GrantReceivedPeriod" id="Narr_QjoCiANx-UeddkCTpbt71Q">three-year</ix:nonNumeric> period related to the development of the Company&#8217;s androgen receptor n-terminus blocker program for prostate cancer. A final payment of $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_Uot5G89xX0qdEQQjGB5lPQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="0" id="Narr_xKj5gcK2-0eNaJSoTvhlYQ">229,201</ix:nonFraction> was recorded as a receivable as at September 30, 2020. During the fiscal year ended September 30, 2021, the Company determined that the receivable was deemed uncollectible. The impairment of the CPRIT receivable is recorded against research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If the Company is found to have used any grant proceeds for purposes other than intended, is in violation of the terms of the grant, or fails to maintain the required level of operations in the State of Texas for <ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_stpr_TX_30zEwfkPH0eCYhn7ePIwpw" format="ixt-sec:durwordsen" name="epix:GrantRequirementNumberOfYearsOfOperationsInTexas" id="Narr_9Lbnp0zByU6fbETiTnBy2A">three&#160;years</ix:nonNumeric> following the final payment of grant funds, then the Company could be required to repay any grant proceeds received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the grant, the Company is also required to pay a royalty to CPRIT, comprised of <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementScenarioAxis_epix_AggregateRoyaltyPaymentUpTo24000000Member_5AdkqvcbzUyIueGZN5F9LQ" decimals="2" format="ixt:numdotdecimal" name="epix:RoyaltyPercentRevenue" scale="-2" id="Narr_cb83JnUWPEKKk6d-aWNeWw">4</ix:nonFraction>% of revenues the Company receives from sale of commercial product or commercial service, until aggregate royalty payments equal $<ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_KZCcAZEQ0ky6YptH37I2xw" decimals="0" format="ixt:numdotdecimal" name="epix:ThresholdLimitForAggregateRoyaltyPayments" scale="0" id="Narr_fjoqktijT0K2xs-BQ1roBQ">24,000,000</ix:nonFraction>, and <ix:nonFraction unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ" contextRef="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementScenarioAxis_epix_AggregateRoyaltyPaymentAfter24000000Member_xk53XTvPeE29Kge7zRUczA" decimals="2" format="ixt:numdotdecimal" name="epix:RoyaltyPercentRevenue" scale="-2" id="Narr_JkPVQTOACkmudTHqbHJ6VQ">2</ix:nonFraction>% of revenues thereafter. The Company has the option to terminate the grant agreement by paying a one-time, non-refundable buyout fee, based on certain factors including the grant proceeds, and the number of&#160;months between the termination date and the buyout fee payment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The NTD Technology is held under a license agreement signed in fiscal 2010 (the &#8220;License Agreement&#8221;). As consideration for the License Agreement, the Company issued common shares of the Company. The License Agreement contains an annual royalty as a percentage of annual net revenue and a percentage of any annual sublicensing revenue earned with respect to the NTD Technology. The License Agreement stipulates annual minimum advance royalty payments of C$<ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_XqG7x_Aqjk2REwmcJTq1IQ" decimals="0" format="ixt:numdotdecimal" name="epix:MinimumAdvanceRoyaltyPayments" scale="0" id="Narr_RdNZUQ6-VUaZ_Z7w4ghRPQ">85,000</ix:nonFraction><span style="white-space:pre-wrap;">.  In addition, there are certain milestone payments for the first compound, to be paid in stages as to C</span>$<ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_XqG7x_Aqjk2REwmcJTq1IQ" decimals="0" format="ixt:numdotdecimal" name="epix:AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" scale="0" id="Narr_dlxL6UnjBEiCtt1XwA2nCg">50,000</ix:nonFraction> at the start of a Phase II clinical trial, C$<ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_XqG7x_Aqjk2REwmcJTq1IQ" decimals="0" format="ixt:numdotdecimal" name="epix:AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial" scale="0" id="Narr_P9Wclsdgq0mKaG98d3SYkA">900,000</ix:nonFraction> at the start of a Phase III clinical trial, C$<ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_XqG7x_Aqjk2REwmcJTq1IQ" decimals="0" format="ixt:numdotdecimal" name="epix:AmountOfMilestonePaymentsAtApplicationForMarketingApproval" scale="0" id="Narr_VOpLxmAIvUOsZj0MsBr57w">1,450,000</ix:nonFraction> at application for marketing approval, and with further milestone payments on the second and additional compounds</p><ix:nonNumeric contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="Tb_eSWhKHoGHEStW8AkfkDZ4Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has the following obligations over the next five&#160;years:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Contractual obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Minimum annual royalty per License Agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="As_Of_9_30_2021_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_4dedr1AwQkWdcCVB7ocbbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Tc_99eYYLMSRk2KLtnNvlJBag_3_3">85,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="As_Of_9_30_2021_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_4dedr1AwQkWdcCVB7ocbbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" id="Tc_iHpzPbhICE2HmoUvRaiufw_3_6">85,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="As_Of_9_30_2021_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_4dedr1AwQkWdcCVB7ocbbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" id="Tc_z5_TNCXnlEKHwfptr7CPjQ_3_9">85,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="As_Of_9_30_2021_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_4dedr1AwQkWdcCVB7ocbbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInFourthYear" scale="0" id="Tc_NLgqFaNVAUqn7YxmM-QsIA_3_12">85,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="As_Of_9_30_2021_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_4dedr1AwQkWdcCVB7ocbbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInFifthYear" scale="0" id="Tc_BOZdxngja0miosZr9Tgunw_3_15">85,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vendor Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Tc_ir1v_Pta5U-jrMeviyI-gg_4_3">25,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" id="Tc_Lvhif_fkkkSMvCWtFF39XQ_4_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" id="Tc_KmCD0fcuJEOQ1EdrNnkmLQ_4_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInFourthYear" scale="0" id="Tc_llcphLzn7EKH9sDrAABgOA_4_12">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInFifthYear" scale="0" id="Tc_n4tvJyM4FU-NkBHU6ClVuw_4_15">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_ConsultingAgreementMember_cW0iNp2Vx0-QozLErFC7rg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Tc_6-LpcjoL1EGQhAFt6zmMMg_6_3">35,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_ConsultingAgreementMember_cW0iNp2Vx0-QozLErFC7rg" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" id="Tc_9i6QpB6Ao0WLGYVuuu4ATg_6_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_ConsultingAgreementMember_cW0iNp2Vx0-QozLErFC7rg" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" id="Tc_yXnJYYQprkaXmMfJR-XZ8A_6_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_ConsultingAgreementMember_cW0iNp2Vx0-QozLErFC7rg" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInFourthYear" scale="0" id="Tc_Tk9fH_-Pak-tlk7l482UBw_6_12">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_ConsultingAgreementMember_cW0iNp2Vx0-QozLErFC7rg" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInFifthYear" scale="0" id="Tc_wiy3HlERpEK6dTwSTKgZwQ_6_15">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease on US office spaces</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_RMrB863qE0qS6tVtlOO3Ng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Tc_UdajkJCjQ0SUERVUXnrgrQ_7_3">113,288</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_RMrB863qE0qS6tVtlOO3Ng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" id="Tc_F8t7wum83kab6zRSW8G77g_7_6">119,586</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_RMrB863qE0qS6tVtlOO3Ng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" id="Tc__PmmOJe_EEqsKBXQzNuXGA_7_9">81,509</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_RMrB863qE0qS6tVtlOO3Ng" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInFourthYear" scale="0" id="Tc_qJ7liv6xKUaicF1WZ0t1oQ_7_12">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_RMrB863qE0qS6tVtlOO3Ng" decimals="0" format="ixt:zerodash" name="us-gaap:ContractualObligationDueInFifthYear" scale="0" id="Tc_HDS4ihkSIE-HPJcPw8YPLA_7_15">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Collaborative agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On February 25, 2021, the Company announced a clinical collaboration with Astellas Pharma Inc. (&#8220;Astellas&#8221;) to evaluate the combination of EPI-7386 and Astellas/Pfizer&#8217;s androgen receptor inhibitor, enzalutamide, for patients with mCRPC. Under the terms of the agreement, ESSA will sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of the combination of EPI-7386 and enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies. Astellas will supply enzalutamide for the trial. ESSA will retain all rights to EPI-7386. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_8n0LDB2oWUOfxNfRY9FNtw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="font-style:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="font-style:normal;white-space:pre-wrap;">On April 28, 2021, the Company announced that it had entered into a clinical trial collaboration and supply agreement with Bayer to evaluate EPI-7386 in combination with Bayer&#8217;s androgen receptor inhibitor, darolutamide, in patients with mCRPC.  Under the terms of the agreement, following review of certain clinical data, Bayer may sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the combination of EPI-7386 and darolutamide in mCRPC patients. ESSA will supply EPI-7386 for the trial and will retain all rights to EPI-7386. </span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_35fe64e0_031d_4b4b_b76e_ed5b6908c4e2"></a><a id="Item9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">None.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e04e0d07_c717_431e_a6bd_b92f869b0cb0"></a><a id="Item9A"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of end of the period covered by this Annual Report on Form&#160;10-K, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the design and operating effectiveness of our disclosure controls and procedures as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act of 1934. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms. Any such information is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on our evaluation of our disclosure controls and procedures as of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were, in design and operation, effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over our financial reporting, defined in Rule&#160;13a-15(f)&#160;and Rule&#160;15d-15(f)&#160;of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute, assurances. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Management has assessed the effectiveness of our internal control over financial reporting as at September 30, 2021. In making its assessment, management used the criteria set forth in the internal control&#160;&#8211; integrated framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 COSO framework) to evaluate the effectiveness of our internal control over financial reporting. Based on this evaluation, management has concluded that our internal control over financial reporting was effective as of September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Attestation Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The effectiveness of our internal control over financial reporting as of September 30, 2021 has been audited by Davidson&#160;&amp; Company LLP, an independent registered public accounting firm, as stated in their report included elsewhere in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There were no changes in our internal control over financial reporting during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_5e4330c2_a92b_4c82_9311_663df329cad7"></a><a id="Item9B"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B.&#160;&#160;&#160;&#160;&#160;Other Information </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">None.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8758e70d_cc77_4812_aaa4_7cc13379467b"></a><a id="PARTIII"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;10.</b></span>&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information required by Item&#160;10. of Form&#160;10-K is incorporated by reference to our proxy statement for the 2022 annual meeting of shareholders (the &#8220;2022 Proxy Statement&#8221;), to be filed with the SEC within 120&#160;days after the end of the fiscal&#160;year ended September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3bf567aa_27b3_4fc3_9107_fcbb12a46c7d"></a><a id="Item11"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;11.</b></span>&#160;&#160;&#160;Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information required by Item&#160;11. of Form&#160;10-K is incorporated by reference to our 2022 Proxy Statement, to be filed with the SEC within 120&#160;days after the end of the fiscal&#160;year ended September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3e3eeb2b_d4a5_49be_843a_0b95c23a7448"></a><a id="Item12"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;12.</b></span>&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information required by Item&#160;12. of Form&#160;10-K is incorporated by reference to our 2022 Proxy Statement, to be filed with the SEC within 120&#160;days after the end of the fiscal&#160;year ended September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_64b7042c_c643_4a9b_b0e5_79e09e9340f2"></a><a id="Item13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;13.</b></span>&#160;&#160;&#160;Certain Relationships and Related Transactions and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information required by Item&#160;13. of Form&#160;10-K is incorporated by reference to our 2022 Proxy Statement, to be filed with the SEC within 120&#160;days after the end of the fiscal&#160;year ended September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_386435b0_3381_4d5c_9143_88af905f7421"></a><a id="Item14"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;14.</b></span>&#160;&#160;&#160;Principal Accounting Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information required by Item&#160;14. of Form&#160;10-K is incorporated by reference to our 2022 Proxy Statement, to be filed with the SEC within 120&#160;days after the end of the fiscal&#160;year ended September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8f8d1af4_482c_4e66_b933_65c2195f98cb"></a><a id="PARTIV"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;15.</b></span>&#160;&#160;&#160;Exhibits, Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a)(1)&#160;Financial Statements&#8212;The financial statements included in Item&#160;8 are filed as part of this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a)(2)&#160;Financial Statement Schedules&#8212;All schedules have been omitted because they are not applicable or required, or the information required to be set forth therein is included in the consolidated Financial Statements or notes thereto included in Item&#160;8 of this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a)(3)&#160;Exhibits&#8212;The exhibits required by Item&#160;601 of Regulation S-K are listed in paragraph (b)&#160;below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(b)&#160;Exhibits&#8212;The exhibits listed on the Exhibit&#160;Index below are filed herewith or are incorporated by reference to exhibits previously filed with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dfd8005a_1ce1_4c03_9635_0e6f52f9473b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EXHIBITS INDEX</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1633932/000095012315003628/filename2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Articles of Incorporation (incorporated by reference to Exhibit 1 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8217;s Registration Statement on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(File No.&#160;377-00939), originally filed with the SEC on February 24, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1633932/000119312518168196/d587995dex41.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Specimen common share certificate (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-8, filed with the Commission on May 18, 2018 (File No. 333-225056))</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20210930xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Description of Capital Stock</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1633932/000095012315003628/filename3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Cancer Research Contract between CPRIT and the Company, dated July&#160;9, 2014 (incorporated by reference to Exhibit 4.1 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8217;s Registration Statement on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(File No.&#160;377-00939), originally filed with the SEC on February 24, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1633932/000095012315004249/filename2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">License Agreement between the BC Cancer Agency, UBC and the Company, dated December&#160;22, 2010, as amended on February&#160;10, 2011 and May&#160;27, 2014&#8224; (incorporated by reference to Exhibit 4.2 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8217;s Registration Statement on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(File No.&#160;377-00939), originally filed with the SEC on February 24, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1633932/000127956915002373/v426821_ex4-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Sublease for 2130 West Holcombe Boulevard, Houston, Texas, United States dated April&#160;7, 2015 (incorporated by reference to Exhibit 4.8 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8217;s Annual Report on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(File No.&#160;001-37410), originally filed with the SEC on December 11, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1633932/000095012315004249/filename5.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Employment Agreement for David Wood (incorporated by reference to Exhibit 4.9 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8217;s Registration Statement on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(File No.&#160;377-00939), originally filed with the SEC on April 7, 2015)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1633932/000127956916004844/ex49.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Employment Agreement for David Parkinson (incorporated by reference to Exhibit 4.9 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8217;s Annual Report on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(File No.&#160;001-37410), originally filed with the SEC on December 14, 2016)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1633932/000127956916004844/ex410.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Employment Agreement for Peter Virsik (incorporated by reference to Exhibit 4.10 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8217;s Annual Report on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">File (No.&#160;001-37410), originally filed with the SEC on December 14, 2016)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1633932/000110465919074530/tm1919820d1_ex4-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Employment Agreement for Alessandra Cesano (incorporated by reference to Exhibit 4.7 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8217;s Annual Report on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(File No.&#160;001-37410), originally filed with the SEC on December 20, 2019)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1633932/000127956918002468/tv507810_ex4-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Subscription Agreement between the Company and Clarus Lifesciences III,&#160;L.P. dated January&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">14, 2016  (incorporated by reference to Exhibit 4.8 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8217;s Annual Report on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(File No.&#160;001-37410), originally filed with the SEC on December 13, 2018)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1633932/000127956918002468/tv507810_ex4-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consulting Agreement for Dr.&#160;Marianne Sadar (incorporated by reference to Exhibit 4.10 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8217;s Annual Report on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(File No.&#160;001-37410), originally filed with the SEC on December 13, 2018)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1633932/000127956918002468/tv507810_ex4-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consulting Agreement for Dr.&#160;Raymond Andersen (incorporated by reference to Exhibit 4.11 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8217;s Annual Report on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(File No.&#160;001-37410), originally filed with the SEC on December 13, 2018)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1633932/000127956918002468/tv507810_ex4-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Lease for 400 Oyster Point Boulevard, South San Francisco, California, United States dated March&#160;5, 2018 (incorporated by reference to Exhibit 4.12 to the Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#8217;s Annual Report on Form 20-F </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(File No.&#160;001-37410), originally filed with the SEC on December 13, 2018)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20210930xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">List of Subsidiaries</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20210930xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consent of Davidson&#160;&amp; Company LLP, an Independent Registered Public Accounting Firm</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20210930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of the Chief Executive Officer pursuant to Rule&#160;13a-14(a)&#160;of the Securities and Exchange Act of 1934, as amended</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20210930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of the Chief Financial Officer pursuant to Rule&#160;13a-14(a)&#160;of the Securities and Exchange Act of 1934, as amended</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20210930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section&#160;1350 as added by Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document &#8211; The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document. *</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document *</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document *</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document *</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document *</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document *</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:91.66%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2021 formatted in Inline XBRL (included in Exhibit 101).</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">&#8224;Confidential treatment has been requested for portions of this document. The omitted portions of this document have been filed with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">* Filed herewith.</p><a id="_cc365a31_d34a_44a2_a3c9_a39f436bcd33"></a><a id="Item16"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;16.</b></span>&#160;&#160;&#160;Form&#160;10-K Summary </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Not applicable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_cec0adce_bfe4_4ffa_959c_4496b1e135af"></a><a id="SIGNATURES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Dated: November 18, 2021</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:46.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:51.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">E</span><span style="font-size:7.5pt;font-style:italic;font-weight:bold;">SSA</span><span style="font-size:10pt;font-style:italic;font-weight:bold;"> P</span><span style="font-size:7.5pt;font-style:italic;font-weight:bold;">HARMA</span><span style="font-size:10pt;font-style:italic;font-weight:bold;">&#160;INC.</span></p></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:51.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:51.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 18, 2021</p></td><td style="vertical-align:top;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:10pt;">/</span><span style="font-size:7.5pt;">S</span><span style="font-size:10pt;">/ D</span><span style="font-size:7.5pt;">AVID PARKINSON</span></p></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:46.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Parkinson</p></td></tr><tr><td style="vertical-align:top;width:48.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:46.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the requirements of the Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">David Parkinson</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Parkinson</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">David Wood</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer (Principal Financial Officer and</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Wood</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal Accounting Officer)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Richard M. Glickman</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard M. Glickman</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Marella Thorell</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marella Thorell</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Alex Martin</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marella Thorell</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Sandy Zweifach</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sandy Zweifach</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Franklin Berger</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Franklin Berger</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Scott Requadt</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Scott Requadt</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <i style="font-style:italic;">Gary Sollis</i></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gary Sollis</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>tmb-20210930xex4d2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/18/2021 01:43:06 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 4.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following description of the capital stock of ESSA Pharma Inc. (the &#8220;Company,&#8221; &#8220;our&#8221; and &#8220;we&#8221;) is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Company&#8217;s Articles of Incorporation, which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit is a part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Common Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are authorized to issue an unlimited number of common shares, without par value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Holders of our common shares are entitled to receive notice of any meetings of our shareholders, and to attend and to cast one vote per common share at all such meetings. Holders of common shares are entitled to receive on a pro rata basis such dividends on the common shares, if any, as and when declared by our board of directors at its discretion, from funds legally available therefor, and, upon the liquidation, dissolution or winding up of the Company, are entitled to receive on a pro rata basis the net assets of the Company after payment of debts and other liabilities, in each case subject to the rights, privileges, restrictions and conditions attaching to any other series or class of shares ranking senior in priority to or on a pro rata basis with, the holders of common shares with respect to dividends or liquidation. Our common shares do not carry any pre-emptive, subscription, redemption or conversion rights, nor do they contain any sinking or purchase fund provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our common shares are listed on the Nasdaq Capital Market under the symbol &#8220;EPIX.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preferred Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may issue our preferred shares from time to time in one or more series. The terms of each series of preferred shares, including the number of shares, the designation, rights, preferences, privileges, priorities, restrictions, conditions and limitations, will be determined at the time of creation of each such series by our board of directors, without shareholder approval, provided that all preferred shares will rank equally within their class as to dividends and distributions in the event of our dissolution, liquidation or winding-up.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>tmb-20210930xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/18/2021 01:43:10 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit </b><b style="font-weight:bold;">21</b><b style="font-weight:bold;">.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">List of Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:middle;width:35.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:30.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:30.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Name</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Abbreviation</b></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Place of Incorporation</b></p></td></tr><tr><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ESSA Pharmaceuticals Corp.</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">ESSA Texas</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">State of Texas</p></td></tr><tr><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Realm Therapeutics, plc</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Realm</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">United Kingdom</p></td></tr><tr><td style="vertical-align:top;width:35.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Realm Therapeutics, Inc.</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Realm USA</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">State of Delaware</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>tmb-20210930xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/18/2021 01:43:12 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20210930xex23d1002.jpg" alt="Graphic" style="display:inline-block;height:31.8pt;width:540pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We consent to the incorporation by reference in the registration statements on Form S-3 (No. 333-250971 and No. 333-250967) and Form S-8 (No. 333-245143, No. 333-239541, No. 333-225056 and No. 333-210217) of ESSA Pharma Inc. of our report dated November 18, 2021, relating to the consolidated financial statements of ESSA Pharma Inc., for the years ended September 30, 2021, 2020 and 2019 which appears in the annual report on Form 10-K of ESSA Pharma Inc. dated November 18, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">&#8220;DAVIDSON &amp; COMPANY LLP&#8221;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1.15pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Vancouver, Canada </p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Chartered Professional Accountants</p></td></tr><tr style="height:1.15pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:1.15pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">November 18, 2021</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20210930xex23d1001.jpg" alt="Graphic" style="display:inline-block;height:81.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:314.25pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>tmb-20210930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/18/2021 01:43:15 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">I, David Parkinson, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">1. I have reviewed this Annual Report on Form 10-K of ESSA Pharma Corp.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 18, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:40%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Parkinson&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>tmb-20210930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/18/2021 01:43:17 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">I, David Wood, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">1. I have reviewed this Annual Report on Form 10-K of ESSA Pharma Corp.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 18, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:40%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Wood</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>tmb-20210930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/18/2021 01:43:20 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit </b><b style="font-weight:bold;">32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF CEO AND CFO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the annual report of ESSA Pharma Inc. (the &quot;Registrant&quot;) filed under cover of Form 10-K for the annual period ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &quot;Report&quot;), David Parkinson as Chief Executive Officer of the Registrant and David Wood as Chief Financial Officer of the Registrant, each hereby certifies, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:middle;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ David Parkinson</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name:</p></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">David Parkinson</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:</p></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">November 18, 2021</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:middle;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ David Wood</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name: </p></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">David Wood</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Financial Officer&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date:</p></td><td style="vertical-align:middle;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">November 18, 2021</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This certification accompanies the Report pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Registrant for purposes of &#167;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tmb-20210930x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20210930x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '] Z0# 2(  A$! Q$!_\0
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MJS* F[ W CKCD@\?G63'JFISVDEU]M*&R2+?&L2;;@[B&+9!(R!QM(QGOTH
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MV3_OVW^% !]F@_YXQ_\ ?(H^S0?\\8_^^11YZ?W9/^_;?X4>>G]V3_OVW^%
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MA0 ?9H/^>,?_ 'R*/LT'_/&/_OD4>>G]V3_OVW^%'GI_=D_[]M_A0 ?9H/\
MGC'_ -\BC[-!_P \8_\ OD4]7#C(!_%2/YTZ@#&U)5CN%$:A1L!PHQW-%+JO
M_'TO^X/YFB@#3MO^/6'_ '!_*J?]B6?]HO>L)6=CN\IIF,2M@@L$SM#$'KC^
M9S<MO^/6'_<'\JEH S%\/Z:MO)#Y4K+)MRSW$CN-IRNURQ9<'D8(P:23P]ID
ML$4+0/LCW@8GD#,&.6#$-EP3U#9SWK4HH I7.DVEVNV99N'$BE)Y$*,%V_*5
M8%>,C P.3ZU$=!TTR0/]F*^2J(BK(RJ0ARH90<-@\C(.*TJ* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS@C/?-;-% !3'BCD.7C1C[C-/HH B^S0?\\8_P#OD4?9H/\ GC'_ -\BI:*
M(OLT'_/&/_OD4?9H/^>,?_?(J6B@"+[-!_SQC_[Y%'V:#_GC'_WR*EHH B^S
M0?\ /&/_ +Y%'V:#_GC'_P!\BI:* (OLT'_/&/\ [Y%'V:#_ )XQ_P#?(J6B
M@"+[-!_SQC_[Y%'V:#_GC'_WR*EHH B^S0?\\8_^^11]F@_YXQ_]\BI:* (O
MLT'_ #QC_P"^11]F@_YXQ_\ ?(J6B@"+[-!_SQC_ .^11]F@_P">,?\ WR*E
MHH B^S0?\\8_^^11]F@_YXQ_]\BI:* (OLT'_/&/_OD4?9H/^>,?_?(J6B@"
M+[-!_P \8_\ OD4?9H/^>,?_ 'R*EHH B^S0?\\8_P#OD4?9H/\ GC'_ -\B
MI:* (OLT'_/&/_OD4?9H/^>,?_?(J6B@"+[-!_SQC_[Y%'V:#_GC'_WR*EHH
M B^S0?\ /&/_ +Y%'V:#_GC'_P!\BI:* (OLT'_/&/\ [Y%'V:#_ )XQ_P#?
M(J6B@"+[-!_SQC_[Y%'V:#_GC'_WR*EHH B^S0?\\8_^^11]F@_YXQ_]\BI:
M* (OLT'_ #QC_P"^11]F@_YXQ_\ ?(J6B@"+[-!_SQC_ .^11]F@_P">,?\
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M_?(J6B@"+[-!_P \8_\ OD4?9H/^>,?_ 'R*EHH B^S0?\\8_P#OD4?9H/\
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M&_QJ6B@"+R$_O2?]_&_QH\A/[TG_ '\;_&I:* (O(3^])_W\;_&CR$_O2?\
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M [56.OZ8&MQ]H+"=4=&6)V4!SA2Q PN3P-V* -*BBB@ HHHH **** "BBB@
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M?DO^%2T4 1>4_P#S\2?DO^%'E/\ \_$GY+_A4M% $7E/_P _$GY+_A1Y3_\
M/Q)^2_X5+10!%Y3_ //Q)^2_X4>4_P#S\2?DO^%2T4 1>4__ #\2?DO^%'E/
M_P _$GY+_A4M% $7E/\ \_$GY+_A1Y3_ //Q)^2_X5+10!%Y3_\ /Q)^2_X4
M>4__ #\2?DO^%2T4 1>4_P#S\2?DO^%'E/\ \_$GY+_A4M% $7E/_P _$GY+
M_A1Y3_\ /Q)^2_X5+10!%Y3_ //Q)^2_X4>4_P#S\2?DO^%2T4 1>4__ #\2
M?DO^%'E/_P _$GY+_A4M% $7E/\ \_$GY+_A1Y3_ //Q)^2_X5+10!%Y3_\
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M]]W^A%Y3_P#/Q)^2_P"%'E/_ ,_$GY+_ (5+17M'(1>4_P#S\2?DO^%'E/\
M\_$GY+_A4M% $7E/_P _$GY+_A1Y3_\ /Q)^2_X5+10!%Y3_ //Q)^2_X4>4
M_P#S\2?DO^%2T4 1>4__ #\2?DO^%'E/_P _$GY+_A4M% $7E/\ \_$GY+_A
M1Y3_ //Q)^2_X5+10!%Y3_\ /Q)^2_X4>4__ #\2?DO^%2UB^)-773-,E\FY
M2.];;Y2\$]1DX^F>M14J1IQ<Y;(NG3E4FH1W9J^4_P#S\2?DO^%'E/\ \_$G
MY+_A7":3XJUJ2Z=6B?4/D.(T0*5.1\WRKT[?C6S_ &]KS_<T!QCKN)_P%<U/
M'4IJZO\ <_T.NIE]6$K-K[U^IT7E/_S\2?DO^%'E/_S\2?DO^%<[_:GBA_N:
M-",]-S?S^84?:O%[_P#+A9QX_P!H<_\ CYJOK4>D9?<S/ZI+K*/WHZ+RG_Y^
M)/R7_"CRG_Y^)/R7_"N<QXO?O9QY^G'\ZY?2M*U*/6;*1["Z55N$+,T+  ;A
MDDXK.IC7%I*#U[Z&U/ J2DW46G;7_(].52HP7+>YQ_2G445W'GF/JO\ Q]+_
M +@_F:*-5_X^E_W!_,T4 :=M_P >L/\ N#^52U%;?\>L/^X/Y5"^J6$>I1Z<
MUW"+V12ZP%QO('M_GH?0T 6Z*IQZKITL$TT>H6KQ0'$TBS*5C_WCGC\:'U?3
M8[:&Y?4;18)CB*5IE"N?13G!_"@"Y14-U=VUC 9[NXAMX00#)*X10?J:C?4K
M".6"-[VV62X ,*M*H,H_V1GG\* +5%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4R::."(R2N$0=2:J7^J0V(VG]Y,?NQKU_'TJE#IUSJ,HN-28A!RD
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M_P"_A_PJ6B@"+=/_ ,\X_P#OX?\ "C=/_P \X_\ OX?\*EHH BW3_P#/./\
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M_P \X_\ OX?\*EHH BW3_P#/./\ [^'_  HW3_\ /./_ +^'_"I:* (MT_\
MSSC_ ._A_P *-T__ #SC_P"_A_PJ6B@"+=/_ ,\X_P#OX?\ "C=/_P \X_\
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M+=/_ ,\X_P#OX?\ "C=/_P \X_\ OX?\*EHH BW3_P#/./\ [^'_  HW3_\
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MA/Z;<5K+YJ*%6&)5'0!R /\ QVIJ*U,B+=/_ ,\X_P#OX?\ "C=/_P \X_\
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MU_\ GWD_-?\ &I:* (O-?_GWD_-?\:/-?_GWD_-?\:EHH B\U_\ GWD_-?\
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MI.$E'5?\^E;44L<T:R1N&1NA%;87&0KWBURS6\7NO\UYD5*3AKNGU'$A022
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M% !1110 4444 %%%% &/JO\ Q]+_ +@_F:*-5_X^E_W!_,T4 :=M_P >L/\
MN#^58[S7$/B13>7%Y# [>7:JBH;>7*CAS@L'R#C) X '4@[%M_QZP_[@_E50
M:-9C4FOCYS2$AA&TS&-7P1O"9VAB#UQ_7(!G>;JSV&IQ1W$D]U#=HBM D:,$
MQ&S!0_R]&;&XGZFH#?7MW$(;;4+NW>"WEDD>:*(RF16V[7 7;@<_=Z\8/KJ1
MZ!8PI.L;7J^>P:0_;Y]Q([YWY'0#CL*)/#NERP10M;OLC# ;9G4L&.6#$'+A
MB,D-G/>@".YNKF[CTN*"X:T-X-[R1JK,H";L#<".N.2#Q^=9,>J:G/:277VT
MH;)(M\:Q)MN#N(8MD$C('&TC&>_2NAN=)M+M=LRS<.)%*3R(48+M^4JP*\9&
M!@<GUJ(Z#IID@?[,5\E41%61E4A#E0R@X;!Y&0<4 :5,>14."'/T0G^5/HH
MB\]/[LG_ '[;_"CST_NR?]^V_P *EHH B\]/[LG_ '[;_"CST_NR?]^V_P *
MEHH B\]/[LG_ '[;_"CST_NR?]^V_P *EHH B\]/[LG_ '[;_"CST_NR?]^V
M_P *EHH B\]/[LG_ '[;_"CST_NR?]^V_P *EHH B\]/[LG_ '[;_"CST_NR
M?]^V_P *EHH B\]/[LG_ '[;_"CST_NR?]^V_P *EHH B\]/[LG_ '[;_"CS
MT_NR?]^V_P *EHH B\]/[LG_ '[;_"CST_NR?]^V_P *EHH B\]/[LG_ '[;
M_"CST_NR?]^V_P *EHH B\]/[LG_ '[;_"CST_NR?]^V_P *EHH B\]/[LG_
M '[;_"CST_NR?]^V_P *EHH B\]/[LG_ '[;_"CST_NR?]^V_P *EHH B\]/
M[LG_ '[;_"CST_NR?]^V_P *EHH B\]/[LG_ '[;_"CST_NR?]^V_P *EHH
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M[LG_ '[;_"CST_NR?]^V_P *EHH B\]/[LG_ '[;_"CST_NR?]^V_P *EHH
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M$9K^(YYSB.6VMU/\3."1_GZ5 USITO-]K+R]]D:-C^7]*WET#2DZ64?XY/\
M.IDTK3T^[8VP/KY0S3_LNG/7$2E/U>GW*R%]9DO@27]=SGFU3P]! XB@>9MO
M&5/)^IZ?A3;'4]0N[<0:1IZ0#_EI*3N /U/_ ->M^^DTO3;7S+M(8H7/E_ZK
M.20>, >QJG:^(- M[39;W<<<47 7:P/X C)KHC2PE"7NJ,6O1,.6O5C>S:^9
M%!X8\Z03ZK=R74G]T$A1[>O\JW(+:"UC$<$21H.RC%<])XO%PYBTK3[B[?\
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M #KLK>VAM(%@@C6.-1@**D50JA5 "@8 ':EIQA;5ZLF4[Z+1!1115D!1110
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MR* ):*B^S0?\\8_^^11]F@_YXQ_]\B@"6BHOLT'_ #QC_P"^11]F@_YXQ_\
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M_P"^14K T5/GMK]_YE/'UW!POIY:?D/CC2) D:*BCHJC %.J+[-!_P \8_\
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MKLZB^S0?\\8_^^11]F@_YXQ_]\BG2I\D;-W?5]PK5/:2NE9=%V):*B^S0?\
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MLT'_ #QC_P"^11]F@_YXQ_\ ?(H EHJ+[-!_SQC_ .^11]F@_P">,?\ WR*
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M]FE^4?U*A5P<)*R_#_@G*)>::DC&>1LC!'E1AB?QR,5=AO(G_P"/30[VZ/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC?XT>0G]Z3_OXW^- $M%1>0G]Z3_ +^-_C1Y"?WI/^_C?XT 2T5%Y"?WI/\
MOXW^-'D)_>D_[^-_C0!+147D)_>D_P"_C?XT>0G]Z3_OXW^- $M%1>0G]Z3_
M +^-_C1Y"?WI/^_C?XT 2T5%Y"?WI/\ OXW^-'D)_>D_[^-_C0!+147D)_>D
M_P"_C?XT>0G]Z3_OXW^- $M%1>0G]Z3_ +^-_C1Y"?WI/^_C?XT 2T5%Y"?W
MI/\ OXW^-'D)_>D_[^-_C0!+147D)_>D_P"_C?XT>0G]Z3_OXW^- $M%1>0G
M]Z3_ +^-_C1Y"?WI/^_C?XT 2T5%Y"?WI/\ OXW^-'D)_>D_[^-_C0!+147D
M)_>D_P"_C?XT>0G]Z3_OXW^- $M%1>0G]Z3_ +^-_C1Y"?WI/^_C?XT 2T5%
MY"?WI/\ OXW^-'D)_>D_[^-_C0!+147D)_>D_P"_C?XT>0G]Z3_OXW^- $M%
M1>0G]Z3_ +^-_C1Y"?WI/^_C?XT 2T5%Y"?WI/\ OXW^-'D)_>D_[^-_C0!+
M147D)_>D_P"_C?XT>0G]Z3_OXW^- $M%1>0G]Z3_ +^-_C1Y"?WI/^_C?XT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^F#^-=,_?HJ7;3]5^IE'W:C7?4Z2BHML_P#STC_[]G_&C;/_ ,](_P#OV?\
M&N8U):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2
M/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_
M //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_Q
MHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^
M_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\
M](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*B
MVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\:
M):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV
M?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2
M/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_
M //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_Q
MHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^
M_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\
M](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*B
MVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\:
M):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV
M?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2
M/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_
M //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_Q
MHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^
M_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\
M](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\: ):*B
MVS_\](_^_9_QHVS_ //2/_OV?\: ):*BVS_\](_^_9_QHVS_ //2/_OV?\:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4;I_^><?_?P_X4 2T5%NG_YYQ_\ ?P_X4;I_^><?_?P_X4 2T5%NG_YYQ_\
M?P_X4;I_^><?_?P_X4 2T5%NG_YYQ_\ ?P_X4;I_^><?_?P_X4 2T5%NG_YY
MQ_\ ?P_X4;I_^><?_?P_X4 2T5%NG_YYQ_\ ?P_X4;I_^><?_?P_X4 2T5%N
MG_YYQ_\ ?P_X4;I_^><?_?P_X4 2T5%NG_YYQ_\ ?P_X4;I_^><?_?P_X4 2
MT5%NG_YYQ_\ ?P_X4;I_^><?_?P_X4 2T5%NG_YYQ_\ ?P_X4;I_^><?_?P_
MX4 2T5%NG_YYQ_\ ?P_X4;I_^><?_?P_X4 2T5%NG_YYQ_\ ?P_X4;I_^><?
M_?P_X4 2T5%NG_YYQ_\ ?P_X4;I_^><?_?P_X4 2T5%NG_YYQ_\ ?P_X4;I_
M^><?_?P_X4 2T5%NG_YYQ_\ ?P_X4;I_^><?_?P_X4 2T5%NG_YYQ_\ ?P_X
M4;I_^><?_?P_X4 2T5%NG_YYQ_\ ?P_X4;I_^><?_?P_X4 2T5%NG_YYQ_\
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M)>_14NL=/\OU,E[M1KOJ=%1117.:A1110 4444 %%%% !1110 4444 %%%%
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M[EV+>7*T3-A"P7<I!'K@'MZ9K ANIY[%[F2_N?.M(X/L^V<J) 7(#,H.'WX
MYSGM@T =O113'=E.!&[^X(_J: 'T5%YK_P#/O)^:_P"-'FO_ ,^\GYK_ (T
M2T5%YK_\^\GYK_C1YK_\^\GYK_C0!+147FO_ ,^\GYK_ (T>:_\ S[R?FO\
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M47FO_P ^\GYK_C1YK_\ /O)^:_XT 2T5%YK_ //O)^:_XT>:_P#S[R?FO^-
M$M%1>:__ #[R?FO^-'FO_P ^\GYK_C0!+147FO\ \^\GYK_C1YK_ //O)^:_
MXT 2T5%YK_\ /O)^:_XT>:__ #[R?FO^- $M%1>:_P#S[R?FO^-'FO\ \^\G
MYK_C0!+147FO_P ^\GYK_C1YK_\ /O)^:_XT 2T5%YK_ //O)^:_XT>:_P#S
M[R?FO^- $M%1>:__ #[R?FO^-'FO_P ^\GYK_C0!+147FO\ \^\GYK_C1YK_
M //O)^:_XT 2T5%YK_\ /O)^:_XT>:__ #[R?FO^- $M%1>:_P#S[R?FO^-'
MFO\ \^\GYK_C0!+147FO_P ^\GYK_C1YK_\ /O)^:_XT 2T5%YK_ //O)^:_
MXT>:_P#S[R?FO^- $M%1>:__ #[R?FO^-'FO_P ^\GYK_C0!+147FO\ \^\G
MYK_C1YK_ //O)^:_XT 2T5%YK_\ /O)^:_XT>:__ #[R?FO^- $M%1>:_P#S
M[R?FO^-'FO\ \^\GYK_C0!+147FO_P ^\GYK_C1YK_\ /O)^:_XT 2T5%YK_
M //O)^:_XT>:_P#S[R?FO^- $M%1>:__ #[R?FO^-'FO_P ^\GYK_C0!+147
MFO\ \^\GYK_C1YK_ //O)^:_XT 2T5%YK_\ /O)^:_XT>:__ #[R?FO^- $M
M%1>:_P#S[R?FO^-'FO\ \^\GYK_C0!+147FO_P ^\GYK_C1YK_\ /O)^:_XT
M 2T5%YK_ //O)^:_XT>:_P#S[R?FO^- $M%1>:__ #[R?FO^-'FO_P ^\GYK
M_C0!+147FO\ \^\GYK_C1YK_ //O)^:_XT 2T5%YK_\ /O)^:_XT>:__ #[R
M?FO^- $M%1>:_P#S[R?FO^-'FO\ \^\GYK_C0!+147FO_P ^\GYK_C1YK_\
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MY. !FE?3K&2>&=[.W:: 8AD:)2T8]%../PJS10 4444 %%%% !1110 4444
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M@CO+K[0PXEE(< ^NT8S^=)I/PSL+.=WU"<7\97Y4,;1[3GKD/S]#7:?:8/\
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M,'_/:/\ [Z% $M%-5U<91@P]0<TZ@#'U7_CZ7_<'\S11JO\ Q]+_ +@_F:*
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MLVLRVUP+N1(7T5PH2ZB?=L)&=[8XV'.,]L9/!R->&:.XB66%U>-N593D'Z4
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M-O-5^5E8%,/*3D D.V3C)QCG@5T-CIMKIRLMLCC=C)>1G.!T&6).!DX'09H
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MRM);;6\X *&$H.<'J2%Q_#UR,5/?VD=[K26FHYFLY8B\$1X3S!PP/J<89?\
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M1@YQ6MIMD]C'*K2JXDD,NU5PJ,P!8#D\%MS?\"IUC9&S-P?,W+-)YNT+@*Q
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MHH **** "BBB@ HHHH KWEC;WZ1QW,8DC202!#T+#ID=\'GZ@58HHH ****
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M_P"/6'_<'\JEJ*V_X]8?]P?RJ6@ HHHH **** "BBB@ HHHH **** "BBB@
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MJA'0/J=A%=):R7ULEPX#+$TJAV!X! SDU#=:JMM=_9H[2YNI%4/+Y 4^4I.
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M>AZ4 =+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 8^J_P#'TO\ N#^9HHU7_CZ7_<'\S10!IVW_ !ZP
M_P"X/Y5+65'JGEQ(GDYVJ!G=U_2G?VO_ -,/_'__ *U &G169_:__3#_ ,?_
M /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G16
M9_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/
M_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_
M /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G16
M9_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/
M_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_
M /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G16
M9_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/
M_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_
M /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G16
M9_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/
M_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_
M /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G16
M9_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/
M_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_
M /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G16
M9_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/
M_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_
M /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G16
M9_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/
M_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_
M /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G16
M9_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/
M_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_
M /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G16
M9_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/
M_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_
M /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G16
M9_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/
M_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_
M /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G16
M9_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/
M_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_
M /K4?VO_ -,/_'__ *U &G169_:__3#_ ,?_ /K4?VO_ -,/_'__ *U $6J_
8\?2_[@_F:*ANKC[5*'V[<+C&<T4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tmb-20210930x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20210930x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #P G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM:\-ZS>7&IP11Q2VXC0I*&RVX'M6&*KTY49)21TX3#U8UHN46D>F4445X9]
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MZJ?:LVBO6E%25F>/&3B[H^@_#OQ&T+7D2.2=;&\/!@N& R?]ENA_G[5UX8,
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M;'C*TWKF"U_TB3C(^7[H_P"^L?E7J5)J$')]#R*<'.:BNI[CX8TA="\-V.G
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M?_SXVO\ WY7_  H_LO3_ /GQM?\ ORO^%6Z*+L.6/8J?V7I__/C:_P#?E?\
M"IH;:"V!$$,<0)R1&@7/Y5+11=C44MD%%%%(84444 %%%% !44]M#=1F.XAC
MEC/59%# _@:EHH!JYR>I?#?POJ66;3EMI#_';,8_T''Z5Q>K?!F>,,^D:DLO
M'^JNEVG_ +Z''Z5[!171#%58;2.:I@Z,]XGRYJ^A:IH-SY&IV4MNQ/RLPRK?
M1AP:SZ^J-0TVSU6RDL[ZW2>WD&&1QG\1Z'WKYV\9>&V\+>(9;$,SV[J)8';J
M4/8^X((KU,+B_;>[)69X^+P3H>]%W1@5O^"]<?0/%5E=[B(7<0SCL48X_0X/
MX5@4C?=-=DXJ<7%]3BA)PDI+H?68I:HZ-.;G0["X8Y:2VC<GW*@U>KYAJSL?
M6Q=U<****0PHHHH *0C((/(-+10!AZEX.\/:MDW>DVS.?^6B)L;\UP:X[5?@
MUITP9]+OY[5^R3#S$_/@_P Z]-HK:%>K#X9&%3#4JGQ1/G+7O 6O^'U:6>U^
MT6J]9[;YU ]2.H_$5S/6OK(@&O'_ (I>"[:PA_M[3(A$A<+=0H,*">C@=N>#
M]17I8;'.<E"IN>5BLO\ 9Q<Z;T/+:4%E(96*L#D$'!!]:2BO2/+/I7P9K9\0
M>%;*_<@S%-DW^^O!_/K^-;U>:?!BY9]!U&V)^6*Y#+[;E'^%>EU\W7@H5911
M]3AIN=&,F%%%,ED2*)Y)&"H@+,Q[ =36)N>3?&36\O9:)$W _P!(G /U"#_T
M(_E7E%:?B+5GUWQ#?:DY.)I24'H@X4?D!697T>&I>SIJ)\OB:OM:KD%>V_"#
M1OLGAZ?5)%Q)>R80_P#3->!^9W5XO:VLM[>06D S+/(L:#W)P*^GK.VMM"T2
M&W#+';6< 4L>  HY-<F95>6"CW.S*Z+E4<^WZE_-1?:K?S/+\^+?_=WC/Y5Y
M)XA\87VLSO'!(]O8@X6-3@N/5C_2N<QSG)SZU\96SF$96A&Z/T##\.5)PYJL
M^5]K7/H/->?_ !<T?[=X834(US+82;B0.?+;AOUP?PKG/#_BZ_T6=$DD>XLL
M_/$YR5'JI[&O5I4M=<T>2/(DM;N$KD=U85Z>7YA"M)3CHUNCQLVRJIAHN$]4
M]F?+5%6+^RETW4;FQG!$MO(T;?4'%5Z^Q3NKH^%:L[,]1^#FM^5>WFB2O\LP
M\^$'^\.& _#!_"O8J^6]$U231=;L]2BSFWE#D#^)>C#\1FOJ"WGCN;>.>)@T
M<JAT8=P1D5XN84N6IS+J>[EM7FI\CZ$E%%%<!Z04444 %%%% !1110 4444
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MVG_"U?%G_/W;_P#@.M'_  M7Q9_S]V__ (#K7%T5C]6H_P J-OK5;^9G:?\
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MK_\ 3Q #^3C^1_.O7*^;Q%/V=1Q/J,-5]K24@HHHK$Z HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
E44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tmb-20210930x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20210930x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" SD"?8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *X'QG\7= \#:VNDZG9ZE+.T*SAK:*-EVDD#EG!S\I[5WU8^J^
M%/#VN7*W.JZ)I][.J[!+/;J[[?3)&<<GCWH X!?VA?!3(K%-44D9*FV7(]N&
MIW_#0?@GTU/_ ,!A_P#%5Q7QU^'N@>'=#L-;T6Q6R=[H6TT41.Q@59@V#T(V
M$<>M>%4 ?4LW[1'@R)04M]7F)[);H,?FXJ'_ (:.\'_] W7/^_$/_P =K!\!
M? WP[K_A'2]:U2[U+S[N+S&ABE14&20/X2>F#UKLXO@/X"C'S:?=2_[]V_\
M0B@#$/[2/AC)QI&KD=LK'_\ %U-#^T=X2<J)=-UF,DX)\F)@/?\ UF?TK7D^
M!/@%UPNFW"'U6[DS^I-8VH?LY^%K@$V6HZG:/C@,Z2*/P*@_K0!N6/QS\!WK
M*KZG-:LW3[1;.!^:@@5VNE:_H^NQ&72=4M+U0,G[/,KE?J <C\:^:O$O[/\
MXGT:)Y]*F@UB!1DK$/+FQ_N$D'Z!B?:O+TDOM)O\H]Q97D#8RI:.2-A^1!H
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MH!-IU_:WD1_CMY5D'Y@U;KY?_9XT07_CBZU20933K8E?^NDGRC] _P"E?4%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!OQ0_B?X>6CSN7N[%C9S,3RVT#:?Q4KSZYKOZ "BBB@ HHHH **** "BBB@
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M:;\;YH=%;,L>NXMQ'P QF^Y] 3M_"OL:@ HHHH **** "BBB@ KE/B#XXL_
MGAJ349PLMU(?+M+?./-D]_\ 9'4G^I%=77QW\6O&#^+_ !Q=212[M/LB;:T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&:.1< Y1@>O3I4E?/>L_LZ7]CF[\,Z_OGCY2*Y7RG_"13U_ ?6N1TSXE>/\
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M68X KD_"OPU\,^#+][_1K26.ZDA,#R23L^4+!B,$XZJ.U8WQ"^$=KXZNGO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \K_:"8CX9X!(!OH@<'J,-7RI7
MU!^T;(5^'EBH<C?JD8(!ZCRI3_/%?+] 'VS\.O\ DF_AO_L'0_\ H KIJY/X
M8,6^&/ATL23]B0<^@XKK* "BBB@ HHKR?XL?%NW\*6LNC:+,DVN2*5=E.5M
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MOK*]MM2L8+VSF2>VG0212(<AE(R"*\!^.'PO\AIO%VB0?NF.[4($_A/_ #U
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M /\ 6 ?W@.OJ.>HY /8]'U>QU[2+;5--G6>TN4#QNO\ (CL0>".Q%>0>-_\
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M.G>=>)]VZNV\UU/J/X5/N *[2B@ HHHH **** "BBB@ HHHH **** "BBB@
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M$>Q- %3Q%X'L]5^(.@>*KC5FMGL!Y*VQ Q.V690"2,'+'(P<@ <5VK,%4LQ
M4#))[5X1XCM+C3_VD/#<,FJ7UY#<*+I8[F3<L)8RJ50  !?D';/UK9^)^K3Z
M[X]\.?#ZWF:.TO)%N-1VD@R1Y)\O([;58D>Z^E 'J-AK6E:I)+'I^IV=V\1Q
M(MO.LA0^X!.*NLRHC.[!549+$X %>7_&33CI'A.S\3:,$LK_ $*>(PR0J%_=
M,P0QD#JN2O'3@^M8_P 6-1/B/X+V/B2VO+NV6=86>VAEVQOOX97'\6#GOVH
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M>1W5W;71FN#%\R1X4KMW="?FZ#ICG%>"U]&Q?LU:4"?-\17C#MM@5?ZFI?\
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M&WTV+?<R ?:+N0?O)3_1?11Q]3S75444 %>!_M$^+<I9>$K.3<[D7-X%Y/\
MTS3\>6Q[+7K7C#PU>^)]-@M;'Q!?Z+)'-YC3V3LK.,$;3AAQSG\*\XG_ &=-
M-O)WN+SQ-JEQ<R'=)+(JLSMW))R?UH ],\&>'H_"OA#3-&C W6\($K#^*0\N
M?Q8FMVO._#7PSU3P]K5G>-XZUN]M+8G%C/(QB==I !&_'&<].U>B4 %>:?'+
MPVNN_#NXNT4?:=+;[4A]4Z./^^3G_@(KTNO)M3^#6J:LD\-Y\0]=FMIF):WE
M9GCQG.-I?&* /(_@EXN3PQXY2VNIA'8:FHMY2QPJOG,;'\>,]@QKZUKQ'_AF
MS1/^@]J'_?M*[SP3X(OO",LYN?%.IZQ#)&L<<-VS%8<'^$%B!Z4 >??M'>&O
MM&EZ;XDA3+VS_9;@C^XW*$_1LC_@=>9?"?1;GQ9XXTC3IW>73=-D:^>-CE4
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M1LVAWCDPMC/D/U,9/\CW'T-?6M4=9T>QU_2+G2]2@6>TN$*2(?Y@]B.H/8T
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MX!N83(VLM 1_!-;2!OT4BN8\1?'NUN<:9X)T^YU+4[CY(97A(4,?[J?>8^Q
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M ?/'_"N_B5_T"-5_[_?_ &5'_"N_B5_T"-5_[_?_ &5?0_V3XJ?]!3PK_P"
MTW^-'V3XJ?\ 04\*_P#@--_C0!\\?\*[^)7_ $"-5_[_ '_V5'_"N_B5_P!
MC5?^_P!_]E7T/]D^*G_04\*_^ TW^-'V3XJ?]!3PK_X#3?XT ?/'_"N_B5_T
M"-5_[_?_ &5'_"N_B5_T"-5_[_?_ &5?0_V3XJ?]!3PK_P" TW^-'V3XJ?\
M04\*_P#@--_C0!\\?\*[^)7_ $"-5_[_ '_V5'_"N_B5_P! C5?^_P!_]E7T
M/]D^*G_04\*_^ TW^-'V3XJ?]!3PK_X#3?XT ?/'_"N_B5_T"-5_[_?_ &5'
M_"N_B5_T"-5_[_?_ &5?0_V3XJ?]!3PK_P" TW^-'V3XJ?\ 04\*_P#@--_C
M0!\\?\*[^)7_ $"-5_[_ '_V5'_"N_B5_P! C5?^_P!_]E7T/]D^*G_04\*_
M^ TW^-'V3XJ?]!3PK_X#3?XT ?/'_"N_B5_T"-5_[_?_ &5'_"N_B5_T"-5_
M[_?_ &5?0_V3XJ?]!3PK_P" TW^-'V3XJ?\ 04\*_P#@--_C0!\\?\*[^)7_
M $"-5_[_ '_V5'_"N_B5_P! C5?^_P!_]E7T/]D^*G_04\*_^ TW^-'V3XJ?
M]!3PK_X#3?XT ?/'_"N_B5_T"-5_[_?_ &5'_"N_B5_T"-5_[_?_ &5?0_V3
MXJ?]!3PK_P" TW^-'V3XJ?\ 04\*_P#@--_C0!\\?\*[^)7_ $"-5_[_ '_V
M5'_"N_B5_P! C5?^_P!_]E7T/]D^*G_04\*_^ TW^-'V3XJ?]!3PK_X#3?XT
M ?/'_"N_B5_T"-5_[_?_ &5'_"N_B5_T"-5_[_?_ &5?0_V3XJ?]!3PK_P"
MTW^-'V3XJ?\ 04\*_P#@--_C0!\\?\*[^)7_ $"-5_[_ '_V5'_"N_B5_P!
MC5?^_P!_]E7T/]D^*G_04\*_^ TW^-'V3XJ?]!3PK_X#3?XT ?/'_"N_B5_T
M"-5_[_?_ &5'_"N_B5_T"-5_[_?_ &5?0_V3XJ?]!3PK_P" TW^-'V3XJ?\
M04\*_P#@--_C0!\\?\*[^)7_ $"-5_[_ '_V5'_"N_B5_P! C5?^_P!_]E7T
M/]D^*G_04\*_^ TW^-'V3XJ?]!3PK_X#3?XT ?/'_"N_B5_T"-5_[_?_ &5'
M_"N_B5_T"-5_[_?_ &5?0_V3XJ?]!3PK_P" TW^-'V3XJ?\ 04\*_P#@--_C
M0!\\?\*[^)7_ $"-5_[_ '_V5?07P:TC6=%\"FTURWG@O/M<C[)VRVTA<'J?
M0U+]D^*G_04\*_\ @--_C74:!'KD>FE?$,]C-?;S\UDC+'LXQPW.>M ''_&[
M2)=6^%^H&%-\EFZ7>/\ 94X8_@I8_A4_P9U%=1^%>C$'Y[=7MW&<X*N0/_'=
MI_&N[DC2:)XI45XW4JRL,@@]0:\U\/\ A+7/AOJFH1Z#:C6/#M[)YRV8G6*X
MM9.!\I?"N, #E@>!Z<@'8:AXBCL?%NC: (]\NHQSREL_ZM8P#^I/Z&O+_@3_
M ,C1X_\ ^OV+_P!#GK?M_#_C#5/B(WC&\L[.R2TLFMM/TZ>ZR26!R9&16 Y)
M)QGL.V:3X=> _$?@O7]5N[J?2KJVU>02W/E/(KPLI<C8"I##+D$$CUSV(!@Z
M7_R=9K?_ %Y+_P"B(:[SQ=XR.E:KIWAK2?+E\0ZHVV!7&4MX^=TK@<D !B!W
MP?2N<M/ OBNW^*5UXX+Z+ON0(GLA/*0(PJID/Y?WL(#]W&>/>LWQSX*\:#XK
MV/C#PK#;712-4Q<2JJQ':R,&!()4J?X>>30!DZ_I<&D_M%^$88I))I7M4DGG
ME;=)-(6F!9CZX &!@      5/^TM_P @CP__ -=YO_05JWXP^'_C5_%>A>,=
M(DL[_7(=HNXF(C@C(/&Q6.=F&(/S;N,CD\7?'/PX\6>.M*TNRO-0TN-[(M(]
MQOD)F=\%@$" (JG@<G( Z=* /7*\3^!/_(T>/_\ K]B_]#GKU_3'U-K4_P!J
MP6D5P#@?99FD5Q@?-\RJ5.<\<_4UY-X:\">,_#OCOQ!%9_9H= U>Y6:6_$O[
MU8P[,$C .X/AV4DC'.0>* ,'X,Z'H^H^+?&=CKFEV5_<PW"E!=VZ2[<22A\;
M@<9)7/X5[79^$_#6FW<=W8^'])M;E#\DT%E&CK]"!D5YYXC\ ^)-#^(+^-O
MXMIY;D$7NGS.$\W.-V"<##8!ZC##//2NMTFU\3:YJ%IJ'B6TM-,M[-C)#I]O
M/YS/*1@/(_ PH)PHSR<D\"@#SKXK_P#);O /_7>V_P#2D5Z+\4X9)_A?XA2+
M.X6A<X]%(8_H#7-^,/A_XE\4>.=)\11S:3:KI,J-!"TLDAE"2;P6.P8SZ#./
M4UZ-'#-?Z4]OJUK;HTZ-'-##*98RIR,;BJDY'L* /,/@WX:\+ZQ\,=-N+S0-
M*O+M7F2::>SCD<D2L1EB"3\I6MOXA>'M+TGX8>)1HNE6-A)):9D^R6Z1%U4@
MG.T#/&:YKP[X3\>?#+5KVT\/65IKN@7<ID2.6Y6!X3T#$GO@ ' .<#I7H&F:
M!>7T&HW/B<V\MUJ4'V:2VM\F*"#!_=@GEB2S$M@9X&, 4 8/P.F27X2:0BGF
M)YT;Z^<[?R85R_@K_DY;QA_UY/\ ^AP5/X-\+?$'X=ZA>Z-I=E8:KH=Q*98;
MFXNO*$)Z9( +9P!D $<<&H?#GP^\;:;\4M8UM[VV2"ZVK-?.O,JL\4KB*,$X
M&5*#<>!ZD4 >UU\__M-?\RM_V]_^T:^@*\H^)_PX\1?$2\LPMQI=E:V#2B F
M21WD#[,EAL 4_)T&?K0!ZH(HQ*91&@D/!;')_&N-^+G_ "2KQ!_UP7_T-:Z7
M26UAH'&L0V,<P8!&LY7=7&.I#*-ISGCGZUC>/M#U;Q-X9NM#TW[%&EXFR6XN
M97!C ((VJJG=G'<C'O0!D?!+_DD.A?\ ;Q_Z425QVL(]E^U3HL\^[RY[;]T?
M8P2)Q_P(&N_^'?AW6O"'ARU\/W_V">UM1(4N8)GWDLY?:4*8Q\QYW>G'>H_B
M#X'F\3G3-5TJ>.VUW2)Q/:22YV. 02C8[$@<_7U- $7QDN([?X3ZZTG.](XU
M'J6E0#_'\*\WURUEL_V5M+BF)+LT<HS_ '7F9U_1A7>^*_#^O?$6'3](OM/;
M1M)BG6>_:2=)'G*]$CV$_+R?F;:>!\O%6?B)X.U?Q5X;A\-:.--M-. C+2SR
M/O79]U%0+C' Y+>V.] '&_$*&27]FO073.V*TT]WQZ>6J_S(KKO GA+PCJ7@
M'0+R3PWHT\LEA#YLLEC$S.X0!B25R3N!YJ]I?A74+KP(_A'Q+'8/:1V4=G%/
M9RN6=57 9E9!M8;5(P3D^E<CX0T;XE> (9/#]KIFG:UI(=FM;E[L0B')R<@Y
M;!)S@ X.>: /1)]!\,6NDR:,^FZ;:V-^_E-;1Q)$LKD$XPH'S87([\>U>'>+
M_ VL_""^7Q9X1U&8Z8)56>&0Y* GA7[.A/&>H)'?FO0O%?@KQ-?>'+6YT^\M
M9_$L6KQ:I*[$I$2B,JQIGHJ@J.>N&)Y-:7B'2]:\>^&$T*_TMM'BN9(S?R23
MQRD(CA\1;"<DE1RVW /0]* )]8T7PY\3O#=G;:BJ^=/:1WT&QML\"R+PPSV[
M8(P<>U>7>';?Q#\(?B9IGANXOFO/#^L3>7!P=I+$*&"_P.&*YQP0?R[_ %K0
M/$>D?$33/$?AVQAO=,ATM=-N+$3B.0HKLPV[L+D97&3V(XSFM.[\-W/B7QGH
MVO:G;_9+31ED:UMG=6EDE?&6?:2H"[1@ G)].A .%\:_\G+>#_\ KR3_ -#G
MJ+6$>R_:IT6>?=Y<]M^Z/L8)$X_X$#6]K?@3Q9J_Q'T[QB'T6-].010VGGRD
M2(&<C<^S@G>>BG'OWVO'G@BZ\41Z3JVGR06GB+295GMV9F,3$$$QL0 2N0,'
M'KQR: &_&2XCM_A/KK2<[TCC4>I:5 /\?PKS?7+66S_96TN*8DNS1RC/]UYF
M=?T85WOBOP_KWQ%AT_2+[3VT;28IUGOVDG21YRO1(]A/R\GYFVG@?+Q5KXB>
M#=5\5>&(?#>C_P!G6E@-A:2=WW($^ZBJ%QCCJ3^'>@"/_FWK_N5/_;2J7P&(
M'PKM"3@"XF_]"K5/A_Q)_P *N/A8)I7VO[%_9@G^T2>68?*\OS,>7G?C^'I_
MM=J@\">"]9\,^#+KPQ?SV3P.DOE7=M(^\-)G(*%0.,Y!#>V.] !I>NQ?$C5-
M1BM7_P"*6T]_(E<'']H2XR5)_P">0&,C^+(SQD'DOV;/^17UG_K]7_T 4WX:
M>"?B#X;2^\/WJV-GH-Q*9)KE7$DS94*?)VM\I( &7''4#-.\"^!O'_@K5]3T
MVP_L_P#L-K@7"3SS8>XVYVH"H)3(V[LJ>G% !\)?^2N_$3_K]E_]'R5[97E?
M@[P)XL\*^,=6UZ271KM=8F:2ZA$TL9BW.7)0[#NQN/! SZBO5* .-\56KZ]X
MJT/0XKVZL_(674Y)[;9O0IB.,?.K+R96/(/W?:O+?CCX;O=!BT/Q(FLZCJ,U
MO<^4'O!$?+/WTQY:)QE6ZY_"O3]/TCQ9;^-+W7KI-&EAO(H;;R%N90UO"C,?
ME;R_G.78X(4$]QUI?B5X6U3QIX<;0['[#%%*RR-<W$K[HV5@0%0(0<C(SN&/
M0T ><?'VY76O 7A?6[<YMIY-XQT_>1[A_P"@FO<=-OHM3TNTOX&#17,*3(1T
M*L 1_.O/+#X<:G=?#27P3XAGLI8(4_T*^MI'+JVXLNY"H&%SCACD<<=:SO!]
MC\4_">GCPV=*TN_LX<K:ZA->;4B7/0J/G8#J!@>F>E &=^TG [^&]$N5/[N.
M\>-OJR9'_H)KV73;Z+4]+M+^!@T5S"DR$="K $?SKE]3^']OK'@"X\-W]X\U
MQ.S3O>E>?M!8OOQGIDXV_P!WBN3\'V/Q3\)Z>/#9TK2[^SARMKJ$UYM2)<]"
MH^=@.H&!Z9Z4 9_[2<$K^&M%N5R88KQT?'0,R9&?^^37M,5Q'+:I<!L1.@<$
M^A&:Y:^\!6NJ^ [GPWJ5T]Q+<EII;PC#&X9B_F 9X 8\+_=&*QH;#QK;^ _^
M$2%A$U^MN;)-7%ROD"'[H<@GS-X3MM(R,YH Y;]G2-Y8/%&I#<+:YNXUC4]B
MH=C^.'7\JD^!/_(T>/\ _K]B_P#0YZ]-\%^%+3P9X7M=&M&W^6"TLI&#+(?O
M-CM[#L *\[T;PEXV\#>/M;N= TZPU+1]8E,I>>Z\KR3N++NZMQO8<*<CTH K
M:7_R=9K?_7DO_HB&C5/^3K-$_P"O)O\ T1-6K9_#_P 3VOQ<D\5Q7MEY<L"K
M=2SJ6\QB &6-%(*A0J@%CV'7FI+OP+XKN/BG;>. ^BA[53%'9>?+AH]K)S)Y
M?#8<G[N,X'/6@#&^.W_(T> /^OV7_P!#@H_:3_Y%?1O^OUO_ $ UT'Q%\!^(
M?&FOZ-=VLVF6MMI#F6$RR2,\K,4)# * H!0 8)SGMTH^+/@S7/&_@BSBM;>V
M&KVLXF:VCGRCC:5*J[!?4') Z&@#KO&'BW3?!?A^;5]28E%.R*)?O32'HJ_D
M?H 37CGQIL+Q_AOI>M:V0VL75_'F-<[+6-HI#Y2#VPNX]6(]  -3Q[X"\<^-
M/!]I<WAMWUI+@2-IT,VV*./9MPI8[=^<DG./FQG@9L>*O GC?QU\/XQKTUDF
MN6KK):V5L=J-QAO,8D@N0>,848]S@ N?&/\ Y(C'_P!NO]*V?^;>O^Y4_P#;
M2N=O_!?Q#\7>!(]&UN?1[5Y/*W+O8F%8N@PH*EF/+'=C@ "NJ/A_Q)_PJX^%
M@FE?:_L7]F"?[1)Y9A\KR_,QY>=^/X>G^UVH R_@+_R2RT_Z^)O_ $*N?^!/
M_(T>/_\ K]B_]#GKMOAIX5UCP7X?_L/4'L9[>-VDBN+>1]Y+')5D*XP/4'VQ
MWKC_  UX$\9^'?'?B"*S^S0Z!J]RLTM^)?WJQAV8)& =P?#LI)&.<@\4 6_'
M7PCTGQJC>(_#5W':ZI*/-22)OW-RW8DC[K<?>'X@]:M_!7Q7J^NZ-J>DZ\\D
MFIZ-.()))1\Y4[@ Q[L"C#/7IGU,WP[T_P 8>#=#/AW5-'6^@MV<V=Y;7483
M:3G:X<A@,DD$ \<8XYZ'P3X3/AFVU*XNI(Y=3U6\DO;QX@=@=R3L7/.U<GD]
M<D\=* *7Q8TS5-7^'=_9:-#--?.\11(3AB!(I.#],U\Y?\*[^)7_ $"-5_[_
M '_V5?66MIJ\FE2KH4MI%J&5\M[Q&:,#/.0O/3-<I]D^*G_04\*_^ TW^- '
MSQ_PKOXE?] C5?\ O]_]E1_PKOXE?] C5?\ O]_]E7T/]D^*G_04\*_^ TW^
M-'V3XJ?]!3PK_P" TW^- 'SQ_P *[^)7_0(U7_O]_P#94?\ "N_B5_T"-5_[
M_?\ V5?0_P!D^*G_ $%/"O\ X#3?XT?9/BI_T%/"O_@--_C0!\\?\*[^)7_0
M(U7_ +_?_94?\*[^)7_0(U7_ +_?_95]#_9/BI_T%/"O_@--_C1]D^*G_04\
M*_\ @--_C0!\\?\ "N_B5_T"-5_[_?\ V5'_  KOXE?] C5?^_W_ -E7T/\
M9/BI_P!!3PK_ . TW^-'V3XJ?]!3PK_X#3?XT ?/'_"N_B5_T"-5_P"_W_V5
M'_"N_B5_T"-5_P"_W_V5?0_V3XJ?]!3PK_X#3?XT?9/BI_T%/"O_ (#3?XT
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M#_9/BI_T%/"O_@--_C1]D^*G_04\*_\ @--_C0!\\?\ "N_B5_T"-5_[_?\
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MXJ?]!3PK_P" TW^- 'SQ_P *[^)7_0(U7_O]_P#94?\ "N_B5_T"-5_[_?\
MV5?0_P!D^*G_ $%/"O\ X#3?XT?9/BI_T%/"O_@--_C0!\\?\*[^)7_0(U7_
M +_?_94?\*[^)7_0(U7_ +_?_95]#_9/BI_T%/"O_@--_C1]D^*G_04\*_\
M@--_C0!\\?\ "N_B5_T"-5_[_?\ V5'_  KOXE?] C5?^_W_ -E7T/\ 9/BI
M_P!!3PK_ . TW^-'V3XJ?]!3PK_X#3?XT ?/'_"N_B5_T"-5_P"_W_V5'_"N
M_B5_T"-5_P"_W_V5?0_V3XJ?]!3PK_X#3?XT?9/BI_T%/"O_ (#3?XT ?/'_
M  KOXE?] C5?^_W_ -E1_P *[^)7_0(U7_O]_P#95]#_ &3XJ?\ 04\*_P#@
M--_C1]D^*G_04\*_^ TW^- 'SQ_PKOXE?] C5?\ O]_]E1_PKOXE?] C5?\
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M5;&/6[NX-^J&Y0.C*3M3&<YQNP/]H5Z7X<U=-<\/V>H*1NEC'F =G'##\P:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"/44Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXJ^(4?B?1S8/HX@<.KI+]HW[2/;8.HR.M8?@V[:R\8Z3*IQNN%C/T?Y3^C4
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M)'53U!'N#@_A3&>">#[/2M1\1066KEA;S@HA5]N)/X<GWZ?4BO5?^%7>&?\
MGC<_]_S7D6O^'M0\.:@UK>Q$#/[N91\D@]0?Z=JUM,^(WB/3+=8!<I<QJ,+]
MH3<0/KP3^)H$>C_\*N\,_P#/&Y_[_FI+7X;^'+6YANH8I]\3K(A\XD9!R*\N
MU3Q]XBU:)H9;[R86X9+=0F1Z9Z_K7:_"G4]7FMI+&>WDDTR($PW#<!&SR@/\
M0^G3\:0STB::.W@DFF=4BC4L[L<!0.237SYXP\2R>)M;>X&Y;6+*6\9[+ZGW
M/4_@.U=C\4?%>X_\(_92<##7;*>O<)_4_A[URO@?PNWB76@)5(L;?#W#>OHG
MU/\ +- '.1O-:SQRQL\4J%71AP0>H(_0U] ^#?$T?B;1$G8J+N+"7"#LWJ/8
M]?S':N9^)?A%;JP&LV$($UL@6:-!]Z,=#CU7^7TKSOPKXBF\-:W'>)N:!ODG
MC'\:=_Q'44Q'T-<_\>LW^X?Y5\O5]."YAO-+-S;R"2&6$NCCH01Q7S'2&?0D
MU\^F_#P7D1Q+%IJLA]&\L8_7%>!6L#WM]#;AOGGE5 S>K'&3^=?0MM8KJ?@N
M"Q=MJW&GK$6],Q@9KY^O["\T?49+2ZC:&XA;'ITZ$'T[@TP/==-\ ^'=/M4B
M.G17,@&&EG&\L?7G@?A7,_$G1-"TGPXLMKI]O;W4LZHC1K@XP2?PP/Y5@6GQ
M7UZWM5AEAL[AU&!+(C!C[G! /Z5S6L:MJ_B2634+YI)DAPN57$<0)X [#/YG
M%(1J?#C_ )'W3/\ MK_Z*>O?*\#^''_(^Z9_VU_]%/7OE PHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%T;6QU**6?LA#*6^FX#/X4 9<?PS\+QR[S92.,Y"M.^/T-;_ /8>E?V<-/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP,9H ^B**\1^UW/P^^.>G^'M.NISH6L1(_V*60ND+.77Y,_=PR9^AQZ8]NH
M**** "BBB@ HK/U>/5IK0Q:1<6MM.P(\^XC,H3T(0$9/U/'H:\J^ .MZGX@A
M\2:AJU[-=W3SPYDE.<#:W '0#V'% 'LM%<%\5/%%YH6CV&F:5-Y.JZW=K96\
MHZQ D!G'N,@#_>K*\=01?#;3-+\2Z%&8EM+E(=1B4_\ '["PP3)_?D! PQYY
M/.* /4J*R=6O+J3P^9]'!EN+D1I;R*NX()&"^:1W"AMY]EKQ[XU>'[3PEI&C
M^(=#GN;;6DO%MVNA.S33J49LL2?F.4'_ 'U0![O17(^+- O_ !K\-I='\V.T
MOKZ&W:1I <1L'1W&!S_"17E,7[/.OP1B.+Q='&@Z*D<@ _#=0!]"45Y3\)-!
M_P"$,\'^(=3N91=NUW<,9E!'G1P%E!YYY8.?QJ7Q]X&BF\!ZAK,T\_\ PDEG
M;M>F_CF96#*-S(O/"8! 4>@/7D@'J-%<!\'/%5YXL\ 0W6H2F:\M9WM993UD
M*A6!/J=K+DUW] !12$9!!SSZ'%>$P/J<OQZN?!I\0ZX-$BC#B(:A)O\ ]0LF
M/,SO^\WKGM0![O17CUKXEU;P3\8X?"-]J5SJ&BZHB/:->2&26!FR -YY8;E*
M\Y[=P<^PT %%%% !117$^ _!^J^%]3\2W.I:FMY'J=]]HMU!)V+\QR<]&.X
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M]: /6J*** "BBN:\>>+(O!?A"\UET$DJ 1V\1/#RMPH/MW/L#0!TM%>>^'_
MUGK_ (3MKWQ8CZCK&H0BXEGF8[K<N,A8ATCV@@?+CD9J3X1+J<'A&ZL-7NI[
MFZL-2N+3S)F+-M0@#D\X]/8T =]1110 44 @@$'(-% !1110!GZQKFE^'[$W
MNKW]O96X. \SA=Q] .I/L.:C\.^(+'Q1H<&L::TC6<[.(VD7:6".R$X[ E3C
MV]*H>/XHYOAWXD$L:.%TRY=0R@X81,01[BL+X)?\DAT+_MX_]*)* /0****
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M0P,DMS?7&?L]E;@-++CK@$@ >K,0H[FJ]]X@@T'P4VNZBY:.WLUFDYP7;:,
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M*7_ 5ZKH]R;W1+"Z8DF>VCD)/7YE!_K7E7[1K%_!&EVR*6EEU1"JKR3B.08
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MD5UAC*+G.2NXGY3D<]*O_LX_\D\U#_L*R?\ HJ*C]G'_ ))YJ'_85D_]%14
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M7.@?"'3_ !+'&KZCJ%K;B ,,J)98PV2/8;CCO@#O6)XR_P"37K;_ +!6F_\
MH4-=EX=O]/TKX3:#J&JO''9VVD6LLCR+D+B)<''KG&.^: /,?BMIDGA_X:^&
M];WRCQ&+R$W&H,Q\YG>)W<$_W=RC"] !@"O0_BOXON/"'@QYM/.-3O91:VA
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M&* \<J@ !/'#-N89."* .7\#:!=W.O:IXWUJW>#4-4Q':6T@^:UM1C:I]&8
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M8_S K(\5V5[\1[;2="73KZQL/M"7&K27,+1;%4?ZE"<;R2?O+E1C.>U>D44
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M\V!P.:X;6?!GC74?A7K<UQI\B:GJ6N'4Y;")@\AA*XVX'<-@X'.%'TKZ"HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ+;P!91+!I-Q=7=PO[F9T(MD//#/W;@G:.<#J*]!KQ_]H[_DGFG_ /85C_\
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M>(K(S*VTQP,9FW>F$!.>V.M=57@GCRSM;?\ :+\'1PVT,:-%;L51 H)\Z7G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOU!KS7X,^#EUCX1ZE;WES=6L.K7FY)K20)($C*X(8@XRR,#P>* .RU&SN/\
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M1I\\ODW&J[XY-L;':Z[>5.,$>E &C\"_^23Z9_UUG_\ 1K5Z+)(D43R2,%1
M69CT '4UY)\!-"\GP=::W_:NJ/YZS0_8'N,VL?[W[RQXX;Y>N>Y]:[CQU*[>
M&GTV%B)]6FCT^,JV"!*<.0?:/>W_  &@!W@>-W\.C4YE(FU6:34'!7:0)#E
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MVVZS\>D;K(?T6J_P:U2/5/A;HY0C?;*UM(!_"48X_P#'2I_&@#FM<M;OX3?
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MG'_DGFH?]A63_P!%14?"#_DH?Q._["H_]&W% 'L%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !4%ZEU+9RI93Q6]RRXCEEB,JJ?4J&7/YBIZ*
M /-=(^%NHZ'XMO\ Q/9^* VIWP=9_.T\-&P=@Q&T.".5&.>U;OQ"\"6GCW0!
M8S3&VNH'\VUN0,^6^,<CN#W_  ]*ZVB@#@-%\->-[F&&Q\6Z[I]SIL#+N2SB
M;S;L*05$KD# R!D <XP3@FE\6_#R_P#%GB'3M6E\0I:_V5-YVGQ16.?+;*ME
MR7^?E%Z;>!^-=]10!QGC?P"OCKPK#I^I7D:ZG;GS(;V&$HJR8P?D+$[3W&X^
MO:J>B^&O&]S##8^+==T^YTV!EW)9Q-YMV%(*B5R!@9 R .<8)P37?T4 >,?&
MR.>;QI\.8K:80W#ZBZQ2LNX(QDM\,1D9P><9KLKGPEJ/B+Q;IFL>(GLTM-))
MDL[&U=I \QQ^\D9E7I@$*!P>Y[X'Q$T#Q+XC\:>&;[2]"=K;0+S[0TLMU$@N
M,M$V$&XD8\LCY@.M>F6-Q-=644T]G+9RN,M!,R,R'T)1F4_@30!R7Q"\!3>/
M[6WL)]8%GIT+B;RH[7?(TH##<7+?=VL1MQUYR> (/&?P^O\ QSH6GZ5JFOQI
M';/YTKP6.UII0&56YD(4;6.1SD\Y'2N\HH Y[5_"R^)?!TN@^(+E;MYDP]S#
M#Y1W Y5PN3@CCO@\\ '%<Y?^"/$.O^&K+PKK6I6ATFW:,7%W 7^T7D<9^52A
M&U#PI+;FR1T%>B44 8.O>'I-2\*2>'],NHM-MI8?LKG[/YN("A4H@W#:<8Y.
M<<\=QA:;\/[[2_AY<^#K?7HC:2I)"D[V.72*0L9%_P!9@D[C@]L]#7=T4 <M
MX.\'MX5\+_\ ".SWR:AIR!UB5[?RV"N69U8[B&!+'' Q[]N0T7X=>,?!6HW=
MMX2U[3ET*ZE,AAU")W> XQE0/O'H,DC.!Q7K%% &=HNE#1].%NUP]S.[M+<7
M,@ ::1CEF(' ] !P  !TK1HHH X.]LO^$6^):>(5&W3-=C2ROF[17"\0N?0,
M/D^I'K75Z]H=CXDT.[TC4HO,M;E-C@=0>H8>A! (]Q5N[M+>_M);2[A2:WF4
MI)&XRK ]B*2RM5L;**U2261(EVJTSEW([98\GZGGUH X>R\)^*;7PB_A%M4L
M7T_RC:QZD XN$MSQL\O&W<%X#;^..#BNMT_0M.TWP]%H5O;K_9T4'V<1-R&0
MC!!]<Y.?7)K2HH \_C\$:U9^%;CP=9:A;KHDQ>-+MV8W,$#MEH@F-K'!90Q8
M8!'RFNUTO3+31M*M=-L8A%:VT8BC0=@/ZU;HH P?%>AZAXBTF;2[;54L+6YA
MDAN2+;S9'5AC"L6 7C.>#G/;%9_@;P=>>"M-CTE-82\TR,.4C>TV2*[-NSO#
MXQR>-O?KVKKJ;(ADB= [(6!&Y>H]Q[T <+K-G_PF'Q"TVS W:5X=D%Y=-_"]
MV1^ZC'NH^<_[RCO7>54TW3+32+%+2SBV1*2QR2S.Q.2S,>68GDD\FK= !7#)
MX*OM \9WOB+PQ+:"/4P#J&G73-''(X)(D1U5BIR6)RIZGUX[FB@#FO#WA8Z;
MK.J:_J$R7&L:D5$KQ@B.&)0 L: \X&.3W/.!6?:^$=1\->(]2U7PU+:/::F_
MG76FW;-&@F_OQR*K%<Y.1M/\L=K10!RUGX6N+KQ7'XFUZ:":\MHC#8VUN#Y5
MJK?>;<W+.>F[ XXQ5[Q9IUWK&@OIEJJE;N:**Y+$#; 7'F_7*!ACWK;HH
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F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tmb-20210930xex23d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20210930xex23d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M OL# 2(  A$! Q$!_\0
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M2T^\FL[SQ!8P7$+%)(Y)-I4CJ.:Z6O#_ -I.&/\ X1[1)MH\P7;KNQS@I_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ^(_ W]I:MK>H3W5Q)+%O#*H0*^ 5 7@\=3GJ:]"=$@LV2- L<<>%51@  <
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M1C'%:OPUU72]8^'ND'33$8H;5()85(/ENJ@,K#USS[YSWKQOQ18?\('XNO\
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MEQ=7T4.)XY(K:X:)95,K9#;<'VX/2@#3\"^-[V]^&EUK^OE));!YHVEB7 N
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MJ"RM9;JYE6*"%2\DCG 51U)H FHKD_\ A9W@C_H9]-_[^T?\+.\$?]#/IO\
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MB@%CCG%=)/XJTK2]%LM1UG4K&TBN@!'*)LQ.2,C:W<$#- &Y17)_\+.\$?\
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M#:5[_P#@/!_\;KIJ* .9_P"$&TKW_P# >#_XW1_P@VE>_P#X#P?_ !NNFHH
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MTWC'8D],9SCI5:W\'V=G=17-K>7L4J"96977]XDDAD9#\O3>201@C)YKHJ*
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L_&Z/^$&TK_-O!_\ &ZZ:B@"AI6DV^CV[P6WW7?>?D1>< ?PJ!VJ_110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tmb-20210930xex23d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20210930xex23d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !M :,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HJ"]O;;3K.6[O)TAMXEW/(YP *\UUGXJ:??*;33&OH4)PURD:Y
M(]@6!'Z&KA!R>AAB,1"A'FE]QZC17E6E:-=:Q9O?Z1KS37,?+1,61P??)_\
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M?*!S[Y!/XT 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N$U;PK
MJ6G:LVJ^'6VEB2T*D @GK@'@@^E=W15PFX/0YL5A:>)BE/1K5-;KT/,YM#U[
MQ+>*=5TBT  "M+*GED#ZJ<FNQT3PEHN@$26-A$EP5PTQRS'UP220/:MNBG.H
MY:;(C#8*%%N3;DWU>Y2U6>2VM8WC;:3<1(3[&101^1-8CZSJ;6]LS-9P-,L,
MV[#%51F *G)]QSQWKIRH888 CKS3&@B="CQ(RD;=I4$8]*S.PYR3Q+>"6[\N
MUB9(O,506P<H.">>0?8< @\U:;5-0ANY$E2U,4#PI*5W98N<<>F,CZ^U;'V>
M#S#)Y,>\C:6VC)'IGTI^Q222HR<$\>G2@#E!XBO;F14B>WB42POYC#@QON&"
M-QQ]T=<'GH*L'7KB-)RI@Q!YCD3-\TP$KJ%3'?"^_) ]ZWQ:6P1T%O$%<Y8;
M!AOKZTXV\+%"T,9*'<A*CY3ZCTH P&U^[A1IIHX$A=IDB #%@4; +?7'3C'K
M4VCZM<:C?%)=J[$D5E3&"RLHSP3C@],FMIH8V4JT:%3G@J._6B.&*$ 11(@
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M78E C%67!VLNY3CT(.:QO^$HD@U'5K:]:W@6PNHUW;2=T#Q[PW7[V0R_4>]
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MP^*]+NMRV\LCN72.,+'S(74LI7U&U6.?051\+^*X=0TW1X+R9I-2NX07(CP
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M#9!"C.1GD@<X^M96D>*Y["Q-SJ-S/?2S&Z98< %(X)F0E<#)8@H .Y%6=/\
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' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>tmb-20210930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/18/2021 1:42:45 AM-->
<!--Modified on: 11/18/2021 1:42:45 AM-->
<xsd:schema targetNamespace="http://www.essapharma.com/20210930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:epix="http://www.essapharma.com/20210930">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.essapharma.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails" id="DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails">
        <link:definition>40402 - Disclosure - REALM ACQUISITION (Schedule of Net Assets Acquired) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" id="DisclosurePrepaidsScheduleOfPrepaidExpensesDetails">
        <link:definition>40601 - Disclosure - PREPAIDS (Schedule of Prepaid Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" id="DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails">
        <link:definition>40701 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails">
        <link:definition>41401 - Disclosure - INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" id="DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails">
        <link:definition>41402 - Disclosure - INCOME TAXES (Significant Components of Future Tax Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" id="StatementConsolidatedStatementOfChangesInShareholdersEquity">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureNatureOfOperations" id="DisclosureNatureOfOperations">
        <link:definition>10101 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10201 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureRealmAcquisition" id="DisclosureRealmAcquisition">
        <link:definition>10401 - Disclosure - REALM ACQUISITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestments" id="DisclosureShortTermInvestments">
        <link:definition>10501 - Disclosure - SHORT-TERM INVESTMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosurePrepaids" id="DisclosurePrepaids">
        <link:definition>10601 - Disclosure - PREPAIDS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities" id="DisclosureAccountsPayableAndAccruedLiabilities">
        <link:definition>10701 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureOperatingLease" id="DisclosureOperatingLease">
        <link:definition>10801 - Disclosure - OPERATING LEASE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureLongTermDebt" id="DisclosureLongTermDebt">
        <link:definition>10901 - Disclosure - LONG-TERM DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilities" id="DisclosureDerivativeLiabilities">
        <link:definition>11001 - Disclosure - DERIVATIVE LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquity" id="DisclosureShareholdersEquity">
        <link:definition>11101 - Disclosure - SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows" id="DisclosureSupplementalDisclosureWithRespectToCashFlows">
        <link:definition>11201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11301 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11401 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSegmentedInformation" id="DisclosureSegmentedInformation">
        <link:definition>11501 - Disclosure - SEGMENTED INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk" id="DisclosureFinancialInstrumentsAndRisk">
        <link:definition>11601 - Disclosure - FINANCIAL INSTRUMENTS AND RISK</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureCommitments" id="DisclosureCommitments">
        <link:definition>11701 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy" id="DisclosureBasisOfPresentationPolicy">
        <link:definition>20202 - Disclosure - BASIS OF PRESENTATION (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy" id="DisclosureSignificantAccountingPoliciesPolicy">
        <link:definition>20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationTables" id="DisclosureBasisOfPresentationTables">
        <link:definition>30203 - Disclosure - BASIS OF PRESENTATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureRealmAcquisitionTables" id="DisclosureRealmAcquisitionTables">
        <link:definition>30403 - Disclosure - REALM ACQUISITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosurePrepaidsTables" id="DisclosurePrepaidsTables">
        <link:definition>30603 - Disclosure - PREPAIDS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" id="DisclosureAccountsPayableAndAccruedLiabilitiesTables">
        <link:definition>30701 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseTables" id="DisclosureOperatingLeaseTables">
        <link:definition>30803 - Disclosure - OPERATING LEASE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureLongTermDebtTables" id="DisclosureLongTermDebtTables">
        <link:definition>30903 - Disclosure - LONG-TERM DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables" id="DisclosureDerivativeLiabilitiesTables">
        <link:definition>31003 - Disclosure - DERIVATIVE LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityTables" id="DisclosureShareholdersEquityTables">
        <link:definition>31103 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31401 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureCommitmentsTables" id="DisclosureCommitmentsTables">
        <link:definition>31703 - Disclosure - COMMITMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails" id="DisclosureNatureOfOperationsNarrativeDetails">
        <link:definition>40101 - Disclosure - NATURE OF OPERATIONS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" id="DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails">
        <link:definition>40201 - Disclosure - BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails" id="DisclosureRealmAcquisitionNarrativeDetails">
        <link:definition>40401 - Disclosure - REALM ACQUISITION (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails" id="DisclosureShortTermInvestmentsNarrativeDetails">
        <link:definition>40501 - Disclosure - SHORT-TERM INVESTMENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails" id="DisclosureOperatingLeaseNarrativeDetails">
        <link:definition>40801 - Disclosure - OPERATING LEASE (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" id="DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails">
        <link:definition>40802 - Disclosure - OPERATING LEASE (Schedule of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails" id="DisclosureLongTermDebtNarrativeDetails">
        <link:definition>40901 - Disclosure - LONG-TERM DEBT (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails" id="DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails">
        <link:definition>40902 - Disclosure - LONG-TERM DEBT (Schedule of Term Loan Repayment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails" id="DisclosureDerivativeLiabilitiesNarrativeDetails">
        <link:definition>41001 - Disclosure - DERIVATIVE LIABILITIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" id="DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails">
        <link:definition>41002 - Disclosure - DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesScheduleOfChangesOfDerivativeLiabilitiesDetails" id="DisclosureDerivativeLiabilitiesScheduleOfChangesOfDerivativeLiabilitiesDetails">
        <link:definition>41003 - Disclosure - DERIVATIVE LIABILITIES (Schedule of Changes of Derivative Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails" id="DisclosureShareholdersEquityNarrativeDetails">
        <link:definition>41101 - Disclosure - SHAREHOLDERS' EQUITY (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" id="DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails">
        <link:definition>41102 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Share Based Compensation Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" id="DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails">
        <link:definition>41103 - Disclosure - SHAREHOLDERS' EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" id="DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails">
        <link:definition>41104 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" id="DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails">
        <link:definition>41105 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Stock Option Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails" id="DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails">
        <link:definition>41106 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Warrants Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" id="DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails">
        <link:definition>41107 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Warrants Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails" id="DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails">
        <link:definition>41201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" id="DisclosureRelatedPartyTransactionsNarrativeDetails">
        <link:definition>41301 - Disclosure - RELATED PARTY TRANSACTIONS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>41403 - Disclosure - INCOME TAXES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureSegmentedInformationNarrativeDetails" id="DisclosureSegmentedInformationNarrativeDetails">
        <link:definition>41501 - Disclosure - SEGMENTED INFORMATION (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails" id="DisclosureFinancialInstrumentsAndRiskNarrativeDetails">
        <link:definition>41601 - Disclosure - FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails" id="DisclosureCommitmentsNarrativeDetails">
        <link:definition>41701 - Disclosure - COMMITMENTS (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails" id="DisclosureCommitmentsScheduleOfContractualObligationsDetails">
        <link:definition>41702 - Disclosure - COMMITMENTS (Schedule of Contractual Obligations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_FinancingCosts" name="FinancingCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_IncomeTaxReconciliationFinancingCosts" name="IncomeTaxReconciliationFinancingCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets" name="DeferredTaxAssetsEquipmentAndIntangibleAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_DeferredTaxAssetsFinancingCosts" name="DeferredTaxAssetsFinancingCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_PaymentOfSubleaseTerminationCosts" name="PaymentOfSubleaseTerminationCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_FinancialInstrumentsAndRiskAbstract" name="FinancialInstrumentsAndRiskAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_WorkingCapital" name="WorkingCapital" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ScheduleOfPrepaidExpensesTableTextBlock" name="ScheduleOfPrepaidExpensesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised" name="StockIssuedDuringPeriodValuePreFundedWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_PreFundedWarrantsExercised" name="PreFundedWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability" name="BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities" name="ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_AggregateRoyaltyPaymentUpTo24000000Member" name="AggregateRoyaltyPaymentUpTo24000000Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_AggregateRoyaltyPaymentAfter24000000Member" name="AggregateRoyaltyPaymentAfter24000000Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_GrantReceivedPeriod" name="GrantReceivedPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_RoyaltyPercentRevenue" name="RoyaltyPercentRevenue" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_NatureAndContinuanceOfOperationsAbstract" name="NatureAndContinuanceOfOperationsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" name="ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_BasisOfPresentationTable" name="BasisOfPresentationTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_BasisOfPresentationLineItems" name="BasisOfPresentationLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_EssaPharmaceuticalsCorpMember" name="EssaPharmaceuticalsCorpMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_RealmTherapeuticsPlcMember" name="RealmTherapeuticsPlcMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_RealmTherapeuticsIncMember" name="RealmTherapeuticsIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_GovernmentAssistancePolicyPolicyTextBlock" name="GovernmentAssistancePolicyPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_BusinessCombinationConversionRatioPerShare" name="BusinessCombinationConversionRatioPerShare" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare" name="BusinessCombinationConversionRatioPerAmericanDepositoryShare" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare" name="BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_SiliconValleyBankTermLoanMember" name="SiliconValleyBankTermLoanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_LongTermDebtRepaymentRollForward" name="LongTermDebtRepaymentRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_RepaymentsOfLongTermDebtPrincipal" name="RepaymentsOfLongTermDebtPrincipal" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_RepaymentsOfLongTermDebtInterest" name="RepaymentsOfLongTermDebtInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_DebtInstrumentAccretion" name="DebtInstrumentAccretion" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_WallStreetJournalPrimeRateMember" name="WallStreetJournalPrimeRateMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_DebtInstrumentAdditionalBorrowingCapacityLapsed" name="DebtInstrumentAdditionalBorrowingCapacityLapsed" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_PercentageOfFinalPaymentOnAmountAdvanced" name="PercentageOfFinalPaymentOnAmountAdvanced" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_RepaymentsOfLongTermDebtFinalPayment" name="RepaymentsOfLongTermDebtFinalPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ClassOfWarrantOrRightGranted" name="ClassOfWarrantOrRightGranted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_OperatingLeaseRightOfUseAssetAbstract" name="OperatingLeaseRightOfUseAssetAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_FairValueOfWarrantIssued" name="FairValueOfWarrantIssued" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_TwoYearWarrantMember" name="TwoYearWarrantMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_SevenYearWarrantMember" name="SevenYearWarrantMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_GrantAmount" name="GrantAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ThresholdLimitForAggregateRoyaltyPayments" name="ThresholdLimitForAggregateRoyaltyPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_EmployeeSharePurchasePlanMember" name="EmployeeSharePurchasePlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" name="ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward" name="ClassOfWarrantOrRightNumberOfWarrantsRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ClassOfWarrantOrRightExpired" name="ClassOfWarrantOrRightExpired" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" name="ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted" name="ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised" name="ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" name="ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_July2020FinancingMember" name="July2020FinancingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_August2019FinancingMember" name="August2019FinancingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ClarusLifesciencesIiiL.pMember" name="ClarusLifesciencesIiiL.pMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_PreFundedWarrantsIssuedForCommonShares" name="PreFundedWarrantsIssuedForCommonShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" name="ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_PurchaseRightsOfferingTerm" name="PurchaseRightsOfferingTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" name="MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_CashAcquisitionFromAcquisitionOfBusiness" name="CashAcquisitionFromAcquisitionOfBusiness" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_PrefundedWarrantExercisedValue" name="PrefundedWarrantExercisedValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_PrefundedWarrantExercisedShares" name="PrefundedWarrantExercisedShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" name="ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_TermOfUnderwritersOption" name="TermOfUnderwritersOption" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_PrepaidExpensesTextBlock" name="PrepaidExpensesTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_MinimumAdvanceRoyaltyPayments" name="MinimumAdvanceRoyaltyPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" name="AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial" name="AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" name="AmountOfMilestonePaymentsAtApplicationForMarketingApproval" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_RepaymentsOfFinalPaymentOfDebt" name="RepaymentsOfFinalPaymentOfDebt" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_VendorAgreementMember" name="VendorAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_LeaseOnUsOfficeSpacesMember" name="LeaseOnUsOfficeSpacesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits" name="PrepaidPreclinicalAndClinicalExpensesAndDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_OperatingLeaseLiabilitiesAccretionExpenses" name="OperatingLeaseLiabilitiesAccretionExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_FinancingCostsMember" name="FinancingCostsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_OperatingLeasePaymentsFinancingActivities" name="OperatingLeasePaymentsFinancingActivities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_StockOptionPlanMember" name="StockOptionPlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_PercentageOfEffectiveInterestInSubsidiaries" name="PercentageOfEffectiveInterestInSubsidiaries" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_IncreaseInMarketPriceOfWarrantsBy10Member" name="IncreaseInMarketPriceOfWarrantsBy10Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_DecreaseInMarketPriceOfWarrantsBy10Member" name="DecreaseInMarketPriceOfWarrantsBy10Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_DecreaseInVolatilityOfWarrantsBy10Member" name="DecreaseInVolatilityOfWarrantsBy10Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_IncreaseInVolatilityOfWarrantsBy10Member" name="IncreaseInVolatilityOfWarrantsBy10Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice" name="IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility" name="IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ExercisePriceOneInUsdMember" name="ExercisePriceOneInUsdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ExercisePriceTwoInUsdMember" name="ExercisePriceTwoInUsdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ExercisePriceThreeInUsdMember" name="ExercisePriceThreeInUsdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ExercisePriceFourInUsdMember" name="ExercisePriceFourInUsdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ExercisePriceFiveInUsdMember" name="ExercisePriceFiveInUsdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ExercisePriceSixInUsdMember" name="ExercisePriceSixInUsdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ExercisePriceOneInCadMember" name="ExercisePriceOneInCadMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ExercisePriceTwoInCadMember" name="ExercisePriceTwoInCadMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_WarrantsExercisePriceOneMember" name="WarrantsExercisePriceOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_WarrantsExercisePriceTwoMember" name="WarrantsExercisePriceTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_WarrantsExercisePriceThreeMember" name="WarrantsExercisePriceThreeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_WarrantsExercisePriceFiveMember" name="WarrantsExercisePriceFiveMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_UnitsIssuedInPrivatePlacementConversionRatio" name="UnitsIssuedInPrivatePlacementConversionRatio" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights" name="MinimumNumberOfSharesRequiredToBeHeldForNominationRights" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_FinanceExpenseOperatingActivities" name="FinanceExpenseOperatingActivities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_IncomeTaxReconciliationTaxableCapitalGains" name="IncomeTaxReconciliationTaxableCapitalGains" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ExercisePriceSevenInUsdMember" name="ExercisePriceSevenInUsdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_EquityIncentivePlansMember" name="EquityIncentivePlansMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_GrantRequirementNumberOfYearsOfOperationsInTexas" name="GrantRequirementNumberOfYearsOfOperationsInTexas" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" name="ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_TenPercentChangeInForeignExchangeRateMember" name="TenPercentChangeInForeignExchangeRateMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_OperatingLeaseRightOfUseAssetsCurrent" name="OperatingLeaseRightOfUseAssetsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_InterestIncomeOperatingActivities" name="InterestIncomeOperatingActivities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_IncomeTaxExpenseRecoveryOperatingActivities" name="IncomeTaxExpenseRecoveryOperatingActivities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_OperatingLeaseLiabilitiesAddition" name="OperatingLeaseLiabilitiesAddition" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_OperatingLeaseRightOfUseAssetAddition" name="OperatingLeaseRightOfUseAssetAddition" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_February2021financingMember" name="February2021financingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ExercisePriceEightInUsdMember" name="ExercisePriceEightInUsdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_InterestFromShortTermInvestments" name="InterestFromShortTermInvestments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_UnderwriterOptionToPurchaseAdditionalSecurities" name="UnderwriterOptionToPurchaseAdditionalSecurities" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_StockOptionsAndRsuPlanMember" name="StockOptionsAndRsuPlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ExercisePriceNineInUsdMember" name="ExercisePriceNineInUsdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_ExercisePriceTenInUsdMember" name="ExercisePriceTenInUsdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_SouthFransicoOfficeMember" name="SouthFransicoOfficeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_HoustonOfficeMember" name="HoustonOfficeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="epix_CashCanadaDepositInsuranceCorporationInsuredAmount" name="CashCanadaDepositInsuranceCorporationInsuredAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>tmb-20210930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/18/2021 1:42:45 AM-->
<!--Modified on: 11/18/2021 1:42:45 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.essapharma.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails" roleURI="http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" roleURI="http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" />
  <calculationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent_637727965642009855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent_637727965642009855" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637727965642009855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637727965642009855" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637727965642009855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637727965642009855" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637727965642009855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637727965642009855" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637727965642009855" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_637727965642019902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637727965642009855" xlink:to="us-gaap_ShortTermInvestments_637727965642019902" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseRightOfUseAssetsCurrent" xlink:label="epix_OperatingLeaseRightOfUseAssetsCurrent_637727965642019902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637727965642009855" xlink:to="epix_OperatingLeaseRightOfUseAssetsCurrent_637727965642019902" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637727965642019902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637727965642009855" xlink:to="us-gaap_PrepaidExpenseCurrent_637727965642019902" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_637727965642019902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637727965642009855" xlink:to="us-gaap_ReceivablesNetCurrent_637727965642019902" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637727965642019902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637727965642019902" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_637727965642019902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637727965642019902" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_637727965642019902" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637727965642019902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637727965642019902" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637727965642019902" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637727965642019902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637727965642019902" xlink:to="us-gaap_LiabilitiesCurrent_637727965642019902" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637727965642029857" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637727965642019902" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637727965642029857" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637727965642029857" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637727965642019902" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637727965642029857" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637727965642029857" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637727965642029857" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637727965642029857" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637727965642029857" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637727965642029857" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637727965642029857" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637727965642029857" xlink:to="us-gaap_AdditionalPaidInCapital_637727965642029857" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637727965642029857" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637727965642029857" xlink:to="us-gaap_CommonStockValue_637727965642029857" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637727965642029857" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637727965642029857" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637727965642029857" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637727965642039854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637727965642039854" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637727965642039854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637727965642039854" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637727965642039854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637727965642039854" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637727965642039854" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_637727965642039854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637727965642039854" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_637727965642039854" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_637727965642039854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637727965642039854" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_637727965642039854" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637727965642039854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637727965642039854" xlink:to="us-gaap_OperatingExpenses_637727965642039854" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FinancingCosts" xlink:label="epix_FinancingCosts_637727965642049856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637727965642039854" xlink:to="epix_FinancingCosts_637727965642049856" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637727965642049856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637727965642039854" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637727965642049856" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637727965642049856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637727965642039854" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637727965642049856" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637727965642049856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637727965642049856" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_CashAcquisitionFromAcquisitionOfBusiness" xlink:label="epix_CashAcquisitionFromAcquisitionOfBusiness_637727965642049856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" xlink:to="epix_CashAcquisitionFromAcquisitionOfBusiness_637727965642049856" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeasePaymentsFinancingActivities" xlink:label="epix_OperatingLeasePaymentsFinancingActivities_637727965642049856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" xlink:to="epix_OperatingLeasePaymentsFinancingActivities_637727965642049856" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637727965642049856" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637727965642049856" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_637727965642059852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_637727965642059852" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637727965642059852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" xlink:to="us-gaap_ProceedsFromWarrantExercises_637727965642059852" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfFinalPaymentOfDebt" xlink:label="epix_RepaymentsOfFinalPaymentOfDebt_637727965642059852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" xlink:to="epix_RepaymentsOfFinalPaymentOfDebt_637727965642059852" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PaymentOfSubleaseTerminationCosts" xlink:label="epix_PaymentOfSubleaseTerminationCosts_637727965642059852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" xlink:to="epix_PaymentOfSubleaseTerminationCosts_637727965642059852" order="7" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_637727965642059852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" xlink:to="us-gaap_RepaymentsOfDebt_637727965642059852" order="8" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_637727965642059852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" xlink:to="us-gaap_PaymentsOfFinancingCosts_637727965642059852" order="9" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637727965642059852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637727965642059852" order="10" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_637727965642059852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_637727965642059852" order="11" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637727965642069855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642049856" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637727965642069855" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637727965642069855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637727965642069855" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_637727965642069855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637727965642069855" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_637727965642069855" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_InterestFromShortTermInvestments" xlink:label="epix_InterestFromShortTermInvestments_637727965642069855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637727965642069855" xlink:to="epix_InterestFromShortTermInvestments_637727965642069855" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_637727965642069855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637727965642069855" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_637727965642069855" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromOtherDeposits" xlink:label="us-gaap_ProceedsFromOtherDeposits_637727965642069855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637727965642069855" xlink:to="us-gaap_ProceedsFromOtherDeposits_637727965642069855" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense_637727965642079965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" xlink:to="us-gaap_AccretionExpense_637727965642079965" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_637727965642079965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_637727965642079965" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637727965642079965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637727965642079965" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_InterestIncomeOperatingActivities" xlink:label="epix_InterestIncomeOperatingActivities_637727965642079965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" xlink:to="epix_InterestIncomeOperatingActivities_637727965642079965" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncomeTaxExpenseRecoveryOperatingActivities" xlink:label="epix_IncomeTaxExpenseRecoveryOperatingActivities_637727965642079965" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" xlink:to="epix_IncomeTaxExpenseRecoveryOperatingActivities_637727965642079965" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FinanceExpenseOperatingActivities" xlink:label="epix_FinanceExpenseOperatingActivities_637727965642089858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" xlink:to="epix_FinanceExpenseOperatingActivities_637727965642089858" order="6" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637727965642089858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637727965642089858" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_637727965642089858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_637727965642089858" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_637727965642089858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_637727965642089858" order="9" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables_637727965642089858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" xlink:to="us-gaap_IncreaseDecreaseInReceivables_637727965642089858" order="10" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637727965642099971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" xlink:to="us-gaap_NetIncomeLoss_637727965642099971" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637727965642099971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637727965642099971" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637727965642099971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642079965" xlink:to="us-gaap_ShareBasedCompensation_637727965642099971" order="13" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails" xlink:type="extended" xlink:title="40402 - Disclosure - REALM ACQUISITION (Schedule of Net Assets Acquired) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637727965642099971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637727965642099971" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets_637727965642099971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets_637727965642099971" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_637727965642109863" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_637727965642109863" order="3" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - PREPAIDS (Schedule of Prepaid Expenses) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637727965642109863" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidInsurance_637727965642109863" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits" xlink:label="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_637727965642109863" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_637727965642109863" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_637727965642109863" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_637727965642109863" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637727965642109863" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent_637727965642109863" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637727965642109863" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637727965642109863" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_637727965642120854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedVacationCurrent_637727965642120854" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" xlink:type="extended" xlink:title="41401 - Disclosure - INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_637727965642120854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_637727965642120854" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncomeTaxReconciliationFinancingCosts" xlink:label="epix_IncomeTaxReconciliationFinancingCosts_637727965642120854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="epix_IncomeTaxReconciliationFinancingCosts_637727965642120854" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_637727965642120854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_637727965642120854" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncomeTaxReconciliationTaxableCapitalGains" xlink:label="epix_IncomeTaxReconciliationTaxableCapitalGains_637727965642120854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="epix_IncomeTaxReconciliationTaxableCapitalGains_637727965642120854" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637727965642120854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637727965642120854" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_637727965642120854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_637727965642120854" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_637727965642129963" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_637727965642129963" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_637727965642129963" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_637727965642129963" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" xlink:type="extended" xlink:title="41402 - Disclosure - INCOME TAXES (Significant Components of Future Tax Assets) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637727965642129963" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637727965642129963" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637727965642129963" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_637727965642129963" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637727965642129963" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637727965642129963" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637727965642129963" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637727965642129963" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637727965642129963" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637727965642129963" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DeferredTaxAssetsEquipmentAndIntangibleAssets" xlink:label="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_637727965642129963" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637727965642129963" xlink:to="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_637727965642129963" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DeferredTaxAssetsFinancingCosts" xlink:label="epix_DeferredTaxAssetsFinancingCosts_637727965642129963" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637727965642129963" xlink:to="epix_DeferredTaxAssetsFinancingCosts_637727965642129963" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="us-gaap_DeferredTaxAssetsInvestments_637727965642140221" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637727965642129963" xlink:to="us-gaap_DeferredTaxAssetsInvestments_637727965642140221" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_637727965642140221" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637727965642129963" xlink:to="us-gaap_DeferredTaxAssetsOther_637727965642140221" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>tmb-20210930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/18/2021 1:42:45 AM-->
<!--Modified on: 11/18/2021 1:42:45 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#StatementConsolidatedStatementOfChangesInShareholdersEquity" roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquityTables" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureNatureOfOperationsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureRealmAcquisitionNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails" roleURI="http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShortTermInvestmentsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureOperatingLeaseNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureLongTermDebtNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails" roleURI="http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureDerivativeLiabilitiesNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquityNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureRelatedPartyTransactionsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureFinancialInstrumentsAndRiskNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureCommitmentsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureCommitmentsScheduleOfContractualObligationsDetails" roleURI="http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <definitionLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637727965642140221" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637727965642140221" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="epix_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="epix_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PrefundedWarrantExercisedValue" xlink:label="epix_PrefundedWarrantExercisedValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_PrefundedWarrantExercisedValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PrefundedWarrantExercisedShares" xlink:label="epix_PrefundedWarrantExercisedShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_PrefundedWarrantExercisedShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityTables" xlink:type="extended" xlink:title="31103 - Disclosure - SHAREHOLDERS' EQUITY (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637727965642190275" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637727965642190275" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_EmployeeSharePurchasePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_StockOptionPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" xlink:label="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails" xlink:type="extended" xlink:title="40101 - Disclosure - NATURE OF OPERATIONS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637727965642210202" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637727965642210202" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsPlcMember" xlink:label="epix_RealmTherapeuticsPlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="epix_RealmTherapeuticsPlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BasisOfPresentationTable" xlink:label="epix_BasisOfPresentationTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="epix_BasisOfPresentationTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637727965642210202" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_637727965642210202" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EssaPharmaceuticalsCorpMember" xlink:label="epix_EssaPharmaceuticalsCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="epix_EssaPharmaceuticalsCorpMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsPlcMember" xlink:label="epix_RealmTherapeuticsPlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_OwnershipDomain" xlink:to="epix_RealmTherapeuticsPlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsIncMember" xlink:label="epix_RealmTherapeuticsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_OwnershipDomain" xlink:to="epix_RealmTherapeuticsIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BasisOfPresentationLineItems" xlink:label="epix_BasisOfPresentationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="epix_BasisOfPresentationLineItems" xlink:to="epix_BasisOfPresentationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PercentageOfEffectiveInterestInSubsidiaries" xlink:label="epix_PercentageOfEffectiveInterestInSubsidiaries" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="epix_BasisOfPresentationLineItems" xlink:to="epix_PercentageOfEffectiveInterestInSubsidiaries" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SignificantAccountingPoliciesTable" xlink:label="epix_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="epix_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637727965642220226" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_637727965642220226" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SignificantAccountingPoliciesLineItems" xlink:label="epix_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="epix_SignificantAccountingPoliciesLineItems" xlink:to="epix_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="epix_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="epix_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="epix_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REALM ACQUISITION (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsPlcMember" xlink:label="epix_RealmTherapeuticsPlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="epix_RealmTherapeuticsPlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationConversionRatioPerShare" xlink:label="epix_BusinessCombinationConversionRatioPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="epix_BusinessCombinationConversionRatioPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare" xlink:label="epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare" xlink:label="epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails" xlink:type="extended" xlink:title="40402 - Disclosure - REALM ACQUISITION (Schedule of Net Assets Acquired) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsPlcMember" xlink:label="epix_RealmTherapeuticsPlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="epix_RealmTherapeuticsPlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - SHORT-TERM INVESTMENTS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637727965642260456" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637727965642260456" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentInterestRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - OPERATING LEASE (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637727965642270223" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637727965642270223" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FinancingCostsMember" xlink:label="epix_FinancingCostsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="epix_FinancingCostsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637727965642280397" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637727965642280397" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SouthFransicoOfficeMember" xlink:label="epix_SouthFransicoOfficeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="epix_SouthFransicoOfficeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_HoustonOfficeMember" xlink:label="epix_HoustonOfficeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="epix_HoustonOfficeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseLiabilitiesAccretionExpenses" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_OperatingLeaseLiabilitiesAccretionExpenses" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - OPERATING LEASE (Schedule of Operating Leases) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseRightOfUseAssetAbstract" xlink:label="epix_OperatingLeaseRightOfUseAssetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="epix_OperatingLeaseRightOfUseAssetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="epix_OperatingLeaseRightOfUseAssetAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseRightOfUseAssetsCurrent" xlink:label="epix_OperatingLeaseRightOfUseAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="epix_OperatingLeaseRightOfUseAssetAbstract" xlink:to="epix_OperatingLeaseRightOfUseAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseRightOfUseAssetAddition" xlink:label="epix_OperatingLeaseRightOfUseAssetAddition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="epix_OperatingLeaseRightOfUseAssetAbstract" xlink:to="epix_OperatingLeaseRightOfUseAssetAddition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="epix_OperatingLeaseRightOfUseAssetAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseLiabilitiesAddition" xlink:label="epix_OperatingLeaseLiabilitiesAddition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="epix_OperatingLeaseLiabilitiesAddition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseLiabilitiesAccretionExpenses" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="epix_OperatingLeaseLiabilitiesAccretionExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - LONG-TERM DEBT (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_637727965642310264" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_637727965642310264" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SiliconValleyBankTermLoanMember" xlink:label="epix_SiliconValleyBankTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="epix_SiliconValleyBankTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_637727965642319989" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_637727965642319989" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WallStreetJournalPrimeRateMember" xlink:label="epix_WallStreetJournalPrimeRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="epix_WallStreetJournalPrimeRateMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DebtInstrumentAdditionalBorrowingCapacityLapsed" xlink:label="epix_DebtInstrumentAdditionalBorrowingCapacityLapsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="epix_DebtInstrumentAdditionalBorrowingCapacityLapsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PercentageOfFinalPaymentOnAmountAdvanced" xlink:label="epix_PercentageOfFinalPaymentOnAmountAdvanced" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="epix_PercentageOfFinalPaymentOnAmountAdvanced" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtPrincipal" xlink:label="epix_RepaymentsOfLongTermDebtPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="epix_RepaymentsOfLongTermDebtPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtInterest" xlink:label="epix_RepaymentsOfLongTermDebtInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="epix_RepaymentsOfLongTermDebtInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfFinancingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtFinalPayment" xlink:label="epix_RepaymentsOfLongTermDebtFinalPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="epix_RepaymentsOfLongTermDebtFinalPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightGranted" xlink:label="epix_ClassOfWarrantOrRightGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="epix_ClassOfWarrantOrRightGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FairValueOfWarrantIssued" xlink:label="epix_FairValueOfWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="epix_FairValueOfWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails" xlink:type="extended" xlink:title="40902 - Disclosure - LONG-TERM DEBT (Schedule of Term Loan Repayment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SiliconValleyBankTermLoanMember" xlink:label="epix_SiliconValleyBankTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="epix_SiliconValleyBankTermLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_LongTermDebtRepaymentRollForward" xlink:label="epix_LongTermDebtRepaymentRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="epix_LongTermDebtRepaymentRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="epix_LongTermDebtRepaymentRollForward" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtPrincipal" xlink:label="epix_RepaymentsOfLongTermDebtPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="epix_LongTermDebtRepaymentRollForward" xlink:to="epix_RepaymentsOfLongTermDebtPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtInterest" xlink:label="epix_RepaymentsOfLongTermDebtInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="epix_LongTermDebtRepaymentRollForward" xlink:to="epix_RepaymentsOfLongTermDebtInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DebtInstrumentAccretion" xlink:label="epix_DebtInstrumentAccretion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="epix_LongTermDebtRepaymentRollForward" xlink:to="epix_DebtInstrumentAccretion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtFinalPayment" xlink:label="epix_RepaymentsOfLongTermDebtFinalPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="epix_LongTermDebtRepaymentRollForward" xlink:to="epix_RepaymentsOfLongTermDebtFinalPayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - DERIVATIVE LIABILITIES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637727965642360257" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637727965642360257" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637727965642370231" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637727965642370231" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637727965642370231" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637727965642370231" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_TwoYearWarrantMember" xlink:label="epix_TwoYearWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="epix_TwoYearWarrantMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SevenYearWarrantMember" xlink:label="epix_SevenYearWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="epix_SevenYearWarrantMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DerivativeTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637727965642380646" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_637727965642380646" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncreaseInMarketPriceOfWarrantsBy10Member" xlink:label="epix_IncreaseInMarketPriceOfWarrantsBy10Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="epix_IncreaseInMarketPriceOfWarrantsBy10Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DecreaseInMarketPriceOfWarrantsBy10Member" xlink:label="epix_DecreaseInMarketPriceOfWarrantsBy10Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="epix_DecreaseInMarketPriceOfWarrantsBy10Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncreaseInVolatilityOfWarrantsBy10Member" xlink:label="epix_IncreaseInVolatilityOfWarrantsBy10Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="epix_IncreaseInVolatilityOfWarrantsBy10Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DecreaseInVolatilityOfWarrantsBy10Member" xlink:label="epix_DecreaseInVolatilityOfWarrantsBy10Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="epix_DecreaseInVolatilityOfWarrantsBy10Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_UnitsIssuedInPrivatePlacementConversionRatio" xlink:label="epix_UnitsIssuedInPrivatePlacementConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DerivativeLineItems" xlink:to="epix_UnitsIssuedInPrivatePlacementConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice" xlink:label="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DerivativeLineItems" xlink:to="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility" xlink:label="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DerivativeLineItems" xlink:to="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:type="extended" xlink:title="41002 - Disclosure - DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637727965642410252" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_637727965642410252" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DerivativeTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - SHAREHOLDERS' EQUITY (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_February2021financingMember" xlink:label="epix_February2021financingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="epix_February2021financingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_July2020FinancingMember" xlink:label="epix_July2020FinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="epix_July2020FinancingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_August2019FinancingMember" xlink:label="epix_August2019FinancingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="epix_August2019FinancingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsPlcMember" xlink:label="epix_RealmTherapeuticsPlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="epix_RealmTherapeuticsPlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637727965642440211" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637727965642440211" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClarusLifesciencesIiiL.pMember" xlink:label="epix_ClarusLifesciencesIiiL.pMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="epix_ClarusLifesciencesIiiL.pMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637727965642560361" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637727965642560361" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockOptionsAndRsuPlanMember" xlink:label="epix_StockOptionsAndRsuPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="epix_StockOptionsAndRsuPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EquityIncentivePlansMember" xlink:label="epix_EquityIncentivePlansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_EquityIncentivePlansMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="epix_EquityIncentivePlansMember" xlink:to="epix_EmployeeSharePurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_TwoYearWarrantMember" xlink:label="epix_TwoYearWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="epix_TwoYearWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SevenYearWarrantMember" xlink:label="epix_SevenYearWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="epix_SevenYearWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_UnderwriterOptionToPurchaseAdditionalSecurities" xlink:label="epix_UnderwriterOptionToPurchaseAdditionalSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_UnderwriterOptionToPurchaseAdditionalSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_TermOfUnderwritersOption" xlink:label="epix_TermOfUnderwritersOption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_TermOfUnderwritersOption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PreFundedWarrantsIssuedForCommonShares" xlink:label="epix_PreFundedWarrantsIssuedForCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_PreFundedWarrantsIssuedForCommonShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsForCommissions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_UnitsIssuedInPrivatePlacementConversionRatio" xlink:label="epix_UnitsIssuedInPrivatePlacementConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_UnitsIssuedInPrivatePlacementConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights" xlink:label="epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" xlink:label="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PurchaseRightsOfferingTerm" xlink:label="epix_PurchaseRightsOfferingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_PurchaseRightsOfferingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" xlink:label="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="41102 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Share Based Compensation Expenses) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_EmployeeSharePurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_StockOptionPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" xlink:type="extended" xlink:title="41103 - Disclosure - SHAREHOLDERS' EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_EmployeeSharePurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="epix_StockOptionPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" xlink:type="extended" xlink:title="41105 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Stock Option Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965642689944" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965642689944" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceOneInUsdMember" xlink:label="epix_ExercisePriceOneInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceOneInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceTwoInUsdMember" xlink:label="epix_ExercisePriceTwoInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceTwoInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceThreeInUsdMember" xlink:label="epix_ExercisePriceThreeInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceThreeInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceFourInUsdMember" xlink:label="epix_ExercisePriceFourInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceFourInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceFiveInUsdMember" xlink:label="epix_ExercisePriceFiveInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceFiveInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceSixInUsdMember" xlink:label="epix_ExercisePriceSixInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceSixInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceSevenInUsdMember" xlink:label="epix_ExercisePriceSevenInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceSevenInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceEightInUsdMember" xlink:label="epix_ExercisePriceEightInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceEightInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceNineInUsdMember" xlink:label="epix_ExercisePriceNineInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceNineInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceTenInUsdMember" xlink:label="epix_ExercisePriceTenInUsdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceTenInUsdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceOneInCadMember" xlink:label="epix_ExercisePriceOneInCadMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceOneInCadMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceTwoInCadMember" xlink:label="epix_ExercisePriceTwoInCadMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="epix_ExercisePriceTwoInCadMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="41107 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Warrants Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WarrantsExercisePriceOneMember" xlink:label="epix_WarrantsExercisePriceOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="epix_WarrantsExercisePriceOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WarrantsExercisePriceTwoMember" xlink:label="epix_WarrantsExercisePriceTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="epix_WarrantsExercisePriceTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WarrantsExercisePriceThreeMember" xlink:label="epix_WarrantsExercisePriceThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="epix_WarrantsExercisePriceThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WarrantsExercisePriceFiveMember" xlink:label="epix_WarrantsExercisePriceFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="epix_WarrantsExercisePriceFiveMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - RELATED PARTY TRANSACTIONS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637727965642730231" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_637727965642730231" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41403 - Disclosure - INCOME TAXES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637727965642740332" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_637727965642740332" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637727965642740332" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637727965642740332" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails" xlink:type="extended" xlink:title="41601 - Disclosure - FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_TenPercentChangeInForeignExchangeRateMember" xlink:label="epix_TenPercentChangeInForeignExchangeRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="epix_TenPercentChangeInForeignExchangeRateMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WorkingCapital" xlink:label="epix_WorkingCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_WorkingCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_CashCanadaDepositInsuranceCorporationInsuredAmount" xlink:label="epix_CashCanadaDepositInsuranceCorporationInsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_CashCanadaDepositInsuranceCorporationInsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" xlink:label="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails" xlink:type="extended" xlink:title="41701 - Disclosure - COMMITMENTS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637727965642769945" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637727965642769945" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_LicenseAgreementMember" xlink:label="epix_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="epix_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TX" xlink:label="stpr_TX" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_TX" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637727965642769945" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637727965642769945" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AggregateRoyaltyPaymentUpTo24000000Member" xlink:label="epix_AggregateRoyaltyPaymentUpTo24000000Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="epix_AggregateRoyaltyPaymentUpTo24000000Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AggregateRoyaltyPaymentAfter24000000Member" xlink:label="epix_AggregateRoyaltyPaymentAfter24000000Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="epix_AggregateRoyaltyPaymentAfter24000000Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637727965642790412" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637727965642790412" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_GrantAmount" xlink:label="epix_GrantAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_GrantAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_GrantReceivedPeriod" xlink:label="epix_GrantReceivedPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_GrantReceivedPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_GrantsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_GrantRequirementNumberOfYearsOfOperationsInTexas" xlink:label="epix_GrantRequirementNumberOfYearsOfOperationsInTexas" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_GrantRequirementNumberOfYearsOfOperationsInTexas" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ThresholdLimitForAggregateRoyaltyPayments" xlink:label="epix_ThresholdLimitForAggregateRoyaltyPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_ThresholdLimitForAggregateRoyaltyPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RoyaltyPercentRevenue" xlink:label="epix_RoyaltyPercentRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_RoyaltyPercentRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_MinimumAdvanceRoyaltyPayments" xlink:label="epix_MinimumAdvanceRoyaltyPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_MinimumAdvanceRoyaltyPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" xlink:label="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails" xlink:type="extended" xlink:title="41702 - Disclosure - COMMITMENTS (Schedule of Contractual Obligations) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_LicenseAgreementMember" xlink:label="epix_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="epix_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_VendorAgreementMember" xlink:label="epix_VendorAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="epix_VendorAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ConsultingAgreementMember" xlink:label="epix_ConsultingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="epix_ConsultingAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_LeaseOnUsOfficeSpacesMember" xlink:label="epix_LeaseOnUsOfficeSpacesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="epix_LeaseOnUsOfficeSpacesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligationDueInThirdYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligationDueInFourthYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractualObligationDueInFifthYear" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>tmb-20210930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/18/2021 1:42:45 AM-->
<!--Modified on: 11/18/2021 1:42:45 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments (Note 5)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaids (Note 6)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, end of year</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseRightOfUseAssetsCurrent" xlink:label="epix_OperatingLeaseRightOfUseAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_OperatingLeaseRightOfUseAssetsCurrent" xlink:to="epix_OperatingLeaseRightOfUseAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_OperatingLeaseRightOfUseAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's right to use underlying asset under operating lease, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_OperatingLeaseRightOfUseAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="epix_OperatingLeaseRightOfUseAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets (Note 8)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets (Note 8)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities (Note 7)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, end of year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of operating lease liabilities (Note 8)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liabilities (Note 10)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivatives with expected life greater than one year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities (Note 8)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares 43,984,346 issued and outstanding (September 30, 2020 - 32,064,411) (Note 11)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital (Note 11)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING EXPENSES (Abstract)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FinancingCosts" xlink:label="epix_FinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_FinancingCosts" xlink:to="epix_FinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_FinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of financing costs incurred during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_FinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_FinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing costs (Notes 8 and 9)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Gain (Loss) on Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability gain (loss) (Note 10)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss for the year before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss for the year before taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax recovery (expense) (Note 14)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax (recovery) expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss and comprehensive loss for the year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted loss per common share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding - basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH FLOWS FROM OPERATING ACTIVITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Items not affecting cash and cash equivalents:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of lease liability</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncomeTaxExpenseRecoveryOperatingActivities" xlink:label="epix_IncomeTaxExpenseRecoveryOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_IncomeTaxExpenseRecoveryOperatingActivities" xlink:to="epix_IncomeTaxExpenseRecoveryOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_IncomeTaxExpenseRecoveryOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense Recovery Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_IncomeTaxExpenseRecoveryOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense Recovery Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_IncomeTaxExpenseRecoveryOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax recovery</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_InterestIncomeOperatingActivities" xlink:label="epix_InterestIncomeOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_InterestIncomeOperatingActivities" xlink:to="epix_InterestIncomeOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_InterestIncomeOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_InterestIncomeOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_InterestIncomeOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FinanceExpenseOperatingActivities" xlink:label="epix_FinanceExpenseOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_FinanceExpenseOperatingActivities" xlink:to="epix_FinanceExpenseOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_FinanceExpenseOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance expense, operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_FinanceExpenseOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance expense, operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_FinanceExpenseOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized foreign exchange</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in non-cash working capital items:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaids</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Income Taxes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH FLOWS FROM INVESTING ACTIVITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromOtherDeposits" xlink:label="us-gaap_ProceedsFromOtherDeposits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherDeposits" xlink:to="us-gaap_ProceedsFromOtherDeposits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale, Maturity and Collection of Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of short-term investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from short-term investments sold</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_InterestFromShortTermInvestments" xlink:label="epix_InterestFromShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_InterestFromShortTermInvestments" xlink:to="epix_InterestFromShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_InterestFromShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest from short-term investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_InterestFromShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest from short-term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_InterestFromShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest from short-term investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH FLOWS FROM FINANCING ACTIVITIES</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_CashAcquisitionFromAcquisitionOfBusiness" xlink:label="epix_CashAcquisitionFromAcquisitionOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_CashAcquisitionFromAcquisitionOfBusiness" xlink:to="epix_CashAcquisitionFromAcquisitionOfBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_CashAcquisitionFromAcquisitionOfBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash inflow from acquisition of business.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_CashAcquisitionFromAcquisitionOfBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Acquisition From Acquisition of Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_CashAcquisitionFromAcquisitionOfBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash acquired on acquisition of Realm</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Merger Related Costs, Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs on acquisition of Realm</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PaymentOfSubleaseTerminationCosts" xlink:label="epix_PaymentOfSubleaseTerminationCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PaymentOfSubleaseTerminationCosts" xlink:to="epix_PaymentOfSubleaseTerminationCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PaymentOfSubleaseTerminationCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow on payment of sublease termination costs during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PaymentOfSubleaseTerminationCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment Of Sublease Termination Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_PaymentOfSubleaseTerminationCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination costs on Realm sublease</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds on issuance of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate gross proceeds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issuance transaction costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment to Acquire Shares through Employee Share Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares purchased through employee share purchase plan</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeasePaymentsFinancingActivities" xlink:label="epix_OperatingLeasePaymentsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_OperatingLeasePaymentsFinancingActivities" xlink:to="epix_OperatingLeasePaymentsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_OperatingLeasePaymentsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash flow arising out of lease payments during the period, which are classified as financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_OperatingLeasePaymentsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Payments, Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_OperatingLeasePaymentsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan principal repaid</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfFinalPaymentOfDebt" xlink:label="epix_RepaymentsOfFinalPaymentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_RepaymentsOfFinalPaymentOfDebt" xlink:to="epix_RepaymentsOfFinalPaymentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_RepaymentsOfFinalPaymentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for repayment of final payment of loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_RepaymentsOfFinalPaymentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments Of Final Payment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_RepaymentsOfFinalPaymentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan final payment paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and financing costs paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of foreign exchange on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in cash and cash equivalents for the year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance, in shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance, in shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of Realm</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of Realm, in shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issuance costs</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="epix_StockIssuedDuringPeriodValueWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="epix_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="epix_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="epix_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised, in shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing , in shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PrefundedWarrantExercisedValue" xlink:label="epix_PrefundedWarrantExercisedValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PrefundedWarrantExercisedValue" xlink:to="epix_PrefundedWarrantExercisedValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PrefundedWarrantExercisedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of prefunded warrant exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PrefundedWarrantExercisedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prefunded Warrant Exercised, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_PrefundedWarrantExercisedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded warrants exercised</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PrefundedWarrantExercisedShares" xlink:label="epix_PrefundedWarrantExercisedShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PrefundedWarrantExercisedShares" xlink:to="epix_PrefundedWarrantExercisedShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PrefundedWarrantExercisedShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of prefunded warrant exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PrefundedWarrantExercisedShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prefunded Warrant Exercised, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_PrefundedWarrantExercisedShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded warrants exercised, shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised, shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued through employee share purchase plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued through employee share purchase plan, shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_NatureAndContinuanceOfOperationsAbstract" xlink:label="epix_NatureAndContinuanceOfOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_NatureAndContinuanceOfOperationsAbstract" xlink:to="epix_NatureAndContinuanceOfOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_NatureAndContinuanceOfOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_NatureAndContinuanceOfOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REALM ACQUISITION</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REALM ACQUISITION</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHORT-TERM INVESTMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-term Investments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHORT-TERM INVESTMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PREPAIDS</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PrepaidExpensesTextBlock" xlink:label="epix_PrepaidExpensesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PrepaidExpensesTextBlock" xlink:to="epix_PrepaidExpensesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PrepaidExpensesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PrepaidExpensesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_PrepaidExpensesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PREPAIDS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING LEASE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING LEASE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LONG-TERM DEBT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LONG-TERM DEBT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DERIVATIVE LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DERIVATIVE LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Supplemental Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEGMENTED INFORMATION</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEGMENTED INFORMATION</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FinancialInstrumentsAndRiskAbstract" xlink:label="epix_FinancialInstrumentsAndRiskAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_FinancialInstrumentsAndRiskAbstract" xlink:to="epix_FinancialInstrumentsAndRiskAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_FinancialInstrumentsAndRiskAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">na</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_FinancialInstrumentsAndRiskAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL INSTRUMENTS AND RISK</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL INSTRUMENTS AND RISK</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Consolidation and Functional Currency</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Exchange</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_GovernmentAssistancePolicyPolicyTextBlock" xlink:label="epix_GovernmentAssistancePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_GovernmentAssistancePolicyPolicyTextBlock" xlink:to="epix_GovernmentAssistancePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_GovernmentAssistancePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_GovernmentAssistancePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_GovernmentAssistancePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and Diluted Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" xlink:label="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" xlink:to="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the functional currency and effective interest in subsidiaries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Functional Currency and Effective Interest in Subsidiaries [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Functional Currency of Company and its Subsidiaries</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Net Assets Acquired</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ScheduleOfPrepaidExpensesTableTextBlock" xlink:label="epix_ScheduleOfPrepaidExpensesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ScheduleOfPrepaidExpensesTableTextBlock" xlink:to="epix_ScheduleOfPrepaidExpensesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ScheduleOfPrepaidExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of information pertaining to prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ScheduleOfPrepaidExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Prepaid Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ScheduleOfPrepaidExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Prepaid Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" xlink:label="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" xlink:to="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of operating lease related assets and liabilities and other related information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Operating Lease Balance Sheet Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Operating Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Term Loan Repayment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Changes to Derivative Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant outstanding and Exercise price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Assumptions for the Valuation of Stock Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Stock Option Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Warrants Activity</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" xlink:label="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" xlink:to="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of warrants outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Warrants or Rights Outstanding [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Warrants Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Income Taxes at Statutory Rates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Components of Future Tax Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of contractual obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Contractual Obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Effective Date of Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Name of Acquired Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Name of acquired entity</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BasisOfPresentationTable" xlink:label="epix_BasisOfPresentationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_BasisOfPresentationTable" xlink:to="epix_BasisOfPresentationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_BasisOfPresentationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about basis of presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_BasisOfPresentationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation [Table]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BasisOfPresentationLineItems" xlink:label="epix_BasisOfPresentationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_BasisOfPresentationLineItems" xlink:to="epix_BasisOfPresentationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_BasisOfPresentationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent basis of presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_BasisOfPresentationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PercentageOfEffectiveInterestInSubsidiaries" xlink:label="epix_PercentageOfEffectiveInterestInSubsidiaries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PercentageOfEffectiveInterestInSubsidiaries" xlink:to="epix_PercentageOfEffectiveInterestInSubsidiaries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PercentageOfEffectiveInterestInSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of effective interest in subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PercentageOfEffectiveInterestInSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of effective interest in subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_PercentageOfEffectiveInterestInSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SignificantAccountingPoliciesTable" xlink:label="epix_SignificantAccountingPoliciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_SignificantAccountingPoliciesTable" xlink:to="epix_SignificantAccountingPoliciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SignificantAccountingPoliciesLineItems" xlink:label="epix_SignificantAccountingPoliciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_SignificantAccountingPoliciesLineItems" xlink:to="epix_SignificantAccountingPoliciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent summary of significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realm acquisition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New shares issued on acquisition</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationConversionRatioPerShare" xlink:label="epix_BusinessCombinationConversionRatioPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_BusinessCombinationConversionRatioPerShare" xlink:to="epix_BusinessCombinationConversionRatioPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_BusinessCombinationConversionRatioPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ratio of New ESSA Shares to be issued to the shareholders for every share in Realm.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_BusinessCombinationConversionRatioPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Conversion Ratio Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_BusinessCombinationConversionRatioPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion ratio per share</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare" xlink:label="epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare" xlink:to="epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ratio of New ESSA Shares to be issued to the shareholders for every American Depository share in Realm.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Conversion Ratio Per American Depository Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion ratio per American Depository Share (ADS)</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare" xlink:label="epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare" xlink:to="epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares that represents one American Depository share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Number of Shares Represents One American Depository Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares represented by each American Depository Share (ADS)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of net assets acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total net assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs incurred</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net assets of Realm acquired:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets" xlink:to="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount due from customers or clients for goods or services, including trade receivables and amounts due from others and other current assets, acquired at the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Receivables and Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables and other current assets</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:to="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and accrued liabilities assumed at the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accounts Payable And Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Guaranteed investment certificates, interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid insurance</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits" xlink:label="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits" xlink:to="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of prepaid preclinical and clinical expenses and deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Preclinical and Clinical Expenses and Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid CMC and clinical expenses and deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other deposits and prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Vacation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued vacation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental borrowing rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining lease term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease costs</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseLiabilitiesAccretionExpenses" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_OperatingLeaseLiabilitiesAccretionExpenses" xlink:to="epix_OperatingLeaseLiabilitiesAccretionExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of accretion expense on operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities Accretion Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update and Change in Accounting Principle [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING LEASE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Description [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING LEASE</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseRightOfUseAssetAbstract" xlink:label="epix_OperatingLeaseRightOfUseAssetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_OperatingLeaseRightOfUseAssetAbstract" xlink:to="epix_OperatingLeaseRightOfUseAssetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_OperatingLeaseRightOfUseAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_OperatingLeaseRightOfUseAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_OperatingLeaseRightOfUseAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseRightOfUseAssetAddition" xlink:label="epix_OperatingLeaseRightOfUseAssetAddition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_OperatingLeaseRightOfUseAssetAddition" xlink:to="epix_OperatingLeaseRightOfUseAssetAddition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_OperatingLeaseRightOfUseAssetAddition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right of use asset addition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_OperatingLeaseRightOfUseAssetAddition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Right Of Use Asset Addition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_OperatingLeaseRightOfUseAssetAddition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Addition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseLiabilitiesAddition" xlink:label="epix_OperatingLeaseLiabilitiesAddition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_OperatingLeaseLiabilitiesAddition" xlink:to="epix_OperatingLeaseLiabilitiesAddition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_OperatingLeaseLiabilitiesAddition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities addition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_OperatingLeaseLiabilitiesAddition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities Addition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_OperatingLeaseLiabilitiesAddition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Addition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LONG-TERM DEBT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount drawn from term loan facility</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DebtInstrumentAdditionalBorrowingCapacityLapsed" xlink:label="epix_DebtInstrumentAdditionalBorrowingCapacityLapsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_DebtInstrumentAdditionalBorrowingCapacityLapsed" xlink:to="epix_DebtInstrumentAdditionalBorrowingCapacityLapsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_DebtInstrumentAdditionalBorrowingCapacityLapsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of addition borrowing capacity lapsed during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_DebtInstrumentAdditionalBorrowingCapacityLapsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Additional Borrowing Capacity Lapsed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_DebtInstrumentAdditionalBorrowingCapacityLapsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing capacity lapsed</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Ending balance (in dollar per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Beginning balance (in dollar per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable rate of interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt maturity date</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PercentageOfFinalPaymentOnAmountAdvanced" xlink:label="epix_PercentageOfFinalPaymentOnAmountAdvanced" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PercentageOfFinalPaymentOnAmountAdvanced" xlink:to="epix_PercentageOfFinalPaymentOnAmountAdvanced_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PercentageOfFinalPaymentOnAmountAdvanced_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of final payment on amount advanced due to early payment or termination of contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PercentageOfFinalPaymentOnAmountAdvanced_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Final Payment on Amount Advanced</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_PercentageOfFinalPaymentOnAmountAdvanced_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of final payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Loan payment</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtPrincipal" xlink:label="epix_RepaymentsOfLongTermDebtPrincipal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_RepaymentsOfLongTermDebtPrincipal" xlink:to="epix_RepaymentsOfLongTermDebtPrincipal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_RepaymentsOfLongTermDebtPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for principal amount of debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_RepaymentsOfLongTermDebtPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long Term Debt, Principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_RepaymentsOfLongTermDebtPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal repaid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_RepaymentsOfLongTermDebtPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount paid</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtInterest" xlink:label="epix_RepaymentsOfLongTermDebtInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_RepaymentsOfLongTermDebtInterest" xlink:to="epix_RepaymentsOfLongTermDebtInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_RepaymentsOfLongTermDebtInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for interest amount of debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_RepaymentsOfLongTermDebtInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long Term Debt, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_RepaymentsOfLongTermDebtInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_RepaymentsOfLongTermDebtInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtFinalPayment" xlink:label="epix_RepaymentsOfLongTermDebtFinalPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_RepaymentsOfLongTermDebtFinalPayment" xlink:to="epix_RepaymentsOfLongTermDebtFinalPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_RepaymentsOfLongTermDebtFinalPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for final payment for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_RepaymentsOfLongTermDebtFinalPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long Term Debt, Final Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_RepaymentsOfLongTermDebtFinalPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_RepaymentsOfLongTermDebtFinalPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final payment</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightGranted" xlink:label="epix_ClassOfWarrantOrRightGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ClassOfWarrantOrRightGranted" xlink:to="epix_ClassOfWarrantOrRightGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of warrant</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FairValueOfWarrantIssued" xlink:label="epix_FairValueOfWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_FairValueOfWarrantIssued" xlink:to="epix_FairValueOfWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_FairValueOfWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrant issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_FairValueOfWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_FairValueOfWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrant issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional transaction cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest rate</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_LongTermDebtRepaymentRollForward" xlink:label="epix_LongTermDebtRepaymentRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_LongTermDebtRepaymentRollForward" xlink:to="epix_LongTermDebtRepaymentRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_LongTermDebtRepaymentRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_LongTermDebtRepaymentRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Repayment [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_LongTermDebtRepaymentRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LONG-TERM DEBT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term debt, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term debt, Beginning balance</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DebtInstrumentAccretion" xlink:label="epix_DebtInstrumentAccretion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_DebtInstrumentAccretion" xlink:to="epix_DebtInstrumentAccretion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_DebtInstrumentAccretion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of accretion of debt during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_DebtInstrumentAccretion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Accretion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_DebtInstrumentAccretion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_DerivativeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DERIVATIVE LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unit price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of units issued</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_UnitsIssuedInPrivatePlacementConversionRatio" xlink:label="epix_UnitsIssuedInPrivatePlacementConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_UnitsIssuedInPrivatePlacementConversionRatio" xlink:to="epix_UnitsIssuedInPrivatePlacementConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_UnitsIssuedInPrivatePlacementConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Units issued in private placement, conversion ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_UnitsIssuedInPrivatePlacementConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Units issued in private placement, conversion ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_UnitsIssuedInPrivatePlacementConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Units issued in private placement, conversion ratio</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice" xlink:label="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice" xlink:to="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in derivative liability due to change in market price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in derivative liability due to change in market price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in derivative liability due to change in market price</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility" xlink:label="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility" xlink:to="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in derivative liability due to change in Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in derivative liability due to change in Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in derivative liability due to change in volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumptions to fair value of the derivative warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivatives with expected life of less than one year</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_UnderwriterOptionToPurchaseAdditionalSecurities" xlink:label="epix_UnderwriterOptionToPurchaseAdditionalSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_UnderwriterOptionToPurchaseAdditionalSecurities" xlink:to="epix_UnderwriterOptionToPurchaseAdditionalSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_UnderwriterOptionToPurchaseAdditionalSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriter option to purchase additional securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_UnderwriterOptionToPurchaseAdditionalSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriter option to purchase additional securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_UnderwriterOptionToPurchaseAdditionalSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriter option to purchase additional securities</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_TermOfUnderwritersOption" xlink:label="epix_TermOfUnderwritersOption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_TermOfUnderwritersOption" xlink:to="epix_TermOfUnderwritersOption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_TermOfUnderwritersOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of underwriters option to purchase additions shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_TermOfUnderwritersOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of Underwriters Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_TermOfUnderwritersOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of underwriters option</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PreFundedWarrantsIssuedForCommonShares" xlink:label="epix_PreFundedWarrantsIssuedForCommonShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PreFundedWarrantsIssuedForCommonShares" xlink:to="epix_PreFundedWarrantsIssuedForCommonShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PreFundedWarrantsIssuedForCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of pre funded warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PreFundedWarrantsIssuedForCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre Funded Warrants Issued for Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_PreFundedWarrantsIssuedForCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of pre funded warrants issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of each prefunded warrant into common share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCommissions" xlink:to="us-gaap_PaymentsForCommissions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Commissions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash commissions paid</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights" xlink:label="epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights" xlink:to="epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum number of shares required to be held for nomination rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum number of shares required to be held for nomination rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum number of shares required to be held for nomination rights</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSUs outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price percentage of common share granted</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" xlink:label="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" xlink:to="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of contribution by each employee to employee share purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contribution Per Employee To Employee Share Purchase Plan, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee contribution percentage</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PurchaseRightsOfferingTerm" xlink:label="epix_PurchaseRightsOfferingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PurchaseRightsOfferingTerm" xlink:to="epix_PurchaseRightsOfferingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PurchaseRightsOfferingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of purchase rights offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PurchaseRightsOfferingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Rights, Offering Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_PurchaseRightsOfferingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering term</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" xlink:label="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" xlink:to="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of common share each employee is eligible under employee share purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Eligible Common Shares Under Employee Share Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligibility to common shares amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option expiration period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average assumptions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life of share purchase options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected annualized volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options expired/forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options, Exercise price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options expired/forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life (years)</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:label="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:to="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant Or Right, Number of Warrants [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants, Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants, Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightExercised" xlink:label="epix_ClassOfWarrantOrRightExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ClassOfWarrantOrRightExercised" xlink:to="epix_ClassOfWarrantOrRightExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant Or Right, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightExpired" xlink:label="epix_ClassOfWarrantOrRightExpired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ClassOfWarrantOrRightExpired" xlink:to="epix_ClassOfWarrantOrRightExpired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ClassOfWarrantOrRightExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ClassOfWarrantOrRightExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant Or Right, Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="epix_ClassOfWarrantOrRightExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants expired (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:to="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant Or Right, Weighted Average Exercise Price [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted" xlink:to="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of class of warrant or rights granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant Or Right Weighted Average Exercise Price, Warrants Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price, warrants granted (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised" xlink:to="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of class of warrant or rights exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant Or Right Weighted Average Exercise Price, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price, warrants exercised (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" xlink:to="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of class of warrant or rights expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant Or Right Weighted Average Exercise Price, Warrants Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price, warrants expired (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiry Date</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised" xlink:label="epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised" xlink:to="epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares issued upon cashless exercise of pre-funded warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Pre Funded Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued upon cashless exercise of pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PreFundedWarrantsExercised" xlink:label="epix_PreFundedWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_PreFundedWarrantsExercised" xlink:to="epix_PreFundedWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_PreFundedWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of pre-funded warrants exercised for common shares issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_PreFundedWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre Funded Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_PreFundedWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded warrants exercised</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability" xlink:label="epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability" xlink:to="epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Amount of transaction cost for business acquisition through accounts payable and accrued liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Transaction Cost, Through Accounts Payable And Accrued Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs incurred through accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities" xlink:label="epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities" xlink:to="epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Amount of cost related to share issuance through accounts payable and accrued liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Issuance Cost Through Accounts Payable And Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issuance costs incurred through accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to related parties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax recovery at statutory income tax rates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible share-based payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncomeTaxReconciliationTaxableCapitalGains" xlink:label="epix_IncomeTaxReconciliationTaxableCapitalGains" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_IncomeTaxReconciliationTaxableCapitalGains" xlink:to="epix_IncomeTaxReconciliationTaxableCapitalGains_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_IncomeTaxReconciliationTaxableCapitalGains_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) taxable capital gains</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_IncomeTaxReconciliationTaxableCapitalGains_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Reconciliation Taxable Capital Gains</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_IncomeTaxReconciliationTaxableCapitalGains_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxable capital gains</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other permanent differences including foreign exchange</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncomeTaxReconciliationFinancingCosts" xlink:label="epix_IncomeTaxReconciliationFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_IncomeTaxReconciliationFinancingCosts" xlink:to="epix_IncomeTaxReconciliationFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_IncomeTaxReconciliationFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to financing costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_IncomeTaxReconciliationFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Reconciliation Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="epix_IncomeTaxReconciliationFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issue costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in statutory, foreign tax, foreign exchange rates and other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating losses carried forward</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DeferredTaxAssetsEquipmentAndIntangibleAssets" xlink:label="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets" xlink:to="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equipment and intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Equipment And Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment and intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="us-gaap_DeferredTaxAssetsInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInvestments" xlink:to="us-gaap_DeferredTaxAssetsInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment tax credits</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DeferredTaxAssetsFinancingCosts" xlink:label="epix_DeferredTaxAssetsFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_DeferredTaxAssetsFinancingCosts" xlink:to="epix_DeferredTaxAssetsFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_DeferredTaxAssetsFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from financing costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_DeferredTaxAssetsFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_DeferredTaxAssetsFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Credit Carry forwards Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal R&amp;D credit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross future tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net future tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General corporate income tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-capital loss carry-forwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of industries</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WorkingCapital" xlink:label="epix_WorkingCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_WorkingCapital" xlink:to="epix_WorkingCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_WorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents amount of working capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_WorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working Capital</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_CashCanadaDepositInsuranceCorporationInsuredAmount" xlink:label="epix_CashCanadaDepositInsuranceCorporationInsuredAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_CashCanadaDepositInsuranceCorporationInsuredAmount" xlink:to="epix_CashCanadaDepositInsuranceCorporationInsuredAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_CashCanadaDepositInsuranceCorporationInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Canada Deposit Insurance Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_CashCanadaDepositInsuranceCorporationInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Canada Deposit Insurance Corporation Insured amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_CashCanadaDepositInsuranceCorporationInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, CDIC insured amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, FDIC Insured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, FDIC insured amount</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" xlink:label="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" xlink:to="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency risk, fluctuation in the net income (loss) reported due to change in exchange rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency risk, fluctuation in the net income(loss) reported due to change in exchange rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency risk, fluctuation in the net income (loss) reported due to change in exchange rate</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_GrantAmount" xlink:label="epix_GrantAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_GrantAmount" xlink:to="epix_GrantAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_GrantAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The total grant amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_GrantAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="epix_GrantAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total grant amount</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_GrantReceivedPeriod" xlink:label="epix_GrantReceivedPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_GrantReceivedPeriod" xlink:to="epix_GrantReceivedPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_GrantReceivedPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period for which grants received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_GrantReceivedPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Received Period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final Payment of grant</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_GrantRequirementNumberOfYearsOfOperationsInTexas" xlink:label="epix_GrantRequirementNumberOfYearsOfOperationsInTexas" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_GrantRequirementNumberOfYearsOfOperationsInTexas" xlink:to="epix_GrantRequirementNumberOfYearsOfOperationsInTexas_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_GrantRequirementNumberOfYearsOfOperationsInTexas_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant requirement, number of years of operations in Texas</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_GrantRequirementNumberOfYearsOfOperationsInTexas_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant requirement, number of years of operations in Texas</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_GrantRequirementNumberOfYearsOfOperationsInTexas_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant requirement, number of years of operations in Texas</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ThresholdLimitForAggregateRoyaltyPayments" xlink:label="epix_ThresholdLimitForAggregateRoyaltyPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ThresholdLimitForAggregateRoyaltyPayments" xlink:to="epix_ThresholdLimitForAggregateRoyaltyPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ThresholdLimitForAggregateRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents threshold limit of aggregate royalty payments payable to CPRIT before decrease in royalty rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ThresholdLimitForAggregateRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Limit for Aggregate Royalty Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="epix_ThresholdLimitForAggregateRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold limit for aggregate royalty payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RoyaltyPercentRevenue" xlink:label="epix_RoyaltyPercentRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_RoyaltyPercentRevenue" xlink:to="epix_RoyaltyPercentRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_RoyaltyPercentRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of revenues company is required to pay as royalty.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_RoyaltyPercentRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Percent, Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_RoyaltyPercentRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty percent revenue</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_MinimumAdvanceRoyaltyPayments" xlink:label="epix_MinimumAdvanceRoyaltyPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_MinimumAdvanceRoyaltyPayments" xlink:to="epix_MinimumAdvanceRoyaltyPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_MinimumAdvanceRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents amount of minimum annual royalty payments per annum.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_MinimumAdvanceRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Advance Royalty Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_MinimumAdvanceRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum advance royalty payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" xlink:to="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payments made at the start of second phase of clinical trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Of Milestone Payments At Start Of Second Phase Clinical Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total amount of milestone payments after start of a Phase II clinical trial</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial" xlink:to="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payments made at the start of third phase of clinical trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Of Milestone Payments At Start Of Third PhaseClinicalTrial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total amount of milestone payments after start of a Phase III clinical trial</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" xlink:label="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" xlink:to="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payments made at application for marketing approval.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Of Milestone Payments At Application For Marketing Approval</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total amount of milestone payments at application for marketing approval</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFourthYear" xlink:to="us-gaap_ContractualObligationDueInFourthYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInFourthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInFourthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFifthYear" xlink:to="us-gaap_ContractualObligationDueInFifthYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInFifthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInFifthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Shares [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Loss [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Deficit) [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_EmployeeSharePurchasePlanMember" xlink:to="epix_EmployeeSharePurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_EmployeeSharePurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Employee Share Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_EmployeeSharePurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Share Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_EmployeeSharePurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Share Purchase Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_StockOptionPlanMember" xlink:to="epix_StockOptionPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_StockOptionPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_StockOptionPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_StockOptionPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsPlcMember" xlink:label="epix_RealmTherapeuticsPlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_RealmTherapeuticsPlcMember" xlink:to="epix_RealmTherapeuticsPlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_RealmTherapeuticsPlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Realm Therapeutics plc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_RealmTherapeuticsPlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realm Therapeutics Plc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_RealmTherapeuticsPlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realm Therapeutics Plc [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EssaPharmaceuticalsCorpMember" xlink:label="epix_EssaPharmaceuticalsCorpMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_EssaPharmaceuticalsCorpMember" xlink:to="epix_EssaPharmaceuticalsCorpMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_EssaPharmaceuticalsCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to ESSA Pharmaceuticals Corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_EssaPharmaceuticalsCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Essa Pharmaceuticals Corp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_EssaPharmaceuticalsCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESSA Pharmaceuticals Corp [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsIncMember" xlink:label="epix_RealmTherapeuticsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_RealmTherapeuticsIncMember" xlink:to="epix_RealmTherapeuticsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_RealmTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Realm Therapeutics plc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_RealmTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realm Therapeutics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_RealmTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realm Therapeutics Inc [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type Of Adoption [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update201602 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASU 2016-02 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FinancingCostsMember" xlink:label="epix_FinancingCostsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_FinancingCostsMember" xlink:to="epix_FinancingCostsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_FinancingCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to financing costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_FinancingCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Costs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_FinancingCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing costs [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SouthFransicoOfficeMember" xlink:label="epix_SouthFransicoOfficeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_SouthFransicoOfficeMember" xlink:to="epix_SouthFransicoOfficeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_SouthFransicoOfficeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent the information pertaining to south fransico office.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_SouthFransicoOfficeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">South Fransico Office [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_SouthFransicoOfficeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">South San Francisco Office [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_HoustonOfficeMember" xlink:label="epix_HoustonOfficeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_HoustonOfficeMember" xlink:to="epix_HoustonOfficeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_HoustonOfficeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent the information pertaining to houston office.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_HoustonOfficeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Houston Office [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_HoustonOfficeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Houston Office [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longterm Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SiliconValleyBankTermLoanMember" xlink:label="epix_SiliconValleyBankTermLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_SiliconValleyBankTermLoanMember" xlink:to="epix_SiliconValleyBankTermLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_SiliconValleyBankTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to silicon valley bank term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_SiliconValleyBankTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Silicon Valley Bank Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_SiliconValleyBankTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SVB Term Loan [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WallStreetJournalPrimeRateMember" xlink:label="epix_WallStreetJournalPrimeRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_WallStreetJournalPrimeRateMember" xlink:to="epix_WallStreetJournalPrimeRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_WallStreetJournalPrimeRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to wall street journal prime rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_WallStreetJournalPrimeRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wall Street Journal Prime Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_WallStreetJournalPrimeRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WSJ Prime Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_TwoYearWarrantMember" xlink:label="epix_TwoYearWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_TwoYearWarrantMember" xlink:to="epix_TwoYearWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_TwoYearWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to two year warrant member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_TwoYearWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Year Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_TwoYearWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2 Year Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SevenYearWarrantMember" xlink:label="epix_SevenYearWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_SevenYearWarrantMember" xlink:to="epix_SevenYearWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_SevenYearWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to seven year warrant member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_SevenYearWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Seven Year Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_SevenYearWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">7 Year Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncreaseInMarketPriceOfWarrantsBy10Member" xlink:label="epix_IncreaseInMarketPriceOfWarrantsBy10Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_IncreaseInMarketPriceOfWarrantsBy10Member" xlink:to="epix_IncreaseInMarketPriceOfWarrantsBy10Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_IncreaseInMarketPriceOfWarrantsBy10Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in market Price of warrants by 10% [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_IncreaseInMarketPriceOfWarrantsBy10Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase In Market Price Of Warrants By10 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_IncreaseInMarketPriceOfWarrantsBy10Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in market Price of warrants by 10% [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DecreaseInMarketPriceOfWarrantsBy10Member" xlink:label="epix_DecreaseInMarketPriceOfWarrantsBy10Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_DecreaseInMarketPriceOfWarrantsBy10Member" xlink:to="epix_DecreaseInMarketPriceOfWarrantsBy10Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_DecreaseInMarketPriceOfWarrantsBy10Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in market Price of warrants by 10% [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_DecreaseInMarketPriceOfWarrantsBy10Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease In Market Price Of Warrants By10 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_DecreaseInMarketPriceOfWarrantsBy10Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in market Price of warrants by 10% [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncreaseInVolatilityOfWarrantsBy10Member" xlink:label="epix_IncreaseInVolatilityOfWarrantsBy10Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_IncreaseInVolatilityOfWarrantsBy10Member" xlink:to="epix_IncreaseInVolatilityOfWarrantsBy10Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_IncreaseInVolatilityOfWarrantsBy10Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in Volatility of warrants by 10% [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_IncreaseInVolatilityOfWarrantsBy10Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase In Volatility Of Warrants By10 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_IncreaseInVolatilityOfWarrantsBy10Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in Volatility of warrants by 10% [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DecreaseInVolatilityOfWarrantsBy10Member" xlink:label="epix_DecreaseInVolatilityOfWarrantsBy10Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_DecreaseInVolatilityOfWarrantsBy10Member" xlink:to="epix_DecreaseInVolatilityOfWarrantsBy10Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_DecreaseInVolatilityOfWarrantsBy10Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in Volatility of warrants by 10% [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_DecreaseInVolatilityOfWarrantsBy10Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease In Volatility Of Warrants By10 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_DecreaseInVolatilityOfWarrantsBy10Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in Volatility of warrants by 10% [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free Interest Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Life [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Annualized Volatility [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Expected Dividend Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Discount For Lack Of Marketability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity Discount [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_February2021financingMember" xlink:label="epix_February2021financingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_February2021financingMember" xlink:to="epix_February2021financingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_February2021financingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to February 2021 financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_February2021financingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">February2021financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_February2021financingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">February 2021 Financing [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_July2020FinancingMember" xlink:label="epix_July2020FinancingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_July2020FinancingMember" xlink:to="epix_July2020FinancingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_July2020FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to July 2020 financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_July2020FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July2020 Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_July2020FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">July 2020 Financing [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_August2019FinancingMember" xlink:label="epix_August2019FinancingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_August2019FinancingMember" xlink:to="epix_August2019FinancingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_August2019FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to august 2019 financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_August2019FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">August2019 Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_August2019FinancingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">August 2019 Financing [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over Allotment Option [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClarusLifesciencesIiiL.pMember" xlink:label="epix_ClarusLifesciencesIiiL.pMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ClarusLifesciencesIiiL.pMember" xlink:to="epix_ClarusLifesciencesIiiL.pMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ClarusLifesciencesIiiL.pMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Clarus Lifesciences III, L.P.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ClarusLifesciencesIiiL.pMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clarus Lifesciences Iii L.p [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ClarusLifesciencesIiiL.pMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clarus Lifesciences III, L.P [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU's [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockOptionsAndRsuPlanMember" xlink:label="epix_StockOptionsAndRsuPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_StockOptionsAndRsuPlanMember" xlink:to="epix_StockOptionsAndRsuPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_StockOptionsAndRsuPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options and RSU Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_StockOptionsAndRsuPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options And Rsu Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_StockOptionsAndRsuPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options and RSU Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EquityIncentivePlansMember" xlink:label="epix_EquityIncentivePlansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_EquityIncentivePlansMember" xlink:to="epix_EquityIncentivePlansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_EquityIncentivePlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity incentive plans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_EquityIncentivePlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_EquityIncentivePlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plans [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceOneInUsdMember" xlink:label="epix_ExercisePriceOneInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceOneInUsdMember" xlink:to="epix_ExercisePriceOneInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceOneInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price one in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceOneInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price One In Usd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ExercisePriceOneInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $2.20 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceTwoInUsdMember" xlink:label="epix_ExercisePriceTwoInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceTwoInUsdMember" xlink:to="epix_ExercisePriceTwoInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceTwoInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Two in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceTwoInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Two In Usd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ExercisePriceTwoInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $3.23 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceThreeInUsdMember" xlink:label="epix_ExercisePriceThreeInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceThreeInUsdMember" xlink:to="epix_ExercisePriceThreeInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceThreeInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Three in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceThreeInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Three In Usd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ExercisePriceThreeInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $3.59 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceFourInUsdMember" xlink:label="epix_ExercisePriceFourInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceFourInUsdMember" xlink:to="epix_ExercisePriceFourInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceFourInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Four in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceFourInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Four In Usd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ExercisePriceFourInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $3.81 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceFiveInUsdMember" xlink:label="epix_ExercisePriceFiveInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceFiveInUsdMember" xlink:to="epix_ExercisePriceFiveInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceFiveInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Five in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceFiveInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Five In Usd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ExercisePriceFiveInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $4.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceSixInUsdMember" xlink:label="epix_ExercisePriceSixInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceSixInUsdMember" xlink:to="epix_ExercisePriceSixInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceSixInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Six in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceSixInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Six In Usd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ExercisePriceSixInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $4.67 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceSevenInUsdMember" xlink:label="epix_ExercisePriceSevenInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceSevenInUsdMember" xlink:to="epix_ExercisePriceSevenInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceSevenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Seven in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceSevenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Seven In Usd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ExercisePriceSevenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $7.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceEightInUsdMember" xlink:label="epix_ExercisePriceEightInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceEightInUsdMember" xlink:to="epix_ExercisePriceEightInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceEightInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Eight in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceEightInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Eight In Usd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ExercisePriceEightInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $13.96 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceNineInUsdMember" xlink:label="epix_ExercisePriceNineInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceNineInUsdMember" xlink:to="epix_ExercisePriceNineInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceNineInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Nine in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceNineInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Nine In Usd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ExercisePriceNineInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $29.63 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceTenInUsdMember" xlink:label="epix_ExercisePriceTenInUsdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceTenInUsdMember" xlink:to="epix_ExercisePriceTenInUsdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceTenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Ten in USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceTenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Ten In Usd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ExercisePriceTenInUsdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $31.62 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceOneInCadMember" xlink:label="epix_ExercisePriceOneInCadMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceOneInCadMember" xlink:to="epix_ExercisePriceOneInCadMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceOneInCadMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price One in CAD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceOneInCadMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price One In Cad [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ExercisePriceOneInCadMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price C$4.90 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceTwoInCadMember" xlink:label="epix_ExercisePriceTwoInCadMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ExercisePriceTwoInCadMember" xlink:to="epix_ExercisePriceTwoInCadMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ExercisePriceTwoInCadMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Two in CAD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ExercisePriceTwoInCadMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Two In Cad [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ExercisePriceTwoInCadMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price C$5.06 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WarrantsExercisePriceOneMember" xlink:label="epix_WarrantsExercisePriceOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_WarrantsExercisePriceOneMember" xlink:to="epix_WarrantsExercisePriceOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_WarrantsExercisePriceOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_WarrantsExercisePriceOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_WarrantsExercisePriceOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price $66.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WarrantsExercisePriceTwoMember" xlink:label="epix_WarrantsExercisePriceTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_WarrantsExercisePriceTwoMember" xlink:to="epix_WarrantsExercisePriceTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_WarrantsExercisePriceTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_WarrantsExercisePriceTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_WarrantsExercisePriceTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price $42.80 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WarrantsExercisePriceThreeMember" xlink:label="epix_WarrantsExercisePriceThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_WarrantsExercisePriceThreeMember" xlink:to="epix_WarrantsExercisePriceThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_WarrantsExercisePriceThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_WarrantsExercisePriceThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_WarrantsExercisePriceThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price $4.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WarrantsExercisePriceFiveMember" xlink:label="epix_WarrantsExercisePriceFiveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_WarrantsExercisePriceFiveMember" xlink:to="epix_WarrantsExercisePriceFiveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_WarrantsExercisePriceFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_WarrantsExercisePriceFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_WarrantsExercisePriceFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price $0.0001 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable And Accrued Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U [S]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UNITED STATES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Country [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canada</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Country [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Us</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_TenPercentChangeInForeignExchangeRateMember" xlink:label="epix_TenPercentChangeInForeignExchangeRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_TenPercentChangeInForeignExchangeRateMember" xlink:to="epix_TenPercentChangeInForeignExchangeRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_TenPercentChangeInForeignExchangeRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ten percent Change in Foreign Exchange Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_TenPercentChangeInForeignExchangeRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ten Percent Change In Foreign Exchange Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_TenPercentChangeInForeignExchangeRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">10% Change in Foreign Exchange Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_LicenseAgreementMember" xlink:label="epix_LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_LicenseAgreementMember" xlink:to="epix_LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to license agreement .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TX" xlink:label="stpr_TX" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_TX" xlink:to="stpr_TX_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_TX_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">T [X]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_TX_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Texas</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Related to Androgen Receptor n-terminus Blocker Program for Prostate Cancer [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AggregateRoyaltyPaymentUpTo24000000Member" xlink:label="epix_AggregateRoyaltyPaymentUpTo24000000Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_AggregateRoyaltyPaymentUpTo24000000Member" xlink:to="epix_AggregateRoyaltyPaymentUpTo24000000Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_AggregateRoyaltyPaymentUpTo24000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to aggregate royalty payments up to $24,000,000.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_AggregateRoyaltyPaymentUpTo24000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Royalty Payment Up To24000000 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_AggregateRoyaltyPaymentUpTo24000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Royalty payment Up To $24,000,000</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AggregateRoyaltyPaymentAfter24000000Member" xlink:label="epix_AggregateRoyaltyPaymentAfter24000000Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_AggregateRoyaltyPaymentAfter24000000Member" xlink:to="epix_AggregateRoyaltyPaymentAfter24000000Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_AggregateRoyaltyPaymentAfter24000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to aggregate royalty payments exceeds $24,000,000.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_AggregateRoyaltyPaymentAfter24000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Royalty Payment After24000000 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_AggregateRoyaltyPaymentAfter24000000Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Royalty payment After $24,000,000</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite Lived Intangible Assets Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technology Based Intangible Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technology-based intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_VendorAgreementMember" xlink:label="epix_VendorAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_VendorAgreementMember" xlink:to="epix_VendorAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_VendorAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Vendor agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_VendorAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vendor Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_VendorAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vendor Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ConsultingAgreementMember" xlink:label="epix_ConsultingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_ConsultingAgreementMember" xlink:to="epix_ConsultingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_ConsultingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Consulting Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_ConsultingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_ConsultingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_LeaseOnUsOfficeSpacesMember" xlink:label="epix_LeaseOnUsOfficeSpacesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="epix_LeaseOnUsOfficeSpacesMember" xlink:to="epix_LeaseOnUsOfficeSpacesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="epix_LeaseOnUsOfficeSpacesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Lease on US office spaces.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="epix_LeaseOnUsOfficeSpacesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease On Us Office Spaces [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="epix_LeaseOnUsOfficeSpacesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease on US Office Spaces [Member]</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>tmb-20210930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/18/2021 1:42:45 AM-->
<!--Modified on: 11/18/2021 1:42:45 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.essapharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.essapharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#StatementConsolidatedStatementOfChangesInShareholdersEquity" roleURI="http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureNatureOfOperations" roleURI="http://www.essapharma.com/role/DisclosureNatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureBasisOfPresentation" roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureRealmAcquisition" roleURI="http://www.essapharma.com/role/DisclosureRealmAcquisition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShortTermInvestments" roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosurePrepaids" roleURI="http://www.essapharma.com/role/DisclosurePrepaids" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureAccountsPayableAndAccruedLiabilities" roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureOperatingLease" roleURI="http://www.essapharma.com/role/DisclosureOperatingLease" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureLongTermDebt" roleURI="http://www.essapharma.com/role/DisclosureLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureDerivativeLiabilities" roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquity" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureSupplementalDisclosureWithRespectToCashFlows" roleURI="http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.essapharma.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureIncomeTaxes" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureSegmentedInformation" roleURI="http://www.essapharma.com/role/DisclosureSegmentedInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureFinancialInstrumentsAndRisk" roleURI="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureCommitments" roleURI="http://www.essapharma.com/role/DisclosureCommitments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureBasisOfPresentationPolicy" roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureSignificantAccountingPoliciesPolicy" roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureBasisOfPresentationTables" roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureRealmAcquisitionTables" roleURI="http://www.essapharma.com/role/DisclosureRealmAcquisitionTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosurePrepaidsTables" roleURI="http://www.essapharma.com/role/DisclosurePrepaidsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesTables" roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureOperatingLeaseTables" roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureLongTermDebtTables" roleURI="http://www.essapharma.com/role/DisclosureLongTermDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureDerivativeLiabilitiesTables" roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquityTables" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureCommitmentsTables" roleURI="http://www.essapharma.com/role/DisclosureCommitmentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureNatureOfOperationsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" roleURI="http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureRealmAcquisitionNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails" roleURI="http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShortTermInvestmentsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" roleURI="http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureOperatingLeaseNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" roleURI="http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureLongTermDebtNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails" roleURI="http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureDerivativeLiabilitiesNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureDerivativeLiabilitiesScheduleOfChangesOfDerivativeLiabilitiesDetails" roleURI="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesScheduleOfChangesOfDerivativeLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquityNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" roleURI="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureRelatedPartyTransactionsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureSegmentedInformationNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureSegmentedInformationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureFinancialInstrumentsAndRiskNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureCommitmentsNarrativeDetails" roleURI="http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20210930.xsd#DisclosureCommitmentsScheduleOfContractualObligationsDetails" roleURI="http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.essapharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637727965642860249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637727965642860249" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637727965642860249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637727965642860249" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637727965642860249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637727965642860249" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637727965642860249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637727965642860249" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637727965642860249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637727965642860249" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637727965642870272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637727965642870272" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637727965642870272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637727965642870272" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_637727965642870272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry_637727965642870272" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637727965642870272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637727965642870272" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637727965642870272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637727965642870272" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637727965642870272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637727965642870272" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637727965642870272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637727965642870272" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637727965642870272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637727965642870272" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637727965642870272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637727965642870272" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637727965642870272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637727965642870272" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637727965642870272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637727965642870272" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637727965642880376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637727965642880376" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637727965642880376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637727965642880376" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637727965642880376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637727965642880376" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637727965642880376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637727965642880376" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637727965642880376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637727965642880376" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637727965642880376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637727965642880376" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637727965642880376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637727965642880376" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637727965642880376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637727965642880376" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637727965642890355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637727965642890355" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637727965642890355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637727965642890355" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637727965642890355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637727965642890355" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637727965642890355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637727965642890355" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637727965642890355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637727965642890355" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637727965642890355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637727965642890355" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637727965642890355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637727965642890355" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637727965642890355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637727965642890355" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637727965642890355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637727965642890355" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637727965642900327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637727965642900327" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637727965642900327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637727965642900327" order="35" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637727965642900327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637727965642900327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637727965642900327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637727965642900327" xlink:to="us-gaap_AssetsCurrentAbstract_637727965642900327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637727965642900327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637727965642900327" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637727965642900327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_637727965642910316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637727965642900327" xlink:to="us-gaap_ShortTermInvestments_637727965642910316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_637727965642910316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637727965642900327" xlink:to="us-gaap_ReceivablesNetCurrent_637727965642910316" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637727965642910316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637727965642900327" xlink:to="us-gaap_PrepaidExpenseCurrent_637727965642910316" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseRightOfUseAssetsCurrent" xlink:label="epix_OperatingLeaseRightOfUseAssetsCurrent_637727965642910316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637727965642900327" xlink:to="epix_OperatingLeaseRightOfUseAssetsCurrent_637727965642910316" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637727965642910316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637727965642900327" xlink:to="us-gaap_AssetsCurrent_637727965642910316" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent_637727965642910316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637727965642900327" xlink:to="us-gaap_DepositsAssetsNoncurrent_637727965642910316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637727965642910316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637727965642900327" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637727965642910316" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637727965642910316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637727965642900327" xlink:to="us-gaap_Assets_637727965642910316" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637727965642910316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637727965642910316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637727965642910316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637727965642910316" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637727965642910316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637727965642910316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637727965642910316" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637727965642910316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637727965642920307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637727965642910316" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637727965642920307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637727965642920307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637727965642910316" xlink:to="us-gaap_LiabilitiesCurrent_637727965642920307" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_637727965642920307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637727965642910316" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_637727965642920307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637727965642920307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637727965642910316" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637727965642920307" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637727965642920307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637727965642910316" xlink:to="us-gaap_Liabilities_637727965642920307" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637727965642920307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637727965642910316" xlink:to="us-gaap_StockholdersEquityAbstract_637727965642920307" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637727965642920307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637727965642920307" xlink:to="us-gaap_CommonStockValue_637727965642920307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637727965642920307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637727965642920307" xlink:to="us-gaap_AdditionalPaidInCapital_637727965642920307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637727965642930237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637727965642920307" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637727965642930237" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637727965642930237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637727965642920307" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637727965642930237" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637727965642930237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637727965642920307" xlink:to="us-gaap_StockholdersEquity_637727965642930237" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637727965642930237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637727965642910316" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637727965642930237" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637727965642930237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637727965642930237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637727965642930237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637727965642930237" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637727965642930237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637727965642930237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637727965642930237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637727965642930237" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637727965642930237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FinancingCosts" xlink:label="epix_FinancingCosts_637727965642940222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637727965642930237" xlink:to="epix_FinancingCosts_637727965642940222" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637727965642940222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637727965642930237" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637727965642940222" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637727965642940222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637727965642930237" xlink:to="us-gaap_OperatingExpenses_637727965642940222" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637727965642940222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637727965642940222" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_637727965642940222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_637727965642940222" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_637727965642940222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_637727965642940222" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637727965642940222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637727965642940222" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637727965642940222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637727965642940222" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637727965642940222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637727965642940222" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637727965642940222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637727965642940222" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637727965642940222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637727965642940222" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637727965642950284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" xlink:to="us-gaap_NetIncomeLoss_637727965642950284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637727965642950284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637727965642950284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense_637727965642950284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" xlink:to="us-gaap_AccretionExpense_637727965642950284" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_637727965642950284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_637727965642950284" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncomeTaxExpenseRecoveryOperatingActivities" xlink:label="epix_IncomeTaxExpenseRecoveryOperatingActivities_637727965642950284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" xlink:to="epix_IncomeTaxExpenseRecoveryOperatingActivities_637727965642950284" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_InterestIncomeOperatingActivities" xlink:label="epix_InterestIncomeOperatingActivities_637727965642950284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" xlink:to="epix_InterestIncomeOperatingActivities_637727965642950284" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FinanceExpenseOperatingActivities" xlink:label="epix_FinanceExpenseOperatingActivities_637727965642950284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" xlink:to="epix_FinanceExpenseOperatingActivities_637727965642950284" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637727965642950284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637727965642950284" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637727965642950284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" xlink:to="us-gaap_ShareBasedCompensation_637727965642950284" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637727965642950284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637727965642950284" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables_637727965642960267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637727965642950284" xlink:to="us-gaap_IncreaseDecreaseInReceivables_637727965642960267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_637727965642960267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637727965642950284" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_637727965642960267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637727965642960267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637727965642950284" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637727965642960267" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_637727965642960267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637727965642950284" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_637727965642960267" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642960267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637727965642950284" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637727965642960267" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637727965642960267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637727965642960267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromOtherDeposits" xlink:label="us-gaap_ProceedsFromOtherDeposits_637727965642960267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637727965642960267" xlink:to="us-gaap_ProceedsFromOtherDeposits_637727965642960267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_637727965642960267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637727965642960267" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_637727965642960267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_637727965642960267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637727965642960267" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_637727965642960267" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_InterestFromShortTermInvestments" xlink:label="epix_InterestFromShortTermInvestments_637727965642960267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637727965642960267" xlink:to="epix_InterestFromShortTermInvestments_637727965642960267" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637727965642970205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637727965642960267" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637727965642970205" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_CashAcquisitionFromAcquisitionOfBusiness" xlink:label="epix_CashAcquisitionFromAcquisitionOfBusiness_637727965642970205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" xlink:to="epix_CashAcquisitionFromAcquisitionOfBusiness_637727965642970205" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_637727965642970205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_637727965642970205" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PaymentOfSubleaseTerminationCosts" xlink:label="epix_PaymentOfSubleaseTerminationCosts_637727965642970205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" xlink:to="epix_PaymentOfSubleaseTerminationCosts_637727965642970205" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637727965642970205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637727965642970205" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637727965642970205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637727965642970205" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637727965642970205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637727965642970205" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637727965642980317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" xlink:to="us-gaap_ProceedsFromWarrantExercises_637727965642980317" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_637727965642980317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_637727965642980317" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeasePaymentsFinancingActivities" xlink:label="epix_OperatingLeasePaymentsFinancingActivities_637727965642980317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" xlink:to="epix_OperatingLeasePaymentsFinancingActivities_637727965642980317" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_637727965642980317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" xlink:to="us-gaap_RepaymentsOfDebt_637727965642980317" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfFinalPaymentOfDebt" xlink:label="epix_RepaymentsOfFinalPaymentOfDebt_637727965642980317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" xlink:to="epix_RepaymentsOfFinalPaymentOfDebt_637727965642980317" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_637727965642980317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" xlink:to="us-gaap_PaymentsOfFinancingCosts_637727965642980317" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642990398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637727965642970205" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637727965642990398" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637727965642990398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637727965642990398" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637727965642990398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637727965642990398" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637727965642990398" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637727965642990398" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6377279656429903981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6377279656429903981" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637727965643000249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637727965643000249" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637727965643000249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643000249" xlink:to="us-gaap_StatementEquityComponentsAxis_637727965643000249" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637727965643000249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637727965643000249" xlink:to="us-gaap_CommonStockMember_637727965643000249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637727965643000249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637727965643000249" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637727965643000249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637727965643000249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637727965643000249" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637727965643000249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637727965643000249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637727965643000249" xlink:to="us-gaap_RetainedEarningsMember_637727965643000249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637727965643000249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637727965643000249" xlink:to="us-gaap_EquityComponentDomain_637727965643000249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637727965643000249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643000249" xlink:to="us-gaap_StatementLineItems_637727965643000249" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637727965643000249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_StockholdersEquity_637727965643000249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637727965643000249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_SharesOutstanding_637727965643000249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_637727965643010237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_637727965643010237" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637727965643010237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_637727965643010237" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637727965643010237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637727965643010237" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="epix_StockIssuedDuringPeriodValueWarrantsExercised_637727965643010237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="epix_StockIssuedDuringPeriodValueWarrantsExercised_637727965643010237" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="epix_StockIssuedDuringPeriodSharesWarrantsExercised_637727965643010237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="epix_StockIssuedDuringPeriodSharesWarrantsExercised_637727965643010237" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637727965643010237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637727965643010237" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637727965643010237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637727965643010237" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PrefundedWarrantExercisedValue" xlink:label="epix_PrefundedWarrantExercisedValue_637727965643010237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="epix_PrefundedWarrantExercisedValue_637727965643010237" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PrefundedWarrantExercisedShares" xlink:label="epix_PrefundedWarrantExercisedShares_637727965643010237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="epix_PrefundedWarrantExercisedShares_637727965643010237" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637727965643010237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637727965643010237" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637727965643020261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637727965643020261" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_637727965643020261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_637727965643020261" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_637727965643020261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_637727965643020261" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637727965643020261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637727965643020261" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637727965643020261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_NetIncomeLoss_637727965643020261" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637727965643020261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_StockholdersEquity_637727965643020261" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637727965643020261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643000249" xlink:to="us-gaap_SharesOutstanding_637727965643020261" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureNatureOfOperations" xlink:type="extended" xlink:title="10101 - Disclosure - NATURE OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_NatureAndContinuanceOfOperationsAbstract" xlink:label="epix_NatureAndContinuanceOfOperationsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637727965643030326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_NatureAndContinuanceOfOperationsAbstract" xlink:to="us-gaap_NatureOfOperations_637727965643030326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10201 - Disclosure - BASIS OF PRESENTATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_637727965643030326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_637727965643030326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637727965643040344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637727965643040344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureRealmAcquisition" xlink:type="extended" xlink:title="10401 - Disclosure - REALM ACQUISITION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_637727965643040344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_637727965643040344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShortTermInvestments" xlink:type="extended" xlink:title="10501 - Disclosure - SHORT-TERM INVESTMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_637727965643040344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_637727965643040344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosurePrepaids" xlink:type="extended" xlink:title="10601 - Disclosure - PREPAIDS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PrepaidExpensesTextBlock" xlink:label="epix_PrepaidExpensesTextBlock_637727965643040344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="epix_PrepaidExpensesTextBlock_637727965643040344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities" xlink:type="extended" xlink:title="10701 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637727965643040344" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637727965643040344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureOperatingLease" xlink:type="extended" xlink:title="10801 - Disclosure - OPERATING LEASE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_637727965643050427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_637727965643050427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureLongTermDebt" xlink:type="extended" xlink:title="10901 - Disclosure - LONG-TERM DEBT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637727965643050427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_637727965643050427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureDerivativeLiabilities" xlink:type="extended" xlink:title="11001 - Disclosure - DERIVATIVE LIABILITIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_637727965643050427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_637727965643050427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquity" xlink:type="extended" xlink:title="11101 - Disclosure - SHAREHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637727965643050427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637727965643050427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows" xlink:type="extended" xlink:title="11201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_637727965643050427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_637727965643050427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11301 - Disclosure - RELATED PARTY TRANSACTIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637727965643060354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637727965643060354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11401 - Disclosure - INCOME TAXES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637727965643060354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637727965643060354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSegmentedInformation" xlink:type="extended" xlink:title="11501 - Disclosure - SEGMENTED INFORMATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_637727965643060354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_637727965643060354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk" xlink:type="extended" xlink:title="11601 - Disclosure - FINANCIAL INSTRUMENTS AND RISK" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FinancialInstrumentsAndRiskAbstract" xlink:label="epix_FinancialInstrumentsAndRiskAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_637727965643060354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_FinancialInstrumentsAndRiskAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_637727965643060354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureCommitments" xlink:type="extended" xlink:title="11701 - Disclosure - COMMITMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637727965643060354" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637727965643060354" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy" xlink:type="extended" xlink:title="20202 - Disclosure - BASIS OF PRESENTATION (Policy)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637727965643070335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637727965643070335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_637727965643070335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_637727965643070335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637727965643070335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates_637727965643070335" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy" xlink:type="extended" xlink:title="20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637727965643070335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637727965643070335" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock_637727965643070335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock_637727965643070335" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637727965643070335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637727965643070335" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_GovernmentAssistancePolicyPolicyTextBlock" xlink:label="epix_GovernmentAssistancePolicyPolicyTextBlock_637727965643070335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="epix_GovernmentAssistancePolicyPolicyTextBlock_637727965643070335" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637727965643070335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637727965643070335" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637727965643070335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637727965643070335" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637727965643070335" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637727965643070335" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637727965643080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637727965643080242" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637727965643080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637727965643080242" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637727965643080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637727965643080242" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637727965643080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637727965643080242" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureBasisOfPresentationTables" xlink:type="extended" xlink:title="30203 - Disclosure - BASIS OF PRESENTATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock" xlink:label="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock_637727965643080242" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock_637727965643080242" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureRealmAcquisitionTables" xlink:type="extended" xlink:title="30403 - Disclosure - REALM ACQUISITION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_637727965643150224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_637727965643150224" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosurePrepaidsTables" xlink:type="extended" xlink:title="30603 - Disclosure - PREPAIDS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ScheduleOfPrepaidExpensesTableTextBlock" xlink:label="epix_ScheduleOfPrepaidExpensesTableTextBlock_637727965643160400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="epix_ScheduleOfPrepaidExpensesTableTextBlock_637727965643160400" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" xlink:type="extended" xlink:title="30701 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637727965643160400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637727965643160400" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureOperatingLeaseTables" xlink:type="extended" xlink:title="30803 - Disclosure - OPERATING LEASE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock" xlink:label="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock_637727965643160400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock_637727965643160400" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureLongTermDebtTables" xlink:type="extended" xlink:title="30903 - Disclosure - LONG-TERM DEBT (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_637727965643160400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_637727965643160400" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables" xlink:type="extended" xlink:title="31003 - Disclosure - DERIVATIVE LIABILITIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637727965643160400" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637727965643160400" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_637727965643170218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_637727965643170218" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityTables" xlink:type="extended" xlink:title="31103 - Disclosure - SHAREHOLDERS' EQUITY (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643170218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643170218" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637727965643170218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643170218" xlink:to="us-gaap_PlanNameAxis_637727965643170218" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637727965643170218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637727965643170218" xlink:to="us-gaap_PlanNameDomain_637727965643170218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember_637727965643170218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637727965643170218" xlink:to="epix_EmployeeSharePurchasePlanMember_637727965643170218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember_637727965643170218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637727965643170218" xlink:to="epix_StockOptionPlanMember_637727965643170218" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643170218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643170218" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643170218" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_637727965643170218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643170218" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_637727965643170218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637727965643170218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643170218" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637727965643170218" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637727965643170218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643170218" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637727965643170218" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_637727965643170218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643170218" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_637727965643170218" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637727965643180238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643170218" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637727965643180238" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock" xlink:label="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock_637727965643180238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643170218" xlink:to="epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock_637727965643180238" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31401 - Disclosure - INCOME TAXES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637727965643180238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637727965643180238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637727965643180238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637727965643180238" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureCommitmentsTables" xlink:type="extended" xlink:title="31703 - Disclosure - COMMITMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_637727965643180238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_637727965643180238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails" xlink:type="extended" xlink:title="40101 - Disclosure - NATURE OF OPERATIONS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_NatureAndContinuanceOfOperationsAbstract" xlink:label="epix_NatureAndContinuanceOfOperationsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637727965643190248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_NatureAndContinuanceOfOperationsAbstract" xlink:to="us-gaap_StatementTable_637727965643190248" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637727965643190248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643190248" xlink:to="us-gaap_BusinessAcquisitionAxis_637727965643190248" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637727965643190248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637727965643190248" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637727965643190248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsPlcMember" xlink:label="epix_RealmTherapeuticsPlcMember_637727965643190248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637727965643190248" xlink:to="epix_RealmTherapeuticsPlcMember_637727965643190248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637727965643190248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643190248" xlink:to="us-gaap_StatementLineItems_637727965643190248" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_637727965643190248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643190248" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_637727965643190248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_637727965643190248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643190248" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_637727965643190248" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BasisOfPresentationTable" xlink:label="epix_BasisOfPresentationTable_637727965643190248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="epix_BasisOfPresentationTable_637727965643190248" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_637727965643190248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_BasisOfPresentationTable_637727965643190248" xlink:to="srt_OwnershipAxis_637727965643190248" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637727965643200232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_637727965643190248" xlink:to="srt_OwnershipDomain_637727965643200232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EssaPharmaceuticalsCorpMember" xlink:label="epix_EssaPharmaceuticalsCorpMember_637727965643200232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637727965643200232" xlink:to="epix_EssaPharmaceuticalsCorpMember_637727965643200232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsPlcMember" xlink:label="epix_RealmTherapeuticsPlcMember_637727965643200232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637727965643200232" xlink:to="epix_RealmTherapeuticsPlcMember_637727965643200232" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsIncMember" xlink:label="epix_RealmTherapeuticsIncMember_637727965643200232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637727965643200232" xlink:to="epix_RealmTherapeuticsIncMember_637727965643200232" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BasisOfPresentationLineItems" xlink:label="epix_BasisOfPresentationLineItems_637727965643200232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_BasisOfPresentationTable_637727965643190248" xlink:to="epix_BasisOfPresentationLineItems_637727965643200232" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PercentageOfEffectiveInterestInSubsidiaries" xlink:label="epix_PercentageOfEffectiveInterestInSubsidiaries_637727965643200232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_BasisOfPresentationLineItems_637727965643200232" xlink:to="epix_PercentageOfEffectiveInterestInSubsidiaries_637727965643200232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SignificantAccountingPoliciesTable" xlink:label="epix_SignificantAccountingPoliciesTable_637727965643200232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="epix_SignificantAccountingPoliciesTable_637727965643200232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637727965643200232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_SignificantAccountingPoliciesTable_637727965643200232" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637727965643200232" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637727965643200232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637727965643200232" xlink:to="us-gaap_TypeOfAdoptionMember_637727965643200232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_637727965643200232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_637727965643200232" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_637727965643200232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SignificantAccountingPoliciesLineItems" xlink:label="epix_SignificantAccountingPoliciesLineItems_637727965643200232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_SignificantAccountingPoliciesTable_637727965643200232" xlink:to="epix_SignificantAccountingPoliciesLineItems_637727965643200232" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637727965643210280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_SignificantAccountingPoliciesLineItems_637727965643200232" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637727965643210280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637727965643210280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_SignificantAccountingPoliciesLineItems_637727965643200232" xlink:to="us-gaap_OperatingLeaseLiability_637727965643210280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637727965643210280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_SignificantAccountingPoliciesLineItems_637727965643200232" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637727965643210280" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REALM ACQUISITION (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637727965643210280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637727965643210280" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637727965643210280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637727965643210280" xlink:to="us-gaap_BusinessAcquisitionAxis_637727965643210280" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637727965643210280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637727965643210280" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637727965643210280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsPlcMember" xlink:label="epix_RealmTherapeuticsPlcMember_637727965643210280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637727965643210280" xlink:to="epix_RealmTherapeuticsPlcMember_637727965643210280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_637727965643210280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637727965643210280" xlink:to="us-gaap_BusinessAcquisitionLineItems_637727965643210280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_637727965643210280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637727965643210280" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_637727965643210280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_637727965643210280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637727965643210280" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_637727965643210280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_637727965643210280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637727965643210280" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_637727965643210280" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationConversionRatioPerShare" xlink:label="epix_BusinessCombinationConversionRatioPerShare_637727965643220321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637727965643210280" xlink:to="epix_BusinessCombinationConversionRatioPerShare_637727965643220321" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare" xlink:label="epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare_637727965643220321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637727965643210280" xlink:to="epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare_637727965643220321" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare" xlink:label="epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare_637727965643220321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637727965643210280" xlink:to="epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare_637727965643220321" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_637727965643220321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637727965643210280" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_637727965643220321" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_637727965643220321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637727965643210280" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_637727965643220321" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails" xlink:type="extended" xlink:title="40402 - Disclosure - REALM ACQUISITION (Schedule of Net Assets Acquired) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637727965643220321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637727965643220321" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637727965643220321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637727965643220321" xlink:to="us-gaap_BusinessAcquisitionAxis_637727965643220321" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637727965643220321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637727965643220321" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637727965643220321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsPlcMember" xlink:label="epix_RealmTherapeuticsPlcMember_637727965643220321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637727965643220321" xlink:to="epix_RealmTherapeuticsPlcMember_637727965643220321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_637727965643220321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637727965643220321" xlink:to="us-gaap_BusinessAcquisitionLineItems_637727965643220321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637727965643220321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637727965643220321" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637727965643220321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637727965643230217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637727965643220321" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_637727965643230217" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets_637727965643230217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637727965643220321" xlink:to="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets_637727965643230217" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_637727965643230217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637727965643220321" xlink:to="epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_637727965643230217" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_637727965643230217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_637727965643220321" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_637727965643230217" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - SHORT-TERM INVESTMENTS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637727965643230217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_StatementTable_637727965643230217" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637727965643230217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643230217" xlink:to="srt_RangeAxis_637727965643230217" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637727965643230217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637727965643230217" xlink:to="srt_RangeMember_637727965643230217" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637727965643230217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637727965643230217" xlink:to="srt_MaximumMember_637727965643230217" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637727965643240491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637727965643230217" xlink:to="srt_MinimumMember_637727965643240491" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637727965643240491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643230217" xlink:to="us-gaap_StatementLineItems_637727965643240491" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate_637727965643240491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643240491" xlink:to="us-gaap_InvestmentInterestRate_637727965643240491" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - PREPAIDS (Schedule of Prepaid Expenses) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637727965643240491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidInsurance_637727965643240491" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits" xlink:label="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_637727965643240491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits_637727965643240491" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_637727965643240491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_637727965643240491" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637727965643240491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent_637727965643240491" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_637413751595209570" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637727965643240491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637413751595209570" xlink:to="us-gaap_AccountsPayableCurrent_637727965643240491" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637727965643240491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637413751595209570" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637727965643240491" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_637727965643250379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637413751595209570" xlink:to="us-gaap_AccruedVacationCurrent_637727965643250379" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637727965643250379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_637413751595209570" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637727965643250379" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - OPERATING LEASE (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637727965643250379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_StatementTable_637727965643250379" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637727965643250379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643250379" xlink:to="us-gaap_IncomeStatementLocationAxis_637727965643250379" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637727965643250379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637727965643250379" xlink:to="us-gaap_IncomeStatementLocationDomain_637727965643250379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637727965643250379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637727965643250379" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637727965643250379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FinancingCostsMember" xlink:label="epix_FinancingCostsMember_637727965643250379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637727965643250379" xlink:to="epix_FinancingCostsMember_637727965643250379" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637727965643250379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643250379" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637727965643250379" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637727965643250379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637727965643250379" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637727965643250379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SouthFransicoOfficeMember" xlink:label="epix_SouthFransicoOfficeMember_637727965643250379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637727965643250379" xlink:to="epix_SouthFransicoOfficeMember_637727965643250379" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_HoustonOfficeMember" xlink:label="epix_HoustonOfficeMember_637727965643250379" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637727965643250379" xlink:to="epix_HoustonOfficeMember_637727965643250379" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637727965643260229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643250379" xlink:to="us-gaap_StatementLineItems_637727965643260229" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_637727965643260229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643260229" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_637727965643260229" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_637727965643260229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643260229" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_637727965643260229" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637727965643260229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643260229" xlink:to="us-gaap_OperatingLeaseCost_637727965643260229" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseLiabilitiesAccretionExpenses" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses_637727965643260229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643260229" xlink:to="epix_OperatingLeaseLiabilitiesAccretionExpenses_637727965643260229" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - OPERATING LEASE (Schedule of Operating Leases) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637727965643260229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637727965643260229" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637727965643260229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637727965643260229" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637727965643260229" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637727965643260229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637727965643260229" xlink:to="us-gaap_TypeOfAdoptionMember_637727965643260229" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_637727965643260229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_637727965643260229" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_637727965643260229" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637727965643260229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637727965643260229" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637727965643260229" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637727965643270297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637727965643260229" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637727965643270297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseRightOfUseAssetAbstract" xlink:label="epix_OperatingLeaseRightOfUseAssetAbstract_637727965643270297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637727965643270297" xlink:to="epix_OperatingLeaseRightOfUseAssetAbstract_637727965643270297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637727965643270297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_OperatingLeaseRightOfUseAssetAbstract_637727965643270297" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637727965643270297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseRightOfUseAssetsCurrent" xlink:label="epix_OperatingLeaseRightOfUseAssetsCurrent_637727965643270297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_OperatingLeaseRightOfUseAssetAbstract_637727965643270297" xlink:to="epix_OperatingLeaseRightOfUseAssetsCurrent_637727965643270297" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseRightOfUseAssetAddition" xlink:label="epix_OperatingLeaseRightOfUseAssetAddition_637727965643270297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_OperatingLeaseRightOfUseAssetAbstract_637727965643270297" xlink:to="epix_OperatingLeaseRightOfUseAssetAddition_637727965643270297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637727965643270297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_OperatingLeaseRightOfUseAssetAbstract_637727965643270297" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_637727965643270297" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_637727965643270297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_637727965643270297" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_637727965643270297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637727965643270297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_637727965643270297" xlink:to="us-gaap_OperatingLeaseLiability_637727965643270297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseLiabilitiesAddition" xlink:label="epix_OperatingLeaseLiabilitiesAddition_637727965643270297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_637727965643270297" xlink:to="epix_OperatingLeaseLiabilitiesAddition_637727965643270297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_OperatingLeaseLiabilitiesAccretionExpenses" xlink:label="epix_OperatingLeaseLiabilitiesAccretionExpenses_637727965643270297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_637727965643270297" xlink:to="epix_OperatingLeaseLiabilitiesAccretionExpenses_637727965643270297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637727965643270297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_637727965643270297" xlink:to="us-gaap_OperatingLeasePayments_637727965643270297" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - LONG-TERM DEBT (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637727965643280258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637727965643280258" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_637727965643280258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637727965643280258" xlink:to="us-gaap_LongtermDebtTypeAxis_637727965643280258" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_637727965643280258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_637727965643280258" xlink:to="us-gaap_LongtermDebtTypeDomain_637727965643280258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SiliconValleyBankTermLoanMember" xlink:label="epix_SiliconValleyBankTermLoanMember_637727965643280258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_637727965643280258" xlink:to="epix_SiliconValleyBankTermLoanMember_637727965643280258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_637727965643280258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637727965643280258" xlink:to="us-gaap_VariableRateAxis_637727965643280258" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_637727965643280258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_637727965643280258" xlink:to="us-gaap_VariableRateDomain_637727965643280258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WallStreetJournalPrimeRateMember" xlink:label="epix_WallStreetJournalPrimeRateMember_637727965643280258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_637727965643280258" xlink:to="epix_WallStreetJournalPrimeRateMember_637727965643280258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637727965643280258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637727965643280258" xlink:to="us-gaap_DebtInstrumentLineItems_637727965643280258" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637727965643290272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="us-gaap_DebtInstrumentFaceAmount_637727965643290272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637727965643290272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637727965643290272" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DebtInstrumentAdditionalBorrowingCapacityLapsed" xlink:label="epix_DebtInstrumentAdditionalBorrowingCapacityLapsed_637727965643290272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="epix_DebtInstrumentAdditionalBorrowingCapacityLapsed_637727965643290272" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637727965643290272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637727965643290272" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637727965643290272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637727965643290272" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_637727965643290272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="us-gaap_DebtInstrumentMaturityDate_637727965643290272" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PercentageOfFinalPaymentOnAmountAdvanced" xlink:label="epix_PercentageOfFinalPaymentOnAmountAdvanced_637727965643290272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="epix_PercentageOfFinalPaymentOnAmountAdvanced_637727965643290272" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637727965643290272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637727965643290272" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtPrincipal" xlink:label="epix_RepaymentsOfLongTermDebtPrincipal_637727965643290272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="epix_RepaymentsOfLongTermDebtPrincipal_637727965643290272" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtInterest" xlink:label="epix_RepaymentsOfLongTermDebtInterest_637727965643290272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="epix_RepaymentsOfLongTermDebtInterest_637727965643290272" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_637727965643300337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="us-gaap_PaymentsOfFinancingCosts_637727965643300337" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtFinalPayment" xlink:label="epix_RepaymentsOfLongTermDebtFinalPayment_637727965643300337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="epix_RepaymentsOfLongTermDebtFinalPayment_637727965643300337" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightGranted" xlink:label="epix_ClassOfWarrantOrRightGranted_637727965643300337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="epix_ClassOfWarrantOrRightGranted_637727965643300337" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637727965643300337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637727965643300337" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FairValueOfWarrantIssued" xlink:label="epix_FairValueOfWarrantIssued_637727965643300337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="epix_FairValueOfWarrantIssued_637727965643300337" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_637727965643300337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="us-gaap_DeferredFinanceCostsNet_637727965643300337" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_637727965643300337" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643280258" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_637727965643300337" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails" xlink:type="extended" xlink:title="40902 - Disclosure - LONG-TERM DEBT (Schedule of Term Loan Repayment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637727965643310272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637727965643310272" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_637727965643310272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637727965643310272" xlink:to="us-gaap_LongtermDebtTypeAxis_637727965643310272" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_637727965643310272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_637727965643310272" xlink:to="us-gaap_LongtermDebtTypeDomain_637727965643310272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SiliconValleyBankTermLoanMember" xlink:label="epix_SiliconValleyBankTermLoanMember_637727965643310272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_637727965643310272" xlink:to="epix_SiliconValleyBankTermLoanMember_637727965643310272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637727965643310272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637727965643310272" xlink:to="us-gaap_DebtInstrumentLineItems_637727965643310272" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_LongTermDebtRepaymentRollForward" xlink:label="epix_LongTermDebtRepaymentRollForward_637727965643310272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637727965643310272" xlink:to="epix_LongTermDebtRepaymentRollForward_637727965643310272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637727965643310272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_LongTermDebtRepaymentRollForward_637727965643310272" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637727965643310272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtPrincipal" xlink:label="epix_RepaymentsOfLongTermDebtPrincipal_637727965643310272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_LongTermDebtRepaymentRollForward_637727965643310272" xlink:to="epix_RepaymentsOfLongTermDebtPrincipal_637727965643310272" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtInterest" xlink:label="epix_RepaymentsOfLongTermDebtInterest_637727965643310272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_LongTermDebtRepaymentRollForward_637727965643310272" xlink:to="epix_RepaymentsOfLongTermDebtInterest_637727965643310272" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DebtInstrumentAccretion" xlink:label="epix_DebtInstrumentAccretion_637727965643310272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_LongTermDebtRepaymentRollForward_637727965643310272" xlink:to="epix_DebtInstrumentAccretion_637727965643310272" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RepaymentsOfLongTermDebtFinalPayment" xlink:label="epix_RepaymentsOfLongTermDebtFinalPayment_637727965643320159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_LongTermDebtRepaymentRollForward_637727965643310272" xlink:to="epix_RepaymentsOfLongTermDebtFinalPayment_637727965643320159" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637727965643320159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_LongTermDebtRepaymentRollForward_637727965643310272" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637727965643320159" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - DERIVATIVE LIABILITIES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable_637727965643320159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeTable_637727965643320159" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637727965643320159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable_637727965643320159" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637727965643320159" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637727965643320159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637727965643320159" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637727965643320159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637727965643320159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637727965643320159" xlink:to="us-gaap_PrivatePlacementMember_637727965643320159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637727965643320159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable_637727965643320159" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637727965643320159" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637727965643320159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637727965643320159" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637727965643320159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637727965643320159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637727965643320159" xlink:to="us-gaap_FairValueInputsLevel3Member_637727965643320159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637727965643330273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable_637727965643320159" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637727965643330273" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637727965643330273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637727965643330273" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637727965643330273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_TwoYearWarrantMember" xlink:label="epix_TwoYearWarrantMember_637727965643330273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637727965643330273" xlink:to="epix_TwoYearWarrantMember_637727965643330273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SevenYearWarrantMember" xlink:label="epix_SevenYearWarrantMember_637727965643330273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637727965643330273" xlink:to="epix_SevenYearWarrantMember_637727965643330273" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637727965643330273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable_637727965643320159" xlink:to="srt_StatementScenarioAxis_637727965643330273" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637727965643330273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637727965643330273" xlink:to="srt_ScenarioUnspecifiedDomain_637727965643330273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncreaseInMarketPriceOfWarrantsBy10Member" xlink:label="epix_IncreaseInMarketPriceOfWarrantsBy10Member_637727965643330273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637727965643330273" xlink:to="epix_IncreaseInMarketPriceOfWarrantsBy10Member_637727965643330273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DecreaseInMarketPriceOfWarrantsBy10Member" xlink:label="epix_DecreaseInMarketPriceOfWarrantsBy10Member_637727965643330273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637727965643330273" xlink:to="epix_DecreaseInMarketPriceOfWarrantsBy10Member_637727965643330273" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncreaseInVolatilityOfWarrantsBy10Member" xlink:label="epix_IncreaseInVolatilityOfWarrantsBy10Member_637727965643330273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637727965643330273" xlink:to="epix_IncreaseInVolatilityOfWarrantsBy10Member_637727965643330273" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DecreaseInVolatilityOfWarrantsBy10Member" xlink:label="epix_DecreaseInVolatilityOfWarrantsBy10Member_637727965643330273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637727965643330273" xlink:to="epix_DecreaseInVolatilityOfWarrantsBy10Member_637727965643330273" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems_637727965643330273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable_637727965643320159" xlink:to="us-gaap_DerivativeLineItems_637727965643330273" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637727965643340236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems_637727965643330273" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637727965643340236" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637727965643340236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems_637727965643330273" xlink:to="us-gaap_SharesIssuedPricePerShare_637727965643340236" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637727965643340236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems_637727965643330273" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637727965643340236" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637727965643340236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems_637727965643330273" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637727965643340236" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_UnitsIssuedInPrivatePlacementConversionRatio" xlink:label="epix_UnitsIssuedInPrivatePlacementConversionRatio_637727965643340236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems_637727965643330273" xlink:to="epix_UnitsIssuedInPrivatePlacementConversionRatio_637727965643340236" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637727965643340236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems_637727965643330273" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637727965643340236" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice" xlink:label="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice_637727965643340236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems_637727965643330273" xlink:to="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice_637727965643340236" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility" xlink:label="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility_637727965643340236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems_637727965643330273" xlink:to="epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility_637727965643340236" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails" xlink:type="extended" xlink:title="41002 - Disclosure - DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable_637727965643350284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeTable_637727965643350284" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637727965643350284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable_637727965643350284" xlink:to="us-gaap_MeasurementInputTypeAxis_637727965643350284" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637727965643350284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637727965643350284" xlink:to="us-gaap_MeasurementInputTypeDomain_637727965643350284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637727965643350284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637727965643350284" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637727965643350284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637727965643350284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637727965643350284" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637727965643350284" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637727965643350284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637727965643350284" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637727965643350284" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_637727965643350284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637727965643350284" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_637727965643350284" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_637727965643350284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637727965643350284" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_637727965643350284" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637727965643350284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable_637727965643350284" xlink:to="srt_RangeAxis_637727965643350284" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637727965643360316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637727965643350284" xlink:to="srt_RangeMember_637727965643360316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember_637727965643360316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637727965643360316" xlink:to="srt_WeightedAverageMember_637727965643360316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems_637727965643360316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable_637727965643350284" xlink:to="us-gaap_DerivativeLineItems_637727965643360316" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_637727965643360316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems_637727965643360316" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_637727965643360316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesScheduleOfChangesOfDerivativeLiabilitiesDetails" xlink:type="extended" xlink:title="41003 - Disclosure - DERIVATIVE LIABILITIES (Schedule of Changes of Derivative Liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_637727965643360316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_637727965643360316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_637727965643360316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_637727965643360316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_6377279656433603161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_6377279656433603161" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_637727965643360316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_637727965643360316" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_63772796564336031612" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_63772796564336031612" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - SHAREHOLDERS' EQUITY (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643370271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643370271" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637727965643370271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643370271" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637727965643370271" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637727965643370271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637727965643370271" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637727965643370271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_February2021financingMember" xlink:label="epix_February2021financingMember_637727965643370271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637727965643370271" xlink:to="epix_February2021financingMember_637727965643370271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_July2020FinancingMember" xlink:label="epix_July2020FinancingMember_637727965643370271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637727965643370271" xlink:to="epix_July2020FinancingMember_637727965643370271" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_August2019FinancingMember" xlink:label="epix_August2019FinancingMember_637727965643370271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637727965643370271" xlink:to="epix_August2019FinancingMember_637727965643370271" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637727965643370271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637727965643370271" xlink:to="us-gaap_OverAllotmentOptionMember_637727965643370271" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637727965643370271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637727965643370271" xlink:to="us-gaap_PrivatePlacementMember_637727965643370271" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637727965643370271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643370271" xlink:to="us-gaap_BusinessAcquisitionAxis_637727965643370271" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637727965643370271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637727965643370271" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637727965643370271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RealmTherapeuticsPlcMember" xlink:label="epix_RealmTherapeuticsPlcMember_637727965643370271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637727965643370271" xlink:to="epix_RealmTherapeuticsPlcMember_637727965643370271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637727965643380222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643370271" xlink:to="dei_LegalEntityAxis_637727965643380222" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637727965643380222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637727965643380222" xlink:to="dei_EntityDomain_637727965643380222" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClarusLifesciencesIiiL.pMember" xlink:label="epix_ClarusLifesciencesIiiL.pMember_637727965643380222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637727965643380222" xlink:to="epix_ClarusLifesciencesIiiL.pMember_637727965643380222" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637727965643380222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643370271" xlink:to="srt_RangeAxis_637727965643380222" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637727965643380222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637727965643380222" xlink:to="srt_RangeMember_637727965643380222" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637727965643380222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637727965643380222" xlink:to="srt_MinimumMember_637727965643380222" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637727965643380222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637727965643380222" xlink:to="srt_MaximumMember_637727965643380222" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637727965643390010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643370271" xlink:to="us-gaap_AwardTypeAxis_637727965643390010" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637727965643390010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637727965643390010" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637727965643390010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_637727965643390010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637727965643390010" xlink:to="us-gaap_EmployeeStockMember_637727965643390010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637727965643390010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637727965643390010" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637727965643390010" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockOptionsAndRsuPlanMember" xlink:label="epix_StockOptionsAndRsuPlanMember_637727965643390010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637727965643390010" xlink:to="epix_StockOptionsAndRsuPlanMember_637727965643390010" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637727965643390010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643370271" xlink:to="us-gaap_PlanNameAxis_637727965643390010" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637727965643390010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637727965643390010" xlink:to="us-gaap_PlanNameDomain_637727965643390010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EquityIncentivePlansMember" xlink:label="epix_EquityIncentivePlansMember_637727965643390010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637727965643390010" xlink:to="epix_EquityIncentivePlansMember_637727965643390010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember_637727965643390010" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_EquityIncentivePlansMember_637727965643390010" xlink:to="epix_EmployeeSharePurchasePlanMember_637727965643390010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637727965643400255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643370271" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637727965643400255" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637727965643400255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637727965643400255" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637727965643400255" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_TwoYearWarrantMember" xlink:label="epix_TwoYearWarrantMember_637727965643400255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637727965643400255" xlink:to="epix_TwoYearWarrantMember_637727965643400255" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_SevenYearWarrantMember" xlink:label="epix_SevenYearWarrantMember_637727965643400255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637727965643400255" xlink:to="epix_SevenYearWarrantMember_637727965643400255" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643370271" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637727965643400255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637727965643400255" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637727965643400255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637727965643400255" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637727965643400255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_SharesIssuedPricePerShare_637727965643400255" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_UnderwriterOptionToPurchaseAdditionalSecurities" xlink:label="epix_UnderwriterOptionToPurchaseAdditionalSecurities_637727965643410250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="epix_UnderwriterOptionToPurchaseAdditionalSecurities_637727965643410250" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_TermOfUnderwritersOption" xlink:label="epix_TermOfUnderwritersOption_637727965643410250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="epix_TermOfUnderwritersOption_637727965643410250" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PreFundedWarrantsIssuedForCommonShares" xlink:label="epix_PreFundedWarrantsIssuedForCommonShares_637727965643410250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="epix_PreFundedWarrantsIssuedForCommonShares_637727965643410250" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637727965643410250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637727965643410250" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637727965643410250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637727965643410250" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions_637727965643410250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_PaymentsForCommissions_637727965643410250" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637727965643420215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637727965643420215" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_637727965643420215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_637727965643420215" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_UnitsIssuedInPrivatePlacementConversionRatio" xlink:label="epix_UnitsIssuedInPrivatePlacementConversionRatio_637727965643420215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="epix_UnitsIssuedInPrivatePlacementConversionRatio_637727965643420215" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights" xlink:label="epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights_637727965643420215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights_637727965643420215" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637727965643420215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637727965643420215" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637727965643420215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637727965643420215" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637727965643430459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637727965643430459" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage" xlink:label="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage_637727965643430459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage_637727965643430459" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PurchaseRightsOfferingTerm" xlink:label="epix_PurchaseRightsOfferingTerm_637727965643430459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="epix_PurchaseRightsOfferingTerm_637727965643430459" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan" xlink:label="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan_637727965643430459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan_637727965643430459" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637727965643430459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637727965643430459" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637727965643440500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637727965643440500" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637727965643440500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643400255" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637727965643440500" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="41102 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Share Based Compensation Expenses) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643450237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643450237" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637727965643450237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643450237" xlink:to="us-gaap_PlanNameAxis_637727965643450237" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637727965643450237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637727965643450237" xlink:to="us-gaap_PlanNameDomain_637727965643450237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember_637727965643450237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637727965643450237" xlink:to="epix_EmployeeSharePurchasePlanMember_637727965643450237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember_637727965643450237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637727965643450237" xlink:to="epix_StockOptionPlanMember_637727965643450237" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637727965643450237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643450237" xlink:to="us-gaap_IncomeStatementLocationAxis_637727965643450237" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637727965643450237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637727965643450237" xlink:to="us-gaap_IncomeStatementLocationDomain_637727965643450237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637727965643450237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637727965643450237" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637727965643450237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637727965643450237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637727965643450237" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637727965643450237" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643450237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643450237" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643450237" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637727965643450237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643450237" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637727965643450237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails" xlink:type="extended" xlink:title="41103 - Disclosure - SHAREHOLDERS' EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643460254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643460254" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637727965643460254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643460254" xlink:to="us-gaap_PlanNameAxis_637727965643460254" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637727965643460254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637727965643460254" xlink:to="us-gaap_PlanNameDomain_637727965643460254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_EmployeeSharePurchasePlanMember" xlink:label="epix_EmployeeSharePurchasePlanMember_637727965643460254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637727965643460254" xlink:to="epix_EmployeeSharePurchasePlanMember_637727965643460254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockOptionPlanMember" xlink:label="epix_StockOptionPlanMember_637727965643460254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637727965643460254" xlink:to="epix_StockOptionPlanMember_637727965643460254" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643460254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643460254" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643460254" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637727965643460254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643460254" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637727965643460254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637727965643460254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637727965643460254" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637727965643460254" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637727965643460254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637727965643460254" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637727965643460254" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637727965643460254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637727965643460254" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637727965643460254" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637727965643460254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637727965643460254" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637727965643460254" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="41104 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Stock Option Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637727965643470351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637727965643470351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637727965643470351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637727965643470351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637727965643470351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637727965643470351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637727965643470351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637727965643470351" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637727965643470351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637727965643470351" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637727965643470351" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637727965643470351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637727965643470351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637727965643470351" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6377279656434703511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637727965643470351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6377279656434703511" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637727965643470351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637727965643470351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637727965643470351" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637727965643470351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637727965643470351" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637727965643470351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637727965643470351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637727965643470351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637727965643470351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637727965643470351" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637727965643470351" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637727965643470351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637727965643470351" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637727965643470351" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637727965643480244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637727965643470351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637727965643480244" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637727965643480244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637727965643470351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637727965643480244" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637727965643480244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637727965643470351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637727965643480244" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails" xlink:type="extended" xlink:title="41105 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Stock Option Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643480244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643480244" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637727965643480244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643480244" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637727965643480244" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637727965643480244" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceOneInUsdMember" xlink:label="epix_ExercisePriceOneInUsdMember_637727965643480244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" xlink:to="epix_ExercisePriceOneInUsdMember_637727965643480244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceTwoInUsdMember" xlink:label="epix_ExercisePriceTwoInUsdMember_637727965643480244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" xlink:to="epix_ExercisePriceTwoInUsdMember_637727965643480244" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceThreeInUsdMember" xlink:label="epix_ExercisePriceThreeInUsdMember_637727965643489960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" xlink:to="epix_ExercisePriceThreeInUsdMember_637727965643489960" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceFourInUsdMember" xlink:label="epix_ExercisePriceFourInUsdMember_637727965643489960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" xlink:to="epix_ExercisePriceFourInUsdMember_637727965643489960" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceFiveInUsdMember" xlink:label="epix_ExercisePriceFiveInUsdMember_637727965643489960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" xlink:to="epix_ExercisePriceFiveInUsdMember_637727965643489960" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceSixInUsdMember" xlink:label="epix_ExercisePriceSixInUsdMember_637727965643489960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" xlink:to="epix_ExercisePriceSixInUsdMember_637727965643489960" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceSevenInUsdMember" xlink:label="epix_ExercisePriceSevenInUsdMember_637727965643489960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" xlink:to="epix_ExercisePriceSevenInUsdMember_637727965643489960" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceEightInUsdMember" xlink:label="epix_ExercisePriceEightInUsdMember_637727965643489960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" xlink:to="epix_ExercisePriceEightInUsdMember_637727965643489960" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceNineInUsdMember" xlink:label="epix_ExercisePriceNineInUsdMember_637727965643489960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" xlink:to="epix_ExercisePriceNineInUsdMember_637727965643489960" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceTenInUsdMember" xlink:label="epix_ExercisePriceTenInUsdMember_637727965643489960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" xlink:to="epix_ExercisePriceTenInUsdMember_637727965643489960" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceOneInCadMember" xlink:label="epix_ExercisePriceOneInCadMember_637727965643489960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" xlink:to="epix_ExercisePriceOneInCadMember_637727965643489960" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ExercisePriceTwoInCadMember" xlink:label="epix_ExercisePriceTwoInCadMember_637727965643489960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637727965643480244" xlink:to="epix_ExercisePriceTwoInCadMember_637727965643489960" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643489960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643480244" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643489960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637727965643500258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643489960" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637727965643500258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637727965643500258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643489960" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637727965643500258" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637727965643500258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643489960" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637727965643500258" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails" xlink:type="extended" xlink:title="41106 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Warrants Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward" xlink:label="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_637727965643500258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_637727965643500258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637727965643500258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_637727965643500258" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637727965643500258" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightGranted" xlink:label="epix_ClassOfWarrantOrRightGranted_637727965643500258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_637727965643500258" xlink:to="epix_ClassOfWarrantOrRightGranted_637727965643500258" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightExercised" xlink:label="epix_ClassOfWarrantOrRightExercised_637727965643500258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_637727965643500258" xlink:to="epix_ClassOfWarrantOrRightExercised_637727965643500258" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightExpired" xlink:label="epix_ClassOfWarrantOrRightExpired_637727965643500258" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_637727965643500258" xlink:to="epix_ClassOfWarrantOrRightExpired_637727965643500258" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637727965643510481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward_637727965643500258" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637727965643510481" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_637727965643510481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_637727965643510481" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637727965643510481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_637727965643510481" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637727965643510481" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted_637727965643510481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_637727965643510481" xlink:to="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted_637727965643510481" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised_637727965643510481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_637727965643510481" xlink:to="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised_637727965643510481" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired" xlink:label="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired_637727965643510481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_637727965643510481" xlink:to="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired_637727965643510481" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6377279656435104811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward_637727965643510481" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6377279656435104811" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="41107 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Warrants Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643510481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643510481" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637727965643510481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643510481" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637727965643510481" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637727965643520215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637727965643510481" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637727965643520215" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WarrantsExercisePriceOneMember" xlink:label="epix_WarrantsExercisePriceOneMember_637727965643520215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637727965643520215" xlink:to="epix_WarrantsExercisePriceOneMember_637727965643520215" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WarrantsExercisePriceTwoMember" xlink:label="epix_WarrantsExercisePriceTwoMember_637727965643520215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637727965643520215" xlink:to="epix_WarrantsExercisePriceTwoMember_637727965643520215" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WarrantsExercisePriceThreeMember" xlink:label="epix_WarrantsExercisePriceThreeMember_637727965643520215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637727965643520215" xlink:to="epix_WarrantsExercisePriceThreeMember_637727965643520215" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WarrantsExercisePriceFiveMember" xlink:label="epix_WarrantsExercisePriceFiveMember_637727965643520215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637727965643520215" xlink:to="epix_WarrantsExercisePriceFiveMember_637727965643520215" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643520215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637727965643510481" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643520215" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637727965643520215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643520215" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637727965643520215" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637727965643520215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643520215" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637727965643520215" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_637727965643520215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637727965643520215" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_637727965643520215" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised" xlink:label="epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised_637727965643530356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised_637727965643530356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_PreFundedWarrantsExercised" xlink:label="epix_PreFundedWarrantsExercised_637727965643530356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="epix_PreFundedWarrantsExercised_637727965643530356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability" xlink:label="epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability_637727965643530356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability_637727965643530356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities" xlink:label="epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities_637727965643530356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities_637727965643530356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - RELATED PARTY TRANSACTIONS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637727965643530356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637727965643530356" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637727965643530356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637727965643530356" xlink:to="us-gaap_BalanceSheetLocationAxis_637727965643530356" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637727965643530356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637727965643530356" xlink:to="us-gaap_BalanceSheetLocationDomain_637727965643530356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_637727965643530356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637727965643530356" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_637727965643530356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637727965643540074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637727965643530356" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637727965643540074" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637727965643540074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637727965643540074" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637727965643540074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails" xlink:type="extended" xlink:title="41401 - Disclosure - INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637727965643540074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637727965643540074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637727965643540074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637727965643540074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_637727965643540074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_637727965643540074" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncomeTaxReconciliationTaxableCapitalGains" xlink:label="epix_IncomeTaxReconciliationTaxableCapitalGains_637727965643540074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="epix_IncomeTaxReconciliationTaxableCapitalGains_637727965643540074" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_637727965643540074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_637727965643540074" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_IncomeTaxReconciliationFinancingCosts" xlink:label="epix_IncomeTaxReconciliationFinancingCosts_637727965643540074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="epix_IncomeTaxReconciliationFinancingCosts_637727965643540074" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_637727965643540074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_637727965643540074" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_637727965643540074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_637727965643540074" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_637727965643540074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_637727965643540074" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637727965643550255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637727965643550255" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails" xlink:type="extended" xlink:title="41402 - Disclosure - INCOME TAXES (Significant Components of Future Tax Assets) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_637727965643550255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_637727965643550255" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637727965643550255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637727965643550255" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637727965643550255" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DeferredTaxAssetsEquipmentAndIntangibleAssets" xlink:label="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_637727965643550255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637727965643550255" xlink:to="epix_DeferredTaxAssetsEquipmentAndIntangibleAssets_637727965643550255" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="us-gaap_DeferredTaxAssetsInvestments_637727965643550255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637727965643550255" xlink:to="us-gaap_DeferredTaxAssetsInvestments_637727965643550255" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_DeferredTaxAssetsFinancingCosts" xlink:label="epix_DeferredTaxAssetsFinancingCosts_637727965643550255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637727965643550255" xlink:to="epix_DeferredTaxAssetsFinancingCosts_637727965643550255" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637727965643550255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637727965643550255" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637727965643550255" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_637727965643550255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637727965643550255" xlink:to="us-gaap_DeferredTaxAssetsOther_637727965643550255" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637727965643560349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637727965643550255" xlink:to="us-gaap_DeferredTaxAssetsGross_637727965643560349" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637727965643560349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637727965643550255" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637727965643560349" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637727965643560349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637727965643550255" xlink:to="us-gaap_DeferredTaxAssetsNet_637727965643560349" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41403 - Disclosure - INCOME TAXES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637727965643560349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable_637727965643560349" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637727965643560349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643560349" xlink:to="srt_StatementGeographicalAxis_637727965643560349" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637727965643560349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637727965643560349" xlink:to="srt_SegmentGeographicalDomain_637727965643560349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="country_US_637727965643560349" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637727965643560349" xlink:to="country_US_637727965643560349" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637727965643570257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643560349" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637727965643570257" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637727965643570257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637727965643570257" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637727965643570257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637727965643570257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637727965643570257" xlink:to="us-gaap_DomesticCountryMember_637727965643570257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_637727965643570257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637727965643570257" xlink:to="us-gaap_ForeignCountryMember_637727965643570257" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637727965643570257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643560349" xlink:to="us-gaap_StatementLineItems_637727965643570257" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637727965643570257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643570257" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637727965643570257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637727965643570257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643570257" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637727965643570257" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637727965643570257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643570257" xlink:to="us-gaap_OperatingLossCarryforwards_637727965643570257" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureSegmentedInformationNarrativeDetails" xlink:type="extended" xlink:title="41501 - Disclosure - SEGMENTED INFORMATION (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_637727965643570257" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments_637727965643570257" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails" xlink:type="extended" xlink:title="41601 - Disclosure - FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_FinancialInstrumentsAndRiskAbstract" xlink:label="epix_FinancialInstrumentsAndRiskAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637727965643580317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="epix_FinancialInstrumentsAndRiskAbstract" xlink:to="us-gaap_StatementTable_637727965643580317" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637727965643580317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643580317" xlink:to="srt_StatementScenarioAxis_637727965643580317" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637727965643580317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637727965643580317" xlink:to="srt_ScenarioUnspecifiedDomain_637727965643580317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_TenPercentChangeInForeignExchangeRateMember" xlink:label="epix_TenPercentChangeInForeignExchangeRateMember_637727965643580317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637727965643580317" xlink:to="epix_TenPercentChangeInForeignExchangeRateMember_637727965643580317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637727965643580317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637727965643580317" xlink:to="us-gaap_StatementLineItems_637727965643580317" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_WorkingCapital" xlink:label="epix_WorkingCapital_637727965643580317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643580317" xlink:to="epix_WorkingCapital_637727965643580317" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_CashCanadaDepositInsuranceCorporationInsuredAmount" xlink:label="epix_CashCanadaDepositInsuranceCorporationInsuredAmount_637727965643580317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643580317" xlink:to="epix_CashCanadaDepositInsuranceCorporationInsuredAmount_637727965643580317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount_637727965643580317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643580317" xlink:to="us-gaap_CashFDICInsuredAmount_637727965643580317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate" xlink:label="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate_637727965643580317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637727965643580317" xlink:to="epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate_637727965643580317" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails" xlink:type="extended" xlink:title="41701 - Disclosure - COMMITMENTS (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_637727965643590502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable_637727965643590502" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637727965643590502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637727965643590502" xlink:to="us-gaap_TypeOfArrangementAxis_637727965643590502" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637727965643590502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637727965643590502" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637727965643590502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_LicenseAgreementMember" xlink:label="epix_LicenseAgreementMember_637727965643590502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637727965643590502" xlink:to="epix_LicenseAgreementMember_637727965643590502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637727965643590502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637727965643590502" xlink:to="srt_StatementGeographicalAxis_637727965643590502" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637727965643590502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637727965643590502" xlink:to="srt_SegmentGeographicalDomain_637727965643590502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TX" xlink:label="stpr_TX_637727965643590502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637727965643590502" xlink:to="stpr_TX_637727965643590502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637727965643590502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637727965643590502" xlink:to="srt_ProductOrServiceAxis_637727965643590502" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637727965643590502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637727965643590502" xlink:to="srt_ProductsAndServicesDomain_637727965643590502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_637727965643600302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637727965643590502" xlink:to="us-gaap_GrantMember_637727965643600302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637727965643600302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637727965643590502" xlink:to="srt_StatementScenarioAxis_637727965643600302" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637727965643600302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637727965643600302" xlink:to="srt_ScenarioUnspecifiedDomain_637727965643600302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AggregateRoyaltyPaymentUpTo24000000Member" xlink:label="epix_AggregateRoyaltyPaymentUpTo24000000Member_637727965643600302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637727965643600302" xlink:to="epix_AggregateRoyaltyPaymentUpTo24000000Member_637727965643600302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AggregateRoyaltyPaymentAfter24000000Member" xlink:label="epix_AggregateRoyaltyPaymentAfter24000000Member_637727965643600302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637727965643600302" xlink:to="epix_AggregateRoyaltyPaymentAfter24000000Member_637727965643600302" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637727965643600302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637727965643590502" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637727965643600302" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637727965643600302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637727965643600302" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637727965643600302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="us-gaap_TechnologyBasedIntangibleAssetsMember_637727965643600302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637727965643600302" xlink:to="us-gaap_TechnologyBasedIntangibleAssetsMember_637727965643600302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_637727965643600302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637727965643590502" xlink:to="us-gaap_OtherCommitmentsLineItems_637727965643600302" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_GrantAmount" xlink:label="epix_GrantAmount_637727965643609971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643600302" xlink:to="epix_GrantAmount_637727965643609971" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_GrantReceivedPeriod" xlink:label="epix_GrantReceivedPeriod_637727965643609971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643600302" xlink:to="epix_GrantReceivedPeriod_637727965643609971" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable_637727965643609971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643600302" xlink:to="us-gaap_GrantsReceivable_637727965643609971" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_GrantRequirementNumberOfYearsOfOperationsInTexas" xlink:label="epix_GrantRequirementNumberOfYearsOfOperationsInTexas_637727965643609971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643600302" xlink:to="epix_GrantRequirementNumberOfYearsOfOperationsInTexas_637727965643609971" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ThresholdLimitForAggregateRoyaltyPayments" xlink:label="epix_ThresholdLimitForAggregateRoyaltyPayments_637727965643609971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643600302" xlink:to="epix_ThresholdLimitForAggregateRoyaltyPayments_637727965643609971" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_RoyaltyPercentRevenue" xlink:label="epix_RoyaltyPercentRevenue_637727965643609971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643600302" xlink:to="epix_RoyaltyPercentRevenue_637727965643609971" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_MinimumAdvanceRoyaltyPayments" xlink:label="epix_MinimumAdvanceRoyaltyPayments_637727965643609971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643600302" xlink:to="epix_MinimumAdvanceRoyaltyPayments_637727965643609971" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial_637727965643609971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643600302" xlink:to="epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial_637727965643609971" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial" xlink:label="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial_637727965643609971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643600302" xlink:to="epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial_637727965643609971" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval" xlink:label="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval_637727965643620467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643600302" xlink:to="epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval_637727965643620467" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails" xlink:type="extended" xlink:title="41702 - Disclosure - COMMITMENTS (Schedule of Contractual Obligations) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_637727965643620467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable_637727965643620467" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637727965643620467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637727965643620467" xlink:to="srt_ProductOrServiceAxis_637727965643620467" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637727965643620467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637727965643620467" xlink:to="srt_ProductsAndServicesDomain_637727965643620467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember_637727965643620467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637727965643620467" xlink:to="us-gaap_RoyaltyMember_637727965643620467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637727965643620467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637727965643620467" xlink:to="us-gaap_TypeOfArrangementAxis_637727965643620467" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637727965643620467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637727965643620467" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637727965643620467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_LicenseAgreementMember" xlink:label="epix_LicenseAgreementMember_637727965643620467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637727965643620467" xlink:to="epix_LicenseAgreementMember_637727965643620467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_VendorAgreementMember" xlink:label="epix_VendorAgreementMember_637727965643630275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637727965643620467" xlink:to="epix_VendorAgreementMember_637727965643630275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_ConsultingAgreementMember" xlink:label="epix_ConsultingAgreementMember_637727965643630275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637727965643620467" xlink:to="epix_ConsultingAgreementMember_637727965643630275" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20210930.xsd#epix_LeaseOnUsOfficeSpacesMember" xlink:label="epix_LeaseOnUsOfficeSpacesMember_637727965643630275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637727965643620467" xlink:to="epix_LeaseOnUsOfficeSpacesMember_637727965643630275" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_637727965643630275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637727965643620467" xlink:to="us-gaap_OtherCommitmentsLineItems_637727965643630275" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_637727965643630275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643630275" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_637727965643630275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear_637727965643630275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643630275" xlink:to="us-gaap_ContractualObligationDueInSecondYear_637727965643630275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear_637727965643630275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643630275" xlink:to="us-gaap_ContractualObligationDueInThirdYear_637727965643630275" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear_637727965643630275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643630275" xlink:to="us-gaap_ContractualObligationDueInFourthYear_637727965643630275" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear_637727965643630275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637727965643630275" xlink:to="us-gaap_ContractualObligationDueInFifthYear_637727965643630275" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>tmb-20210930x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:epix="http://www.essapharma.com/20210930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tmb-20210930.xsd" xlink:type="simple"/>
    <context id="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7TyLnsxiZkm33Ed-1uTPOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:TwoYearWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:SevenYearWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_R-OfI-78tEubD9EHvwxUZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Xn7g0Te520GAvoVLIuOBjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Qr_emV94JEaOw_wTone2GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QEC_5wIz9U2D4cVesXTV0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_r3QV4PsPVU2qBc_HlNDLwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GwqowEA_CUeSgGO-fqQICA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_iDxFp3CBoUyduJ7ED7-iBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Qsq5hVVbp0yyXHTenb2ZaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_86DwwqBAdEWFbExnOSHKzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d_ASZ3MtTkuEthOiE92plw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rbJc2rOPu0KwHjun-BlNLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UBkybJOYYUOqeW1pxoqlrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2GRojpFcoki1Uc0vSHlB6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0yAp7cE-MUSaXxmCP5yQmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iCrDPxN440W6E11tKIReqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JUboWpxLbki2h1YPzqSmdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HeTz-es_FUOKI2zSdF0t_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="As_Of_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_xthkLsF1tU2jKESbtnAPiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">epix:February2021financingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-22</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_IVc9duJPY0u5zFzTth4c9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">epix:July2020FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_BRMWk_Qg8UerO040qIU5dA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_mbmDp3ur_EKGdhOHg5IO0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_jO7GpLA2mEqKLGWR63S2zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInCadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_wGr8DRkOREKQQphM6FzNzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceThreeInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_bXZJbL6ROEGmQrETPpTNlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_qaj1qKiQnkaOQmjeCWPVtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSixInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_zuHf0nv_ZkuPd0J8bn1NBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSevenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_7aa-mYodb0C8Ab3SyV0S2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_0jMN-msT_kSZlDa8zsXivA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInCadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_DeJ3daQ9SkyjDkICey1iBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceNineInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_lOFEC9XHq0q7TKCRGrQ1gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFourInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_oZ40Ld43p02RRIboS_eC8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFiveInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_K5b0pB-fBkuoUKefft0NWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceEightInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_wlpmAoIsWkC93lTFzSx58Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_ShZSeTSzbUaq092C2OXCQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTwoInCadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_eWAgb-BJak-hBFlUcl4JKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceThreeInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_N-YP2HmjGk2zaMleH3iyZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceTenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_VvO15Me_VUKyqrliUVeTGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSixInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_hiBG1IedoEC4ewOINgWhIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceSevenInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_H4_0hNFzBUGvroxmeu8AMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_oPWk0JmRaEyyBh0fzA7Y4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceOneInCadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember__kUWs0yIX0ye8hi1Zc6tpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceNineInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_-Tmwt7iVW0SBnjnGzdbEZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFourInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_LTgKbV_VaEKbcbftrCEzCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceFiveInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_1PenuuxZeEyE5f-LOycT4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">epix:ExercisePriceEightInUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_zeWUu5tnb0Wgo8Zb8VADZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_XbywsLIR-0K_GbIr8abXkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_WEBFjPZWXUWEyRoGCQubVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_wiQZ0GbLlkimzzAcX5zh1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_SMYfJ5aGWk-8_6eAqyWYbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_U7-LX1-3mUqaUlE6IXrBYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_00qP2q4hEkunoH2xAUStyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_taVuJ4126U26vyjixzsKcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9blgNKOQw0-dAjx9wbg0OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RPs6X-s5OUmfzGYNLQRNYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uiguQmWhpEG-xHaL8MHmpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_epix_SouthFransicoOfficeMember_X6eZYkSuvEC6FzZjAFnRZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">epix:SouthFransicoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_epix_HoustonOfficeMember_ZJp_lQNFrUuwmx7ZRbXpsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">epix:HoustonOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_U1mgWv7DPEuRz4Cu7N7uCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_YemvLESzuEy-rvMFb5JkQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_Uot5G89xX0qdEQQjGB5lPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_rj2UHMCflEe1q86RKPHdAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_apbVsSWBtk-56toVL5ECFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_98MIq4VaTEK2WLibJUF1nA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_E5NkLJ4ccEW-hVrvKYeF-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_-Vb12dGpuEmhyC8WUpSCCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_5REs_qrLRkG1-jsr4Wd88A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_P2nPti2-iUCuSEEd1ouQ-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Y0xPeL08wEaJiqQOv0tbTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_Juvh3KilQk6ebtQh2shs2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_vNbAiWbcgEmqGICZO6KNCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_Owqnc6-qBky5k4C7VJfSvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_PY96o3zHKEWmfUlTziLA5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_sshfj9h3UEqQ_5aRwRdsVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_hzqNHICFq0eM1Zmd4JcmoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DzMDwGmdD0qgqtbE68ow2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_hAyflyNNBEWF35w4BVawNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_us-gaap_VariableRateAxis_epix_WallStreetJournalPrimeRateMember_Y1By_7fOBkCONtSvQElMhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">epix:WallStreetJournalPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-18</startDate>
            <endDate>2016-11-18</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_4dedr1AwQkWdcCVB7ocbbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:VendorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_RMrB863qE0qS6tVtlOO3Ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LeaseOnUsOfficeSpacesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_ConsultingAgreementMember_cW0iNp2Vx0-QozLErFC7rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_epix_StockOptionsAndRsuPlanMember_k54Kg0Qt60iP9qnC85_xSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">epix:StockOptionsAndRsuPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_BIcTAMLdhk2c5modB4s8VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_RfUnofClWECxZ2F7pgy_Mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_5XGUa66jJ0abwyCuuh-5NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">epix:August2019FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-27</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_QlJ05My24UihYsCtnSc8oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceThreeMember_Poysa79t_k26dJwrtpr7cA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceOneMember_peg5Z3r7MkaJuDu2VWniig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_TR1RCu8S8U-alcwoR2y6RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:WarrantsExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_2x7YFW6kN0SPIIof17z1gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-18</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6U4ydYiIA0OEYvfjKh5H-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_fqbH1auJ50GUwQiIlByUJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_TDUXu41ajUSQhlC8jIdvlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_BTVGr7R3tkSQWqwCNPWc3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_h64usUGAzEWawEzuZH2-hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_67NPSE9QlEiBk2PCAmKn_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_C8RcT1oob06aTUsGlCRHHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_nL-lTHW6WU6Z5yoLkjYTEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_vvA5BqUJTUC4h92fKpnqdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_3oGU29vPGEui7qvSdXkMuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_O_W2ARKP1US6svZnbqUj6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_idUWwoe5Nk-eyz-isT07Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_G_hgzoPX3UCgJ-qR7IE_LA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_5sfNjYNtMEWcos30T-GAsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_I94A-tgVzEeSta5_6-UjwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_KbHplZS_S0-4Q0j_S03PtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EclFUGrZHEu0hCdXhGSRtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:TwoYearWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zBSTNeNKaU6nRdYrbBaOkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">epix:SevenYearWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve_0ZTn0TU-gXeCf2aO7nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_KZCcAZEQ0ky6YptH37I2xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">epix:February2021financingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-22</startDate>
            <endDate>2021-02-22</endDate>
        </period>
    </context>
    <context id="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_9O-seddiG0O-DtG3IZ7HSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">epix:July2020FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jbYIpU0s4Uy0gHFtYiCEog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93sQ70dbA0m6nn-4DY6rIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementScenarioAxis_epix_AggregateRoyaltyPaymentUpTo24000000Member_5AdkqvcbzUyIueGZN5F9LQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:AggregateRoyaltyPaymentUpTo24000000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementScenarioAxis_epix_AggregateRoyaltyPaymentAfter24000000Member_xk53XTvPeE29Kge7zRUczA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:AggregateRoyaltyPaymentAfter24000000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_kVSb8-wpv0K1-njgvNHdsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_27_2019_To_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_I44o30_JAkC59GqmUmKdIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">epix:August2019FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-27</startDate>
            <endDate>2019-08-27</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipn3WcQ-WkyTVclyeT1LWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_RealmTherapeuticsPlcMember_F9zuOVt_vk2IQHvJ990kRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">epix:RealmTherapeuticsPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_RealmTherapeuticsIncMember_spJ0dJs8xkexamG5z198jQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">epix:RealmTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_XOz0eBSbkU2BL3yWpajTpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">epix:EssaPharmaceuticalsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_epix_FinancingCostsMember_q3XBHIhLlEORxUBDy4pazA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">epix:FinancingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_1_31_2016_dei_LegalEntityAxis_epix_ClarusLifesciencesIiiL.pMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_nZaedBWVMkOE0FrReIaxeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">epix:ClarusLifesciencesIiiL.pMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_IncreaseInVolatilityOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9H1bHzeQPUejA4aXszVdcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:IncreaseInVolatilityOfWarrantsBy10Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_DecreaseInVolatilityOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_WLVJwCesyEOoKBOC_nuHTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:DecreaseInVolatilityOfWarrantsBy10Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_IncreaseInMarketPriceOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_TVV9GdC9SUqfmn3lDBu8_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:IncreaseInMarketPriceOfWarrantsBy10Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_DecreaseInMarketPriceOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_gtQZa6KYHEGyPwd35QmJOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:DecreaseInMarketPriceOfWarrantsBy10Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_stpr_TX_30zEwfkPH0eCYhn7ePIwpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2014_To_2_28_2014_srt_ProductOrServiceAxis_us-gaap_GrantMember_3kTJC-T1iU2z88W1B5pfng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-02-01</startDate>
            <endDate>2014-02-28</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_srt_StatementScenarioAxis_epix_TenPercentChangeInForeignExchangeRateMember_bvuH6gka5U6JPsf7-52JbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">epix:TenPercentChangeInForeignExchangeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2017_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_Aizgt9l5YUetmoZ6ZgsyMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DOZiFA-O_USUr64PZMvTXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_9_30_2019_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_uhVPf69j8U6JNC0OpomEGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_ZnXLMrzY2kKNEOanG51mYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">epix:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">epix:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-18</startDate>
            <endDate>2016-11-18</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">epix:RealmTherapeuticsPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">epix:RealmTherapeuticsPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-31</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_XqG7x_Aqjk2REwmcJTq1IQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">epix:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_3J-meWS_KUKrbz1_u2iGlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_11_18_2021_iz31dcV6aUOIbNIDv5A8Qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001633932</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Y_NMesmjSO1UGw6iRoGrNeyg">
        <measure>epix:Y</measure>
    </unit>
    <unit id="Unit_Standard_segment_bQM1D9rk7USEKwcghht0TA">
        <measure>epix:segment</measure>
    </unit>
    <unit id="Unit_Divide_CAD_shares_HPEmoMmb7kGhCh3wegQo4A">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tc_5506VaekE0O27JvC4c9vlQ_2_1">0001633932</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tc_qR7I-Dcy1kCeK1QuUIk72Q_3_1">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tc_f0vaQ9NNkUuZmq4mfplB8A_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tc_VxwrGzQ65UeUWMxAhPWGzQ_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tc_iOLzkWaM8k6vC4fYTXz7sw_6_1">false</dei:AmendmentFlag>
    <epix:UnitsIssuedInPrivatePlacementConversionRatio
      contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EclFUGrZHEu0hCdXhGSRtg"
      decimals="1"
      id="Hidden_Cq_ppVfGcEWPX38oEjsM7A"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.5</epix:UnitsIssuedInPrivatePlacementConversionRatio>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw"
      id="Hidden_LQbZKgvpMkSuPJkLK-6o4A">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw"
      id="Hidden_smbzU3-LrEiEpofGJXZ0jQ">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7TyLnsxiZkm33Ed-1uTPOw"
      id="Hidden_93qUCOn8jU2BvXa947ry6Q">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7TyLnsxiZkm33Ed-1uTPOw"
      id="Hidden_QDBLvhGsQUeMEe7FQU06dg">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw"
      id="Hidden_6BX3OeUYGUyxMKVAjbP3ng">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7TyLnsxiZkm33Ed-1uTPOw"
      id="Hidden_BNXa2upcvUaUska1jS5ngQ">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw"
      id="Hidden_RPrZ07gL9EKwo3zFCZTqrQ">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw"
      id="Hidden_VdjHFZpuu0Gaw-U_hHH3mg">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw"
      id="Hidden_-5WrOmKIy0aUmOgHj7jFrA">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw"
      id="Hidden_oH1NQJf7jEaRneoPXDn_6A">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw"
      id="Hidden_XtTWqNg7CkSa4uffoyvABg">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <epix:TermOfUnderwritersOption
      contextRef="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_9O-seddiG0O-DtG3IZ7HSA"
      id="Hidden_AZRAwVMkb0-1Z3ZiwRVKQw">P30D</epix:TermOfUnderwritersOption>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="INF"
      id="Hidden_jETlY65jEkmfBRASRzirag"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">32064411</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="INF"
      id="Hidden_MU1HXvcdzECgRj3WjIKibw"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">43984346</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Hidden_I8yCBUa3N0W0JSccZZb-kw"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-34349</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Hidden_Y6jwuf91OUyOdeLUzsBsTA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-288647</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Hidden_qGTwKPFLwU6oUyoQmQDV4A"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">37920</us-gaap:IncomeTaxExpenseBenefit>
    <epix:UnitsIssuedInPrivatePlacementConversionRatio
      contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EclFUGrZHEu0hCdXhGSRtg"
      decimals="INF"
      id="Hidden_zEYEXFo-FkWGt12ydoujMA"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.5</epix:UnitsIssuedInPrivatePlacementConversionRatio>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_AwDd63Q7NkqPQFm-VTNjkw"
      id="Hidden_qojYrx_Z1UW0vuZx-arG5A">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_TwoYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_7TyLnsxiZkm33Ed-1uTPOw"
      id="Hidden_EsUTpCDv1Eui8u7BVbNk7g">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <epix:TermOfUnderwritersOption
      contextRef="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg"
      id="Hidden_jpTTNPtrr0yX_oiBe_gYnw">P30D</epix:TermOfUnderwritersOption>
    <dei:DocumentType
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_jKyefAlw3UeykAetHgdqbA">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_ggk0HrcwZUaZBCw2hP8ezw">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_DLEtlkYb8E6dzQJA9svmFQ">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_FOjiIGS4yEePX0umJt9DGg">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_qfzGatCz-0uqm2d0wCc2rw">001-37410</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_xh0yK7XxZ0auxhG8xBe9zw">ESSA Pharma&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_WNoOF2AfdE6Q6uPC8jW2ZQ">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressCountry
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_MkeKbz19zkCn_FLXboLBQQ">CA</dei:EntityAddressCountry>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tc_nAmP3VugO0iKerfHqoXhXA_1_1">47-2569713</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_Rp_gOw2oA0maaHi6kS0Y1w">Suite 720</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_UdbQTGJRH0KZDQoXO7RRXA">999 West Broadway</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_FnJUKDZqmE-TEwEuQxH07A">Vancouver</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_KT0ivOLqAkq-vaNDWRQeDA">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_XD31pMqfs0-fI1qV1jUowA">V5Z 1K5</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_T1rVB6xk5kaXa-A9apfoxw">778</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_TsM2TD1pDUuF4VI0AfNkVw">331-0962</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tc_xz9_PE8X7U-kk615-soo1g_2_0">Common Shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tc_9ukBP23gd02_A6Ufl43XXg_2_2">EPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_xVdinSWeo0KvHd0eOYLLOw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_QjtqGzyQ8k6E1DP0GMBVwg">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_Aa1ZimF7ckWBuVZuMvqgmA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_P1S_kRU850KQEAXRfdwCJg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_f-hOahE_uUKxdM6zcS5agg">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tc_cq1bpCWJDU-fG1rBWSU1xw_1_0">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tc_uubHWEnrRU6EKHVoqMYDsQ_2_4">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tc_lF5bMtxghUmUlERbi-jwNg_3_4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_ITVVf5L48EaoEwalwRKzRQ">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Narr_hkPb24hP40uBRc5Nus4jPg">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_3_31_2021_3J-meWS_KUKrbz1_u2iGlw"
      decimals="-5"
      id="Narr_6rB7L9l6gEO_So-GMfHOjg"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">915900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_18_2021_iz31dcV6aUOIbNIDv5A8Qw"
      decimals="INF"
      id="Narr_M1y6-1zWYEqgK5GVIlwjzw"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">43984346</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_Euhj1Mz5yUqV046gkOVB-A_7_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">137825024</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_oXJR9UfEN0GEaRjfKyyPVg_7_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">56320763</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_Jl6DQfTzHkykSlNfEe_9Dw_8_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">57102159</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_tISGrD9UI0OviWYqHpJLvw_8_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">22011337</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_bd-WodXH0kOO-DB_0u6enw_9_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">489012</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_fFtW49RqXE2VxikQpqkHtw_9_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">309538</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_RIg4K2BAZkKcgK6BxuXW5A_10_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2181882</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_sP0PzynIQEixiJ-HSgVBeA_10_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1600128</us-gaap:PrepaidExpenseCurrent>
    <epix:OperatingLeaseRightOfUseAssetsCurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_-PJQUkhRRkepxAGldjJ7Aw_11_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:OperatingLeaseRightOfUseAssetsCurrent>
    <epix:OperatingLeaseRightOfUseAssetsCurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_UJoYL5HimkuQ9P1J6mY37g_11_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">55162</epix:OperatingLeaseRightOfUseAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_3-k__joZ5U6YVhPtttVwEw_13_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">197598077</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_DhFhr6SrTEWwcEHHBkZ3Zg_13_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">80296928</us-gaap:AssetsCurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_-4_4mvPTxkeNP4cMQBVM9Q_15_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">259455</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_IhGRQWEM9U2KPeNG3PVGQg_15_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">277637</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_O86ZSdZbSkSuo-SPYuFLMA_16_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">308286</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_ZqJS3zdEZE2w8aydWUoZNQ_16_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_UBP9phsBiUCWC7OD0oP94w_18_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">198165818</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_R-o21wz46kqXIwLsez3AWA_18_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">80574565</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_Gv3NmvlLmE-kUYs8zLkp4w_23_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3808944</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_RY4CJN_zTUu87_tmYRZdzA_23_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1144230</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_OGih-VpdGUKNh-Fix_4_cw_24_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">120719</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_h385ElsEmkaQJTxw4lFXZA_24_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">59094</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_aq80aBGnKE-sOloVLU0tUQ_26_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3929663</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_WSZI36yPLUOBWLjD13VnoQ_26_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1203324</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_WMOQ5-4BTESpCKHIK4S5RQ_28_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">20352</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_AFEE7_JMOEWZjx7HbAy4fQ_28_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">127376</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_JsAxQZ_P7EufkiEiREufJw_29_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">210251</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_pgZVm-xxKkCkH7LQN79rIg_29_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_qYbsNmhSC0Oeo-lKLW9_Ig_31_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">4160266</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_WxPnAtDEFUGv4rs7jD2ojw_31_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1330700</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="INF"
      id="Narr_KyTANoU_sk6cbJ9WN7YWLw"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">43984346</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="INF"
      id="Narr_aoJuDU5ChE2WYB7gClMKAQ"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">32064411</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_ZWZVpVaTo0Ce-wA7nSPL4w_37_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">277415176</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_gkpRhYl6TUaP-YjHL2rPPQ_37_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">131086364</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_CGBhUkYMvU-7I7__tQg_cA_38_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">36442620</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_3Me9W2S_qUisU_Vj0-_YgA_38_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">31204284</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_SjM83KoyUUqUHMXSLLQW2w_39_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-2076479</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_gUCn5GaJpUyARuFJi5dBbg_39_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-2076479</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_-wamogYAwkqZY20YkZRQzw_40_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-117775765</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_WTE4-uNLjkOqa-ZFf2RdVQ_40_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-80970304</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_fDdrr4-ItkiBN1eiwY0zdg_42_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">194005552</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_jeNcrDAuuUeFb8EGSdH9Jw_42_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">79243865</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc__sHj1-Kjkk-QXW48icL9-w_44_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">198165818</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_j0urWbcx20aqHeDAcoXsDg_44_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">80574565</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_zFcdYIaLkEmbMtHMfjDj6g_7_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">24258989</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_xdR3s5RNCUi3LaH7EZKVQA_7_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">12145968</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_TU0cqi2emUygUypaI2DOUw_7_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">6696234</us-gaap:ResearchAndDevelopmentExpense>
    <epix:FinancingCosts
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_l72TRPS23U2FqhkSlU_Hsw_8_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">22220</epix:FinancingCosts>
    <epix:FinancingCosts
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_m0Jb581RGkuxiOAAa2d35A_8_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">618109</epix:FinancingCosts>
    <epix:FinancingCosts
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_cqeh5c4HEkirspH_pdPP7w_8_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">602744</epix:FinancingCosts>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_AKhiALs_2USDZTxErKDSPQ_9_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">12884581</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_TlzUVd3bqk-2cyqaIDYRFA_9_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">11373952</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_CqFGm6E1jE6M5PqncVBLFg_9_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">5455189</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_7yQ81RovNkG1WUDoWX-9Hg_11_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">37165790</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_CY0eTTxK3UOm2q0UR6UzQA_11_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">24138029</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_kGxmZokYt0K4QyR9m6NKkQ_11_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">12754167</us-gaap:OperatingExpenses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_jyhlDdCn2UqX1hZ9t5n7dg_13_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-16041</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_aJWd8qL5cUKx2Oyjsss6SQ_13_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-44851</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_PkN_UXB2gEyINX-dZs5ZBA_13_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">7845</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc__8aDzO9azUOR44sCknXwJg_14_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">234997</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_Isx30LuFV0CqLnonvpNAWQ_14_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">559719</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_g4omYabbBEuCTUWpgg-Rfg_14_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">26251</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_Gu0qNKX_lkia-nZ5Y8ZxLA_15_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">107024</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_Z0FfiRxOTESAiQibWUhOhg_15_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-110856</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_7ge6eg2OQ0CvEpuboYf_KA_15_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1159</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_mgGrg92rGkK3xrabiaW1_g_17_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-36839810</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_CTqjwJMi1UKaJMwgEZPfug_17_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-23734017</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_nhFDQLl11UShfYf1h_K9QQ_17_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-12718912</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_Wtu5VHtfFEmAouLIp0Rr7w_19_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-34349</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_kEZdiX_uU0iShUeKNNafSQ_19_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-288647</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_hgEGkLD0qUO0Wj38_QX70w_19_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">37920</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_aAvLeiQ6TUOnKMER5jRMiw_21_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-36805461</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_3L3YBYHzYE-f8DMtqg7VbA_21_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-23445370</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_A8lPeIWpwUqIm25wvfWHEw_21_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-12756832</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="2"
      id="Tc_wmARO_RkMkCfgNByVoUtwQ_23_3"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">-0.96</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="2"
      id="Tc_4-CH7hRBGEScizgVkl-7ZQ_23_6"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">-1.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="2"
      id="Tc_5HiuQKkHZEGb3o95X-761A_23_9"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">-1.51</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_86D2vwR_MkGyx1KDNQpLJg_25_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">38480378</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_kc2hv90jPU23Mam22zui2g_25_6"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">22443893</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_y3rq5pM1NU6K64U_aFXuzg_25_9"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">8433441</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_suulakwyrUS3no9gMmTMYw_4_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-36805461</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_4dABUYvMNkaJYpnxaegXCw_4_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-23445370</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_PeGNpVsLbkqtgSGue0iSVQ_4_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-12756832</us-gaap:NetIncomeLoss>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_VYVoraCaxkuxKDhTyAI0vA_6_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">109464</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_UQrY2ik7Y0iM2ar4pAqdIQ_6_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">110324</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_mA7-2Hjk2kKnx7K8KJ72Vw_6_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionExpense
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_9fD5ZvFCi02JpJv-_jIhKQ_7_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">9570</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_m2x9mK2ymkO0izBJSFovkQ_7_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">12992</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_8VJHNyq_KEetc0yOPbITQA_7_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:AccretionExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_-V1aZm3tC0CrCH14GBc8tg_8_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">107024</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_SYaCf_b0-UOQs5h_PxEH1g_8_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-110856</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_WaGY6moSkUCNTYgtRmbvmw_8_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1159</us-gaap:DerivativeGainLossOnDerivativeNet>
    <epix:IncomeTaxExpenseRecoveryOperatingActivities
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_o6Gu5DYgQkWSD1XOT5QLeg_9_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:IncomeTaxExpenseRecoveryOperatingActivities>
    <epix:IncomeTaxExpenseRecoveryOperatingActivities
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_KWqlyRf7jkyZJLsE6AND-w_9_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">280000</epix:IncomeTaxExpenseRecoveryOperatingActivities>
    <epix:IncomeTaxExpenseRecoveryOperatingActivities
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_r0rc7qbb7kOA8dYBrTe4jA_9_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:IncomeTaxExpenseRecoveryOperatingActivities>
    <epix:InterestIncomeOperatingActivities
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_QFZewL6xukOunP8tCpAMmQ_10_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">76056</epix:InterestIncomeOperatingActivities>
    <epix:InterestIncomeOperatingActivities
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_zEUQe7zlwkSf5REJ8Y5Tog_10_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:InterestIncomeOperatingActivities>
    <epix:InterestIncomeOperatingActivities
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_eoXu__LIkUynUbbOzFpsPQ_10_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:InterestIncomeOperatingActivities>
    <epix:FinanceExpenseOperatingActivities
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_2fGeyNuuQ0C88nw8-b64ww_11_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">31192</epix:FinanceExpenseOperatingActivities>
    <epix:FinanceExpenseOperatingActivities
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_j1LuGxeAsUufjg0ynutg3A_11_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">211079</epix:FinanceExpenseOperatingActivities>
    <epix:FinanceExpenseOperatingActivities
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_LY3mhQK240WPTmz2MKczWw_11_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">602744</epix:FinanceExpenseOperatingActivities>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_w5YJ-rUJgEeUm06uWRddHw_12_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_3l-wUYxZXE-w29TF51uLVw_12_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-13059</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_ISurLJkhe0mCF4edh5AQsw_12_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-16457</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_VvEobFg8402zIwrUSVzJvQ_13_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">9476113</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_ZDPhiwl4CU6gx22ingOzfg_13_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">7522608</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_qJ55nHGzv0OsFpWFmi52AA_13_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1146707</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_Md3LtCxslEGLFVMO8sw04A_16_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">157575</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_errh-n4Sd0ucjKaT4Qc-BA_16_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-89938</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_wZZDpPN2gk-tDPFigI9DNg_16_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">59665</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_yRBtS4XhaEGEaU99BdN9dQ_17_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">563572</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_cAsCvE7SjE-H49WQAdX5lQ_17_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1262280</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_TGFnjl965UadYCrncOFKaQ_17_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">179416</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_pPdaSi9NJ0eB-vTa-Kp3rw_18_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2667738</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_1jHyb66yaEiY51u0L8RejQ_18_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-46358</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_2qTWb0y6sUmiuM05Enya8Q_18_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-1014049</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_8mgKeFxR7UWnv9xnV0UAUw_19_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_zqYODgs29EKaK_0gL_kwjg_19_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-20000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_OZEDPuiA-k2sSDc5sWYd3A_19_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-4722</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_IzzwxiLnMEamTBEhTinktA_21_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-25415611</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_xQ5jkAKRt0aONlP9vgMxyw_21_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-16983152</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_cJxRrVCJiUyrQDv90aNedQ_21_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-12249935</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromOtherDeposits
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_8Rm4oLOYyEuPHupG8WWPpA_24_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:ProceedsFromOtherDeposits>
    <us-gaap:ProceedsFromOtherDeposits
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_Et4T-oruFU20NnMxI583xg_24_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">274085</us-gaap:ProceedsFromOtherDeposits>
    <us-gaap:ProceedsFromOtherDeposits
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_ojGhSQ8470-8h--weP0m-A_24_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">201399</us-gaap:ProceedsFromOtherDeposits>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_ZmMNWyFFoUaBuxf_n1PYpQ_25_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">57026103</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_1fVqe5v_X0mD7CgY8A2MoA_25_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">22011337</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_su6_AkBzukKEDMbn2SErFQ_25_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_9q3CN3i8CkekzDuFiAW6iw_26_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">22000000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_CQFv3hEQkUOp8jhj0d4ZUA_26_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_5ITSpjwg90aia2yqXTUVZg_26_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <epix:InterestFromShortTermInvestments
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_Tcg9L4F4uU-JBN9P1k4mkg_27_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">11337</epix:InterestFromShortTermInvestments>
    <epix:InterestFromShortTermInvestments
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_eS0ETEP08keEtIjG4R7uWQ_27_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:InterestFromShortTermInvestments>
    <epix:InterestFromShortTermInvestments
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_ODJyMuJyYUah-UEws7uEuQ_27_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:InterestFromShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_z2oxKHm-gEupyDzN4lv9RQ_29_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-35014766</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_qMZpTrPVO0iAvt_g5ysPuw_29_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-21737252</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_vViB0Bb2IUufcACu1OwHqw_29_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">201399</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <epix:CashAcquisitionFromAcquisitionOfBusiness
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_CqBHjjDAyEKvYFN3RLdmjg_32_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:CashAcquisitionFromAcquisitionOfBusiness>
    <epix:CashAcquisitionFromAcquisitionOfBusiness
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_Hnb07zHIpkeGu_WGFAQibg_32_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:CashAcquisitionFromAcquisitionOfBusiness>
    <epix:CashAcquisitionFromAcquisitionOfBusiness
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_bemKBnUD0kOAMrRkHL_b5w_32_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">22244248</epix:CashAcquisitionFromAcquisitionOfBusiness>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_cak59ALNWUKK8k4jbaVqZQ_33_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_eHUkS1MpGEunczZlDp3p5A_33_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">64804</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_4PJNpB6LZE2obuza7hB0qw_33_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1860341</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <epix:PaymentOfSubleaseTerminationCosts
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_kvLMniv0TkqVqi4ApC7pkw_34_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:PaymentOfSubleaseTerminationCosts>
    <epix:PaymentOfSubleaseTerminationCosts
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_SSfyT6Ge-Eq68m7a1R7RjA_34_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:PaymentOfSubleaseTerminationCosts>
    <epix:PaymentOfSubleaseTerminationCosts
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_TwnnhOH8XUGEaB0edSGK8A_34_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">246906</epix:PaymentOfSubleaseTerminationCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_CoqLW24YQEerKcGz_W9SzA_35_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">149999985</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_smxczNMpeE2mk4WWDVCfsQ_35_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">48990000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_7ksvCxBfUk2wYAdEt7iJ8g_35_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">36000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_vicUNAs4gkaovQKQ3ckjXA_36_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">9229450</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_bCma0vTRk0KPhiRD-NYJwQ_36_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3447954</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_9eTfwaA6ZUOZ5Q7Z5lAoCw_36_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2362329</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_F4DKonoJl0ymloL8BX4X9g_37_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1186833</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_7x5ipA5WaU2WCptvaNChWg_37_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">915</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_BVHsT9e4NEKOOfWeRXmCpQ_37_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_0OrXfnwhVEi0HBSE7Dk2pw_38_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">596</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_VCyDRLDzXUWzTpTY6UKkXQ_38_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">257172</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_fa_2sMiSnkO9utt6gEjyKQ_38_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_HQ34sss7SUm73uOW7x4Brg_39_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">133071</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_sQOn31CboEur-jTvBEbMjg_39_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">80714</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_vamDE0FYDUCtdvpVb37pdA_39_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <epix:OperatingLeasePaymentsFinancingActivities
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_XaYYj1J9x0SbzyE6iwrTnA_40_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">100282</epix:OperatingLeasePaymentsFinancingActivities>
    <epix:OperatingLeasePaymentsFinancingActivities
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_s4z7ODKY-0uzFHhyNQ29sg_40_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">119384</epix:OperatingLeasePaymentsFinancingActivities>
    <epix:OperatingLeasePaymentsFinancingActivities
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_IfXqSALHvkOOAW-x8tfOJg_40_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:OperatingLeasePaymentsFinancingActivities>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_MMUZLSzUgECEeizlh23g4A_41_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_zwAF02lGkEShjxnk8qOLFQ_41_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3199799</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_XGqTVL8y50-J-IMh0Q4kyA_41_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2808823</us-gaap:RepaymentsOfDebt>
    <epix:RepaymentsOfFinalPaymentOfDebt
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_Hb9fDzD3_0y_GnOIbDjqTw_42_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:RepaymentsOfFinalPaymentOfDebt>
    <epix:RepaymentsOfFinalPaymentOfDebt
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_WeLh4RSea0uNITYxZ4o8Pg_42_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">688000</epix:RepaymentsOfFinalPaymentOfDebt>
    <epix:RepaymentsOfFinalPaymentOfDebt
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_VvRyZlYMUkWHgtIsATZzFA_42_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</epix:RepaymentsOfFinalPaymentOfDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_AOEX1FsnK06uCa0uVSfpDQ_43_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_Eac5IR43IkONPYFQnq9tTg_43_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">32235</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_Wk_wgL5n0EmIitQGcWirIQ_43_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">401929</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_86xQRZ6QrkS_TWf-waaxMw_45_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">141990753</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_O5idSx7QNEGTE_86ClTF4w_45_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">41776625</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_bC8V7fL3f0SqhcpO49IG3Q_45_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">50563920</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_6NTJLGwdgUOGoJRE4opgrw_47_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-56115</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_ZHJ9LFnpOU24IQ-bGuzIVg_47_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-58181</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_pofZBUCkuk2g7pJTOF0ovg_47_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-21805</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_X4GT9vfCtk-JtYb9V5gLoA_48_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">81504261</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_tjwkn0m6HUueEPZQ0qGHDA_48_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2998040</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_em1Av77NTk6PKG4ZGCXYlA_48_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">38493579</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_29B2z-gshE2rFnW0XgLS2Q_49_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">56320763</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA"
      decimals="0"
      id="Tc_Oiw0q3D7OEmLWHPWMxQ6WQ_49_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">53322723</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ"
      decimals="0"
      id="Tc_HzEJmHHSXEWYNrUS2su49Q_49_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">14829144</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_A2XkIIkt0EKWMzCoygG0Nw_51_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">137825024</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_li6WA2FgTkSchmEXgvzvsg_51_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">56320763</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA"
      decimals="0"
      id="Tc_YnLCyv_idEi6PmNI82MFXw_51_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">53322723</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HeTz-es_FUOKI2zSdF0t_Q"
      decimals="INF"
      id="Tc_5P4nKoV64kim9KDRMeZh-g_6_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">5776098</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HeTz-es_FUOKI2zSdF0t_Q"
      decimals="0"
      id="Tc_g_iPJ-E65kOcFNN5OTLrvw_6_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">40205997</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UBkybJOYYUOqeW1pxoqlrA"
      decimals="0"
      id="Tc_IIkY8GLabkuaZ-BMIfSxcQ_6_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">15573597</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2GRojpFcoki1Uc0vSHlB6w"
      decimals="0"
      id="Tc_ERceFFpoOk6wsUF8PseSKw_6_11"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-2076479</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rbJc2rOPu0KwHjun-BlNLQ"
      decimals="0"
      id="Tc_fRThXwJsjUq9wSi63JZe2A_6_14"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-44768102</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ"
      decimals="0"
      id="Tc_UWfBpoFFEUCu9Rhy0RNWAg_6_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">8935013</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA"
      decimals="INF"
      id="Tc_Z1poAJ12S0e1FI79dyfRew_7_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">6718150</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA"
      decimals="0"
      id="Tc_MhsgCB2suEinmtqlGQDFpQ_7_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">20247296</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_dA_2oOcNY0Cpg64PAfqe8A_7_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">20247296</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA"
      decimals="INF"
      id="Tc_vBsquQ7iHUOYWdR3OTyFrg_8_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">6080596</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA"
      decimals="0"
      id="Tc_l3Am7cHgFEiLms9WLaM_SA_8_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">12161192</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipn3WcQ-WkyTVclyeT1LWQ"
      decimals="0"
      id="Tc_4DMtAEE1_E-16a6lDlDUJQ_8_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">23838808</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_GKsO-3FtGkiHulaU8Gf5hw_8_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">36000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA"
      decimals="0"
      id="Tc_R7kU7XmH70-sAqGoXup9IA_9_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2826443</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipn3WcQ-WkyTVclyeT1LWQ"
      decimals="0"
      id="Tc_TJhLJ2LSyEiI3XSkPlemqQ_9_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1764982</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_Z3C2HVKAak2mhnY4q8UaiQ_9_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">4591425</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <epix:PrefundedWarrantExercisedShares
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA"
      decimals="INF"
      id="Tc_HW8gji9FZ0SMWrLV7StNdg_10_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">2187530</epix:PrefundedWarrantExercisedShares>
    <epix:PrefundedWarrantExercisedValue
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uDFT_Ii8R0myiSYFTGxTTA"
      decimals="0"
      id="Tc_9k60aYrMF0u-YbcXLO17iw_10_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">8757066</epix:PrefundedWarrantExercisedValue>
    <epix:PrefundedWarrantExercisedValue
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipn3WcQ-WkyTVclyeT1LWQ"
      decimals="0"
      id="Tc_-jiSKXEdkEOLf4-AVcHNdQ_10_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-8755996</epix:PrefundedWarrantExercisedValue>
    <epix:PrefundedWarrantExercisedValue
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_IX3X9omBE0C1AeBK_kNX9A_10_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1070</epix:PrefundedWarrantExercisedValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ipn3WcQ-WkyTVclyeT1LWQ"
      decimals="0"
      id="Tc_4sPwkVMGI02lMrLcb4VQHA_11_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1146707</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_jDe4_amd0kig9ob1ndwvqQ_11_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1146707</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_uiguQmWhpEG-xHaL8MHmpA"
      decimals="0"
      id="Tc_PAoJdrzjrUyr_KWeo_KrXA_12_14"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-12756832</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_A3VuGaeh2kOtm5gRmSSdJw_12_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-12756832</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JUboWpxLbki2h1YPzqSmdg"
      decimals="INF"
      id="Tc_NnQsegkFbEm-3ELUBTMp9A_14_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">20762374</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JUboWpxLbki2h1YPzqSmdg"
      decimals="0"
      id="Tc_bqLVVW15uke-L55wsJv2Qw_14_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">78545108</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_86DwwqBAdEWFbExnOSHKzA"
      decimals="0"
      id="Tc_FC1cZQS2tUmmAfcTX3NfUw_14_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">30038134</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d_ASZ3MtTkuEthOiE92plw"
      decimals="0"
      id="Tc_YihY6JK9r0uhikNglihFXw_14_11"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-2076479</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Qsq5hVVbp0yyXHTenb2ZaA"
      decimals="0"
      id="Tc_Y4mM0lJrxUGJ-J5M3H8lng_14_14"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-57524934</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA"
      decimals="0"
      id="Tc_M65mkpH07kOSufsGwVmBTw_14_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">48981829</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA"
      decimals="INF"
      id="Tc_XBYo15E2M0ibV-bnLI4UQw_15_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">8165000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA"
      decimals="0"
      id="Tc_EkW060Aj1E60my-8uCgZpw_15_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">48990000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_z731uxeh8kWHJ6vWwStf_Q_15_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">48990000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA"
      decimals="0"
      id="Tc_l0tXJ1WvJUyIKKpc0TGhXA_16_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3136949</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93sQ70dbA0m6nn-4DY6rIw"
      decimals="0"
      id="Tc_mbfdTszyPkmPS8IViC3UZw_16_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">7054</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_I4XVeD8wTkqDrHtsD4gxHw_16_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3144003</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <epix:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA"
      decimals="INF"
      id="Tc_c4U2ngXmZ0aAZEwe_gxzsw_17_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">3120115</epix:StockIssuedDuringPeriodSharesWarrantsExercised>
    <epix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA"
      decimals="0"
      id="Tc_jfYHHDTKfEmGJgJzyvY_2w_17_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">6549631</epix:StockIssuedDuringPeriodValueWarrantsExercised>
    <epix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93sQ70dbA0m6nn-4DY6rIw"
      decimals="0"
      id="Tc_oelGudUID0aT7NHXPhvV5Q_17_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-6292459</epix:StockIssuedDuringPeriodValueWarrantsExercised>
    <epix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_97chih8ZLkiLSnzzig2qBg_17_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">257172</epix:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA"
      decimals="INF"
      id="Tc_utph5Htsx0CCjm5WkdvJDw_18_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">416</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA"
      decimals="0"
      id="Tc_GiBcW1N7IE-a9iusjH7hXQ_18_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1648</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93sQ70dbA0m6nn-4DY6rIw"
      decimals="0"
      id="Tc_NOFi0oMxuUCveK4kenNmZA_18_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-733</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_QixIh14IV0S30VAUfSK3xA_18_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">915</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA"
      decimals="INF"
      id="Tc_IAcTn24ZWUS4fIq4zZQcyA_19_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">16506</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1hOcEHYkLkqXRlyeAvcIwA"
      decimals="0"
      id="Tc_pPgZz4WKbUmMTpyNMLD3pg_19_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">136926</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93sQ70dbA0m6nn-4DY6rIw"
      decimals="0"
      id="Tc_S1suUJSOFUyM73GF2b2j_g_19_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-56212</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_xe3GPan1xUWSU-IUHDti5w_19_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">80714</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_93sQ70dbA0m6nn-4DY6rIw"
      decimals="0"
      id="Tc_ByF-lkXAlE2aRKNJVx-klw_20_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">7522608</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_u3CoKSggHk6aihX2vRjkWA_20_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">7522608</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RPs6X-s5OUmfzGYNLQRNYw"
      decimals="0"
      id="Tc_F90ULODYYEKcW_9v9GBAIg_21_14"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-23445370</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_Swo-2fH7nki8dwJFlaoA8A_21_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-23445370</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iCrDPxN440W6E11tKIReqA"
      decimals="INF"
      id="Tc_Cunii9_-pU--_vZqBpI68Q_23_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">32064411</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iCrDPxN440W6E11tKIReqA"
      decimals="0"
      id="Tc__6F-m0RMC0uoWw3ibu1XwA_23_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">131086364</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GwqowEA_CUeSgGO-fqQICA"
      decimals="0"
      id="Tc_f4qnhKEsdE6U5SqMxUr9cw_23_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">31204284</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_iDxFp3CBoUyduJ7ED7-iBw"
      decimals="0"
      id="Tc_l--k__cjT0mkua4Rxl_erQ_23_11"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-2076479</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_r3QV4PsPVU2qBc_HlNDLwA"
      decimals="0"
      id="Tc_s2SYsCBoLU2bN5D3OLgD3g_23_14"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-80970304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_QupzEiHQ90u6zzFAStCpsw_23_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">79243865</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ"
      decimals="INF"
      id="Tc_69g2g5qn90aHzlRJYFLVLw_24_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">5555555</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ"
      decimals="0"
      id="Tc_YGbjrxuaQUebMolFdxG82w_24_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">149999985</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_4acXuV5DTESAR0-NMzzKeg_24_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">149999985</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ"
      decimals="0"
      id="Tc_koIXb3HaSE6XE7RI_bjbwg_25_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">9229450</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_Pg9YToE5KES-nqfvmRYrWw_25_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">9229450</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <epix:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ"
      decimals="INF"
      id="Tc_YNOhge2kmkKipFFNvP5Hdw_26_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">6024807</epix:StockIssuedDuringPeriodSharesWarrantsExercised>
    <epix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ"
      decimals="0"
      id="Tc_nF2T7mUUIE-ZLBctgUDsBw_26_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3254460</epix:StockIssuedDuringPeriodValueWarrantsExercised>
    <epix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jbYIpU0s4Uy0gHFtYiCEog"
      decimals="0"
      id="Tc_Zl247r9RKUSHfRIDwTPoiA_26_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-3253864</epix:StockIssuedDuringPeriodValueWarrantsExercised>
    <epix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_y_6JuCOK-UWV26uxeSyHiw_26_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">596</epix:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ"
      decimals="INF"
      id="Tc_16VikJCX1Uu9M0ZxgBF9Og_27_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">323610</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ"
      decimals="0"
      id="Tc_5RFQO647R0Gp15vKUsn5MQ_27_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2105467</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jbYIpU0s4Uy0gHFtYiCEog"
      decimals="0"
      id="Tc_v3nTkQbeM06SYPTSVNdQXg_27_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-918634</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_Mi9dEkYQgEO7rk7tTlCDJg_27_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1186833</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ"
      decimals="INF"
      id="Tc_7VK9zL24gE2AAAKn9--UMA_28_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">15963</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NggNsB55_USYd-RZpyJzpQ"
      decimals="0"
      id="Tc_2cL3EktA_kq_sNZ8ZJqsBw_28_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">198350</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jbYIpU0s4Uy0gHFtYiCEog"
      decimals="0"
      id="Tc_IeZoFMg7ekGzmc1Q31mJdw_28_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-65279</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_r6MdyUoWz0qAIfV2VjEgVg_28_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">133071</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jbYIpU0s4Uy0gHFtYiCEog"
      decimals="0"
      id="Tc__CX9KMufwke1fAJt7KhVmw_29_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">9476113</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_jPobs12dtk6rNqVRP2jlFA_29_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">9476113</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9blgNKOQw0-dAjx9wbg0OA"
      decimals="0"
      id="Tc_v8UhPxcVvU6J8KurO2jZ1g_30_14"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-36805461</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_cedGW7eN2kmAieG3Rf0cCA_30_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-36805461</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0yAp7cE-MUSaXxmCP5yQmA"
      decimals="INF"
      id="Tc_Byy4aSeh3UmFegPoEJ8T0w_32_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">43984346</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0yAp7cE-MUSaXxmCP5yQmA"
      decimals="0"
      id="Tc_LEdB5F2tVUiLZOObcWJjoA_32_5"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">277415176</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Qr_emV94JEaOw_wTone2GA"
      decimals="0"
      id="Tc_JoceRYSs5UGaAxVp74LGsw_32_8"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">36442620</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QEC_5wIz9U2D4cVesXTV0A"
      decimals="0"
      id="Tc_oFuh4DGqTEavlGvRT8SmVg_32_11"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-2076479</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Xn7g0Te520GAvoVLIuOBjQ"
      decimals="0"
      id="Tc_f1GUlRLFfUuDb2PBS7dzhQ_32_14"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-117775765</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_vFMX8rP0sEeY8RPdJ57B5A_32_17"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">194005552</us-gaap:StockholdersEquity>
    <us-gaap:NatureOfOperations
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_uIF-98fBck2gH-q8PWRlfg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1.&#160;&#160;&#160;&#160;&#160;NATURE OF OPERATIONS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Nature of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;ESSA Pharma&#160;Inc. (the &#x201c;Company&#x201d;) was incorporated under the laws of the Province of British Columbia on January&#160;6, 2009. The Company&#x2019;s head office address is Suite&#160;720&#160;&#x2013; 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;th&lt;/sup&gt;&#160;Floor at 595 Burrard Street, Three Bentall Centre, Vancouver, BC, V7X 1L3. The Company is listed on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;) under the symbol &#x201c;EPIX&#x201d;. On October 30, 2020 the Company&#x2019;s common shares delisted in Canada from the TSX Venture Exchange.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (the &#x201c;NTD Technology&#x201d;) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As at September 30, 2021, no products are in commercial production or use.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Acquisition of Realm Therapeutics plc&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On July&#160;31, 2019, the Company acquired all of the issued and outstanding shares of Realm Therapeutics plc (&#x201c;Realm&#x201d;) pursuant to a Scheme of Arrangement as sanctioned on July&#160;29, 2019 by the High Court of Justice in England and Wales (the &#x201c;Realm Acquisition&#x201d;) (Note&#160;4).&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1
      contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA"
      id="Narr_SNaH69tqsEq0p4M3dkjT5A">2019-07-31</us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity
      contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA"
      id="Narr_0QOTSXVpUk6t1PwlJwTxHA">Realm Therapeutics plc (&#x201c;Realm&#x201d;)</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_flD09CbtFEuWTbskZbCcSw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2.&#160;&#160;&#160;&#160;&#160;BASIS OF PRESENTATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;These accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;All amounts expressed in these accompanying consolidated financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise indicated. References to &#x201c;$&#x201d; are to United States dollars and references to &#x201c;C$&#x201d; are to Canadian dollars.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of Consolidation and Functional Currency&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Consolidation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounts of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated upon consolidation. The consolidated financial statements comprise the accounts of ESSA Pharma&#160;Inc., the parent company, and its wholly owned subsidiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Functional Currency&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency of an entity is the currency of the primary economic environment in which the entity operates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The functional currency of the Company and its subsidiaries have been determined as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Country of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effective&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Functional&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESSA Pharma&#160;Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Canada&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESSA Pharmaceuticals Corp.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;USA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Realm Therapeutics plc &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Pound Sterling&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Realm Therapeutics&#160;Inc. &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;USA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;In the process of liquidation and dissolution as at September 30, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liabilities, the valuation of equity instruments issued for services, income taxes and the product development and relocation grant. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Income tax&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Derivative financial instruments&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;Certain warrants are treated as derivative financial liabilities. The estimated fair value, based on the Black-Scholes model, is adjusted on a quarterly basis with gains or losses recognized in the statement of loss and comprehensive loss. The Black-Scholes model is based on significant assumptions such as volatility, dividend yield, expected term and liquidity discounts (Note&#160;10).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Share-based payments and compensation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying common shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note&#160;11.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_ltpxfEnljUqPyN1J1GXGQQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;These accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;All amounts expressed in these accompanying consolidated financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise indicated. References to &#x201c;$&#x201d; are to United States dollars and references to &#x201c;C$&#x201d; are to Canadian dollars.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_MLc7S-VKY0G7txkBoOnuCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of Consolidation and Functional Currency&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Consolidation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounts of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated upon consolidation. The consolidated financial statements comprise the accounts of ESSA Pharma&#160;Inc., the parent company, and its wholly owned subsidiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Functional Currency&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency of an entity is the currency of the primary economic environment in which the entity operates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The functional currency of the Company and its subsidiaries have been determined as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Country of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effective&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Functional&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESSA Pharma&#160;Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Canada&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESSA Pharmaceuticals Corp.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;USA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Realm Therapeutics plc &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Pound Sterling&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Realm Therapeutics&#160;Inc. &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;USA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;In the process of liquidation and dissolution as at September 30, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_Q9NQIz_aJEy3At9rVqJmoA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The functional currency of the Company and its subsidiaries have been determined as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Country of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effective&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Functional&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESSA Pharma&#160;Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Canada&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;ESSA Pharmaceuticals Corp.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;USA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Realm Therapeutics plc &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Pound Sterling&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Realm Therapeutics&#160;Inc. &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;USA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;US Dollar&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;In the process of liquidation and dissolution as at September 30, 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;</epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock>
    <epix:PercentageOfEffectiveInterestInSubsidiaries
      contextRef="Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_XOz0eBSbkU2BL3yWpajTpA"
      decimals="2"
      id="Tc_bAekOqqNPEyTai9hs8g9nA_5_4"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">1</epix:PercentageOfEffectiveInterestInSubsidiaries>
    <epix:PercentageOfEffectiveInterestInSubsidiaries
      contextRef="Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_RealmTherapeuticsPlcMember_F9zuOVt_vk2IQHvJ990kRA"
      decimals="2"
      id="Tc_K14zwJy55Uq4cQYMPD8rMw_6_4"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">1</epix:PercentageOfEffectiveInterestInSubsidiaries>
    <epix:PercentageOfEffectiveInterestInSubsidiaries
      contextRef="Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_RealmTherapeuticsIncMember_spJ0dJs8xkexamG5z198jQ"
      decimals="2"
      id="Tc_s9RGm99OcEe4oSZk0L9Q3w_7_4"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">1</epix:PercentageOfEffectiveInterestInSubsidiaries>
    <us-gaap:UseOfEstimates
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_6nwV0_QZskyVJvCZRXxEug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liabilities, the valuation of equity instruments issued for services, income taxes and the product development and relocation grant. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Income tax&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Derivative financial instruments&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;Certain warrants are treated as derivative financial liabilities. The estimated fair value, based on the Black-Scholes model, is adjusted on a quarterly basis with gains or losses recognized in the statement of loss and comprehensive loss. The Black-Scholes model is based on significant assumptions such as volatility, dividend yield, expected term and liquidity discounts (Note&#160;10).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Share-based payments and compensation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying common shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note&#160;11.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_gTyJ3oQBrUiA7kCEvM2sLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3.&#160;&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist primarily of cash in banks and high-interest savings accounts and cash collateral which are recorded at cost, which approximates fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-term investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s short-term investments consist of guaranteed investment certificates and term deposits with original maturities exceeding three months and less than one year. The investments are recorded at cost plus accrued interest, which approximates fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Foreign exchange&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions in currencies other than the United States dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are included in comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;On translation of the entities whose functional currency is other than the United States dollar, revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Assets and liabilities are translated at the rate of exchange at the reporting date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;Translation gains and losses are recorded in other comprehensive income (loss) as the cumulative translation adjustment along with the historical effects of a change in the functional currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Government assistance&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Government grants, including grants from similar bodies, consisting of investment tax credits are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Research grants that compensate the Company for expenses incurred are recognized in the statement of operations and comprehensive loss on a systematic basis in the same&#160;years in which the expenses are recognized. Grants that compensate the Company for the cost of an asset are recognized on a systematic basis over the useful life of the asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Research and development costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Expenditures on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred. Investment tax credits related to current expenditures are included in the determination of net income as the expenditures are incurred when there is reasonable assurance they will be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Fair Value of financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities, long-term debt and derivative liabilities. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides disclosures that enable users to evaluate (a)&#160;the significance of financial instruments for the entity&#x2019;s financial position and performance; and (b)&#160;the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and at the date of the statement of financial position, and how the entity manages these risks.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 1&#160;&#x2013; quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 2&#160;&#x2013; inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:40.3pt;margin:0pt 0pt 12pt 0pt;"&gt;directly (i.e., as prices) or indirectly (i.e., derived from prices); and&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 3&#160;&#x2013; inputs for the asset or liability that are not based on observable market data (unobservable inputs).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of cash and cash equivalents, receivables and accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The derivative liabilities are measured using level 3 inputs (Note 10).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Share-based payments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Share based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity settled share-based payment transactions and measured at the fair value of at grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Share-based compensation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company grants stock options to acquire common shares of the Company to directors, officers, employees and consultants. The Company has elected to early adopt ASU 2018-07 which treats the measurement of employee and nonemployee options similarly and has been applied to all periods presented. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of stock options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the requisite service or vesting period as applicable. Consideration paid for the shares on the exercise of stock options is credited to share capital. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basic and diluted loss per share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per share is computed by dividing the loss available to common shareholders by the weighted average number of common shares outstanding during the&#160;year. The computation of diluted earnings per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the &#x201c;if converted&#x201d; method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the weighted-average method. Since the Company has losses, the exercise of outstanding options and warrants has not been included in this calculation as it would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one&#160;year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of a lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the assessment unless there is reasonable certainty that the Company will renew.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at period end.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Deferred tax is recognized in respect of temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes and an excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary that is essentially permanent in duration.  The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted at the financial position reporting date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A valuation allowance is recognized for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets are reviewed at each reporting date and a valuation allowance is recorded to the extent that it is no longer more likely than not that the related tax benefit will be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent accounting pronouncements adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2018-18&#160;&#x2013; Collaborative Arrangements (Topic 808)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;In November 2018, the FASB issued ASU 2018-18, &#x201c;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#x201d;. This ASU: (i) clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer, (ii) provides guidance specifying that a distinct good or service is the unit of account for evaluating whether a transaction is with a customer, and (iii) precludes a company from presenting transactions with a collaborative arrangement participant that are not in the scope of ASC 606 together with revenue from contracts with customers. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020. The Company will present collaboration revenue separate from product revenues. The adoption of this new accounting standard did not have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2018-15&#160;&#x2013; Intangibles &#x2013; Goodwill and Other (Subtopic 350-40)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;In August 2018, the FASB issued ASU 2018&#x2013;15, Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350&#x2013;40). This ASU addresses the accounting for implementation costs incurred by a customer in a cloud computing arrangement that is a service contract and also adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The amendment aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020 and has applied it prospectively to all implementation costs incurred after October 1, 2020. The adoption of this new accounting standard did not have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2018-13&#160;&#x2013; Fair Value Measurement (Topic 820-10)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820-10): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (&#x201c;ASU 2018-13&#x201d;), which changes the fair value measurement disclosure requirements of ASC Topic 820, Fair Value Measurements and Disclosures. Under this ASU, certain disclosure requirements for fair value measurements are eliminated, amended or added. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October&#160;1, 2020. The adoption of the standard had no impact on the Company&#x2019;s consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2019-12&#160;&#x2013; Income Taxes (Topic 740)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#x201c;ASU 2019-12&#x201d;), which simplifies the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new ASU also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company&#x2019;s consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2016-13&#160;&#x2013; Financial Instruments-Credit Losses (Topic 326)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In June&#160;2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including trade receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. This guidance is effective for annual reporting periods beginning after December&#160;15, 2019, with early adoption permitted. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company&#x2019;s consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Recently accounting pronouncements not yet adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2020-06&#160;&lt;/i&gt;&lt;i style="font-style:italic;font-weight:normal;white-space:pre-wrap;"&gt;&#x2013; Debt with Conversion and Other Options (Subtopic  470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;white-space:pre-wrap;"&gt;In August 2020, the FASB issued ASU No. 2020-06 (&#x201c;ASU 2020-06&#x201d;) &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic   815-40):   Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity.&#x201d; ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP.  Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity&#x2019;s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company&#x2019;s accounting.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2020-10&#160;&#x2013; Codification Improvements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2020, the FASB issued ASU 2020-10, Codification Improvements. The guidance contains improvements to the Codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the Disclosure Section of the Codification. The guidance also contains Codifications that are varied in nature and may affect the application of the guidance in cases in which the original guidance may have been unclear. For public business entities, the amendments in the ASU are effective for fiscal years beginning after December 15, 2020. For all other entities, the amendments are effective for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022. Early adoption is permitted. We do not expect the adoption of ASU 2020-10 to have a material impact on our consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2021-04&#160;&#x2013; Earnings per share&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40). &#160;The new ASU addresses issuer&#x2019;s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company will evaluate the impact of the pronouncement closer to the effective date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#x2019;s present or future consolidated financial statement presentation or disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_L4TDvh_oS0mY2iAhNFNrPw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist primarily of cash in banks and high-interest savings accounts and cash collateral which are recorded at cost, which approximates fair value.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_q6WvRgAP4EOv8MCaWv5lAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-term investments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s short-term investments consist of guaranteed investment certificates and term deposits with original maturities exceeding three months and less than one year. The investments are recorded at cost plus accrued interest, which approximates fair value.&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_FxnV6UerO0OMmioHjjq6Ig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Foreign exchange&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions in currencies other than the United States dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are included in comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;On translation of the entities whose functional currency is other than the United States dollar, revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Assets and liabilities are translated at the rate of exchange at the reporting date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;Translation gains and losses are recorded in other comprehensive income (loss) as the cumulative translation adjustment along with the historical effects of a change in the functional currency.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <epix:GovernmentAssistancePolicyPolicyTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_c1Fay8HhkUe463Aj0IfqCQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Government assistance&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Government grants, including grants from similar bodies, consisting of investment tax credits are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Research grants that compensate the Company for expenses incurred are recognized in the statement of operations and comprehensive loss on a systematic basis in the same&#160;years in which the expenses are recognized. Grants that compensate the Company for the cost of an asset are recognized on a systematic basis over the useful life of the asset.&lt;/p&gt;</epix:GovernmentAssistancePolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_9JmREIua5k-n-t3lKG9Lmw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Research and development costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Expenditures on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred. Investment tax credits related to current expenditures are included in the determination of net income as the expenditures are incurred when there is reasonable assurance they will be realized.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_gEtNrFvz50eees_oZ-PeLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Fair Value of financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities, long-term debt and derivative liabilities. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides disclosures that enable users to evaluate (a)&#160;the significance of financial instruments for the entity&#x2019;s financial position and performance; and (b)&#160;the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and at the date of the statement of financial position, and how the entity manages these risks.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 1&#160;&#x2013; quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 2&#160;&#x2013; inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:40.3pt;margin:0pt 0pt 12pt 0pt;"&gt;directly (i.e., as prices) or indirectly (i.e., derived from prices); and&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 3&#160;&#x2013; inputs for the asset or liability that are not based on observable market data (unobservable inputs).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of cash and cash equivalents, receivables and accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The derivative liabilities are measured using level 3 inputs (Note 10).&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_PVJPKQbVvESuwnZCtoKgWQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Share-based payments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Share based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity settled share-based payment transactions and measured at the fair value of at grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Share-based compensation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company grants stock options to acquire common shares of the Company to directors, officers, employees and consultants. The Company has elected to early adopt ASU 2018-07 which treats the measurement of employee and nonemployee options similarly and has been applied to all periods presented. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of stock options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the requisite service or vesting period as applicable. Consideration paid for the shares on the exercise of stock options is credited to share capital. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_Hqpubk9D5EudJHcafk7IHw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basic and diluted loss per share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per share is computed by dividing the loss available to common shareholders by the weighted average number of common shares outstanding during the&#160;year. The computation of diluted earnings per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the &#x201c;if converted&#x201d; method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the weighted-average method. Since the Company has losses, the exercise of outstanding options and warrants has not been included in this calculation as it would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_G0EE0efWBkiHwS7TxI-vlA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one&#160;year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of a lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the assessment unless there is reasonable certainty that the Company will renew.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_dqnjv9TJE066eOSJHBhZJg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at period end.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Deferred tax is recognized in respect of temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes and an excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary that is essentially permanent in duration.  The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted at the financial position reporting date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A valuation allowance is recognized for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets are reviewed at each reporting date and a valuation allowance is recorded to the extent that it is no longer more likely than not that the related tax benefit will be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_ZIUT_RxK20Kn3J_d-ibGtA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent accounting pronouncements adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2018-18&#160;&#x2013; Collaborative Arrangements (Topic 808)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;In November 2018, the FASB issued ASU 2018-18, &#x201c;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#x201d;. This ASU: (i) clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer, (ii) provides guidance specifying that a distinct good or service is the unit of account for evaluating whether a transaction is with a customer, and (iii) precludes a company from presenting transactions with a collaborative arrangement participant that are not in the scope of ASC 606 together with revenue from contracts with customers. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020. The Company will present collaboration revenue separate from product revenues. The adoption of this new accounting standard did not have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2018-15&#160;&#x2013; Intangibles &#x2013; Goodwill and Other (Subtopic 350-40)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;In August 2018, the FASB issued ASU 2018&#x2013;15, Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350&#x2013;40). This ASU addresses the accounting for implementation costs incurred by a customer in a cloud computing arrangement that is a service contract and also adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The amendment aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020 and has applied it prospectively to all implementation costs incurred after October 1, 2020. The adoption of this new accounting standard did not have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2018-13&#160;&#x2013; Fair Value Measurement (Topic 820-10)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820-10): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (&#x201c;ASU 2018-13&#x201d;), which changes the fair value measurement disclosure requirements of ASC Topic 820, Fair Value Measurements and Disclosures. Under this ASU, certain disclosure requirements for fair value measurements are eliminated, amended or added. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October&#160;1, 2020. The adoption of the standard had no impact on the Company&#x2019;s consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2019-12&#160;&#x2013; Income Taxes (Topic 740)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#x201c;ASU 2019-12&#x201d;), which simplifies the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new ASU also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company&#x2019;s consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2016-13&#160;&#x2013; Financial Instruments-Credit Losses (Topic 326)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In June&#160;2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including trade receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. This guidance is effective for annual reporting periods beginning after December&#160;15, 2019, with early adoption permitted. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company&#x2019;s consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Recently accounting pronouncements not yet adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2020-06&#160;&lt;/i&gt;&lt;i style="font-style:italic;font-weight:normal;white-space:pre-wrap;"&gt;&#x2013; Debt with Conversion and Other Options (Subtopic  470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;white-space:pre-wrap;"&gt;In August 2020, the FASB issued ASU No. 2020-06 (&#x201c;ASU 2020-06&#x201d;) &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic   815-40):   Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity.&#x201d; ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP.  Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity&#x2019;s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company&#x2019;s accounting.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2020-10&#160;&#x2013; Codification Improvements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2020, the FASB issued ASU 2020-10, Codification Improvements. The guidance contains improvements to the Codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the Disclosure Section of the Codification. The guidance also contains Codifications that are varied in nature and may affect the application of the guidance in cases in which the original guidance may have been unclear. For public business entities, the amendments in the ASU are effective for fiscal years beginning after December 15, 2020. For all other entities, the amendments are effective for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022. Early adoption is permitted. We do not expect the adoption of ASU 2020-10 to have a material impact on our consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;ASU 2021-04&#160;&#x2013; Earnings per share&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40). &#160;The new ASU addresses issuer&#x2019;s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company will evaluate the impact of the pronouncement closer to the effective date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#x2019;s present or future consolidated financial statement presentation or disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_40GmSPs_tEu8rDu4cPt5xg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4.&#160;&#160;&#160;&#160;&#160;REALM ACQUISITION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On July&#160;31, 2019, the Company acquired all of the issued and outstanding shares of Realm. Realm shareholders received a total of 6,718,150 common shares of the Company (&#x201c;New ESSA Shares&#x201d;) at a ratio of 0.05763 of a New ESSA Share per share of Realm (or 1.4409 New ESSA Shares for every one Realm ADS, representing 25 Realm shares). The fair value of the Realm net assets on July&#160;31, 2019, substantially all of which consisted of cash, was $20,247,296. Additionally, the Company incurred issuance costs of $1,925,145.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Realm is not considered to be a business under the definitions of ASU 2017-01; accordingly, the Realm Acquisition is accounted for as a financing transaction. The shares issued in connection with the acquisition of Realm were valued on the basis of the value of assets received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Net assets of Realm acquired:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,244,248&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Receivables and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 240,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,236,952)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total net assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,247,296&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1
      contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA"
      id="Narr_CoPC29hiNUOeJnnGzvd2HQ">2019-07-31</us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA"
      decimals="INF"
      id="Narr_1uluBOmYyEupkM5iH-8kkg"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">6718150</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <epix:BusinessCombinationConversionRatioPerShare
      contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA"
      decimals="INF"
      id="Narr_phJA7WSSbE-pMmIkjkyY4g"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.05763</epix:BusinessCombinationConversionRatioPerShare>
    <epix:BusinessCombinationConversionRatioPerAmericanDepositoryShare
      contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA"
      decimals="INF"
      id="Narr_wxLQgiKHJE24a6RUh0IpTA"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">1.4409</epix:BusinessCombinationConversionRatioPerAmericanDepositoryShare>
    <epix:BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare
      contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA"
      decimals="INF"
      id="Narr_BRXzRL7wbEaXShYZ46aAPQ"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">25</epix:BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw"
      decimals="0"
      id="Narr_1jUK4tnMCUizmNZsuEXhWg"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">20247296</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw"
      decimals="0"
      id="Narr_LlhmcA7eu0C6pdT2kykBmA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1925145</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_81gjTpZERUK1Ho4ilG31_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Realm is not considered to be a business under the definitions of ASU 2017-01; accordingly, the Realm Acquisition is accounted for as a financing transaction. The shares issued in connection with the acquisition of Realm were valued on the basis of the value of assets received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Net assets of Realm acquired:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,244,248&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Receivables and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 240,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,236,952)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total net assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,247,296&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw"
      decimals="0"
      id="Tc_3yTFIixD60qJzT_3nBglzQ_2_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">22244248</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <epix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets
      contextRef="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw"
      decimals="0"
      id="Tc_iopHfOgvwkyCPVnrAralxg_3_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">240000</epix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets>
    <epix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities
      contextRef="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw"
      decimals="0"
      id="Tc_-1UvZIuynU6bgvOSArKIxg_4_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2236952</epix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw"
      decimals="0"
      id="Tc_ru6XsfFkvkSUwY-GwGIUJA_6_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">20247296</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_8-sABns-3ky0_11m_zsF9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5.&#160;&#160;&#160;&#160;&#160;SHORT-TERM INVESTMENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term investments consist of guaranteed investment certificates (&#x201c;GICs&#x201d;) held at financial institutions purchased in accordance with the Company&#x2019;s treasury policy. These GICs and term deposits bear interest at 0.22%-0.40% per annum and have maturities of up to 12 months.&lt;/p&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:InvestmentInterestRate
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_U1mgWv7DPEuRz4Cu7N7uCw"
      decimals="4"
      id="Narr_HT2nWraKLEm7Nmq0xAr2vg"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.0022</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_YemvLESzuEy-rvMFb5JkQw"
      decimals="4"
      id="Narr_0WtX1yWQA0KFdFGK_qtGDQ"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.0040</us-gaap:InvestmentInterestRate>
    <epix:PrepaidExpensesTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_EGUpfZ2S2ECUn4v2dEUhtA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6.&#160;&#160;&#160;&#160;&#160;PREPAIDS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,751,052&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 825,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid CMC and clinical expenses and deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 650,586&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other deposits and prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 190,317&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,181,882&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,600,128&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</epix:PrepaidExpensesTextBlock>
    <epix:ScheduleOfPrepaidExpensesTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_Io4xC7HSkEKF_RcVerVr5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,751,052&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 825,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid CMC and clinical expenses and deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240,513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 650,586&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other deposits and prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 190,317&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,181,882&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,600,128&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</epix:ScheduleOfPrepaidExpensesTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_TCnvMTmsCUeyQevqhJeqyw_4_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1751052</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_GBid3uEI6kWGp_v_xO7bPA_4_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">825014</us-gaap:PrepaidInsurance>
    <epix:PrepaidPreclinicalAndClinicalExpensesAndDeposits
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_vX4sHP8M406AmXN-Abf2jQ_5_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">240513</epix:PrepaidPreclinicalAndClinicalExpensesAndDeposits>
    <epix:PrepaidPreclinicalAndClinicalExpensesAndDeposits
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_00cwCX9ob0az8D0mLcq_nw_5_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">650586</epix:PrepaidPreclinicalAndClinicalExpensesAndDeposits>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_jDxWXlFvuUWin94RmhsbZw_6_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">190317</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_jyPACk37t0KHXJxtjzcl9g_6_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">124528</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_BE8wWjU2WUK87L9ATL1HQg_8_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2181882</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_k5A1Exwjl0Ca5onF59jkhg_8_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1600128</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_U5gGGLvqe0md8wzyR2V_uA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7.&#160;&#160;&#160;&#160;&#160;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,425,871&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 678,643&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,062,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 310,604&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 320,632&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154,983&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,808,944&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,144,230&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_ptNZxfYysEGBBiLvAwRnJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,425,871&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 678,643&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,062,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 310,604&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 320,632&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154,983&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,808,944&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,144,230&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_og6eO4xorkiFGr5a0Ivhqg_4_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1425871</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_1QFfQtgO10mG58a8LIyMOQ_4_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">678643</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_omSeYepn7Ealsj4_l6MwKQ_5_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2062441</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_sMU_GFcLik2JxTOZEIpLJA_5_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">310604</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_cgrFfluFDUalX0uRfZiz5g_6_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">320632</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_TtUQcblwdU2hjVcXLRitUg_6_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">154983</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_WZ0c_5OtbUe7YAu534NBog_8_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3808944</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_tGMax2RP10mFDhFkNGbRJA_8_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1144230</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_ShPuH3cO50-XUo__2ymyIQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;8.&#160;&#160;&#160;&#160;&#160;OPERATING LEASE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company&#x2019;s operating leases included on the balance sheet are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease right-of-use asset&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2018 and 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Addition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 165,486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,324)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,162&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Addition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 362,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (109,464)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 308,286&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2018 and 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Addition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 165,486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,992&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (119,384)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59,094&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Addition&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 362,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,570&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (100,282)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 330,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes a right-of-use asset for the right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company&#x2019;s obligation to make payments over the lease term. The present value of the lease payments is calculated using an incremental borrowing rate as the Company&#x2019;s leases do not provide an implicit interest rate. At September 30, 2021, the Company&#x2019;s incremental borrowing rate was 5.0% and the remaining lease term for the South Francisco office was 32&#160;months and Houston office was 22 months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease costs of $100,282 (2020 - $119,384) and accretion expense of $9,570 (2020 - $12,992) have been recorded in &#x201c;general and administrative expenses&#x201d; and &#x201c;financing costs&#x201d; in the statement of operations and comprehensive loss respectively.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <epix:ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_trA71C5hZE2RJQ5aM-yTbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company&#x2019;s operating leases included on the balance sheet are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease right-of-use asset&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2018 and 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Addition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 165,486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,324)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,162&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Addition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 362,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (109,464)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 308,286&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2018 and 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Addition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 165,486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,992&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (119,384)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59,094&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Addition&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 362,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,570&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (100,282)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 330,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</epix:ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA"
      decimals="0"
      id="Tc_l4NDfF7CDEibVNg_JElq9A_2_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_00qP2q4hEkunoH2xAUStyg"
      decimals="0"
      id="Tc_5E06BJ8lx0K3dNWrtsdiWA_3_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">165486</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_6faTOv_Gh0SEcai4f8dCEw_4_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">110324</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <epix:OperatingLeaseRightOfUseAssetsCurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_yiqWXcrctka6qCnxVpbY3g_6_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">55162</epix:OperatingLeaseRightOfUseAssetsCurrent>
    <epix:OperatingLeaseRightOfUseAssetAddition
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_9RYqgNJjVUu6WXQeApNCsQ_7_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">362588</epix:OperatingLeaseRightOfUseAssetAddition>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_LYx3VDwJA0GiqnCmk-aYVw_8_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">109464</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_Lrv0ujh1FUmypbObkzsD3w_10_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">308286</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA"
      decimals="0"
      id="Tc_tP8_K-8CxEuJ6dbax783qQ_14_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_00qP2q4hEkunoH2xAUStyg"
      decimals="0"
      id="Tc_2v8mm1lRqkSVOs8eK4lkEQ_15_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">165486</us-gaap:OperatingLeaseLiability>
    <epix:OperatingLeaseLiabilitiesAccretionExpenses
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_vrdwFGN_CUeDaRHTyY-ElA_16_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">12992</epix:OperatingLeaseLiabilitiesAccretionExpenses>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_uqBkjd9eV0WNjrSDjAmiiw_17_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">119384</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_Japv4df6iESeTODkJBjBHg_19_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">59094</us-gaap:OperatingLeaseLiability>
    <epix:OperatingLeaseLiabilitiesAddition
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_9yEy6ixOKEyUWb3YOjwVNA_20_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">362588</epix:OperatingLeaseLiabilitiesAddition>
    <epix:OperatingLeaseLiabilitiesAccretionExpenses
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_lhTEKEhspk6M-1cr42YAXA_21_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">9570</epix:OperatingLeaseLiabilitiesAccretionExpenses>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_7yMrPVftDkOvWf5o3XjYlg_22_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">100282</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_EiItkImhiESqfd1wmQM3AA_24_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">330970</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="3"
      id="Narr_fIBdpzmXHE6eQgpO-FlR0g"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.050</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_epix_SouthFransicoOfficeMember_X6eZYkSuvEC6FzZjAFnRZA"
      id="Narr_D_ntuHNS60iU-c3CvxrHjw">P32M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_epix_HoustonOfficeMember_ZJp_lQNFrUuwmx7ZRbXpsA"
      id="Narr_wSzNXTDWGU-LA4x6jRG5eQ">P22M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_taVuJ4126U26vyjixzsKcg"
      decimals="0"
      id="Narr_5CnXNL3bckqUDRhHWnyb7Q"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">100282</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Narr_Lw-NeLuZe025ssfWOc4grw"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">119384</us-gaap:OperatingLeaseCost>
    <epix:OperatingLeaseLiabilitiesAccretionExpenses
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_epix_FinancingCostsMember_q3XBHIhLlEORxUBDy4pazA"
      decimals="0"
      id="Narr_BnBNPgDBS0WUS2KpwU4QHg"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">9570</epix:OperatingLeaseLiabilitiesAccretionExpenses>
    <epix:OperatingLeaseLiabilitiesAccretionExpenses
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Narr_Do1SkEcIvEmKQdvseMQQxA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">12992</epix:OperatingLeaseLiabilitiesAccretionExpenses>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_eYZPmYHmkEqnJ3julhPPZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9.&#160;&#160;&#160;&#160;&#160;LONG-TERM DEBT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On November&#160;18, 2016, Silicon Valley Bank (&#x201c;SVB&#x201d;) entered into a $10,000,000 capital term loan facility agreement (&#x201c;SVB Term Loan&#x201d;) with the Company. The Company drew down $8,000,000 from the SVB Term Loan. The option to draw an additional $2,000,000 lapsed on July&#160;31, 2017.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The SVB Term Loan bore interest at the Wall Street Journal Prime Rate (&#x201c;WSJ Prime Rate&#x201d;) plus 3% per annum and with a maturity date of September&#160;1, 2020. The SVB Term Loan required a final payment of 8.6% of the amount advanced (&#x201c;Final Payment&#x201d;), due upon the earlier of the maturity or termination of the SVB Term Loan. The Company was required to make interest only payments until December&#160;31, 2017. The SVB Term Loan contained a voluntary prepayment option whereby the principal amount can be prepaid in whole, or in part, for a fixed fee if a prepayment is made on or before the second anniversary of the SVB Term Loan. In the year ended September 30, 2020, the Company repaid the SVB Term Loan in full totalling $3,708,955, comprising $3,199,799 in principal, $32,235 in accrued interest, $211,079 in financing costs and the Final Payment of $688,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the $8,000,000 draw, the Company granted an aggregate of 7,477 warrants to SVB (the &#x201c;SVB Warrants&#x201d;), exercisable at a price of $42.80 per share for a period of seven years until November&#160;18, 2023, with a fair value of $167,022. The Company incurred total additional transaction costs of $220,898 related to the SVB Term Loan and First Amendment. The transaction costs and Final Payment were being amortized into profit and loss over the estimated term of the facility, being the legal term, resulting in an effective interest rate of 12.6% (2019&#160;- 12.19%).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The SVB Term Loan was fully repaid during the fiscal&#160;year ended September 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;SVB Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loan&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, September&#160;30,&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,316,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Principal repaid&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,808,823)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Interest paid&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (401,929)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 602,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, September&#160;30,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,708,955&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Principal repaid&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,199,799)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Interest paid&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,235)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 211,079&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Final payment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (688,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, September&#160;30,&#160;2020 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_2x7YFW6kN0SPIIof17z1gw"
      decimals="0"
      id="Narr_StpbXoQ3WEy9FOHQvw1QPA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g"
      decimals="0"
      id="Narr_HxTJh-Ek10O9FNVQQkOT_w"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">8000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <epix:DebtInstrumentAdditionalBorrowingCapacityLapsed
      contextRef="As_Of_7_31_2017_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_Aizgt9l5YUetmoZ6ZgsyMQ"
      decimals="0"
      id="Narr_Z8cZBjGvDEKUt0lWvmjUVA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2000000</epix:DebtInstrumentAdditionalBorrowingCapacityLapsed>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_us-gaap_VariableRateAxis_epix_WallStreetJournalPrimeRateMember_Y1By_7fOBkCONtSvQElMhA"
      decimals="2"
      id="Narr_6IDpjbfVE0OPLGmhp2Nb2g"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.03</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g"
      id="Narr_k1yN_J7JFk-5lObBLn2JFg">2020-09-01</us-gaap:DebtInstrumentMaturityDate>
    <epix:PercentageOfFinalPaymentOnAmountAdvanced
      contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g"
      decimals="3"
      id="Narr_R4aAiAIbNke7IZt-RQM1FA"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.086</epix:PercentageOfFinalPaymentOnAmountAdvanced>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DOZiFA-O_USUr64PZMvTXg"
      decimals="0"
      id="Narr_vFJZHaBqjkSEx_DaOgm9YQ"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3708955</us-gaap:RepaymentsOfLongTermDebt>
    <epix:RepaymentsOfLongTermDebtPrincipal
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_kVSb8-wpv0K1-njgvNHdsg"
      decimals="0"
      id="Narr_T_py3fRFFk6rrULB5tcD9w"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3199799</epix:RepaymentsOfLongTermDebtPrincipal>
    <epix:RepaymentsOfLongTermDebtInterest
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_kVSb8-wpv0K1-njgvNHdsg"
      decimals="0"
      id="Narr_wBbDYI-JXEeK8uSR6j_lqw"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">32235</epix:RepaymentsOfLongTermDebtInterest>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_kVSb8-wpv0K1-njgvNHdsg"
      decimals="0"
      id="Narr_PyfN_hrlk0mbKNLRciawWA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">211079</us-gaap:PaymentsOfFinancingCosts>
    <epix:RepaymentsOfLongTermDebtFinalPayment
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_kVSb8-wpv0K1-njgvNHdsg"
      decimals="0"
      id="Narr_taxYHE9AlkyQrTuhel0axw"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">688000</epix:RepaymentsOfLongTermDebtFinalPayment>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g"
      decimals="0"
      id="Narr_xdDXmUJSgUacfqmkTobPxA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">8000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <epix:ClassOfWarrantOrRightGranted
      contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g"
      decimals="0"
      id="Narr_HJTi0eO_ek60iRoF9A4QeA"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">7477</epix:ClassOfWarrantOrRightGranted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_2x7YFW6kN0SPIIof17z1gw"
      decimals="2"
      id="Narr_sChQESU5DU-ZQQoStv9lkQ"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">42.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_2x7YFW6kN0SPIIof17z1gw"
      id="Narr_3Bb3nLKB00O21f4gKstM8Q">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <epix:FairValueOfWarrantIssued
      contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_fDiICenBvU6wrMe6yUDP7g"
      decimals="0"
      id="Narr_yRMXmOkyNkuA7JhaJLa8-A"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">167022</epix:FairValueOfWarrantIssued>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_2x7YFW6kN0SPIIof17z1gw"
      decimals="0"
      id="Narr_IVxASKEItUeRqd_RVyXgqw"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">220898</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_hzqNHICFq0eM1Zmd4JcmoQ"
      decimals="3"
      id="Narr_VVQd6FMLH0ql36S1fDjfzA"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.126</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_sshfj9h3UEqQ_5aRwRdsVg"
      decimals="4"
      id="Narr_84IXlWrth0CFEVYFEuMxyQ"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.1219</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_JJtB23-9Z0uKwnB8VfJGIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The SVB Term Loan was fully repaid during the fiscal&#160;year ended September 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;SVB Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loan&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, September&#160;30,&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,316,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Principal repaid&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,808,823)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Interest paid&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (401,929)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 602,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, September&#160;30,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,708,955&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Principal repaid&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,199,799)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Interest paid&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,235)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 211,079&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Final payment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (688,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance, September&#160;30,&#160;2020 and 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_9_30_2018_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_hAyflyNNBEWF35w4BVawNQ"
      decimals="0"
      id="Tc_kditqIc6CUWHgNTCVzv4pQ_4_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">6316963</us-gaap:DebtInstrumentCarryingAmount>
    <epix:RepaymentsOfLongTermDebtPrincipal
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_uhVPf69j8U6JNC0OpomEGA"
      decimals="0"
      id="Tc_FWXvYl_NcUWHN2CwZzPfNg_5_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2808823</epix:RepaymentsOfLongTermDebtPrincipal>
    <epix:RepaymentsOfLongTermDebtInterest
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_uhVPf69j8U6JNC0OpomEGA"
      decimals="0"
      id="Tc_dybYQwif2EaBzJ_BS3iDjA_6_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">401929</epix:RepaymentsOfLongTermDebtInterest>
    <epix:DebtInstrumentAccretion
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_uhVPf69j8U6JNC0OpomEGA"
      decimals="0"
      id="Tc_cADbaDRhlEqq4W3Qt6fONg_7_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">602744</epix:DebtInstrumentAccretion>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_9_30_2019_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DzMDwGmdD0qgqtbE68ow2Q"
      decimals="0"
      id="Tc_GVR-zEAatESYMPLO9ehEbA_9_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3708955</us-gaap:DebtInstrumentCarryingAmount>
    <epix:RepaymentsOfLongTermDebtPrincipal
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DOZiFA-O_USUr64PZMvTXg"
      decimals="0"
      id="Tc_5sNhKv02tEe2XHysoEcSig_11_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3199799</epix:RepaymentsOfLongTermDebtPrincipal>
    <epix:RepaymentsOfLongTermDebtInterest
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DOZiFA-O_USUr64PZMvTXg"
      decimals="0"
      id="Tc_37VgeYP5hUuUfJx-aXzWbw_12_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">32235</epix:RepaymentsOfLongTermDebtInterest>
    <epix:DebtInstrumentAccretion
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DOZiFA-O_USUr64PZMvTXg"
      decimals="0"
      id="Tc_HvK33KZWfUi-EV_9zWEzRA_13_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">211079</epix:DebtInstrumentAccretion>
    <epix:RepaymentsOfLongTermDebtFinalPayment
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DOZiFA-O_USUr64PZMvTXg"
      decimals="0"
      id="Tc_TJ_55UwzSUOnyHJymnZcbA_14_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">688000</epix:RepaymentsOfLongTermDebtFinalPayment>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_hzqNHICFq0eM1Zmd4JcmoQ"
      decimals="0"
      id="Tc_6RKwKR-k6EidYbXMU4wXRQ_16_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_5ehuSCSx6ESoV9BH3qgnCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10.&#160;&#160;&#160;&#160;&#160;DERIVATIVE LIABILITIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In January&#160;2016, the Company completed a private placement of 227,273 units of the Company at $66.00 per unit (&#x201c;Unit&#x201d;) for gross proceeds of $14,999,992. Each Unit consisted of one common share of the Company, one &lt;span style="-sec-ix-hidden:Hidden_LQbZKgvpMkSuPJkLK-6o4A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;7-year&lt;/span&gt;&lt;/span&gt; cash and cashless exercise warrant (the &#x201c;&lt;span style="-sec-ix-hidden:Hidden_smbzU3-LrEiEpofGJXZ0jQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;7-Year&lt;/span&gt;&lt;/span&gt; Warrants&#x201d;), and &lt;span style="-sec-ix-hidden:Hidden_Cq_ppVfGcEWPX38oEjsM7A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;one half&lt;/span&gt;&lt;/span&gt; of one &lt;span style="-sec-ix-hidden:Hidden_93qUCOn8jU2BvXa947ry6Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;2-year&lt;/span&gt;&lt;/span&gt; cash exercise warrant (the &#x201c;&lt;span style="-sec-ix-hidden:Hidden_QDBLvhGsQUeMEe7FQU06dg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;2-Year&lt;/span&gt;&lt;/span&gt; Warrants&#x201d;). The &lt;span style="-sec-ix-hidden:Hidden_6BX3OeUYGUyxMKVAjbP3ng;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;7-Year&lt;/span&gt;&lt;/span&gt; Warrants and &lt;span style="-sec-ix-hidden:Hidden_BNXa2upcvUaUska1jS5ngQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;2-Year&lt;/span&gt;&lt;/span&gt; Warrants have an exercise price of $66.00 per common share (collectively, the &#x201c;2016 Warrants&#x201d;). The holders of the &lt;span style="-sec-ix-hidden:Hidden_RPrZ07gL9EKwo3zFCZTqrQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;7-Year&lt;/span&gt;&lt;/span&gt; Warrants may elect, in lieu of exercising the &lt;span style="-sec-ix-hidden:Hidden_VdjHFZpuu0Gaw-U_hHH3mg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;7-Year&lt;/span&gt;&lt;/span&gt; Warrants for cash, a cashless exercise option, in whole or in part, to receive common shares equal to the fair value of the &lt;span style="-sec-ix-hidden:Hidden_-5WrOmKIy0aUmOgHj7jFrA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;7-Year&lt;/span&gt;&lt;/span&gt; Warrants based on the number of &lt;span style="-sec-ix-hidden:Hidden_oH1NQJf7jEaRneoPXDn_6A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;7-Year&lt;/span&gt;&lt;/span&gt; Warrants to be exercised multiplied by a ten-day weighted average market price less the exercise price with the difference divided by the weighted average market price. If a warrant holder exercises this option, there will be variability in the number of shares issued per &lt;span style="-sec-ix-hidden:Hidden_XtTWqNg7CkSa4uffoyvABg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;7-Year&lt;/span&gt;&lt;/span&gt; Warrant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Additionally, the 2016 Warrants contain provisions which may require the Company to redeem the 2016 Warrants, at the option of the holder, in the event of a major transaction, such as a change of control or sale of the Company&#x2019;s assets (&#x201c;Major Transaction&#x201d;). The redemption value would be subject to a Black-Scholes valuation at the time of exercise. In the event the consideration for a Major Transaction payable to the common shareholders is in cash, in whole or in part, the redemption of the 2016 Warrants would be made in cash pro-rata to the composition of the consideration. The potential for a cash settlement for the 2016 Warrants outside the control of the Company, in accordance with U.S. GAAP, requires the 2016 Warrants to be treated as financial liabilities measured at fair value through profit or loss. The 2016 Warrants are not traded in an active market.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Valuation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liabilities on September 30, 2021 and 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;white-space:nowrap;width:31.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.49&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.22&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected annualized volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97.3&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Liquidity discount&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Sensitivity&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The derivative warrants are a recurring Level 3 fair value measurement. The key level 3 inputs used by management to determine the fair value are the market price, expected volatility and liquidity discount. If the market price were to increase by a factor of 10% this would increase the obligation by approximately $745,868 as at September 30, 2021. If the market price were to decrease by a factor of 10% this would decrease the obligation by approximately $429,170 as at September 30, 2021. If the volatility were to increase by 10%, this would increase the obligation by approximately $741,813 as at September 30, 2021. If the volatility were to decrease by 10%, this would decrease the obligation by approximately $423,842 as at September 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following table is a continuity schedule of changes to the Company&#x2019;s derivative liabilities:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Balance, September&#160;30,&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,159)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Balance, September&#160;30,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,520&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 110,856&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Balance, September&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 127,376&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (107,024)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Balance, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Derivatives with expected life of less than one&#160;year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Derivatives with expected life greater than one&#160;year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve_0ZTn0TU-gXeCf2aO7nQ"
      decimals="0"
      id="Narr_SuD-yr0dUUWQUmTOPxeqoQ"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">227273</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6U4ydYiIA0OEYvfjKh5H-w"
      decimals="2"
      id="Narr_bEkm6WPZFEmi0lfFOmH2-w"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">66.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve_0ZTn0TU-gXeCf2aO7nQ"
      decimals="0"
      id="Narr_WWL4CnUHC0WsQxz5Ap_-ng"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">14999992</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <epix:UnitsIssuedInPrivatePlacementConversionRatio
      contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve_0ZTn0TU-gXeCf2aO7nQ"
      decimals="0"
      id="Narr_qXRkJgtZm0Ww2U2SlxDjMA"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">1</epix:UnitsIssuedInPrivatePlacementConversionRatio>
    <epix:UnitsIssuedInPrivatePlacementConversionRatio
      contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zBSTNeNKaU6nRdYrbBaOkA"
      decimals="0"
      id="Narr_oJeKtknp_USWLjZYk8GR0g"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">1</epix:UnitsIssuedInPrivatePlacementConversionRatio>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6U4ydYiIA0OEYvfjKh5H-w"
      decimals="2"
      id="Narr_iwbv0ggszEWVkr0MNZId3g"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">66.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_wnvi4tmOdUempSQ5DK_DiA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liabilities on September 30, 2021 and 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;white-space:nowrap;width:31.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.49&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.22&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected annualized volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97.3&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Liquidity discount&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_98MIq4VaTEK2WLibJUF1nA"
      decimals="4"
      id="Tc_2lkCIFklgEmbHUrSFTZHzw_5_2"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.0049</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Y0xPeL08wEaJiqQOv0tbTw"
      decimals="4"
      id="Tc_y94tbUQ78UmA216Gjs96IA_5_5"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.0022</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_-Vb12dGpuEmhyC8WUpSCCQ"
      decimals="2"
      id="Tc_ktyu_6vhiEaSx6ZywAmzhA_6_2"
      unitRef="Unit_Standard_Y_NMesmjSO1UGw6iRoGrNeyg">1.28</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_vNbAiWbcgEmqGICZO6KNCA"
      decimals="2"
      id="Tc_gA8ejfyV9k29QRGeEKCGJA_6_5"
      unitRef="Unit_Standard_Y_NMesmjSO1UGw6iRoGrNeyg">2.28</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_E5NkLJ4ccEW-hVrvKYeF-Q"
      decimals="3"
      id="Tc_Nya645t9Z0yWmOVkmWQHJg_7_2"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.860</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_Juvh3KilQk6ebtQh2shs2Q"
      decimals="3"
      id="Tc_aSruU8ykNkWbeHIBxWzEvg_7_5"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.973</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_5REs_qrLRkG1-jsr4Wd88A"
      decimals="4"
      id="Tc_Phnh5HNqK0qldRcvVQKTIA_8_2"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_Owqnc6-qBky5k4C7VJfSvg"
      decimals="4"
      id="Tc_feU-pa7zCU-X7LzZDH8a5A_8_5"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_P2nPti2-iUCuSEEd1ouQ-A"
      decimals="2"
      id="Tc_B5-AkeABJUCZV-GKsgoHgw_9_2"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.20</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_PY96o3zHKEWmfUlTziLA5A"
      decimals="2"
      id="Tc_fyiqxRJt_0-YdmHbzBffZQ_9_5"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.20</us-gaap:DerivativeLiabilityMeasurementInput>
    <epix:IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice
      contextRef="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_IncreaseInMarketPriceOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_TVV9GdC9SUqfmn3lDBu8_A"
      decimals="0"
      id="Narr_ApcVmZnSS02y6tdb2S7EIA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">745868</epix:IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice>
    <epix:IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice
      contextRef="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_DecreaseInMarketPriceOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_gtQZa6KYHEGyPwd35QmJOg"
      decimals="0"
      id="Narr_X9EmMV2hlEqyArFLMHiByg"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">429170</epix:IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice>
    <epix:IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility
      contextRef="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_IncreaseInVolatilityOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9H1bHzeQPUejA4aXszVdcA"
      decimals="0"
      id="Narr_NqAEPNj2PUOxjRgSKom0wA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">741813</epix:IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility>
    <epix:IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility
      contextRef="As_Of_9_30_2021_srt_StatementScenarioAxis_epix_DecreaseInVolatilityOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_WLVJwCesyEOoKBOC_nuHTw"
      decimals="0"
      id="Narr_4FLdDuxuSEmVyEoEl7Yjbg"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">423842</epix:IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_54x4ReT6rES-MWJ4ybgRUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following table is a continuity schedule of changes to the Company&#x2019;s derivative liabilities:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Balance, September&#160;30,&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,159)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Balance, September&#160;30,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,520&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 110,856&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Balance, September&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 127,376&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (107,024)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Balance, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Derivatives with expected life of less than one&#160;year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Derivatives with expected life greater than one&#160;year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ"
      decimals="0"
      id="Tc_k19jZgemAEyEftkdaVRDtg_3_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">17679</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_40LCIPy7wkqjNm5xtKh-fg_4_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1159</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA"
      decimals="0"
      id="Tc_HDvc4D3U_0GDg64hZ4z1aA_6_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">16520</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_SP18waGS_EKhX9zKmkzjbg_7_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-110856</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_FGwiBvIEQkqG9-ywLBA2tg_9_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">127376</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_jK3DWkhcwkqZiJ6AVTDQaw_10_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">107024</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_n7NSk8rHmk6MbnRiuoSNIg_12_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">20352</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_xY_gEvvbjU-X8GIG1ATaYw_14_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_xtlkQJRwfEaamAAJFxKFqw_15_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">20352</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_OGo6FvMF3ESBCPh85Cr9xw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11.&#160;&#160;&#160;&#160;&#160;SHAREHOLDERS&#x2019; EQUITY&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Authorized&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Unlimited common shares, without par value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Unlimited preferred shares, without par value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;February 2021 Financing&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 22, 2021, the Company completed an underwritten public offering for aggregate gross proceeds of $149,999,985 (the &#x201c;&lt;b style="font-weight:bold;"&gt;February 2021 Financing&lt;/b&gt;&#x201d;). The Company issued a total of 5,555,555 common shares of the Company at a public offering price of $27.00 per share, which includes the underwriters having exercised their &lt;span style="-sec-ix-hidden:Hidden_jpTTNPtrr0yX_oiBe_gYnw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;30-day&lt;/span&gt;&lt;/span&gt; option to purchase an additional 724,637 common shares. In connection with the February 2021 Financing, the Company paid cash commissions of $8,999,999 and incurred other transaction costs of $229,451.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;July&#160;2020 Financing&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On July&#160;31, 2020, the Company completed an underwritten public offering for aggregate gross proceeds of US$48,990,000 (the &#x201c;&lt;b style="font-weight:bold;"&gt;July&#160;2020 Financing&lt;/b&gt;&#x201d;). The Company issued a total of 7,100,000 common shares of the Company at a public offering price of US$6.00 per share. Additionally, the underwriters exercised a &lt;span style="-sec-ix-hidden:Hidden_AZRAwVMkb0-1Z3ZiwRVKQw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;30-day&lt;/span&gt;&lt;/span&gt; option to purchase up to an additional 1,065,000 common shares. In connection with the July 2020 Financing, the Company paid cash commissions of $2,939,400 and incurred other transaction costs of $212,256.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;August&#160;2019 Financing&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On August&#160;27, 2019, the Company closed a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the &#x201c;&lt;b style="font-weight:bold;"&gt;August&#160;2019 Financing&lt;/b&gt;&#x201d;). The Company issued a total of 6,080,596 common shares and 11,919,404 pre-funded warrants in lieu of common shares of the Company at a price of $2.00 per security for aggregate gross proceeds of $36,000,000. Each pre-funded warrant entitles the holder thereof to acquire one common share at a nominal exercise price for a period of five years. In connection with the August&#160;2019 Financing, the Company paid cash commissions of $1,978,770 and incurred other transaction costs of $698,162.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Realm Acquisition&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On July&#160;31, 2019, the Company issued 6,718,150 shares in relation to the Realm Acquisition (Note&#160;4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Nomination Rights&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with a January&#160;2016 private placement of 227,273 Units, a Unit consisting of one common share, one &lt;span style="-sec-ix-hidden:Hidden_qojYrx_Z1UW0vuZx-arG5A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;7-year&lt;/span&gt;&lt;/span&gt; warrant and &lt;span style="-sec-ix-hidden:Hidden_zEYEXFo-FkWGt12ydoujMA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;one&lt;/span&gt;&lt;/span&gt;-half of one &lt;span style="-sec-ix-hidden:Hidden_EsUTpCDv1Eui8u7BVbNk7g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;2-year&lt;/span&gt;&lt;/span&gt; warrant, of the Company, Clarus Lifesciences III,&#160;L.P. (&#x201c;&lt;b style="font-weight:bold;"&gt;Clarus&lt;/b&gt;&#x201d;) acquired 106,061 common shares. Clarus is entitled to nominate two directors to the board of directors of the Company, one of which must be an independent director and preapproved by the Company. These nomination rights will continue for so long as Clarus holds greater than or equal to 53,030 common shares, subject to adjustment in certain circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Equity incentive plans&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Restricted share units plan&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has adopted a Restricted Share Unit Plan (&#x201c;RSU Plan&#x201d;) consistent with the policies and rules&#160;of the TSX-V and Nasdaq. Pursuant to the RSU Plan, RSUs may be granted with vesting criteria and periods are approved by the Board of Directors at its discretion. The RSUs issued under the RSU Plan may be accounted for as either equity-settled or cash-settled share-based payments. At September 30, 2021, there are no RSUs outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As at September 30, 2021 the Stock Option Plan and RSU Plan have a combined maximum of 7,342,788 common shares which may be reserved for issuance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Employee Share Purchase Plan&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has adopted an Employee Share Purchase Plan (&#x201c;ESPP&#x201d;) under which qualifying employees may be granted purchase rights (&#x201c;Purchase Rights&#x201d;) to the Company&#x2019;s common shares at not less of 85% of the market price at the lesser of the date the Purchase Right is granted or exercisable. The Company currently holds offerings consisting of six-month periods commencing on January&#160;1 and July&#160;1 and ending on June&#160;30 and December&#160;31 of each calendar&#160;year. As at September 30, 2021, the ESPP has a maximum of 252,418 (2020&#160;&#x2013;268,381) common shares reserved for issuance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Eligible employees are able to contribute up to 15% of their gross base earnings for purchases under the ESPP through regular payroll deductions. Purchase of shares under the ESPP are limited for each employee at $25,000 worth of the Company&#x2019;s common shares (determined using the lesser of (i)&#160;the market price of a common share on the first day of an applicable purchase period and (ii)&#160;the market price of a common share on the purchase date) for each calendar&#160;year in which a purchase right is outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;During the&#160;year ended September 30, 2021, the Company issued a total of 15,963 (2020&#160;&#x2013;16,506; 2019 - nil) common shares upon the exercise of Purchase Rights. The Company recognizes compensation expense for purchase rights on a straight-line basis over the service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:middle;white-space:nowrap;width:32.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the year ended September&#160;30,&#160; &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,299&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,984&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68,431&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 71,017&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company measures the purchase rights based on their estimated grant date fair value using the Black-Scholes option pricing model and the estimated number of shares that can be purchased. The following weighted average assumptions were used for the valuation of purchase rights:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.19&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.44&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life of share purchase rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected annualized volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61.54&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90.34&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Stock options&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has adopted a Stock Option Plan consistent with the policies and rules&#160;of the TSX-V and Nasdaq. Pursuant to the Stock Option Plan, options may be granted with expiry terms of up to 10 years, and vesting criteria and periods are approved by the Board of Directors at its discretion. The options issued under the Stock Option Plan are accounted for as equity-settled share-based payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock option transactions are summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price*&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 900,459&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 255,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.77&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options expired/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,998)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,122,461&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,218,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (416)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.20)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options expired/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (30,461)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28.46)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,309,584&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,889,646&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (323,610)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.68)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options expired/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (72,390)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.46)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance outstanding, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,803,230&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance exercisable, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,799,226&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.49&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;*&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Options exercisable in Canadian dollars as at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;September 30, 2021&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding options.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;At September 30, 2021, options were outstanding enabling holders to acquire common shares as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual life (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,584&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.70&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,794,603&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.59&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,667&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.05&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 185,816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 539,518&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.22&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 183,511&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,508,146&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;13.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 190,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;29.63&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.58&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;31.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.90&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 163,154&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.81&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,803,230&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.15&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Share-based compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;year ended September 30, 2021, the Company granted a total of 1,889,646 (2020&#160;&#x2013; 4,218,000, 2019 - 255,000) stock options with a weighted average fair value of $8.04 per option (2020&#160;&#x2013; $2.98, 2019 - $3.00).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company recognized share-based payments expense for options granted and vesting, net of recoveries on cancellations of unvested options, during the&#160;years ended September 30, 2021, 2020 and 2019 with allocations to its functional expense as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the year ended September&#160;30,&#160; &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Research and development expense &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,611,083&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,853,388&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304,786&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,796,599&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,598,202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 841,921&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,407,682&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,451,590&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,146,707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following weighted average assumptions were used for the Black-Scholes option-pricing model valuation of stock options granted:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.44&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.55&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.55&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life of options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected annualized volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78.16&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.33&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant transactions are summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,663,937&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,919,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.0001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,188,999)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.002)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31.17)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,393,092&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,120,115)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.08)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,272,977&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,038,227)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.06)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance outstanding and exercisable, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,234,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.84&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;*&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Warrants exercisable in Canadian dollars as at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;September 30, 2021&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding warrants.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;At September 30, 2021, warrants were outstanding enabling holders to acquire common shares as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiry Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;227,273&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt; (1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;US$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 66.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;January&#160;14, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;US$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;November&#160;18, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;80,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;US$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;January&#160;9, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2,920,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;US$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.0001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;August&#160;23, 2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,234,750&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Detailed terms of the 2016 Warrants are included in Note&#160;10.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg"
      decimals="0"
      id="Narr_y3Sd-SWchUysmVD7P7BDmg"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">149999985</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg"
      decimals="INF"
      id="Narr_3ZXTDynLS0SaIc_LSjLb0w"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">5555555</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_xthkLsF1tU2jKESbtnAPiQ"
      decimals="2"
      id="Narr_lca7Xs8GgEuSQg-wuGog-A"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">27.00</us-gaap:SharesIssuedPricePerShare>
    <epix:UnderwriterOptionToPurchaseAdditionalSecurities
      contextRef="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg"
      decimals="INF"
      id="Narr_rVPT6dmJoUCevgixdVhNiA"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">724637</epix:UnderwriterOptionToPurchaseAdditionalSecurities>
    <us-gaap:PaymentsForCommissions
      contextRef="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg"
      decimals="0"
      id="Narr_NOWGk7K6RUC3S3aOV9rrCA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">8999999</us-gaap:PaymentsForCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_2_22_2021_To_2_22_2021_us-gaap_SubsidiarySaleOfStockAxis_epix_February2021financingMember_T_DEcfsJX0qN5j2CWCi3qg"
      decimals="0"
      id="Narr_GWwfUM0X9E-hR8NWqr3ieQ"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">229451</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_9O-seddiG0O-DtG3IZ7HSA"
      decimals="0"
      id="Narr_ABYLinpWxEGZWOxH3q1q8w"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">48990000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_9O-seddiG0O-DtG3IZ7HSA"
      decimals="0"
      id="Narr_Lfvv5RufRkWEf3_8jy5UuA"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">7100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_IVc9duJPY0u5zFzTth4c9w"
      decimals="2"
      id="Narr_eahQ5EF68U6eWBw6Yu38Dg"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">6.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_R-OfI-78tEubD9EHvwxUZw"
      decimals="0"
      id="Narr_6JJSQRRMgkqYePnf1atlfg"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">1065000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PaymentsForCommissions
      contextRef="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_9O-seddiG0O-DtG3IZ7HSA"
      decimals="0"
      id="Narr_IFtZ25vEhkOeeqPSXte2XA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2939400</us-gaap:PaymentsForCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_31_2020_To_7_31_2020_us-gaap_SubsidiarySaleOfStockAxis_epix_July2020FinancingMember_9O-seddiG0O-DtG3IZ7HSA"
      decimals="0"
      id="Narr_wU_-QIsRpEuQq0of2BR09w"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">212256</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_27_2019_To_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_I44o30_JAkC59GqmUmKdIA"
      decimals="2"
      id="Narr_cvSi5MRGWEGIbYIdZtpEjA"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">6080596</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <epix:PreFundedWarrantsIssuedForCommonShares
      contextRef="Duration_8_27_2019_To_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_I44o30_JAkC59GqmUmKdIA"
      decimals="2"
      id="Narr_qlPJKRhzoUqWkbCOkpAXKw"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">11919404</epix:PreFundedWarrantsIssuedForCommonShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_5XGUa66jJ0abwyCuuh-5NQ"
      decimals="2"
      id="Narr_rUONmfm1qEik9zWHAiR0NQ"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">2.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_8_27_2019_To_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_I44o30_JAkC59GqmUmKdIA"
      decimals="0"
      id="Narr_FfCu1TyA8ESWsQ2-oYIfZw"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">36000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_5XGUa66jJ0abwyCuuh-5NQ"
      decimals="0"
      id="Narr_MWnX3IQDJkWUuV41VEaxhA"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_5XGUa66jJ0abwyCuuh-5NQ"
      id="Narr_ZUQ7oHXmMkyP99b48K8x6Q">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:PaymentsForCommissions
      contextRef="Duration_8_27_2019_To_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_I44o30_JAkC59GqmUmKdIA"
      decimals="0"
      id="Narr_bH430mOrS0iR_kAWwawdtA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1978770</us-gaap:PaymentsForCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_8_27_2019_To_8_27_2019_us-gaap_SubsidiarySaleOfStockAxis_epix_August2019FinancingMember_I44o30_JAkC59GqmUmKdIA"
      decimals="0"
      id="Narr_swygk2ZWlUSf46VLDFD_tA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">698162</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA"
      decimals="0"
      id="Narr_keA-r_YGRkO-l8hybO0SZw"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">6718150</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve_0ZTn0TU-gXeCf2aO7nQ"
      decimals="0"
      id="Narr_9J8-hJCLr0erT2oHcwrRxw"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">227273</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <epix:UnitsIssuedInPrivatePlacementConversionRatio
      contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Ve_0ZTn0TU-gXeCf2aO7nQ"
      decimals="INF"
      id="Narr_uKH9nxDx6kqEJFUv-zQMIA"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">1</epix:UnitsIssuedInPrivatePlacementConversionRatio>
    <epix:UnitsIssuedInPrivatePlacementConversionRatio
      contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_ClassOfWarrantOrRightAxis_epix_SevenYearWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zBSTNeNKaU6nRdYrbBaOkA"
      decimals="INF"
      id="Narr_fEz2Q9_t-Eug0Jkis-jaOQ"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">1</epix:UnitsIssuedInPrivatePlacementConversionRatio>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2016_To_1_31_2016_dei_LegalEntityAxis_epix_ClarusLifesciencesIiiL.pMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_nZaedBWVMkOE0FrReIaxeg"
      decimals="0"
      id="Narr_MoXdLIeMkEyP-i1-SaA6oA"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">106061</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <epix:MinimumNumberOfSharesRequiredToBeHeldForNominationRights
      contextRef="Duration_1_1_2016_To_1_31_2016_dei_LegalEntityAxis_epix_ClarusLifesciencesIiiL.pMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_nZaedBWVMkOE0FrReIaxeg"
      decimals="0"
      id="Narr_mBNGPYPEmk6-j3pAfeZ2Fg"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">53030</epix:MinimumNumberOfSharesRequiredToBeHeldForNominationRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_XbywsLIR-0K_GbIr8abXkg"
      decimals="0"
      id="Narr_OOjesnPNbU6MDssrNGzK7Q"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_epix_StockOptionsAndRsuPlanMember_k54Kg0Qt60iP9qnC85_xSA"
      decimals="0"
      id="Narr_K6xbIBRi5kuY7Oq6iyIYFA"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">7342788</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_10_1_2020_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_BRMWk_Qg8UerO040qIU5dA"
      decimals="2"
      id="Narr_AQtWyt3wqkWy1I5N4W8c6Q"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <epix:PurchaseRightsOfferingTerm
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw"
      id="Narr_Tk3cywg8p0qGCoWd_-9w7Q">P6M</epix:PurchaseRightsOfferingTerm>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_BIcTAMLdhk2c5modB4s8VQ"
      decimals="INF"
      id="Narr_5zgbjhyek06mXjmVHYzhZA"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">252418</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_RfUnofClWECxZ2F7pgy_Mg"
      decimals="0"
      id="Narr_JRpFK825k0WlVsrGUXLmfg"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">268381</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <epix:ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage
      contextRef="Duration_10_1_2020_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_ZnXLMrzY2kKNEOanG51mYg"
      decimals="2"
      id="Narr_rjardE4TLUeOvCQHFJgPyA"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.15</epix:ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage>
    <epix:MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw"
      decimals="0"
      id="Narr__QfEmWaeEE6j1TZp8A_pDQ"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">25000</epix:MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw"
      id="Tb_8NNKT6tZH0q561jGLw9J8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;During the&#160;year ended September 30, 2021, the Company issued a total of 15,963 (2020&#160;&#x2013;16,506; 2019 - nil) common shares upon the exercise of Purchase Rights. The Company recognizes compensation expense for purchase rights on a straight-line basis over the service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:middle;white-space:nowrap;width:32.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the year ended September&#160;30,&#160; &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,299&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,984&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68,431&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 71,017&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw"
      decimals="0"
      id="Narr_iHeEw83QWkyZCKwotjOWtQ"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">15963</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ"
      decimals="0"
      id="Narr_nV5YVUCA0k6ZWD9Hm6F7xA"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">16506</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_KbHplZS_S0-4Q0j_S03PtQ"
      decimals="INF"
      id="Narr_dv66pyDi8kSPiqL6Se8QdQ"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_TDUXu41ajUSQhlC8jIdvlg"
      decimals="0"
      id="Tc_gcUZ-JD8S0KG8OyCNxYEnw_4_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">32299</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_C8RcT1oob06aTUsGlCRHHw"
      decimals="0"
      id="Tc_DhHTzK2exketeFftLA4zNw_4_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">24984</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_idUWwoe5Nk-eyz-isT07Fw"
      decimals="0"
      id="Tc_g4VM4zXKSUidtDlxkhEUeg_4_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_h64usUGAzEWawEzuZH2-hg"
      decimals="0"
      id="Tc_OgOmUUJHh0OxZTn0BEnm-Q_5_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">36132</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_vvA5BqUJTUC4h92fKpnqdA"
      decimals="0"
      id="Tc_vB1ZmKLAyk-qfHDLCu3p5w_5_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">46033</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_5sfNjYNtMEWcos30T-GAsg"
      decimals="0"
      id="Tc_bHAjQ-yml0CZdg5TcxYfVQ_5_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw"
      decimals="0"
      id="Tc_SSiI-GC9OUaYdfwKZ3nK0A_6_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">68431</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ"
      decimals="0"
      id="Tc_UQQNb0BWqUChL2V0iHto-Q_6_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">71017</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_KbHplZS_S0-4Q0j_S03PtQ"
      decimals="0"
      id="Tc_avTqOUlO4UK23IcBNFfBZA_6_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw"
      id="Tb_e7Dm0z6YP0a2D4nKbwLrxA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company measures the purchase rights based on their estimated grant date fair value using the Black-Scholes option pricing model and the estimated number of shares that can be purchased. The following weighted average assumptions were used for the valuation of purchase rights:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.19&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.44&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life of share purchase rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected annualized volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61.54&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90.34&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw"
      decimals="4"
      id="Tc_Z75XQ3elC02ebNBi4U2xLQ_5_2"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.0019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ"
      decimals="4"
      id="Tc_-7kIG1tBWEePBYEynmYe2Q_5_4"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.0144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_KbHplZS_S0-4Q0j_S03PtQ"
      decimals="4"
      id="Tc_PmH38fekakuhZe_SXw5UbA_5_6"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw"
      id="Tc_J_5tTxtobk-m408kySsdLw_6_2">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ"
      id="Tc_ZZWsh5GVmkiBxG1BL9lkVw_6_4">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw"
      decimals="4"
      id="Tc_U2b_mc5r8USVPKxUD76_cA_7_2"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.6154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ"
      decimals="4"
      id="Tc_hW4Pb_RcUkqzXNS_xQ2R5w_7_4"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.9034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_KbHplZS_S0-4Q0j_S03PtQ"
      decimals="4"
      id="Tc_-nW-xoMO8UyOa1n7PrVrTQ_7_6"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw"
      decimals="4"
      id="Tc_leCXCHJ2NkmfU49wQJpQTQ_8_2"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_9zT6jVm3_UqBlD55ffK6JQ"
      decimals="4"
      id="Tc_jwSCuZ-kRk28UtEMrLHSzw_8_4"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_KbHplZS_S0-4Q0j_S03PtQ"
      decimals="4"
      id="Tc_WdsCnTni2EmdxjWCa-eBSA_8_6"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_zeWUu5tnb0Wgo8Zb8VADZA"
      id="Narr_hCvx-FypfUmx-dgZa5zKiA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_jDAKGRAp4k66s2yNCd3cxg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock option transactions are summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price*&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 900,459&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 255,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.77&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options expired/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,998)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,122,461&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,218,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (416)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.20)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options expired/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (30,461)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28.46)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,309,584&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,889,646&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (323,610)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.68)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Options expired/forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (72,390)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.46)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance outstanding, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,803,230&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance exercisable, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,799,226&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.49&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;*&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Options exercisable in Canadian dollars as at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;September 30, 2021&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding options.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ"
      decimals="0"
      id="Tc_LxMkWJbIykaxOKWRCfb-og_5_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">900459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ"
      decimals="2"
      id="Tc_k_iywfugqEOfDygQR1Yegw_5_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">4.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_Ae1J-s-AcE-H-V-KrnAqiw_6_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">255000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="2"
      id="Tc_mxwWiHF39UmUMR-V5ewY8A_6_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">3.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_Zhzk5wMWLkWiM6l5XiicKA_7_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">32998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="2"
      id="Tc_FeBVZiCSrkCnScdYZkohdw_7_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">4.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA"
      decimals="0"
      id="Tc_5Ny6pPA1iUe3kjwEYIzbKg_9_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">1122461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA"
      decimals="2"
      id="Tc_EPdzYkUmBUOsmrpBs2gU8w_9_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">4.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_h9lDkKzeb06bL_2fmWrqxw_10_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">4218000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="2"
      id="Tc_jHPRV4iMxki5xdbRccEVaQ_10_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">3.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_mQIfZrfj_EKeU5z_4f9EaQ_11_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">416</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="2"
      id="Tc_EOStpRgP20aVosHUrMr3wQ_11_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">2.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_9BtSVYiWaEW6QDGVUPbGFQ_12_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">30461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="2"
      id="Tc_DsS2Hhm9A0S4onKzCDYNaw_12_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">28.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_CYnShLUbwE2dCUFgxRx4Ew_14_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">5309584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="2"
      id="Tc_igdj1OAWikG0pRp3-2j-5g_14_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_PQ84bx8m7U2-D8B8ymstAQ_15_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">1889646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="2"
      id="Tc_p-khy2Jq50OMH7VQVguWdQ_15_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">9.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_h_VauAH6nkO86mG-Dlc_bQ_16_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">323610</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="2"
      id="Tc_kytCg_Rlm0Woz0IlE22C2A_16_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">3.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_uTA9sQkPWU-CqeUJUWrCkg_17_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">72390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="2"
      id="Tc_h11q0GG8h0CszfTpx6oTrg_17_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">4.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_N5DFDc_N2Ei_TBIs7i8YRg_19_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">6803230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="2"
      id="Tc_zw8sD7pmakWUTWR7p5PGUw_19_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">5.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_yaDzGDlbeU-8mGuXM4ugYg_20_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">2799226</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="2"
      id="Tc_Fp2SKIyA8kau2pDr8zn0nA_20_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">3.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_1QyQx0eNi0-3VaJEEgBd7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;At September 30, 2021, options were outstanding enabling holders to acquire common shares as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual life (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,584&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.70&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,794,603&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.59&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,667&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.05&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 185,816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 539,518&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.22&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 183,511&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,508,146&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;13.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 190,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;29.63&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.58&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;31.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.90&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 163,154&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.81&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,803,230&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.15&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_H4_0hNFzBUGvroxmeu8AMg"
      decimals="2"
      id="Tc_zavlz1nQPUKEkAWABEB7ng_4_1"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">2.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_H4_0hNFzBUGvroxmeu8AMg"
      decimals="INF"
      id="Tc_kRYAEemgykahyLjZnTl2yA_4_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">4584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInUsdMember_7aa-mYodb0C8Ab3SyV0S2w"
      id="Tc_d-eJEHHLe0Wo1r19hdpE6Q_4_5">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_wlpmAoIsWkC93lTFzSx58Q"
      decimals="2"
      id="Tc_XeeXGLbH806h5mZIARz7YQ_5_1"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_wlpmAoIsWkC93lTFzSx58Q"
      decimals="INF"
      id="Tc_jmFF_Sl97kOKFIJj4VyhQg_5_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">3794603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInUsdMember_mbmDp3ur_EKGdhOHg5IO0Q"
      id="Tc_hR9370S8u0a-DAIOm50xwQ_5_5">P8Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_eWAgb-BJak-hBFlUcl4JKw"
      decimals="2"
      id="Tc_vtxxXwGeoEmaXGh9Rb1U4Q_6_1"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_eWAgb-BJak-hBFlUcl4JKw"
      decimals="INF"
      id="Tc_fIpTHT9Q0kGsvFC5qt5REQ_6_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">26667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceThreeInUsdMember_wGr8DRkOREKQQphM6FzNzQ"
      id="Tc_Ols_GoHVZk-GkJSxGjvCmQ_6_5">P8Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_-Tmwt7iVW0SBnjnGzdbEZw"
      decimals="2"
      id="Tc_0RULs7sJsEqDso3lxkm2XA_7_1"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_-Tmwt7iVW0SBnjnGzdbEZw"
      decimals="INF"
      id="Tc_v7F_7wl31EGOHfj-Basg1w_7_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">185816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFourInUsdMember_lOFEC9XHq0q7TKCRGrQ1gQ"
      id="Tc_J81RjlOl-UmqnDSRNJyg-g_7_5">P7Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_LTgKbV_VaEKbcbftrCEzCw"
      decimals="2"
      id="Tc_QZFSICBu1EKZMteXaSwU_g_8_1"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">4.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_LTgKbV_VaEKbcbftrCEzCw"
      decimals="INF"
      id="Tc_4aoeu1wQJkiX0qGgzobNLA_8_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">539518</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceFiveInUsdMember_oZ40Ld43p02RRIboS_eC8A"
      id="Tc_ksd32_Z_N0qXtWFKDDkL4w_8_5">P6Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_VvO15Me_VUKyqrliUVeTGQ"
      decimals="2"
      id="Tc_i04yv6oKAEm-_M6YUdOclg_9_1"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">4.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_VvO15Me_VUKyqrliUVeTGQ"
      decimals="INF"
      id="Tc_vDT15-YShkyCVsOMnjN8sA_9_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">183511</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSixInUsdMember_qaj1qKiQnkaOQmjeCWPVtA"
      id="Tc_deobwbmdG0GxVLgF3xk1dg_9_5">P8Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_hiBG1IedoEC4ewOINgWhIw"
      decimals="2"
      id="Tc_29Y-AfCJyEq1QWDmOUvrOg_10_1"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">7.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_hiBG1IedoEC4ewOINgWhIw"
      decimals="INF"
      id="Tc_bkcOMwlmzUCMmldEm0wsQw_10_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">1508146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceSevenInUsdMember_zuHf0nv_ZkuPd0J8bn1NBg"
      id="Tc_0VWDc-oLr06nkJMFNAoy1A_10_5">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_1PenuuxZeEyE5f-LOycT4w"
      decimals="2"
      id="Tc_82DG02hYxESNI62UqscdMA_11_1"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">13.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_1PenuuxZeEyE5f-LOycT4w"
      decimals="INF"
      id="Tc_Lxr_bszu_UyXsJmwP1BY3A_11_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceEightInUsdMember_K5b0pB-fBkuoUKefft0NWw"
      id="Tc_m8QQpYP1vEyZm5fwGOiHXA_11_5">P9Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember__kUWs0yIX0ye8hi1Zc6tpA"
      decimals="2"
      id="Tc_FR7jZ4lWtE2K89teZW15YQ_12_1"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">29.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember__kUWs0yIX0ye8hi1Zc6tpA"
      decimals="INF"
      id="Tc_bJvqXoFhw0GL0NNy_4s1TQ_12_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceNineInUsdMember_DeJ3daQ9SkyjDkICey1iBg"
      id="Tc_WqLh3NRCDki1K07lzwOVDw_12_5">P9Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_N-YP2HmjGk2zaMleH3iyZw"
      decimals="2"
      id="Tc_9it7BgB1L0S2cKpgNXXqLg_13_1"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">31.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_N-YP2HmjGk2zaMleH3iyZw"
      decimals="INF"
      id="Tc_zN62supZ8k-6mpk4EEiICA_13_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTenInUsdMember_bXZJbL6ROEGmQrETPpTNlQ"
      id="Tc_cmFwLniOU0ODs3qOR1w5Yw_13_5">P9Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_oPWk0JmRaEyyBh0fzA7Y4A"
      decimals="2"
      id="Tc_LkQbV3V11k6p2soxhGGmtQ_14_1"
      unitRef="Unit_Divide_CAD_shares_HPEmoMmb7kGhCh3wegQo4A">4.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_oPWk0JmRaEyyBh0fzA7Y4A"
      decimals="INF"
      id="Tc_pO1vKne8B0Gv87HdGUsjiw_14_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">163154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceOneInCadMember_0jMN-msT_kSZlDa8zsXivA"
      id="Tc_XqGuSPqeq0K6IvR0-M3KAQ_14_5">P5Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_ShZSeTSzbUaq092C2OXCQA"
      decimals="2"
      id="Tc_RPzf65USzkaz49hXt1-RUA_15_1"
      unitRef="Unit_Divide_CAD_shares_HPEmoMmb7kGhCh3wegQo4A">5.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_ShZSeTSzbUaq092C2OXCQA"
      decimals="INF"
      id="Tc_XmxFlF1pFUqYt9xBD8tX8A_15_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">32231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_epix_ExercisePriceTwoInCadMember_jO7GpLA2mEqKLGWR63S2zg"
      id="Tc_ULXegc_Z8k2T3DK2k7v0kA_15_5">P7Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="INF"
      id="Tc_JRrCUSbN8kmYU11jk4wmmw_16_3"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">6803230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tc_2rXLSR61QEOdLDMPRRUlhQ_16_5">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Narr_iaC6MQPNpEOYILPsJzACcA"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">1889646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="2"
      id="Narr_mQ15ZXcrpkqxGOBDN4uNqg"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">8.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="2"
      id="Narr_8QuhkjKDkU-oOI03ZMr8RQ"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">2.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="2"
      id="Narr_ALbErH-QL0y77T8y4pW4mQ"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g"
      id="Tb_Fmmt2GvfbUGHK35Gpl-reA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company recognized share-based payments expense for options granted and vesting, net of recoveries on cancellations of unvested options, during the&#160;years ended September 30, 2021, 2020 and 2019 with allocations to its functional expense as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the year ended September&#160;30,&#160; &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Research and development expense &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,611,083&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,853,388&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304,786&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,796,599&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,598,202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 841,921&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,407,682&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,451,590&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,146,707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_fqbH1auJ50GUwQiIlByUJA"
      decimals="0"
      id="Tc_W9LHYHank06nDwcpqzmQVQ_4_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3611083</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_67NPSE9QlEiBk2PCAmKn_w"
      decimals="0"
      id="Tc_EJURUghihkiUu7X3Za9YrA_4_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1853388</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_O_W2ARKP1US6svZnbqUj6w"
      decimals="0"
      id="Tc_BRsIAfcyeUK6wxmfgJR-xg_4_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">304786</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_BTVGr7R3tkSQWqwCNPWc3g"
      decimals="0"
      id="Tc_4kmv6Ym-t0ieuD83POil3A_5_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">5796599</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_nL-lTHW6WU6Z5yoLkjYTEQ"
      decimals="0"
      id="Tc_OATptCyvcU-mVPy1rTKvyQ_5_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">5598202</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_G_hgzoPX3UCgJ-qR7IE_LA"
      decimals="0"
      id="Tc_xhrHkpl0S0-7j1Hesjlxfg_5_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">841921</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g"
      decimals="0"
      id="Tc_PUY4zvDRs0KYidvqroZtXQ_6_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">9407682</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_3oGU29vPGEui7qvSdXkMuw"
      decimals="0"
      id="Tc_lDKUMTBPvEKQ3gthz3bhXg_6_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">7451590</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_I94A-tgVzEeSta5_6-UjwQ"
      decimals="0"
      id="Tc_foXh8UJ8hEWmg4-uFNWieg_6_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1146707</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g"
      id="Tb_0Lo6wp0FmU6FKJdhvmT1kQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following weighted average assumptions were used for the Black-Scholes option-pricing model valuation of stock options granted:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.44&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.55&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.55&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life of options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected annualized volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78.16&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.33&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g"
      decimals="4"
      id="Tc_Gu78OkRfSUWMsKdhKXVoPw_5_2"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.0044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_3oGU29vPGEui7qvSdXkMuw"
      decimals="4"
      id="Tc_2gdDZ5BChkWkhtEK8g_ABw_5_4"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.0155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_I94A-tgVzEeSta5_6-UjwQ"
      decimals="4"
      id="Tc_T7qeKy8dzE66CaPs3RIvLg_5_6"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.0255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g"
      id="Tc_sSiMx4DnYkqLaY05ejujqw_6_2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_3oGU29vPGEui7qvSdXkMuw"
      id="Tc_rKIZL5uJs0yeo4O_pahjUg_6_4">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_I94A-tgVzEeSta5_6-UjwQ"
      id="Tc_q1TaMhyJZkWhrtzuU5a4iA_6_6">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g"
      decimals="4"
      id="Tc_XtoNAOboQkStTQCoBzYI4Q_7_2"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.7816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_3oGU29vPGEui7qvSdXkMuw"
      decimals="4"
      id="Tc_nhePNdiCp0qIDvKn3D4JsQ_7_4"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.7700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_I94A-tgVzEeSta5_6-UjwQ"
      decimals="4"
      id="Tc_SKFMFnSuB0GaSYcVPbzpVQ_7_6"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.7933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_gisJycMlSUe1Xr7ZULxg8g"
      decimals="4"
      id="Tc_n2rJl3cAlk2334m8LpuFGQ_8_2"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_10_1_2019_To_9_30_2020_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_3oGU29vPGEui7qvSdXkMuw"
      decimals="4"
      id="Tc_knl-jeICSUeRLqM6lbNxig_8_4"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_10_1_2018_To_9_30_2019_us-gaap_PlanNameAxis_epix_StockOptionPlanMember_I94A-tgVzEeSta5_6-UjwQ"
      decimals="4"
      id="Tc_JyN2-hklLkW-_5VXx3EiIg_8_6"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_pJTBwr3yr02sDy_rKZ1zbA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant transactions are summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,663,937&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,919,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.0001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,188,999)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.002)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31.17)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,393,092&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,120,115)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.08)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, September&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,272,977&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,038,227)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.06)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance outstanding and exercisable, September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,234,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.84&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;*&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Warrants exercisable in Canadian dollars as at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;September 30, 2021&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding warrants.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ"
      decimals="0"
      id="Tc_kOWrk1tJ_0OJy0q6WbKCIA_5_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">2663937</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ"
      decimals="2"
      id="Tc_SUqNOzEkAEOxaQDtjf5fJw_5_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">6.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <epix:ClassOfWarrantOrRightGranted
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_fcs_fcPldkGR0NwX6b2xPw_6_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">11919404</epix:ClassOfWarrantOrRightGranted>
    <epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="4"
      id="Tc_BaH1-r-jBkOEgaym5EfThA_6_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">0.0001</epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted>
    <epix:ClassOfWarrantOrRightExercised
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_zwbAi8gJXU-h-RaSblOPsQ_7_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">2188999</epix:ClassOfWarrantOrRightExercised>
    <epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="3"
      id="Tc_z4p3neRT-EOyhQN_Ov5woQ_7_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">-0.002</epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised>
    <epix:ClassOfWarrantOrRightExpired
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_BhCslbCwDEmAWghtTTzgyg_8_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">1250</epix:ClassOfWarrantOrRightExpired>
    <epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="2"
      id="Tc_YwWsJNg2V0WLcHtZGXGewQ_8_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">-31.17</epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA"
      decimals="0"
      id="Tc_Wp-AAycrlEafigkc4h86OQ_10_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">12393092</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2019_bc7tAzOKDUu7hWvqX5x9TA"
      decimals="2"
      id="Tc_VGVydudZu0mOcdC2rQSEEg_10_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">1.31</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <epix:ClassOfWarrantOrRightExercised
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_9yXpAzfhSkagkXly0diTeA_11_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">3120115</epix:ClassOfWarrantOrRightExercised>
    <epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="3"
      id="Tc_7cwYFYLaW0a7a6fdL1IFrw_11_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">-0.08</epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_jD6VNGaDrkmDmwJu7sydHQ_13_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">9272977</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="2"
      id="Tc_5nAhebTPy0SBjQRwFdsUcQ_13_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">1.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <epix:ClassOfWarrantOrRightExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_JzOQSkh8dEKsrGCH0A0mBw_14_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">6038227</epix:ClassOfWarrantOrRightExercised>
    <epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="3"
      id="Tc_-QWB7TTG60-pDJz4EGBnPQ_14_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">-0.06</epix:ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_DUU0pYfsLEy52OJi2ip_ew_16_2"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">3234750</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="2"
      id="Tc_u4ikvv9puEqTUs_csz8ppQ_16_5"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">4.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <epix:ScheduleOfWarrantsOrRightsOutstandingTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_eC166xY3IUe-POH07imSsg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;At September 30, 2021, warrants were outstanding enabling holders to acquire common shares as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiry Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;227,273&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt; (1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;US$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 66.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;January&#160;14, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;US$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;November&#160;18, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;80,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;US$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;January&#160;9, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2,920,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;US$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.0001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;August&#160;23, 2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,234,750&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Detailed terms of the 2016 Warrants are included in Note&#160;10.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</epix:ScheduleOfWarrantsOrRightsOutstandingTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceOneMember_peg5Z3r7MkaJuDu2VWniig"
      decimals="0"
      id="Tc_fHPrz9aNME6ONkNwhhzIIg_4_0"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">227273</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceOneMember_peg5Z3r7MkaJuDu2VWniig"
      decimals="2"
      id="Tc_m7LErgkG5UuOfOnKYmUhKg_4_3"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">66.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceOneMember_peg5Z3r7MkaJuDu2VWniig"
      id="Tc_vFzinmJ8rkKyjP78btaCKw_4_5">2023-01-14</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_QlJ05My24UihYsCtnSc8oA"
      decimals="0"
      id="Tc_5929N8OnkkCzmcq-5cdHDQ_5_0"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">7477</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_QlJ05My24UihYsCtnSc8oA"
      decimals="2"
      id="Tc_VWQrFnWfdUKL68J-C2ni2A_5_3"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">42.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceTwoMember_QlJ05My24UihYsCtnSc8oA"
      id="Tc_c2GdZ55qbkCf3a-vk_BW3g_5_5">2023-11-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceThreeMember_Poysa79t_k26dJwrtpr7cA"
      decimals="0"
      id="Tc_JS8lyMRNHU-ChlJtJ4wVmQ_6_0"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">80000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceThreeMember_Poysa79t_k26dJwrtpr7cA"
      decimals="2"
      id="Tc_1flxYzcLFkOZNyEGtSMCxQ_6_3"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">4.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceThreeMember_Poysa79t_k26dJwrtpr7cA"
      id="Tc_WNbtKfhw4U2-qsGwGUeszg_6_5">2023-01-09</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_TR1RCu8S8U-alcwoR2y6RA"
      decimals="0"
      id="Tc_DtjyhZklnEasOW4hDeJxqg_7_0"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">2920000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_TR1RCu8S8U-alcwoR2y6RA"
      decimals="4"
      id="Tc_C5j6O3ZqX0-hIPx3wAEhNg_7_3"
      unitRef="Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceFiveMember_TR1RCu8S8U-alcwoR2y6RA"
      id="Tc_bGAbnDA1PE2YA52CjiUtDw_7_5">2024-08-23</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_-3lehuHRp0mIZ5ilc_CdaA_8_0"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">3234750</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_dLcyAccqFUqfK11i0kz7bg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12.&#160;&#160;&#160;&#160;SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;year ended September 30, 2021, the Company:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;issued &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;81,303&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; common shares upon the cashless exercise of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;94,723&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; pre-funded warrants.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;There were no significant non-cash financing or investing activities during the year ended September 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;year ended September&#160;30, 2019, the Company:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;issued &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;1,652,530&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; common shares upon the cashless exercise of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;1,653,999&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; pre-funded warrants;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;incurred &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$64,804&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; in transaction costs related to the Realm Transaction through accounts payable and accrued liabilities (Note&#160;4); and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;incurred &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$303,951&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; in share issuance costs through accounts payable and accrued liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <epix:StockIssuedDuringPeriodValuePreFundedWarrantsExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Narr_N5JP6z4o70WzMiASZ4M4Qg"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">81303</epix:StockIssuedDuringPeriodValuePreFundedWarrantsExercised>
    <epix:PreFundedWarrantsExercised
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Narr_LwfynKy5mEamyR4PQyl6nw"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">94723</epix:PreFundedWarrantsExercised>
    <epix:StockIssuedDuringPeriodValuePreFundedWarrantsExercised
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Narr_Q_2AVTreXUecBOZWu0E-pw"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">1652530</epix:StockIssuedDuringPeriodValuePreFundedWarrantsExercised>
    <epix:PreFundedWarrantsExercised
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Narr_fVzZTLNCWk6iJaODjO6zLg"
      unitRef="Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA">1653999</epix:PreFundedWarrantsExercised>
    <epix:BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Narr_Uc2Nx_hiUEG1ELsWyCYEAA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">64804</epix:BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability>
    <epix:ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Narr_PgIedhpt7UWl3MI1ch2X8w"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">303951</epix:ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_7dElGTJv-062x-J0aZ4GDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;13.&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Included in accounts payable and accrued liabilities at September 30, 2021 is $82,036 (2020&#160;- $87,846) due to related parties with respect to key management personnel compensation and expense reimbursements. Amounts due to related parties are non-interest bearing, with no fixed terms of repayment.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_9_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_rj2UHMCflEe1q86RKPHdAA"
      decimals="0"
      id="Narr_21DhuCALeEOPEOxodxFcmQ"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">82036</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_9_30_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_apbVsSWBtk-56toVL5ECFQ"
      decimals="0"
      id="Narr_cpeLtz-yTECeHLkbSF312g"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">87846</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_ZwCeWM_mLEm-5vBHGZ-SVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14.&#160;&#160;&#160;&#160;INCOME TAXES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following is a reconciliation of income taxes calculated at the combined Canadian federal and provincial income statutory corporate tax rate of 27.0% (2020 &#x2013; 27.0%, 2019 &#x2013; 27.0%) to the tax expense:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;For the&#160;years ended September&#160;30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss for the&#160;year before income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (36,839,810)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23,734,017)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,718,912)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax recovery at statutory income tax rates&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,947,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,408,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,434,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-deductible share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,575,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,031,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 227,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Taxable capital gains&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 346,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other permanent differences including foreign exchange&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Share issue costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,492,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (849,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (720,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in statutory, foreign tax, foreign exchange rates and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,260,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,013,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 458,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (725,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (307,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (196,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,344,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,210,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,354,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_I8yCBUa3N0W0JSccZZb-kw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"&gt; (34,000)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Y6jwuf91OUyOdeLUzsBsTA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"&gt; (289,000)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_qGTwKPFLwU6oUyoQmQDV4A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"&gt; 38,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax attributes are subject to review, and potential adjustment, by tax authorities. The Company has recorded an income tax recovery of $34,349 for the&#160;year ended September 30, 2021 (2020&#160;&#x2013; recovery of $288,647, 2019 &#x2013; expense of $37,920) in relation to taxable income generated by its US subsidiary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;For the years ended September 30, 2021 and 2020, the Company did not record a provision for income taxes due to a full valuation allowance against our deferred tax assets. The significant components of the Company&#x2019;s deferred tax assets are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating losses carried forward&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,749,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,297,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equipment and intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investment tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,025,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,462,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal R&amp;amp;D credit&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 210,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,169,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,875,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,169,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22,875,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net future tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As at September 30, 2021, the Company has non-capital loss carry-forwards of approximately $78,416,000 (2020 - $64,494,000) available to offset future taxable income in Canada and approximately $40,843,000 (2020 - $20,249,000) available to offset future taxable income in the US. These non-capital loss carryforwards begin to expire in 2031.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="2"
      id="Narr_6oDupUI2gEK8jRgQT_dG_w"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.270</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="2"
      id="Narr_bMR2VTR1_EeEcB8CcUP7iw"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.270</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="2"
      id="Narr_UKY28GzEh0yAgiruLS-MrQ"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.270</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_PSKL-HdKNke79X363yjHzQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;For the&#160;years ended September&#160;30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss for the&#160;year before income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (36,839,810)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23,734,017)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,718,912)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax recovery at statutory income tax rates&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,947,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,408,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,434,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-deductible share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,575,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,031,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 227,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Taxable capital gains&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 346,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other permanent differences including foreign exchange&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Share issue costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,492,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (849,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (720,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in statutory, foreign tax, foreign exchange rates and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,260,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,013,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 458,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (725,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (307,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (196,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,344,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,210,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,354,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Total income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_I8yCBUa3N0W0JSccZZb-kw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"&gt; (34,000)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Y6jwuf91OUyOdeLUzsBsTA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"&gt; (289,000)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_qGTwKPFLwU6oUyoQmQDV4A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"&gt; 38,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_4pnbVKBbUEGBBo19-WMYqQ_3_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-36839810</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_1T62A9WSk0-qnt_2qTCZsA_3_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-23734017</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_H98U4rT7gE-mZI9RwaOPWg_3_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-12718912</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_dVO94cuX2UGsL06jsS-WOg_5_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-9947000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_AH8YC9GX5EyjO6m5_4XWgw_5_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-6408000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_wf7j5fjtI0qqUnErZQs8zQ_5_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-3434000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_7usEyvaFok680RXBFTM72A_6_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1575000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_zjS2guZqYkqSLnJU4atapw_6_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">2031000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_iUmDsgwRDE2bYbCMfLwRJA_6_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">227000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <epix:IncomeTaxReconciliationTaxableCapitalGains
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_7yZI9jDGiUKf_5AowV5Pgg_7_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">346000</epix:IncomeTaxReconciliationTaxableCapitalGains>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_amJFCwlRTUa4cM2XeKaBLA_8_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-49000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_2CMOV7WPVEySmVp6zBzjzA_8_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">21000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_el1QNOu6ikOz6JmAmAyYRA_8_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <epix:IncomeTaxReconciliationFinancingCosts
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_CopV32Rp1kuZg7VAXoM7Iw_9_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-2492000</epix:IncomeTaxReconciliationFinancingCosts>
    <epix:IncomeTaxReconciliationFinancingCosts
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_J9Y-FH06IES-oH8xDiDGuw_9_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-849000</epix:IncomeTaxReconciliationFinancingCosts>
    <epix:IncomeTaxReconciliationFinancingCosts
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_uRttlQBdW0yF_Bj9XlLkzQ_9_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-720000</epix:IncomeTaxReconciliationFinancingCosts>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_2_N0aY7Whk-Lx1a7KjaK7A_10_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1260000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_i5LzVqZJs0OU2Ss_059hQw_10_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1013000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_R7SxSGLAX0Oor6XVyn2MXA_10_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">458000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_vVnNX59EdkGHx0FNCh-z9Q_11_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-725000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_9D_u4y-rUk-noURCx1QnlA_11_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-307000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_m8zpwmDCzUWVEpQ8127O0Q_11_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-196000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Tc_1jKCew__dU2QTnFgo9ZDPw_12_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">10344000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Tc_dyOp_QjTIkmYVuZTQc4mIQ_12_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">4210000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Tc_Kw-RqYyE5EOk87k8F1QtWg_12_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3354000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Narr_fWbgQYo040GZ0CmKQ-_q2g"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-34349</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2019_To_9_30_2020_mLpQ9B2k4kq3wGT_iIAbaQ"
      decimals="0"
      id="Narr_NQdJ9SMRC0K_hKOdEffujw"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">-288647</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_10_1_2018_To_9_30_2019_GYO2na0NGUq-GxCTZWri4w"
      decimals="0"
      id="Narr_jjrlCBS-_02-XYKp8oB-xA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">37920</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_ZiVTbFEcL0y0BOBHsyXmxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating losses carried forward&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,749,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,297,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equipment and intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investment tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,025,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,462,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal R&amp;amp;D credit&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 210,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,169,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,875,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,169,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22,875,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net future tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_wCw9wg0nBE-2Tw4L67euHQ_3_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">29749000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_J5jl0bPN2kOXFEjnsmX5-A_3_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">21297000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <epix:DeferredTaxAssetsEquipmentAndIntangibleAssets
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_KPokMXSSLkSutZLllu1qYA_4_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">77000</epix:DeferredTaxAssetsEquipmentAndIntangibleAssets>
    <epix:DeferredTaxAssetsEquipmentAndIntangibleAssets
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_A4DW_GMx3kaVDKU0UFEWmw_4_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">77000</epix:DeferredTaxAssetsEquipmentAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_u1wUxxdq9kiFF6oOAGoMaQ_5_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">29000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_xxXhE_mdwUe_bUPZgvwlzw_5_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">39000</us-gaap:DeferredTaxAssetsInvestments>
    <epix:DeferredTaxAssetsFinancingCosts
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_tUfxvPdo70i2qUsS8p6lJw_6_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">3025000</epix:DeferredTaxAssetsFinancingCosts>
    <epix:DeferredTaxAssetsFinancingCosts
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_yvPf3tP4tk-XMizn6qCDTg_6_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">1462000</epix:DeferredTaxAssetsFinancingCosts>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_ABh0j-yL90Gzcoyh5NDcsg_7_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">210000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_R8XczcN1L0GsLjv6d9pksQ_7_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_Z9Ln3tlAAkWkbHjJGyaagQ_8_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">79000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_P30CTndgcUiTLh1RhuzJYQ_8_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_HP97auE5e0qPMZq3ElvzxQ_10_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">33169000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_y2uHoyZCv0iYKj4hiF4smQ_10_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">22875000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_02wyqdGpiUCnQxeY85ZPzQ_11_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">33169000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_ZG0m2Gq60UmxCWAL5F25ug_11_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">22875000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Tc_nQJyDH1xkkqqG1jjq4qSOw_13_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw"
      decimals="0"
      id="Tc_Pb7LaFi8HkeS9crK8pheWg_13_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_9_30_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_wiQZ0GbLlkimzzAcX5zh1g"
      decimals="0"
      id="Narr_LysVAO5ZAEqcqA5lpsJ6bA"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">78416000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_9_30_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_U7-LX1-3mUqaUlE6IXrBYg"
      decimals="0"
      id="Narr_5Fxt73d5hE-qwWDI3rQuow"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">64494000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_9_30_2021_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_WEBFjPZWXUWEyRoGCQubVA"
      decimals="0"
      id="Narr_JRoBnKvwT06EpyteN1MILw"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">40843000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_9_30_2020_srt_StatementGeographicalAxis_country_US_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_SMYfJ5aGWk-8_6eAqyWYbg"
      decimals="0"
      id="Narr_PxqGuj_VrEqAk8RMA-wVZw"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">20249000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_UYNoXACFW02C4zeMCKMO_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;15.&#160;&#160;&#160;&#160;SEGMENTED INFORMATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company works in one industry being the development of small molecule drugs for prostate cancer. The Company&#x2019;s right of use asset is located in the USA.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      decimals="0"
      id="Narr_JIy69_XLcUWqtpWDR7EAZg"
      unitRef="Unit_Standard_segment_bQM1D9rk7USEKwcghht0TA">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_MYYmubqubk2_brR-4KLA-Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;16.&#160;&#160;&#160;&#160;FINANCIAL INSTRUMENTS AND RISK&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities, long-term debt and derivative liabilities. The fair value of cash and cash equivalents, receivables and accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The derivative liabilities are measured using level 3 inputs (Note&#160;10).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of judgement, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair values.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Financial risk factors&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s risk exposures and the impact on the Company&#x2019;s financial instruments are summarized below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Credit risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and receivables. The Company&#x2019;s receivables are refunds from vendors. The Company limits its exposure to credit loss by placing its cash with major financial institutions. The Company considers highly liquid investments with a maturity of up to twelve months when purchased to be short-term investments. As at September 30, 2021, cash and cash equivalents consisted of cash in Canada and the United States.  and term deposits in Canada. Balances exceed amounts insured by the Canada Deposit Insurance Corporation for up to C&lt;/span&gt;$100,000 and by the Federal Deposit Insurance Corporation for up to $250,000. Amounts due from government agencies are considered to have minimal credit risk.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Liquidity risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at September 30, 2021, the Company had working capital of $193,668,414. The Company does not generate revenue and will be reliant on external financing to fund operations. Debt and equity financing are dependent on market conditions and may not be available on favorable terms.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Market risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;"&gt;Market risk is the risk of loss that may arise from changes in market factors such as interest rates, and foreign exchange rates.&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;"&gt;(a)&lt;/span&gt;Interest rate risk&lt;/div&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;As at September 30, 2021, the Company has cash and cash equivalents balances and GICs which are interest bearing. Interest income is not significant to the Company&#x2019;s projected operational budget and related interest rate fluctuations are not significant to the Company&#x2019;s risk assessment.&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"&gt;&lt;span style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;"&gt;(b)&lt;/span&gt;Foreign currency risk&lt;/div&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;The Company&#x2019;s foreign currency risk exposure relates to net monetary assets denominated in Canadian, UK pound and Euro dollars. The Company maintains its cash and cash equivalents in US dollars and converts on an as needed basis to discharge Canadian denominated expenditures. A 10% change in the foreign exchange rate between the Canadian, UK Pound, Euro and U.S. dollar in relation to Canadian, UK Pound, Euro dollars held at September 30, 2021 would result in a fluctuation of $27,261 in the net loss recognized for the period. The Company does not currently engage in hedging activities.&lt;/p&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <epix:CashCanadaDepositInsuranceCorporationInsuredAmount
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Narr_dCuR3EKNbU-85y7wSXeefQ"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">100000</epix:CashCanadaDepositInsuranceCorporationInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Narr_PuNR4mZGF0yLUqc6wznjFg"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">250000</us-gaap:CashFDICInsuredAmount>
    <epix:WorkingCapital
      contextRef="As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A"
      decimals="0"
      id="Narr_wA-EaKob60af77JnS0Ilag"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">193668414</epix:WorkingCapital>
    <epix:ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate
      contextRef="Duration_10_1_2020_To_9_30_2021_srt_StatementScenarioAxis_epix_TenPercentChangeInForeignExchangeRateMember_bvuH6gka5U6JPsf7-52JbA"
      decimals="0"
      id="Narr_W7Ukptudu02LYwEo20ATXg"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">27261</epix:ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_8n0LDB2oWUOfxNfRY9FNtw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;17.&#160;&#160;&#160;&#160;COMMITMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Product Development and Relocation Grant&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2014 the Company was awarded a product development and relocation grant by CPRIT whereby the Company received $12,000,000 on eligible expenditures over a three-year period related to the development of the Company&#x2019;s androgen receptor n-terminus blocker program for prostate cancer. A final payment of $229,201 was recorded as a receivable as at September 30, 2020. During the fiscal year ended September 30, 2021, the Company determined that the receivable was deemed uncollectible. The impairment of the CPRIT receivable is recorded against research and development expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;If the Company is found to have used any grant proceeds for purposes other than intended, is in violation of the terms of the grant, or fails to maintain the required level of operations in the State of Texas for three&#160;years following the final payment of grant funds, then the Company could be required to repay any grant proceeds received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the grant, the Company is also required to pay a royalty to CPRIT, comprised of 4% of revenues the Company receives from sale of commercial product or commercial service, until aggregate royalty payments equal $24,000,000, and 2% of revenues thereafter. The Company has the option to terminate the grant agreement by paying a one-time, non-refundable buyout fee, based on certain factors including the grant proceeds, and the number of&#160;months between the termination date and the buyout fee payment date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;License Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The NTD Technology is held under a license agreement signed in fiscal 2010 (the &#x201c;License Agreement&#x201d;). As consideration for the License Agreement, the Company issued common shares of the Company. The License Agreement contains an annual royalty as a percentage of annual net revenue and a percentage of any annual sublicensing revenue earned with respect to the NTD Technology. The License Agreement stipulates annual minimum advance royalty payments of C$85,000&lt;span style="white-space:pre-wrap;"&gt;.  In addition, there are certain milestone payments for the first compound, to be paid in stages as to C&lt;/span&gt;$50,000 at the start of a Phase II clinical trial, C$900,000 at the start of a Phase III clinical trial, C$1,450,000 at application for marketing approval, and with further milestone payments on the second and additional compounds&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company has the following obligations over the next five&#160;years:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Contractual obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Minimum annual royalty per License Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;85,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vendor Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consulting Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease on US office spaces&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113,288&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 119,586&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,509&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Collaborative agreements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;On February 25, 2021, the Company announced a clinical collaboration with Astellas Pharma Inc. (&#x201c;Astellas&#x201d;) to evaluate the combination of EPI-7386 and Astellas/Pfizer&#x2019;s androgen receptor inhibitor, enzalutamide, for patients with mCRPC. Under the terms of the agreement, ESSA will sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of the combination of EPI-7386 and enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies. Astellas will supply enzalutamide for the trial. ESSA will retain all rights to EPI-7386. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"&gt;&lt;span style="font-style:normal;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"&gt;&lt;span style="font-style:normal;white-space:pre-wrap;"&gt;On April 28, 2021, the Company announced that it had entered into a clinical trial collaboration and supply agreement with Bayer to evaluate EPI-7386 in combination with Bayer&#x2019;s androgen receptor inhibitor, darolutamide, in patients with mCRPC.  Under the terms of the agreement, following review of certain clinical data, Bayer may sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the combination of EPI-7386 and darolutamide in mCRPC patients. ESSA will supply EPI-7386 for the trial and will retain all rights to EPI-7386. &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <epix:GrantAmount
      contextRef="Duration_2_1_2014_To_2_28_2014_srt_ProductOrServiceAxis_us-gaap_GrantMember_3kTJC-T1iU2z88W1B5pfng"
      decimals="0"
      id="Narr_so1wGh4kTkK3gVCoLJ7Ivg"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">12000000</epix:GrantAmount>
    <epix:GrantReceivedPeriod
      contextRef="Duration_2_1_2014_To_2_28_2014_srt_ProductOrServiceAxis_us-gaap_GrantMember_3kTJC-T1iU2z88W1B5pfng"
      id="Narr_QjoCiANx-UeddkCTpbt71Q">P3Y</epix:GrantReceivedPeriod>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_9_30_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_Uot5G89xX0qdEQQjGB5lPQ"
      decimals="0"
      id="Narr_xKj5gcK2-0eNaJSoTvhlYQ"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">229201</us-gaap:GrantsReceivable>
    <epix:GrantRequirementNumberOfYearsOfOperationsInTexas
      contextRef="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_stpr_TX_30zEwfkPH0eCYhn7ePIwpw"
      id="Narr_9Lbnp0zByU6fbETiTnBy2A">P3Y</epix:GrantRequirementNumberOfYearsOfOperationsInTexas>
    <epix:RoyaltyPercentRevenue
      contextRef="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementScenarioAxis_epix_AggregateRoyaltyPaymentUpTo24000000Member_5AdkqvcbzUyIueGZN5F9LQ"
      decimals="2"
      id="Narr_cb83JnUWPEKKk6d-aWNeWw"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.04</epix:RoyaltyPercentRevenue>
    <epix:ThresholdLimitForAggregateRoyaltyPayments
      contextRef="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_KZCcAZEQ0ky6YptH37I2xw"
      decimals="0"
      id="Narr_fjoqktijT0K2xs-BQ1roBQ"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">24000000</epix:ThresholdLimitForAggregateRoyaltyPayments>
    <epix:RoyaltyPercentRevenue
      contextRef="Duration_10_1_2020_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementScenarioAxis_epix_AggregateRoyaltyPaymentAfter24000000Member_xk53XTvPeE29Kge7zRUczA"
      decimals="2"
      id="Narr_JkPVQTOACkmudTHqbHJ6VQ"
      unitRef="Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ">0.02</epix:RoyaltyPercentRevenue>
    <epix:MinimumAdvanceRoyaltyPayments
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_XqG7x_Aqjk2REwmcJTq1IQ"
      decimals="0"
      id="Narr_RdNZUQ6-VUaZ_Z7w4ghRPQ"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">85000</epix:MinimumAdvanceRoyaltyPayments>
    <epix:AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_XqG7x_Aqjk2REwmcJTq1IQ"
      decimals="0"
      id="Narr_dlxL6UnjBEiCtt1XwA2nCg"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">50000</epix:AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial>
    <epix:AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_XqG7x_Aqjk2REwmcJTq1IQ"
      decimals="0"
      id="Narr_P9Wclsdgq0mKaG98d3SYkA"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">900000</epix:AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial>
    <epix:AmountOfMilestonePaymentsAtApplicationForMarketingApproval
      contextRef="Duration_10_1_2020_To_9_30_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TechnologyBasedIntangibleAssetsMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_XqG7x_Aqjk2REwmcJTq1IQ"
      decimals="0"
      id="Narr_VOpLxmAIvUOsZj0MsBr57w"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">1450000</epix:AmountOfMilestonePaymentsAtApplicationForMarketingApproval>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA"
      id="Tb_eSWhKHoGHEStW8AkfkDZ4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company has the following obligations over the next five&#160;years:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Contractual obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Minimum annual royalty per License Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;85,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vendor Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;C$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consulting Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease on US office spaces&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113,288&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 119,586&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,509&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_9_30_2021_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_4dedr1AwQkWdcCVB7ocbbw"
      decimals="0"
      id="Tc_99eYYLMSRk2KLtnNvlJBag_3_3"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">85000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_9_30_2021_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_4dedr1AwQkWdcCVB7ocbbw"
      decimals="0"
      id="Tc_iHpzPbhICE2HmoUvRaiufw_3_6"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">85000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_9_30_2021_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_4dedr1AwQkWdcCVB7ocbbw"
      decimals="0"
      id="Tc_z5_TNCXnlEKHwfptr7CPjQ_3_9"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">85000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear
      contextRef="As_Of_9_30_2021_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_4dedr1AwQkWdcCVB7ocbbw"
      decimals="0"
      id="Tc_NLgqFaNVAUqn7YxmM-QsIA_3_12"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">85000</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="As_Of_9_30_2021_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_us-gaap_TypeOfArrangementAxis_epix_LicenseAgreementMember_4dedr1AwQkWdcCVB7ocbbw"
      decimals="0"
      id="Tc_BOZdxngja0miosZr9Tgunw_3_15"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">85000</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg"
      decimals="0"
      id="Tc_ir1v_Pta5U-jrMeviyI-gg_4_3"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">25000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg"
      decimals="0"
      id="Tc_Lvhif_fkkkSMvCWtFF39XQ_4_6"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">0</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg"
      decimals="0"
      id="Tc_KmCD0fcuJEOQ1EdrNnkmLQ_4_9"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">0</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg"
      decimals="0"
      id="Tc_llcphLzn7EKH9sDrAABgOA_4_12"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">0</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg"
      decimals="0"
      id="Tc_n4tvJyM4FU-NkBHU6ClVuw_4_15"
      unitRef="Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw">0</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_ConsultingAgreementMember_cW0iNp2Vx0-QozLErFC7rg"
      decimals="0"
      id="Tc_6-LpcjoL1EGQhAFt6zmMMg_6_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">35000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_ConsultingAgreementMember_cW0iNp2Vx0-QozLErFC7rg"
      decimals="0"
      id="Tc_9i6QpB6Ao0WLGYVuuu4ATg_6_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_ConsultingAgreementMember_cW0iNp2Vx0-QozLErFC7rg"
      decimals="0"
      id="Tc_yXnJYYQprkaXmMfJR-XZ8A_6_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_ConsultingAgreementMember_cW0iNp2Vx0-QozLErFC7rg"
      decimals="0"
      id="Tc_Tk9fH_-Pak-tlk7l482UBw_6_12"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_ConsultingAgreementMember_cW0iNp2Vx0-QozLErFC7rg"
      decimals="0"
      id="Tc_wiy3HlERpEK6dTwSTKgZwQ_6_15"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_RMrB863qE0qS6tVtlOO3Ng"
      decimals="0"
      id="Tc_UdajkJCjQ0SUERVUXnrgrQ_7_3"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">113288</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_RMrB863qE0qS6tVtlOO3Ng"
      decimals="0"
      id="Tc_F8t7wum83kab6zRSW8G77g_7_6"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">119586</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_RMrB863qE0qS6tVtlOO3Ng"
      decimals="0"
      id="Tc__PmmOJe_EEqsKBXQzNuXGA_7_9"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">81509</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_RMrB863qE0qS6tVtlOO3Ng"
      decimals="0"
      id="Tc_qJ7liv6xKUaicF1WZ0t1oQ_7_12"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_LeaseOnUsOfficeSpacesMember_RMrB863qE0qS6tVtlOO3Ng"
      decimals="0"
      id="Tc_HDS4ihkSIE-HPJcPw8YPLA_7_15"
      unitRef="Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg">0</us-gaap:ContractualObligationDueInFifthYear>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867607048056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 18, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ESSA Pharma&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2569713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Suite 720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">999 West Broadway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vancouver<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">BC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V5Z 1K5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">331-0962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001633932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 915.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,984,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867607028264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>ASSETS, Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 137,825,024<span></span>
</td>
<td class="nump">$ 56,320,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments (Note 5)</a></td>
<td class="nump">57,102,159<span></span>
</td>
<td class="nump">22,011,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">489,012<span></span>
</td>
<td class="nump">309,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaids (Note 6)</a></td>
<td class="nump">2,181,882<span></span>
</td>
<td class="nump">1,600,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_OperatingLeaseRightOfUseAssetsCurrent', window );">Operating lease right-of-use assets (Note 8)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55,162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">197,598,077<span></span>
</td>
<td class="nump">80,296,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">259,455<span></span>
</td>
<td class="nump">277,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets (Note 8)</a></td>
<td class="nump">308,286<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">198,165,818<span></span>
</td>
<td class="nump">80,574,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>LIABILITIES, Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities (Note 7)</a></td>
<td class="nump">3,808,944<span></span>
</td>
<td class="nump">1,144,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities (Note 8)</a></td>
<td class="nump">120,719<span></span>
</td>
<td class="nump">59,094<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,929,663<span></span>
</td>
<td class="nump">1,203,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities (Note 10)</a></td>
<td class="nump">20,352<span></span>
</td>
<td class="nump">127,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities (Note 8)</a></td>
<td class="nump">210,251<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,160,266<span></span>
</td>
<td class="nump">1,330,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares 43,984,346 issued and outstanding (September 30, 2020 - 32,064,411) (Note 11)</a></td>
<td class="nump">277,415,176<span></span>
</td>
<td class="nump">131,086,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital (Note 11)</a></td>
<td class="nump">36,442,620<span></span>
</td>
<td class="nump">31,204,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,076,479)<span></span>
</td>
<td class="num">(2,076,479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(117,775,765)<span></span>
</td>
<td class="num">(80,970,304)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders equity</a></td>
<td class="nump">194,005,552<span></span>
</td>
<td class="nump">79,243,865<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 198,165,818<span></span>
</td>
<td class="nump">$ 80,574,565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_OperatingLeaseRightOfUseAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease, current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_OperatingLeaseRightOfUseAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529658744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">43,984,346<span></span>
</td>
<td class="nump">32,064,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">43,984,346<span></span>
</td>
<td class="nump">32,064,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606504088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 24,258,989<span></span>
</td>
<td class="nump">$ 12,145,968<span></span>
</td>
<td class="nump">$ 6,696,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_FinancingCosts', window );">Financing costs (Notes 8 and 9)</a></td>
<td class="nump">22,220<span></span>
</td>
<td class="nump">618,109<span></span>
</td>
<td class="nump">602,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administration</a></td>
<td class="nump">12,884,581<span></span>
</td>
<td class="nump">11,373,952<span></span>
</td>
<td class="nump">5,455,189<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(37,165,790)<span></span>
</td>
<td class="num">(24,138,029)<span></span>
</td>
<td class="num">(12,754,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange</a></td>
<td class="num">(16,041)<span></span>
</td>
<td class="num">(44,851)<span></span>
</td>
<td class="nump">7,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions', window );">Interest income</a></td>
<td class="nump">234,997<span></span>
</td>
<td class="nump">559,719<span></span>
</td>
<td class="nump">26,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative liability gain (loss) (Note 10)</a></td>
<td class="nump">107,024<span></span>
</td>
<td class="num">(110,856)<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss for the year before taxes</a></td>
<td class="num">(36,839,810)<span></span>
</td>
<td class="num">(23,734,017)<span></span>
</td>
<td class="num">(12,718,912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax recovery (expense) (Note 14)</a></td>
<td class="nump">34,349<span></span>
</td>
<td class="nump">288,647<span></span>
</td>
<td class="num">(37,920)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss and comprehensive loss for the year</a></td>
<td class="num">$ (36,805,461)<span></span>
</td>
<td class="num">$ (23,445,370)<span></span>
</td>
<td class="num">$ (12,756,832)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per common share</a></td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (1.04)<span></span>
</td>
<td class="num">$ (1.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding - basic and diluted</a></td>
<td class="nump">38,480,378<span></span>
</td>
<td class="nump">22,443,893<span></span>
</td>
<td class="nump">8,433,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_FinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financing costs incurred during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_FinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDepositsWithFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867614724152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the year</a></td>
<td class="num">$ (36,805,461)<span></span>
</td>
<td class="num">$ (23,445,370)<span></span>
</td>
<td class="num">$ (12,756,832)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Items not affecting cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">109,464<span></span>
</td>
<td class="nump">110,324<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion of lease liability</a></td>
<td class="nump">9,570<span></span>
</td>
<td class="nump">12,992<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative liability loss</a></td>
<td class="num">(107,024)<span></span>
</td>
<td class="nump">110,856<span></span>
</td>
<td class="num">(1,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_IncomeTaxExpenseRecoveryOperatingActivities', window );">Income tax recovery</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(280,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_InterestIncomeOperatingActivities', window );">Interest income</a></td>
<td class="num">(76,056)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_FinanceExpenseOperatingActivities', window );">Finance expense</a></td>
<td class="nump">31,192<span></span>
</td>
<td class="nump">211,079<span></span>
</td>
<td class="nump">602,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,059<span></span>
</td>
<td class="nump">16,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based payments</a></td>
<td class="nump">9,476,113<span></span>
</td>
<td class="nump">7,522,608<span></span>
</td>
<td class="nump">1,146,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash working capital items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(157,575)<span></span>
</td>
<td class="nump">89,938<span></span>
</td>
<td class="num">(59,665)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaids</a></td>
<td class="num">(563,572)<span></span>
</td>
<td class="num">(1,262,280)<span></span>
</td>
<td class="num">(179,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">2,667,738<span></span>
</td>
<td class="num">(46,358)<span></span>
</td>
<td class="num">(1,014,049)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="num">(4,722)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(25,415,611)<span></span>
</td>
<td class="num">(16,983,152)<span></span>
</td>
<td class="num">(12,249,935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherDeposits', window );">Deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">274,085<span></span>
</td>
<td class="nump">201,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(57,026,103)<span></span>
</td>
<td class="num">(22,011,337)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from short-term investments sold</a></td>
<td class="nump">22,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_InterestFromShortTermInvestments', window );">Interest from short-term investments</a></td>
<td class="nump">11,337<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(35,014,766)<span></span>
</td>
<td class="num">(21,737,252)<span></span>
</td>
<td class="nump">201,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_CashAcquisitionFromAcquisitionOfBusiness', window );">Cash acquired on acquisition of Realm</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,244,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Transaction costs on acquisition of Realm</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(64,804)<span></span>
</td>
<td class="num">(1,860,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_PaymentOfSubleaseTerminationCosts', window );">Termination costs on Realm sublease</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(246,906)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds on issuance of common shares</a></td>
<td class="nump">149,999,985<span></span>
</td>
<td class="nump">48,990,000<span></span>
</td>
<td class="nump">36,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">(9,229,450)<span></span>
</td>
<td class="num">(3,447,954)<span></span>
</td>
<td class="num">(2,362,329)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">1,186,833<span></span>
</td>
<td class="nump">915<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrants exercised</a></td>
<td class="nump">596<span></span>
</td>
<td class="nump">257,172<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Shares purchased through employee share purchase plan</a></td>
<td class="nump">133,071<span></span>
</td>
<td class="nump">80,714<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_OperatingLeasePaymentsFinancingActivities', window );">Lease payments</a></td>
<td class="num">(100,282)<span></span>
</td>
<td class="num">(119,384)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Loan principal repaid</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,199,799)<span></span>
</td>
<td class="num">(2,808,823)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_RepaymentsOfFinalPaymentOfDebt', window );">Loan final payment paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(688,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Interest and financing costs paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(32,235)<span></span>
</td>
<td class="num">(401,929)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">141,990,753<span></span>
</td>
<td class="nump">41,776,625<span></span>
</td>
<td class="nump">50,563,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange on cash and cash equivalents</a></td>
<td class="num">(56,115)<span></span>
</td>
<td class="num">(58,181)<span></span>
</td>
<td class="num">(21,805)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents for the year</a></td>
<td class="nump">81,504,261<span></span>
</td>
<td class="nump">2,998,040<span></span>
</td>
<td class="nump">38,493,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">56,320,763<span></span>
</td>
<td class="nump">53,322,723<span></span>
</td>
<td class="nump">14,829,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">$ 137,825,024<span></span>
</td>
<td class="nump">$ 56,320,763<span></span>
</td>
<td class="nump">$ 53,322,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_CashAcquisitionFromAcquisitionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from acquisition of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_CashAcquisitionFromAcquisitionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_FinanceExpenseOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance expense, operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_FinanceExpenseOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_IncomeTaxExpenseRecoveryOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense Recovery Operating Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_IncomeTaxExpenseRecoveryOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_InterestFromShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest from short-term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_InterestFromShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_InterestIncomeOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest income operating activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_InterestIncomeOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_OperatingLeasePaymentsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash flow arising out of lease payments during the period, which are classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_OperatingLeasePaymentsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PaymentOfSubleaseTerminationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow on payment of sublease termination costs during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PaymentOfSubleaseTerminationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_RepaymentsOfFinalPaymentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayment of final payment of loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_RepaymentsOfFinalPaymentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for receipts of deposits classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606139496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Shares [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Retained Earnings (Deficit) [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Sep. 30, 2018</a></td>
<td class="nump">$ 40,205,997<span></span>
</td>
<td class="nump">$ 15,573,597<span></span>
</td>
<td class="num">$ (2,076,479)<span></span>
</td>
<td class="num">$ (44,768,102)<span></span>
</td>
<td class="nump">$ 8,935,013<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, in shares at Sep. 30, 2018</a></td>
<td class="nump">5,776,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Acquisition of Realm</a></td>
<td class="nump">$ 20,247,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,247,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Acquisition of Realm, in shares</a></td>
<td class="nump">6,718,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">$ (2,826,443)<span></span>
</td>
<td class="num">(1,764,982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,591,425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Financing</a></td>
<td class="nump">$ 12,161,192<span></span>
</td>
<td class="nump">23,838,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Financing , in shares</a></td>
<td class="nump">6,080,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_PrefundedWarrantExercisedValue', window );">Pre-funded warrants exercised</a></td>
<td class="nump">$ 8,757,066<span></span>
</td>
<td class="num">(8,755,996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_PrefundedWarrantExercisedShares', window );">Pre-funded warrants exercised, shares</a></td>
<td class="nump">2,187,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,146,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,146,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,756,832)<span></span>
</td>
<td class="num">(12,756,832)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 78,545,108<span></span>
</td>
<td class="nump">30,038,134<span></span>
</td>
<td class="num">(2,076,479)<span></span>
</td>
<td class="num">(57,524,934)<span></span>
</td>
<td class="nump">48,981,829<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, in shares at Sep. 30, 2019</a></td>
<td class="nump">20,762,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">$ (3,136,949)<span></span>
</td>
<td class="num">(7,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,144,003)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">$ 6,549,631<span></span>
</td>
<td class="num">(6,292,459)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised, in shares</a></td>
<td class="nump">3,120,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Financing</a></td>
<td class="nump">$ 48,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,990,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Financing , in shares</a></td>
<td class="nump">8,165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">$ 1,648<span></span>
</td>
<td class="num">(733)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued through employee share purchase plan</a></td>
<td class="nump">$ 136,926<span></span>
</td>
<td class="num">(56,212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued through employee share purchase plan, shares</a></td>
<td class="nump">16,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,522,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,522,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,445,370)<span></span>
</td>
<td class="num">(23,445,370)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 131,086,364<span></span>
</td>
<td class="nump">31,204,284<span></span>
</td>
<td class="num">(2,076,479)<span></span>
</td>
<td class="num">(80,970,304)<span></span>
</td>
<td class="nump">79,243,865<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, in shares at Sep. 30, 2020</a></td>
<td class="nump">32,064,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">$ (9,229,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,229,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">$ 3,254,460<span></span>
</td>
<td class="num">(3,253,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised, in shares</a></td>
<td class="nump">6,024,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Financing</a></td>
<td class="nump">$ 149,999,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,999,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Financing , in shares</a></td>
<td class="nump">5,555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">$ 2,105,467<span></span>
</td>
<td class="num">(918,634)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,186,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">323,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued through employee share purchase plan</a></td>
<td class="nump">$ 198,350<span></span>
</td>
<td class="num">(65,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued through employee share purchase plan, shares</a></td>
<td class="nump">15,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,476,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,476,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,805,461)<span></span>
</td>
<td class="num">(36,805,461)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2021</a></td>
<td class="nump">$ 277,415,176<span></span>
</td>
<td class="nump">$ 36,442,620<span></span>
</td>
<td class="num">$ (2,076,479)<span></span>
</td>
<td class="num">$ (117,775,765)<span></span>
</td>
<td class="nump">$ 194,005,552<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, in shares at Sep. 30, 2021</a></td>
<td class="nump">43,984,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PrefundedWarrantExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of prefunded warrant exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PrefundedWarrantExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PrefundedWarrantExercisedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prefunded warrant exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PrefundedWarrantExercisedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529608952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_NatureAndContinuanceOfOperationsAbstract', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESSA Pharma&#160;Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the Province of British Columbia on January&#160;6, 2009. The Company&#8217;s head office address is Suite&#160;720&#160;&#8211; 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;Floor at 595 Burrard Street, Three Bentall Centre, Vancouver, BC, V7X 1L3. The Company is listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;EPIX&#8221;. On October 30, 2020 the Company&#8217;s common shares delisted in Canada from the TSX Venture Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (the &#8220;NTD Technology&#8221;) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As at September 30, 2021, no products are in commercial production or use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Acquisition of Realm Therapeutics plc</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July&#160;31, 2019, the Company acquired all of the issued and outstanding shares of Realm Therapeutics plc (&#8220;Realm&#8221;) pursuant to a Scheme of Arrangement as sanctioned on July&#160;29, 2019 by the High Court of Justice in England and Wales (the &#8220;Realm Acquisition&#8221;) (Note&#160;4).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_NatureAndContinuanceOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_NatureAndContinuanceOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529648120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All amounts expressed in these accompanying consolidated financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise indicated. References to &#8220;$&#8221; are to United States dollars and references to &#8220;C$&#8221; are to Canadian dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of Consolidation and Functional Currency</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Consolidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accounts of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated upon consolidation. The consolidated financial statements comprise the accounts of ESSA Pharma&#160;Inc., the parent company, and its wholly owned subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Functional Currency</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">The functional currency of an entity is the currency of the primary economic environment in which the entity operates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The functional currency of the Company and its subsidiaries have been determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Country of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effective</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Functional</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharma&#160;Inc.</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Canada</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharmaceuticals Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Realm Therapeutics plc <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">United Kingdom</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Pound Sterling</p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Realm Therapeutics&#160;Inc. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">In the process of liquidation and dissolution as at September 30, 2021.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liabilities, the valuation of equity instruments issued for services, income taxes and the product development and relocation grant. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Income tax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Derivative financial instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Certain warrants are treated as derivative financial liabilities. The estimated fair value, based on the Black-Scholes model, is adjusted on a quarterly basis with gains or losses recognized in the statement of loss and comprehensive loss. The Black-Scholes model is based on significant assumptions such as volatility, dividend yield, expected term and liquidity discounts (Note&#160;10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based payments and compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying common shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note&#160;11.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606503096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of cash in banks and high-interest savings accounts and cash collateral which are recorded at cost, which approximates fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Short-term investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s short-term investments consist of guaranteed investment certificates and term deposits with original maturities exceeding three months and less than one year. The investments are recorded at cost plus accrued interest, which approximates fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Foreign exchange</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Transactions in currencies other than the United States dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are included in comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">On translation of the entities whose functional currency is other than the United States dollar, revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Assets and liabilities are translated at the rate of exchange at the reporting date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Translation gains and losses are recorded in other comprehensive income (loss) as the cumulative translation adjustment along with the historical effects of a change in the functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Government assistance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Government grants, including grants from similar bodies, consisting of investment tax credits are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research grants that compensate the Company for expenses incurred are recognized in the statement of operations and comprehensive loss on a systematic basis in the same&#160;years in which the expenses are recognized. Grants that compensate the Company for the cost of an asset are recognized on a systematic basis over the useful life of the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Research and development costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Expenditures on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred. Investment tax credits related to current expenditures are included in the determination of net income as the expenditures are incurred when there is reasonable assurance they will be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Fair Value of financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities, long-term debt and derivative liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company provides disclosures that enable users to evaluate (a)&#160;the significance of financial instruments for the entity&#8217;s financial position and performance; and (b)&#160;the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and at the date of the statement of financial position, and how the entity manages these risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 1&#160;&#8211; quoted prices (unadjusted) in active markets for identical assets or liabilities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 2&#160;&#8211; inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:40.3pt;margin:0pt 0pt 12pt 0pt;">directly (i.e., as prices) or indirectly (i.e., derived from prices); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 3&#160;&#8211; inputs for the asset or liability that are not based on observable market data (unobservable inputs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of cash and cash equivalents, receivables and accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The derivative liabilities are measured using level 3 inputs (Note 10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Share-based payments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Share based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity settled share-based payment transactions and measured at the fair value of at grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company grants stock options to acquire common shares of the Company to directors, officers, employees and consultants. The Company has elected to early adopt ASU 2018-07 which treats the measurement of employee and nonemployee options similarly and has been applied to all periods presented. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of stock options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the requisite service or vesting period as applicable. Consideration paid for the shares on the exercise of stock options is credited to share capital. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basic and diluted loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic loss per share is computed by dividing the loss available to common shareholders by the weighted average number of common shares outstanding during the&#160;year. The computation of diluted earnings per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the &#8220;if converted&#8221; method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the weighted-average method. Since the Company has losses, the exercise of outstanding options and warrants has not been included in this calculation as it would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one&#160;year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of a lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the assessment unless there is reasonable certainty that the Company will renew.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at period end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Deferred tax is recognized in respect of temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes and an excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary that is essentially permanent in duration.  The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted at the financial position reporting date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A valuation allowance is recognized for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets are reviewed at each reporting date and a valuation allowance is recorded to the extent that it is no longer more likely than not that the related tax benefit will be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2018-18&#160;&#8211; Collaborative Arrangements (Topic 808)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In November 2018, the FASB issued ASU 2018-18, &#8220;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#8221;. This ASU: (i) clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer, (ii) provides guidance specifying that a distinct good or service is the unit of account for evaluating whether a transaction is with a customer, and (iii) precludes a company from presenting transactions with a collaborative arrangement participant that are not in the scope of ASC 606 together with revenue from contracts with customers. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020. The Company will present collaboration revenue separate from product revenues. The adoption of this new accounting standard did not have a significant impact on the Company&#8217;s consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2018-15&#160;&#8211; Intangibles &#8211; Goodwill and Other (Subtopic 350-40)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In August 2018, the FASB issued ASU 2018&#8211;15, Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350&#8211;40). This ASU addresses the accounting for implementation costs incurred by a customer in a cloud computing arrangement that is a service contract and also adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The amendment aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020 and has applied it prospectively to all implementation costs incurred after October 1, 2020. The adoption of this new accounting standard did not have a significant impact on the Company&#8217;s consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2018-13&#160;&#8211; Fair Value Measurement (Topic 820-10)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820-10): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (&#8220;ASU 2018-13&#8221;), which changes the fair value measurement disclosure requirements of ASC Topic 820, Fair Value Measurements and Disclosures. Under this ASU, certain disclosure requirements for fair value measurements are eliminated, amended or added. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October&#160;1, 2020. The adoption of the standard had no impact on the Company&#8217;s consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2019-12&#160;&#8211; Income Taxes (Topic 740)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#8220;ASU 2019-12&#8221;), which simplifies the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new ASU also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company&#8217;s consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2016-13&#160;&#8211; Financial Instruments-Credit Losses (Topic 326)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In June&#160;2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including trade receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. This guidance is effective for annual reporting periods beginning after December&#160;15, 2019, with early adoption permitted. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company&#8217;s consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Recently accounting pronouncements not yet adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2020-06&#160;</i><i style="font-style:italic;font-weight:normal;white-space:pre-wrap;">&#8211; Debt with Conversion and Other Options (Subtopic  470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;white-space:pre-wrap;">In August 2020, the FASB issued ASU No. 2020-06 (&#8220;ASU 2020-06&#8221;) &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic   815-40):   Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity.&#8221; ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP.  Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity&#8217;s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company&#8217;s accounting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2020-10&#160;&#8211; Codification Improvements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the FASB issued ASU 2020-10, Codification Improvements. The guidance contains improvements to the Codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the Disclosure Section of the Codification. The guidance also contains Codifications that are varied in nature and may affect the application of the guidance in cases in which the original guidance may have been unclear. For public business entities, the amendments in the ASU are effective for fiscal years beginning after December 15, 2020. For all other entities, the amendments are effective for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022. Early adoption is permitted. We do not expect the adoption of ASU 2020-10 to have a material impact on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2021-04&#160;&#8211; Earnings per share</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40). &#160;The new ASU addresses issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company will evaluate the impact of the pronouncement closer to the effective date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statement presentation or disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529769800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REALM ACQUISITION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>REALM ACQUISITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">REALM ACQUISITION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;&#160;&#160;&#160;&#160;REALM ACQUISITION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July&#160;31, 2019, the Company acquired all of the issued and outstanding shares of Realm. Realm shareholders received a total of 6,718,150 common shares of the Company (&#8220;New ESSA Shares&#8221;) at a ratio of 0.05763 of a New ESSA Share per share of Realm (or 1.4409 New ESSA Shares for every one Realm ADS, representing 25 Realm shares). The fair value of the Realm net assets on July&#160;31, 2019, substantially all of which consisted of cash, was $20,247,296. Additionally, the Company incurred issuance costs of $1,925,145.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Realm is not considered to be a business under the definitions of ASU 2017-01; accordingly, the Realm Acquisition is accounted for as a financing transaction. The shares issued in connection with the acquisition of Realm were valued on the basis of the value of assets received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Net assets of Realm acquired:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,244,248</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receivables and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 240,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and accrued liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,236,952)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total net assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,247,296</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606607960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>SHORT-TERM INVESTMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">SHORT-TERM INVESTMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5.&#160;&#160;&#160;&#160;&#160;SHORT-TERM INVESTMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term investments consist of guaranteed investment certificates (&#8220;GICs&#8221;) held at financial institutions purchased in accordance with the Company&#8217;s treasury policy. These GICs and term deposits bear interest at 0.22%-0.40% per annum and have maturities of up to 12 months.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606606792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAIDS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>PREPAIDS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_PrepaidExpensesTextBlock', window );">PREPAIDS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">6.&#160;&#160;&#160;&#160;&#160;PREPAIDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,751,052</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 825,014</p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid CMC and clinical expenses and deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 650,586</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other deposits and prepaid expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 190,317</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,528</p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, end of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,181,882</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,600,128</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529789704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">7.&#160;&#160;&#160;&#160;&#160;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,425,871</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 678,643</p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,062,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,604</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 320,632</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154,983</p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, end of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,808,944</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,144,230</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529743784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>OPERATING LEASE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;&#160;&#160;OPERATING LEASE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s operating leases included on the balance sheet are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease right-of-use asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2018 and 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 165,486</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,324)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,162</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 362,588</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (109,464)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308,286</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2018 and 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 165,486</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,992</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (119,384)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59,094</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Addition</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 362,588</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,570</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (100,282)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 330,970</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes a right-of-use asset for the right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company&#8217;s obligation to make payments over the lease term. The present value of the lease payments is calculated using an incremental borrowing rate as the Company&#8217;s leases do not provide an implicit interest rate. At September 30, 2021, the Company&#8217;s incremental borrowing rate was 5.0% and the remaining lease term for the South Francisco office was 32&#160;months and Houston office was 22 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease costs of $100,282 (2020 - $119,384) and accretion expense of $9,570 (2020 - $12,992) have been recorded in &#8220;general and administrative expenses&#8221; and &#8220;financing costs&#8221; in the statement of operations and comprehensive loss respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867607104984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM DEBT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9.&#160;&#160;&#160;&#160;&#160;LONG-TERM DEBT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November&#160;18, 2016, Silicon Valley Bank (&#8220;SVB&#8221;) entered into a $10,000,000 capital term loan facility agreement (&#8220;SVB Term Loan&#8221;) with the Company. The Company drew down $8,000,000 from the SVB Term Loan. The option to draw an additional $2,000,000 lapsed on July&#160;31, 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The SVB Term Loan bore interest at the Wall Street Journal Prime Rate (&#8220;WSJ Prime Rate&#8221;) plus 3% per annum and with a maturity date of September&#160;1, 2020. The SVB Term Loan required a final payment of 8.6% of the amount advanced (&#8220;Final Payment&#8221;), due upon the earlier of the maturity or termination of the SVB Term Loan. The Company was required to make interest only payments until December&#160;31, 2017. The SVB Term Loan contained a voluntary prepayment option whereby the principal amount can be prepaid in whole, or in part, for a fixed fee if a prepayment is made on or before the second anniversary of the SVB Term Loan. In the year ended September 30, 2020, the Company repaid the SVB Term Loan in full totalling $3,708,955, comprising $3,199,799 in principal, $32,235 in accrued interest, $211,079 in financing costs and the Final Payment of $688,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the $8,000,000 draw, the Company granted an aggregate of 7,477 warrants to SVB (the &#8220;SVB Warrants&#8221;), exercisable at a price of $42.80 per share for a period of seven years until November&#160;18, 2023, with a fair value of $167,022. The Company incurred total additional transaction costs of $220,898 related to the SVB Term Loan and First Amendment. The transaction costs and Final Payment were being amortized into profit and loss over the estimated term of the facility, being the legal term, resulting in an effective interest rate of 12.6% (2019&#160;- 12.19%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The SVB Term Loan was fully repaid during the fiscal&#160;year ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SVB Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loan</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, September&#160;30,&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,316,963</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Principal repaid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,808,823)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest paid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (401,929)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 602,744</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, September&#160;30,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,708,955</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Principal repaid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,199,799)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest paid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,235)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211,079</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Final payment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (688,000)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, September&#160;30,&#160;2020 and 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867530274232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10.&#160;&#160;&#160;&#160;&#160;DERIVATIVE LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2016, the Company completed a private placement of 227,273 units of the Company at $66.00 per unit (&#8220;Unit&#8221;) for gross proceeds of $14,999,992. Each Unit consisted of one common share of the Company, one <span style="-sec-ix-hidden:Hidden_LQbZKgvpMkSuPJkLK-6o4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-year</span></span> cash and cashless exercise warrant (the &#8220;<span style="-sec-ix-hidden:Hidden_smbzU3-LrEiEpofGJXZ0jQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrants&#8221;), and <span style="-sec-ix-hidden:Hidden_Cq_ppVfGcEWPX38oEjsM7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one half</span></span> of one <span style="-sec-ix-hidden:Hidden_93qUCOn8jU2BvXa947ry6Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2-year</span></span> cash exercise warrant (the &#8220;<span style="-sec-ix-hidden:Hidden_QDBLvhGsQUeMEe7FQU06dg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2-Year</span></span> Warrants&#8221;). The <span style="-sec-ix-hidden:Hidden_6BX3OeUYGUyxMKVAjbP3ng;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrants and <span style="-sec-ix-hidden:Hidden_BNXa2upcvUaUska1jS5ngQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2-Year</span></span> Warrants have an exercise price of $66.00 per common share (collectively, the &#8220;2016 Warrants&#8221;). The holders of the <span style="-sec-ix-hidden:Hidden_RPrZ07gL9EKwo3zFCZTqrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrants may elect, in lieu of exercising the <span style="-sec-ix-hidden:Hidden_VdjHFZpuu0Gaw-U_hHH3mg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrants for cash, a cashless exercise option, in whole or in part, to receive common shares equal to the fair value of the <span style="-sec-ix-hidden:Hidden_-5WrOmKIy0aUmOgHj7jFrA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrants based on the number of <span style="-sec-ix-hidden:Hidden_oH1NQJf7jEaRneoPXDn_6A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrants to be exercised multiplied by a ten-day weighted average market price less the exercise price with the difference divided by the weighted average market price. If a warrant holder exercises this option, there will be variability in the number of shares issued per <span style="-sec-ix-hidden:Hidden_XtTWqNg7CkSa4uffoyvABg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-Year</span></span> Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, the 2016 Warrants contain provisions which may require the Company to redeem the 2016 Warrants, at the option of the holder, in the event of a major transaction, such as a change of control or sale of the Company&#8217;s assets (&#8220;Major Transaction&#8221;). The redemption value would be subject to a Black-Scholes valuation at the time of exercise. In the event the consideration for a Major Transaction payable to the common shareholders is in cash, in whole or in part, the redemption of the 2016 Warrants would be made in cash pro-rata to the composition of the consideration. The potential for a cash settlement for the 2016 Warrants outside the control of the Company, in accordance with U.S. GAAP, requires the 2016 Warrants to be treated as financial liabilities measured at fair value through profit or loss. The 2016 Warrants are not traded in an active market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Valuation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liabilities on September 30, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:31.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.49</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Liquidity discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Sensitivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The derivative warrants are a recurring Level 3 fair value measurement. The key level 3 inputs used by management to determine the fair value are the market price, expected volatility and liquidity discount. If the market price were to increase by a factor of 10% this would increase the obligation by approximately $745,868 as at September 30, 2021. If the market price were to decrease by a factor of 10% this would decrease the obligation by approximately $429,170 as at September 30, 2021. If the volatility were to increase by 10%, this would increase the obligation by approximately $741,813 as at September 30, 2021. If the volatility were to decrease by 10%, this would decrease the obligation by approximately $423,842 as at September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table is a continuity schedule of changes to the Company&#8217;s derivative liabilities:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Balance, September&#160;30,&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,679</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,159)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Balance, September&#160;30,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,520</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 110,856</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 127,376</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (107,024)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,352</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Derivatives with expected life of less than one&#160;year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Derivatives with expected life greater than one&#160;year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,352</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867528369768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;&#160;&#160;SHAREHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Authorized</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unlimited common shares, without par value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Unlimited preferred shares, without par value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">February 2021 Financing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On February 22, 2021, the Company completed an underwritten public offering for aggregate gross proceeds of $149,999,985 (the &#8220;<b style="font-weight:bold;">February 2021 Financing</b>&#8221;). The Company issued a total of 5,555,555 common shares of the Company at a public offering price of $27.00 per share, which includes the underwriters having exercised their <span style="-sec-ix-hidden:Hidden_jpTTNPtrr0yX_oiBe_gYnw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">30-day</span></span> option to purchase an additional 724,637 common shares. In connection with the February 2021 Financing, the Company paid cash commissions of $8,999,999 and incurred other transaction costs of $229,451.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">July&#160;2020 Financing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July&#160;31, 2020, the Company completed an underwritten public offering for aggregate gross proceeds of US$48,990,000 (the &#8220;<b style="font-weight:bold;">July&#160;2020 Financing</b>&#8221;). The Company issued a total of 7,100,000 common shares of the Company at a public offering price of US$6.00 per share. Additionally, the underwriters exercised a <span style="-sec-ix-hidden:Hidden_AZRAwVMkb0-1Z3ZiwRVKQw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">30-day</span></span> option to purchase up to an additional 1,065,000 common shares. In connection with the July 2020 Financing, the Company paid cash commissions of $2,939,400 and incurred other transaction costs of $212,256.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">August&#160;2019 Financing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On August&#160;27, 2019, the Company closed a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the &#8220;<b style="font-weight:bold;">August&#160;2019 Financing</b>&#8221;). The Company issued a total of 6,080,596 common shares and 11,919,404 pre-funded warrants in lieu of common shares of the Company at a price of $2.00 per security for aggregate gross proceeds of $36,000,000. Each pre-funded warrant entitles the holder thereof to acquire one common share at a nominal exercise price for a period of five years. In connection with the August&#160;2019 Financing, the Company paid cash commissions of $1,978,770 and incurred other transaction costs of $698,162.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Realm Acquisition</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July&#160;31, 2019, the Company issued 6,718,150 shares in relation to the Realm Acquisition (Note&#160;4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Nomination Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with a January&#160;2016 private placement of 227,273 Units, a Unit consisting of one common share, one <span style="-sec-ix-hidden:Hidden_qojYrx_Z1UW0vuZx-arG5A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7-year</span></span> warrant and <span style="-sec-ix-hidden:Hidden_zEYEXFo-FkWGt12ydoujMA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one</span></span>-half of one <span style="-sec-ix-hidden:Hidden_EsUTpCDv1Eui8u7BVbNk7g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2-year</span></span> warrant, of the Company, Clarus Lifesciences III,&#160;L.P. (&#8220;<b style="font-weight:bold;">Clarus</b>&#8221;) acquired 106,061 common shares. Clarus is entitled to nominate two directors to the board of directors of the Company, one of which must be an independent director and preapproved by the Company. These nomination rights will continue for so long as Clarus holds greater than or equal to 53,030 common shares, subject to adjustment in certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Equity incentive plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Restricted share units plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has adopted a Restricted Share Unit Plan (&#8220;RSU Plan&#8221;) consistent with the policies and rules&#160;of the TSX-V and Nasdaq. Pursuant to the RSU Plan, RSUs may be granted with vesting criteria and periods are approved by the Board of Directors at its discretion. The RSUs issued under the RSU Plan may be accounted for as either equity-settled or cash-settled share-based payments. At September 30, 2021, there are no RSUs outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As at September 30, 2021 the Stock Option Plan and RSU Plan have a combined maximum of 7,342,788 common shares which may be reserved for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Employee Share Purchase Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has adopted an Employee Share Purchase Plan (&#8220;ESPP&#8221;) under which qualifying employees may be granted purchase rights (&#8220;Purchase Rights&#8221;) to the Company&#8217;s common shares at not less of 85% of the market price at the lesser of the date the Purchase Right is granted or exercisable. The Company currently holds offerings consisting of six-month periods commencing on January&#160;1 and July&#160;1 and ending on June&#160;30 and December&#160;31 of each calendar&#160;year. As at September 30, 2021, the ESPP has a maximum of 252,418 (2020&#160;&#8211;268,381) common shares reserved for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Eligible employees are able to contribute up to 15% of their gross base earnings for purchases under the ESPP through regular payroll deductions. Purchase of shares under the ESPP are limited for each employee at $25,000 worth of the Company&#8217;s common shares (determined using the lesser of (i)&#160;the market price of a common share on the first day of an applicable purchase period and (ii)&#160;the market price of a common share on the purchase date) for each calendar&#160;year in which a purchase right is outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the&#160;year ended September 30, 2021, the Company issued a total of 15,963 (2020&#160;&#8211;16,506; 2019 - nil) common shares upon the exercise of Purchase Rights. The Company recognizes compensation expense for purchase rights on a straight-line basis over the service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:middle;white-space:nowrap;width:32.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended September&#160;30,&#160; </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,299</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,984</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,431</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 71,017</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company measures the purchase rights based on their estimated grant date fair value using the Black-Scholes option pricing model and the estimated number of shares that can be purchased. The following weighted average assumptions were used for the valuation of purchase rights:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.44</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life of share purchase rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61.54</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90.34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Stock options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has adopted a Stock Option Plan consistent with the policies and rules&#160;of the TSX-V and Nasdaq. Pursuant to the Stock Option Plan, options may be granted with expiry terms of up to 10 years, and vesting criteria and periods are approved by the Board of Directors at its discretion. The options issued under the Stock Option Plan are accounted for as equity-settled share-based payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock option transactions are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price*</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 900,459</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.59</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 255,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.77</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,998)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.10)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,122,461</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.59</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,218,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.31</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (416)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.20)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (30,461)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28.46)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,309,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.42</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,889,646</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.87</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (323,610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.68)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (72,390)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.46)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance outstanding, September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,803,230</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.20</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance exercisable, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,799,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.49</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Options exercisable in Canadian dollars as at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">September 30, 2021</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding options.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At September 30, 2021, options were outstanding enabling holders to acquire common shares as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual life (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,584</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.70</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,794,603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.59</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,667</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.05</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 185,816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 539,518</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 183,511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,508,146</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 190,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">29.63</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.58</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">31.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.90</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163,154</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.81</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,803,230</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.15</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Share-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended September 30, 2021, the Company granted a total of 1,889,646 (2020&#160;&#8211; 4,218,000, 2019 - 255,000) stock options with a weighted average fair value of $8.04 per option (2020&#160;&#8211; $2.98, 2019 - $3.00).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company recognized share-based payments expense for options granted and vesting, net of recoveries on cancellations of unvested options, during the&#160;years ended September 30, 2021, 2020 and 2019 with allocations to its functional expense as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended September&#160;30,&#160; </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expense </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,611,083</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,853,388</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,786</p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,796,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,598,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 841,921</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,407,682</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,451,590</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,146,707</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following weighted average assumptions were used for the Black-Scholes option-pricing model valuation of stock options granted:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.44</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.55</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.55</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78.16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant transactions are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,663,937</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.13</p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,919,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0001</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,188,999)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.002)</p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31.17)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,393,092</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.31</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,120,115)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.08)</p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,272,977</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.73</p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,038,227)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.06)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance outstanding and exercisable, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,234,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.84</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Warrants exercisable in Canadian dollars as at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">September 30, 2021</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding warrants.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">At September 30, 2021, warrants were outstanding enabling holders to acquire common shares as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiry Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">227,273</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January&#160;14, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">November&#160;18, 2023</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">80,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January&#160;9, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,920,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August&#160;23, 2024</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,234,750</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Detailed terms of the 2016 Warrants are included in Note&#160;10.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529791128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">12.&#160;&#160;&#160;&#160;SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended September 30, 2021, the Company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">81,303</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> common shares upon the cashless exercise of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">94,723</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> pre-funded warrants.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There were no significant non-cash financing or investing activities during the year ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended September&#160;30, 2019, the Company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">1,652,530</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> common shares upon the cashless exercise of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">1,653,999</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> pre-funded warrants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">incurred </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$64,804</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> in transaction costs related to the Realm Transaction through accounts payable and accrued liabilities (Note&#160;4); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">incurred </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$303,951</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> in share issuance costs through accounts payable and accrued liabilities.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606577976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">13.&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Included in accounts payable and accrued liabilities at September 30, 2021 is $82,036 (2020&#160;- $87,846) due to related parties with respect to key management personnel compensation and expense reimbursements. Amounts due to related parties are non-interest bearing, with no fixed terms of repayment.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529791128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;&#160;&#160;&#160;INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a reconciliation of income taxes calculated at the combined Canadian federal and provincial income statutory corporate tax rate of 27.0% (2020 &#8211; 27.0%, 2019 &#8211; 27.0%) to the tax expense:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">For the&#160;years ended September&#160;30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Loss for the&#160;year before income tax</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (36,839,810)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23,734,017)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,718,912)</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax recovery at statutory income tax rates</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,947,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,408,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,434,000)</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-deductible share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,575,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,031,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 227,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxable capital gains</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346,000</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other permanent differences including foreign exchange</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share issue costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,492,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (849,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (720,000)</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in statutory, foreign tax, foreign exchange rates and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,260,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,013,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 458,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (725,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (307,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (196,000)</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,344,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,210,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,354,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_I8yCBUa3N0W0JSccZZb-kw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> (34,000)</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Y6jwuf91OUyOdeLUzsBsTA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> (289,000)</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qGTwKPFLwU6oUyoQmQDV4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> 38,000</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax attributes are subject to review, and potential adjustment, by tax authorities. The Company has recorded an income tax recovery of $34,349 for the&#160;year ended September 30, 2021 (2020&#160;&#8211; recovery of $288,647, 2019 &#8211; expense of $37,920) in relation to taxable income generated by its US subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the years ended September 30, 2021 and 2020, the Company did not record a provision for income taxes due to a full valuation allowance against our deferred tax assets. The significant components of the Company&#8217;s deferred tax assets are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating losses carried forward</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,749,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,297,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equipment and intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investment tax credits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,025,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,462,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal R&amp;D credit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 210,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,169,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,875,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,169,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,875,000)</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net future tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As at September 30, 2021, the Company has non-capital loss carry-forwards of approximately $78,416,000 (2020 - $64,494,000) available to offset future taxable income in Canada and approximately $40,843,000 (2020 - $20,249,000) available to offset future taxable income in the US. These non-capital loss carryforwards begin to expire in 2031.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606561256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTED INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTED INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTED INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15.&#160;&#160;&#160;&#160;SEGMENTED INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company works in one industry being the development of small molecule drugs for prostate cancer. The Company&#8217;s right of use asset is located in the USA.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529461368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_FinancialInstrumentsAndRiskAbstract', window );"><strong>FINANCIAL INSTRUMENTS AND RISK</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS AND RISK</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16.&#160;&#160;&#160;&#160;FINANCIAL INSTRUMENTS AND RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities, long-term debt and derivative liabilities. The fair value of cash and cash equivalents, receivables and accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The derivative liabilities are measured using level 3 inputs (Note&#160;10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of judgement, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Financial risk factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s risk exposures and the impact on the Company&#8217;s financial instruments are summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Credit risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and receivables. The Company&#8217;s receivables are refunds from vendors. The Company limits its exposure to credit loss by placing its cash with major financial institutions. The Company considers highly liquid investments with a maturity of up to twelve months when purchased to be short-term investments. As at September 30, 2021, cash and cash equivalents consisted of cash in Canada and the United States.  and term deposits in Canada. Balances exceed amounts insured by the Canada Deposit Insurance Corporation for up to C</span>$100,000 and by the Federal Deposit Insurance Corporation for up to $250,000. Amounts due from government agencies are considered to have minimal credit risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Liquidity risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at September 30, 2021, the Company had working capital of $193,668,414. The Company does not generate revenue and will be reliant on external financing to fund operations. Debt and equity financing are dependent on market conditions and may not be available on favorable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Market risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Market risk is the risk of loss that may arise from changes in market factors such as interest rates, and foreign exchange rates.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">(a)</span>Interest rate risk</div><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">As at September 30, 2021, the Company has cash and cash equivalents balances and GICs which are interest bearing. Interest income is not significant to the Company&#8217;s projected operational budget and related interest rate fluctuations are not significant to the Company&#8217;s risk assessment.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:36pt;white-space:nowrap;">(b)</span>Foreign currency risk</div><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company&#8217;s foreign currency risk exposure relates to net monetary assets denominated in Canadian, UK pound and Euro dollars. The Company maintains its cash and cash equivalents in US dollars and converts on an as needed basis to discharge Canadian denominated expenditures. A 10% change in the foreign exchange rate between the Canadian, UK Pound, Euro and U.S. dollar in relation to Canadian, UK Pound, Euro dollars held at September 30, 2021 would result in a fluctuation of $27,261 in the net loss recognized for the period. The Company does not currently engage in hedging activities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_FinancialInstrumentsAndRiskAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>na</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_FinancialInstrumentsAndRiskAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529525240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17.&#160;&#160;&#160;&#160;COMMITMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Product Development and Relocation Grant</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2014 the Company was awarded a product development and relocation grant by CPRIT whereby the Company received $12,000,000 on eligible expenditures over a three-year period related to the development of the Company&#8217;s androgen receptor n-terminus blocker program for prostate cancer. A final payment of $229,201 was recorded as a receivable as at September 30, 2020. During the fiscal year ended September 30, 2021, the Company determined that the receivable was deemed uncollectible. The impairment of the CPRIT receivable is recorded against research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If the Company is found to have used any grant proceeds for purposes other than intended, is in violation of the terms of the grant, or fails to maintain the required level of operations in the State of Texas for three&#160;years following the final payment of grant funds, then the Company could be required to repay any grant proceeds received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the grant, the Company is also required to pay a royalty to CPRIT, comprised of 4% of revenues the Company receives from sale of commercial product or commercial service, until aggregate royalty payments equal $24,000,000, and 2% of revenues thereafter. The Company has the option to terminate the grant agreement by paying a one-time, non-refundable buyout fee, based on certain factors including the grant proceeds, and the number of&#160;months between the termination date and the buyout fee payment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The NTD Technology is held under a license agreement signed in fiscal 2010 (the &#8220;License Agreement&#8221;). As consideration for the License Agreement, the Company issued common shares of the Company. The License Agreement contains an annual royalty as a percentage of annual net revenue and a percentage of any annual sublicensing revenue earned with respect to the NTD Technology. The License Agreement stipulates annual minimum advance royalty payments of C$85,000<span style="white-space:pre-wrap;">.  In addition, there are certain milestone payments for the first compound, to be paid in stages as to C</span>$50,000 at the start of a Phase II clinical trial, C$900,000 at the start of a Phase III clinical trial, C$1,450,000 at application for marketing approval, and with further milestone payments on the second and additional compounds</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has the following obligations over the next five&#160;years:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Contractual obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Minimum annual royalty per License Agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">85,000</p></td></tr><tr><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vendor Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease on US office spaces</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,288</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 119,586</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,509</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Collaborative agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On February 25, 2021, the Company announced a clinical collaboration with Astellas Pharma Inc. (&#8220;Astellas&#8221;) to evaluate the combination of EPI-7386 and Astellas/Pfizer&#8217;s androgen receptor inhibitor, enzalutamide, for patients with mCRPC. Under the terms of the agreement, ESSA will sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of the combination of EPI-7386 and enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies. Astellas will supply enzalutamide for the trial. ESSA will retain all rights to EPI-7386. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="font-style:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="font-style:normal;white-space:pre-wrap;">On April 28, 2021, the Company announced that it had entered into a clinical trial collaboration and supply agreement with Bayer to evaluate EPI-7386 in combination with Bayer&#8217;s androgen receptor inhibitor, darolutamide, in patients with mCRPC.  Under the terms of the agreement, following review of certain clinical data, Bayer may sponsor and conduct a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the combination of EPI-7386 and darolutamide in mCRPC patients. ESSA will supply EPI-7386 for the trial and will retain all rights to EPI-7386. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867528454920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Policy)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All amounts expressed in these accompanying consolidated financial statements and the accompanying notes are expressed in United States dollars, except per share data and where otherwise indicated. References to &#8220;$&#8221; are to United States dollars and references to &#8220;C$&#8221; are to Canadian dollars.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation and Functional Currency</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of Consolidation and Functional Currency</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Consolidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accounts of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated upon consolidation. The consolidated financial statements comprise the accounts of ESSA Pharma&#160;Inc., the parent company, and its wholly owned subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Functional Currency</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">The functional currency of an entity is the currency of the primary economic environment in which the entity operates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The functional currency of the Company and its subsidiaries have been determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Country of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effective</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Functional</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharma&#160;Inc.</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Canada</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharmaceuticals Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Realm Therapeutics plc <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">United Kingdom</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Pound Sterling</p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Realm Therapeutics&#160;Inc. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">In the process of liquidation and dissolution as at September 30, 2021.</span></td></tr></table><div style="margin-top:10pt;"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liabilities, the valuation of equity instruments issued for services, income taxes and the product development and relocation grant. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Income tax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Derivative financial instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Certain warrants are treated as derivative financial liabilities. The estimated fair value, based on the Black-Scholes model, is adjusted on a quarterly basis with gains or losses recognized in the statement of loss and comprehensive loss. The Black-Scholes model is based on significant assumptions such as volatility, dividend yield, expected term and liquidity discounts (Note&#160;10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based payments and compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying common shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note&#160;11.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867534076008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policy)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of cash in banks and high-interest savings accounts and cash collateral which are recorded at cost, which approximates fair value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-term Investments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Short-term investments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s short-term investments consist of guaranteed investment certificates and term deposits with original maturities exceeding three months and less than one year. The investments are recorded at cost plus accrued interest, which approximates fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Exchange</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Foreign exchange</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Transactions in currencies other than the United States dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are included in comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">On translation of the entities whose functional currency is other than the United States dollar, revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Assets and liabilities are translated at the rate of exchange at the reporting date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.3pt;margin:0pt 0pt 12pt 0pt;">Translation gains and losses are recorded in other comprehensive income (loss) as the cumulative translation adjustment along with the historical effects of a change in the functional currency.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_GovernmentAssistancePolicyPolicyTextBlock', window );">Government Assistance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Government assistance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Government grants, including grants from similar bodies, consisting of investment tax credits are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research grants that compensate the Company for expenses incurred are recognized in the statement of operations and comprehensive loss on a systematic basis in the same&#160;years in which the expenses are recognized. Grants that compensate the Company for the cost of an asset are recognized on a systematic basis over the useful life of the asset.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Research and development costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Expenditures on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in profit or loss as incurred. Investment tax credits related to current expenditures are included in the determination of net income as the expenditures are incurred when there is reasonable assurance they will be realized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Fair Value of financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, receivables, accounts payable and accrued liabilities, long-term debt and derivative liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company provides disclosures that enable users to evaluate (a)&#160;the significance of financial instruments for the entity&#8217;s financial position and performance; and (b)&#160;the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and at the date of the statement of financial position, and how the entity manages these risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 1&#160;&#8211; quoted prices (unadjusted) in active markets for identical assets or liabilities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 2&#160;&#8211; inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:40.3pt;margin:0pt 0pt 12pt 0pt;">directly (i.e., as prices) or indirectly (i.e., derived from prices); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 3&#160;&#8211; inputs for the asset or liability that are not based on observable market data (unobservable inputs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of cash and cash equivalents, receivables and accounts payable and accrued liabilities approximates their carrying values due to their short term to maturity. The derivative liabilities are measured using level 3 inputs (Note 10).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Share-based payments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Share based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity settled share-based payment transactions and measured at the fair value of at grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company grants stock options to acquire common shares of the Company to directors, officers, employees and consultants. The Company has elected to early adopt ASU 2018-07 which treats the measurement of employee and nonemployee options similarly and has been applied to all periods presented. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of stock options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the requisite service or vesting period as applicable. Consideration paid for the shares on the exercise of stock options is credited to share capital. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basic and diluted loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic loss per share is computed by dividing the loss available to common shareholders by the weighted average number of common shares outstanding during the&#160;year. The computation of diluted earnings per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the &#8220;if converted&#8221; method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the weighted-average method. Since the Company has losses, the exercise of outstanding options and warrants has not been included in this calculation as it would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one&#160;year are recognized on the balance sheet as ROU assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company typically only includes an initial lease term in its assessment of a lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the assessment unless there is reasonable certainty that the Company will renew.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.15pt;margin:0pt 0pt 12pt 0pt;">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at period end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Deferred tax is recognized in respect of temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes and an excess of the amount for financial reporting over the tax basis of an investment in a foreign subsidiary that is essentially permanent in duration.  The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted at the financial position reporting date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A valuation allowance is recognized for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets are reviewed at each reporting date and a valuation allowance is recorded to the extent that it is no longer more likely than not that the related tax benefit will be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2018-18&#160;&#8211; Collaborative Arrangements (Topic 808)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In November 2018, the FASB issued ASU 2018-18, &#8220;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#8221;. This ASU: (i) clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer, (ii) provides guidance specifying that a distinct good or service is the unit of account for evaluating whether a transaction is with a customer, and (iii) precludes a company from presenting transactions with a collaborative arrangement participant that are not in the scope of ASC 606 together with revenue from contracts with customers. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020. The Company will present collaboration revenue separate from product revenues. The adoption of this new accounting standard did not have a significant impact on the Company&#8217;s consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2018-15&#160;&#8211; Intangibles &#8211; Goodwill and Other (Subtopic 350-40)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In August 2018, the FASB issued ASU 2018&#8211;15, Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350&#8211;40). This ASU addresses the accounting for implementation costs incurred by a customer in a cloud computing arrangement that is a service contract and also adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The amendment aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this accounting standard as of October 1, 2020 and has applied it prospectively to all implementation costs incurred after October 1, 2020. The adoption of this new accounting standard did not have a significant impact on the Company&#8217;s consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2018-13&#160;&#8211; Fair Value Measurement (Topic 820-10)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820-10): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (&#8220;ASU 2018-13&#8221;), which changes the fair value measurement disclosure requirements of ASC Topic 820, Fair Value Measurements and Disclosures. Under this ASU, certain disclosure requirements for fair value measurements are eliminated, amended or added. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October&#160;1, 2020. The adoption of the standard had no impact on the Company&#8217;s consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2019-12&#160;&#8211; Income Taxes (Topic 740)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&#8220;ASU 2019-12&#8221;), which simplifies the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new ASU also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates. These changes aim to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company&#8217;s consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2016-13&#160;&#8211; Financial Instruments-Credit Losses (Topic 326)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In June&#160;2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including trade receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. This guidance is effective for annual reporting periods beginning after December&#160;15, 2019, with early adoption permitted. The Company has adopted this standard as of October 1, 2020. The adoption of the standard had no impact on the Company&#8217;s consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Recently accounting pronouncements not yet adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2020-06&#160;</i><i style="font-style:italic;font-weight:normal;white-space:pre-wrap;">&#8211; Debt with Conversion and Other Options (Subtopic  470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;white-space:pre-wrap;">In August 2020, the FASB issued ASU No. 2020-06 (&#8220;ASU 2020-06&#8221;) &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic   815-40):   Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity.&#8221; ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP.  Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity&#8217;s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company&#8217;s accounting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2020-10&#160;&#8211; Codification Improvements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the FASB issued ASU 2020-10, Codification Improvements. The guidance contains improvements to the Codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the Disclosure Section of the Codification. The guidance also contains Codifications that are varied in nature and may affect the application of the guidance in cases in which the original guidance may have been unclear. For public business entities, the amendments in the ASU are effective for fiscal years beginning after December 15, 2020. For all other entities, the amendments are effective for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022. Early adoption is permitted. We do not expect the adoption of ASU 2020-10 to have a material impact on our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">ASU 2021-04&#160;&#8211; Earnings per share</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40). &#160;The new ASU addresses issuer&#8217;s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company will evaluate the impact of the pronouncement closer to the effective date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future consolidated financial statement presentation or disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_GovernmentAssistancePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_GovernmentAssistancePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529824536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock', window );">Schedule of Functional Currency of Company and its Subsidiaries</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The functional currency of the Company and its subsidiaries have been determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Country of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effective</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Functional</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharma&#160;Inc.</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Canada</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ESSA Pharmaceuticals Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Realm Therapeutics plc <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">United Kingdom</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Pound Sterling</p></td></tr><tr><td style="vertical-align:bottom;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Realm Therapeutics&#160;Inc. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">US Dollar</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">In the process of liquidation and dissolution as at September 30, 2021.</span></td></tr></table><div style="margin-top:10pt;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the functional currency and effective interest in subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529811496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REALM ACQUISITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>REALM ACQUISITION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Net Assets Acquired</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Realm is not considered to be a business under the definitions of ASU 2017-01; accordingly, the Realm Acquisition is accounted for as a financing transaction. The shares issued in connection with the acquisition of Realm were valued on the basis of the value of assets received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Net assets of Realm acquired:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,244,248</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receivables and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 240,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and accrued liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,236,952)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total net assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,247,296</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529824536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAIDS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>PREPAIDS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ScheduleOfPrepaidExpensesTableTextBlock', window );">Schedule of Prepaid Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,751,052</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 825,014</p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid CMC and clinical expenses and deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 650,586</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other deposits and prepaid expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 190,317</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,528</p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, end of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,181,882</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,600,128</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ScheduleOfPrepaidExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ScheduleOfPrepaidExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529461368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,425,871</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 678,643</p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,062,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,604</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 320,632</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154,983</p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, end of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,808,944</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,144,230</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529824536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>OPERATING LEASE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock', window );">Schedule of Operating Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#8217;s operating leases included on the balance sheet are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease right-of-use asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2018 and 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 165,486</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,324)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,162</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 362,588</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (109,464)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308,286</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2018 and 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 165,486</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,992</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (119,384)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59,094</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Addition</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 362,588</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,570</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (100,282)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 330,970</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of operating lease related assets and liabilities and other related information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867530278488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Term Loan Repayment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The SVB Term Loan was fully repaid during the fiscal&#160;year ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SVB Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loan</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, September&#160;30,&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,316,963</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Principal repaid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,808,823)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest paid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (401,929)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 602,744</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, September&#160;30,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,708,955</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Principal repaid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,199,799)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Interest paid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,235)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211,079</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Final payment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (688,000)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance, September&#160;30,&#160;2020 and 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529615608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liabilities on September 30, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:31.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.49</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Liquidity discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Changes to Derivative Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table is a continuity schedule of changes to the Company&#8217;s derivative liabilities:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Balance, September&#160;30,&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,679</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,159)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Balance, September&#160;30,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,520</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 110,856</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 127,376</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (107,024)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Balance, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,352</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Derivatives with expected life of less than one&#160;year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Derivatives with expected life greater than one&#160;year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,352</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606378408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock option transactions are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price*</b></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 900,459</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.59</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 255,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.77</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,998)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.10)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,122,461</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.59</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,218,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.31</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (416)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.20)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (30,461)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28.46)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,309,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.42</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,889,646</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.87</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (323,610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.68)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Options expired/forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (72,390)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.46)</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance outstanding, September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,803,230</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.20</p></td></tr><tr><td style="vertical-align:bottom;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance exercisable, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,799,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.49</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Options exercisable in Canadian dollars as at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">September 30, 2021</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding options.</span></td></tr></table><div style="margin-top:10pt;"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Stock Option Outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At September 30, 2021, options were outstanding enabling holders to acquire common shares as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual life (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,584</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.70</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,794,603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.59</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,667</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.05</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 185,816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 539,518</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.22</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 183,511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,508,146</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 190,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">29.63</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.58</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">31.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.90</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163,154</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.81</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:39.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,803,230</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.15</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant transactions are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,663,937</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.13</p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,919,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0001</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,188,999)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.002)</p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31.17)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,393,092</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.31</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,120,115)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.08)</p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance, September&#160;30,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,272,977</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.73</p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,038,227)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.06)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Balance outstanding and exercisable, September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,234,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.84</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Symbol';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">*</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Warrants exercisable in Canadian dollars as at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">September 30, 2021</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> are translated at current rates to reflect the current weighted average exercise price in US dollars for all outstanding warrants.</span></td></tr></table><div style="margin-top:10pt;"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock', window );">Summary of Warrants Outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">At September 30, 2021, warrants were outstanding enabling holders to acquire common shares as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiry Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">227,273</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January&#160;14, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">November&#160;18, 2023</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">80,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January&#160;9, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:47.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,920,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.0001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August&#160;23, 2024</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,234,750</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Detailed terms of the 2016 Warrants are included in Note&#160;10.</span></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember', window );">Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Share Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the&#160;year ended September 30, 2021, the Company issued a total of 15,963 (2020&#160;&#8211;16,506; 2019 - nil) common shares upon the exercise of Purchase Rights. The Company recognizes compensation expense for purchase rights on a straight-line basis over the service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:middle;white-space:nowrap;width:32.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended September&#160;30,&#160; </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,299</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,984</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,431</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 71,017</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted Average Assumptions for the Valuation of Stock Options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company measures the purchase rights based on their estimated grant date fair value using the Black-Scholes option pricing model and the estimated number of shares that can be purchased. The following weighted average assumptions were used for the valuation of purchase rights:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.44</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life of share purchase rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61.54</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90.34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember', window );">Stock Options Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Share Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company recognized share-based payments expense for options granted and vesting, net of recoveries on cancellations of unvested options, during the&#160;years ended September 30, 2021, 2020 and 2019 with allocations to its functional expense as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the year ended September&#160;30,&#160; </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expense </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,611,083</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,853,388</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,786</p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,796,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,598,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 841,921</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,407,682</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,451,590</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,146,707</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted Average Assumptions for the Valuation of Stock Options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following weighted average assumptions were used for the Black-Scholes option-pricing model valuation of stock options granted:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.44</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.55</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.55</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected annualized volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78.16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867528373672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Income Taxes at Statutory Rates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">For the&#160;years ended September&#160;30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Loss for the&#160;year before income tax</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (36,839,810)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23,734,017)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,718,912)</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax recovery at statutory income tax rates</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,947,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,408,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,434,000)</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-deductible share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,575,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,031,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 227,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxable capital gains</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346,000</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other permanent differences including foreign exchange</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share issue costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,492,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (849,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (720,000)</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in statutory, foreign tax, foreign exchange rates and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,260,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,013,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 458,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (725,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (307,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (196,000)</p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,344,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,210,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,354,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Total income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_I8yCBUa3N0W0JSccZZb-kw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> (34,000)</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Y6jwuf91OUyOdeLUzsBsTA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> (289,000)</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qGTwKPFLwU6oUyoQmQDV4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> 38,000</span></span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of Future Tax Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating losses carried forward</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,749,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,297,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equipment and intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investment tax credits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,000</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,025,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,462,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal R&amp;D credit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 210,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,169,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,875,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,169,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,875,000)</p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net future tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606602120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Contractual Obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has the following obligations over the next five&#160;years:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Contractual obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Minimum annual royalty per License Agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">85,000</p></td></tr><tr><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vendor Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease on US office spaces</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,288</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 119,586</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,509</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606274456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NATURE OF OPERATIONS (Narrative) (Details) - Realm Therapeutics Plc [Member]<br></strong></div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1', window );">Acquisition date</a></td>
<td class="text">Jul. 31,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Name of acquired entity</a></td>
<td class="text">Realm Therapeutics plc (&#8220;Realm&#8221;)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e848-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e845-128460<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the acquired entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionNameOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=epix_RealmTherapeuticsPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=epix_RealmTherapeuticsPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606250312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=epix_EssaPharmaceuticalsCorpMember', window );">ESSA Pharmaceuticals Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_PercentageOfEffectiveInterestInSubsidiaries', window );">Effective interest</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=epix_RealmTherapeuticsPlcMember', window );">Realm Therapeutics Plc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_PercentageOfEffectiveInterestInSubsidiaries', window );">Effective interest</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=epix_RealmTherapeuticsIncMember', window );">Realm Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_PercentageOfEffectiveInterestInSubsidiaries', window );">Effective interest</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PercentageOfEffectiveInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of effective interest in subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PercentageOfEffectiveInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=epix_EssaPharmaceuticalsCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=epix_EssaPharmaceuticalsCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=epix_RealmTherapeuticsPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=epix_RealmTherapeuticsPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=epix_RealmTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=epix_RealmTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867677875992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 308,286<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">330,970<span></span>
</td>
<td class="nump">59,094<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (117,775,765)<span></span>
</td>
<td class="num">(80,970,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606205080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REALM ACQUISITION (Narrative) (Details) - Realm Therapeutics Plc [Member]<br></strong></div></th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Realm acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1', window );">Acquisition date</a></td>
<td class="text">Jul. 31,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Name of acquired entity</a></td>
<td class="text">Realm Therapeutics plc (&#8220;Realm&#8221;)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">New shares issued on acquisition | shares</a></td>
<td class="nump">6,718,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_BusinessCombinationConversionRatioPerShare', window );">Conversion ratio per share</a></td>
<td class="nump">0.05763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare', window );">Conversion ratio per American Depository Share (ADS)</a></td>
<td class="nump">1.4409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare', window );">Number of shares represented by each American Depository Share (ADS) | shares</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Fair value of net assets acquired | $</a></td>
<td class="nump">$ 20,247,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Issuance costs incurred | $</a></td>
<td class="nump">$ 1,925,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of New ESSA Shares to be issued to the shareholders for every American Depository share in Realm.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_BusinessCombinationConversionRatioPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of New ESSA Shares to be issued to the shareholders for every share in Realm.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_BusinessCombinationConversionRatioPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that represents one American Depository share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e848-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e845-128460<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the acquired entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionNameOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=epix_RealmTherapeuticsPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=epix_RealmTherapeuticsPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867534375256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REALM ACQUISITION (Schedule of Net Assets Acquired) (Details) - Realm Therapeutics Plc [Member]<br></strong></div></th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets of Realm acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 22,244,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets', window );">Receivables and other current assets</a></td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(2,236,952)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net assets</a></td>
<td class="nump">$ 20,247,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and accrued liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables and amounts due from others and other current assets, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=epix_RealmTherapeuticsPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=epix_RealmTherapeuticsPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606169736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS (Narrative) (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Guaranteed investment certificates, interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Guaranteed investment certificates, interest rate</a></td>
<td class="nump">0.22%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529731016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAIDS (Schedule of Prepaid Expenses) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>PREPAIDS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 1,751,052<span></span>
</td>
<td class="nump">$ 825,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits', window );">Prepaid CMC and clinical expenses and deposits</a></td>
<td class="nump">240,513<span></span>
</td>
<td class="nump">650,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Other deposits and prepaid expenses</a></td>
<td class="nump">190,317<span></span>
</td>
<td class="nump">124,528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Balance, end of year</a></td>
<td class="nump">$ 2,181,882<span></span>
</td>
<td class="nump">$ 1,600,128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of prepaid preclinical and clinical expenses and deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529701320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 1,425,871<span></span>
</td>
<td class="nump">$ 678,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,062,441<span></span>
</td>
<td class="nump">310,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued vacation</a></td>
<td class="nump">320,632<span></span>
</td>
<td class="nump">154,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Balance, end of year</a></td>
<td class="nump">$ 3,808,944<span></span>
</td>
<td class="nump">$ 1,144,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867528487624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_OperatingLeaseLiabilitiesAccretionExpenses', window );">Accretion expense</a></td>
<td class="nump">$ 9,570<span></span>
</td>
<td class="nump">$ 12,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=epix_SouthFransicoOfficeMember', window );">South San Francisco Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">32 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=epix_HoustonOfficeMember', window );">Houston Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">22 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 100,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=epix_FinancingCostsMember', window );">Financing costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_OperatingLeaseLiabilitiesAccretionExpenses', window );">Accretion expense</a></td>
<td class="nump">$ 9,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_OperatingLeaseLiabilitiesAccretionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion expense on operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_OperatingLeaseLiabilitiesAccretionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=epix_SouthFransicoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=epix_SouthFransicoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=epix_HoustonOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=epix_HoustonOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=epix_FinancingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=epix_FinancingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867608484296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE (Schedule of Operating Leases) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_OperatingLeaseRightOfUseAssetAbstract', window );"><strong>Operating lease right-of-use asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 308,286<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_OperatingLeaseRightOfUseAssetsCurrent', window );">Operating lease right-of-use assets, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_OperatingLeaseRightOfUseAssetAddition', window );">Addition</a></td>
<td class="nump">362,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization</a></td>
<td class="num">(109,464)<span></span>
</td>
<td class="num">(110,324)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">330,970<span></span>
</td>
<td class="nump">59,094<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_OperatingLeaseLiabilitiesAddition', window );">Addition</a></td>
<td class="nump">362,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_OperatingLeaseLiabilitiesAccretionExpenses', window );">Accretion</a></td>
<td class="nump">9,570<span></span>
</td>
<td class="nump">12,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="num">$ (100,282)<span></span>
</td>
<td class="num">(119,384)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_OperatingLeaseRightOfUseAssetAbstract', window );"><strong>Operating lease right-of-use asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_OperatingLeaseLiabilitiesAccretionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion expense on operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_OperatingLeaseLiabilitiesAccretionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_OperatingLeaseLiabilitiesAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liabilities addition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_OperatingLeaseLiabilitiesAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_OperatingLeaseRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_OperatingLeaseRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_OperatingLeaseRightOfUseAssetAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease right of use asset addition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_OperatingLeaseRightOfUseAssetAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_OperatingLeaseRightOfUseAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease, current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_OperatingLeaseRightOfUseAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867533995400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 18, 2016</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.84<span></span>
</td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32,235<span></span>
</td>
<td class="nump">$ 401,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightGranted', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,919,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=epix_SiliconValleyBankTermLoanMember', window );">SVB Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Amount drawn from term loan facility</a></td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_DebtInstrumentAdditionalBorrowingCapacityLapsed', window );">Borrowing capacity lapsed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 42.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">Sep.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_PercentageOfFinalPaymentOnAmountAdvanced', window );">Percentage of final payment</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Total Loan payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,708,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_RepaymentsOfLongTermDebtPrincipal', window );">Principal amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,199,799<span></span>
</td>
<td class="nump">3,199,799<span></span>
</td>
<td class="nump">$ 2,808,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_RepaymentsOfLongTermDebtInterest', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,235<span></span>
</td>
<td class="nump">32,235<span></span>
</td>
<td class="nump">$ 401,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_RepaymentsOfLongTermDebtFinalPayment', window );">Final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688,000<span></span>
</td>
<td class="nump">$ 688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightGranted', window );">Warrants granted (in shares)</a></td>
<td class="nump">7,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_FairValueOfWarrantIssued', window );">Fair value of warrant issued</a></td>
<td class="nump">$ 167,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Additional transaction cost</a></td>
<td class="nump">$ 220,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.60%<span></span>
</td>
<td class="nump">12.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=epix_SiliconValleyBankTermLoanMember', window );">SVB Term Loan [Member] | WSJ Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate of interest</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ClassOfWarrantOrRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ClassOfWarrantOrRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_DebtInstrumentAdditionalBorrowingCapacityLapsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition borrowing capacity lapsed during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_DebtInstrumentAdditionalBorrowingCapacityLapsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_FairValueOfWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_FairValueOfWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PercentageOfFinalPaymentOnAmountAdvanced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of final payment on amount advanced due to early payment or termination of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PercentageOfFinalPaymentOnAmountAdvanced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_RepaymentsOfLongTermDebtFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for final payment for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_RepaymentsOfLongTermDebtFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_RepaymentsOfLongTermDebtInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest amount of debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_RepaymentsOfLongTermDebtInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_RepaymentsOfLongTermDebtPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for principal amount of debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_RepaymentsOfLongTermDebtPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=epix_SiliconValleyBankTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=epix_SiliconValleyBankTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=epix_WallStreetJournalPrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=epix_WallStreetJournalPrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606410232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT (Schedule of Term Loan Repayment) (Details) - SVB Term Loan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_LongTermDebtRepaymentRollForward', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long term debt, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,708,955<span></span>
</td>
<td class="nump">$ 6,316,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_RepaymentsOfLongTermDebtPrincipal', window );">Principal repaid</a></td>
<td class="num">$ (3,199,799)<span></span>
</td>
<td class="num">(3,199,799)<span></span>
</td>
<td class="num">(2,808,823)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_RepaymentsOfLongTermDebtInterest', window );">Interest paid</a></td>
<td class="num">(32,235)<span></span>
</td>
<td class="num">(32,235)<span></span>
</td>
<td class="num">(401,929)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_DebtInstrumentAccretion', window );">Accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,079<span></span>
</td>
<td class="nump">602,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_RepaymentsOfLongTermDebtFinalPayment', window );">Final payment</a></td>
<td class="num">(688,000)<span></span>
</td>
<td class="num">$ (688,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long term debt, Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,708,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_DebtInstrumentAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion of debt during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_DebtInstrumentAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_LongTermDebtRepaymentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_LongTermDebtRepaymentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_RepaymentsOfLongTermDebtFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for final payment for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_RepaymentsOfLongTermDebtFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_RepaymentsOfLongTermDebtInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest amount of debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_RepaymentsOfLongTermDebtInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_RepaymentsOfLongTermDebtPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for principal amount of debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_RepaymentsOfLongTermDebtPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=epix_SiliconValleyBankTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=epix_SiliconValleyBankTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867527065720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITIES (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.84<span></span>
</td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Increase in market Price of warrants by 10% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice', window );">Increase (decrease) in derivative liability due to change in market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 745,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Decrease in market Price of warrants by 10% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice', window );">Increase (decrease) in derivative liability due to change in market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Increase in Volatility of warrants by 10% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility', window );">Increase (decrease) in derivative liability due to change in volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">741,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Decrease in Volatility of warrants by 10% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility', window );">Increase (decrease) in derivative liability due to change in volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 423,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">227,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Unit price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 66.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Fair value of units issued</a></td>
<td class="nump">$ 14,999,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 66.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_UnitsIssuedInPrivatePlacementConversionRatio', window );">Units issued in private placement, conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | 2 Year Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_UnitsIssuedInPrivatePlacementConversionRatio', window );">Units issued in private placement, conversion ratio</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | 7 Year Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_UnitsIssuedInPrivatePlacementConversionRatio', window );">Units issued in private placement, conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in derivative liability due to change in market price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in derivative liability due to change in Volatility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_UnitsIssuedInPrivatePlacementConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Units issued in private placement, conversion ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_UnitsIssuedInPrivatePlacementConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=epix_IncreaseInMarketPriceOfWarrantsBy10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=epix_IncreaseInMarketPriceOfWarrantsBy10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=epix_DecreaseInMarketPriceOfWarrantsBy10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=epix_DecreaseInMarketPriceOfWarrantsBy10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=epix_IncreaseInVolatilityOfWarrantsBy10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=epix_IncreaseInVolatilityOfWarrantsBy10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=epix_DecreaseInVolatilityOfWarrantsBy10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=epix_DecreaseInVolatilityOfWarrantsBy10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=epix_TwoYearWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=epix_TwoYearWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=epix_SevenYearWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=epix_SevenYearWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867533625864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details) - Weighted Average [Member]<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>Y</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>Y</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions to fair value of the derivative warrant liabilities</a></td>
<td class="nump">0.0049<span></span>
</td>
<td class="nump">0.0022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Life [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions to fair value of the derivative warrant liabilities</a></td>
<td class="nump">1.28<span></span>
</td>
<td class="nump">2.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Annualized Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions to fair value of the derivative warrant liabilities</a></td>
<td class="nump">0.860<span></span>
</td>
<td class="nump">0.973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions to fair value of the derivative warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember', window );">Liquidity Discount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Assumptions to fair value of the derivative warrant liabilities</a></td>
<td class="nump">0.20<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867528122888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITIES (Schedule of Changes of Derivative Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Beginning balance</a></td>
<td class="nump">$ 127,376<span></span>
</td>
<td class="nump">$ 16,520<span></span>
</td>
<td class="nump">$ 17,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value</a></td>
<td class="num">(107,024)<span></span>
</td>
<td class="nump">110,856<span></span>
</td>
<td class="num">(1,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Ending balance</a></td>
<td class="nump">20,352<span></span>
</td>
<td class="nump">127,376<span></span>
</td>
<td class="nump">16,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivatives with expected life of less than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivatives with expected life greater than one year</a></td>
<td class="nump">$ 20,352<span></span>
</td>
<td class="nump">$ 127,376<span></span>
</td>
<td class="nump">$ 16,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867521449816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 22, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 27, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,999,985<span></span>
</td>
<td class="nump">$ 48,990,000<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issuance transaction costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,229,450<span></span>
</td>
<td class="nump">$ 3,447,954<span></span>
</td>
<td class="nump">$ 2,362,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,889,646<span></span>
</td>
<td class="nump">4,218,000<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.04<span></span>
</td>
<td class="nump">$ 2.98<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember', window );">Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,963<span></span>
</td>
<td class="nump">16,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_PurchaseRightsOfferingTerm', window );">Offering term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan', window );">Maximum eligibility to common shares amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU's [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price percentage of common share granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,418<span></span>
</td>
<td class="nump">268,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage', window );">Employee contribution percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Stock Options and RSU Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,342,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=epix_RealmTherapeuticsPlcMember', window );">Realm Therapeutics Plc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">New shares issued on acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,718,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=epix_February2021financingMember', window );">February 2021 Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds | $</a></td>
<td class="nump">$ 149,999,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">5,555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="nump">$ 27.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_UnderwriterOptionToPurchaseAdditionalSecurities', window );">Underwriter option to purchase additional securities</a></td>
<td class="nump">724,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_TermOfUnderwritersOption', window );">Term of underwriters option</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Cash commissions paid | $</a></td>
<td class="nump">$ 8,999,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issuance transaction costs | $</a></td>
<td class="nump">$ 229,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=epix_July2020FinancingMember', window );">July 2020 Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_TermOfUnderwritersOption', window );">Term of underwriters option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Cash commissions paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,939,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issuance transaction costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=epix_August2019FinancingMember', window );">August 2019 Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,080,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_PreFundedWarrantsIssuedForCommonShares', window );">Number of pre funded warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,919,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Conversion of each prefunded warrant into common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Cash commissions paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,978,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issuance transaction costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 698,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,065,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_UnitsIssuedInPrivatePlacementConversionRatio', window );">Units issued in private placement, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | 2 Year Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_UnitsIssuedInPrivatePlacementConversionRatio', window );">Units issued in private placement, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | 7 Year Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_UnitsIssuedInPrivatePlacementConversionRatio', window );">Units issued in private placement, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Clarus Lifesciences III, L.P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights', window );">Minimum number of shares required to be held for nomination rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of contribution by each employee to employee share purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of common share each employee is eligible under employee share purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum number of shares required to be held for nomination rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PreFundedWarrantsIssuedForCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pre funded warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PreFundedWarrantsIssuedForCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PurchaseRightsOfferingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of purchase rights offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PurchaseRightsOfferingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_TermOfUnderwritersOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of underwriters option to purchase additions shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_TermOfUnderwritersOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_UnderwriterOptionToPurchaseAdditionalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriter option to purchase additional securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_UnderwriterOptionToPurchaseAdditionalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_UnitsIssuedInPrivatePlacementConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Units issued in private placement, conversion ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_UnitsIssuedInPrivatePlacementConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=epix_StockOptionsAndRsuPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=epix_StockOptionsAndRsuPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=epix_RealmTherapeuticsPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=epix_RealmTherapeuticsPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=epix_February2021financingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=epix_February2021financingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=epix_July2020FinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=epix_July2020FinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=epix_August2019FinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=epix_August2019FinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=epix_TwoYearWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=epix_TwoYearWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=epix_SevenYearWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=epix_SevenYearWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=epix_ClarusLifesciencesIiiL.pMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=epix_ClarusLifesciencesIiiL.pMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867533938344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule of Share Based Compensation Expenses) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember', window );">Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation Expense</a></td>
<td class="nump">$ 68,431<span></span>
</td>
<td class="nump">$ 71,017<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember', window );">Employee Share Purchase Plan [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation Expense</a></td>
<td class="nump">32,299<span></span>
</td>
<td class="nump">24,984<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember', window );">Employee Share Purchase Plan [Member] | General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation Expense</a></td>
<td class="nump">36,132<span></span>
</td>
<td class="nump">46,033<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember', window );">Stock Options Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation Expense</a></td>
<td class="nump">9,407,682<span></span>
</td>
<td class="nump">7,451,590<span></span>
</td>
<td class="nump">1,146,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember', window );">Stock Options Plan [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation Expense</a></td>
<td class="nump">3,611,083<span></span>
</td>
<td class="nump">1,853,388<span></span>
</td>
<td class="nump">304,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember', window );">Stock Options Plan [Member] | General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation Expense</a></td>
<td class="nump">$ 5,796,599<span></span>
</td>
<td class="nump">$ 5,598,202<span></span>
</td>
<td class="nump">$ 841,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606339880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember', window );">Employee Share Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.19%<span></span>
</td>
<td class="nump">1.44%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of share purchase options</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected annualized volatility</a></td>
<td class="nump">61.54%<span></span>
</td>
<td class="nump">90.34%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember', window );">Stock Options Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.44%<span></span>
</td>
<td class="nump">1.55%<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of share purchase options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected annualized volatility</a></td>
<td class="nump">78.16%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">79.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=epix_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=epix_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606407640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Summary of Stock Option Activity) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">5,309,584<span></span>
</td>
<td class="nump">1,122,461<span></span>
</td>
<td class="nump">900,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,889,646<span></span>
</td>
<td class="nump">4,218,000<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(323,610)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options expired/forfeited (in shares)</a></td>
<td class="num">(72,390)<span></span>
</td>
<td class="num">(30,461)<span></span>
</td>
<td class="num">(32,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">6,803,230<span></span>
</td>
<td class="nump">5,309,584<span></span>
</td>
<td class="nump">1,122,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Balance exercisable (in shares)</a></td>
<td class="nump">2,799,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="nump">$ 4.59<span></span>
</td>
<td class="nump">$ 4.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">9.87<span></span>
</td>
<td class="nump">3.31<span></span>
</td>
<td class="nump">3.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="num">(3.68)<span></span>
</td>
<td class="num">(2.20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired/forfeited (in dollars per share)</a></td>
<td class="num">(4.46)<span></span>
</td>
<td class="num">(28.46)<span></span>
</td>
<td class="num">(4.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">5.20<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="nump">$ 4.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 3.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867521662184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Summary of Stock Option Outstanding) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="nump">$ 4.59<span></span>
</td>
<td class="nump">$ 4.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options | shares</a></td>
<td class="nump">6,803,230<span></span>
</td>
<td class="nump">6,803,230<span></span>
</td>
<td class="nump">5,309,584<span></span>
</td>
<td class="nump">1,122,461<span></span>
</td>
<td class="nump">900,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceOneInUsdMember', window );">Exercise Price $2.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="nump">$ 2.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options | shares</a></td>
<td class="nump">4,584<span></span>
</td>
<td class="nump">4,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwoInUsdMember', window );">Exercise Price $3.23 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="nump">$ 3.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options | shares</a></td>
<td class="nump">3,794,603<span></span>
</td>
<td class="nump">3,794,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">8 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceThreeInUsdMember', window );">Exercise Price $3.59 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options | shares</a></td>
<td class="nump">26,667<span></span>
</td>
<td class="nump">26,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">8 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFourInUsdMember', window );">Exercise Price $3.81 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="nump">$ 3.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options | shares</a></td>
<td class="nump">185,816<span></span>
</td>
<td class="nump">185,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFiveInUsdMember', window );">Exercise Price $4.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options | shares</a></td>
<td class="nump">539,518<span></span>
</td>
<td class="nump">539,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">6 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceSixInUsdMember', window );">Exercise Price $4.67 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="nump">$ 4.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options | shares</a></td>
<td class="nump">183,511<span></span>
</td>
<td class="nump">183,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">8 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceSevenInUsdMember', window );">Exercise Price $7.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options | shares</a></td>
<td class="nump">1,508,146<span></span>
</td>
<td class="nump">1,508,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceEightInUsdMember', window );">Exercise Price $13.96 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="nump">$ 13.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options | shares</a></td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceNineInUsdMember', window );">Exercise Price $29.63 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="nump">$ 29.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTenInUsdMember', window );">Exercise Price $31.62 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="nump">$ 31.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options | shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 8 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceOneInCadMember', window );">Exercise Price C$4.90 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options | shares</a></td>
<td class="nump">163,154<span></span>
</td>
<td class="nump">163,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">5 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwoInCadMember', window );">Exercise Price C$5.06 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options, Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options | shares</a></td>
<td class="nump">32,231<span></span>
</td>
<td class="nump">32,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceOneInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceOneInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwoInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwoInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceThreeInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceThreeInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFourInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFourInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFiveInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceFiveInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceSixInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceSixInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceSevenInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceSevenInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceEightInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceEightInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceNineInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceNineInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTenInUsdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTenInUsdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceOneInCadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceOneInCadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwoInCadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=epix_ExercisePriceTwoInCadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867614904824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Summary of Warrants Activity) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants, Beginning balance (in shares)</a></td>
<td class="nump">9,272,977<span></span>
</td>
<td class="nump">12,393,092<span></span>
</td>
<td class="nump">2,663,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightGranted', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,919,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="num">(6,038,227)<span></span>
</td>
<td class="num">(3,120,115)<span></span>
</td>
<td class="num">(2,188,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants, Ending balance (in shares)</a></td>
<td class="nump">3,234,750<span></span>
</td>
<td class="nump">9,272,977<span></span>
</td>
<td class="nump">12,393,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price, Beginning balance (in dollar per share)</a></td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted', window );">Weighted average exercise price, warrants granted (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised', window );">Weighted average exercise price, warrants exercised (in dollar per share)</a></td>
<td class="num">(0.06)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired', window );">Weighted average exercise price, warrants expired (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price, Ending balance (in dollar per share)</a></td>
<td class="nump">$ 4.84<span></span>
</td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ClassOfWarrantOrRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ClassOfWarrantOrRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ClassOfWarrantOrRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ClassOfWarrantOrRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of class of warrant or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of class of warrant or rights expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of class of warrant or rights granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529903240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Summary of Warrants Outstanding) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Warrant outstanding and Exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">3,234,750<span></span>
</td>
<td class="nump">9,272,977<span></span>
</td>
<td class="nump">12,393,092<span></span>
</td>
<td class="nump">2,663,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.84<span></span>
</td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceOneMember', window );">Warrants Exercise Price $66.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Warrant outstanding and Exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">227,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 66.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Jan. 14,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceTwoMember', window );">Warrants Exercise Price $42.80 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Warrant outstanding and Exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">7,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 42.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Nov. 18,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceThreeMember', window );">Warrants Exercise Price $4.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Warrant outstanding and Exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Jan.  09,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceFiveMember', window );">Warrants Exercise Price $0.0001 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Warrant outstanding and Exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">2,920,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Aug. 23,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=epix_WarrantsExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529699384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised', window );">Number of shares issued upon cashless exercise of pre-funded warrants</a></td>
<td class="nump">81,303<span></span>
</td>
<td class="nump">1,652,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_PreFundedWarrantsExercised', window );">Pre-funded warrants exercised</a></td>
<td class="nump">94,723<span></span>
</td>
<td class="nump">1,653,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability', window );">Transaction costs incurred through accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities', window );">Share issuance costs incurred through accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Amount of transaction cost for business acquisition through accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_PreFundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pre-funded warrants exercised for common shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_PreFundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Amount of cost related to share issuance through accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issued upon cashless exercise of pre-funded warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529646488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 82,036<span></span>
</td>
<td class="nump">$ 87,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867535436968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss for the year before income tax</a></td>
<td class="num">$ (36,839,810)<span></span>
</td>
<td class="num">$ (23,734,017)<span></span>
</td>
<td class="num">$ (12,718,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax recovery at statutory income tax rates</a></td>
<td class="num">(9,947,000)<span></span>
</td>
<td class="num">(6,408,000)<span></span>
</td>
<td class="num">(3,434,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible share-based payments</a></td>
<td class="nump">1,575,000<span></span>
</td>
<td class="nump">2,031,000<span></span>
</td>
<td class="nump">227,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_IncomeTaxReconciliationTaxableCapitalGains', window );">Taxable capital gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other permanent differences including foreign exchange</a></td>
<td class="num">(49,000)<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_IncomeTaxReconciliationFinancingCosts', window );">Share issue costs</a></td>
<td class="num">(2,492,000)<span></span>
</td>
<td class="num">(849,000)<span></span>
</td>
<td class="num">(720,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Change in statutory, foreign tax, foreign exchange rates and other</a></td>
<td class="nump">1,260,000<span></span>
</td>
<td class="nump">1,013,000<span></span>
</td>
<td class="nump">458,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses</a></td>
<td class="num">(725,000)<span></span>
</td>
<td class="num">(307,000)<span></span>
</td>
<td class="num">(196,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">10,344,000<span></span>
</td>
<td class="nump">4,210,000<span></span>
</td>
<td class="nump">3,354,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="num">$ (34,349)<span></span>
</td>
<td class="num">$ (288,647)<span></span>
</td>
<td class="nump">$ 37,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_IncomeTaxReconciliationFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_IncomeTaxReconciliationFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_IncomeTaxReconciliationTaxableCapitalGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) taxable capital gains</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_IncomeTaxReconciliationTaxableCapitalGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867628189112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Significant Components of Future Tax Assets) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating losses carried forward</a></td>
<td class="nump">$ 29,749,000<span></span>
</td>
<td class="nump">$ 21,297,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_DeferredTaxAssetsEquipmentAndIntangibleAssets', window );">Equipment and intangible assets</a></td>
<td class="nump">77,000<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investment tax credits</a></td>
<td class="nump">29,000<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_DeferredTaxAssetsFinancingCosts', window );">Financing costs</a></td>
<td class="nump">3,025,000<span></span>
</td>
<td class="nump">1,462,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal R&amp;D credit</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">79,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross future tax assets</a></td>
<td class="nump">33,169,000<span></span>
</td>
<td class="nump">22,875,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(33,169,000)<span></span>
</td>
<td class="num">(22,875,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net future tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_DeferredTaxAssetsEquipmentAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equipment and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_DeferredTaxAssetsEquipmentAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_DeferredTaxAssetsFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_DeferredTaxAssetsFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867606289016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">General corporate income tax rate</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (recovery) expense</a></td>
<td class="num">$ (34,349)<span></span>
</td>
<td class="num">$ (288,647)<span></span>
</td>
<td class="nump">$ 37,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Non-capital loss carry-forwards</a></td>
<td class="nump">78,416,000<span></span>
</td>
<td class="nump">64,494,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Us</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Non-capital loss carry-forwards</a></td>
<td class="nump">$ 40,843,000<span></span>
</td>
<td class="nump">$ 20,249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529812104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTED INFORMATION (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTED INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of industries</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867528166136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details) - 12 months ended Sep. 30, 2021<br></strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>CAD ($)</div></th>
<th class="th"><div>USD ($)</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_WorkingCapital', window );">Working Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,668,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_CashCanadaDepositInsuranceCorporationInsuredAmount', window );">Cash, CDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=epix_TenPercentChangeInForeignExchangeRateMember', window );">10% Change in Foreign Exchange Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate', window );">Foreign currency risk, fluctuation in the net income (loss) reported due to change in exchange rate</a></td>
<td class="nump">$ 27,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_CashCanadaDepositInsuranceCorporationInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Canada Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_CashCanadaDepositInsuranceCorporationInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign currency risk, fluctuation in the net income (loss) reported due to change in exchange rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=epix_TenPercentChangeInForeignExchangeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=epix_TenPercentChangeInForeignExchangeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867521420360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants Related to Androgen Receptor n-terminus Blocker Program for Prostate Cancer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_GrantAmount', window );">Total grant amount</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_GrantReceivedPeriod', window );">Grant Received Period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Final Payment of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_ThresholdLimitForAggregateRoyaltyPayments', window );">Threshold limit for aggregate royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants Related to Androgen Receptor n-terminus Blocker Program for Prostate Cancer [Member] | Aggregate Royalty payment Up To $24,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_RoyaltyPercentRevenue', window );">Royalty percent revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants Related to Androgen Receptor n-terminus Blocker Program for Prostate Cancer [Member] | Aggregate Royalty payment After $24,000,000</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_RoyaltyPercentRevenue', window );">Royalty percent revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_TX', window );">Texas | Grants Related to Androgen Receptor n-terminus Blocker Program for Prostate Cancer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_GrantRequirementNumberOfYearsOfOperationsInTexas', window );">Grant requirement, number of years of operations in Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=epix_LicenseAgreementMember', window );">License Agreement [Member] | Technology-based intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_MinimumAdvanceRoyaltyPayments', window );">Minimum advance royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial', window );">Total amount of milestone payments after start of a Phase II clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial', window );">Total amount of milestone payments after start of a Phase III clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval', window );">Total amount of milestone payments at application for marketing approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments made at application for marketing approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments made at the start of second phase of clinical trial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments made at the start of third phase of clinical trial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_GrantAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total grant amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_GrantAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_GrantReceivedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period for which grants received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_GrantReceivedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_GrantRequirementNumberOfYearsOfOperationsInTexas">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant requirement, number of years of operations in Texas</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_GrantRequirementNumberOfYearsOfOperationsInTexas</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_MinimumAdvanceRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents amount of minimum annual royalty payments per annum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_MinimumAdvanceRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_RoyaltyPercentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of revenues company is required to pay as royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_RoyaltyPercentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_epix_ThresholdLimitForAggregateRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents threshold limit of aggregate royalty payments payable to CPRIT before decrease in royalty rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">epix_ThresholdLimitForAggregateRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>epix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=epix_AggregateRoyaltyPaymentUpTo24000000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=epix_AggregateRoyaltyPaymentUpTo24000000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=epix_AggregateRoyaltyPaymentAfter24000000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=epix_AggregateRoyaltyPaymentAfter24000000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=epix_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=epix_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139867529880344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS (Schedule of Contractual Obligations) (Details) - Sep. 30, 2021<br></strong></div></th>
<th class="th"><div>CAD ($)</div></th>
<th class="th"><div>USD ($)</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=epix_VendorAgreementMember', window );">Vendor Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=epix_ConsultingAgreementMember', window );">Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=epix_LeaseOnUsOfficeSpacesMember', window );">Lease on US Office Spaces [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2022</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2023</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2024</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2025</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2026</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=epix_VendorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=epix_VendorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=epix_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=epix_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=epix_LeaseOnUsOfficeSpacesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=epix_LeaseOnUsOfficeSpacesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=epix_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=epix_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$>>7&\X"+K,7X/>5$'I_DPUP^(?E\E]02P,$%     @ +3AR4\D$R0<Z!0
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M!+?LSL!^OY5VD]8W[AU*\\YL\1M02P,$%     @ +3AR4\K<MVX7 @  ) 4
M !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6R55%UOVR 4_2O(3YO4!7\E
MZRK'4N)D:J6NC>IN>R;V38P"Q@-2=_]^@!TK59,I?3%<N.?<<ZZ!I!5RIRH
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M"VTNB9M6YAD#:1/,_D8(?0CL31D>QO0?4$L#!!0    ( "TX<E/O58A>Q 0
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MPMB*JG.K;K1<E[W,5&KHC,K+%72[HC ">+^0D!#J&_.!IG_N_0%02P,$%
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M.%R4V:[^ OMS5I994C_=Z&BM\TK O'^79>7/B^H[\>//,B[^ 5!+ P04
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M23<F?HIWP_:+L*5$,U&\A.J@?W;2(]L-L&[C31.'QL)XC*"X#.^;;1# _=*
MZ&83#.Q^18S_!E!+ P04    "  M.')3P+1-]68)   8&0  &    'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;*U9;6\;N1'^*X3Z@@10)%G.M4'B&+"=Y!H4
MES.BI/U,[5):GKGDAN1*47]]GQER7V0KOB97X'#6[I+#>7GFF1GF8N_\7:B4
MBN)K;6QX/:EB;%[.YZ&H5"W#S#7*XLO&^5I&//KM/#1>R9(WU6:^7"S^-J^E
MMI/+"WYWZR\O7!N-MNK6B]#6M?2':V7<_O7D;-*]^*BW5:07\\N+1F[52L7/
MS:W'T[R74NI:V:"=%5YM7D^NSEY>/Z?UO.!?6NW#Z+<@2];.W='#^_+U9$$*
M*:.*2!(D_NS4C3*&!$&-+UGFI#^2-HY_=]+?L>VP92V#NG'FW[J,U>O)BXDH
MU4:V)GYT^W^H;,]/)*]P)O#_Q3ZM72XGHFA#='7># UJ;=-?^37[8;3AQ>(;
M&Y9YPY+U3@>QEF]DE)<7WNV%I]601C_85-X-Y;2EH*RBQU>-??'R^FKU?B5^
M?2=N/[Y=O?WPZ>K3^U\_7,PC1-.">9'%7"<QRV^(.5N*7YR-51!O;:G*8P%S
MZ-0KMNP4NUX^*G&EFIDX7TS%<K$\>T3>>6_H.<L[_W%#C^0^[^4^9[G/_Z@#
M'Q>SG(F3DL2U##H(MQ&W7@5EHV0P?ZKP $@7KFZD/6B[%86SP1E=RJA*L=%6
MVD)+(P)V*&11#**2.R762EF!_&VDQSIM68@OL5H!>K$26V65E\8<Z(MJ2!HM
M:6VD4QJO(;<Q*M#>6"GQV6I:LZ)S6-&K6GE=2/'DKW]ZL5PN7GV>K6;BYZNK
M6WX^>_5T1NK_'Y2GI!:51H[0>09"0J04A;_45U)=@+1$H7P$.8VDRA 4)-9*
MAI;D2"R4VHN=-*V:B2N#)3493')P&I:7V=KO=[JT);OI:)MUY"L8<7S L2M+
M9XST8=H9TRB0:46;<)QDP?M*X=%!OM]KZ*9M"4] QDQ\5!M\0U2#B$[D4/PY
MAX"/QNN3![)D?VK[S?W]-]+*4DO;;9T-<+WI/</D"Y'O6LM,#/_<M)Z$'^ZM
MZF#!KH>,T*Z#AGROL[?ZT%-@R:M!U@JZ-LXG= )Y#@$-_)&6VBBRWZ>B#5W(
M@!GZ,L8UM"APS$R\MU'Y9WF3B%[:(%EO1&(MC62?D#VM114T^C]09PN 06,O
MC$,L R%SO#%%VFCP-P.E;;"@&)N>4N+WT41J>8ITO.>JMZO5E;@%.FH)"XK9
M]*0'2&V-#?O*48*[O<5!8R_/3D:)=-L,[XON/<Y%['&"C@>AD]/''UD%KZG:
M"P7C7*T++-]I[RS90YC?5[JH>&66@W[#$QQGCQU+ZV]RB#JCCM RT$6I$$]X
M7C$N-C#<[<-+AO3B_-4?_GM#(?"LU-O-1G&3,7;B_?4(CO/ :T+\\!9**M!7
M+[8S]D?UN@^(E*N2OY\M7XG/*_&&DW:\LE!M)"H-,,NC_G[&E[/%0OQEM/PC
M0%]3;+QL>'D0C2G$D[.G'9W\$PE5NCKOO(6#B&*4-Y1H)[:S>KS_Q''T_KW-
M4'+(/8:[T5_:,;>4.B!SVO0<B-%75+KJ-3BS:R)@#A*'XA0B,$F,]ZGJ."6)
MRLCZ3HK7G,S4(!-^N8CV-0_D!$T16C1M%ETNPQ[,6<L[(+Y7A&Q 66KK)A/&
M&@TTP!];8HX='Q,KF"498ZQEHCV"==W30"IM4_A'KK71$:E ]0,M?*!?4)/8
MCKDO%4$Z>/1VM"_[,64FBNUF2@17MF@ MM.1 @/OHG06L85O8"Z:8F*KUH!?
M]-;J#6!E(SBGU+# BXT'0&+EPL@+,[$:EA)G0H/D/CKC4?^A*3%MF6BQA#([
MR7EXY ;Z1B6^#S6))N*R(?HVAQ(QR.4E*+_3!6V$<(<R$^57-=1S@+%L$8D2
MT3&N8;U2X32N2$=L40(B,:JG DU$)+4)'<A0"BBXZ8GZBG'X4U1*G1YK>0"7
M02O*I-QVX1RU(S^E7@(N26)^%ZZ)5U7"$4%&%)5$]+D7M..:V+F7J-V#OQ$;
M*G:P/#2)Z!#/]2$[GW;HF)(!14I5-+GM5.>]K':NT-D'Z61X>/R8,9X!WVVP
MYL  ?$0.NRWG3/H>OB5ZC9[I'MP>9%_D\L/22#!W62*XUA>IS\WNH4B#[E.7
M"3BQUB.P5I(""&SF9.HC03*& #4N<+2IN5/3)"7E3\HF#H^@<'CN8<O?,!QV
MV< 62N^9L![0 :M_E K9B4PLF5>.,W><I6//\-JAMI)=4X(BH23KD2HL*7*G
M#D.*ON3*E]*($=C5Y3X=AS0CP&E+O2U3!N')J*\YO7HZO6-VSMW]=U$IBB'#
M@:E[(XN.![4OVAKQ22T>_NM\?ZR=!-B)9(F@0*N!TVJ:(<:IV)5XBK8'2W08
MPGJ':%-JEM0,:<-D^AM(-30>!$93&"]$7V/57ABUU<$D%Q$+C+!@225203$O
MJ_P[<]-.\[7)AC-FH*^4_#SHD%$E=?G43[-9"2PT/26:Q'NZ\.!!*XM=)Q!Q
MNY.Z7];MU5%#1HA/GB')A!CB!4BNDP2CTMO0HO/+I^XUIJZU$GU+35Y@03R>
MPDT  JAN3$0R&[)A^P=+R,PW0Q$8<FS,]#<9.'NDC>1!C48:'!]3HUB>$C!*
MHDRC&7;E:(*<'GOMVLCB[MFJ0,M-L'6E,E/R1LK@;HS]TDI/+=(A#[!I%+\W
M5HQLSQE\1":T*I>.,0'3ZZ3M"55(DU[=\ T^S($2.T=0I/A/P1 [75)C<-#*
ME*G)*,@<RNK,.-2C$5C0G>5)Y<D'5"OT>$]!OC3*/DMG-_(P3,ND/50?1L(C
M7#6-T=@QY#M["GG1<%_D'I9YGIF/2KMU]EDA0Y5FP5+Y/(.MTDI" D>R[#A[
M"&Y7<4[T#ESNASTE<^)(?41/(1YI3-HZ5"<Q:C-F1Z;FNXD\4M&]1M^O/$.^
M1$..'D^8[ 4%GG0'A6WKPS#!]\3\OQ@Q5AZ_^^GLP%[))LZZ%IH8>"26VZ:'
M83W6M&?PK@"0$#JS)C,17^\P,]+Y0Q1SUB1M-&T%0DJ&?<H#DO2@;<I6YC;L
M4T7,UK4TF''<=ZBB;=/&\!!>.8?Z!NBTG]&V46JG::*N*=,8::DG[3/'Z$V_
M)5WT.$[ Z2CQ\K0SSCU^E<OAR2ZFSA=N]QI,UCV(-N2L4#\>4[Z40I*WW4U6
M2O.SV:D+UOGHMKI6?LMW\CPLV)@NKONW_;7_5;KM'I:G?S/X1?HM4:11&VQ=
MS/[^TT3X= ^?'J)K^.X;_5YT-?^L%)H63POP?>.@:'Z@ _I_#+G\+U!+ P04
M    "  M.')35A25=C88  !73@  &    'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;.U<:7/;2)+]*PAOQ(8405(4?;3'=CM"ENT>3;2/:-DSGXM 4:P6B&+C
M$,W^]?/RJ$*!AZS>GHV=W=@OM@@"69E9>;S,2O#5QM>WS=+:-ONV*JOFQT?+
MMEV_.#MK\J5=F6;BU[;"-PM?KTR+C_7-6;.NK2GXH55Y-IM.GYVMC*L>O7[%
MUS[7KU_YKBU=93_76=.M5J;>OK&EW_SXZ/Q1N/"+NUFV=.'L]:NUN;'7MOVZ
M_ESCTUFD4KB5K1KGJZRVBQ\?79R_>/.$[N<;_N[LIDG^SDB2N?>W].&J^/'1
ME!BRI<U;HF#PWYV]M&5)A,#&;TKS45R2'DS_#M3?L^R096X:>^G+?[BB7?[X
MZ/FCK+ +TY7M+W[S5ZOR/"5ZN2\;_C?;R+V/9X^RO&M:O]*'P<'*5?*_^:9Z
M2!YX/CWRP$P?F#'?LA!S^=:TYO6KVF^RFNX&-?J#1>6GP9RK:%.NVQK?.CS7
MOKZ^^NGCU?NKRXN/7[*+R\M/7S]^N?KX4_;YT\]7EU?OKE^=M5B$;CW+E> ;
M(3@[0O!\EGWP5;MLLG=588LA@3-P%UF<!1;?S.ZE>&W7D^SQ=)3-IK/S>^@]
MCB(_9GJ/_Q4B#U9X$E=XPBL\^=<I]7Z"CR?9=VAFEZ999J8JLIS^L+]U[LZ4
MMFJ;>[[)/9RK:;-U[>"1KMQF?B%WN0JV7MTV_-P2ECUV56MKBYL;<^>J&WR3
MY[XC*I$T;+$TN,O B)<NQZ*UA>/FOH8A9*;%#4T["M^MU[7_AG5;VV0+X^H,
M7'46@BY]W8Y!9@4N[K#BBGG]LK39I5^M3;7]S_]X/CO_X663-8=O#6)!F)O.
MU :<8_W^CBRW=>L6+N>UB7TF4=BU;QR>W[AVF?G:W;@*HH##KG:MPZWV6PY*
MD#YKE[6UV4H,G2B4MFEPU529KVRVM::>,,LI7X?4D:W+CG59=\RC*/F[2D)$
M0KRIB".L>6.S+Q"S,1SI&MJ]O*MK6^7$M6^7MA;>\%?VM7(MEKINF6A!>U;O
ML1;IUGP7XOV=<25)[H5*P=>A8?K0)HM/LHN6+UIH!=]; SEJJ!8JQ^-K6SM?
MC$AUMD46R$S36#6BTIDY%F%5*V7=<>*^928+6WF$0=.RMK*%ZB$1E^YBADJ^
MR0@WLBXS-9"-%%W:K/+5^'LL[1->PLI@)SFLA/4TR7ZQ=[;JU*KL-Z3.YBA+
M.SKN]UH,S#=D/9E=+)# 4K4?UOJ[0.T&F5B9]XVL[IJP<\H$Y\.:Z.=E5X@J
M<ZBZMDO*MW>6GYUDGX:/Z,(P9M'(AIE<=!4S 2WH-FPS]R"S&\$P_J?T=?'0
M3:9':R4360C7HUW30A/Q0E76@7U(? R<BH*&:L>&^)7-3NB14Q@BKY)WJXZ(
MWMGA!A:_=AK03.G! \<M>B"Q2U$'^Y/)E'DGNCFP;Y/L)W]GZTJ(-A1%397;
M].H-Q=-FI*9#HLN5;%'[5=:XE:-X,O<%M#D*H9C-;Y&&X-9\R_(:P70O+N(S
M/A5=GII<;64_U$00G25ZZM?LL8BBR&UX=++/;USCIG*_@\X&"J<GR0<:?&$:
MZ&%>,J6N9IDYY*0Q: G65C9L/"\E<3TP009Y!^*\)&*FQQ\KR2\/6TD>W+BR
MS.;,KL6>%Q15&B04Q%$5AA\@PX$NR#)3+A$1>T?")M'.%KOBJP4TY(RL)8@
MG%\;R1^<T??" ?F4R9IM@V=P8TYHV#61EEE)WN,KDK[$:Q.G[EG 'CU,%G8
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MBCL"%3'$)<4>55MP,,[HAS3'B)B3#5A&@. N $B^Y LG<UFL(HAL-8>W&D^
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M%. BN[C^FLVFY\_'TQ_"UB!9MP( 5 LA#(?5>#$4V?%S$$<+!B).T1FKSBV
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M'\E(4_@ [^2?#IO[MO4K_G-I#0 MW8#O%QYY6C_0 O&WY%[_$U!+ P04
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M+12/KO((J7XU]8:1G5\'&VGL<O'7VFYS4"[!QK=2FJ/A"H3_A]EO4$L#!!0
M   ( "TX<E.B OQC>0(  (,&   9    >&PO=V]R:W-H965T<R]S:&5E=#$S
M+GAM;+5576_:,!3]*U8V[2DBB6,@[0 IH4Q#HATJ[:8]FN1"HB9V9IO2_OO9
M#KA46JNJZEYBWX]S[KUV=#S:<W$G2P"%'IJ:R;%7*M6>!X',2VBH[/$6F(YL
MN&BHTJ;8!K(50 L+:NH A^$@:&C%O,G(^I9B,N([55<,E@+)7=-0\9A!S?=C
M+_*.CNMJ6RKC"":CEFYA!>JV70IM!8ZEJ!I@LN(,"=B,O30ZSXC)MPD_*]C+
MDSTRDZPYOS/&O!A[H6D(:LB58:!ZN8<IU+4ATFW\.7!ZKJ0!GNZ/[-_L['J6
M-94PY?6OJE#EV$L\5,"&[FIUS???X3!/W_#EO);VB_9=+M$5\YU4O#F M=U4
MK%OIP^$<3@!)^ ( 'P#8]MT5LEU>4$4G(\'W2)ALS68V=E2+ULU5S%S*2@D=
MK31.3=+I],?MU<T*+=/?:;:8H?3J FGG]>WL BWF:39?S&_FL]4H4+J:P03Y
M@3GKF/$+S!%&EYRI4J(9*Z!X3A#H-EVO^-AKAE]E7$';0W'H(QSBZ!6^V,T>
M6[[X0V=_5HJX4L26(O_AF%]G_O(IP6'\%0U[Z*U%T!'ST:N^( 7-&H2]I;=%
MS5V:3_CNJFF>\QU3$K7TD:YK<('/*/()[OO),-+[P3#Q!R0VZ6('!8('+6P2
MY%,G?CC /B&1\\11Z ]"XB#W-*=62UP"U@DQ=G;4)_Y9$K][E(S6E.7@(V %
MXAOT"%2<C!/[29CX9X38T2)"?!R[<_O77QJ<"$,#8FOE3R)[7IU&.*]3V+03
MEJ?T3IXOJ=A63*(:-AH:]H9]#XE.\CI#\=;*S)HK+5IV6^I7 H1)T/$-Y^IH
MF +NW9G\!5!+ P04    "  M.')3?F^LY#<$  "@"P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6RU5EESVS80_BL[K-M)9FB1A Y+MJP9V76.F:3Q
MV&G[#)&@B#$(J  H6?GU78"')5NV,VGZ0N+8_?#M!>QTH_2=*1BS<%\*:<Z#
MPMK5:129M& E-3VU8A)W<J5+:G&JEY%9:48SKU2*B,3Q*"HIE\%LZM>N]6RJ
M*BNX9-<:3%665&\OF%";\R )VH4;OBRL6XAFTQ5=LEMF_UQ=:YQ%'4K&2R8-
M5Q(TR\^#>7)Z,7#R7N OSC9F9PS.DH52=V[R,3L/8D>("99:AT#QMV:73 @'
MA#3^:3"#[DBGN#MNT=]YV]&6!37L4HF_>6:+\V <0,9R6@E[HS8?6&//T.&E
M2AC_A4TMFXP"2"MC5=DH(X.2R_I/[QL_["B,XV<42*- /._Z(,_R=VKI;*K5
M!K231C0W\*9Z;23'I0O*K=6XRU'/SKY<7]W,OW[\XSU\NIK?7DTCBZ!N*TH;
M@(L:@#P#D!#XK*0M#%S)C&7[ !&RZ2B1EM(%>1'QEJUZT(]#(#%)7L#K=R;V
M/5[_1TS<0QQTB ././AQI[T,,.[!(PSX6C"X5.6*RNUOOXQ)<G)F $M/4\OE
M$@3#S#/ 92HJ]#)@/EM46%!!9<J@KE^J&5 #N1)8:N84'$[</WOU_V7_&- N
MDX]5?EP9!V@0NA6]J \, 8-D6;E@NHE4,@8J,S>8=,)'?I20,YAG&?=%V&XE
MHV$X&(]@7BIM^3>ZM]G^WR1)'/;)X.VK%CQ+B\0[;(;#,!F1IV3Z(Q(.Q^/7
MR,23<##Z3V22'3+]>!P2],#W!NE[@R<X77"!!F*Z_&]12U/-#GHI(>%D0N"3
MI[*B6[R^K3D4V$G8'_^\P$[">#)XRO=)@)_E/0F')_'KM.,88T9^6@K@VN3D
MP9"=*P#?NU0M)?^&4:2'"A*?8W\#^"VP"MR66ZCP%M9BZQ)B7[).#\MT&?J@
MTT<)LPUA4_"TP*/Q>3?> TZOF<":BHJ!ROWBDYMJ(?BR+ASD4M*['3>J-7O,
MH.=M/8@L]F/ #:14I)6@%J^]RGB[I+L(-7,25,!":;R_W086@K\!#S%L;M!,
M@506CU9KGC$/5:X$3[E%3*3&C/4P/9C; ]$+#V*_P&:#=(:]^%?O<A\PYEJE
MAWIU[NAB=(MM4P'O-"8/-ZE"G^0\K4'Z!,KZG75('Y1K#>2N &D%>D_NA%09
M%X<<CIH,AC>^@HYQH:U$GQ)=?;![[/J,#\I171L/&K[$WT)!U_@ ,29]KFKW
M*O&ZL$A\MF02*8@:-<.^A1OK**%* VV\9'+F11JMG$MG.?+VC%L)7C]VQJ)#
MG9<=J^9I5++V1XH1T:QPS2(>(90QR,JLF._YQ+9WZ-&/=KJFDNFE[PTQW50E
M;=U =:M=^SFONZX'\;IW_4SUDDN79#FJQKV385!79CNQ:N5[L(6RV-'Y88$M
M---. /=SI6P[<0=T3?GL7U!+ P04    "  M.')3SD%5&IL%  "L#0  &0
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M.LR$7P;"PNG*W\:GVN%N[U\7 L<H0P3X/M,X5S8+4K#Y>>;H7U!+ P04
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MDJ9LLSYZ6X(F[K'%WI: F(::LDW-?BA0ZZ)+"1@%8(<?5=&YEO!W6T+";LC
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MW$2S^V.?DY[DK@C9$64XLK8XDW[(G5 <;QA]G^MEZ2(%,XU<@'  7\%F@E4
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MZKHB$14>,E9Z\SCA*P#E7N#L#5%I_,$-Y=LDO9J:: -A\9QR T&IQX8D *6
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MK]/%S5UZOU["P_7F"M;+=+5<;&!S!XOS] J^W-P]I-/ $*_-#K(#QT7'$;_
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M312]$N7?+-?;LTDR03DM2%/J3^+N+6W]61A]F2B5_1?=N;-!.$%9H[2H6F%
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M3_0-=]AQAX$[_-\+/(_ICWKP+@H>2H2%EA53KZ'"+7 %6B$-.=6'>84=<E6
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MBRRKHEDYC@%QVZW2RR4\V_M;]DH,\;S;AQE,_(*U(GEX=:RI9 ,]-)[SFH.
MN\I@%_0#U_3-G9@AXU%H?H-'"YZ/K]4,Y6)2MO/NJ%RJD/8&I0,<M45P'>Y]
MTURENH\!]WT!B9"SSVW5,[0CA288=@<Z_Q]ZD,V]EAP=1[#?LX  0[AU)4 *
MOE9K<B6@/Y!$5]4&VOEGASS'UP5@?8QJL56-U057&6\3CZ58:OW9AS\DP*16
MZN30BF!0<C56&.26S2+D\B! 4:GW_<\HM8VPQ(8LRK[.DV]3D5--&XI*6A#K
M*./CF$DS(9\8<HGJ!87]I!L^G8!=OKB]NSRA V;:Z5+O2_+>&=XP3]R?H_PY
M,S @%#QW(B-UHRWP(<:W( CI.M,HT!+Z KQ27-G"FZQ!W?(JRP'#T/BNM$ Q
M'2@S]:M R$A)F1TK!V%B75295YU>"5$>RIG(J^1RYKG\87UCK%657G,3+5'D
M!LCT!%D=GVG[E"QY :\_!WJ_B2I=RIF272IT8Q(*"(!_-_GWZ?#\_-7P;')V
M6$.EAQ6FK14Y AY<W2CI-@\B\7C!W^"4$[:@!^3$06U7H3 $Q[DA%([=&5$D
M[\UN:G(1(+C'W=Q!R"C:AK+&S.-<(8!!V# 3[59U=*K7VE@9CIPLO4;>^(5K
M Y;>9W&!O?]LA/+S,R"0II-,L&90!H:!-'#QR,B=)SLVC2V2K'D%IE#^BO'A
M4P3<0\W@],QP9/F\-E+?ZQ??G*KX3+\L=O7-JS_=SK@4#+L3Z-&?!2$.MQJA
MKKLOQA6^)HZ=L>NS:3X8_*F84<K,Q-3+'G*[X-&6.G:T,GX.0%!+VQ:IU5VZ
MX-,WFI-L8/!1C$PFP&OQXOA1L,.W:$,@5VP/QUCGE329@Z-@,4JXH(EJH(?2
M\IB_G>.9!5# 0W7_"^80URJ']K8-'@U@K?XC?_/5D,=^?.3FHUF"[OOY3D7>
MXL&4 4M\8.$9#_^H9$+2,9-":7!-U6%%>[<.W$6(Q(W PQI=C\/6/[L2E7,2
MGS6/E1YJ 8Q.[I'U=O%^X'B'.5CV\'XT'W4NLT9!DEF0Z>\IN5V$%=GR>&V#
M=5K+U1)QMY333;]&A(.F+X?3\\DN"DZ;]"2FJT?=\(&"B9C74(G&ET\05:X(
M/B*16^D,2T6EL+!<F/.Q_-BM:-R[=-:$%/#5FF<31D>^?^Z_[F_OU_G2^K@]
M7_W!-"NN#TM+B)Z,7OXX0(G*=3J_)-_(%7;A$R[$\E@13L"!-V!]Z7$>ZE[8
MP/Y_&E>_ U!+ P04    "  M.')3B")\*:H'   L%0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6S%6&MOV\82_2L+7=^+7H#6@[(3)WX CI+V&JA;
MPW9Z/Z_(D;@(R65WEY;57]\S0U*B+-M(V@(!$IE<[LS.G#GS(,]6UGWQ&5%0
MCT5>^O-!%D+U?C3R24:%]D-;48DG"^L*'7#KEB-?.=*I"!7Y*!Z/WXP*;<K!
MQ9FLW;B+,UN'W)1TXY2OBT*[]0?*[>I\,!ET"[=FF05>&%V<57I)=Q0^5S<.
M=Z.-EM045'IC2^5H<3ZXG+S_<,3[9<-OAE:^=ZW8D[FU7_CF*CT?C-D@RBD)
MK$'CSP/-*,]9$<SXO=4YV!S)@OWK3ON/XCM\F6M/,YO_WZ0A.Q^<#%1*"UWG
MX=:N_D>M/\>L+[&YEU^U:O9.I@.5U#[8HA6&!84IF[_ZL<6A)W R?D$@;@5B
ML;LY2*S\J(.^.'-VI1SOAC:^$%=%&L:9DH-R%QR>&LB%B]FOU]=7]]>??KF_
M.QL%*.3E4=(*?VB$XQ>$)[&ZMF7(O/I4II3N*AC!DHTY<6?.A_A5C7=4#=5T
M'*EX'$]>T3?=N#<5?=-O=6]'V]%&VY%H._IK8+TJS-GUWE<ZH?,!TL>3>Z#!
MQ>3M4/6TJAMGTSH)ZB,](%\JL#\H7:;J%G>)%A[_Y#06KTKU(\U=C40"5I,C
M%3)2,UM4NERKE?9*K[1#3)165:LS?:+3;74N1>=\K68WMU?W:I61(]SU=3I*
M"/F3JH-)'(W'8_ZO($JY69IY3HH>42A2$VHXI^P#.1P=,D=TN";M5$7.6#E4
M!V@)5K3W;;*+_H'_^==)/'E[ZME49Y=4B@55L$Z5AX$<<J'V:@X7ON H^ @?
M"H4JQ=<^X!"5Z#(A-U27:F%*G:M*K[N##N+X703<!"HHM@U6.*UU5+-+?!\4
M.!FHF..4EICCH?I8.U,NQ=Z%\0F4BY/$:; O,(EVH$RIL9]AR'  /^N=RB:E
M1 4>UR7R6PH8'@S5/38:Z#!N!S")64^!Z;NT1&'V03'CM$LRB7P?=0F;)S]4
M5SOXLY:%K4L)5:8?2-6>]>%)PQ; G!"EOL&\=I7U''BH<.Q6J4P9!(^(59E2
M/1B;-W1K#6<4?'<C2B,%70MM<L^G<D\)^-\"]'MM'"S(V7B60F-RHD^T\YX[
M"3L>W=.C;@P3!DIP^#Y'#]K&[0DG&K<6<-E+O,H=.!);YZF:]PR!A8X@_QPF
M7;8,U6= X%YT]PG@.O=VYP!1KYQ=ZSRL>4&"'<&:HG*& P)]1__F7P=<RAHA
M>"9KX;NSA?(Z%W@@79!+#/O?%@= U5OEZF02BD# 8'*0:.EHR=AVEK2P>05;
ML?\@/NIJ0B0,B_=,PL2P")R-]SWS,MV8:ROA!1<%R0P^:H,2CG><#DV%PLD<
M08W:0X<!\T&D2EL>HI<C<$+_>;W&]*$6A$?<L%,N4R@$0J4%Q@#KF#%)7J<=
M%W:CU[C ZV4M:0Q7BJ;/S2FLJ&5&9RI;GK+%G=36@ V]^/E0_0Q,D6OJ<N,0
M@_'+_4<0-LE*F]NET""CG',_E1J:MT);%+Q9<NU@;YK:@T(V5C_PT5PUX_'I
MWD&R/CG]+XJA1Z Q4Z5M\K190OO&/66GKW$HDP1"/M-2YG=*1A/;?2=Q'F//
MI1S_2B9,QR.IN,ACB 3,@*RPW5%2Z/@CP.YO6W=;?3UO0.)P=C+(> 9I94+&
MQ:]"$>V:SB[@+UGM@ZEJ;E:^.P?1-D5=*)T^<&?93P:8-3LX.9;6..06K5,T
M1( <-1F@ -J&B87)">-=25OY+A0+XWR0'.<"'+'=<]YF).B>(? ,'=>#9_-I
M6^DLH%FV55*:LM":'D%/U(6F,+X7VHRGI]_][PQ,<<A01KMO.7IHS#]3_CGB
MGV/^>?/=#;[N*+%+:U#U&4;-#E1+CJ^]^@T-%)S8JM@ =:#B9DMO14:F^/3O
M+WW'\'N\33%O]UT^4--=C_?M_K:5GPG-@7O#YSMD[@+A4C*?^][>R60:Q2<G
M.ROOHN.3-[V5DTET/'[W34;@'3+7<\L5^*%7V;<G_]H?[X^?&R+!.!2'1";\
M!.\:AAM!LM4+OZ3V7?J 5U[4A1N4[$*C*B5#]4/;)[J'77O@BD(/.J^[!HP:
M-.]Z'*K;IYNKP[=3>,\5N1,>W2S,'^1>&=A-F9FYP56$"?D/J ^Z0 .*FM$1
MVL5W,;>8W=[,7IR:]+8W?;J[NX1(CO)?@390Q#:AU<@XH]E=1'<RBE$OZW2]
MYYG7"PIKKJTY.N'<Y(;;$53@Y2PWW-@!/3$M=++NSG\-CKYG7*;%DYYW63M&
MES:@[&*6D3D"8U'HVI0G-O\0T'6]&5.)V<#)+417AD?U35 ; .JJRM>[!G2M
M)#C,<\,>6HZD^VB^Y"\6TD4Z1X9] EYBPL1L<?(Z^^0-Q@3XQA @6C*90&>/
MEF+$$W(R9*WAV\E&8/B@UQS[7KPV.,/P?@BVV[^.?*EV=DL^*/N+W-NV5TP;
M_.6)9^JVK6^<QLBGH]:9 F/\/T?32%62RXG]@I?(8!+_MXC;1V6?N'WNM/':
M2.^03'1]#<6>^Q SZGW!PDO(4K[3\:2*%Y#F8]9F=?,I\++Y K;=WGQ'O-9N
MR<-F3@N(CH=OCP>-&=U-L)5\#YO;$&PAEQEIQ)PWX/G"VM#=\ &;#Z07?P)0
M2P,$%     @ +3AR4X87-MJ,"0  +AH  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&ULK5EI;QLY$OTKA/9  BB2K1P3)(X!VTEV@\5DC"C>_4QU4VJ.
MV60/R9:B_?7[JL@^9"N><7: (.Z#+-;QWF.Q=;9S_C942D7QK38VO)M4,39O
MYO-05*J68>8:9?%F[7PM(V[]9AX:KV3)DVHS7YR<O)K74MO)^1D_N_;G9ZZ-
M1EMU[45HZUKZ_:4R;O=N<CKI'GS1FRK2@_GY62,W:JGB37/M<3?OK92Z5C9H
M9X57ZW>3B],WEZ]H/ _XMU:[,+H6%,G*N5NZ^52^FYR00\JH(I(%B3];=:6,
M(4-PX[=L<](O21/'UYWUCQP[8EG)H*Z<^8\N8_5N\GHB2K66K8E?W.Z?*L?S
MDNP5S@3^7^S2V!<_3431ANCJ/!D>U-JFO_);SL-HPNN3[TQ8Y D+]CLMQ%Z^
MEU&>GWFW$YY&PQI=<*@\&\YI2T591H^W&O/B^>7%\M-2_/)17'_YL/SP^>O%
MUT^_?!9/KIW1Q?[IV3QB#1HY+[*]RV1O\1U[IPOQL[.Q"N*#+55Y:& .YWH/
M%YV'EXL'+2Y5,Q//3Z9B<;(X?<#>\S[BYVSO^6,B?L#NB][N"[;[XGMV9=!!
MN+6X]BHH&R6A[E@"?\",^%KA!A N7-U(N]=V(PIG ZI4RJA*L=96VD)+(P)F
M*+ F!E')K1(KI:P 7QOI,4Y;-N)+C%: 6JS$1EGEI3%[>J,:LD9#6AMIE<9K
MV&V,"C0W5DK<6$UCEK0..WI1*Z\+*9[\_2^O%XN3MS>SY4S\X^+BFN]/WSZ=
MD?M_@O-$8E%I<(+6,S 2(E$2^5+?R'4!D1*%\A%B-+(J0U"P6"L96K(C,5!J
M+[;2M&HF+@R&U!0PV<%J&%[F:!^?=&E+3M/!-.LH5PCB<('#5);.&.G#M NF
M41#/BB9A.<F&=Y7"K8-]O]/P3=L2F8"-F?BBUGB'J@81G<BE^&LN 2^-QT<7
M9,O^V/2KN_.OI)6EEK:;.GN -R][WKS\8X"_ZG/+<@VG/K:6M1L9OFH]N;<_
M1J@_T_Z=41UP&1RP$=I5T,B U[F>/3@)>E3W(&N%;#;.)_Z &PZ0"_R2AMHH
M,C*FH@T=J(!J>C-F'DDPEIF)3S8J_RQ/$M%+&R3[#:RLI)%<-8JGM=B7C?XO
MW-F  O#8"^. MD#<&4],6#0:.PI#N6TPH!B'GDC[^W@GMSQA,=Y)U8?E\D)<
M [^U1 3%;'HT ^2VQH1=Y4B"W,YBH7&69T>K1+ZMA^=%]QSK IU80<>]T"GI
MXY?L@M?4?PB%X%RM"PS?:N\LQ4.LW%6ZJ'ADMH,.R!-A9@\M2^.O<HFZH [0
M,@A:J5!/9%XQ+M8(W.W"&R;=R?.W__??*RJ!9Z<^K->*VYYQ$N^.1W&<!UX3
MXH>G<%)!8'NS7; _ZM==0"0UD?S^=/%6W"S%>Y:5\<A"M9'$/B LCT;@!F].
M3T[$WT;#OP#T-=7&RX:'!]&80CPY?=H)WK] J-+5>>8U$D0BJ+PAHAV9SN[Q
M_"/+T?-/-D/)@7L,=Z-_:\?:4NH YK3I/M">LZ3-M5Y!U;MNYB'Y?-7+YZL'
MY>T&U*-*APA4 Z3'!/)Q%ACE2==2.!G=C]P(-0L*'1N(0]QJ])T!!!+9 KS0
MREKT_DP]["^UO 7K>D<HC]B\V[K)HK7"L0($C"VIUY:7B152*QGG[&627J)6
MW4M1:@"FJ)%<::,CZ$B[+ XV@:[@)BDNZV]J%6CAT=/1O%S+I YH2=93$MFR
M19NTF8X<&+0?#4816^0&X>*H0(K9&FB<WEB]!K1MA.Z5&A%XL?8 ::Q<&&5A
M)I;#4-)M>)#21VL\F#^T;J8MDS27<&8K60L.TD#OJ!'J2TVF23QMB+[-I40-
M\A87E-_J@B;"N,-6%^4W-70]($39HA(EJF-<PWZE]L*X(BVQP3842=4]M3$D
MAE*;T($,VQ$5-]U1]S4N?ZI*J=-M+??04WA%;,[-*=916\I3ZKB0DF3F=^&:
MM%TE'!%D1%%)5)\[9CO>E[OTTO;BL8>@-K3A(O+0)+%%/5?[G'R:H6,B S9*
M5=%Y=JNZ[&6W<Y>0<Y!61H;'MQGC&?#=!&OV#, '['#:,F?2^_ ]TRMTEG?@
M=H]]D;= MD:&N1<5P;6^2*>!G!ZJ-+:<U(L#3NSU"*R5I ("FYE,?27(QE"@
MQ@6N-K7 :IJL)/XD-G%Y!)7#<Z=?_HHC<\<&CE!ZSX)U3P[8_0,JY"2RL&1=
M.63NF*7CS/#887^GN*8$14))]B/M\N3(K=H/%'W#NV^B$2.PZPUZ.@XT(\!I
M2R< E@S"DU'?,KUZ.;UE=<YGH$=)*39DA@-+]UH6G0YJ7[0UZI/:3/SK<G_H
MG038261)H""K@6DUS1!C*G9M!E7;0R4Z#&&\0[6)FB4U9-JPF/X*40V-AX#1
M694'HK>R:B>,VNA@4HI(!498L.02N:!8EU6^SMJTU?PQ:<V,&>0KD9^/@Q14
M26<AZNDYK 06.F,FF<1S^@S$Q]%L=I5 Q"U7ZL#9M[<'32$A/F6&+!-B2!=@
MN4X6C$I/0XON,Z^ZTSB;KI3HVWK* AOB0SS2!"! ZL9")',@:XY_B(3"?#]L
M @/'QDI_E8&S VTD'V?IX(?E8VI6RV,&1B3*,IIA5X[.V=/#K%T:6=P^6Q9H
M^PFVKE1F2ME(#.X.^[^UTE.;ML_'_/3!XL[19A1[9O"!F-"HO'6,!9@>)V^/
MN$*>].Z&[^AA+I38.H(BU7\*A=CJDAJ#O5:F3$U&0>$0J[/B4)](8$&'F$]+
M3SYCMT*?^13B2P?^9VGM1NZ';PKD/5P?CJ4'N&H:HS%CX#MG"KQHN"]R][=Y
M_K)PL+5;9Y\5,E3I/%HJG\^!RS22D,"5+#O-'HK;[3A'>@?>[H<Y)6OBR'U4
M3Z$>Z:BV<=B=Q*C-F!V$FK_@Y&,=??WI^Y5GX$LTE.CQ*9>SH*"3;J\P;;4?
MOG/TPOQ'@A@[C^O^A+CGK.009UT+30H\,LMMT_VR'GK:*WBW 9 16K.F,%%?
M[W!NI?6'*F;6)&\T305"2H9]X@%9NM<VY2AS&_:U(F7K6AJ<L]PC7-&V:6.X
M#Z_,H;X!.IYGM&U$[72:J&MB&B,M]:0]<XQ>]U/2YS#'!)R.B)=/7&/N\:.\
M'1[M8NK\6?).@\F^!]&&S KUXS7E3W<@>=M][TLT/W[LFX^^X=?*;_B7"CXL
MV)@^Y_=/^Q]#+M)O ,/P]$O*S])O2"*-6F/JR>RGEQ/ATZ\3Z2:ZAG\10+\7
M7<V7E4+3XFD WJ\=',TWM$#_$]'Y_P!02P,$%     @ +3AR4[),;4\)&0
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MOYX]Q@VTXA_6;'SRMT)2%L[=X8?K_-<'4\3(%"9K$(2&_^[-E2D*A 1X_"E
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MQ?#*)*7(#B5VHP/YR$B,%[(3/L0,;JVWS&& %1* ) P8*72H8TE-%HU(=0V
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M?3L*0#<SLQ&LJOR<6BM+4\]O"_K-H'8&=)XK9?>""]#^N":_ 5!+ P04
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MJ4^R4B+H%5Q1%TVM16=AFMZ7POQ9A3KIUPGGR&4!PH+2#E)-]S]#(@*G88G
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MY*#?#4 U);,9&%G[,C65QA8]WUW8OPPJ%V#79U*:S<!MT/ZW1K\!4$L#!!0
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M=E#?%XS)=T-?(.T/QN W4$L#!!0    ( "TX<E-V07<$&0,  #D(   9
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MS=S<F2CM!/-^)83>=>PY[F[AY"]02P,$%     @ +3AR4S[5_3D( @  Y00
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MX07N@'-'9&7\/G(&74L'/)^?V+]X[];+CAJX4_P'R[&<!I\"DD-!:XYKU3S
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M]L#QS<K^$D"Y OM\+:79=]RI,_QD\E=02P,$%     @ +3AR4X FI&.3 @
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M.4 8!WV^Y%SM-V8XM=^B^"]02P,$%     @ +3AR4WRQ!ZP% P  6PD  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULK59;;]HP%/XK5K1)K;21Q-PK
M0 )*+]+:(EBWAVD/)CD0JXF=V:9T_WZV$P)MP6)27\!V_%W.L7WLWH:+)YD
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M1!0W>=%1/+>7X8(K?;7:9J)?/R#,!/U]R;G:=HQ ]9X:_ -02P,$%     @
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M+0V;%18&OG=PNQS[LZ^Q,/@/%0/N*RKL+ZE/JQG3BBW\4YSV05^7$;XV_;$
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M5P3+_4<^0/Z_8$SL;W('U2GFX']02P,$%     @ +3AR4VC>V7$B P  3PL
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M7.GV9(>%_N( 80#Z><:YVD[,!LTWS/ O4$L#!!0    ( "TX<E,;)%TIF0@
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M3*Z(/5=&Z/Q$:APIU^G[=.>8?M"5J,,A$UWQ_5R!X7 )'LZ4(S6X&M]<LU?
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M\I<"?^DE^4O;5C:Z1F(*_*5#\I>V<95RC(\5K+6KIPO\I5?AKZ:5QCJ#5K^
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M!L]XD\&J]H[7KT!@,22!10M9!<7\^,V;WJZ>+A!87(7 FE9XH5^G)##6$5@
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MCL_F=:^N1)1K@/I_RY@\#72 ZI(U_Q]02P,$%     @ +3AR4TFXGTFV P
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M\J876?<SM.H733119I*KIU3AY'AV<78UO?CT?C*]FCT'T\]?WW[Y 4YF.6T
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MXL?S(V^^D2S-SG373*H38K9<$[P@7!NHYTO&Y-U&'Q/+/Q[&_P!02P,$%
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M2[;%)=)].5<F\EN6C.=8:"X+4+@9>,/N]:AG\UW"3XX'?30&ZV0MY:,-)MG
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M4-H#9G\IA-Y.;,/I/DBC?U!+ P04    "  M.')3*6.=B8X$  #F$0  &0
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MP ^[L,.)9-M\(S-G4FV+\L.-VKD"UP^H^RO&Y,N)WAN5>^')?U!+ P04
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MB".8 _" (7'<O ?WWD?AYCT5;O];._X-4$L#!!0    ( "TX<E.7BKL<P
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M+W]9?NV<W.,7G--M17W^"U!+ P04    "  M.')3I7\.<>X!  "0)@  $P
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M[YU;_W'\^"P[V_1O^6S\(]KB!5!+ 0(4 Q0    ( "TX<E,'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ +3AR4U]022ON    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ +3AR4YE<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  M.')3
M?8 ?"^0%  !M&0  &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ +3AR4\D$R0<Z!0  /Q,  !@
M     ("!)PX  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M "TX<E/*W+=N%P(  "0%   8              " @9<3  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    "  M.')3[U6(7L0$  !+#P  &
M            @('D%0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ +3AR4PWAB>:H"   \B0  !@              ("!WAH  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( "TX<E/4!F/Q1 <  *(A
M   8              " @;PC  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    "  M.')3$_5U/^<#  !1"   &               @($V*P
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ +3AR4\"T3?5F
M"0  &!D  !@              ("!4R\  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( "TX<E-6%)5V-A@  %=.   8              "
M@>\X  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  M.')3
MAOZE'M<#  "9"   &0              @(%;40  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( "TX<E/=S(#\F@(  (P%   9
M      " @6E5  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ +3AR4UL_<+YJ @  *P8  !D              ("!.E@  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  M.')3H@+\8WD"  "#!@
M&0              @(';6@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( "TX<E-^;ZSD-P0  * +   9              " @8M=  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ +3AR4\Y!51J;
M!0  K T  !D              ("!^6$  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    "  M.')3=!*PD5H&  "J$0  &0
M@('+9P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "TX
M<E/;BOYQO P  &4K   9              " @5QN  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ +3AR4W^(NRP) P  4P<  !D
M         ("!3WL  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    "  M.')3#%9"=H@"  "9!0  &0              @(&/?@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( "TX<E,7D^,.# 8  ,<0
M   9              " @4Z!  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ +3AR4\\\GVE  @  _00  !D              ("!D8<
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  M.')3:7UT
MY,T&  #?$   &0              @($(B@  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( "TX<E.((GPIJ@<  "P5   9
M  " @0R1  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M+3AR4X87-MJ,"0  +AH  !D              ("![9@  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    "  M.')3LDQM3PD9  "Q4P  &0
M            @(&PH@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( "TX<E.G1<G.Y (  ,0&   9              " @?"[  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ +3AR4]2)+'KV @
M@@8  !D              ("!"[\  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    "  M.')3%47LV'\"   T!@  &0              @($X
MP@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( "TX<E,5
MQ/PAE0(  %P&   9              " @>[$  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ +3AR4^:!C_?I @  /P@  !D
M     ("!NL<  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "TX<E-TUE5IL@(  .\'   9              "
M@33@  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ +3AR
M4[3IKR\1 @  500  !D              ("!'>,  'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    "  M.')3HD]9[YT"  "S!P  &0
M        @(%EY0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( "TX<E/)LLF;T0(  &P(   9              " @3GH  !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ +3AR4W9!=P09 P  .0@
M !D              ("!0>L  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    "  M.')3(8 *SW@"  "1!0  &0              @(&1[@
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( "TX<E,^U?TY
M" (  .4$   9              " @4#Q  !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ +3AR4Y,>TAAY @  < 8  !D
M ("!?_,  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  M
M.')3@":D8Y,"  "7!@  &0              @($O]@  >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( "TX<E-\L0>L!0,  %L)   9
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M970T."YX;6Q02P$"% ,4    "  M.')3:-[9<2(#  !/"P  &0
M    @($&#0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M "TX<E-Q>6L$]0(  ,\(   9              " @5\0 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ +3AR4QLD72F9"   -BT  !D
M             ("!BQ,! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    "  M.')3?O.8%:,#  !G#@  &0              @(%;' $ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( "TX<E/6:5.)? ,
M "0.   9              " @34@ 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ +3AR4YY8WIGH P  Q X  !D              ("!
MZ",! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  M.')3
M<T&K6B,&  #+*0  &0              @($'* $ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( "TX<E/:BS#MM0,  ' -   9
M      " @6$N 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ +3AR4TFXGTFV P  A!   !D              ("!33(! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  M.')3KT+)XND"  ")!P
M&0              @($Z-@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( "TX<E,DWVBF0 (  .D$   9              " @5HY 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ +3AR4QJ_VX(^
M!   FPT  !D              ("!T3L! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    "  M.')32_&Y/1<#  "H"0  &0
M@(%&0 $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( "TX
M<E-^BJ$NW (  %4(   9              " @91# 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ +3AR4WIW4\ $ @  300  !D
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M<R\N<F5L<U!+ 0(4 Q0    ( "TX<E.]3YHR6 4  *4K   /
M  "  :A8 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  M.')3'M^97AP"
M   ])P  &@              @ $M7@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  M.')3I7\.<>X!  "0)@  $P
M@ &!8 $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     2@!* #T4  "@8@$
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>156</ContextCount>
  <ElementCount>360</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureNatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REALM ACQUISITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureRealmAcquisition</Role>
      <ShortName>REALM ACQUISITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - SHORT-TERM INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShortTermInvestments</Role>
      <ShortName>SHORT-TERM INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - PREPAIDS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosurePrepaids</Role>
      <ShortName>PREPAIDS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - OPERATING LEASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureOperatingLease</Role>
      <ShortName>OPERATING LEASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - LONG-TERM DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureLongTermDebt</Role>
      <ShortName>LONG-TERM DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - DERIVATIVE LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureDerivativeLiabilities</Role>
      <ShortName>DERIVATIVE LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquity</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11501 - Disclosure - SEGMENTED INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSegmentedInformation</Role>
      <ShortName>SEGMENTED INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11601 - Disclosure - FINANCIAL INSTRUMENTS AND RISK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11701 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureCommitments</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>20202 - Disclosure - BASIS OF PRESENTATION (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy</Role>
      <ShortName>BASIS OF PRESENTATION (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30203 - Disclosure - BASIS OF PRESENTATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureBasisOfPresentationTables</Role>
      <ShortName>BASIS OF PRESENTATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureBasisOfPresentation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REALM ACQUISITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureRealmAcquisitionTables</Role>
      <ShortName>REALM ACQUISITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureRealmAcquisition</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30603 - Disclosure - PREPAIDS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosurePrepaidsTables</Role>
      <ShortName>PREPAIDS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosurePrepaids</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30701 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30803 - Disclosure - OPERATING LEASE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureOperatingLeaseTables</Role>
      <ShortName>OPERATING LEASE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureOperatingLease</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30903 - Disclosure - LONG-TERM DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureLongTermDebtTables</Role>
      <ShortName>LONG-TERM DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureLongTermDebt</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31003 - Disclosure - DERIVATIVE LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables</Role>
      <ShortName>DERIVATIVE LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureDerivativeLiabilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31103 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquity</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31401 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31703 - Disclosure - COMMITMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureCommitmentsTables</Role>
      <ShortName>COMMITMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureCommitments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40101 - Disclosure - NATURE OF OPERATIONS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails</Role>
      <ShortName>NATURE OF OPERATIONS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureNatureOfOperations</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40201 - Disclosure - BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails</Role>
      <ShortName>BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureBasisOfPresentationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REALM ACQUISITION (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails</Role>
      <ShortName>REALM ACQUISITION (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureRealmAcquisitionTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40402 - Disclosure - REALM ACQUISITION (Schedule of Net Assets Acquired) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails</Role>
      <ShortName>REALM ACQUISITION (Schedule of Net Assets Acquired) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureRealmAcquisitionTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40501 - Disclosure - SHORT-TERM INVESTMENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails</Role>
      <ShortName>SHORT-TERM INVESTMENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShortTermInvestments</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40601 - Disclosure - PREPAIDS (Schedule of Prepaid Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails</Role>
      <ShortName>PREPAIDS (Schedule of Prepaid Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosurePrepaidsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40701 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40801 - Disclosure - OPERATING LEASE (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails</Role>
      <ShortName>OPERATING LEASE (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureOperatingLeaseTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40802 - Disclosure - OPERATING LEASE (Schedule of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails</Role>
      <ShortName>OPERATING LEASE (Schedule of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureOperatingLeaseTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40901 - Disclosure - LONG-TERM DEBT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails</Role>
      <ShortName>LONG-TERM DEBT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureLongTermDebtTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40902 - Disclosure - LONG-TERM DEBT (Schedule of Term Loan Repayment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails</Role>
      <ShortName>LONG-TERM DEBT (Schedule of Term Loan Repayment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureLongTermDebtTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41001 - Disclosure - DERIVATIVE LIABILITIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails</Role>
      <ShortName>DERIVATIVE LIABILITIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41002 - Disclosure - DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails</Role>
      <ShortName>DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41003 - Disclosure - DERIVATIVE LIABILITIES (Schedule of Changes of Derivative Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesScheduleOfChangesOfDerivativeLiabilitiesDetails</Role>
      <ShortName>DERIVATIVE LIABILITIES (Schedule of Changes of Derivative Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41101 - Disclosure - SHAREHOLDERS' EQUITY (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41102 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Share Based Compensation Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule of Share Based Compensation Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41103 - Disclosure - SHAREHOLDERS' EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41104 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41105 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Stock Option Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Summary of Stock Option Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41106 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Warrants Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Summary of Warrants Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41107 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Warrants Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Summary of Warrants Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureShareholdersEquityTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41301 - Disclosure - RELATED PARTY TRANSACTIONS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41401 - Disclosure - INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails</Role>
      <ShortName>INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41402 - Disclosure - INCOME TAXES (Significant Components of Future Tax Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails</Role>
      <ShortName>INCOME TAXES (Significant Components of Future Tax Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41403 - Disclosure - INCOME TAXES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>INCOME TAXES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41501 - Disclosure - SEGMENTED INFORMATION (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureSegmentedInformationNarrativeDetails</Role>
      <ShortName>SEGMENTED INFORMATION (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureSegmentedInformation</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41601 - Disclosure - FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41701 - Disclosure - COMMITMENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails</Role>
      <ShortName>COMMITMENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureCommitmentsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="tmb-20210930x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41702 - Disclosure - COMMITMENTS (Schedule of Contractual Obligations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails</Role>
      <ShortName>COMMITMENTS (Schedule of Contractual Obligations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.essapharma.com/role/DisclosureCommitmentsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="tmb-20210930x10k.htm">tmb-20210930x10k.htm</File>
    <File>tmb-20210930.xsd</File>
    <File>tmb-20210930_cal.xml</File>
    <File>tmb-20210930_def.xml</File>
    <File>tmb-20210930_lab.xml</File>
    <File>tmb-20210930_pre.xml</File>
    <File>tmb-20210930xex21d1.htm</File>
    <File>tmb-20210930xex23d1.htm</File>
    <File>tmb-20210930xex31d1.htm</File>
    <File>tmb-20210930xex31d2.htm</File>
    <File>tmb-20210930xex32d1.htm</File>
    <File>tmb-20210930xex4d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tmb-20210930x10k001.jpg</File>
    <File>tmb-20210930x10k002.jpg</File>
    <File>tmb-20210930x10k003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tmb-20210930x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 156,
   "dts": {
    "calculationLink": {
     "local": [
      "tmb-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20210930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20210930x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tmb-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 484,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 18,
    "http://www.essapharma.com/20210930": 4,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 27
   },
   "keyCustom": 73,
   "keyStandard": 287,
   "memberCustom": 44,
   "memberStandard": 28,
   "nsprefix": "epix",
   "nsuri": "http://www.essapharma.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - REALM ACQUISITION",
     "role": "http://www.essapharma.com/role/DisclosureRealmAcquisition",
     "shortName": "REALM ACQUISITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - SHORT-TERM INVESTMENTS",
     "role": "http://www.essapharma.com/role/DisclosureShortTermInvestments",
     "shortName": "SHORT-TERM INVESTMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "epix:PrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - PREPAIDS",
     "role": "http://www.essapharma.com/role/DisclosurePrepaids",
     "shortName": "PREPAIDS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "epix:PrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "role": "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - OPERATING LEASE",
     "role": "http://www.essapharma.com/role/DisclosureOperatingLease",
     "shortName": "OPERATING LEASE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - LONG-TERM DEBT",
     "role": "http://www.essapharma.com/role/DisclosureLongTermDebt",
     "shortName": "LONG-TERM DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - DERIVATIVE LIABILITIES",
     "role": "http://www.essapharma.com/role/DisclosureDerivativeLiabilities",
     "shortName": "DERIVATIVE LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - SHAREHOLDERS' EQUITY",
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquity",
     "shortName": "SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS",
     "role": "http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows",
     "shortName": "SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://www.essapharma.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - INCOME TAXES",
     "role": "http://www.essapharma.com/role/DisclosureIncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - SEGMENTED INFORMATION",
     "role": "http://www.essapharma.com/role/DisclosureSegmentedInformation",
     "shortName": "SEGMENTED INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - FINANCIAL INSTRUMENTS AND RISK",
     "role": "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - COMMITMENTS",
     "role": "http://www.essapharma.com/role/DisclosureCommitments",
     "shortName": "COMMITMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - BASIS OF PRESENTATION (Policy)",
     "role": "http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy",
     "shortName": "BASIS OF PRESENTATION (Policy)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)",
     "role": "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policy)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - BASIS OF PRESENTATION (Tables)",
     "role": "http://www.essapharma.com/role/DisclosureBasisOfPresentationTables",
     "shortName": "BASIS OF PRESENTATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - REALM ACQUISITION (Tables)",
     "role": "http://www.essapharma.com/role/DisclosureRealmAcquisitionTables",
     "shortName": "REALM ACQUISITION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "epix:PrepaidExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "epix:ScheduleOfPrepaidExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - PREPAIDS (Tables)",
     "role": "http://www.essapharma.com/role/DisclosurePrepaidsTables",
     "shortName": "PREPAIDS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "epix:PrepaidExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "epix:ScheduleOfPrepaidExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30701 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "role": "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "epix:ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - OPERATING LEASE (Tables)",
     "role": "http://www.essapharma.com/role/DisclosureOperatingLeaseTables",
     "shortName": "OPERATING LEASE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "epix:ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - LONG-TERM DEBT (Tables)",
     "role": "http://www.essapharma.com/role/DisclosureLongTermDebtTables",
     "shortName": "LONG-TERM DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - DERIVATIVE LIABILITIES (Tables)",
     "role": "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables",
     "shortName": "DERIVATIVE LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - SHAREHOLDERS' EQUITY (Tables)",
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
     "shortName": "SHAREHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31401 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.essapharma.com/role/DisclosureIncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31703 - Disclosure - COMMITMENTS (Tables)",
     "role": "http://www.essapharma.com/role/DisclosureCommitmentsTables",
     "shortName": "COMMITMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - NATURE OF OPERATIONS (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails",
     "shortName": "NATURE OF OPERATIONS (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_XOz0eBSbkU2BL3yWpajTpA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "epix:PercentageOfEffectiveInterestInSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails",
     "shortName": "BASIS OF PRESENTATION (Schedule of Functional Currency of Company and its Subsidiaries) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "epix:ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_srt_OwnershipAxis_epix_EssaPharmaceuticalsCorpMember_XOz0eBSbkU2BL3yWpajTpA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "epix:PercentageOfEffectiveInterestInSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - REALM ACQUISITION (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails",
     "shortName": "REALM ACQUISITION (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_7_31_2019_To_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_EUyBoT0vEEaq8huChR2CXA",
      "decimals": "INF",
      "lang": null,
      "name": "epix:BusinessCombinationConversionRatioPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - REALM ACQUISITION (Schedule of Net Assets Acquired) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails",
     "shortName": "REALM ACQUISITION (Schedule of Net Assets Acquired) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_7_31_2019_us-gaap_BusinessAcquisitionAxis_epix_RealmTherapeuticsPlcMember_CpUVbpoAoESU9H8qmqP_Qw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_YemvLESzuEy-rvMFb5JkQw",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - SHORT-TERM INVESTMENTS (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails",
     "shortName": "SHORT-TERM INVESTMENTS (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_YemvLESzuEy-rvMFb5JkQw",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "epix:ScheduleOfPrepaidExpensesTableTextBlock",
       "epix:PrepaidExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - PREPAIDS (Schedule of Prepaid Expenses) (Details)",
     "role": "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails",
     "shortName": "PREPAIDS (Schedule of Prepaid Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "epix:ScheduleOfPrepaidExpensesTableTextBlock",
       "epix:PrepaidExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Schedule of Accounts Payable and Accrued Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - OPERATING LEASE (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
     "shortName": "OPERATING LEASE (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - OPERATING LEASE (Schedule of Operating Leases) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
     "shortName": "OPERATING LEASE (Schedule of Operating Leases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "epix:ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "lang": null,
      "name": "epix:OperatingLeaseRightOfUseAssetAddition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - LONG-TERM DEBT (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails",
     "shortName": "LONG-TERM DEBT (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_11_18_2016_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_2x7YFW6kN0SPIIof17z1gw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2019_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_DzMDwGmdD0qgqtbE68ow2Q",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - LONG-TERM DEBT (Schedule of Term Loan Repayment) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails",
     "shortName": "LONG-TERM DEBT (Schedule of Term Loan Repayment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2018_us-gaap_LongtermDebtTypeAxis_epix_SiliconValleyBankTermLoanMember_hAyflyNNBEWF35w4BVawNQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - DERIVATIVE LIABILITIES (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
     "shortName": "DERIVATIVE LIABILITIES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_srt_StatementScenarioAxis_epix_IncreaseInMarketPriceOfWarrantsBy10Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_TVV9GdC9SUqfmn3lDBu8_A",
      "decimals": "0",
      "lang": null,
      "name": "epix:IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_98MIq4VaTEK2WLibJUF1nA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails",
     "shortName": "DERIVATIVE LIABILITIES (Fair Value Measurement Inputs and Valuation Techniques) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_98MIq4VaTEK2WLibJUF1nA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccretionExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - DERIVATIVE LIABILITIES (Schedule of Changes of Derivative Liabilities) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesScheduleOfChangesOfDerivativeLiabilitiesDetails",
     "shortName": "DERIVATIVE LIABILITIES (Schedule of Changes of Derivative Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2018_gbNIj0Ji9UGpcvXSjAlGuQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - SHAREHOLDERS' EQUITY (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
     "shortName": "SHAREHOLDERS' EQUITY (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Share Based Compensation Expenses) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule of Share Based Compensation Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - SHAREHOLDERS' EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails",
     "shortName": "SHAREHOLDERS' EQUITY (Weighted Average Assumptions for the Valuation of Purchase Rights) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_us-gaap_PlanNameAxis_epix_EmployeeSharePurchasePlanMember_o3U0HZcwakmPn4ARQ2sBBw",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41104 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Stock Option Activity) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails",
     "shortName": "SHAREHOLDERS' EQUITY (Summary of Stock Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_LKrB7fDTUEOKiLQlEl3BnQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41105 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Stock Option Outstanding) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails",
     "shortName": "SHAREHOLDERS' EQUITY (Summary of Stock Option Outstanding) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2020_t8baaUWlNUWZzLAQUEvCLw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41106 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Warrants Activity) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails",
     "shortName": "SHAREHOLDERS' EQUITY (Summary of Warrants Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "lang": null,
      "name": "epix:ClassOfWarrantOrRightExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41107 - Disclosure - SHAREHOLDERS' EQUITY (Summary of Warrants Outstanding) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails",
     "shortName": "SHAREHOLDERS' EQUITY (Summary of Warrants Outstanding) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "epix:ScheduleOfWarrantsOrRightsOutstandingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_epix_WarrantsExercisePriceOneMember_peg5Z3r7MkaJuDu2VWniig",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "epix:StockIssuedDuringPeriodValuePreFundedWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails",
     "shortName": "SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "epix:StockIssuedDuringPeriodValuePreFundedWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZFVN2JauZkGScLzhKsCsWA",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_rj2UHMCflEe1q86RKPHdAA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - RELATED PARTY TRANSACTIONS (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_rj2UHMCflEe1q86RKPHdAA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HeTz-es_FUOKI2zSdF0t_Q",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY",
     "role": "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity",
     "shortName": "CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HeTz-es_FUOKI2zSdF0t_Q",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails",
     "shortName": "INCOME TAXES (Reconciliation of Income Taxes at Statutory Rates) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41402 - Disclosure - INCOME TAXES (Significant Components of Future Tax Assets) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails",
     "shortName": "INCOME TAXES (Significant Components of Future Tax Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41403 - Disclosure - INCOME TAXES (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "shortName": "INCOME TAXES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_qibeEwVRHEaa07t53xYZYQ",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_bQM1D9rk7USEKwcghht0TA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - SEGMENTED INFORMATION (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureSegmentedInformationNarrativeDetails",
     "shortName": "SEGMENTED INFORMATION (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_bQM1D9rk7USEKwcghht0TA",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "epix:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_8MxAA18AjkWCUCRnmolF8A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "epix:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_2_1_2014_To_2_28_2014_srt_ProductOrServiceAxis_us-gaap_GrantMember_3kTJC-T1iU2z88W1B5pfng",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "epix:GrantAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - COMMITMENTS (Narrative) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
     "shortName": "COMMITMENTS (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_2_1_2014_To_2_28_2014_srt_ProductOrServiceAxis_us-gaap_GrantMember_3kTJC-T1iU2z88W1B5pfng",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "epix:GrantAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_wo_CqFhP30O9pBTiuvhaRg",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41702 - Disclosure - COMMITMENTS (Schedule of Contractual Obligations) (Details)",
     "role": "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails",
     "shortName": "COMMITMENTS (Schedule of Contractual Obligations) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_epix_VendorAgreementMember_oGjsHlcwYESTHXMl2ZLyjg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_CAD_qQHyMgSBHECcLwbGY6DSQw",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - NATURE OF OPERATIONS",
     "role": "http://www.essapharma.com/role/DisclosureNatureOfOperations",
     "shortName": "NATURE OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - BASIS OF PRESENTATION",
     "role": "http://www.essapharma.com/role/DisclosureBasisOfPresentation",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.essapharma.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20210930x10k.htm",
      "contextRef": "Duration_10_1_2020_To_9_30_2021_8-FnW9Z85kaHHVpgdNIEbA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 73,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "U [S]",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "epix_AggregateRoyaltyPaymentAfter24000000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to aggregate royalty payments exceeds $24,000,000.",
        "label": "Aggregate Royalty Payment After24000000 [Member]",
        "terseLabel": "Aggregate Royalty payment After $24,000,000"
       }
      }
     },
     "localname": "AggregateRoyaltyPaymentAfter24000000Member",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_AggregateRoyaltyPaymentUpTo24000000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to aggregate royalty payments up to $24,000,000.",
        "label": "Aggregate Royalty Payment Up To24000000 [Member]",
        "terseLabel": "Aggregate Royalty payment Up To $24,000,000"
       }
      }
     },
     "localname": "AggregateRoyaltyPaymentUpTo24000000Member",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments made at application for marketing approval.",
        "label": "Amount Of Milestone Payments At Application For Marketing Approval",
        "terseLabel": "Total amount of milestone payments at application for marketing approval"
       }
      }
     },
     "localname": "AmountOfMilestonePaymentsAtApplicationForMarketingApproval",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments made at the start of second phase of clinical trial.",
        "label": "Amount Of Milestone Payments At Start Of Second Phase Clinical Trial",
        "terseLabel": "Total amount of milestone payments after start of a Phase II clinical trial"
       }
      }
     },
     "localname": "AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments made at the start of third phase of clinical trial.",
        "label": "Amount Of Milestone Payments At Start Of Third PhaseClinicalTrial",
        "terseLabel": "Total amount of milestone payments after start of a Phase III clinical trial"
       }
      }
     },
     "localname": "AmountOfMilestonePaymentsAtStartOfThirdPhaseclinicaltrial",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_August2019FinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to august 2019 financing.",
        "label": "August2019 Financing [Member]",
        "terseLabel": "August 2019 Financing [Member]"
       }
      }
     },
     "localname": "August2019FinancingMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_BasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent basis of presentation.",
        "label": "Basis of Presentation [Line Items]"
       }
      }
     },
     "localname": "BasisOfPresentationLineItems",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "epix_BasisOfPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about basis of presentation.",
        "label": "Basis of Presentation [Table]"
       }
      }
     },
     "localname": "BasisOfPresentationTable",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "epix_BusinessCombinationConversionRatioPerAmericanDepositoryShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of New ESSA Shares to be issued to the shareholders for every American Depository share in Realm.",
        "label": "Business Combination, Conversion Ratio Per American Depository Share",
        "terseLabel": "Conversion ratio per American Depository Share (ADS)"
       }
      }
     },
     "localname": "BusinessCombinationConversionRatioPerAmericanDepositoryShare",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "epix_BusinessCombinationConversionRatioPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of New ESSA Shares to be issued to the shareholders for every share in Realm.",
        "label": "Business Combination, Conversion Ratio Per Share",
        "terseLabel": "Conversion ratio per share"
       }
      }
     },
     "localname": "BusinessCombinationConversionRatioPerShare",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "epix_BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares that represents one American Depository share.",
        "label": "Business Combination, Number of Shares Represents One American Depository Share",
        "terseLabel": "Number of shares represented by each American Depository Share (ADS)"
       }
      }
     },
     "localname": "BusinessCombinationNumberOfSharesRepresentsOneAmericanDepositoryShare",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables and accrued liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accounts Payable And Accrued Liabilities",
        "negatedLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables and amounts due from others and other current assets, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Receivables and Other Current Assets",
        "terseLabel": "Receivables and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivablesAndOtherCurrentAssets",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Amount of transaction cost for business acquisition through accounts payable and accrued liabilities.",
        "label": "Business Combination, Transaction Cost, Through Accounts Payable And Accrued Liability",
        "terseLabel": "Transaction costs incurred through accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationTransactionCostThroughAccountsPayableAndAccruedLiability",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_CashAcquisitionFromAcquisitionOfBusiness": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash inflow from acquisition of business.",
        "label": "Cash Acquisition From Acquisition of Business",
        "terseLabel": "Cash acquired on acquisition of Realm"
       }
      }
     },
     "localname": "CashAcquisitionFromAcquisitionOfBusiness",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_CashCanadaDepositInsuranceCorporationInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Canada Deposit Insurance Corporation.",
        "label": "Cash Canada Deposit Insurance Corporation Insured amount",
        "terseLabel": "Cash, CDIC insured amount"
       }
      }
     },
     "localname": "CashCanadaDepositInsuranceCorporationInsuredAmount",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_ClarusLifesciencesIiiL.pMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Clarus Lifesciences III, L.P.",
        "label": "Clarus Lifesciences Iii L.p [Member]",
        "terseLabel": "Clarus Lifesciences III, L.P [Member]"
       }
      }
     },
     "localname": "ClarusLifesciencesIiiL.pMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ClassOfWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Class of Warrant Or Right, Exercised",
        "negatedLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercised",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "epix_ClassOfWarrantOrRightExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants expired.",
        "label": "Class of Warrant Or Right, Expired",
        "negatedLabel": "Warrants expired (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpired",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "epix_ClassOfWarrantOrRightGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants granted.",
        "label": "Class Of Warrant Or Right, Granted",
        "terseLabel": "Warrants granted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightGranted",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "epix_ClassOfWarrantOrRightNumberOfWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Class of Warrant Or Right, Number of Warrants [Roll Forward]",
        "terseLabel": "Number of Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsRollForward",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "epix_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Class of Warrant Or Right, Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of class of warrant or rights exercised.",
        "label": "Class of Warrant Or Right Weighted Average Exercise Price, Warrants Exercised",
        "terseLabel": "Weighted average exercise price, warrants exercised (in dollar per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of class of warrant or rights expired.",
        "label": "Class of Warrant Or Right Weighted Average Exercise Price, Warrants Expired",
        "terseLabel": "Weighted average exercise price, warrants expired (in dollar per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "epix_ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of class of warrant or rights granted.",
        "label": "Class of Warrant Or Right Weighted Average Exercise Price, Warrants Granted",
        "terseLabel": "Weighted average exercise price, warrants granted (in dollar per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsGranted",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "epix_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Consulting Agreement.",
        "label": "Consulting Agreement [Member]",
        "terseLabel": "Consulting Agreement [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of contribution by each employee to employee share purchase plan.",
        "label": "Contribution Per Employee To Employee Share Purchase Plan, Percentage",
        "terseLabel": "Employee contribution percentage"
       }
      }
     },
     "localname": "ContributionPerEmployeeToEmployeeSharePurchasePlanPercentage",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "epix_DebtInstrumentAccretion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accretion of debt during the reporting period.",
        "label": "Debt Instrument, Accretion",
        "terseLabel": "Accretion"
       }
      }
     },
     "localname": "DebtInstrumentAccretion",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_DebtInstrumentAdditionalBorrowingCapacityLapsed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition borrowing capacity lapsed during the period.",
        "label": "Debt Instrument, Additional Borrowing Capacity Lapsed",
        "terseLabel": "Borrowing capacity lapsed"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalBorrowingCapacityLapsed",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_DecreaseInMarketPriceOfWarrantsBy10Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in market Price of warrants by 10% [Member]",
        "label": "Decrease In Market Price Of Warrants By10 [Member]",
        "terseLabel": "Decrease in market Price of warrants by 10% [Member]"
       }
      }
     },
     "localname": "DecreaseInMarketPriceOfWarrantsBy10Member",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_DecreaseInVolatilityOfWarrantsBy10Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in Volatility of warrants by 10% [Member]",
        "label": "Decrease In Volatility Of Warrants By10 [Member]",
        "terseLabel": "Decrease in Volatility of warrants by 10% [Member]"
       }
      }
     },
     "localname": "DecreaseInVolatilityOfWarrantsBy10Member",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_DeferredTaxAssetsEquipmentAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equipment and intangible assets.",
        "label": "Deferred Tax Assets Equipment And Intangible Assets",
        "terseLabel": "Equipment and intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsEquipmentAndIntangibleAssets",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_DeferredTaxAssetsFinancingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from financing costs.",
        "label": "Deferred Tax Assets Financing Costs",
        "terseLabel": "Financing costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsFinancingCosts",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_EmployeeSharePurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Employee Share Purchase Plan.",
        "label": "Employee Share Purchase Plan [Member]",
        "terseLabel": "Employee Share Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeSharePurchasePlanMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_EquityIncentivePlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity incentive plans [Member]",
        "label": "Equity Incentive Plans [Member]",
        "terseLabel": "Equity Incentive Plans [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlansMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_EssaPharmaceuticalsCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ESSA Pharmaceuticals Corp.",
        "label": "Essa Pharmaceuticals Corp [Member]",
        "terseLabel": "ESSA Pharmaceuticals Corp [Member]"
       }
      }
     },
     "localname": "EssaPharmaceuticalsCorpMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ExercisePriceEightInUsdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eight in USD [Member]",
        "label": "Exercise Price Eight In Usd [Member]",
        "terseLabel": "Exercise Price $13.96 [Member]"
       }
      }
     },
     "localname": "ExercisePriceEightInUsdMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ExercisePriceFiveInUsdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Five in USD [Member]",
        "label": "Exercise Price Five In Usd [Member]",
        "terseLabel": "Exercise Price $4.00 [Member]"
       }
      }
     },
     "localname": "ExercisePriceFiveInUsdMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ExercisePriceFourInUsdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Four in USD [Member]",
        "label": "Exercise Price Four In Usd [Member]",
        "terseLabel": "Exercise Price $3.81 [Member]"
       }
      }
     },
     "localname": "ExercisePriceFourInUsdMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ExercisePriceNineInUsdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Nine in USD [Member]",
        "label": "Exercise Price Nine In Usd [Member]",
        "terseLabel": "Exercise Price $29.63 [Member]"
       }
      }
     },
     "localname": "ExercisePriceNineInUsdMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ExercisePriceOneInCadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price One in CAD [Member]",
        "label": "Exercise Price One In Cad [Member]",
        "terseLabel": "Exercise Price C$4.90 [Member]"
       }
      }
     },
     "localname": "ExercisePriceOneInCadMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ExercisePriceOneInUsdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price one in USD [Member]",
        "label": "Exercise Price One In Usd [Member]",
        "terseLabel": "Exercise Price $2.20 [Member]"
       }
      }
     },
     "localname": "ExercisePriceOneInUsdMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ExercisePriceSevenInUsdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Seven in USD [Member]",
        "label": "Exercise Price Seven In Usd [Member]",
        "terseLabel": "Exercise Price $7.00 [Member]"
       }
      }
     },
     "localname": "ExercisePriceSevenInUsdMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ExercisePriceSixInUsdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Six in USD [Member]",
        "label": "Exercise Price Six In Usd [Member]",
        "terseLabel": "Exercise Price $4.67 [Member]"
       }
      }
     },
     "localname": "ExercisePriceSixInUsdMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ExercisePriceTenInUsdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Ten in USD [Member]",
        "label": "Exercise Price Ten In Usd [Member]",
        "terseLabel": "Exercise Price $31.62 [Member]"
       }
      }
     },
     "localname": "ExercisePriceTenInUsdMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ExercisePriceThreeInUsdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Three in USD [Member]",
        "label": "Exercise Price Three In Usd [Member]",
        "terseLabel": "Exercise Price $3.59 [Member]"
       }
      }
     },
     "localname": "ExercisePriceThreeInUsdMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ExercisePriceTwoInCadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Two in CAD [Member]",
        "label": "Exercise Price Two In Cad [Member]",
        "terseLabel": "Exercise Price C$5.06 [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwoInCadMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ExercisePriceTwoInUsdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Two in USD [Member]",
        "label": "Exercise Price Two In Usd [Member]",
        "terseLabel": "Exercise Price $3.23 [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwoInUsdMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_FairValueOfWarrantIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrant issued.",
        "label": "Fair Value of Warrant Issued",
        "terseLabel": "Fair value of warrant issued"
       }
      }
     },
     "localname": "FairValueOfWarrantIssued",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_February2021financingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to February 2021 financing",
        "label": "February2021financing [Member]",
        "terseLabel": "February 2021 Financing [Member]"
       }
      }
     },
     "localname": "February2021financingMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_FinanceExpenseOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance expense, operating activities.",
        "label": "Finance expense, operating activities",
        "terseLabel": "Finance expense"
       }
      }
     },
     "localname": "FinanceExpenseOperatingActivities",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_FinancialInstrumentsAndRiskAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "FINANCIAL INSTRUMENTS AND RISK"
       }
      }
     },
     "localname": "FinancialInstrumentsAndRiskAbstract",
     "nsuri": "http://www.essapharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "epix_FinancingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of financing costs incurred during the reporting period.",
        "label": "Financing Costs",
        "terseLabel": "Financing costs (Notes 8 and 9)"
       }
      }
     },
     "localname": "FinancingCosts",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_FinancingCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to financing costs.",
        "label": "Financing Costs [Member]",
        "terseLabel": "Financing costs [Member]"
       }
      }
     },
     "localname": "FinancingCostsMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency risk, fluctuation in the net income (loss) reported due to change in exchange rate",
        "label": "Foreign currency risk, fluctuation in the net income(loss) reported due to change in exchange rate",
        "terseLabel": "Foreign currency risk, fluctuation in the net income (loss) reported due to change in exchange rate"
       }
      }
     },
     "localname": "ForeignCurrencyRiskFluctuationInNetIncomeLossReportedDueToChangeInExchangeRate",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_GovernmentAssistancePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for government grants.",
        "label": "Government Assistance, Policy [Policy Text Block]",
        "terseLabel": "Government Assistance"
       }
      }
     },
     "localname": "GovernmentAssistancePolicyPolicyTextBlock",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "epix_GrantAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total grant amount.",
        "label": "Grant Amount",
        "verboseLabel": "Total grant amount"
       }
      }
     },
     "localname": "GrantAmount",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_GrantReceivedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for which grants received.",
        "label": "Grant Received Period"
       }
      }
     },
     "localname": "GrantReceivedPeriod",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "epix_GrantRequirementNumberOfYearsOfOperationsInTexas": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant requirement, number of years of operations in Texas",
        "label": "Grant requirement, number of years of operations in Texas",
        "terseLabel": "Grant requirement, number of years of operations in Texas"
       }
      }
     },
     "localname": "GrantRequirementNumberOfYearsOfOperationsInTexas",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "epix_HoustonOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to houston office.",
        "label": "Houston Office [Member]",
        "terseLabel": "Houston Office [Member]"
       }
      }
     },
     "localname": "HoustonOfficeMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_IncomeTaxExpenseRecoveryOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Expense Recovery Operating Activities",
        "label": "Income Tax Expense Recovery Operating Activities",
        "negatedLabel": "Income tax recovery"
       }
      }
     },
     "localname": "IncomeTaxExpenseRecoveryOperatingActivities",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_IncomeTaxReconciliationFinancingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to financing costs.",
        "label": "Income Tax Reconciliation Financing Costs",
        "verboseLabel": "Share issue costs"
       }
      }
     },
     "localname": "IncomeTaxReconciliationFinancingCosts",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_IncomeTaxReconciliationTaxableCapitalGains": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) taxable capital gains",
        "label": "Income Tax Reconciliation Taxable Capital Gains",
        "terseLabel": "Taxable capital gains"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxableCapitalGains",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in derivative liability due to change in market price.",
        "label": "Increase (decrease) in derivative liability due to change in market price",
        "terseLabel": "Increase (decrease) in derivative liability due to change in market price"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilityDueToChangeInMarketPrice",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in derivative liability due to change in Volatility",
        "label": "Increase (decrease) in derivative liability due to change in Volatility",
        "terseLabel": "Increase (decrease) in derivative liability due to change in volatility"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilityDueToChangeInVolatility",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_IncreaseInMarketPriceOfWarrantsBy10Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in market Price of warrants by 10% [Member]",
        "label": "Increase In Market Price Of Warrants By10 [Member]",
        "terseLabel": "Increase in market Price of warrants by 10% [Member]"
       }
      }
     },
     "localname": "IncreaseInMarketPriceOfWarrantsBy10Member",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_IncreaseInVolatilityOfWarrantsBy10Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in Volatility of warrants by 10% [Member]",
        "label": "Increase In Volatility Of Warrants By10 [Member]",
        "terseLabel": "Increase in Volatility of warrants by 10% [Member]"
       }
      }
     },
     "localname": "IncreaseInVolatilityOfWarrantsBy10Member",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_InterestFromShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest from short-term investments.",
        "label": "Interest from short-term investments",
        "terseLabel": "Interest from short-term investments"
       }
      }
     },
     "localname": "InterestFromShortTermInvestments",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_InterestIncomeOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income operating activities",
        "label": "Interest income operating activities",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperatingActivities",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_July2020FinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to July 2020 financing.",
        "label": "July2020 Financing [Member]",
        "terseLabel": "July 2020 Financing [Member]"
       }
      }
     },
     "localname": "July2020FinancingMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_LeaseOnUsOfficeSpacesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Lease on US office spaces.",
        "label": "Lease On Us Office Spaces [Member]",
        "terseLabel": "Lease on US Office Spaces [Member]"
       }
      }
     },
     "localname": "LeaseOnUsOfficeSpacesMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to license agreement .",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_LongTermDebtRepaymentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Long Term Debt Repayment [Roll Forward]",
        "terseLabel": "LONG-TERM DEBT"
       }
      }
     },
     "localname": "LongTermDebtRepaymentRollForward",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "epix_MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of common share each employee is eligible under employee share purchase plan.",
        "label": "Maximum Eligible Common Shares Under Employee Share Purchase Plan",
        "terseLabel": "Maximum eligibility to common shares amount"
       }
      }
     },
     "localname": "MaximumEligibleCommonSharesUnderEmployeeSharePurchasePlan",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_MinimumAdvanceRoyaltyPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents amount of minimum annual royalty payments per annum.",
        "label": "Minimum Advance Royalty Payments",
        "terseLabel": "Minimum advance royalty payments"
       }
      }
     },
     "localname": "MinimumAdvanceRoyaltyPayments",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_MinimumNumberOfSharesRequiredToBeHeldForNominationRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum number of shares required to be held for nomination rights",
        "label": "Minimum number of shares required to be held for nomination rights",
        "terseLabel": "Minimum number of shares required to be held for nomination rights"
       }
      }
     },
     "localname": "MinimumNumberOfSharesRequiredToBeHeldForNominationRights",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "epix_NatureAndContinuanceOfOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "NatureAndContinuanceOfOperationsAbstract",
     "nsuri": "http://www.essapharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "epix_OperatingLeaseLiabilitiesAccretionExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accretion expense on operating lease liabilities.",
        "label": "Operating Lease Liabilities Accretion Expenses",
        "terseLabel": "Accretion",
        "verboseLabel": "Accretion expense"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesAccretionExpenses",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_OperatingLeaseLiabilitiesAddition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liabilities addition.",
        "label": "Operating Lease Liabilities Addition",
        "terseLabel": "Addition"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesAddition",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_OperatingLeasePaymentsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash flow arising out of lease payments during the period, which are classified as financing activities.",
        "label": "Operating Lease Payments, Financing Activities",
        "negatedLabel": "Lease payments"
       }
      }
     },
     "localname": "OperatingLeasePaymentsFinancingActivities",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_OperatingLeaseRightOfUseAssetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating Lease, Right-of-Use Asset [Abstract]",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAbstract",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "epix_OperatingLeaseRightOfUseAssetAddition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right of use asset addition.",
        "label": "Operating Lease Right Of Use Asset Addition",
        "terseLabel": "Addition"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAddition",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_OperatingLeaseRightOfUseAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease, current",
        "label": "Operating lease right-of-use assets, current",
        "verboseLabel": "Operating lease right-of-use assets (Note 8)"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetsCurrent",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_PaymentOfSubleaseTerminationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow on payment of sublease termination costs during the period.",
        "label": "Payment Of Sublease Termination Costs",
        "negatedLabel": "Termination costs on Realm sublease"
       }
      }
     },
     "localname": "PaymentOfSubleaseTerminationCosts",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_PercentageOfEffectiveInterestInSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of effective interest in subsidiaries",
        "label": "Percentage of effective interest in subsidiaries",
        "terseLabel": "Effective interest"
       }
      }
     },
     "localname": "PercentageOfEffectiveInterestInSubsidiaries",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "epix_PercentageOfFinalPaymentOnAmountAdvanced": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of final payment on amount advanced due to early payment or termination of contract.",
        "label": "Percentage of Final Payment on Amount Advanced",
        "terseLabel": "Percentage of final payment"
       }
      }
     },
     "localname": "PercentageOfFinalPaymentOnAmountAdvanced",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "epix_PreFundedWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pre-funded warrants exercised for common shares issued.",
        "label": "Pre Funded Warrants Exercised",
        "terseLabel": "Pre-funded warrants exercised"
       }
      }
     },
     "localname": "PreFundedWarrantsExercised",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "epix_PreFundedWarrantsIssuedForCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pre funded warrants issued.",
        "label": "Pre Funded Warrants Issued for Common Shares",
        "terseLabel": "Number of pre funded warrants issued"
       }
      }
     },
     "localname": "PreFundedWarrantsIssuedForCommonShares",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "epix_PrefundedWarrantExercisedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of prefunded warrant exercised during the period.",
        "label": "Prefunded Warrant Exercised, Shares",
        "terseLabel": "Pre-funded warrants exercised, shares"
       }
      }
     },
     "localname": "PrefundedWarrantExercisedShares",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "epix_PrefundedWarrantExercisedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prefunded warrant exercised during the period.",
        "label": "Prefunded Warrant Exercised, Value",
        "terseLabel": "Pre-funded warrants exercised"
       }
      }
     },
     "localname": "PrefundedWarrantExercisedValue",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_PrepaidExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses [Text Block]",
        "label": "Prepaid Expenses [Text Block]",
        "terseLabel": "PREPAIDS"
       }
      }
     },
     "localname": "PrepaidExpensesTextBlock",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosurePrepaids"
     ],
     "xbrltype": "textBlockItemType"
    },
    "epix_PrepaidPreclinicalAndClinicalExpensesAndDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of prepaid preclinical and clinical expenses and deposits.",
        "label": "Prepaid Preclinical and Clinical Expenses and Deposits",
        "terseLabel": "Prepaid CMC and clinical expenses and deposits"
       }
      }
     },
     "localname": "PrepaidPreclinicalAndClinicalExpensesAndDeposits",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_PurchaseRightsOfferingTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of purchase rights offering.",
        "label": "Purchase Rights, Offering Term",
        "terseLabel": "Offering term"
       }
      }
     },
     "localname": "PurchaseRightsOfferingTerm",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "epix_RealmTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Realm Therapeutics plc.",
        "label": "Realm Therapeutics Inc [Member]",
        "terseLabel": "Realm Therapeutics Inc [Member]"
       }
      }
     },
     "localname": "RealmTherapeuticsIncMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_RealmTherapeuticsPlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Realm Therapeutics plc.",
        "label": "Realm Therapeutics Plc [Member]",
        "terseLabel": "Realm Therapeutics Plc [Member]"
       }
      }
     },
     "localname": "RealmTherapeuticsPlcMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails",
      "http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_RepaymentsOfFinalPaymentOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for repayment of final payment of loan.",
        "label": "Repayments Of Final Payment of Debt",
        "negatedLabel": "Loan final payment paid"
       }
      }
     },
     "localname": "RepaymentsOfFinalPaymentOfDebt",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_RepaymentsOfLongTermDebtFinalPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for final payment for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long Term Debt, Final Payment",
        "negatedLabel": "Final payment",
        "terseLabel": "Final payment"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtFinalPayment",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_RepaymentsOfLongTermDebtInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for interest amount of debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long Term Debt, Interest",
        "negatedLabel": "Interest paid",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtInterest",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_RepaymentsOfLongTermDebtPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for principal amount of debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long Term Debt, Principal",
        "negatedLabel": "Principal repaid",
        "terseLabel": "Principal amount paid"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtPrincipal",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_RoyaltyPercentRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of revenues company is required to pay as royalty.",
        "label": "Royalty Percent, Revenue",
        "terseLabel": "Royalty percent revenue"
       }
      }
     },
     "localname": "RoyaltyPercentRevenue",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "epix_ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the functional currency and effective interest in subsidiaries.",
        "label": "Schedule of Functional Currency and Effective Interest in Subsidiaries [Table Text Block]",
        "terseLabel": "Schedule of Functional Currency of Company and its Subsidiaries"
       }
      }
     },
     "localname": "ScheduleOfFunctionalCurrencyAndEffectiveInterestInSubsidiariesTableTextBlock",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "epix_ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of operating lease related assets and liabilities and other related information.",
        "label": "Schedule Of Operating Lease Balance Sheet Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseBalanceSheetDisclosureTableTextBlock",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "epix_ScheduleOfPrepaidExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to prepaid expenses.",
        "label": "Schedule Of Prepaid Expenses [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesTableTextBlock",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosurePrepaidsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "epix_ScheduleOfWarrantsOrRightsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants outstanding.",
        "label": "Schedule of Warrants or Rights Outstanding [Table Text Block]",
        "terseLabel": "Summary of Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWarrantsOrRightsOutstandingTableTextBlock",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "epix_SevenYearWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven year warrant member.",
        "label": "Seven Year Warrant [Member]",
        "terseLabel": "7 Year Warrants [Member]"
       }
      }
     },
     "localname": "SevenYearWarrantMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Amount of cost related to share issuance through accounts payable and accrued liabilities.",
        "label": "Share Issuance Cost Through Accounts Payable And Accrued Liabilities",
        "terseLabel": "Share issuance costs incurred through accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "ShareIssuanceCostThroughAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent summary of significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "epix_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about significant accounting policies.",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "epix_SiliconValleyBankTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to silicon valley bank term loan.",
        "label": "Silicon Valley Bank Term Loan [Member]",
        "terseLabel": "SVB Term Loan [Member]"
       }
      }
     },
     "localname": "SiliconValleyBankTermLoanMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_SouthFransicoOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to south fransico office.",
        "label": "South Fransico Office [Member]",
        "terseLabel": "South San Francisco Office [Member]"
       }
      }
     },
     "localname": "SouthFransicoOfficeMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Warrants exercised, in shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "epix_StockIssuedDuringPeriodValuePreFundedWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issued upon cashless exercise of pre-funded warrants",
        "label": "Stock Issued During Period, Value, Pre Funded Warrants Exercised",
        "terseLabel": "Number of shares issued upon cashless exercise of pre-funded warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePreFundedWarrantsExercised",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlowsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "epix_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_StockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option Plan [Member]",
        "label": "Stock Option Plan [Member]",
        "terseLabel": "Stock Options Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlanMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_StockOptionsAndRsuPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options and RSU Plan [Member]",
        "label": "Stock Options And Rsu Plan [Member]",
        "terseLabel": "Stock Options and RSU Plan [Member]"
       }
      }
     },
     "localname": "StockOptionsAndRsuPlanMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_TenPercentChangeInForeignExchangeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ten percent Change in Foreign Exchange Rate [Member]",
        "label": "Ten Percent Change In Foreign Exchange Rate [Member]",
        "terseLabel": "10% Change in Foreign Exchange Rate [Member]"
       }
      }
     },
     "localname": "TenPercentChangeInForeignExchangeRateMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_TermOfUnderwritersOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of underwriters option to purchase additions shares.",
        "label": "Term of Underwriters Option",
        "terseLabel": "Term of underwriters option"
       }
      }
     },
     "localname": "TermOfUnderwritersOption",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "epix_ThresholdLimitForAggregateRoyaltyPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents threshold limit of aggregate royalty payments payable to CPRIT before decrease in royalty rate.",
        "label": "Threshold Limit for Aggregate Royalty Payments",
        "verboseLabel": "Threshold limit for aggregate royalty payments"
       }
      }
     },
     "localname": "ThresholdLimitForAggregateRoyaltyPayments",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "epix_TwoYearWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to two year warrant member.",
        "label": "Two Year Warrant [Member]",
        "terseLabel": "2 Year Warrants [Member]"
       }
      }
     },
     "localname": "TwoYearWarrantMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_UnderwriterOptionToPurchaseAdditionalSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriter option to purchase additional securities.",
        "label": "Underwriter option to purchase additional securities",
        "terseLabel": "Underwriter option to purchase additional securities"
       }
      }
     },
     "localname": "UnderwriterOptionToPurchaseAdditionalSecurities",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "epix_UnitsIssuedInPrivatePlacementConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Units issued in private placement, conversion ratio",
        "label": "Units issued in private placement, conversion ratio",
        "terseLabel": "Units issued in private placement, conversion ratio"
       }
      }
     },
     "localname": "UnitsIssuedInPrivatePlacementConversionRatio",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "epix_VendorAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Vendor agreement.",
        "label": "Vendor Agreement [Member]",
        "terseLabel": "Vendor Agreement [Member]"
       }
      }
     },
     "localname": "VendorAgreementMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_WallStreetJournalPrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to wall street journal prime rate.",
        "label": "Wall Street Journal Prime Rate [Member]",
        "terseLabel": "WSJ Prime Rate [Member]"
       }
      }
     },
     "localname": "WallStreetJournalPrimeRateMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_WarrantsExercisePriceFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercise Price Five [Member]",
        "label": "Warrants Exercise Price Five [Member]",
        "terseLabel": "Warrants Exercise Price $0.0001 [Member]"
       }
      }
     },
     "localname": "WarrantsExercisePriceFiveMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_WarrantsExercisePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercise Price One [Member]",
        "label": "Warrants Exercise Price One [Member]",
        "terseLabel": "Warrants Exercise Price $66.00 [Member]"
       }
      }
     },
     "localname": "WarrantsExercisePriceOneMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_WarrantsExercisePriceThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercise Price Three [Member]",
        "label": "Warrants Exercise Price Three [Member]",
        "terseLabel": "Warrants Exercise Price $4.00 [Member]"
       }
      }
     },
     "localname": "WarrantsExercisePriceThreeMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_WarrantsExercisePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercise Price Two [Member]",
        "label": "Warrants Exercise Price Two [Member]",
        "terseLabel": "Warrants Exercise Price $42.80 [Member]"
       }
      }
     },
     "localname": "WarrantsExercisePriceTwoMember",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "epix_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of working capital.",
        "label": "Working Capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.essapharma.com/20210930",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Schedule of contractual obligations",
        "terseLabel": "Schedule of Contractual Obligations"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r186",
      "r189",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r373",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r186",
      "r189",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r373",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationScheduleOfFunctionalCurrencyOfCompanyAndItsSubsidiariesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r124",
      "r172",
      "r173",
      "r344",
      "r372",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r124",
      "r172",
      "r173",
      "r344",
      "r372",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r176",
      "r186",
      "r189",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r373",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r176",
      "r186",
      "r189",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r373",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r172",
      "r174",
      "r375",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r172",
      "r174",
      "r375",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r158",
      "r187",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r337",
      "r339",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance.",
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average [Member]"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "T [X]",
        "terseLabel": "Texas"
       }
      }
     },
     "localname": "TX",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASU 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities (Note 7)",
        "totalLabel": "Balance, end of year"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "verboseLabel": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Accounts Payable And Accrued Liabilities [Member]",
        "terseLabel": "Accounts Payable and Accrued Liabilities [Member]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionExpense": {
     "auth_ref": [
      "r153",
      "r154"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.",
        "label": "Accretion Expense",
        "terseLabel": "Accretion of lease liability"
       }
      }
     },
     "localname": "AccretionExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r8",
      "r30",
      "r175"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Vacation, Current",
        "verboseLabel": "Accrued vacation"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r41",
      "r42",
      "r43",
      "r364",
      "r384",
      "r388"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r77",
      "r78",
      "r79",
      "r276",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r226"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital (Note 11)"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r223",
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r84",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r249",
      "r250",
      "r251",
      "r252",
      "r346",
      "r347",
      "r348",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Items not affecting cash and cash equivalents:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r190",
      "r192",
      "r229",
      "r230"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r164",
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Share issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r192",
      "r216",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Compensation Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r71",
      "r113",
      "r116",
      "r120",
      "r135",
      "r273",
      "r277",
      "r298",
      "r351",
      "r363"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r38",
      "r71",
      "r135",
      "r273",
      "r277",
      "r298"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "ASSETS, Current"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r193",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r284",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r185",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r185",
      "r188",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Issuance costs incurred"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": {
     "auth_ref": [
      "r260",
      "r261",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.",
        "label": "Business Acquisition, Effective Date of Acquisition",
        "verboseLabel": "Acquisition date"
       }
      }
     },
     "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "New shares issued on acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Realm acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionNameOfAcquiredEntity": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the acquired entity.",
        "label": "Business Acquisition, Name of Acquired Entity",
        "verboseLabel": "Name of acquired entity"
       }
      }
     },
     "localname": "BusinessAcquisitionNameOfAcquiredEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "REALM ACQUISITION"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Fair value of net assets acquired",
        "totalLabel": "Total net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]",
        "terseLabel": "Net assets of Realm acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REALM ACQUISITION"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r76",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r23",
      "r65"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r66",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]",
        "verboseLabel": "SHORT-TERM INVESTMENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r59",
      "r65",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r59",
      "r303"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash and cash equivalents for the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "verboseLabel": "Cash, FDIC insured amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSupplementalDisclosureWithRespectToCashFlows"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r170",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Weighted Average Exercise Price, Ending balance (in dollar per share)",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning balance (in dollar per share)",
        "verboseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Conversion of each prefunded warrant into common share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Number of Warrants, Ending balance (in shares)",
        "periodStartLabel": "Number of Warrants, Beginning balance (in shares)",
        "terseLabel": "Number of Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsActivityDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common shares 43,984,346 issued and outstanding (September 30, 2020 - 32,064,411) (Note 11)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation and Functional Currency"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligationDueInFifthYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "ContractualObligationDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInFourthYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "ContractualObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "ContractualObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "ContractualObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LONG-TERM DEBT"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "LONG-TERM DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate of interest"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r12",
      "r161",
      "r352",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "periodEndLabel": "Long term debt, Ending balance",
        "periodStartLabel": "Long term debt, Beginning balance"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r312",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r32",
      "r162",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "LONG-TERM DEBT"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r33",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "verboseLabel": "Debt maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r34",
      "r74",
      "r165",
      "r166",
      "r167",
      "r168",
      "r311",
      "r312",
      "r314",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r25",
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Additional transaction cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross future tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Assets, Investments",
        "terseLabel": "Investment tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net future tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r246",
      "r247"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Operating losses carried forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r246",
      "r247"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r245",
      "r246",
      "r247"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carry forwards Research",
        "verboseLabel": "Federal R&amp;D credit"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesSignificantComponentsOfFutureTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Derivative liability loss",
        "verboseLabel": "Derivative liability gain (loss) (Note 10)"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DERIVATIVE LIABILITIES"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "DERIVATIVE LIABILITIES"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Derivatives with expected life of less than one year"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesScheduleOfChangesOfDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Derivative liabilities (Note 10)",
        "verboseLabel": "Derivatives with expected life greater than one year"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesScheduleOfChangesOfDerivativeLiabilitiesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Assumptions to fair value of the derivative warrant liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "DERIVATIVE LIABILITIES"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails",
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r193",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "verboseLabel": "Summary of Stock Option Outstanding"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r26",
      "r75",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of foreign exchange on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "verboseLabel": "General corporate income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r82",
      "r90",
      "r92",
      "r98",
      "r139",
      "r164",
      "r169",
      "r223",
      "r224",
      "r225",
      "r251",
      "r252",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r293",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r293",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r69",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "FINANCIAL INSTRUMENTS AND RISK"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRisk"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r145",
      "r146",
      "r148",
      "r149",
      "r345",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r145",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Country [Member]",
        "terseLabel": "Us"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r64",
      "r301",
      "r302"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Unrealized foreign exchange"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Exchange"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administration"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grants Related to Androgen Receptor n-terminus Blocker Program for Prostate Cancer [Member]"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Final Payment of grant"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r48",
      "r113",
      "r115",
      "r118",
      "r119",
      "r122",
      "r350",
      "r356",
      "r359",
      "r370"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss for the year before income tax",
        "totalLabel": "Loss for the year before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r236",
      "r238",
      "r244",
      "r253",
      "r255",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r72",
      "r91",
      "r92",
      "r112",
      "r234",
      "r254",
      "r256",
      "r371"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax recovery (expense) (Note 14)",
        "totalLabel": "Total income tax expense",
        "verboseLabel": "Income tax (recovery) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r69",
      "r232",
      "r233",
      "r238",
      "r239",
      "r243",
      "r248",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "verboseLabel": "Change in statutory, foreign tax, foreign exchange rates and other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "verboseLabel": "Tax recovery at statutory income tax rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Non-deductible share-based payments"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "verboseLabel": "Other permanent differences including foreign exchange"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "verboseLabel": "Adjustment to prior years provision versus statutory tax returns and expiry of non-capital losses"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxesAtStatutoryRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "negatedLabel": "Change in fair value"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesScheduleOfChangesOfDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in non-cash working capital items:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaids"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeDepositsWithFinancialInstitutions": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeDepositsWithFinancialInstitutions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentInterestRate": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of interest on investment.",
        "label": "Investment Interest Rate",
        "verboseLabel": "Guaranteed investment certificates, interest rate"
       }
      }
     },
     "localname": "InvestmentInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r134",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING LEASE"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "OPERATING LEASE"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "OPERATING LEASE"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLease"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29",
      "r71",
      "r117",
      "r135",
      "r274",
      "r277",
      "r278",
      "r298"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r71",
      "r135",
      "r298",
      "r353",
      "r366"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r71",
      "r135",
      "r274",
      "r277",
      "r278",
      "r298"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "LIABILITIES, Current"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r34",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Longterm Debt Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureLongTermDebtScheduleOfTermLoanRepaymentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly.",
        "label": "Measurement Input Discount For Lack Of Marketability [Member]",
        "terseLabel": "Liquidity Discount [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountForLackOfMarketabilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input Expected Dividend Rate [Member]",
        "terseLabel": "Dividend [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input Expected Term [Member]",
        "terseLabel": "Expected Life [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input Price Volatility [Member]",
        "terseLabel": "Expected Annualized Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesFairValueMeasurementInputsAndValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r99",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureNatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r59",
      "r61",
      "r64"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r45",
      "r46",
      "r49",
      "r64",
      "r71",
      "r81",
      "r86",
      "r87",
      "r88",
      "r89",
      "r91",
      "r92",
      "r93",
      "r113",
      "r115",
      "r118",
      "r119",
      "r122",
      "r135",
      "r298",
      "r357",
      "r368"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Loss for the year",
        "totalLabel": "Loss and comprehensive loss for the year"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "OPERATING LEASE"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r88",
      "r97",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r249",
      "r250",
      "r251",
      "r252",
      "r346",
      "r347",
      "r348",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "verboseLabel": "Number of industries"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSegmentedInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES (Abstract)",
        "terseLabel": "OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r322",
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities (Note 8)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease liabilities (Note 8)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r318",
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedLabel": "Lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets (Note 8)",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "negatedLabel": "Amortization",
        "terseLabel": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Non-capital loss carry-forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Over Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForCommissions": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for commissions during the current period.",
        "label": "Payments for Commissions",
        "verboseLabel": "Cash commissions paid"
       }
      }
     },
     "localname": "PaymentsForCommissions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Interest and financing costs paid",
        "terseLabel": "Financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for financing costs associated with business combinations.",
        "label": "Payments of Merger Related Costs, Financing Activities",
        "negatedLabel": "Transaction costs on acquisition of Realm"
       }
      }
     },
     "localname": "PaymentsOfMergerRelatedCostsFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Share issuance costs",
        "verboseLabel": "Share issuance transaction costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchase of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r193",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Other deposits and prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAIDS"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r6",
      "r143",
      "r144"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaids (Note 6)",
        "totalLabel": "Balance, end of year"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails",
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r4",
      "r6",
      "r142",
      "r144"
     ],
     "calculation": {
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosurePrepaidsScheduleOfPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds on issuance of common shares",
        "verboseLabel": "Aggregate gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Amount drawn from term loan facility"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Units",
        "terseLabel": "Fair value of units issued"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r55",
      "r218"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Payment to Acquire Shares through Employee Share Purchase Plan",
        "verboseLabel": "Shares purchased through employee share purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherDeposits": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for receipts of deposits classified as other.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "ProceedsFromOtherDeposits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "verboseLabel": "Proceeds from short-term investments sold"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r55",
      "r218"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r24",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r15",
      "r22",
      "r367",
      "r389"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Loan principal repaid"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "terseLabel": "Total Loan payment"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r231",
      "r401"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r69",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "RSU's [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r169",
      "r226",
      "r365",
      "r383",
      "r388"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r82",
      "r90",
      "r92",
      "r139",
      "r223",
      "r224",
      "r225",
      "r251",
      "r252",
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Deficit) [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty [Member]"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionScheduleOfNetAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Schedule of Share Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Term Loan Repayment"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant Components of Future Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Changes to Derivative Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Income Taxes at Statutory Rates"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Net Assets Acquired"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRealmAcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r73",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureRelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r193",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r197",
      "r204",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Weighted Average Assumptions for the Valuation of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r170",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "verboseLabel": "Summary of Warrants Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENTED INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r110",
      "r111",
      "r113",
      "r114",
      "r118",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r127",
      "r128",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENTED INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSegmentedInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "verboseLabel": "RSUs outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "verboseLabel": "Weighted average assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected annualized volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "SHAREHOLDERS' EQUITY",
        "verboseLabel": "Warrant outstanding and Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityScheduleOfShareBasedCompensationExpensesDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityTables",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Balance exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options expired/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "negatedLabel": "Options expired/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted",
        "verboseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r199",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "terseLabel": "Stock options, Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r191",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "negatedLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r69",
      "r193",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r210",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life of share purchase options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityWeightedAverageAssumptionsForValuationOfPurchaseRightsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Price percentage of common share granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Unit price (in dollars per share)",
        "verboseLabel": "Offering price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, in shares",
        "periodStartLabel": "Beginning Balance, in shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r11",
      "r354",
      "r355",
      "r362"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments.",
        "terseLabel": "Short-term investments (Note 5)"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHORT-TERM INVESTMENTS"
       }
      }
     },
     "localname": "ShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r36",
      "r77",
      "r78",
      "r79",
      "r82",
      "r90",
      "r92",
      "r98",
      "r139",
      "r164",
      "r169",
      "r223",
      "r224",
      "r225",
      "r251",
      "r252",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r98",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureFinancialInstrumentsAndRiskNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureNatureOfOperationsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureOperatingLeaseNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShortTermInvestmentsNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r13",
      "r14",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Acquisition of Realm, in shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r13",
      "r14",
      "r164",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued through employee share purchase plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r164",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Financing , in shares",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r164",
      "r169",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "verboseLabel": "Options exercised, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r36",
      "r164",
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Acquisition of Realm"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r13",
      "r14",
      "r164",
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Shares issued through employee share purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r164",
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Financing"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r164",
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r19",
      "r20",
      "r71",
      "r130",
      "r135",
      "r298"
     ],
     "calculation": {
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.essapharma.com/role/StatementConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r169",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology Based Intangible Assets [Member]",
        "terseLabel": "Technology-based intangible assets"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r84",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r249",
      "r250",
      "r251",
      "r252",
      "r346",
      "r347",
      "r348",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureOperatingLeaseScheduleOfOperatingLeasesDetails",
      "http://www.essapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureCommitmentsScheduleOfContractualObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureBasisOfPresentationPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "verboseLabel": "Expiry Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureShareholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrant"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/DisclosureDerivativeLiabilitiesNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://www.essapharma.com/role/DisclosureShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average number of common shares outstanding - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.essapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e845-128460"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e848-128460"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r402": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r403": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r404": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r405": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r406": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r407": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r408": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r409": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r410": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r411": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r412": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001558370-21-016181-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-016181-xbrl.zip
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M+LD,^9@>A3[=3&%LKU.OPPJ3JE#O;5F%K!%,!P?&W/R-JTFQ1JXL<9V&J-1
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MGZO QP ,X6>D\1%3-GN(T@UHY#>D63B".Z&\9>4TCKE]MK-#K43O.UL:U'S
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M"N=04"#]E/.0R0: 62Y+F# <FE<8R*F>2*U$8  *52\!CE1D]L59Y_SJ$DY
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MY5DK4AW.I)5?K5[,#O<@Y'-4]9BYTRW\7;>#G:N".AC9XX5?MEZY%S?M<]B
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ML!]WP"/SD6-!V**@_$\2?"B0 (!5D$F=, I+6 -(2%^NEN8"5&'JALWTF/5
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MN=Q_7V(PZHWO^]JL^\_^<9HBFP>-A#9&IE )0\O#?H)(\J\L@>2G7;]?D+O
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MG=D+M@$A)E%YD"CP5S5J]!$2CSXI-[0(^7<NYAC]3+@4*M>*T]6A."DP5C5
MFPZCZRX3](2<@!GMRRE8J^ _'BIX#A-5"_F>2&85K+KF$XW3E]#\G JU"OW3
MH4+/8:9RUVNX%QO/[RT;>;[KH$W777_JZYA\F2*R 38?EL2(Z9'F: S##%OL
M:SR'M%8K;->'PG8(I\UC.EM:."+-B$GSBT/*;:Q>0[Y3/:1<3AM$M+M>VU:4
M!9HLE?<Z_H'H?7_R,W:?E"'-;:U>3 ^Q]0]F%<C5DUTNZ,1[R.-'VUI$NU75
M&RGGPALIF][H"\.)_K1$A^U=E38&K^C-E#8&KY*#*I Q>,KC-=[\"L\0,F6:
M#K=0"O#*T Y XL=Y+:[H!8+V6EQ[+:Z]% 7_4A1;X-_)AI;Z G/ES2D(X:#L
M4'%S6*L\[0BA*+!#ZRA?_(+"$ [5#H5 P%[5, P1,:3&SC=O/)^3<3==ZP;G
M;:O\XA#.U Z>?$0,0CO];(,LCCQ=+]/[<AL@FM/DQ9\](_L)W9,R2QZB*@U
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M$N'DK:>_#:?_?'H]OY^OY[,5FC[<HM7/T^7LY\7][6RY^C.:_?O'^?IO(.!
M+UFULL-X7%XC;57=>AQNW75JIT :3A9KG_H6C@L@GW7JNO0 )7YT3C2Q@& 6
M^20ZXLVE!51A3",*P%W9P!REL%F_.V!G-]'". !/>:&4&9O+4W9(!@V6LMIM
MF.0@F,1)3>(+80]?_O^SI5R$(4W2589"'WN9F;JG:IBL[00<&?645F]GGO<
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M\^0:&A'X8K:-3P;SP"%!ST80D&>Q97._G[^>8PF*AE";H5+YYS7%I:X/E?,
M1^] ^:(Y4/C2551^D%QN"S@TJ!6YBP/D(D0'<G;<L:[Y36Q:':M8EO$T-YF?
M#K17W9>^=V45QW!15&&B1@2 (U5S8YA=" 6,9@9*#'@!%-0E\[YLPB)4\6JY
M;)O*'F+,MEOLDJALECX+NB23QB*@!J+_F_U^]%X<GX+FDN!YY+GTG@>]2!9L
MRA\(+15V[X<3< SJT;PB6/7 !C"J]:FMJ:MSF6APETF%J%@TZ9>RFG!L%#A.
M4"$,_Y(&2^>?"1WLQ$RP;7W^J#$UMYO9DOV!U08<#F1;F>N1'7M</ASA^L<-
MF47$'X8;1O%+#BX$<&BV\Z.(J#VL!( !W9(AVEQP[P#0)XB+CB2OUDQ0KL#9
MA,)UL!,ZC^UWXF;S*N8$MF=,#Y=/V(E&.D'T\6.]<OCN'(U?*[A"P<I>\(XG
ME,R"RDU2^^:3 M<$8?(I"8%EP-6A=5:)$R6CM,\3?O:"@&46R:TT'+P3(R8X
MO4].KS;L0G]#%E[4$,FIIF2?;E_@<-W(!"(L:W4$#+_-Y#?.)LVXY/<34SY_
M1IQ31;&] ?V Y;PNCDF<$)\EKJFRF:0=]/&M4JTTEL\;01ZW2EG;93Q/D$#3
MWK3>O7HS1@9=.S[-*9_094>/=_LU9^?NU;S.I]5Z38><8=,[P7ASRS*&^6KS
MD^,?L5#E3K56:M =.@XU-$1YJM7K"QFUFJI@/N%F-0#(:H6S2K=S)HAQFXBE
M'RUMW@]FC2FH"H\*M3D6FJ.!M/\XX4!M"@T\N.P\/D"HT*$/1,A"'["0T(,]
M9)@ (E:8;O[SF#X'L@ZGFPT3D2:H>IMY<.,<O,3Q!3/IU =J21(XB'1A,!%7
MVM ###6=J&7L;05S=B,W9X\H?^IVJ003) +5!$@9(ZNVTRES9'[#I2H(RPH<
MJ*KY&!$ BB;FQLBOPS3J#?UVC)DRIF.<D64%9YGW>SQ,<6+D(*+=T6<;A_0@
M-"NU0?_].15CX"LSPUI&8R67UR&Q5"/)@E6Z*;W2"!%Y#-H&$M441HB)->:H
M T5%]Y&B8ITV+:MPC!H7>[.-$ABS0B^0<;$OJUP"(XA%;=7L\( _LV],=K_%
MOD!!U,@$NOO>>4? "\]F\O<8)Q%FO &LS:V.#9'?% +G[1SS#-W]LO,X_5UA
M!.V-[1%[O$J!/K>T@?I\UZ8H[B_V?;*O4<1NJ)^?1WD\)N[P;27RW3'8X,U9
MO5".T[(0K[8'4*1JH&[QI%)E<^C+-TWIC7>Y\_IQAXQ1MA@KXG'[#R?U:X2<
M_$4-X"P2L[ *ZU_GJ_+OW<O.E%(+#H6-%,^[C!*<R@K7HQ-O/UIX.A/?^,+_
M<?^$H]'B4T=6J 2H57^1DR%"=:>U&J(FH#>(FCPL8D('* *V-HWN)M+8'B(Q
MUZ7'S250KY4,;R% KY=4+C\[P))J0N,$$PWC:.]0O1(XT5&FU=;%U1,KK"_6
M[D=3.C,_\ZM23R<DMLO*9D[)]$U@)Y5I4KRP0C=^N.BVTJ0L6/("=]#7^?[7
M-R WP :R ^R0+GM[@[7)7MZ@+U<83&A5M,:)QGHFT@WOE(3&A\F:^O08YA6/
MQK"V_3\:TRK6Z]%4XN9[;X_##! 0*DUD=#Y926V<8*1K)NWX4$UJ?("DK5&?
M9YQ5F 3QV+-/<S6&)?MQDM;E BHC6P>(RX4EYG>8\ I'+YZ+N9&7V V? T9%
M=F0Y(%O@@#>4X1M?+FK!$S"$#J:Z\?'MX_QF(E]S%\OR25$/CQ9GHU=\D"")
M';@%;UK1J&T>PI*?BSXXR3&B+R+>A$'B!>FKB>D#7V15K*AAU+0O4#@S,D%^
M9*K;$?K9:6,]C ]10[3!6X][!W)>'(^(X>.!#TF'4W>Z_KB<H<4=6CS.EM/U
M?/&PLOB"!%-;5%2!B-*&0!VX7KG2RP\7K0#/^17"&@](1I(F,11$T:]K_"5!
MUV3D_7910&R8*;@/34&YWB)Z=@+O'TPW CIQZ'L;]@\"0H_$I!DXY\_7T"O1
M:=DWU0S<-6W@#MZI"45,Z(0P8!CI5C_CVF+3U7Q%W?%Q.5O-'M;,(^TYY/4Q
M]@(<Q[<X=B/OD)KCVHF]>+$5K4*QD4&CPKI&A("[FKEQ1+]J3@6P$[50QMAC
M4I9(X,GJX3*N= X7^0*8Q6W8"!:J3%V7)K'3+5N"LJZ'Z^;NR@[ 4:)>V=+>
MG;(U8*_7$-IX4V?^_F%^-[^9/JS1].9F\?%A/7]XCQX7]_.;^<QBJ+KRG@-O
MZ[E.D%RJ7S<;:G<&/K:;&:%T>J?5$_"8;ZB \?@OV*""#\H8 9C.AC($5"#(
MIO.;</]$%@95F\&:78 [O8["L@!7UAZP@VN);3J:E[/I_0<RCO_]XWPUA['$
M$_2\]6+7#^-CA'67=;6=QS>F*XQ0,[HE/<<USJL4:+U,$_B@@A& B6P@0P!R
M_=4NC)(UCO;SX 6G9[MU;[%4=P'NYCH*EU^K4+<'[-):8AL'8C\OENNK]6SY
M <T?/LU6ZP^SA[7%^$OR^M(TV,A,4#>9F5$"/N1;F*?F:;@Z,H =I(TVIGZC
M>@:.;E4RSE=DAMHC@7?_<Z+&/1,;IH(&,8\1/CC>9O:%IC31A(A%LL/1-(YQ
M[7RIV14XB#0Q@(@:.OT PT0C\8TOS2]GC]/YK='P5I;P$,163GMU;8&.22T5
MQ6H=TH;04\UJY6Y1HX$21AGE_B<997[9*]*QMNY&3XJVP(Z.ID;G1#,3:4PP
M==WHZ/BU,V)E#Z"@TT#=TORG;@YYVM.0VCC_G6_=K]#C]&_3Z_L9FC[<TOW\
MY<?9+;J?3Z_G]_.UU?W\]! C3JV0&0%O[CWGR?.]Q,.Q_@:I.37@GM#23)(S
M[Z:D 'M06XV,O2OEBU+&;'&9LD8"[T$W7C46F=;L!1Z-[NDMH+HI]:(1<.R0
M*R5"0KD%8$]7"&I<8H,G83^\1_>SZ6IF<]R152Y.$\V#9ZYFW617VPG\N-11
MNCQ.JWJ 'K=:@IN.8TY^@G(&B', <,S7L^9@//@6/R7%G%DS@R@; _?8:B5%
M3Y6W!.RA-0(;>^;BX3W?6K^=7:^A#,^ZF47=>E0#M'(N430=S1#M#D,I75BY
M(7UI"L<;(^^%S(<O>!X0H#GNTW.^G_'FF4R24Y=\=;8*JYU1VE $[]6MS57V
M?&-RH-&AO5;&"#);SC^1,.S3#,8RWL 6]5-B*Y*OS\-J)E=S>J_+Q[J<IC/F
M2.#.]AQ3_J@0 -I\;M-NP,")IO8DIYKY_*(1< "1*R5"0KD%8"=7"&J>735=
MSGY>W)-AN/HSFOW[Q_GZ;Y8+9^Y"?T-<EBOZ$"98?QILTA_XD&ULBHMRF#J=
M 0_TYCJT*GF9<OHSXKP0909KFAK0(+! X7@X^*RRAN/3Y-,[/_P\#[9AM.<5
M.6KN*&CWA@X(S<Q0@@.]KI#!H*$&QB/_X^/C_8QF&$_OT>U\=7._6-&22+_,
MUS^CY6SU.+M9H_4"W4Q7/Z.[^\4OEN\Z4#N(MBG00.N"@V9WX)[1U!#G5QET
M^@+VC<8JM+FT@"BG"1)Y";,DA".]P<PQ)JQ88I^^I?+H1,EI'3E!3,!2XVZZ
M1C?@V*"KN(@)=7T 8X&VZ.875N^GZ]DM>IPNUW]#Z^7T836]L5PH4*6T_KJQ
M&861#GG-M6.#[B-TA%XN<7->B#%#(C=8"\A!;0(0)^:!&^[QVOFB?6Y9W0,X
M#FBH*_I]17/ ?JXCM>D8GC_<+#[,T'KZ'S8WY"4:UDUG-5W&-VXK)ZRJ]N,:
MN=W!+R>."'584U"_2H/PUQ5^IHO.)3Z$$<TIK=N?5#<'[J=UBI9V(!5M ?MG
MK<C&^P:S]W33@ 1'\X>[Q?*#Y?JKYWHV.&W3ZCFR4:Q[PE;?;41CNY=#),X#
MY4Q@S42#F* K3Y>7=LA+SY?35I9>_%O5 T1ZW8"Z;5/%\]H/&GV@EX%HHH+I
MD V<8<L^#*'3W?QA^G SG]X3-URMEQ]9 2%VNW,Y7_UO>S.O3'?]V5>_-U!7
M-C2#. MK=@4\$S?5P-@',CZE[$Q0,_)@I@ *!S?A?N\E&0+R9]:><> VN6C1
ME 9P:# R2>EXOPD!P#!AIH?Q0?_BPX>Y[3I[6BK7)KDT)?(:'*(ZX:41A;&[
M1(?)+P4[=JFAQ!#61#JT92"@1?IBTMFC$R?^_[6%ZW4[ T>'9D8H%:[7Z@D8
M#1HJ8%RX/GM&K& TX>^OG-"OZ7\!E% :VAKB0V4V(P;AH48]SZ_I MS?=10N
MS_WJ]H!]6TML\WE=(#ZX+VO,Y3WJGOMOB0L+;^Z. 4L.<GQT<XPB$CV<[#GV
MQQ@OMK,X\?9.@E4/<%\T NZ\<J5$=RVW .R@"D%-AR4A1P=E3A">5_:LL-T[
M)73-4*[QKSF7:O8%[I>-3'!^E:2V(V O;B9_JTLD; %]\?@%-"^W;!";*8?9
M.QYZGE_5'KBWUZI:SC14- ;LU?4RF^<89I3AN6Y_6LM?Y[%XB!Q&V'L.LB"]
M=.DGV+!_^OR]2CU?;D,/N*^W-E7IZ-F4&&"L:*^3\9DLYYRO-<NW:.CL*'('
M!S?V#3?[XNX(!=Q==MG[\ 5' 46W:1Q[<>(0_]+95&_<&2AJF!DASS?3[@D]
MZZRY(L:EL(I#-+(:=HH'S@_<S;=AA)YS:= S<:LD?C-LOMIPUB@XH8(5G$@+
M@C5L7CF.,<$0NCR\Q2_8#P]4M/1-)ZZ[8JK0ZPD4$PW4+U\MKNT&.#IJ(KWY
M56+.@X4\ I?L]3(X_@_"*C=A;'7MY7C1)\<_XL56EKQ8B0.Z?8$C02,3E-9/
M.AT!HT$S^8W#>\(%,38T))(F\<*#!#"FL7BI;N=$^)K(N;D)]Q0*67B].+!B
M9<%F3OPJH 5G'XGRU3AA1@DX:K0P3^D27G,R@!&EC3;FNYF$YQ7]FY8O.?'X
M.HKH3@+[&PRF #&.14B9.5% %L/Q(XZ88'K;N?6]@$.%IMJE6L[570!#@*[D
MIB,ZHX\( \0XP(L>^K8!37IR^4K"\X^T;M-]&,?HD%G$]C-[_ TR/>^N[@'<
MLS74O7Q=3]H<L$?K2&W\7E#ZKE[VFAX4#^Y79TH50#4FW<P(97/@WEFGJ+0"
MTWC\LE;D]I67X$VM RAMTS<?\&?AQD,4!N1/%PM[#GH^:T &N"^;&D;T\:8T
M /N^L2JF[D$8"A>&4)DE/)@8W#Y+[+*-!Y6)NDMJ6+D[O#GZ=&<RO^"096U,
M@\ULN\4N?PB*6 G'R3Q8'9]B;^,YD8?C-7V/OC+OH6/Z0'&E-U/FV1-=$H>>
M8-&+KJ:N2,@=?2="FU(N1K+#:%O<"'*S+"VZBL:9?,A+!21_H%@0<> 4#5#V
MS(1A9Q27=ZJ8!7.)T%RPH"@4^I6)93G;8U2&9;?:]@<GX#;VDKAD48M'0[D5
MR;07/@?>/_!FOJ&[UUL/;Z9DZ9S$4_?WHQ>1?P6;>\]Y\GSV_"#YCB#)IG(6
MZH\+T+FH9[.6CINZ90$X0NY+TRZ<O9 (%2(A+A/*A&(^+XB%4KFL ^D8+/R
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MEI@>X=%'K8+-0QA$V3]904#:G\UD:^SN N_WH^8Z<RC>P%%ET)] >J.N3\:
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M"[5)AILKKX\Q ;V85ZJ./2I-OB2_)8M?6C$Q_^:M J0;$P&*+^V,(DZUS2@
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M0T"%$O\5_36,_K:9'7FRR, )1L/\N.HH+V?$THOZB>\J,'Q &Q2906E:$+C
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M0::!X#HCS.)URS!@3W(>'7_QY'O/3,K;(Z:7%;XDZ\_8?\$?2)N=JK!+(P)
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MW8BGNE?7FM/J.=81?ZF^UH@ONHUQQ$ND-R[TEO)@%5 2%C?G;!#+Q+)<UVX
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MB1ZB@HP;Q$5!CQ;)U8:'"[?TC;UCD-R%T;WC_K;8\B0.YZEYP*!):F18T<1
M5:BA0V=$^-%(G>Z0)&.+"%]$&=.SL!)K8*@RB)WNO=^/WH8JG]O'SI6H7S"]
M08XWTQ<<.<_R *.J'5!LJ%4MNX<B;030J^ME-2[UG5)%*5E+[@A 0?-<FSO\
M%!V=Z$2_V7H!?0@W>%:GUU0W!^I2NHKF2305;:'GS>B(WL&]9_6=YTP 1"5
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M#C^SWX]><IH3QPT2[P53+K$:?"I;0X:>>C5SX%$WA0X[&I(;1^B,-/(RVNA
MB5L"G/[US&DSM^M9SVJH@:/LH,L33#Q[1Z#UECZI'1[HN*?7>X.X^LZ[7D^@
M2&6@_MF"I:X;[&6+MO0M%B^,!XLC!"XH96-_ 3.<"9PS$]CW>OE^*?LTGAZ3
M71C1(AT?@PV.A/B+8=;U:?8%1ZX78U8L9$EW6"M.!/OA!!Q5>C1O_9E**S:
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MS[WC#7[!02/$N>PP'LQ1**M G;/6X\(=E?!=>2.E#PE[!M$7&O[TK/17_SQ
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M3W9]\TG_F#L:0Q8CK48_$HY]#^>5V%LAPX&<H3N2/U-+AX0<0@)>Q@19&92
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MMU:H]#9+%V*V7F^6=)Z1I>&;E!W,,8N/ ]#Z$HO9%KL N80>7()T$" ?+^;
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M^6A?$X\ ZBQ1NCWEYHG"B;*J445-7T&,D:2'=UNVY8[1_AVMT7W@:8;)-IG
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MY;ARLUG#*&^E,2=N5<CCC<Z[!)X<%VP.)QAEJS3E"S?^^+T>/N\X>BBOZPY
M'8Y=87%;0/;:]0=?A,""K*J27XVDE7!P#DS_G=,/\.MQM.\CHVO2W6__L5;X
MM8L=5G1'Q^!7(D.]8UOPGWHP9-R)T]N@1Y!#*UG"L'1C9P*:V;94F\K-(?E6
M7O'RJFLW["[_X4?1&YYLAR(YY7Z8JPWE^" >;8QC3VD-J<L@="DS676789>H
MMD1<4>7X4!ZK8_R9!9=^N2C4$1"J#.[8K*7F+-V7W1+NW3KM*R@IE21,=95C
M#3/"F,FAL, -84O1&3COHK-TN\JQ[!1K535::V*D<^S=)'!UQPBDRSTM,-5.
M:_.^W7F0'&&J&GXPWOPRZJ?2"^!*+G%FQGKC358O;A@(D< =]HK*T:8,G-3[
M'!X%5,H+22X>5&TPW?-FZBA#G9)@YUT!LXA=<<28AQ-,)807-^P5F\>'DK(S
MN'MQG\6+K!'+99 'A'^-B"J>([!4V2NU_4@*HDW7QM9V/.-?6L(&4F3%P#33
M/&X)U419FU).P'9)!R*\H>TCYR"44TL9)HG=R9:1OHF':8(>^#BC'%>*H,O,
MD<;L6),F>>9-#:92P^ O(70=,N?(\6)I.BN8I*]THRO)#IE6R53["*XDF=:/
MN'##F%) V%/M2ZOU=1K9UAHY>/;!JU<PG,3#<3B)T63\+<RATA\\+NH830+I
M(Q%$CKXM)Q66,;917X86[(&?%V("4S)-]*_MSNU7N:.:#D-RY+)*HZYW"!J*
M7C04<YZ9XHHJB1T+(AA[%JMX]0&3^H 47U@Y0)EAR4>4(J%T3PW"NU"XG=!M
MZX=FFN#C4;/^0*OFR-;P;EPL593'EP)29H]=1%+I.(L9Z#\T)TC*AUY846;L
M;#'EP"\^6S.)5H4A2#R U%GZN*!R(#)!04>P?C/S3SCKS#T' .^_;-^!'9HZ
MQC:0A3PUY]51&EGV>;F0F-)AKN(@-,IQ@"245HX'Q:=I'@DKO?229#5)R_^D
MZ:"[18YW3(0X%$_KZZ'=N>^HQ @ZKGFLR!&S4I\P2;28.K8.P-)]@DH=NJZ/
M$N1,5LEK,0)!\BLVC"H%!5;+ HO?0J05$YN+-//1=AS[%PI\INTT'7YQI.W<
MPQ5H<D?!V41#N"%,]";Z$_5,S74GJY_H\MOR)D[@ #-X!XYNN #NQ-#PB7YT
MHU_=*\)L4ZBMAI!,O XJ?J<N*79%6KN/FFNX<RB0MIQ8R>,#B6*LU1O&JE)B
M1T2Z56-QJX)&SYKGH^[TR2&6R!4:395<02-RW%4=#:-DAD4X?R(4UG#V1(%>
MS<CJ/;'"DT!W^89V>MA-#VO=AO"@O,P1)>Z;M,V9@5WD)\%T;B(5;PA'"HD9
MT>*K&LL(?IX@"12]6D2]/9X@<BLU!/42PD;8/]01^SB-. _T<9US0)XJ:WR;
MUE8#>4'7:7L]I(/&DR[1",53"KN&HEY+=B\L>77&(V;,"T6N6?EFA.2.B&=6
M2-9K"/CEY(U9H+1?.O9&YAOZ-_Z\0"O?)-2YY8S1;M3]9WP7U[66X67<Q/=<
M%+?'",<!84W(J]80HI02-^9+Z?R%5:X13YKA_-!,_W MB\Q&^)F!5+8A8//+
M&"-<S=6BI!FA'_4\W 4%D87=,3'T!J%T0RA11,J8%&6O%)4Z,J35%Q^9T)W[
M8+4".GHV<KAS8[J"SFFC<00J*WM,JVJN)26\9#K$;(X=D??[<-ZW34=1F[-O
MFY)!F]'76NASK?WW+B^>ZO/BZ?I*C5LH,2^>8FGJ\TBFS(LG5;!C0>082V;Q
MZ@-FV1=/*@#*#$L^HA0)I3M<2WGQI"*^%) R9[DBDDK'657'>A6H4'SNYI&P
M#LZPR8WT?AL[LTWSR79^:0[V^B:OCN)PTT'+#/U"LC8QG&I:ASW-<3X,:\WQ
MJB)=11F.%$<Y;W)@$%@0478 LF,Y]S3'.Z++?;4F0($.(75G00F1RZX4.>%E
M!!D *W<,:30#J!*7?1%Q&@)DWG[$(;487LC$19L'-X^@@EXB5&KE/YVO1Z=]
M=2LI;TCE@SU7ZK)O"=0,=%OI)K'F?"DLL*"7!>$F<6 =D^7^-#:;/NS 6Q 8
M+A&7L5@8NJOV<1BZ_F V_-%=#'\,6J-A]W$X&BZ&@WD]P]'%BCKP!'F,? ?+
M-:(*LO(%RN.PX)1H4<Y$$G>8;N))E5)FNA (9'KFR!=779/!W']UC:6A.1]S
M#1EKYYZM_T$Q A'+*PPS&9=C-/GD4QC70^_'VA99X1W-<B&%80>I9J'\BLHA
MS8<9!O-B(C?$EC -A@F8FEJ8%XV:[A)?6#U&%$/TF!H<\C:$#GL/R<>/_3^_
M&\"!RM]\C, ;,"FK UMEY>A2;*DH(:RZH?CVDCP##>U\PLS"1^)1EQ"N-I0C
M0PE8*1PIK(JF32M#:^=[;J#':^I20ZFA+F<*PTRA#J/\#2$*]MT.9<DAED\K
MZ;K=N;^NXRK#)Q_%8B%Y8<'*05U&*#64PY8/)4:4*;)*'^QX,\7BE_T[T)Q(
M#+*3&JY</3"E8)(Q0C#+J"B6<[C@6$QHXDLV#4\.*2MP,1,P9;N.EYBNX7]E
MIVKXI[_/(23!]F6N TN#BP9FZ2664PYROB673RZ*V5CL4LN&6]3=%\O= =U8
M&6")75RI997!CP^)#()<TBDZ^0XMW4'IKX;6L^;\ ;Q,:,7'CZLV>3YFKJP6
MWERX92;G<B(K2H(^*$$"YLK-(4$YD:4OVGDSP0_;A#"@C'K\$P&];G,H4$KB
M"@(@BYT&^!G 6K<Y#"@E<06N@'+]-$:Y3X..2BI#A7+W9JR2-3%\<&#X# .;
M]'W'L-;3\"G"!NK:'8-?P4]$#P^FRFE=WK0[UW>JL(2.-\;\7US@BM.7WTFB
M3R!YJ)%@#P45$OR-Q!A2^2:1A$M&M1*:5YFE)>L@0?0;8:G<(+Z4$/B2AZ/J
M/!SUII8X^2O.P2'H,?2+97C1S#NTLB.H9UOP\R[L]PRAASL#\=1O $W$R-S$
M;?%)@F'6DC.E1!7T$J;2@ KQO=#A=N#XW<M'WP<+N[?1K'7Z"I%VM5:HP08P
MIB(EJ)6<0Q27#C=18JAT:.]\F92C@TK3>>R)).%I'L[5,/00A),V^B'XZ +H
M&\OXIP]<WA=\1\$622_X4$=:04]:B:ZTPKZTX)K1VO>F=>C.Y;G?63WWNVUW
MOMZH,B-5_]PO$E?=9V'922,GY".IN,(@DU$YQI)+O'J!2O6L)5=0#E@NB-@0
MID@JW1&D&D+,#/>/)P> 9&!JZML+]@9J01@*XOF4X92]H10:O.^ [H$EN@7@
MHLYQQ>93AE%FZ1Y'U5 E.-T?CF=<;,'6;3YAV,66[J-4[?32AWOQ)3R:<J]0
MY ::SQY.V1OBY)35 CJ^H6A-3[8STO0_)JOPKC&Z.^(B$TM3S:=582U48#LZ
MU3.*&;I<)#QYV?^F'/1\I]]\64X6GH =$^SXS?R:EN6N?7TEZ3(\7\,8-"@R
MJ'FF8 +O)T!V1+#LO@%'H\"(+:<>H)1^I2%EET=-<&7Z'$L$NMQ](JMDE7IX
M20LR>F2ORVXH&/A J*DP/^A(TSG"(VVEV0M.E!\.:] \)(H+3;ON9(4MQVO(
MO&8U9":SQT5=0/\\=**5Z,7%?EE'^V4RM*UMZ;[CD%V5<VHI/!4)MF^RBU]9
MP@P9K&%Q13&(KV<8:S>=16744$G:C2;//U>-HDXA^07MJ+/1V)5A38^?,KTS
M7J]HLC?D^OMDDXOT+'&R9Y>.L!OM]$.94YRX@B>*&]N$W7<'__3A8:]@:H>K
MX]0.\^_=V>#[9 3/5?/_VQK\S\MP\7L=$SN$>LDY_&0+27F7NS\I![ ^0GTM
M>_9V!RPW&I$..KT&(^3QXU FRGC31>E0:)Z<PMI/CZ+[=N=>\A8%#W'J?6^E
MLJOK.UA1_@<%,*\640R#N#2C,"-.E3E"!8YP88;!O)C(TDT^^(=-3^#5\:$N
MT"\KP](L'6ZPR+&%*,75 [H84 ?$"TFL*,[_Y9M(A/93/L:$H@W%ET=:Z<Z;
M>&R[_MIWO4[[ZH$!76+AAN++)V]#7"TG\-39-4W;0[N:22 $U1F.6+YYI"@F
M<D,ND(3G?6H2(SCD5=/;D9L.C[YK6,!UNSH\*[M& !KY&$@HK1XA3GP(Y-&+
MNDF@<%*@?SJ _JXPMYYR_.#!BPWM?'D5/17,@&9N%QO@:#O@>X;N3DV=O'4D
MEZX%QODH9;:.G/)*QQBUZ\8S@0OTW];VVY<E,,)) /XC._;AG_X^ FO-'%@>
MNBL]GOLQ)=*R?VUW.I*M1:>:[UEU454^)FYHPWYB9^_LS\J RJKD-"RYHD@?
MF_CYMV=JCN^.C!5P=0-8.G"'AC'Z;4>>@^DUE((Q%Y3,=%M -.FPGO35T1G-
MM?E:4"L53\'W2A(1S=<P!HUF#L5GPS*V/C[$P='OZ@%(Z5<:PGPYZ@RB]DX'
M,?E[G4',E4.ZE4+,A42X5M!C5:7*I)7QT&Y?M<]CL637!N7>4K8'0F$-':2V
MEE-3L] E,-UGH8)/*<>]?"Y@/!M.I1@UEQE^)\+MSK0_  AL#U13"J:D<HPY
M&?K'Q&-53T-X,P.NYQ@H>DL@<!"W?39_H3*(6N?"I3**DKY?(N1B1MT/#=-!
M;';71_J@9&2FE+\0I*B2&N(0$FN*LI=.%E&/+R?>2N<J@Y( 0?).FFD/K/CN
M-5?]9,14WG;B)_KPH<+0TJ%2C#?D?V*YY&F>7%I9%-FG9T[A5 4TWLZB:6CJ
M._H&3D7TQ3NGBC+0%D$IBW$!4:4#+69JQF;QHBS)Q/(I)=VTVYW;V_-:G_DT
M0\DP(WFQQLI!7;DI-91C!1]*C"A39)4^3>#7@\4O^W>@.9$8Y$4 5ZX>F%(P
MR<S^S#(JBN4<O &+"4U\R:;AR2&E]'N6$UDJ2.O;*"=&8OF&E2/7R=_C5J/"
M2A.+28K=B$]6#-6VM:W@EHSX*B2GGGHDK(84F"N(0JJI.)^\)'H%\H;):/N^
M8UCK:1CH+4BI/@:_@I^(,R%3Y?,E6@G]"%J$56-;('FHD2"O!E1(\#?:4HLK
M?\:<XE*)(+-(Y5G$82]_P2:!$]I\%G9\X=1=+HVPSW.@PS&$">]8I(FTLJZ@
MLF0;3JKFCS M5?#$5G@:8)3<:;)*2.N&XF)/\X2R9TH1+G54FHE>$!>F#GCR
M4=RT.(%Z.'<^V4ZTXPLF5!PSV&J>*4]***?2I/3<K*GP@GCLHTL6>*C>SZ@]
MS33!\O%CH.F;=%F>:V2>=L^/GM6JCF*CJ.T=0SR$D:<-$MR=^)[K:=82'EG0
M>D#@9EZU\Z5>(<TT\O8J5*(;+0N&ZR*/+M*5%;;P^;*(0Q\1=QY4.>>)94\4
M-B:^J^O9KI?'(5R5M.;03O%<+@VXM1)?=K:;12A,N(G8229,(!WM8B=.H*)7
M$^SW"XEK%P+UQ#1^OB2M4'\QG2O.T%3V%LR(11Q:V2!7/=N"8PDM #.D?_P5
M&'O]\V.9&!7%1!)I'!=.I.C]<'ITS$ 05F>YL!_!=V"B@_K8WAI6H.=PDXHC
M5=&VSI1@0M45DZV:7(22+DH*XQ"O!?M$$Q-O YS%1K.B=R)C-'Y=#RQ#[8OV
MWN#]_OF- #54'(^:L@8*Q;:N"?>$GK8S/,V,)Q<7.&_!Q>N3[_D.B#?WI M%
MWG;.E\=B5!7SL1HCB4Q#_FL^!J]9#/8/"9#I.N5T,P4.>JA F[8K^6 :M.OV
MS>W#F?#[Q#J-!T(U=A]!>V=X"/ <X]5'78/"Q(]@%C;Q.4PDLK;.SKBEVSL_
M9E:CLIAXU=AL1)FI(WDB>\$*]@MO?<DI?::DX51(3(EJC"V"*!&%D!J8QMIX
M-4'2KA[X9Q#' _8@7[2Q,R646'W%?"MKH%'O*%]D_S!XWQF.%LWOADVZ4!?6
M_OE1^#0JC)V4RUJ)U#O:%,$FNJ/X%GI#17K[YMBN\(=$Y"^E8;IIW[;/Q5A^
M*F7&G%?$E*0BYW\"M D#R^X;<.">//BQKWG@23.<'YKI4[W]3]>+RUB1J>AX
M'%5L23MU"N>\EY1P787_!"YOAN<.6X;G^/,M>]4*.M *>M!*=J$5]^&2!5KX
M/%K++- WM^W.]?UY9H&.95<WYV^9D' J(%LM;AA?MSQE,$!]7<^0<"K G:M^
M,F(4B12-,E)Q!#&5\*2 D[DY*R*AHO@FPI R!W5M%);L<C4D:LS0@MM\,(>P
M!"O2"'W)H*;;I-10C@"G7HMY=:-NVDV")-25FEI'.6[P8L6,MLK+NK! \0 J
M>M.UEGWP!DQ[A^2/CMEYX>+S:M:%*$R+2EFY&T*8;\ "CF9"Z;O+K6$9Z-2+
M0K2R4(:I;B-)4USRAFQ.:A/23@'"G7JK4Y$**\AK(-W:U#6#QL&2>D5.H"I;
M9?7H6 T]CGE80C^GBG!W:IM,QD#5=5U_&QJRGNS 0A5\<;)*^Y#Q6FBNV2PT
M<6=:46]:B>ZT5K;3\C:@M>\4LN/$W6J%_;I8;2Y6FV#4WK4[MS=G:K6)9&^H
MU48!9*O%C<=J4QNH"UMM%( [5_U\5IM\S)ILM5$(3PHX9:PV:N,KTFI32RS9
MY;I<C)SV8D0!.IUZ9:](A14P5_K%2&%5[5TM$X?)KK5\!M[&7MJFO<X[AIW@
MR^H-A&J(*7 $E%1N0S,6B-3FS'#_>'( B$-,S31/N'<ZZW>;,T!*\K;B$<2L
M^P:/GR)/PG"Z1-?)*(<W>FA[11LXE7SP,F+H(^9T2F]PNA)1<,9*_&&;L!D3
MRG6JQ0;_Y<O@.<URPZ%]U;*U*#R*^L:;L036\M1C*/G=RP@Z[0C*U;V@U#3*
M&;#G_G:K.1]1].;P8J^K>U =W@>OF?J&\2%A^,G@'2'Z:"O\:BO^[,4*K<PT
M&3W*3:08F-FF^60[Z$?1<R/U8^E!>=^^OKU2WCY].D5(MY8HQ]-J K62OJ,<
M.T_(O4J)3U&O(,[OPKR9GN9X1ZOR;3V'@4)A8BY#X30*;N@E"2W);6+#"K?Q
MP-$-EY@_@[^A"XV9LPVSZZ_L)<1#R%(+K)$7LC(L+8D,A&(%#!3L&1V,#]'1
M]L.^HLD[][N7,2!R*B^F[K+W#CE#YKZ>0T:EC?YE3%2N7T&Y@,.M_L Z'@8U
MW>A'J^TA7U5%P^#H.Y>50>0H8%.OH-3&JFWQQ0&7>8L5;T6#3 ((U-6IKBT9
M.Z+<(#KIE689)55RVFTP^^527CF>*\)B:</K<IV:UBK1%YTE)JV0@2:N!Y?!
M)FRP50Q*0Z]LRVHU5IS4\<;5B<N0.]F0*X_+Y0JZT-VDA-UEJ3ZEL?_:[MS4
MU7].^I@\.4R7*^^&'/4NPTZQHUYZ@%VNT\GWL!*&&./7+T-,PK5\T2%6^66]
M"N[B"0!Y/<9ORWF,)[Y\<1H7/IO6,W29 C.BM-!EZ<E'P7A6>&E#-[*N[VU@
M[_X%ED$2U$R@&:B&]'* ]$.)@%;!EY3C6;4L8EU0Q>NTD?P]EI\:U*V"+ZG'
MWQ/Q22B3N;0K_5T.(4I=4H:)!8;6B[ND1*@C%V\2I[B0/7"JD(KJ0(S%+YN'
M&.GB%V(44Y'TJ'DLQ-@$(6XXJ)&ID)'\X>%.R?2X)R8'BY(JB-DOG!Y/MN_P
ML"-3_D*.@CH2%**@6FX8;UPS1Z;\A1L%=23HRK]2;LR-=QYJI(M?F%%,18(N
MJJLE!G@#%A<U,A4NY"BJI(@>]RK38X!L,SSTR%:XT*.HDB)Z?%69'F.#[X(C
M4_Y"CH(ZBKCQH#(W%GSKRN*RJN2>8IG7E*NVRLP([O!Z&M>MZ+[XA1G%5!0S
M0_UK479FI(M?F%%,13$S+ME$1'N?C? 9!U2@IA+F[=(JO&03:8(S\VV[W;G]
MJN)<79J@XCTGRRBX LMHDX:+Q' WER$@7)6-71M>\S7WRCUYS #:7L*_]VPK
M<*WT-1/EC>C0AL-I>W+F T8!99\FJ[TTO_N?FA,\.R\:H_V.V^,^_N(E/COS
M?4'/U%QWC]7$";*KA\O  4%R)/5";2@W\Y"]X,7))]V-3@Q1L;I(3(@$ZN95
M4X82X@ _7G<**4'%8#<<4TD0>>0HV'%N^4;SH9CT:FW .2A BGC-4.-,:4"7
MO^*X(->54F%G.%Q$",J?+0W(TE<<>8*;!#7:75RU;[Y*"GNDSNXB4H)Z\14X
M9I.\-_B\1Q;&]I1A4YGC2QE9I3_\J'"R2?L![(=C]*M+RNY;J"UEB%0-31BG
MJ$):.L&IZ$[2S!4K@/?DQ-'FV1"O.FU5>AJ[DDP]_A,;5ZL7^@G05Z7& _D$
MY#LG<K1Y(5]I;57P>J\$]9J[&6PH,2M04^7'V#MEK*DE0IC=%S>H7L*77<*7
M9;Q3U;[Y.(WLZH9_PDZNE"!DQ/+*85XMHHS+%%$S-6,$-; 7I49:=K3SOY7+
M"CZ4&%&FR"K=G0-_XLJ>'>/G3.070/0:]<"9@E/F/%1 VCHAO?AE<R*]KW$6
M2-.EE6[7X$$:A6#BQ?I0YSS0SI%7T0A56%E0Y!Q.N ]5S@+M''&EAYPZKU>9
M*K#LU">%BE38S.QK)W'U48&$U9"BK/]/=9M;-9DE[RK_[#E82%W-G/1BV;O6
M,A0^,3Z?-<]'G>MK'NDBE[7Z^1*PE(8$G0=(G+L^D0W)W^W,0*F:>?CK3\/;
MS("[ [JWL'N:NWDR[5_N&*G+@QMG/E-2IWUU9$IZF4Y'@^?!>-$=M?K#>6\T
MF;_,!JV?P\7WUFPPGPYZB]9BTNIUY]];3Z/)SWGK3_NOU\:DE-1MK,2AM;(A
M% &AZ;8FYMHB3I%!")RAZ_I@V8>TM]9ABL,?FNG#F1@\^0A9)H>?8BVE1]AU
M^_KV3O(<Q(?=_K I4'Q%KQ+YZ' &D!>#5;5[PT??A:NGZ\(E]]6P HD74!H7
M2@S_V;-=;[%Q;'^]Z>JZ[4,IX<*+3KMP[81_<2#?1X;V:IAP\<+Q0&#SC2%.
MU3I1],8RV+NA*5*S=, CI0&RUU&EVVL,EX0KH;(;T&KWLS-@HB=J4\WQ/A*#
MJ>C>]?IX[SH;C+J+0;\U[<X6O[<6L^YXWNTMAI-Q+?>H)'WE;$[SJ\EUC2+U
M[_$C]0N3&Q1'6\I-)ZSPXIV@RDJNKGO+HV:BB7*^ < ;H<\@2,C^3J3BRN$M
M#KMC7G IH5[04QV;R!64@Y\+(C:$*9)*/Z"*(03+%@EK3.=OH!:$H2!^3)F2
MLC>$0H3)-L^*GE<MK;*;=OM>=J[!"I>70LJ@7*9(7F;Z/EC8"9G@..CY#E(P
M@0SD"LK1H!!4QXAS2ERI]?E$YI:A!?\(%MH[<&= MRT=3I%!DY-5XJ>N-X<?
M\B$S/V90.2[?F?7F^,PZ'/<FSX/6HONW 3REIK^,7NZ$WVX%'V]I7FO_^5;P
M_=J<9O<Z/$B?<Y"EUI Q;X0=&MFN^P3''(H,:EB^8:TG.^!HX10+5G:*28-W
MV%\X.@Q+<SZ" 3B&^**8HK8)^[<>6I#SP*6KH)(O*C=S,1 D.4.=6C4-V0[M
MU9&>:?9_'KPCJSYX!!98&5[7>P)0;,W<SSJ'^F3O!J'?: 9/JU1&)1XV"G$3
M#E*XEOIP'P-WK)&Z\'XHZ'*=CY-\;3>4BP*4H*@]BR P_ ,Z_?2TG>%IYC=X
MI,9:K]AKUY48(L1LB#\^00L3;P.<[O(?ONL%[N5\TTNV=EUY(D),0:$=RBQ3
M7)/$$]PFPO]"*0#<(]S9*]85\I(2"LKQK.RFY D>+8RUE=J=]8T5% VJWT""
M\LP3>:W5E415B"TH/;2RS)JBBZ_?@>8D3JY\;,*UT% &,8LJ*&NTLJSI;9 '
M_M#J1]+  EW7!9Z+W%M#7$W3_H4L2GQDXFBXH1PKJP'I2:D%$R]]8Y''IG3I
MM()NVYU;R0]:BE*$02QA.:=M>/XZH9]>8BJ=P]796!FZ9GGH&L"VT.Y^LGKR
M/5AN/PYX;2 =N@TD\='6X:O(%A)^%]E"6N&7+]:/$UI-L]/?&'@Y,M"JU'TF
MX):-:$!0 LS(;&*MD46EISG.QRJ, 4G:>W*TH!S4W-@QP,\IOEKOM?$7(T<R
MHBA]N^!)I[4<0LBL-;HQ#G_#79!P-= DE@B27JW8Y!7-/$/K#= O5VE5FL2:
MPO*>)O^HX,DD_WXUITJ3H"\L;Q-#>!_I ?ZC!__;\%+KZ@P"#,'9L,X:]%::
MQ":1*JC$;'.@V%=%*!:8L)BWNJCP61"&+&DE!A[I<5V.%/#-@=MY5EX$A=/:
MNFM?WSPTCQ=D20699Y*77NJQ@OE2G?O.N*%\812[K)4F)QFF*O2!"N6X,3L+
M@I#D%&4\H4\G)[M0+_C6_:9]3;\SK]_K]@;<B",?W2 >!/6Q>JJ0<F.9\]:;
M09J3/2]V'2^!%?RO+$[P3X<.?P/VVH&#U- U$_.<G%I6.=088#A@QR\: X1B
M\DJS00C6V9YC'X53RRH#(3\:&22Y)%3BU8H;X^X"_;>U_?8E>)?L?(301_^1
M13[Z\]]?YAF8#S^HA2D7+@=,<\11 D"!JWW7]S;!%$()Z8$OG%;//=Q9WM=H
M$BX@F[H/J(^%H$;I(!57#E$.<%B0I4C9D&$-)02N9^B]<!*CAN+ EJT!!2@H
M8LZUS$(VA &1"S<+ 7!%FX8_LXS20XT*/@*/\K*2'!54#OI"ZSFC7$0+O0S0
M!JL5T-%E4>KA!>X)/0%,]@;4!9F.US'0)646--TK9BZKP">\SASA$;#BO!B2
M[.K<;J2L;I-UI@6GC*?QYJHX=T5X&P*6B0#)!6T?MY@<%8-O*$'%H-\:CI\F
ML^<NBO%;1R-(I*89V-D.(DA>W@EB<1EC?>RCW>UDM:=WU#W24">65V^DY\"2
M'-Q\4E6R#3C%@(Y<$35S:$%=^(&$06X>]X^"X_KN>%P_#<?=<6_8'<%Q/5_,
M7M @G[>ZXWYK-IS_]VD'.-Z+E:(&PMAEKU9+$^;7]O65I-'*"PBK'3,225$[
MYEP'E@9[D&?#3)93!C(.]1/LE[EB*09;U-T7"V7L,E8&6))MEZ2RRL#'AT0&
M02[II-^.XJ?_!;"FP(&2>/&C\.C";_"N!W] =P+D[,X<U=7"G N[ ^Y"A)9.
M!<5N2NLV?7/*1;P7$9*1W7;^0,]IPIAFN"&:+J&NYNE*S Q!!J&J</G!8X!2
M)_4T2UMJ?7B^<@T/[MQ\)\R-Y, #5Q0>$QT)EMTM,J3@<.)OI2%8"A*\B4]+
M@Z1<_6&/1AYJV?I3A%^\BG/E"GH]&MM5@QCT^@<ZWCV9ON[Y$=W'P#L$A [O
M;5"63["PXTU'<K>!/:(+_4+]F70JI9SF 6NUEV,]>[LUPO?9!2_#[H\OPWJ3
MY^?A(KP"J^'5=D(G76L9VDG7D$0&<)D]_CG;D&+P0@\D$_VDW:-ARZ8'Q4/[
MMMV1.U,4 BYE[F(64]U,9 OX@<DJD=>>XJZ*+:L<K.RH'"/*+N')7@YP(YKH
M/>+U&';K\)=DFB1Z/C&^5I1C 3N2QRP0(;OTRQS\]G)DZ,A?H[MV0" -^0H/
M7U(YG$5@E=D+<D@N'66EWHLI0(<BDS^_A"=[L"#KV9A$)/G1R"#)):$2 _CH
MV9CK[1S8^M77X%^?T;^2F,.__7WQMRRZX5_5PI$+BP2.%%F40*S80)TZ-DH^
M,W'FP'F#BPQAML454P;6LA,MLW"4ZSH)<VS4;;3%B#KN$N=88EEE0.0" HL?
MHW!J#E;N(]4WN(_$;Y4Q)5**N(,R*( R(US'1Z$\N=0$^,2.1C)!%K;QS96.
M<G_="'\CV4.5'8D,@ES221^P^'N)[AJ>ME$LJYG]H9G>QU3[0*IXV2WLSDT[
M^/_(5Q7,E=7"FPNWS!U%.9'K18+N"GZH, LPM1M/ U:9&_(V]\FP# ^,C#=P
M%&W\\>-9^X?M]$S-=2F6#8X6E"&/"'M'6;DI,7,EV[4HDAWD&FM;0 WHP=F*
M<MPHBR\78Y@U(GWY$60Z!?K&LDU[_1&D#SY2!^V\R%2W3G1B!A]C="VLBX80
M*3N#CW(<IXGEE2-,F;6)3TI*E.["*Q%^EQI<B9#]=1,_9SKZ\'!_I18<=)5F
M]IIY@E4<^$&04W8@Q0SH $UB4P";7Q)13!=K()H, @HZ(IB*>$X'8KNAW!0'
MMFRQQF#/)6 =LNU$//ZG;SC!Y5G\2AVERG7WC]5MRQU:"_"N8=/O\+;1&#:(
MDUZM[#R$-XWP1W=CF\N1 17U9#N$VQ,L1Y@K-XL<Y<2N.*6.H"U!+$GX=G,&
MWH#E8U].8 LV"V]V$06EQ<&/>$'(/L/SZM;?=I=OZ-D8PRBG5F@6TORBBDIX
M4^4<'YY/)JMGPP2N9UL@EJCKS3W-@;_,4<KSY72CN: 'FT,^20O'P+^1+=Y:
ML[@B6 ]ED]^H0:3%QG!"B?5(8J\XCPB-G1N->-0@*F&.)!9U=SL3"H@Z#;=5
MSYKS!P@B<.UVCOW&3:.<UM(*[+1O[B2_TJR*1T7T$%]<M1OR,G.N;\#2-\%D
MA=ZTH<=KOF9.7DUC'9[C>!]L=J@/-N.OM>Q5*_&]5N*#EZ><37[*J<)T<H*G
MG-G90@TW.%$NY2J R([! 3\NX92$3J!+N4P0N8# XL<H7$-LOM&!F^HDD"JC
M(M*,D!U/M_F2-01FL<_KZSI+\TNH;DHH^<_K56 !.Y+'+! AN_3IX03/ZU7
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M'.9@O4W^\B4$+W*Q^(__#U!+ P04    "  M.')3%[J\S@%] P %]"$ %
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MJ8T%ONTQCFXG2NG,\I:?*6*S^5#*)=1&X$+_R9H<FI+/BM[.*>A>DZ?VKAS
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MA,<_#(>"/X9O4_]D^Q7+7K?W*J3$+HDRN)O1[D]W/_#SL<$1]),_F3A()G@
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M1"*(I_ST$CW1@?QQ=^[/V8E"MTKH5CG"K>(*[H$\E($P&/:C()KJQV&*[P]
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M. .5]H)<>4K46+=H(*WEAEVIC@+?EQ##?"_(=--N(,V7G#HJ"9-0D15ZI$-
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M&>6%#!80F.H8")Q7EFE(]GM,L3DRB1#*U[OE0H1<N*"8Q)J *\IIC6;+,8>
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M+9D=:?6,5;\I'-RRD7,5&NPTE#&;['_ZR^/])TZ/IW-2]3DTJR:NHVMU12_
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MI#HSZOK(09SN;CEYUX7T)'(MP,$H?R"&83<4R0&9. @X=2Z#!;;\X17)#\-
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M[#1B3P%<;*3.+?/]5 /(H>TE9*DYV,S PYB?BJ=OKMD0$LUYZ^2UT0.X8[K
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M:C=T3"&B$N&KA\TFR-YWAJ_"-%<9N,N3>L;XGE&HM/B02\52(&[TG\_VDY4
MVN>94,SAL0X[[_$)'&WS>07CT7+U*0".UUSQ/<UFY+?Z1 ;;$_9*AQO'*U<X
MA]B>RD/G!8[H("E[[I<T!:[914T6IBC,;>=R/CFW KV$X89,'G%D5C2S!8;=
M6.S DCS*A@)SQY#Y* <9H%00$<FY"(*&\_#)/J]BJ"\C"B=!':/I0R:/!-$)
MR01BDW@WL)<,X9_3T=_($-S.I4WJX\37J'^/QM)PK.L*H P\&-]KA6.]+69:
M+27PYN'C\?1V],.1OV8;.H9HIY W6;W=L++^!_B4IEB,25\"<25+/*9K;,0+
M.E9!,83XQJOMZ(KLWGSNFAP/7)-#5U]PIG+4GQ;6RGNN*%%_R5T(6OY<^\NP
MMP8RR>YEIIBA\+[S>05-<G.L7KB%3![Q/7D:-WR!#7Z1K4JM&2/1NJ+?;\;L
M.087<19=/,P>P!V*<F=@II[>$Z\4R)*^=(%:#X,3R]M]0G[!"95.[;YR 8(\
ME(:H>T.F<E@Q56?+Q3@Z1V6EJBRT39(J+1@PRH=$]!EJCN10C@Q.#!Z(N 2&
MU=]C$?8Y. SNX4G\9UD>>LKCA\$7[H-&IPU8HI@2Z4IS06RUS(--NN?>S$SE
M ,P=//-/$T+P-'$O/3QXWGLE5HHUP*QMR.9<W ]5,O(MZ=@VA074"_Q>5(LU
MDA6P:?M40Z;FT2A>QD?_;G5;O;K6A5;UYV)H2?10>_IP9G->@JB4+RL]P:Q.
M*QFAWA1\$3[;?_SMP2%OV2V9(B8S4)B^(@\)DN"H2W=+!Q'>AMS59B8HQ!.9
ME&*WPT<L>.3&(D,MZG[AQ?$<>038H3"'"JF:Y<8IVD#I7I&V9'R.DLMR9:E5
M>M=45A5V25[<'Z@VOO(T@=^(%E"YT#V LS+F^\79(/_M#2Z]7&5SQ!#N/^+@
MF=QSS57NGA7],"I[DT/M*Z]\1D-69>QKRX#!AAJU@1V_>N='I@P9KE+A\/&_
M<U:6EURJ"F$]>2CUX3,:V\9OF^6^K1@-F2LR3:"..A.TB_R_CVTE?!4\ALV)
M9_[!#Q48!1^Z8BLFJT&8'TI\P_R=D[-W#R:OWKD NQAN1NW"SZ-Y6EL29UA=
MI75,\0(W$R5A'OHA8[L[R1/7T.9Z<%CG'$G*4RM-X2G5EO'NW:[NQ#61*E$.
MO9">P'QRB<=Y>(*@UL>(G>#.M/A/VJ>.A*SQ9>U5'*?18Q-!6L=H19VKAU!8
MF5H7OMXQ+AB(BK2Y1,:Y_F3Y"9T&$"1\=+C(L[+L<US8-@]DPP*0]04#JJ?T
M+I#K:6,N3W4Y4)$8!90BJLN@;,\9S7QU\'T!QSF;=^L*Q8%V"?=KZFDG-7/C
M01IBE$^4,>Q8I=+-ZN"IK-"6$D]>:D6Z#.'!(Y=;Z/V"7K-!HT]N!\6!2E8@
MRY1?)5AQMRD2W/4/IP_(2N#R&@%?=2-X6@*J95.Q>#H6C^"]N6URBAD[?7-!
MNI8;?IDA$?('NJBB4GF@01-7BG=R<-[?A4V:KK[F2L;GNY3*'4RI7!L!OC[N
MBT#^EPC\>KIG?@N&TSW#7<[K/JZY\&K$-_B[0+<R!")FZ6*!2A<CEM+C.$A3
M8&7-6XK1JHQ)V6*.%U^JQ?4Q%KME1:L^(UT55T5(AREQ"N>/6'='X322N:65
M5QV]L?9BV:,M0^8A?0KNL:[A"XD#(QJQ0YP500)A5+M6GI(OZM6G=VK2#_?9
M&:W-OM!;3BQ.%RZK6)VG$IBW>P_=4_&-_?W#_E)'5$<, 0U>ZBOU0TO">$B&
MEVYD[#MV;7A73MB)0T+J2PFB2&!M+WE%KD>_049_7&QKWX!^(>*4B=(76XW
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M=2C=INX]GW;L>\)8%.)GDCL:'V]*J907MN%IDT8]R+;>J:'L6MU%)%RAP)%
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MP06!_CJ^V"/2?(*C2!VAL5Y/(=7QH$K2GE$T=1Y06+,7OQO/%N*JZVZ*SF6
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M U-,PS9%\?RB8'P<P)>Q\L&*0_;@";EN6!Q.&&F _II!#351BD;70:/SYU+
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MVE+U?2:&-:B[5MK-BA$>W@5#KJL5O<I%WC1;9;K2P@LK'XF>XX+=?ASL<DJ
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M26=8\L*3"V"07X;__7(P-N!+3=# [;S0I"\]2/NE\=)@+ALCK"G?YT7&J>.
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MI,>Y?&N<9] O"8!("!([8ALMJ\T,AF4T^O540'"!FR_=M$DW;2)3Y8S.1_6
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M+6<%\FX*[^K1N4".!6*@]L=7;[S#K,P[YQ8XX6.4XWW$;<>1LS0T2FD]9,C
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M>AM>RN9.X19;EB:.98[+;^M!#O-)=82B2@ZH$U4M/F$.2;JXZS?GD068+B_
M-$\.RXL]:65O1!TV5"$=F"SK3<3@^* 1G41"Z833.D05S3;N<D89(5TK(5S>
M^Z#T)IZV=&FEG#I7G5!D<3V/LBP)(B#5A[0-_QU;9NB/I4%$[:O'ER**-$K+
M0X<)FB7FYGEH25T+"LG"<YX'F&7=B98PE_2IJM )MWA8L#D;,R6-,:;A/$QS
M^6LN:*8'B_6 TR.+)>WI,6AM9 E&+K_1O[5A"3FUPIK<N$F2-"]$"""3C,-
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M=49!1M$8IK897D:5M33#DU<^-I3*(F\6]I: SOB?H/OBW[BJ6*-P9G"<#5>
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M18M15?[ *K<QIMTU#X NJWG!+&@%)MO'SAB&_1:^4OBLD#6-TIFA_I5F$VS
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MQ:WSIY7TH=-@?G<>I'K&[WYJ52[>,.X1&58LA.YP+KZV(!._VHRX)5?5<86
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M_JRL&V5'*B['A'OLB8"(#W[GN'GZA"!68>48C_/-?]2'XQ=?TE>_;70J7#6
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M]]-0FRP%F%36>]$7(X)G)YGE(>0J7E4TP,2I*!T)AVJPR_TC%MD"SNMRKTA
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MZ C#]*B6:<!L$P+1J-C$R:I$=;)>=&OQ:*K7827Z3H%L?/?)^RH3:51R#8%
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M4/,5P^.9$ Z:RE:8='"TI$_N*Y1\K=/$0_J+^IO&W<84UT#G-G A**N>LS]
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MKD)V&E:%)J_2I<8AI#+DR8V&UWS"!",1H5.<^15^!'M)WMRQ#_OY4;!2'$?
M@T1DW1@\M& $A68@_7E< 74>HR/NB&JWI3Q9KP^_?ME:S'BA?J4\^%S_29^J
M1"AP/;OV'14"=AC\?.X3P]OS2&[:&&6.#'IJJ</WX6!Z&:L;E2 BY&>4R"E!
M;]+)Q790 [CW D-$AUC@P8BG?AC%"IC>I L@!WH6HL9BV1F'NZD)G ME#<\Y
M@?R<GVULPOL-;U%CTD+])%E*QVSNU]0<"/5J>8YF#*8$=I)(?1T+"BIKR\SQ
M'V8GX;.ED_#/ZB0\WTT4O,1+.CL.8+8>P HM/NWF[8T_YBSF;L=)_/.>IY94
MP;ABSIA0K0MRUW#]R*Z?IZ'==@,2&ST_]$6G?LP( _PI1G/,BDC;/U:E.ZH'
M'32P<5)DX3$94J<#(A6X!FKS*E_=%K@+-"/958;3D> T2%3A*(;&9N<-Y\[_
MS$3J/ 9AA0:KWW-EW30[ .R8^J$9]Q/C%]%;*!)'R: P?T(".%_JS6+^NF-*
MBO0W28,HZD8!,D31P.0]9913%YX"X@%A^46O@,2LNBT/YQN4C(6!JID0,FO-
MTQ.F#\9^>'1,)DH"@*SK4DH@*'8W]#9<6)$0M^Z1WROJG4.E*H&7IQ3H3]4Q
M\Y=R>0&F3XC36,ZA*XM92MH!$?75V\34$U%-USSLE2I#&#A&!?;)%WV^;@,)
M6E0XG@=J'(UN&6&(Y!CHY>J%16S[W9LOJ]4?OGSIF5PB84?TBC>KK\+/]8A/
M0VIXVTKUYXG(U$ C5,"6^7ZA_M#]CEFB'2!A B.1UA4^.G"M3EW'F$\8C.DH
M=XCKPE&VN:M\*=+K485M/M9[H:^@D<IVC7EL!_AX34%#>RBF"?J*]+U0-\F&
M;*I$?(&R&=\)8C1>*M<B-/Y^#Z7/9E1DLJF \#D&]UUW<$O?)/<XU*J;=4]'
M8ZTT$ KI=$S!QKZ""-B"4$E6;"*(F2_.:$2*V:TA'];G>8RLCXIZA"MAK?8
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M7G8#I$*LF!4W1/,T?;A"N,XXJC:NGY9[I3)9Z0V-NXU:;S<SSPC=#\L$DB)
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MJ)8K-I')\KJ.N#%RC4-AH/-\EA7KSE5Y?C]VV#.Y..R3"P4\0K<9E52UCVN
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M94'-]?1]G?VEXK=5;<)\_.?]S/T<#[F??<[]&.5FH7:(E5M-,<YT9IW]-,T
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M85A7[Y$Z\PRB)E.8 JYOB@.:?VKH][H@X&?\8Z&!3@N:I#CTKPW4ZG="&BT
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MK*,/)#I1^,8@.G-6/-5*Q2GX*22=BPJU#GYBJ63=F_9&>XE1/>8Y/#!6Y,*
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M!Y!RP+.[>UYS5JD;E,$#O?=9)$"\D?8-C:&>HT,D3IGZ>!7A@Z[)@$<M"_0
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M?FS)&J#1'$RI7K7??JCO0:^U3$"D().BB+-13UAG\XCA>9>VO'!L>]^B6I9
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M%IR2 C%]+PYFOA7+E1;DWW$I.WP;1<\=SWE],!/?#@N,8CT%*\6:*$;1PMB
MMT)\4X14TZSPW]]/Q^, SBFCF 6-O]+52=;QQRO0A5MI_J ";.-A&\-^MH%A
M#J?A='S2IHY"AN7)A&C++5P'S+U/A"F@DHH3DD>S\&0\>31*^EL$3A&8**<F
M-]O=VUDXANOYW*V]_/[P,)R,Q_O9H'HZ1*MWKT'5H=_)9 ,!'QZ'QT='#T#!
MT^EI>#P9DXD%[YH=?OY#OS\!R7$\?72&G\PV'-CL,#R9'#^ - ,=/)D>[LCF
MK-9W0A4Q=KS,+?X_J!YX"AKFU#V!K4WB"!^@(XS^T%RCPA-VBN?.+E4=H5N'
M$WBW\&Q'P>]FU@;'\31X!<Z"0R4;FM5@(P("?55%J;$>R%EG#5K?%&CA@$:=
M_'D*!PU./98[\_*U^U!%"X6]&W61@<'MX$:L,)"[%&PG1)*/8H,3[FX8D]_Z
M(*C!UH8HVH 2Z[[&_IUUX\#M470BJZQ!ZE%)CD47%#!HG2VZ_S2WFF(1BTBL
M'!.=V1QWX5@ .#[Z0-DTH1(AZJN(X6IH7$D1I^0#&MM(CC-TYUA2Q@+(;8%Y
M @H'K_^^(3:,_>!L+$0%<PZ%@SDTG5DCS5%B(PK^*%(TM*B'"^0T5:,B%HGM
M&'5B;K)(._$ 3+E<G'6@.BJ@I>@0\49 M:$(N0(_34<.E!I.0Y )%J0=R(\V
M:WUL7IZ.-PBJR=$#V28GZ+>P8)=G^H6_GR#\#D_#PZ/QHYW7:S4OZ<".-IS7
M-#P[;NNLS3[=+#R='LE0[\?WY<RFSC9IJ_$#$<'D\ 2?]/B[Z[=>,(N(AFG"
M@U&%STGVZQ\DQ$XA'<Q"1>R1(B^;")ZH!?LE+J1TA7)_;/US-)N)KBV]H*V$
MU4C^G"_AQ#"*>P$"4W'WQTN]QE]SV=1?59[6!4I8/"@3>[UX^6OPU]_-<U_2
M2ZO@XI;*0)NEM"H5&%>"WV"B3HY3HJEIG>%87 VEMM4!.T<64B-4)S;<C<%*
MN(Y'*6]U=#H!)UJ!%X_Y%8-B9VMPB4YNU)PJ7Q^=;*>]HF9;,^L<-@:_K#P[
MZRZ+XY63(GD<^\OJQ3[K*VI97;>=W3RXT>5FB9#,V2YR$UQL(&&^_E;5 A\K
M7<]T2EM92I0U,7?$!\"6BVK? 8L.$"K;6Q%$VY[M0D.5&=6D9;(@B3T:<?\2
ME6 ]2>P0*/LG()+S,@U^A/W4\/00SA718GA@1!:5#9:D+%0%,HSJ ]Z\>1,&
M?Q^]'84TGY:R)29,."\D?<C8F,5CC1F'C9VORC0+>A4-P>EHG+Z,$J/Z6B^*
M!@CF H3=ZQ(3]55<R*PIO*)?P">9\2,?R<GSBB7!TJW5 ?PF5B\PXGP#9.MM
MULZIZM,[YV*JZU975EQ8\$DT\.S\_.6[Y[ILX!>ET(]:IZ&Q;^Q@"T6#WRS5
ME<IE4F%PG=9E06"RX$C PO[E98"6"MLRTVI)>:VX+0_NUD)&_1C$@/MKE<>#
M\#(W-^UUX,'-4S>D5YA(C90VY/IST8#1EVL2-8'HX+RY1"0^(7^33/U;DQD*
MGIGJ ;88.1P.;Y1Q#^ZX"'2W>239[E']M#>6:[6RGM"&*.,4]]38)%';1/25
M-NH>T0#VX.G(?HQN!;V_$RZA>D2KR^S'W3&_+?(U-!MZ)0_AFI# *-A"B]OZ
M1,15ARO!$@[IUK3N.1C0H>QF7;CETQ1^: S)#Z [P#RI/LL$<(^E:P*X6E@N
MK,?23\74W<KEW]\R\[,A</^U O>?E6GOD8)2UDU=V@FH:P(*>'RG9]HG7FTG
M-PAJ*D&]*3%0!Q*KF</642/QQ%%2)@;@O"]H?G@6GIW!_TZ/@F?X#C$=[ I0
M@YG#L"4F;D68A$8BZ>F$YQZ%1T?TOU9DRS:?L9Y $==>,^@5;E/[?GHR&H^Q
M>8V_KJ.-7E>DV3YZY."*X!-L\(4;O6?C QR5:#6M[K!J*=J3Z6%X/#MICT)\
M0V7NN6I5N:\YHI;1AE Y&.OB:"I5I?+)G_*YGYT)$CQ%EO4@=BJR$1.,0[V<
MKQV'AV>GCV,&D%B'0PIRQ*QFQXXQ)AD:! &7HLHN'"<S"(Y&E6)B'O^S8@ S
M+T3D?)"0Q;^?'8>GXZ/P\'A"3_T>[+'#PZ-P=L(ATN\GT_#D"#XSFQJ-PC/?
MUE3-LH4EB;/QY"S416>$:BX*BYV_2F93-*5>DJG.+="P5I'MH@REZ-A^E4K,
MY'O\G))-1:R-= <J$_:(6V_$SX+G?Q T\AKAMJ(5@D5&&:TB[*^2' 4_*NX9
MT/-L&G Q<,31NF:#=I) /])9D00>:$JMQC?%[$@JXV9JM!LN"?+) "?:V31F
M C&6R(&W0;5R" #CC/PVR/WQ%1:/TEAW0;,P5$7&RU=JONSKUOEBK99^?PWS
M$\UM7E UBL<M"(%19'3UB=L\  NUY>P>;-&&;Q@HH-CS#/G7%8GCW(Y$Y )U
M[HFZ%\.]V/'N13EQ,<K(@CH@]V-5J1?Z'^Y"CN'98IBA14,=$WGM6TSC5=TR
ME[HF:5WJM\K3)KRM.M&_1_A&= _$3N'-R5..9J/CLS^Y)R+OTZ?CV&#.\S&A
MMP!:TT>B?R9?[@7;ES=P"'?:=;KSWFV[C^85.@?JB]C>Z^_>^>!]FU;EOW6R
MQ;$[SF]>D.LKVQP='PX7L0L7,1N=G XWL0LW,;#$CES$P!*[<A,#2^S(10PL
M\; W\>>Z1&/VP0S7S][U:6?3\S[0)<&R?/;[Q??/__W/<]G=%V7RQ[O0TWM<
MZ)=EIP>YSK6!]RTNV.E]&JYYN.;AFI_F-7^:&I* CXX;K3X&%"X+=#)N9]34
M&\;<MSUP/T5UM"^$?K^MKH-B>JC=,HU_Y9O_'!XP,5<^E]DXY']P,^] $@-)
MN"0Q'DAB( F/)"9G=ZK.;G5*'"NU6/SP=5V[OC0U_N]8\G;7*F]4W^W?=S\[
M9!-JLOZ"F_KB5E^[>HIR8NY%SKS:J6VJ#JDX93+=9/SNUZ5O.)[VD7R:+S"0
MRQ,EEU[5\"W3RYT'<E\BV;D8YUV*4#H)J&37+>W!>BL>^(@!;(T@ON.&X7UT
MXL[3YD/(LNEA.#TZ#<].SQXP]/,TE-PW<?^3:3@Y/ K/$!QFN/]O[_Z/P^.S
MXW Z.]Q&4>VE*V<K[JGB>?_-M<&EVT:O3<,IQJN>B(D^&.0/*O0FI^%DO,GB
MV2_J&/S]+TLNXVEX<KB5AMQE1:@A:@GT*EFFN<'#')RYW8O9?R%C__3T,#PZ
MG>R;L;\;MOU3(X=).#N9A6='TWTCAQWU_9X8?1R%AT='X:0G-/14?,/?N+&8
M._.HPY=;#O??)/SFG,1MB?K9["2<'!^%)V?CYX,#\.TY %O3R?0PG,Q.P_'T
M;*"3@4[6TPG!" "M')]TZ63//,2_8\/VG&>NI%PE6D<?!V=PYZV[[94?XEV<
MA:>3C<IO)^]VL/F_G*J;A2>SPW \Z1%A U5\JU2!BFUR&IY-IELIMOUP .\J
M=?V'H B9D*C5@^O*@??+!/PZCJ'/#S/@AZ1H$"UEGQC" DH-'L'7\@B>!"%9
M)+*!D 9"^ES?DR#L]L#WO%]3SH]11E/9+ZZ4VJ\6Q2==8_J#WRZUG_?Q+18'
M#A?WU"YN;WVP5M3Q951=[;_]\\TEW#ZIXF!V@J.XPO&T6TVUKQ>_;X;OGI$,
MF+>SZ3@\.9X-%#-0S%84,P.* <=HVJ68G?.)-FO&MZ5"H'?&5F8$=STH-*H0
MV7D_K;@GY Y]$GV>A2<GLW!\M$FB[>0M[FBR9<_N?SH+SZ:3<#P>[O^;O/^S
MD^-P>GKT=')J+:WUDR(TTJ&(\MLPMZ:@SPZ/NN2\KY<^6.=?EEQ.3G 8TD N
M [EL1RZ'X7@[9;G+.O$='@66DS0TQPE\M[TQ^K[5FLI/H=;9^!1,N^/!KA^(
MH\?O/PHGQT.KW4 ;GX<6MA\^X5WE'=QYIZ.80V'E4RQC^J0,X=DIM>>=3C8!
M4NTQ9>R>1_#42.AT'!Z!UW!T_'1B$@,%/:ZE!M2#&9JSO<\@GL<Q#M:M@E5T
M:^8K1W%<XF#M+.7AN /<RW[&1F;A*?B;9SW(1#M^B3OJ4^S9]4_"R>%A.)UM
M0KG;R>L?>-B]Q",$HWC"&"MO3 .=5D)/S!X;$H/?'$S^D.D9R&60$0^2,!F'
MX"#NNYOU=Q55RO6G0EVHN9]&V6"";PNH.0Y/)L/HA&_R\H_.PO'9WOG>PU4/
MZ;D>X*_\\J!6Y3)(U+Q79PVVUY,CZNED'$Z/-D%![]>E#_[9X)\-,N*A4PPG
MF&+H*>_>,P_M)_CX=52GUVI(>^TY38+/-1L@Z[_-NY],3\+9R=X5V [LZUSA
M<7C4,YGKJ;A2%U=1J:Z*+%%E12;3R0^!^F<#S#R83$.I+U4X'H;C\5%XM%&'
M[1=A[)OK]<1(ZN0LG![.PM.G6O$XB)I/HXM#'.P\"4^G6U67[)16_6&K_@''
ME:/*QFJM\@T&],BG6JV[7<O <,_[?L];U?4/U[SOUWQ7\?V?:ZPAW)ETZ,,L
MHZ/A6O[E9&H.\9VJFJRNL)G\5QY<5^15L"C*H+Y2P>NT @IB&ON_*BJKX%6>
MJ"2X4*M:+>>J#&;C,)B.IQ-2F/"/\0-N8_VJ?[M2I0INHBK(BZ!4URIO<,80
M+.(6=X)+7SA+OZ6EPZ=+M2K*6B6C )X0O"R6*_Q&FE-Y31)$00R_ IVO\HIB
MNSC!")[WO<7JUT=C'QRH=4>"#XOPN76Q_M$6O7W[1X]'P7]%92J7!?M^=7%Q
M+A9*9<8.TI7D,H'"7"E<<EHD>!1X\?#T59G"0<,%!8NR6/+9%5E6W. (PT44
MUT59O6"N2=+K__AW^(^^W3B#1:)DN9*[,G(#KTGDRGC\IR\B'6*5UZK41#(]
M=&(G3"0G8V?5]-___;_<U7>M?1%QSK:NF(FF).TNU<&\5-&'@V@!;WX193?1
M;27;/#D;S;3T?&&DY(SH=CR:'?TI</Z-Y]$YS&7T\< Y,A&N!YE:U"_D:_IW
M)!C-+Q$>"0CA1:DR2DG@T]==DO^*OF\^H 2B![U(P;1.X\TB"%887Q&]_@3,
MG!6K):(2OD)"3M*Z*26W\@6$]+M_BY:K'W[23(.R(&N0Z7P^6$9_ /\8SIK?
M!GF$ZWKQI=;E*0^?N?#H?MA2GY!V,P3/NAV(/8M6E7JA_^$N!,..0O1(+3'\
M!:Y"LS<18]34A?X%4R+]QB-8QSR0SW0E0EWJA<D+)[SS[7S(X^EH/-ED;#DL
MX#P?!Y(OX%+UJ>F?R6!XP>Q] ^=T)UO)9="+]4>C.3CX3:V^B.A;3Q[.![>G
M#$<L?J;E.!T='0\7L0,7 >['P!$[<1&'H]/A)G;A)D V'0T7L0,7,<BF7;F(
M038][$W<,_=QI]WZ>+L^O<>NOZB%N--;!B\)?_F7[XZ^^\3MSXY&A],O/@QM
M;6ADB_S7_[7!)C^S-1#WUR?N^TVZ<Z<[^9.>YFOH>OJI=#TY'AW.OFJ:^W/I
MWD16^8QFXY#_@>';!TKQWF6!/CQYK*> X?:WO?WQG6+PD\H)OX9\?)FE.:[G
M2Q:\? 4%_PA5/'>X+%]@4]]_T?W<9?GO9 +W,#PZ.PDGD\<8\?;%9?5 QM\J
M&4_"X].S<'+XV1B 7T6%%#DFB^$E^V O[T1C^N,SW<-5 NTE@QV='8?3DTW]
MQ[NO# 8Z_0;H=#(-3\Z^7,?2U] /?U>741:L(BP5X+*C+(VIG&*A^MMB]]CQ
MV*7^DUWBWF_=OAL?3<+9R2;TICUV4P:B'XB^IU/LZ"@\/>Y.7]L'E^:7EX,O
MLX<,]TWPU3%R53@[VS37\)O0&0.E[CBE3L/3L]/P;-+UN_?9G_FUOE+EX+8,
M%MR3Y]\)XJ<\ROS<_51  \D_.9(_F8;3D\]&H/L::NEMJ6))YE.0+8G^?_:^
MK#=Q90OW_4KW/UBM?:YV2R;;$S;N/F=+A)"$#) P9'I!QAAP,#;Q "&__M:J
MLHT9DB;=(;&ACG1V)\24JU:MN5:MS]?0#YHU\\R/:#Z73:N494G<"X&36$7F
M6$'^P,;FV30FE%-3SJDHFA%$EN<WRFAE)IJ)[]?V72TZG]&Z(V1(/)]<^*>A
M#O7[=EZX^;S"<H6WX.UHJ$-9?L=87EQ[))F!6*?NS#3K@YIJ9],$95GL]D*Z
M9)E5\C2HH6R:<C;-LWQAM<=YEB.:AF9I;M2ELV/81L_T:9D9]>AV7YAY5A%Y
MMO IS;ZS:8\HT^\@TPNRA)@^DX<V&,$AU]$\:+6HS:"Q'8UILBB#>R%J(BM+
M(BL6/A 0*9MFA')JRCD5>4%*@16554[-<F33=+6)04[W'5J$1OV[O1!E24)A
MC?06W (-:2C+[Q3+BP++*9GL!5 9C373Q?VYG1Y3NJI7FHQKZ(8Y@5;3-+)Y
MCRA^-4#45OW)KU[<1]<&"2HK<+2_ .7SW>;SW&[%4P#LMF-!U&>UC/IR**B%
M57]&3ZDO7_%'VRR)%?* VKBC70FH)%!)V!3IG>6E/*O*JUF&W86!2Y",6\%/
M8Z"#NV99S#("TCL S@" [:^YDED //MK3O)W )OAS&>(P03@;G9.U[Q!/#?<
M4YZ,[ZTY5XN?PYAMT5$&\S<>.8>F%.6,OQ^L+-NTR9I<HV<9.AH+ * <N^\
M_%-\[<IW3?1?-'SYJI)3Q((<3IA,'N@1@\G-<=70G\>)JUMN5(\_-7WT'\<=
M,ET3_3U<&+P7"&D94)H?P=E5JD=,#S$.F@P:[A)_/R:8/C!&4,P_P[\AU@@
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M'& ](%D1YBV!PP5W(&0:$&0DFZ P0K..[4:ZD&@UQNS^[UO[U!KF9;[ J8J
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M%K(5\YP-CYP<55!8OB F2%-@15%@>0BE(05C^+XUMU:1$V%&83@:0$7T30S
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M]9/H!Z83>*8-#EIX2C>+3K#ACZ\8:1P[]"QG&M[3B@.77QRQQ8>BH-H,B%?
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M3=?=P.@REJGA'3:-"*U4H?VZ=R5HHJCH&2JH":7TB@AIT>X6B8A>S"7T]0Y
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M(\%YG((ZP!6+HLBQ"I>I9@7T"D,J(P$:UN_#FO>3LVE8GYDU[U%8WQAHKC%
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M3VV:%+BT0-.)5#GC-]L_(<!O;7K<[3[&:P'.[UC#E=B!JE"#G!MLU$9N,8@
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M:Q^^]18@I6J:LX+E]A#8IY%)_?:#-FRAGU)A/\!R!H24[D5W;GO1^?]@ 7R
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MOKJ9#9<>3?L*U:M9]:TI5^H4>OUY\XE9RRO)1?A^P!FZUI'J8ST?%3UK_N)
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M6E8QUXMFD5>,3E<>21/JPNHPZ>IDQIGL\G(QF 1#-]N>'YBHZ-FTZ0RR4V)
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M%Y+\O_W4 J@S^)2Y 1\&L><!'U; 3W5#N.(?/\Y3Q.-4@)\A_YT213$U 'X
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MX@O!_N#(R[%8Y%MCL4[__E64(O6%%_"XQ&]<2.X+@0<FA@.# 1//<<& B>G
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MZ-JD$!*!W'6=#.@#*, 4)'P32O1G>AM =BWZS@C+C]V%06!K,7HX+$H$5&N
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M]1QC)$DR!MI3J"%5K_#8P:H#/3MF>B3MZPO]M;XS<KMKA6/!A. 17V^0ZH_
MB>@7)VJPX+>$.2'AD3I7/4F[8$N&J-MW:%*!X)=._ZEF]IO(17(L1?!;R(:
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M0Z3NF<.MQTG&:&X*$=N@->U5WGN+[H_1TZ"2WW$*P;+VUV\$#C)#T1I T(8
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M#17:2$UZ60C>HV-"F.:( (0U!'?S;J!Y$]A*ZIQCX\S?06QLANX])QZ8D-O
MK67)QH3FZGJLF1A\TPU4&FICU#7W1TZ\+IS\._B2[1/ZJ%UZ%R!;Y(E4.<EA
MF!BZSU5,M# :N9M[5HY[^-CA)_"\Z9+D +W05O"" LVFL,A=ZW"80*R!=%C0
M[FW8W;9+Q#KTMZ&'=T+DW0+I;:K585+1B]+@(*?4P8H'YK+/^HCJS2Y7#C$9
M=*?$RUGI9P.&ONMX?*3/]UN:I5];="QRBXZ=(SKVL7C7YT6P?J.ZAEX9M"80
M;A&/>$%/<'-)QRZJ$CQJ!#J\,0.5"&I3L8Z%8\GHN(&?238M@IR:)4V3T= -
MHK-1!Q5IE&>G*K1W8&3DTJ'M&)$HFJ.9 1WM]$%-WP&F$_L,SWJ^LQQ?5%+\
MK#,[;QXDL(4UVM?4&/LK3L6S;X3]-2ERZM#"&P4>CWET$!7"B20?DP8,.XH,
MHA+##O@ARPZ&?#S!LD),B(I03O<?WOY&1QB48NMA+[SB'KB"GKN?W\]6)8-+
M#\(#9O_)T/!A-'AJIY^[E8$I5*+)[O.JU1RPAT_FQ]%TI)K1&:;>EUM,8:K4
MN (\R>X_R952_'8C%C:SNMXI#;+Q1$,+-P>1PS%'U>VTD+D?6;-X:,#HLX>A
MI1?7@^CAD[%Q(3+)Y1(Q9C[<Q&:]3"19F#8'\<,G4[-&8I)+S*8<NTEKX=[3
MK)9;I=&3]CQ/73"8H=8/8N<AA6':&7V'98)1IC!O-XR!R5E)/6=%A889VYRT
MC?;;5//HG:U@^_^_Q:6K]X%TMMDMM4N=4KUV%N]"70V\90,3@PAL8#@%&[C[
MA6[1P-ZBM$#@D@'$?R,; VCO.FA)O#)'"A>D@EFF+!@-1;C'*MZ ZVXS6H=9
M<1R_3$ZL[*3%9A\0 Q"WP/_](6_,7R"<<"MYD=^":B>IQQC$]7;.ULMRZ-OU
MD>LO8<(H-5[7!UFMD653$[G6K4ME52T\KT2VV/SCW[*E;,FF1,(DZ+N?2>3%
M)+*;CKJQ".A% V+>C9ZXPSW'9+DC_WCQ/VV@*2A0TP"8"#U--REOUPA"B1O>
M(NCE/&C3"/& ##]XRO=J;)FWGF:%ME!]GE2,K-&GI;)?O;>B),C(]C3^[X]2
M+>_=:M6:BYI)'WC++F,+I421N Q\88MU'?Z%!(8:CKC41]@*I'_](P V AJ6
M<?%!V%*L3'W^N.6LQ>P^)A=#R=EL_,>_\2 RYH+A&&-OOTW^?U^&L;?C:W!
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M6UC5/\3PWFSKF)Z/)0)C<Y!.>YT"L96A-3:!R?,=\K,E]N_2,1WE%7+;Y>G
MGT5@8&T1_HKHP&=#N ?=V&*+R& D 1UGX%XO$T2<[UX(_UZ0YTWGX,Z7(4"@
MXLQ1?N]^V)\(O!-^N_$,=VQ]&37=USO">W?";+>#C[?<77OWUNW3L&!9G[OL
MC2*?".J]NX;V]ICWG@^9--*MY8XDN]\1>/_-[V#_'$KUA_O66TK[+]X-%27'
MTD&@=I':@G-?L?)2=_#C.^?0B!%A8 3VA+][^U;$B"LQ@G["Z(@1(6!$9)I"
MPHC(-(6$$< TD1$C0L"(R#2%A!&1:0H)(^@G_-U[E"-&?(T17[P]_<. ^BJK
MWCTV#68HV2IX3%[1%PJ<-7RD:#K(\7._0J6+&NV'(M'0TN&'__>+_O4&N0SP
M%%UYFUP$_D1>]JIL^KU#%R</OQW<068%*;M3^QF[*IWM&>78\P&X^]6N9YH]
MAK;01RM^C]=OW=#YFJ_[@H^_)?@?K9QY2B0/+]#&9JL8\":J?(W[LP_TXH/K
ML]\E&]Q .R)1B 7BG66_*P0_7ET )&_(]"]9@"-.7\4D!.'GPR@&>D^*$5)+
M26*/(Q 8<]\@X3%@01@6^5%6X2$6^=$^QT,L,A+71UGD1[GOAUAD)*Z/LLB/
M\J%A6N0)H'/<OV(X5)31Z#\A0$![@ \V;5)'Z]=T@&=/1!N6*YMR3%86BF[-
M_,Y.V\*P4]S]ZGH?2X'/M?H;:/9_7W(]UX%(GP]@/EN8>NYS( 5S:!F*?R45
M5*3RMA;^L/N1KW6L*6=>=(X+5.['AXW:&;[G)3!QRK<:$SU-3POR0O_VJ;5M
M.;\BGZ[EWT[ZL,05]I89\@.DF*%;:"E'U];IZJK/F; 3"_'K'P*/XR>NW7XP
M:_-VPBTR(K<$KN$Q(F^=([B]$4G3S6$;LRP)I<0V[^3T=#.?__9QD&\;D<PD
MW]Z4<&6E*:Z2';EE-K&I0B-"_?H'3\09^OBJL@<S(A%DN:"UN4;<$2)K\\9!
MFMM;&U7FNTM+(:L:HJPWB.JTT63V/6NS46Q+%IW)^=!*HE-);'JE%@]$(Z.O
MM G'*[ 7'1-H&(;_YQU+$\[T]T?!7TXQ%5O4@UM894,U57C:!U8,1>F9N]T)
M/=LN;Q#0W7IMX;&>/PGXMIH&C"?[2L_.93\G5,)S^!R[X;KBDMMX@SR.3*X?
M\M7&-8/GB_D)6EO!NV%2G&D@C:!-(T'%,>+XOK/[M#1_3"G%GU$K$3)+\Y.H
M\-*69K%@R=2<+[;Y=&+"X*/2S)S+W^XV^6U+LTAA Z-49M<:,A_E,^6T1\Q(
MV)(7Q(4)*HX2QXT"[M/21)CFO)@&1GRW7EN(+,T/(L)+6QK2&56G_:I;X;I#
MRR'0-I)CG?<PS=EC0BG/3AO(VM#1]$ >D^WAJC_J0#CSW9@PS#N%84TZW:?-
M/6_*[;7!(H#!DBT/-K.XB36^PC;BS1<<'A,=U@Y/W[:JK99:0')IIL:+?7FT
M+ T(LX2R @6#1(J.)XCC'I:1?8GLRUEW&&^^X/#8E["V,ONV?>$;C:J$IKIS
M/CTIXQU4S;L6LKVM(XG%42P9V9?(OEQV3_'F"PZ1?;EB][Y+!X3BHCVO\7HM
MP9=PHC!,5;.CU !"E\\'A/_VN]#]<W2G6TC,P#TTI#U]5]_^'3D=40]N.&(=
MQS."S][H-*LD,P:ZH?IU5,0S";,D+<OVZBJ=9O?;,QJ*Z'BPL^.K;L/;/HS!
MY8Y!QT?5CL&+*@THO<'=%\'E&",1_&4!EJWLM55.Z<"H(8!PE@X>;06W(L%6
MQW" 8<E*L/7K-Y)\?JCIWV2XUX#;G8AN; @D27J9FAQTEQQ90).6\&G!^3#8
M_1;82W&LQ,07RH,_PIM)G6W';OBZQ8Y!\#T'Z_T=M9&\4!O)9-2K[>!\\$7:
MOWS4+ )[8K ;,N*8^JXU^TT"TKO GCC0@?[V?P+?5OY"XPCXT]]_%H?H)^J6
M+:LB#GW((?PI&7$HU!QBGM!W.^)$'+IU&[(;ZU $"/94A8A4Y0H<^GJ9[ON0
M^:&ZH%T&S#Y"KY^?PL4_@08?.9,_@08?09Y'H,%/0<4CT."G_OR.:!!YS,AC
M1AXS\IB1QXP\9N0Q']9C?K==\L_;8F+H$WG;8X9A[2!\8:MPTP["@=U_&*:?
MKSON%9C^VA2<I3ONMX6 >!PA^'E'W-OZ@2N=+;MM['.EXZRW#6[^"-1ZE47>
M.CR).'E&3MXTP+A1B]%KN)0/6XRJCH:,;$6)J?#.&L5Q8[;H7K2SZ W<S.5[
M_5W'K9R_<'SFV8HP5R6%6W::>4X4T:1+$JO^H-\(S\FWQ!=.IIRN&F=M6S3'
M_G'IU/ITB7)65&U8FJSLE25#[<@"Y2AL=:,)5..Y\AS!GTO/!TFRUR 4/8WB
MBE1-J0D>7Y7A663\US_H$W;M7II7=QG_^B@"/=?:KN/S0Z1FUSP %GHU0Y):
M(8>YJ2ZGU%-];FT:?06':I;X]0_VE+AVM\F'5K,K +(PJ=D5ST$E/G<.ZB8:
M5C?R!#U2-%'S)@-%:/66)"^Q0>>>2S1:# ,$AB?*AO!TC*Z.E.>C-8<'7^XS
MOW+&WCSAPK>A.@NWI\Z(HPQ_RYX-:SL=Q3RIU-+'2BU]1JEW@MM6; -[5N&B
M0+KME6M)&F(D4%I;MQRYO!0HB$6I0!X,0*V)<W3*\2ZS%6?>];A+";\\2 R5
MA \&76="YCJ&IJ96.2Q59G2M R4\$4GX7:&Z9T3QH,FU9V0AFJ8'QFW CPL+
MEOG#7&.48[MS#!+EV,X1FNR4I/.L&&\%)SPN"<:0M&F^U:F75GPF20E#5DCZ
MR 9[(J/X/TJS16FV<VC:I)NH2T)SR&OS3:_:$E8-O$DN@:8!A,6@3T2D:5&F
M+<JT_5#)$+.+K*Q*C>;7-1$SDW6[8[<;0,D>.->641>JK)ARE$VC'K(/V3U"
MW:N:A9T"O&44="7=2^>+>%4S1GR"63:*LP8P"C3$N!\;A3\UK7%4KOQG*],-
MT6RHE&FZ;*6] :(U-9SF7:YBE_.MS1(H4R)2IB^4??_ARO2' -:/E*DK.VFS
M;:HX9\BK:3<M(DJJQ0)E^CQ<#7E[S?-,(_@5/NBWZ@(1'N[++OP'MC,\?6HA
M^)8))4 _/N?VZQ^_B^:V5:3S?*#AW-0[G.1^*TP@T3%1!C. 2>U8,)^@K6<,
M"CI4)$=U8 ?%V%)U)T''3 L00063@>TL;4]7G,!:62/_S^U6#^GX?ZN*CBS.
MGV) =1P/-L]T+7_$T6OB.QK$#'$-.U_ZO3;!E/QW*JN9:J]CKF(;#MS.]V;P
M06?8,/95J+V>*:]N6GG6>CC+K:9OE"[OD:XIH=VQ10\DNL-F!NQ5MM$XN'I_
M<!TLU)(#_:V*MBU,THL5DEW/1KRQ0N3Q0"0W)97]]0^&QM:*:!]ME\5]KBQ@
M]U%S'!O:P&78JNA_./.?#5AJ*S%Q-K.M!:"^M X:FUI@&I#P&=4&EL6RP3 W
MIKI.3%:=H:W N04=2G=<5($U M_W3.!T3G,\>-%P:'D^GV&G4B")RMP#.@TH
MZ;HZ^-2OVT""AJRS@"3.4V""P,(@QU4S:&RZZSNTUV=IJ ,20/<X^<_K[J,$
MU()+]%/:\W%#!=;E['003[QXN*T.PNO87_=,^J__]ZI=UU$Z:NNH]Y:U[4Z%
M^SY[# CE-Z$21^#-OT5]*:Z=[3*3S-,S!OC][.L)WRR@3P3YK]C>SY >1\2$
MG53W2/:JF>KV:Z_[J>X^_* 9UBLFO7[%T3<-P,)=0R[LB0SLK>AK@R#+F"@1
M!"G("5D2$NB($AB4P 4*328E1B:'%"'!=8F[;P#_UVPN5F,JKQ?04H%G"4#Q
M0:XW!@8C<3A2(=W!U&8R(K>N"85Y,I_LU&16P&$,]WID/3^O-HR6*?%SOK29
MCM)ZSEW"D4?/Q-7BH*^TR!J:<\MF9CY8UB5A+!#'STSW69NMMKDTFL;I-=Y0
M1DB>8L'(HV=*U&1432!=G3?& R"!XY5(+> U;>CAR U3I9#%;-S4TE7$YC=,
M:3(';R>/G^DNR$12L5F6:V5;(V(PQX<U!>[-'SV33#61)%::IC2$24[J+IUS
M''XL)(]']BK]!M<CU@2*L$X7[2'U@K)F@8$^&KD:=LH6S@A+WEAWDV6YXA1J
M$AQY-,]L8YR:C,JBP>&>W5[H%:M"B2ST $</[98;\]I"7C@\4G<6K4IJ.&TX
M@/'8\=!4/6NZKI$?H*H]:TUEI*G[3\6/A]H+MT4:U<U"*]47^6J''-DMNR%@
MB>.A6%\Q1IVLP7"Y^01IXIF1U$F.X="C9;7$"N]-I[*EK0UMW)OUB=2*7@K8
M"9XB3K9:0S@;Y9%JA9#F8R29;H&A)UBU&C'*9BDM/:V[SO77/197"C28P E>
M-1H].ZFW^S/>R*Q$'DF:CED&3SW!K#%*C5FS3RMH"?=8*9EOY!)E%@X]6M;
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M_GT#+(A%%P GOG''P#3#EG)-=I;0*,K!U]6T3 Q7XVO<,; ?SL7\'IY!V!S
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MS(R2W*#9*L%#C3'<X35I-U>K 4!*29JV8<'/O*6,K73Z6RCFDR3&XT5/NEU
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M5F1J.?91C+.99[5M9_$I'V!$B4[?L6SO2$Z.&%'\ET6_SNO\NV]PU&64T]#
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M!"7 _"*_]@E/4#U3&J&980Y!V"QGJ9:)Q0Q"9KMD;+I)!CRLJMF7P&R25GR
M+VX!'RDS(""YR\(F(/4/2S,<E:DVJ^MW;"?C_XZ0/E.%F!)K?MR@%UZ^32OA
M@^LU@P?X]#\9Z([5.UH\Y*WPE B+9+EHN%+J/> C!8W!]L+3;Z"^:KDYM)H#
MZDSVQYWRJCGZY!!30.+J;^JQ?:KKPW*\DQ,(QY%B" F VG:E*BL!Y +:>J(H
MC<:_5GYIN5S#"@%>O5XV<[UL8W?9I/6R]6#9B*F+EW[E7H(?X0[.TQ'P ](L
M-,-ZT[UD7Q2#P@&,XS%P<)(K'[)N? '=+2NY>F(KV>5@6%?LMV ;P*<7/\;%
MH/^6]@XH6Q,;$I@%E5V,3<"3U/R R8%5CX:]4B)%V,# B6C39U8LP%8;XLB
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M?7T3[UEX:DGS+4HVA7U\ _OAV_>IV!>I#[Y7[3]J]N<JYOLOU>Q'Q7ZOUQ2
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M\=4L[K\ =\Z0G^TKL6S=MY^%Q5)1?VBR\LRX1'Y1\LFU+&&BYJD<G:(7H7<
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MP4C8<3H52&)-R=+Q"E^8QD<6N5R%%_Z):,8KI3A1?CB:QAAI *\$&2.R:38
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M7P<O8/3OB-]'T>8Y-O"8-:I H]?&S',%S:TJX76]1 +IT+-)_D$N2E +O4H
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M[]E8/3<9 $]Y@A^:5W@3?-!# .+.6&[3A"3>5 Z:Q9KMUKB=N*AR+.UN'Q%
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MM,8W]?'2KVIK-S+++^*'FR<CHM9M$Q$ Y?#N22 QZJP3*"KI=7BIMQ^^/U,
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M9Y7[;=@8)P66AEI9WQ95V6L:/Y.K7CZ5],>+$1 S/F]\_KA5XL&=0.X@.02
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M6J04\^4"*^]"\^7GH^^@M>#E'3A[QI&$54J#-=Q?9)&RQG:7^U-VZ?M51X_
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M)0+8)=!^)YLM(K9:5&5"!AF K/S-1D]\67B&24;AVWYVY_VZ4=Y.W"<FSMP
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M;V,S=R_Y:46.H9\_#7 EA^:HL9,QU,\JXF[PP0>+(9-"R)U5W[YU!DQQR^P
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M*S:;,^DE$_%W55KC^'LZ_>+_XO_B_^+_?7Y<JL]%%\T7P\O1G/\3EZRJ;#'
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MHXE]>R)&QJ7-$UK2FHNF-B_.[/[IF<G>MV<6PF 7)$4]G]#DT'\#E>(!*VS
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MM'=UR]UP3<[9D26ICB=AD37/]L5@@D?J\7NN E(TU$N^\XYE5=#:M?X0A*%
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M2"D]"S$QOCT4>E YL5U\AIJW(/H;=5?=QK 2[\9!;3^8554:QV&7SQMV'Y,
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MRVFQZR9X'J='@\R\EQ2QEPF_4OLSLW\NL6?_J<S^+;'_GM<DP$I/1YL\>BX
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ML[J" AA4D1+;#8QY1<( :5JBYHUC?"><:R5L?=F''^;=((OC?Z!]?:HN^O?
MM7O[6G//9$9:<<<U]9==8<2&LUE;.M/G>)KG&OUV.7BL['Z*\OFQSI?KJARS
M<V MN5\?& 8:2?OYA1E)ZK<:W,W:>Y=7I*:XM*S]Z;-S<L*DLL2/ J7@)L=B
M=1$;OH!?NSCKKPU&ZE3WA6TV66ZZJ$*8>MMDM>%,XH,!^&*V>"=YG/'S)G1N
M+..:V]#6,CJ\Y]K.V9TY*J"V.RGC#BWF>*'+<VVD*!2B]6B\@0%%#+.VV@P?
M]&QTJSX<X3!1BVN'7A]KJK@@0* ""'N6ZD]11R&_O;P3V3I].X+Y],I<X'+$
M'L^J8_G HWN%M8M.%53 C4_-1[O/XY;+Q23$)]63@IQA'I(HO6U,7BA_*9(3
M9M%[W'V=>T+Y:+V%3*(H-=I[X)T6D;=&O*,/G6I9FZ;>PB.#[4*G89+F;R%[
M*AZU@Z_>0704K,Y(9NJ?D[YPI3^$;F1,?#DQ]/[8]K[U)<,O5$ OG7[O%$WE
M'T+?6B!?HMW&0[7#"E55TDSN!5_ @A<87*&#6)J9\)3HPWD>69?=LI_"1^@>
M243ECUZRU0\1YZ0"PTISX6X!L,;2DIJ:-]8WKU_9ON*NV?,%E5^R65HE>^:\
M;Y\0.IWNKC# K*K4DVJ^^"SN<:5,]B($4[/F\%5GOQA^O6\'-WL\/0]*"I)X
M&>H85C) :!&;^AX1^=J()<X"-%3;_S@]G33>:3'@R&_-50>ZV89?U&]+*SET
M\+(E<2@M4P$^17@-S%'IU+C"=_W/;U2WIUX<^\*9ES5 N/5C7G_]2R$Q5\@$
MU1[(6CZ--Y)D [X*ZVU?0M<_+P,'.-IG.KR[7?5V/L<FI_-K1=$[]\_&9OMN
M?6;F,4=2_M.Z2YV^=ZJW%;WWF'CLFSK4BW.PUI65FN"YI9I%^QGWA.:^:SM8
MIJ.V%_3X%K+,]^+%QK-FB3IC&WN2E>^#M-^ HH.OD76]UEB"YFMK8F'O%!\5
M^#O^X(JWO^IX-SE?82VDUMO>,S0NZS+-F#+E_B4H_U?@^;L 6JL[-+U'!=YD
M+!\_2:0"MY56%Y'<3>#XM$V15/LZ9)3(-L@#O@6B_#':!S7%SU/ QW+'M$'[
M)M H305:4W(T^D$$Y[6X[()LQ&'.VK-_.*;Y$Y]!(C RT<G&2X8AUFO))<$\
MW%QL5RNRV0C]#5;9GDSA&[S<])Y-ZO!"#&A=<%?$:'FRR:>Q\?.(S\?&^C<]
M?NHI3S0Q1&@@"]NF@V*UQD:XW,15O8>8W% EW&OU#@'?NO)$=I5D1I &^%N<
ML?9,]?JBM[)IX^!6PH'QYY"0YRO=P7&WU;@VO,9#E0F/>E=-9NWC-A)WC^[\
M_N[]C]AB$@+VBO7#%MN]3Q//Q6L]W3&_91=/VD_.?JF<M-71,!S$^;;M\#A]
MOJ')/3Q*([J;K0VF\[+M)C!$Z\F6!!D3AZG'OB#CL4:9=LJU(;*<.^;QM825
MN&GKK,,?5.#63Z_E4ANSNK$]F]>ZA AC]8<J*SD?Z+^SRPSVK?1@)C7C%Y?,
MYWLVQA:E=8\^)E<U:.8UH7'GV5090U?_@-\7+"<_13F90 PK.Q"//,16A1C%
MF**JOK\OLF[/IQSR9.E]D(ZD!UCI[CI<G9[&E"(J]&0DVH/W4%&*5GOG<]Y$
M<'5R**BN9%<MQ%]\O1 _RD7GZJH"L.>.8[34"5[$?.O^*VU&U9>]1VCE7XQ\
M3"[.8;DUEE$G.V!K?_E>Y-B6\Y &!T%4*.P%LNC=YIZH<3+X]+5=X=>;,XV
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M3#L5F!FF EM'<(+2>N:9;\U80?SHQS2#5,C=W_H&T].1>++,0\1 M72>N8<
MI-4TYZI[)*TXEO_M-,H"A% T)S!%R2D.5VD4ODNMDXDUHP24ZZC4\*:)0TR,
MY JQ(OB"!N/C31"M;&MHO DF2\N=A<.-:86Y207:Q^L'[9"3/ VQ(AN3PFZQ
ML"=8#*)*A'/"4V_LDO:%F6+5OHO8J.E=\<97_MF(Y5)K<[L%_V]9 E(%M"*U
M.D][F9L,_X7_IR%"G?AO4$L#!!0    ( "TX<E--=Y=O@>D  +'J @ 7
M=&UB+3(P,C$P.3,P>#$P:S P,RYJ<&?LO'=44UW[+;KI2 L=02 J( C2F[0$
M]94B B("4H.B M($!4(-@H!T 0$;O=>((IW0B0A([[UW2"@A0$A.WJ_^?N><
M.\:]=XQOG'''?7?&_"?9V5G/6NMYYIQK[1W2&&D.8+VCI:L%4% "  7Y!9 F
M@5L /2TM'2T-/1T=W;ES] Q,G,Q,C(Q,O.P<($X!/K"@ !\__T5A*=&+EZ\)
M\?.+*5^])B.KH*  %E71N"ZG+B6O(/?G12C.G3O'Q,ATGIGYO-PE_DMR_X\/
M4A/ 1L^T= Y'17$9H&2CH&*C(+4!8'([:2C^=@#_."@HJ:AI:.GHSS$PDD_X
MP0I04E!145)3T=!04Y,_#2!_#E"ST;!?DKU!RV'TB.ZR.Z?<Z_A,>J&;Y<U<
M]_LQPO*//8+/,7#SG.?E$[DB*G957$%12?FZBNJM/VYK:>OHWC%^8&)J]M#<
MPN[)TV?V#H[/7[[R]/*&^_B&O D-"W\;$9F0^#XI.>7#QT]9V3FY>?D%A47?
MOE?\J*RJKJEM:6UK[T#_[/PU,#@T/#(Z-CXQO["XM+RRNK:^@=W;/SC$'>&/
M3_Z,BP*@HOCG\;^-BXT<%R4U-14UW9]Q45!Z_WD"&S7-)5E:]AM&=(_<.2[+
MO:;GO!F?6=Y\3DC^/H;KL4<_ [>PPKP(]L_0_A;9_[W @O]?1?:OP/X=UP3
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M=SHT#/7JOGX6-!F29ERR7WYZ$8L?;:E*3ODD5:J8LX$A=Y91T%QVX38^\G0
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M5UUEF\JS&5GEE>F,&S:\J7:FF<$$>T,"V!:PO\.7K&OS?CS+L$(/]@A01VJ
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M@/;U4GB> ,. )J[VWN7[^9?RG5W!&%;@9*?LUGQ^B BV*EJRY([RV*7+3IW
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MD]<^/R\><5+L*)"M,5<O?K)E9$86D[H3XQZT5[8F+ 2QRMZI6AT=B[>FX:3
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MO[KD;*H4L>(\MRK/XC[K"F4R04Q0;5OHXUX7HPMF]'AKIG'GA,'VQH(CU&+
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M,T4/O>F]E"M?6N?.AFXIQIV'^[6?^%<2GWYXKWOM(=0Q8N&I4?6+%VUL6_K
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MX&&0[@(RQH(1=XK/<(<$6<UR%\]4;O4/W7U/@OR9)Q!1=6+L+"@&!^ITZ_A
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M?1'G S>93#_5< L_O%"&76[S[[]X:VJ-6LSJGLS]I7#XP8#5[J6&C[B(\*(
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MCW)\(N7A%U8F(71 393[=U/$VN@UV)KNBF///TL0NP872=#1R6L2I)):N4E
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MY<[E<*R<I*W@,/4S;K[2G>SZO)/+,>__@F7/
M
M
M
M
M
M
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MSY<R!B-N"+\?D4">M[]PX\FHTJ6:AJ29@.Z"0J+]TCTEIPR$&'=:BAYN)+K
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M_.NDD<,Q[K<BQH_%\8%L8$\0?<)Z'886*=O#%T@MDYEGNOQK7[(T5L'^*W>
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M%TK#4_H6Z%K&]DQ=>5_/[]7/7"3Y-'WPI2&2D3HX1$HZ"QNOM=OZ29G@=0/
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M7!1)%MQ[B38OLC:AT^.VS>7"?:I4_]4R>W3JY'X'R\_*_I4-W>J).T%!G+Q
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M1B565A4&(#4"1>AY$+'3:'%6/Y<ZG;E)X];Y!9G)9NP2+0=&E8]%;O; HX
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MBD9BS_6GT=?9U'\Z%E9]@*"W'.@['<7Z$"@V)JG4^GR=RTX;;D2>1C?U5YA
M4MD]T4[QZGPY0_(MDIIIK9(M99V6T&:J( /OZ[E*KN7$O%5%5FX-MB0D&K S
M8I>-*;. I5Z$N1+A":WP^<&FVV:>%L0QTE"B.CF!?DG?,X#Z;T'& _NMN)5)
M_<RZN*T7;W0H?SY7]L;Z"*"5RZD0%D%>=K#V$(G54 L$?-"F6&KT?->3XA?Y
MI50'UG)-[%29]/XB>P816WIG&R-RK$>5 -J3^##7\DJ'H/2N91_BPFGFUDP
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MDJ'P5!>E=9^?V)5O1MQDK>RQ'G_U?VC._9 VNCF^_[E)_TO :948S2(;5O/
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MZS?!10P>S<'J:^4'KT\6@O%%=TA(^UBBYBOJ,F:G+!J:X0?&\/'^B)RM<CP
M\#C<47&Y57IN;&,08DN$;*;&)'BNS,HUQ<OR/&YMYRYX15>2&19[Q;G,I:<=
M>C9?;&K2T.O,_*$P@& +F84_ 6N2"3XO89FD,&$E:4ZCZH33F=,8V^NN^^8&
MG94T'K<1PEP6=Y=-6E,X#C&CX[->U'$&.1^5TR(E5#?!2 JVCC)RE=6 < ^X
MR2NKIDJ/ZL\CNG/!.1?IQ<U_1+.(SFR_U08K;KHK?-,\V'M'(3WPN,I-:6Y?
MZZ72;H1%;?*RP <Y[?0$N&_+\@=/AP[F&#)Y^VFU:,?7K?7A,LEN43_DG&H,
MJ%8LJF.VH P=,Q;74]ZS8X(_Q;O%WNS0Z+375UE;&N@H$.A$?;%TZX>,8M,\
M;KC.99V*G919TJYX72>TO/XZICA"3=O\"Z/Z\W6:F3)Q=#C,EW.5D0C6R*?[
MR/4Z+?_ULD3SEV _#[YU/[_=,7:@.),$%M77Y8'O"C-9-, 6.D,1CL\K>#/Q
MN 2H?J\I&H0\@?EZH:SU$9:L)VW$(59YCRY;+2PA(4MX7B=6)UE$-X!BN%&R
M6>T.@K>CGK[1KS),H:-OZ4/L<->41YD$$;^672KF\[=F#=/Y_0S[3UE10LD&
MO A[&WSA9<Y7S6DK9_F-9;T\# /> 1-9;K4U>COE<@<E=:-DI&UTH^ <6[&S
ME-)[-T"5DT5ZED.B_&"SRG;_NR%T5-<4YC%:_/GTQEB-BBU7V<K<IMSH*YF-
M%P3E)BVX$CX(<1]R0\R8(=1VC1$ZME!#H=6A\Y3TD_<!KN@)8]SW-F1TI_]C
M1.EINB9^@>-!%"7G.QVY26TJT"]90&&)LOEN<13D!7E5N:Q^UL<!MCR\'(23
MJ83G;2-#M6A??J(4!['YFI7&)$51Y_7.W'CP=17)%73&!OBM7[O(-5IZ:%$=
MKJ[K9=R'GV1^?YC_8YR,D#@!P_W$'A<SVF85X7!)AA_)\&H][_?!4_3>A1^4
M$GX?!4LMZ[#%0R1P4CJB8R7GJ=(4J^*@GB_"8E<Z"(C+P)FNT@SAQN>HMK#I
MC8<.FH)DK\P5/]-)'X&"@XWMN3*>T0IN97"B0YR=+Z6,H!]4-I9V;)+5F.AS
M%.&5";\[)24;2D>TD;GIAYV?(2(5//!&FSC&,Q.2^TZERX2 Q_V![W&S]]@^
M3S'%*C55M.N 6%*/RX(9V#)OQ<A7I09#I1(Q+9OA/M8D0#W3E$AJ6;!I=>X3
M3^FCT=QTIBK2M'U=.1']?6;1V;YRC]L([FX:*.1&N]NBIA!U<813)XP]<%^:
M?HA4ZO'>#4!J3"9.'C<UU(5*7+G:"(;%/:HK1;.J#;'SH_6TOD)3/2/<>B8%
MBH*<WP[W5Q9^H"JB$.G__<&K])XD%II4_4E-B\M=?,$)2XPVUK@M(^D5:]DN
MKZV8;GF*9V616!\=GP5 YC+G$9<^<EQ:V-S7(0F,^HJB*/4;QLP3'E5614V>
MPU.ZQ\F9UR2>9>A=GYJF2^.XU-T 9,W4WX='C6%1_3]*JOM U&F>WTG(,V9V
M371@;/%/]QUN )LVL#QA->\W6<<>C3O!OK^]V@_;K_)!B.I#:EB =HL2K9\T
MZUKI>FU#Y/Z&^0Z9='$ EE%-]Y46LMF4!2F[RP*;M&>&-CU)#)=_W@2<]5-=
MQ=M%KS#&O$6E!*TT-/M=A'Y+@R9C+@'<@!Z%D58;4-/7"O?X!S:IQ*F"^ MA
M]\F4*[J//JE_N?LN,$EK9X:" Y8IXT,K/E&LGUNSDUP+5YS"SG*?JX]9:\L%
M[*;?9J]RL;V:/+D6NK@0<1($/X&26_.1(K+6\G>CWJ'N1DV_1=J=W9U46O_<
M,VA/%N#IX=PT5^)JRC3A2U\*-:5%X6#RR%6L8<SES^8Y68XIL;1 XA'OB*DZ
MZ%#2]#4N_E*H+QG@449M$X;-:\HPV"]=D<B'A.M? A5!H5*A;G^$GQG,*;JZ
M"[SK($N&*U)QY-,/2' .^G/#FEY,^9/OE,^:\@L.A.]M*K#$6G>/5?!6L1,]
MNS>8V"Z ]9N!;C)WVI<GQR[Q*TM=K?J\V'>/(K&[#ZUK56P1_,N70U#B,$F&
MIN8,$:[5<2Z#C83@PO@GWHFZ#KX6V:90WM_W8*@=LN QHWFC(7P%8/[5H4;]
M:_*$C"2L)EGU*?<2\9=!CR<=QW$2NIT+!FRI3G0TX'TS=VP;59N^0Z&\$P?O
MXT'VJ8_EXA322NFI[FJ=W@D4L"D42Z[*LV6THOSCW(YPS:W&Z]M,EG]=6"B6
MH;8L*O@Y#[W;15/:)A1N43PW4B"C8*,'29CD) UC!HNPW;]-_?^LJZ!/DQ?K
M*_%-#2+<&$%FA"-\ARK#J2ILVW(F;P@\56%HZ%&69W?QQL[0;UWX@>H]@S7[
M4C X8Z;C)V#RM9S+%[HR-U?OD#4YENK)V\$LM_OOP>2.Z#(R9_H:N/^?W%V:
M]D1'@D>G?+H:778R5U]:PCH\\,:^H*/C6HZ36XT6[2C^/>A4H7? -^43\R<R
M54FY%%J0ZVBM#2CK:^IP?NBOX"SJIZH 0\W/Q:L7R.3TW,=Y[J6&N3EPB',C
M?%,F1J<V%+L<VQV( G[G%].6T:#MAJ3#C>NG';14,J^5+RM9(.OL=(D=RP0H
M/3<5'R440VIJ6((/Q4(1&7;"5K XB1=X9O1N['^W[O[+?PD,E,@_&%6I7K/3
MSK4;0%[6T(SJM,@+HK'"@[]DW..4.[^0.YTU7JYC,]6.%;G,0_SEDF$J[5^;
MZ$JR)(UCQ-',>O6KB]I*]AD DQSU2%TJ(2"\1ASGQ@]=02 Q15"?PE]V"?-R
M3ZW(]F,X[QH7]+'D]WFWH (PKQB[&"_Q,J]IG4P;("C#N0%G9PY9 @531?K@
M0G9JEL11+%/Y?[E,FA#=5V(TL!I_#V9ZL<GIQ[VYSUUS]V-PD5PI0*"&!?/=
MFCDK#*#R=<U.,R-J"S\U,EK0'=*.6^6U8$^Q-]?GVU 59943GVC]WW3;Y^5Q
M#]2)M:>[X#[O(R\6#[S\+$NXFC0. $OIV<=78R1O!KMO2*47V.$3CO'Q$A6Q
M/ 3N=2+W)^AM_45F9%?2R@AA;8I!7&5/#[K!@^I!DX2#1!(?P\=B;7S-_JDV
M1O9A.O-N +FY<<S8PY'EDL?#K#R0V6)_0Z*2RP;PL;DT*6:,G+6ORX3;\A)N
MYRQV3<"76H;:4JX:\R7^:C+3GK!@:.=<[!I*.VR1$,DU"1^\)S$BR+./@U6#
M-LDQ2DQ\\ W/&D$RR.$T*XY1W,R\ <QOK<6)=C66ZUIKC;O5"K[*@YY?CNYI
MV?:OX/=B_%;Z"C@DWT_G=3L1S/)T7.X+S?+3V.I&2Q0\#Z%^;\V\! 3[_725
M8LP2N@&0D;O%]X*[U#D?BQ'.T4Y@/M.<$$=X*CHAY[I=*G",5-*Q1C2WM?US
MU,%,@E3-KI>0!3LQ>/7$]Q3Q?B6*QS"==M>0X5=A?:I0XDZQQYG">V-^KH+5
M+C\?9_IPG]_GU:)]I85] I0Z[R@>ZC73F@O&[XWEGP_JY(T?;@&W\B59)0\%
M,/:F+R^="^YF7N+8F5W<G\22"O&5EPR_%.DH22:4*,E995H0OI?.#)X3MZOK
M,B.'2<F@C:BGW!?$]SW]W7NSR>>?9,B_M0_^/*\Z"FZQFC&0N 'VDI'?7<J'
MA$$0>8_A %G!;4;<,O-6M$$VY*7_#CE^O)P<1T!R  W0@\;)GU^ZXH\3#UXW
M6!AP(I=RZRSO*^>67XF;VJ&@<^WA'$P8C$.V#E#HD\56"Q%G=SVY(-W55 ?#
MK[#2]C'4B!JYD<^>Q8/[&6W.M#? 6\'/E[+&U/80P1Q*CA3/LD?MF&V=$8RL
M8 52E7@O">48V,X\ ^7V;7;3Q=*^QGTU=/UUSPK3,7KZ2>MQ+RJIEK\.AFT]
MQQL_'BCF%,' @*#L^G/1&[NJ\FKZ6"UFQ 'JN/+P:,Q+SFQ-!'L]HWZ-8BN
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M914^P'Q<SP2=/'$G#G-]*I8^%35OQR=P:!OZ,8F)7<<UO?GX Y^WLVE;J7Z
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M$$7_E*#=BO8AXZH)".1,DEG1W83!*H%FD^F1)2F+J6'HAI[=ZPS% 8C>K8O
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MN-6@EE$R $(<TG4\UR/@DJ#M!\2#PQ-X<SX?O"W9AZ>#^9?IJ%([/7]_/!Y
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M;@82E3NK9WP=L2&-OBTU)FY65'RE@Q=N^>EM.'M[H3:R:-E*T^MW=ZOZ5]/
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M,C R,3 Y,S N>'-D4$L! A0#%     @ +3AR4\C[[.:D#@  W<D  !0
M         ( !WA8  '1M8BTR,#(Q,#DS,%]C86PN>&UL4$L! A0#%     @
M+3AR4]#!AO9^*P  A-@" !0              ( !M"4  '1M8BTR,#(Q,#DS
M,%]D968N>&UL4$L! A0#%     @ +3AR4ZN*0K<J=P   MP' !0
M     ( !9%$  '1M8BTR,#(Q,#DS,%]L86(N>&UL4$L! A0#%     @ +3AR
M4PI"&0*+4   S\(% !0              ( !P,@  '1M8BTR,#(Q,#DS,%]P
M<F4N>&UL4$L! A0#%     @ +3AR4Q>ZO,X!?0, !?0A !0
M ( !?1D! '1M8BTR,#(Q,#DS,'@Q,&LN:'1M4$L! A0#%     @ +3AR4SQ<
M5IF%A@  -=,  !<              ( !L)8$ '1M8BTR,#(Q,#DS,'@Q,&LP
M,#$N:G!G4$L! A0#%     @ +3AR4QB.53LU)P  C2X  !<
M ( !:AT% '1M8BTR,#(Q,#DS,'@Q,&LP,#(N:G!G4$L! A0#%     @ +3AR
M4TUWEV^!Z0  L>H" !<              ( !U$0% '1M8BTR,#(Q,#DS,'@Q
M,&LP,#,N:G!G4$L! A0#%     @ +3AR4X?F#)\1!   (!X  !<
M     ( !BBX& '1M8BTR,#(Q,#DS,'AE>#(Q9#$N:'1M4$L! A0#%     @
M+3AR4P)FAE>N!   ^!4  !<              ( !T#(& '1M8BTR,#(Q,#DS
M,'AE>#(S9#$N:'1M4$L! A0#%     @ +3AR4_:=BKT."   9QP  !<
M         ( !LS<& '1M8BTR,#(Q,#DS,'AE>#,Q9#$N:'1M4$L! A0#%
M  @ +3AR4^<64%@""   0AP  !<              ( !]C\& '1M8BTR,#(Q
M,#DS,'AE>#,Q9#(N:'1M4$L! A0#%     @ +3AR4XU^QR^;!@  7"T  !<
M             ( !+4@& '1M8BTR,#(Q,#DS,'AE>#,R9#$N:'1M4$L! A0#
M%     @ +3AR4Z8JB:$%!@  ]@\  !8              ( !_4X& '1M8BTR
G,#(Q,#DS,'AE>#1D,BYH=&U02P4&      \ #P#T P  -E4&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
